FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Singh, JA
Wells, G
Christensen, R
Ghogomu, E
Macdonald, J
Maxwell, L
Tarp, S
Buchbinder, R
Tugwell, P
AF Singh, J. A.
Wells, G.
Christensen, R.
Ghogomu, E.
Macdonald, J.
Maxwell, L.
Tarp, S.
Buchbinder, R.
Tugwell, P.
CA Cochrane Biol Study Grp
TI RISK OF CANCER, SERIOUS LUNG INFECTIONS AND DEATH WITH BIOLOGICS: A
SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED
TRIALS (RCTS)
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Wells, G.; Ghogomu, E.; Maxwell, L.; Tugwell, P.] Univ Ottawa, Ottawa, ON, Canada.
[Christensen, R.] Copenhagen Univ Hosp, Frederiksberg, Denmark.
[Macdonald, J.] Robarts Res Inst, London, ON N6A 5C1, Canada.
[Tarp, S.] Copenhagen Univ Hosp, Frederiksberg, Denmark.
[Buchbinder, R.] Monash Univ, Malvern, Australia.
RI Buchbinder, Rachelle/G-2952-2011
NR 1
TC 0
Z9 1
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 74
EP 74
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901274
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI INCOME AND PATIENT-REPORTED OUTCOMES (PROS) AFTER PRIMARY TOTAL KNEE
ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 81
EP 82
PG 2
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901296
ER
PT J
AU Hirsh, JM
Quinzanos, I
Keniston, A
Caplan, L
AF Hirsh, J. M.
Quinzanos, I.
Keniston, A.
Caplan, L.
TI VERBALLY ADMINISTERED PATIENT GLOBAL ASSESSMENTS AND ASSESSMENTS OF
DISEASE ACTIVITY DEMONSTRATE GOOD CORRELATION WITH TRADITIONAL WRITTEN
VERSIONS: THE TALK-THE-LINE OBSERVATIONAL STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Hirsh, J. M.; Keniston, A.] Denver Hlth, Denver, CO USA.
[Quinzanos, I.; Caplan, L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 149
EP 149
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901485
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI PATIENTS WITH OSTEOARTHRITIS HAVE BETTER FUNCTIONAL OUTCOMES COMPARED TO
RHEUMATOID ARTHRITIS AFTER PRIMARY HIP ARTHROPLASTY: A COHORT STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 351
EP 351
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587902471
ER
PT J
AU Caplan, L
Luong, PT
Richards, JS
Majithia, V
Bobba, S
Qaiyumi, S
Davis, LA
AF Caplan, L.
Luong, P. T.
Richards, J. S.
Majithia, V.
Bobba, S.
Qaiyumi, S.
Davis, L. A.
TI VALIDATION OF MODIFIED DISEASE ACTIVITY AND FUNCTIONAL STATUS
QUESTIONNAIRES IN SPONDYLOARTHRITIS
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Caplan, L.; Luong, P. T.; Bobba, S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Richards, J. S.; Qaiyumi, S.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Majithia, V.] Montgomery Vet Affairs Med Ctr, Jackson, MS USA.
[Davis, L. A.] Denver Hlth, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 534
EP 534
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903361
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI IPSILATERAL LOWER EXTREMITY JOINT INVOLVEMENT INCREASES THE RISK OF POOR
PAIN AND FUNCTION OUTCOMES AFTER HIP OR KNEE ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 552
EP 553
PG 2
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903418
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI UNDERLYING DIAGNOSIS PREDICTS PATIENT-REPORTED OUTCOMES AFTER REVISION
TOTAL HIP ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 553
EP 553
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903419
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI MEDICAL COMORBIDITY IS ASSOCIATED WITH PERSISTENT INDEX HIP PAIN AFTER
PRIMARY THA
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 696
EP 696
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587904154
ER
PT J
AU Brown, RT
Steinman, MA
AF Brown, Rebecca T.
Steinman, Michael A.
TI Characteristics of Emergency Department Visits by Older Versus Younger
Homeless Adults in the United States
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HEALTH-CARE; SUBSTANCE USE; GERIATRIC SYNDROMES; ALCOHOL-PROBLEMS;
FREQUENT USERS; SAN-FRANCISCO; POPULATION; EPIDEMIOLOGY; PEOPLE; URBAN
AB Objectives. We compared the characteristics of emergency department (ED) visits of older versus younger homeless adults.
Methods. We analyzed 2005-2009 data from the National Hospital Ambulatory Medical Care Survey, a nationally representative survey of visits to hospitals and EDs, and used sampling weights, strata, and clustering variables to obtain nationally representative estimates.
Results. The ED visits of homeless adults aged 50 years and older accounted for 36% of annual visits by homeless patients. Although demographic characteristics of ED visits were similar in older and younger homeless adults, clinical and health services characteristics differed. Older homeless adults had fewer discharge diagnoses related to psychiatric conditions (10% vs 20%; P = .002) and drug abuse (7% vs 15%; P = .003) but more diagnoses related to alcohol abuse (31% vs 23%; P = .03) and were more likely to arrive by ambulance (48% vs 36%; P = .02) and to be admitted to the hospital (20% vs 11%; P = .003).
Conclusions. Older homeless adults' patterns of ED care differ from those of younger homeless adults. Health care systems need to account for these differences to meet the needs of the aging homeless population.
C1 [Brown, Rebecca T.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Brown, Rebecca T.; Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94112 USA.
RP Brown, RT (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,UCSF Box VA-181G, San Francisco, CA 94112 USA.
EM rebecca.brown@ucsf.edu
FU National Institute on Aging [T32 AG000212]; American Federation for
Aging Research [1K23 AG030999]
FX R.T. Brown was supported by the National Institute on Aging (grant T32
AG000212). M. A. Steinman was supported by the National Institute on
Aging, and the American Federation for Aging Research (grant 1K23
AG030999).
NR 44
TC 8
Z9 9
U1 1
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2013
VL 103
IS 6
BP 1046
EP 1051
DI 10.2105/AJPH.2012.301006
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3FI
UT WOS:000330977900036
PM 23597348
ER
PT J
AU Varshney, N
Jain, A
Chan, V
Yu, L
Sarraf, D
AF Varshney, Neeta
Jain, Atul
Chan, Vicki
Yu, Le
Sarraf, David
TI Anti-VEGF response in macular hemorrhage and incidence of retinal
pigment epithelial tears
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; INTRAVITREAL BEVACIZUMAB INJECTION;
CARDIOVASCULAR RISK-FACTORS; SUBMACULAR HEMORRHAGE; CHOROIDAL
NEOVASCULARIZATION; PNEUMATIC DISPLACEMENT; RANIBIZUMAB INJECTION;
DEGENERATION; MANAGEMENT; DISEASE
AB Objective: To study the visual and anatomic outcomes of serial anti-vascular endothelial growth factor (anti-VEGF) therapy for severe macular hemorrhage in eyes with exudative age-related macular degeneration (AMD).
Design: Consecutive retrospective analysis.
Participants: Twenty eyes from 20 patients with severe macular hemorrhage (greater than 50% blockage with formal fluorescein angiography [FA]) secondary to wet AMD were studied.
Methods: We performed a chart review of patients at a single centre from May 2006 to September 2009. Presenting visual acuity and diameter of hemorrhage were recorded as well as number of injections, time by which no hemorrhage was remaining, and final anatomic outcome. Cardiovascular risk factors and use of antiplatelet medication or anticoagulation were noted.
Results: Average presenting visual acuity was 1.55 (20/710), and number of injections needed for resolution of hemorrhage was 4. Visual acuity significantly improved from 1.55 (20/710) to 0.70 (20/100) after injections. Thirty-five percent of eyes were found to have an associated retinal pigment epithelial (RPE) tear, and these eyes were found to have received more injections. Final visual acuity was not significantly different in eyes with RPE tears compared with nontear eyes. Eighty-one percent of patients had associated cardiovascular risk factors; antiplatelet therapy and anticoagulation were not found to play a role in hemorrhage size.
Conclusions: RPE tears are found in a significant number of individuals with large macular hemorrhages secondary to exudative macular degeneration, but with continued treatment with anti-VEGF therapy, visual acuity can significantly improve even in the presence of these tears. Eyes with severe macular hemorrhage thus should be considered candidates for anti-VEGF therapy.
C1 [Varshney, Neeta; Chan, Vicki; Yu, Le; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Jain, Atul] San Diego Retina Associates, San Diego, CA USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Sarraf, David] Kaiser Permanente, Woodland Hills, CA USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
FU Karl Kirchgessner Foundation
FX This work was supported by grants from Karl Kirchgessner Foundation
(D.S.).
NR 39
TC 2
Z9 2
U1 1
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2013
VL 48
IS 3
BP 210
EP 215
DI 10.1016/j.jcjo.2013.01.023
PG 6
WC Ophthalmology
SC Ophthalmology
GA AA5OD
UT WOS:000331148400025
PM 23769784
ER
PT J
AU Parrinello, CM
Landay, AL
Hodis, HN
Gange, SJ
Norris, PJ
Young, M
Anastos, K
Tien, PC
Xue, XN
Lazar, J
Benning, L
Tracy, RP
Kaplan, RC
AF Parrinello, Christina M.
Landay, Alan L.
Hodis, Howard N.
Gange, Stephen J.
Norris, Philip J.
Young, Mary
Anastos, Kathryn
Tien, Phyllis C.
Xue, Xiaonan
Lazar, Jason
Benning, Lorie
Tracy, Russell P.
Kaplan, Robert C.
TI Treatment-related changes in serum lipids and inflammation: clinical
relevance remains unclear. Analyses from the Women's Interagency HIV
study
SO AIDS
LA English
DT Article
ID INFECTED WOMEN; DISEASE RISK; ATHEROSCLEROSIS
AB Among 127 HIV-infected women, the magnitude of high-density lipoprotein cholesterol (HDLc) increases after HAART initiation predicted the magnitude of concurrent decreases in inflammation biomarkers. After HAART initiation, changes in low-density lipoprotein cholesterol (LDLc) and inflammation were unrelated. In the same population, predicted risk of coronary heart disease, based upon levels of standard clinical risk factors, was similar before and after HAART. Thus, it remains unknown whether short-term treatment-related changes in standard risk factors may appreciably change risk of cardiovascular disease (CVD).
C1 [Parrinello, Christina M.; Anastos, Kathryn; Xue, Xiaonan; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Landay, Alan L.] Rush Univ, Dept Immunol Microbiol, Med Ctr, Chicago, IL 60612 USA.
[Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA.
[Gange, Stephen J.; Benning, Lorie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, Blood Syst Res Inst, San Francisco, CA 94143 USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Med, Blood Syst Res Inst, San Francisco, CA USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lazar, Jason] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
RP Kaplan, RC (reprint author), 1300 Morris Pk Ave,Belfer 1306C, Bronx, NY 10461 USA.
EM robert.kaplan@einstein.yu.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI42590];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development [UO1-HD-32632]; National Cancer Institute, the National
Institute on Drug Abuse; National Institute on Deafness and Other
Communication Disorders; National Center for Research Resources
(UCSF-CTSI) [UL1 RR024131]; National Heart, Lung and Blood Institute
[1R01HL095140, 1R01HL083760]; University of Washington's CVD and
Metabolic Complications of HIV/AIDS Data Coordinating Center
[5R01HL095126]
FX Data in this manuscript were collected by the WIHS Collaborative Study
Group with centres (Principal Investigators) at New York City/Bronx
Consortium (Kathryn Anastos); Brooklyn, New York (Howard Minkoff);
Washington, District of Columbia Metropolitan Consortium (Mary Young);
The Connie Wofsy Study Consortium of Northern California (Ruth
Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating
Center (Stephen Gange). The WIHS is funded by the National Institute of
Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834,
UO1-AI-34994, UO1-AI-34989, UO1-AI-34993 and UO1-AI42590) and by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (UO1-HD-32632). The study is cofunded by the National Cancer
Institute, the National Institute on Drug Abuse, and the National
Institute on Deafness and Other Communication Disorders. Funding is also
provided by the National Center for Research Resources (UCSF-CTSI Grant
Number UL1 RR024131). Additional cofunding is provided by the National
Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760 to R. C.
K.). Partial funding for laboratory and work as well as assistance with
general study coordination was provided by the University of
Washington's CVD and Metabolic Complications of HIV/AIDS Data
Coordinating Center (5R01HL095126).
NR 6
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2013
VL 27
IS 9
BP 1516
EP 1519
DI 10.1097/QAD.0b013e32835fd8a9
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 301FV
UT WOS:000330519100019
PM 23435295
ER
PT J
AU Weintraub, D
AF Weintraub, Daniel
TI Neuropsychiatric Symptoms in Parkinson Disease and Dementia with Lewy
Bodies: What Geriatric Psychiatry Can Learn
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
ID DISORDER
C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM Daniel.Weintraub@uphs.upenn.edu
FU NINDS NIH HHS [P50 NS053488]
NR 8
TC 6
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2013
VL 21
IS 6
BP 497
EP 500
DI 10.1016/j.jagp.2013.02.020
PG 4
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298XV
UT WOS:000330358900001
PM 23668226
ER
PT J
AU Drye, LT
Scherer, RW
Lanctot, KL
Rosenberg, PB
Herrmann, N
Bachman, D
Mintzer, JE
AF Drye, Lea T.
Scherer, Roberta W.
Lanctot, Krista L.
Rosenberg, Paul B.
Herrmann, Nathan
Bachman, David
Mintzer, Jacobo E.
CA ADMET Res Grp
TI Designing a Trial to Evaluate Potential Treatments for Apathy in
Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET)
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer dementia; apathy; methylphenidate; randomized trial
ID SEVERE ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; CACHE COUNTY;
DOUBLE-BLIND; PSYCHOLOGICAL SYMPTOMS; BEHAVIORAL SYMPTOMS;
DIAGNOSTIC-CRITERIA; CLINICAL-PRACTICE; DEPRESSION; PREVALENCE
AB Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes. Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. Conclusion: The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
C1 [Drye, Lea T.; Scherer, Roberta W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Lanctot, Krista L.; Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
[Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Toronto, ON M5S 1A1, Canada.
[Rosenberg, Paul B.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Rosenberg, Paul B.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
[Bachman, David; Mintzer, Jacobo E.] Med Univ S Carolina, Charleston, SC USA.
[Bachman, David; Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Drye, LT (reprint author), 615 North Wolfe St,W5010, Baltimore, MD 21205 USA.
EM ldrye@jhsph.edu
OI Drye, Lea/0000-0002-2964-1878; Lanctot, Krista L./0000-0001-7024-6637
FU National Institute on Aging; National Institute of Mental Health [R01
AG033032-01]
FX This study was supported by the National Institute on Aging and National
Institute of Mental Health, R01 AG033032-01.
NR 70
TC 6
Z9 6
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2013
VL 21
IS 6
BP 549
EP 559
DI 10.1016/j.jagp.2012.12.018
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298XV
UT WOS:000330358900007
PM 23567407
ER
PT J
AU Khodyakov, D
Stockdale, S
Jones, A
Mango, J
Jones, F
Lizaola, E
AF Khodyakov, Dmitry
Stockdale, Susan
Jones, Andrea
Mango, Joseph
Jones, Felica
Lizaola, Elizabeth
TI On Measuring Community Participation in Research
SO HEALTH EDUCATION & BEHAVIOR
LA English
DT Article
DE community-academic partnerships; community-based participatory research;
community participation in research; evaluation; mixed methods
ID HEALTH
AB Active participation of community partners in research aspects of community-academic partnered projects is often assumed to have a positive impact on the outcomes of such projects. The value of community engagement in research, however, cannot be empirically determined without good measures of the level of community participation in research activities. Based on our recent evaluation of community-academic partnered projects centered around behavioral health issues, this article uses semistructured interview and survey data to outline two complementary approaches to measuring the level of community participation in research-a "three-model" approach that differentiates between the levels of community participation and a Community Engagement in Research Index (CERI) that offers a multidimensional view of community engagement in the research process. The primary goal of this article is to present and compare these approaches, discuss their strengths and limitations, summarize the lessons learned, and offer directions for future research. We find that whereas the three-model approach is a simple measure of the perception of community participation in research activities, CERI allows for a more nuanced understanding by capturing multiple aspects of such participation. Although additional research is needed to validate these measures, our study makes a significant contribution by illustrating the complexity of measuring community participation in research and the lack of reliability in simple scores offered by the three-model approach.
C1 [Khodyakov, Dmitry] RAND Corp, Santa Monica, CA 90401 USA.
[Stockdale, Susan] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA USA.
[Stockdale, Susan; Mango, Joseph; Lizaola, Elizabeth] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Semel Inst, Los Angeles, CA USA.
[Jones, Andrea; Jones, Felica] Hlth African Amer Families, Los Angeles, CA USA.
[Jones, Andrea] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA.
EM dmitry_khodyakov@rand.org
FU NIMH NIH HHS [P30 MH082760, P30MH082760, P30MH068639]
NR 13
TC 12
Z9 12
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1090-1981
EI 1552-6127
J9 HEALTH EDUC BEHAV
JI Health Educ. Behav.
PD JUN
PY 2013
VL 40
IS 3
BP 346
EP 354
DI 10.1177/1090198112459050
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 298AC
UT WOS:000330295200011
PM 23041704
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Hypoxic Pulmonary Vasoconstriction
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article
ID RED-BLOOD-CELLS; STRESS DOPPLER-ECHOCARDIOGRAPHY; MICE PARTIALLY
DEFICIENT; HIGH-ALTITUDE EXPOSURE; HEALTHY-HUMAN LUNG;
VASCULAR-RESPONSE; ARTERY PRESSURE; GAS-EXCHANGE; NITRIC-OXIDE;
TIME-COURSE
AB Hypoxic pulmonary vasoconstriction (HPV) continues to fascinate cardiopulmonary physiologists and clinicians since its definitive description in 1946. Hypoxic vasoconstriction exists in all vertebrate gas exchanging organs. This fundamental response of the pulmonary vasculature in air breathing animals has relevance to successful fetal transition to air breathing at birth and as a mechanism of ventilation-perfusion matching in health and disease. It is a complex process intrinsic to the vascular smooth muscle, but with in vivo modulation by a host of factors including the vascular endothelium, erythrocytes, pulmonary innervation, circulating hormones and acid-base status to name only a few. This review will provide a broad overview of HPV and its mechansms and discuss the advantages and disadvantages of HPV in normal physiology, disease and high altitude.
C1 [Swenson, Erik R.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Swenson, Erik R.] Univ Washington, Dept Physiol & Biophys, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
NR 136
TC 29
Z9 31
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
EI 1557-8682
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
PD JUN
PY 2013
VL 14
IS 2
BP 101
EP 110
DI 10.1089/ham.2013.1010
PG 10
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA 302BL
UT WOS:000330576200003
PM 23795729
ER
PT J
AU Ke, T
Wang, JY
Swenson, ER
Zhang, XN
Hu, YL
Chen, YM
Liu, MC
Zhang, WB
Zhao, F
Shen, XF
Yang, Q
Chen, JY
Luo, WJ
AF Ke, Tao
Wang, Jiye
Swenson, Erik R.
Zhang, Xiangnan
Hu, Yunlong
Chen, Yaoming
Liu, Mingchao
Zhang, Wenbin
Zhao, Feng
Shen, Xuefeng
Yang, Qun
Chen, Jingyuan
Luo, Wenjing
TI Effect of Acetazolamide and Gingko Biloba on the Human Pulmonary
Vascular Response to an Acute Altitude Ascent
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article
DE acetazolamide; gingko Biloba; pulmonary artery systolic pressure; acute
mountain sickness; randomized controlled trial
ID ACUTE MOUNTAIN-SICKNESS; CARBONIC-ANHYDRASE INHIBITION; ARTERY PRESSURE;
DOPPLER-ECHOCARDIOGRAPHY; EDEMA; HYPOXIA; VASOCONSTRICTION; EXTRACT;
TRIAL; HYPERCAPNIA
AB Acetazolamide and gingko biloba are the two most investigated drugs for the prevention of acute mountain sickness (AMS). Evidence suggests that they may also reduce pulmonary artery systolic pressure (PASP). To investigate whether these two drugs for AMS prevention also reduce PASP with rapid airlift ascent to high altitude, a randomized controlled trial was conducted on 28 healthy young men with acetazolamide (125mg bid), gingko biloba (120mg bid), or placebo for 3 days prior to airlift ascent (397m) and for the first 3 days at high altitude (3658m). PASP, AMS, arterial oxygen saturation (Sao(2)), mean arterial pressure (MAP), heart rate (HR), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and peak expiratory flow (PEF) were assessed both at 397m and 3658m. HR, PEF, and PASP increased with altitude exposure (p<0.05), and SaO(2) decreased (p<0.05). PASP with acetazolamide (mean at 3658m, 26.2mm Hg; incremental change, 4.7mm Hg, 95% CI., 2.6-6.9mm Hg) was lower than that with ginkgo biloba (mean at 3658m, 33.7mm Hg, p=0.001; incremental change, 13.1mm Hg, 95%CI., 9.6-16.5mm Hg, p=0.002), and with placebo (mean at 3658m, 34.7mm Hg, p<0.001; 14.4mm Hg, 95% CI., 8.8-20.0mm Hg, p=0.001). The data show that a low prophylactic dosage of acetazolamide, but not gingko biloba, mitigates the early increase of PASP in a quick ascent profile.
C1 [Ke, Tao; Wang, Jiye; Zhang, Xiangnan; Hu, Yunlong; Chen, Yaoming; Liu, Mingchao; Zhang, Wenbin; Shen, Xuefeng; Chen, Jingyuan; Luo, Wenjing] Fourth Mil Med Univ, Dept Occupat & Environm Hlth, Sch Publ Hlth, Minist Educ,Key Lab Hazard Assessment & Control S, Xian 710032, Peoples R China.
[Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98195 USA.
[Zhao, Feng] Fourth Mil Med Univ, Xijing Hosp, Dept Resp Med, Xian 710032, Peoples R China.
[Yang, Qun] Fourth Mil Med Univ, Sch Nursing, Xian, Peoples R China.
RP Chen, JY (reprint author), Fourth Mil Med Univ, Dept Occupat & Environm Hlth, Sch Publ Hlth, Minist Educ,Key Lab Hazard Assessment & Control S, Xian 710032, Peoples R China.
EM jy_chen@fmmu.edu.cn; luowenj@fmmu.edu.cn
FU National Key Technology RD Program [2009BAI85B04]; National Nature
Science Foundation of China [81172621]; Program for Changjiang Scholars
and Innovative Research Team in University (PCSIRT) [IRT1112]
FX This work was supported by the National Key Technology R&D Program
(Grant 2009BAI85B04); National Nature Science Foundation of China (Grant
81172621); and Program for Changjiang Scholars and Innovative Research
Team in University (PCSIRT, IRT1112).
NR 32
TC 5
Z9 6
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
EI 1557-8682
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
PD JUN
PY 2013
VL 14
IS 2
BP 162
EP 167
DI 10.1089/ham.2012.1099
PG 6
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA 302BL
UT WOS:000330576200011
PM 23795737
ER
PT J
AU Mohammadi, S
MacKay, K
Ward, TT
Forrest, GN
AF Mohammadi, Shahrzad
MacKay, Kimberly
Ward, Thomas T.
Forrest, Graeme N.
TI Clinical Outcomes of a Veterans Affairs Outpatient Antimicrobial
Treatment Program
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Article
DE diabetes mellitus; osteomyelitis; outpatient parenteral antibiotic
therapy; Staphylococcus aureus
ID PARENTERAL ANTIBIOTIC-THERAPY; DIABETIC FOOT; EXPERIENCE; MANAGEMENT;
INFECTIONS
AB Objectives: The outpatient parenteral antibiotic therapy (OPAT) program of the Portland Veterans Affairs Medical Center (PVAMC), which has a self-administration model, is staffed by visiting nurses from a specialist infusion company. This study evaluates the clinical outcomes of these patients.
Methods: This study was a retrospective chart review of 262 patients at PVAMC who had received OPAT between 2007 and 2009. Patients were included only if they received ongoing care at PVAMC. The data collected included conditions and organisms being treated and types and durations of antibiotics used. Clinical cure was defined as documented cure at the end of treatment and 90 days post-OPAT.
Results: One hundred ninety patients of 262 were analyzed. The mean age was 63.2 years. Diabetes was the main comorbid factor (17%). The most common indications for OPAT were osteomyelitis (38%), urinary tract infection (23%), and skin and soft tissue infection (12.6%). Mixed bacterial culture (26%) and Staphylococcus aureus (31%) were the most common organisms treated. Vancomycin was the most frequently used antibiotic (26%) followed by ceftriaxone (12%). The median duration of OPAT was 30 days. The rate of clinical cure at end of treatment observed for all infections treated was 78%, which then decreased to 58% at 90 days post-OPAT (P < 0.001). Patients with diabetes and osteomyelitis had an increased risk of relapse at 90 days post-OPAT on multivariate analysis (P = 0.025).
Conclusions: An OPAT program using a self-administration model treating patients who were military veterans had successful outcomes. Patients with diabetes and osteomyelitis had worse clinical outcomes 90 days after the completion of OPAT therapy.
C1 [Mohammadi, Shahrzad] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA.
Portland VA Med Ctr, Dept Pharm, Portland, OR 97239 USA.
RP Mohammadi, S (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3ID, Portland, OR 97239 USA.
EM shahrzad.mohammadi@va.gov
NR 15
TC 3
Z9 4
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD JUN
PY 2013
VL 106
IS 6
BP 345
EP 349
DI 10.1097/SMJ.0b013e3182967e8f
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 298KX
UT WOS:000330323900003
PM 23736174
ER
PT J
AU Ogawa, M
LaRue, AC
Mehrotra, M
AF Ogawa, Makio
LaRue, Amanda C.
Mehrotra, Meenal
TI Hematopoietic stem cells are pluripotent and not just "hematopoietic"
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE Hematopoietic stem cell; Stem cell plasticity; Pluripotent stem cell;
Tissue regeneration
ID MARROW-DERIVED CELLS; ENDOTHELIAL PROGENITOR CELLS; COLONY-STIMULATING
FACTOR; ADULT BONE-MARROW; OSTEOGENESIS IMPERFECTA; IN-VIVO; MESANGIAL
CELLS; ALPORT-SYNDROME; MOUSE MODEL; CEREBRAL-ISCHEMIA
AB Over a decade ago, several preclinical transplantation studies suggested the striking concept of the tissue-reconstituting ability (often referred to as HSC plasticity) of hematopoietic stem cells (HSCs). While this heralded an exciting time of radically new therapies for disorders of many organs and tissues, the concept was soon mired in controversy and remained dormant for almost a decade. This commentary provides a concise review of evidence for HSC plasticity, including more recent findings based on single HSC transplantation in mouse and clinical transplantation studies. There is strong evidence for the concept that HSCs are pluripotent and are the source for the majority, if not all, of the cell types in our body. Also discussed are some biological and experimental issues that need to be considered in the future investigation of HSC plasticity. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ogawa, Makio; LaRue, Amanda C.; Mehrotra, Meenal] Ralph H Johnson VAMC, Dept Pathol & Lab Med, Charleston, SC 29401 USA.
[LaRue, Amanda C.] Ralph H Johnson VAMC, Med Ctr, Dept Vet Affairs, Charleston, SC USA.
[LaRue, Amanda C.; Mehrotra, Meenal] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP Ogawa, M (reprint author), Ralph H Johnson VAMC, Dept Pathol & Lab Med, Charleston, SC 29401 USA.
EM ogawam@musc.edu
FU Biomedical Laboratory Research and Development Program of the Department
of Veterans Affairs; National Institutes of Health [R01 CA148772, K01
AR059097]
FX This work is supported in part by the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs (Merit Award,
ACL). The contents of this manuscript do not represent the views of the
Department of Veterans Affairs or the United States Government. This
work was also supported by National Institutes of Health R01 CA148772
(ACL) and K01 AR059097 (MM).
NR 84
TC 11
Z9 11
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD JUN
PY 2013
VL 51
IS 1
BP 3
EP 8
DI 10.1016/j.bcmd.2013.01.008
PG 6
WC Hematology
SC Hematology
GA 296SU
UT WOS:000330206500002
PM 23453528
ER
PT J
AU Kautza, B
Whelan, S
Stratmirovics, S
Zuckerbraun, B
AF Kautza, B.
Whelan, S.
Stratmirovics, S.
Zuckerbraun, B.
TI HEME OXYGENASE-2 REGULATES HYPOXIA INDUCED MITOCHONDRIAL SIGNALING AND
RESPONSES IN HEPATOCYTES
SO SHOCK
LA English
DT Meeting Abstract
CT 36th Annual Conference of Shock-Society on Shock
CY JUN 01-04, 2013
CL San Diego, CA
SP Shock Soc
C1 [Kautza, B.; Whelan, S.; Stratmirovics, S.; Zuckerbraun, B.] Univ Pittsburgh, Pittsburgh, PA USA.
[Stratmirovics, S.; Zuckerbraun, B.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2013
VL 39
SU 2
BP 49
EP 49
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 297JK
UT WOS:000330251500103
ER
PT J
AU Rice, TR
Sher, L
AF Rice, Timothy R.
Sher, Leo
TI Testosterone, emotion regulation and childhood aggression
SO NEUROPSYCHIATRY
LA English
DT Editorial Material
ID BEHAVIOR PROBLEMS; CHILDREN; BRAIN; MECHANISMS
C1 [Rice, Timothy R.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM trice83@gmail.com
NR 19
TC 1
Z9 1
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
EI 1758-2016
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD JUN
PY 2013
VL 3
IS 3
BP 267
EP 270
DI 10.2217/NPY.13.26
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 257ZU
UT WOS:000327427500002
ER
PT J
AU Valenstein, M
AF Valenstein, Marcia
TI The Promise of Large, Longitudinal Data Sets
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 [Valenstein, Marcia] Univ Michigan, US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
[Valenstein, Marcia] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Valenstein, M (reprint author), Univ Michigan, US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2013
VL 64
IS 6
BP 503
EP 503
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255XF
UT WOS:000327272700001
PM 23728597
ER
PT J
AU Grossbard, JR
Lehavot, K
Hoerster, KD
Jakupcak, M
Seal, KH
Simpson, TL
AF Grossbard, Joel R.
Lehavot, Keren
Hoerster, Katherine D.
Jakupcak, Matthew
Seal, Karen H.
Simpson, Tracy L.
TI Relationships Among Veteran Status, Gender, and Key Health Indicators in
a National Young Adult Sample
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-RELATED PROBLEMS; DUTY MILITARY
PERSONNEL; SUBSTANCE USE DISORDERS; MENTAL-HEALTH; UNITED-STATES; WAR
VETERANS; AFGHANISTAN VETERANS; COMBAT DEPLOYMENT; AMBULATORY-CARE
AB Objective: Although many risk behaviors peak during young adulthood, little is known about health risk factors and access to care. This study assessed health indicators and health care access in a national sample of young adult veterans and civilians. Methods: Data were from the 2010 Behavioral Risk Factor Surveillance System, a national telephone survey. Of 27,471 participants, ages 19-30 years, 2.2% were veterans (74.6% were male) and 97.7% were civilians (37.6% were male). Gender-stratified comparisons assessed health indicators and health care access by veteran status. Multivariate logistic regression was used to examine health indicators and health care access as a function of gender and veteran status. Results: In the overall sample, women were more likely than men to have insurance, to have a regular physician, and to have had a routine checkup and yet were more likely to report financial barriers to care. Women also were more likely than men to report general medical and mental distress and higher lifetime anxiety and depressive disorders, whereas men were more likely to be overweight or obese and to report tobacco use and high-risk drinking. Adjusted analyses revealed a higher likelihood of general medical distress and higher rates of lifetime anxiety disorders among veterans compared with civilians, although there were no differences between veterans and civilians regarding health care utilization and hazardous drinking. Conclusions: Findings extend the literature on health care status and modifiable risk factors for young adults by identifying differences between men and women and between veterans and civilians. Interventions may need to be tailored on the bases of gender and veteran status because of several differences in mental health and general health needs.
C1 [Grossbard, Joel R.; Lehavot, Keren; Hoerster, Katherine D.; Jakupcak, Matthew; Simpson, Tracy L.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Seal, Karen H.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Seal, Karen H.] Univ Calif San Francisco, Dept Med & Psychiat, San Francisco, CA 94143 USA.
RP Grossbard, JR (reprint author), Vet Affairs VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 116 WTRC, Seattle, WA 98108 USA.
EM joel.grossbard@va.gov
FU VA Puget Sound Health Services Research and Development Postdoctoral
Fellowship Program [TP 61-025]
FX This work was supported by grant TP 61-025 from the VA Puget Sound
Health Services Research and Development Postdoctoral Fellowship
Program. This article is the result of work supported by resources from
the VA Puget Sound Health Care System. The views expressed in this
article are those of the authors and do not necessarily reflect the
views of the Department of Veterans Affairs.
NR 49
TC 12
Z9 12
U1 5
U2 10
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2013
VL 64
IS 6
BP 547
EP 553
DI 10.1176/appi.ps.003002012
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255XF
UT WOS:000327272700009
PM 23450338
ER
PT J
AU Wang, ZJ
Kristianto, J
Ooi, CY
Johnson, MG
Litscher, SJ
Pugh, TD
Sandhu, G
Chesler, NC
Blank, RD
AF Wang, Zhijie
Kristianto, Jasmin
Ooi, Chen Yen
Johnson, Michael G.
Litscher, Suzanne J.
Pugh, Thomas D.
Sandhu, Gurpreet
Chesler, Naomi C.
Blank, Robert D.
TI Blood Pressure, Artery Size, and Artery Compliance Parallel Bone Size
and Strength in Mice With Differing Ece1 Expression
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
DE blood pressure; arterial modeling; endothelin converting enzyme 1;
nitric oxide synthase 3; recombinant congenic mice
ID ENDOTHELIN-CONVERTING ENZYME-1; OXIDE SYNTHASE ISOFORMS; ZERO-STRESS
STATE; NITRIC-OXIDE; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN;
PULMONARY-ARTERIES; VASCULAR-DISEASE; CELL-CULTURES; SHEAR-STRESS
AB The recombinant congenic mouse strains HcB-8 and HcB-23 differ in femoral shape, size, and strength, with HcB-8 femora being more gracile, more cylindrical, weaker, and having higher Young's modulus. In previous work, we mapped a robust, pleiotropic quantitative trait locus for these bone traits. Ece1, encoding endothelin converting enzyme 1, is a positional candidate gene for this locus, and was less expressed in HcB-8 bone. We hypothesized that the same genetic factors would impose analogous developmental trajectories on arteries to those in bones. Cardiovascular hemodynamics and biomechanics of carotids were measured in adult HcB-8 and HcB-23 mice. Biological differences in heart and arteries were examined at mRNA and protein levels. As in bone, Ece1 expression was higher in HcB-23 heart and arteries (p < 0.05), and its expression was correlated with that of the endothelin B type receptor target Nos3, encoding endothelial nitric oxide synthase. HcB-8 mice had higher ambulatory blood pressure (p < 0.005) than HcB-23 mice. Ex vivo, at identical pressures, HcB-8 carotid arteries had smaller diameters and lower compliance (p < 0.05), but the same elastic modulus compared to HcB-23 carotid arteries. HcB-8 hearts were heavier than HcB-23 hearts (p < 0.01). HcB-8 has both small, stiff bones and small, stiff arteries, lower expression of Ece1 and Nos3, associated in each case with less favorable function. These findings suggest that endothelin signaling could serve as a nexus for the convergence of skeletal and vascular modeling, providing a potential mechanism for the epidemiologic association between skeletal fragility and atherosclerosis.
C1 [Wang, Zhijie; Ooi, Chen Yen; Chesler, Naomi C.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
[Kristianto, Jasmin; Johnson, Michael G.; Litscher, Suzanne J.; Pugh, Thomas D.; Sandhu, Gurpreet; Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
[Kristianto, Jasmin; Johnson, Michael G.; Litscher, Suzanne J.; Pugh, Thomas D.; Sandhu, Gurpreet; Blank, Robert D.] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA.
[Kristianto, Jasmin; Blank, Robert D.] Univ Wisconsin, Endocrine & Reprod Physiol Program, Madison, WI 53706 USA.
RP Blank, RD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM rdb@medicine.wisc.edu
OI Blank, Robert Daniel/0000-0003-2950-1944
FU ORDBL; RD Service; Department of Veterans Affairs; National Institutes
of Health [HL086939, AR054753]; AHA [10POST2640148]
FX This work was supported by the ORDBL, R&D Service, Department of
Veterans Affairs (RDB), National Institutes of Health Grant Nos.
HL086939 (NCC), AR054753 (RDB), and AHA 10POST2640148 (ZW). Some of the
work was conducted in the Madison VA Geriatrics Research, Education, and
Clinical Center. This report is Madison GRECC manuscript 10-22.
NR 39
TC 3
Z9 3
U1 0
U2 1
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0148-0731
EI 1528-8951
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD JUN
PY 2013
VL 135
IS 6
AR 061003
DI 10.1115/1.4024161
PG 9
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 240GO
UT WOS:000326083300003
PM 23699715
ER
PT J
AU Munoz, A
Boone, TB
Smith, CP
Somogyi, GT
AF Munoz, Alvaro
Boone, Timothy B.
Smith, Christopher P.
Somogyi, George T.
TI Diabetic plasticity of non-adrenergic non-cholinergic and P2X-mediated
rat bladder contractions
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Diabetic bladder dysfunction; Purinergic receptor; Cholinergic receptor;
Non-adrenergic non-cholinergic response; Neurally evoked contraction;
Detrusor muscle
ID CORD-INJURED RATS; URINARY-BLADDER; ELECTRICAL-STIMULATION; OVERACTIVE
BLADDER; NEURALLY INTACT; RELEASE; DYSFUNCTION; UROTHELIUM; RECEPTORS;
TARGETS
AB We investigated the plasticity effects of diabetes mellitus and diuresis on the non-adrenergic non-cholinergic (NANC) and purinergic (P2X-type) contractile responses in longitudinal rat bladder strips. Female Sprague-Dawley rats received streptozotocin to induce diabetes, or sucrose in water to induce diuresis as a control condition for polyuria. Experiments were carried out at four weeks after treatments, using bladders from non-treated rats as control. Urinary bladder strips were electrically stimulated throughout the experiments to generate neurally evoked contractions (NEC). In all cases, P2X-mediated purinergic contractions were evaluated at the beginning and end of the stimulations with alpha,beta-methylene-adenosine triphosphate (alpha,beta MeATP). The NANC responses were assessed by using two independent protocols. First, cholinergic receptors were activated with carbachol (CCh), followed by inhibition of the muscarinic component with atropine. In the second protocol, the application order for CCh and atropine was reversed. The NANC response, unmasked with the application of atropine, and the P2X purinergic contractions were analyzed. NANC contractions in diabetic bladder strips are more resistant to the desensitizing effects caused by activation of cholinergic receptors. In early stages of experimental diabetes, NANC responses in diabetic strips are less sensitive to functional inhibition mediated by the cholinergic activation. However, P2X-mediated purinergic contractions are more sensitive to desensitization in diabetic or diuretic bladders. For instance preventing muscarinic receptor activation with atropine does not counteract the desensitization of purinergic contractions in either diabetic or diuretic strips. We suggest that diabetes may induce a plasticity of the NANC and P2X-mediated bladder contractile responses. The first one may be associated with diabetic neuropathic damage to bladder nerves, while impaired P2X purinergic contractions might be associated with detrusor hypertrophy observed in diabetic and diuretic strips. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Munoz, Alvaro; Smith, Christopher P.; Somogyi, George T.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Munoz, Alvaro; Boone, Timothy B.] Methodist Hosp, Res Inst, Dept Urol, Houston, TX 77030 USA.
[Boone, Timothy B.; Smith, Christopher P.] VA Med Ctr, Houston, TX 77030 USA.
RP Munoz, A (reprint author), Methodist Hosp, Res Inst, 6550 Fannin St SM8-036, Houston, TX 77030 USA.
EM amunoz@tmhs.org
FU National Institutes of Health [RO1-DK069988]
FX We would like to thank Dr. Zaneta Romain for helping during preliminary
experiments. This research was supported by the National Institutes of
Health (RO1-DK069988 to G.T.S.).
NR 31
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD JUN
PY 2013
VL 95
BP 40
EP 45
DI 10.1016/j.brainresbull.2013.03.006
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 235SP
UT WOS:000325741300007
PM 23562604
ER
PT J
AU Kozora, E
Arciniegas, DB
Duggan, E
West, S
Brown, MS
Filley, CM
AF Kozora, Elizabeth
Arciniegas, David B.
Duggan, Emily
West, Sterling
Brown, Mark S.
Filley, Christopher M.
TI White Matter Abnormalities and Working Memory Impairment in Systemic
Lupus Erythematosus
SO COGNITIVE AND BEHAVIORAL NEUROLOGY
LA English
DT Article
DE systemic lupus erythematosus (SLE); working memory; Paced Auditory
Serial Addition Test (PASAT); magnetic resonance spectroscopy (MRS);
white matter
ID SERIAL-ADDITION TASK; PROCESSING SPEED DEFICITS; MULTIPLE-SCLEROSIS;
MAGNETIC-RESONANCE; NEUROPSYCHOLOGICAL BATTERY; COGNITIVE DYSFUNCTION;
QUANTITATIVE MRI; PASAT; SPECTROSCOPY; FATIGUE
AB Objective/Background: Many patients with systemic lupus erythematosus (SLE) have working memory deficits. Few studies have evaluated working memory performance and neurometabolite profile using magnetic resonance spectroscopy in SLE.
Methods: We gave the Paced Auditory Serial Addition Test (PASAT), a measure of working memory, to 73 patients with SLE. We calculated total score, dyads, chunking, and cognitive fatigue. Using magnetic resonance spectroscopy, we determined the ratio of choline to creatine (Ch/Cr) in normal-looking right and left frontal lobe white matter.
Results: Twenty-nine percent of patients showed impaired working memory on the PASAT. Total PASAT score inversely correlated with right and left frontal white matter Ch/Cr. Left frontal white matter Ch/Cr correlated with percent chunking and inversely correlated with total and percent dyads. Right frontal white matter Ch/Cr correlated with percent chunking and inversely correlated with total and percent dyads. There was no relationship between cognitive fatigue and either left or right frontal white matter Ch/Cr. Longer disease duration was associated with higher left frontal white matter Ch/Cr. Correlations remained significant when we considered disease duration and left frontal white matter Ch/Cr against total PASAT score and total dyads.
Conclusions: Patients with SLE were impaired on the PASAT. Lower total PASAT score and fewer dyads correlated with higher left frontal microstructural white matter damage, while cognitive fatigue did not. This pattern suggests that early white matter damage interferes with working memory in SLE and provides further insight into the neurobiological jurbasis of mild cognitive dysfunction related to microstructural white matter injury.
C1 [Kozora, Elizabeth; Duggan, Emily] Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Kozora, Elizabeth; Arciniegas, David B.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA.
[Kozora, Elizabeth; Arciniegas, David B.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO USA.
[West, Sterling] Univ Colorado, Sch Med, Div Rheumatol, Denver, CO USA.
[Brown, Mark S.] Univ Colorado, Sch Med, Div Radiol, Denver, CO USA.
[Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Kozora, E (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.
EM kozorae@njhealth.org
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[RO1 AR049152]
FX Supported by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases RO1 AR049152.
NR 40
TC 3
Z9 3
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1543-3633
J9 COGN BEHAV NEUROL
JI Cogn. Behav. Neurol.
PD JUN
PY 2013
VL 26
IS 2
BP 63
EP 72
DI 10.1097/WNN.0b013e31829d5c74
PG 10
WC Behavioral Sciences; Clinical Neurology
SC Behavioral Sciences; Neurosciences & Neurology
GA 202LV
UT WOS:000323218900005
PM 23812169
ER
PT J
AU Hsiao, JJ
Kaiser, N
Fong, SS
Mendez, MF
AF Hsiao, Julia J.
Kaiser, Natalie
Fong, Sylvia S.
Mendez, Mario F.
TI Suicidal Behavior and Loss of the Future Self in Semantic Dementia
SO COGNITIVE AND BEHAVIORAL NEUROLOGY
LA English
DT Article
DE semantic dementia; memory; autobiographical memory; self; identity
ID AUTOBIOGRAPHICAL MEMORY; AUTONOETIC CONSCIOUSNESS; PERSONAL FAMILIARITY;
ALZHEIMERS-DISEASE; EPISODIC MEMORY; KNOWLEDGE; BATTERY; BRAIN;
IDENTITY; EVENTS
AB Semantic dementia impairs semantic autobiographical memory, but tends to spare its episodic components that are critical for the sense of self. Investigators have recently discovered disturbances in the "future self" in semantic dementia. We report a 63-year-old man with semantic dementia who was hospitalized after suicide attempts that he attributed to his loss of a sense of future self. He complained of a decreased sense of being human, because he could not imagine doing things in the future that he had done in the past. Suicidal thinking and inability to place himself in future tasks persisted despite resolution of depression. Clinical assessment revealed a crossmodal loss of semantic knowledge, and neuroimaging showed bilateral anterior temporal atrophy and hypometabolism. On specific tests of autobiographical memory, identity, attribute knowledge, and future projection, the patient could return to the past and visualize himself in familiar scenarios, but he could not visualize himself even passively in these scenarios in the future. His future self was impaired not from seeing himself disabled; it was from an absence of semantic details of potential experiences, associated with impaired semantic autobiographical memory. His self-representations were concrete and specific rather than abstract and generalizable. This patient and recent publications indicate that semantic dementia impairs the ability to imagine oneself as capable in the future, leading some patients to suicidal behavior. We discuss possible mechanisms for these findings, including the potential role of abstract construals for future thinking.
C1 [Hsiao, Julia J.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Hsiao, Julia J.; Kaiser, Natalie; Fong, Sylvia S.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Div Neurobehav, Los Angeles, CA USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Dept Neurobehav, Bldg 401, Los Angeles, CA 90073 USA.
EM mmendez@ucla.edu
FU US National Institute of Aging [R01AG034499-03]; National Institute on
Aging Alzheimer's Disease Research Center Grant [P50 AG-16570]
FX Supported by US National Institute of Aging #R01AG034499-03 (M.F.M.) and
National Institute on Aging Alzheimer's Disease Research Center Grant
P50 AG-16570 (M.F.M.).
NR 54
TC 4
Z9 4
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1543-3633
J9 COGN BEHAV NEUROL
JI Cogn. Behav. Neurol.
PD JUN
PY 2013
VL 26
IS 2
BP 85
EP 92
DI 10.1097/WNN.0b013e31829c671d
PG 8
WC Behavioral Sciences; Clinical Neurology
SC Behavioral Sciences; Neurosciences & Neurology
GA 202LV
UT WOS:000323218900008
PM 23812172
ER
PT J
AU Sebro, R
Mari-Aparici, C
Hernandez-Pampaloni, M
AF Sebro, Ronnie
Mari-Aparici, Carina
Hernandez-Pampaloni, Miguel
TI Value of true whole-body FDG-PET/CT scanning protocol in oncology:
optimization of its use based on primary diagnosis
SO ACTA RADIOLOGICA
LA English
DT Article
DE PET/CT; oncology; whole body; field of view; staging; restaging; limited
whole body; PET
ID F-18-FDG PET/CT; CLINICAL-VALUE; TOMOGRAPHY
AB Background: No standardized field of view (FOV) currently exists for whole-body (WB) positron emission tomography/computed tomography (PET/CT). Limited WB PET/CT FOV can exclude portions of the head, upper, and lower extremities, because there is little perceived clinical benefit to be gained from imaging these areas.
Purpose: To determine how often utilizing WB PET/CT changes the clinical stage and management compared to each of the limited WB FOVs used for PET/CT.
Material and Methods: We retrospectively identified 556 oncologic patients (804 PET/CT studies) who underwent staging or restaging PET/CT between November 2010 and November 2011. Abnormal hypermetabolic areas that were suspicious for malignancy in areas that are outside of some of the limited fields of view including in the brain, scalp, and calvarium (above the orbital ridge), in the proximal upper extremity (distal to the humeral neck), distal upper extremity (beyond the elbow), proximal lower extremity (distal to the lesser trochanter), and distal lower extremity (beyond the knees) were recorded.
Results: A total of 8.5% (47/556) of patients had abnormal findings outside the most limited FOV (skull base to upper thighs) used in PET/CT. More patients had abnormal hypermetabolic lesions in the lower extremity (5.9%) than in the upper extremity (2.3%). Similarly, more patients had abnormal lesions in the proximal (6.5%) compared to the distal (1.4%) upper and lower extremities. The stage was only changed in one patient (0.2%), however new lesions noted in the brain changed management in six patients (1.1%). Melanoma, lymphoma, multiple myeloma, sarcomas and stage IV lung, breast, prostate, bladder, testicular, and renal cancer were more likely to have findings outside the most limited FOV (skull base to upper thighs).
Conclusion: WB FOV detects additional sites of disease compared to the limited WB FOV, and although these lesions rarely change stage, some of these lesions may change clinical management.
C1 [Sebro, Ronnie; Mari-Aparici, Carina; Hernandez-Pampaloni, Miguel] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Sebro, Ronnie] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Mari-Aparici, Carina] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA.
RP Sebro, R (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
EM Ronnie.sebro@radiology.ucsf.edu
NR 17
TC 4
Z9 4
U1 0
U2 4
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0284-1851
J9 ACTA RADIOL
JI Acta Radiol.
PD JUN
PY 2013
VL 54
IS 5
BP 534
EP 539
DI 10.1177/0284185113476021
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 190EZ
UT WOS:000322323400013
PM 23463863
ER
PT J
AU Riccardi, D
Brennan, SC
Chang, W
AF Riccardi, Daniela
Brennan, Sarah C.
Chang, Wenhan
TI The extracellular calcium-sensing receptor, CaSR, in fetal development
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE calcium-sensing receptor; fetal hypercalcemia; skeletal development;
fetal lung development; growth plate cartilage; osteoblasts; RANK ligand
ID GROWTH-PLATE CHONDROCYTES; INTERSTITIAL LUNG-DISEASE; AIRWAY
SMOOTH-MUSCLE; BRANCHING MORPHOGENESIS; PARATHYROID-HORMONE;
HYPOCALCIURIC HYPERCALCEMIA; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION;
SKELETAL PHENOTYPE; BONE-DEVELOPMENT
AB In fetal mammals, serum levels of both total and ionized calcium significantly exceed those in the adult. This relative fetal hypercalcemia is crucial for skeletal development and is maintained irrespectively of maternal serum calcium levels. Elegant studies by Kovacs and Kronenberg have previously addressed the role of the CaSR in creating and maintaining this relative fetal hypercalcemia, through the regulation of parathyroid hormone-related peptide secretion. More recently we have shown that the CaSR is widely distributed throughout the developing fetus, where the receptor plays major, unexpected roles in ensuring growth and maturation of several organs. In this article, we present evidence for a role of the CaSR in the control of skeletal development, and how fetal hypercalcemia, acting through the CaSR, regulates lung development. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Riccardi, Daniela; Brennan, Sarah C.] Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.
[Chang, Wenhan] Univ Calif San Francisco, San Francisco VAMC, San Francisco, CA 94143 USA.
RP Riccardi, D (reprint author), Cardiff Univ, Sir Martin Evans Bldg,Museum Ave, Cardiff CF10 3AX, S Glam, Wales.
EM riccardi@cf.ac.uk; Wenhan.Chang@ucsf.edu
RI Brennan, Sarah/L-3011-2013; Riccardi, Daniela/A-4674-2010
OI Brennan, Sarah/0000-0002-8719-4367; Riccardi,
Daniela/0000-0002-7322-3163
FU Marie Curie Initial Training Network Multifaceted CaSR [FP7-264663]; UK
BBSRC [BB/D01591X]; US NIH [RO1-AG21353]; US Department Of Veterans
Affairs
FX This work was supported by the Marie Curie Initial Training Network
Multifaceted CaSR (FP7-264663 to DR), by the UK BBSRC (BB/D01591X to
DR), by US NIH Grant (RO1-AG21353 to WC) and by the US Department Of
Veterans Affairs Merit Review Grant and Program Project Award (to WC).
SCB is a Marie Curie Experienced Researcher.
NR 69
TC 14
Z9 15
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-690X
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD JUN
PY 2013
VL 27
IS 3
BP 443
EP 453
DI 10.1016/j.beem.2013.02.010
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 195DY
UT WOS:000322683700014
PM 23856271
ER
PT J
AU Shaz, BH
Shaz, DJ
AF Shaz, B. H.
Shaz, D. J.
TI Oxygen instead of Blood Not in too sick or too low
SO MINERVA ANESTESIOLOGICA
LA English
DT Editorial Material
ID HEALTHY-SUBJECTS; HYPEROXIA
C1 [Shaz, B. H.] New York Blood Ctr, New York, NY 10021 USA.
[Shaz, D. J.] James J Peters Vet Adm Med Ctr, Bronx, NY USA.
RP Shaz, BH (reprint author), New York Blood Ctr, 10 E 67th St, New York, NY 10021 USA.
EM bshaz@nybloodcenter.org
NR 10
TC 1
Z9 1
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0375-9393
J9 MINERVA ANESTESIOL
JI Minerva Anestesiol.
PD JUN
PY 2013
VL 79
IS 6
BP 585
EP 586
PG 2
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA 191PF
UT WOS:000322424400003
PM 23558767
ER
PT J
AU Larter, CZ
Yeh, MM
Haigh, WG
Van Rooyen, DM
Brooling, J
Heydet, D
Nolan, CJ
Teoh, NC
Farrell, GC
AF Larter, Claire Z.
Yeh, Matthew M.
Haigh, W. Geoffrey
Van Rooyen, Derrick M.
Brooling, John
Heydet, Deborah
Nolan, Christopher J.
Teoh, Narci C.
Farrell, Geoffrey C.
TI Dietary Modification Dampens Liver Inflammation and Fibrosis in
Obesity-Related Fatty Liver Disease
SO OBESITY
LA English
DT Article
ID HUMAN NONALCOHOLIC STEATOHEPATITIS; NF-KAPPA-B; DIABETIC MICE;
HEPATOCYTE APOPTOSIS; ALPHA AGONIST; PROGRESSION; STEATOSIS; ADIPOSE;
ROLES; ACIDS
AB Background: Alms1 mutant (foz/foz) mice develop hyperphagic obesity, diabetes, metabolic syndrome, and fatty liver (steatosis). High-fat (HF) feeding converts pathology from bland steatosis to nonalcoholic steatohepatitis (NASH) with fibrosis, which leads to cirrhosis in humans.
Objective: We sought to establish how dietary composition contributes to NASH pathogenesis.
Design and Methods: foz/foz mice were fed HF diet or chow 24 weeks, or switched HF to chow after 12 weeks. Serum ALT, NAFLD activity score (NAS), fibrosis severity, neutrophil, macrophage and apoptosis immunohistochemistry, uncoupling protein (UCP)2, ATP, NF-kappa B activation/expression of chemokines/adhesion molecules/fibrogenic pathways were determined.
Result: HF intake upregulated liver fatty acid and cholesterol transporter, CD36. Dietary switch expanded adipose tissue and decreased hepatomegaly by lowering triglyceride, cholesterol ester, free cholesterol and diacylglyceride content of liver. There was no change in lipogenesis or fatty acid oxidation pathways; instead, CD36 was suppressed. These diet-induced changes in hepatic lipids improved NAS, reduced neutrophil infiltration, normalized UCP2 and increased ATP; this facilitated apoptosis with a change in macrophage phenotype favoring M2 cells. Dietary switch also abrogated NF-kappa B activation and chemokine/adhesion molecule expression, and arrested fibrosis by dampening stellate cell activation.
Conclusion: Reversion to a physiological dietary composition after HF feeding in foz/foz mice alters body weight distribution but not obesity. This attenuates NASH severity and fibrotic progression by suppressing NF-kappa B activation and reducing neutrophil and macrophage activation. However, adipose inflammation persists and is associated with continuing apoptosis in the residual fatty liver disease. Taken together, these findings indicate that other measures, such as weight reduction, may be required to fully reverse obesity-related NASH.
C1 [Larter, Claire Z.; Van Rooyen, Derrick M.; Brooling, John; Heydet, Deborah; Teoh, Narci C.; Farrell, Geoffrey C.] Canberra Hosp, ANU Med Sch, Liver Res Grp, Garran, ACT, Australia.
[Yeh, Matthew M.] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA.
[Haigh, W. Geoffrey] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Haigh, W. Geoffrey] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
[Nolan, Christopher J.] Canberra Hosp, Dept Endocrinol, Garran, ACT, Australia.
RP Farrell, GC (reprint author), Canberra Hosp, ANU Med Sch, Liver Res Grp, Garran, ACT, Australia.
EM geoff.farrell@anu.edu.au
RI Nolan, Christopher/B-2026-2008
FU Australian National Health and Medical Research Council (NHMRC)
[418101]; NHMRC [525473, 585539]
FX This research was supported by Australian National Health and Medical
Research Council (NHMRC) project grant 418101, NHMRC Fellowship 525473
and NHMRC Scholarship 585539
NR 38
TC 9
Z9 9
U1 3
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUN
PY 2013
VL 21
IS 6
BP 1189
EP 1199
DI 10.1002/oby.20123
PG 11
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 192LV
UT WOS:000322487000019
PM 23666886
ER
PT J
AU Timms, AE
Dorschner, MO
Wechsler, J
Choi, KY
Kirkwood, R
Girirajan, S
Baker, C
Eichler, EE
Korvatska, O
Roche, KW
Horwitz, MS
Tsuang, DW
AF Timms, Andrew E.
Dorschner, Michael O.
Wechsler, Jeremy
Choi, Kyu Yeong
Kirkwood, Robert
Girirajan, Santhosh
Baker, Carl
Eichler, Evan E.
Korvatska, Olena
Roche, Katherine W.
Horwitz, Marshall S.
Tsuang, Debby W.
TI Support for the N-Methyl-D-Aspartate Receptor Hypofunction Hypothesis of
Schizophrenia From Exome Sequencing in Multiplex Families
SO JAMA PSYCHIATRY
LA English
DT Article
ID METABOTROPIC GLUTAMATE RECEPTORS; ASSOCIATION; GENETICS; PROTEIN; RISK;
SUSCEPTIBILITY; TRANSLOCATION; INDIVIDUALS; SYNAPSES; PATHWAYS
AB Importance: Schizophrenia is a complex genetic disorder demonstrating considerable heritability. Genetic studies have implicated many different genes and pathways, but much of the genetic liability remains unaccounted for. Investigation of genetic forms of schizophrenia will lead to a better understanding of the underlying molecular pathways, which will then enable targeted approaches for disease prevention and treatment.
Objective: To identify new genetic factors strongly predisposing to schizophrenia in families with multiple affected individuals with schizophrenia.
Design: We performed genome-wide array comparative genomic hybridization, linkage analysis, and exome sequencing in multiplex families with schizophrenia.
Setting: Probands and their family members were recruited from academic medical centers.
Participants: We intended to identify rare disease-causing mutations in 5 large families where schizophrenia transmission appears consistent with single-gene inheritance.
Intervention: Array comparative genomic hybridization was used to identify copy number variants, while exome sequencing was used to identify variants shared in all affected individuals and linkage analysis was used to further filter shared variants of interest. Analysis of select variants was performed in cultured cells to assess their functional consequences.
Main Outcome Measures: Rare inherited disease-related genetic mutations.
Results: No segregating rare copy number variants were detected by array comparative genomic hybridization. However, in all 5 families, exome sequencing detected rare protein-altering variants in 1 of 3 genes associated with the N-methyl-D-aspartate (NMDA) receptor. One pedigree shared a missense and frameshift substitution of GRM5, encoding the metabotropic glutamate receptor subtype 5 (mGluR5), which is coupled to the NMDA receptor and potentiates its signaling; the frameshift disrupts binding to the scaffolding protein tamalin and increases mGluR5 internalization. Another pedigree transmitted a missense substitution in PPEF2, encoding a calmodulin-binding protein phosphatase, which we show influences mGluR5 levels. Three pedigrees demonstrated different missense substitutions within LRP1B, encoding a low-density lipoprotein receptor-related protein tied to both the NMDA receptor and located in a chromosome 2q22 region previously strongly linked to schizophrenia.
Conclusions and Relevance: Exome sequencing of multiplex pedigrees uncovers new genes associated with risk for developing schizophrenia and suggests potential novel therapeutic targets.
C1 [Timms, Andrew E.; Wechsler, Jeremy; Kirkwood, Robert; Horwitz, Marshall S.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Dorschner, Michael O.; Tsuang, Debby W.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA.
[Girirajan, Santhosh; Baker, Carl; Eichler, Evan E.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
[Korvatska, Olena] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Dorschner, Michael O.; Tsuang, Debby W.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Choi, Kyu Yeong; Roche, Katherine W.] NINDS, NIH, Bethesda, MD 20892 USA.
[Girirajan, Santhosh] Penn State Univ, Dept Biochem & Mol Biol, State Coll, PA USA.
[Girirajan, Santhosh] Penn State Univ, Dept Anthropol, State Coll, PA USA.
RP Tsuang, DW (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dwt1@uw.edu
RI Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894; Roche, Katherine/0000-0001-7282-6539
FU National Institutes of Health, US Department of Veterans Affairs; Brain
and Behavior Research Foundation; Office of Research and Development
Medical Research Service, Department of Veterans Affairs; National
Alliance for Research on Schizophrenia and Depression; Consortium on the
Genetics of Schizophrenia [R01MH065558]; VA Merit Review; National
Institute of Health, National Institute of General Medical Sciences
[T32GM007454]
FX This work was supported by the National Institutes of Health, US
Department of Veterans Affairs, and the Brain and Behavior Research
Foundation. Additional material is based on work supported by the Office
of Research and Development Medical Research Service, Department of
Veterans Affairs. Specific funding was provided by a National Alliance
for Research on Schizophrenia and Depression Independent Investigator
Award (Dr Tsuang), Consortium on the Genetics of Schizophrenia grant
R01MH065558 (Dr Tsuang), VA Merit Review (Dr Tsuang), and National
Institute of Health, National Institute of General Medical Sciences
grant T32GM007454 (Dr Timms).
NR 48
TC 52
Z9 53
U1 1
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-622X
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD JUN
PY 2013
VL 70
IS 6
BP 582
EP 590
DI 10.1001/jamapsychiatry.2013.1195
PG 9
WC Psychiatry
SC Psychiatry
GA 188PK
UT WOS:000322204700007
PM 23553203
ER
PT J
AU Vielma, SA
Klein, RL
Levingston, CA
Young, MRI
AF Vielma, Silvana A.
Klein, Richard L.
Levingston, Corinne A.
Young, M. Rita I.
TI Adipocytes as immune regulatory cells
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Adipocytes; Cytokines; Immune regulation; Inflammation; T-cells
ID DIET-INDUCED OBESITY; CANCER-RISK; ADIPONECTIN RECEPTORS;
ADIPOSE-TISSUE; T-CELLS; CYTOKINES; EXPRESSION; LEPTIN; INFLAMMATION;
PROGRESSION
AB Obesity is a chronic inflammatory state and adipocytes are capable of contributing to this inflammation by their production of inflammatory mediators. The present study used fibroblast-derived adipocytes and normal spleen cells as a model to determine if adipocytes can also serve as immune regulatory cells by modulating the functions of conventional immune cells. Media conditioned by the adipocytes stimulated release of the Th1-type cytokines IL-2, IFN-gamma and GM-CSF from cultures of normal spleen cells. The adipocytes also stimulated spleen cell release of inhibitory cytokines, although to varying degrees. This included IL-10, IL-13 and, to a lesser extent, IL-4. Spleen cell production of the inflammatory cytokines IL-6, TNF-alpha and IL-9 was stimulated by adipocytes, although production of the Th17-derived cytokine, IL-17, was not stimulated. The adipocyte-conditioned medium did not stimulate production of predominantly monocytes-derived chemokines CXCL9, CCL2, CCL3, CCL4, but stimulated production of the predominantly T-cell-derived chemokine CCL5. In all cases where cytokine/chemokine production from spleen cells was stimulated by adipocytes, it was to a far greater level than was produced by the adipocytes themselves. Studies initiated to determine the identity of the adipocyte-derived mediators showed that the spleen cell modulation could not be attributed to solely adiponectin or leptin. Studies to determine the source of some of the cytokines whose production was stimulated by adipocytes showed that expression of the inflammatory cytokine IL-6 was not increased in either CD4(+) or CD8(+) T-cell. When the splenic T-cells were examined for IFN-gamma, the adipocyte stimulation of IFN-gamma was within CD8(+) T-cells, not CD4(+) T-cells. These studies show that adipocytes may be able to serve as immune regulatory cells to stimulate conventional immune cells to release a spectrum of immune mediators. Published by Elsevier B.V.
C1 [Vielma, Silvana A.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Vielma, Silvana A.] Univ Los Andes, Dept Clin Microbiol & Parasitol, Merida, Venezuela.
[Klein, Richard L.; Levingston, Corinne A.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Genet Med, Charleston, SC 29425 USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM vielmasa@musc.edu; kleinrl@musc.edu; cos25@musc.edu; Rita.Young@va.gov
FU Biomedical Laboratory and Clinical Sciences Programs of the Department
of Veterans Affairs; National Institute of Health (MRIY) [101-CX000100,
R01-CA128837, R01-DE018268]
FX This work has been supported by awards from the Biomedical Laboratory
and Clinical Sciences Programs of the Department of Veterans Affairs and
by grants from the National Institute of Health (MRIY, 101-CX000100,
R01-CA128837 and R01-DE018268).
NR 50
TC 8
Z9 8
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2013
VL 16
IS 2
BP 224
EP 231
DI 10.1016/j.intimp.2013.04.002
PG 8
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 170ZY
UT WOS:000320895400015
PM 23587489
ER
PT J
AU Whited, JD
Warshaw, EM
Kapur, K
Edison, KE
Thottapurathu, L
Raju, S
Cook, B
Engasser, H
Pullen, S
Moritz, TE
Datta, SK
Marty, L
Foman, NA
Suwattee, P
Ward, DS
Reda, DJ
AF Whited, John D.
Warshaw, Erin M.
Kapur, Kush
Edison, Karen E.
Thottapurathu, Lizy
Raju, Srihari
Cook, Bethany
Engasser, Holly
Pullen, Samantha
Moritz, Thomas E.
Datta, Santanu K.
Marty, Lucinda
Foman, Neal A.
Suwattee, Pitiporn
Ward, Dana S.
Reda, Domenic J.
TI Clinical course outcomes for store and forward teledermatology versus
conventional consultation: a randomized trial
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
ID MANAGEMENT; DIAGNOSIS; ACCURACY; RELIABILITY; SYSTEM; IMPACT
AB We assessed the clinical course of patients after store and forward teledermatology in comparison with conventional consultations. Patients being referred from primary care to dermatology clinics were randomly assigned to teledermatology or a conventional consultation. A total of 392 patients were randomized; 261 patients completed the study and were included in the analysis. Their clinical course was rated on a five-point scale by a panel of three dermatologists, blinded to study assignment, who reviewed serial digital image sets. The clinical course was assessed by comparing images sets between baseline and first clinic visit (if one occurred) and between baseline and nine months. There was no evidence to suggest a difference between the two groups in either clinical course between baseline and nine months post-referral (P = 0.88) or between baseline and the first dermatology clinic visit (P = 0.65). Among teledermatology referrals, subsequent presentation for an in-person dermatology clinic visit was significantly correlated with clinical course (P = 0.023). Store and forward teledermatology did not result in a significant difference in clinical course at either of two post-referral time periods.
C1 [Whited, John D.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA.
[Warshaw, Erin M.; Raju, Srihari; Cook, Bethany; Engasser, Holly; Pullen, Samantha; Foman, Neal A.; Suwattee, Pitiporn] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA.
[Warshaw, Erin M.; Foman, Neal A.; Suwattee, Pitiporn] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA.
[Edison, Karen E.; Ward, Dana S.] Univ Missouri, Dept Dermatol, Columbia, MO 65211 USA.
[Kapur, Kush; Thottapurathu, Lizy; Moritz, Thomas E.; Reda, Domenic J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA.
[Datta, Santanu K.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham Vet Affairs Med Ctr, Durham, NC 27710 USA.
[Marty, Lucinda] St Cloud Vet Affairs Healthcare Syst, St Cloud, MN USA.
RP Whited, JD (reprint author), Durham Vet Affairs Med Ctr, Res & Dev 151,508 Fulton St, Durham, NC 27705 USA.
EM john.whited@va.gov
FU Department of Veterans Affairs Health Services Research and Development
Service [HSRD IIR 05-278]
FX We thank Susan K Ailor, Jon A Dyer and Susan Zurowski for image review.
The study was supported by funding from the Department of Veterans
Affairs Health Services Research and Development Service (HSR&D IIR
05-278). The views expressed in this article are those of the authors
and do not necessarily reflect the position or policy of the US
Department of Veterans Affairs.
NR 16
TC 15
Z9 15
U1 2
U2 6
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1357-633X
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD JUN
PY 2013
VL 19
IS 4
BP 197
EP 204
DI 10.1177/1357633X13487116
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 185EZ
UT WOS:000321949700004
PM 23666440
ER
PT J
AU Spiegel, B
AF Spiegel, Brennan
TI Diagnostic Testing in Extraesophageal GERD: Another Case of "Furor
Medicus" ?
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID IRRITABLE-BOWEL-SYNDROME; SURGERY; IBS
AB Proton pump inhibitors (PPIs) work for most patients with gastroesophageal reflux disease (GERD). But when PPIs fail to work, or when there are atypical extra-esophageal symptoms, diagnostic and management decisions become much more difficult. Although atypical GERD is common, there are limited data about how best to approach these patients. The temptation is often to perform extensive diagnostic testing, sometimes to little avail. In this issue of The Journal, Francis et al. present a new study to help close the research gap in understanding the costs and benefi ts of testing in atypical GERD. The authors conclude that diagnostic testing is very expensive and real-life benefits are modest. This editorial reviews the findings, places them into clinical perspective, and concludes that diagnostic testing in atypical GERD may be another example of "furor medicus" - an old but descriptive term referring to the instinct of doctors to implore "don't just stand there, do something!" The data from Francis et al. suggest we might do the opposite in atypical GERD: "Don't just do something, stand there."
C1 [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Spiegel, B (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ulca.edu
NR 9
TC 2
Z9 2
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUN
PY 2013
VL 108
IS 6
BP 912
EP 914
DI 10.1038/ajg.2013.80
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 176KY
UT WOS:000321304400006
PM 23735914
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI PDR or ADR as a Quality Indicator for Colonoscopy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID COLORECTAL-CANCER; COLON; RATES; RISK
AB Interval (missed) cancers and lower-than-expected mortality reduction of proximal colon cancers after screening colonoscopy drew attention to quality indicators. Small proximal polyps (prone to be advanced neoplasms) missed by colonoscopy are possible contributing factors. In this issue of AJG, the subject of polyp detection rates (PDRs) and adenoma detection rates (ADRs) in the proximal and distal colon is discussed by one group of investigators to address the issue of monitoring performance and to achieve improvement. The authors observed that these two parameters correlated well in segments proximal to the splenic flexure, but not in the left colon. They suggested that caution should be exercised when using PDR as a surrogate for ADR if data from the rectum and sigmoid were included. Avoidance of missed lesions at the time of colonoscopy may require new adjunct measures to enhance ADR. The impact of new adjunct measures on ADR is mixed. In contrast to water immersion, water exchange during insertion has consistently increased ADR during withdrawal inspection. Water exchange may be a suitable alternative platform to replace insertion by air insufflation in the evaluation of new adjunct measures of quality improvement to increase ADR. Payment reforms may be necessary to bring about inclusion of ADR reporting for monitoring of quality performance.
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, North Hills, CA 91343 USA.
EM felix.leung@va.gov
NR 20
TC 6
Z9 6
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUN
PY 2013
VL 108
IS 6
BP 1000
EP 1002
DI 10.1038/ajg.2013.99
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 176KY
UT WOS:000321304400020
PM 23735919
ER
PT J
AU Katon, JG
Reiber, GE
Nelson, KM
AF Katon, Jodie G.
Reiber, Gayle E.
Nelson, Karin M.
TI Peripheral Neuropathy Defined by Monofilament Insensitivity and Diabetes
Status NHANES 1999-2004
SO DIABETES CARE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; SENSORY NEUROPATHY; PREVALENCE;
POLYNEUROPATHY; POPULATION; MELLITUS; FOOT
AB OBJECTIVE-To determine whether diabetes status, including prediabetes, is associated with increased risk of peripheral neuropathy as defined by monofilament insensitivity.
RESEARCH DESIGN AND METHODS-This study used data from the 1999-2004 National Health and Nutrition Examination Survey (n = 7,818). Peripheral neuropathy was defined as one or more insensate sites detected by a Semmes-Weinstein 10-g monofilament. Generalized linear models were used to directly estimate relative risks (RRs) for the association of diabetes status and peripheral neuropathy.
RESULTS-After adjustment compared with no diabetes, prediabetes [RR 1.11(95% CI 0.92-1.34)] and undiagnosed diabetes [1.08 (0.73-1.61)] were associated with modest increases in risk of peripheral neuropathy, and diabetes was associated with a 74% higher risk of peripheral neuropathy [1.74 (1.50-2.01)].
CONCLUSIONS-Diabetes is associated with increased risk of peripheral neuropathy defined by monofilament insensitivity, but prediabetes and undiagnosed diabetes may be associated with only a modest increase in risk.
C1 [Katon, Jodie G.; Reiber, Gayle E.; Nelson, Karin M.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Katon, Jodie G.; Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA.
[Nelson, Karin M.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
RP Katon, JG (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
EM jkaton@uw.edu
FU Office of Research and Development; Health Services Research and
Development; U.S. Department of Veterans Affairs [TPP 61-026, RCS
98-353]
FX This material is based on work supported by the Office of Research and
Development, Health Services Research and Development, U.S. Department
of Veterans Affairs, including a postdoctoral fellowship to J.G.K. (TPP
61-026) and a Senior Career Scientist Award to G.E.R. (grant RCS
98-353).
NR 18
TC 7
Z9 7
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2013
VL 36
IS 6
BP 1604
EP 1606
DI 10.2337/dc12-1102
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 178UJ
UT WOS:000321472600026
PM 23275365
ER
PT J
AU Fukuta, Y
Doi, Y
Muder, RR
Agha, ME
Hensler, AM
Wagener, MM
Clarke, LG
AF Fukuta, Y.
Doi, Y.
Muder, R. R.
Agha, M. E.
Hensler, A. M.
Wagener, M. M.
Clarke, L. G.
TI Risk factors for acquisition of multi-drug resistant Acinetobacter
baumannii among cancer patients
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Meeting Abstract
CT 28th International Congress of Chemotherapy and Infection Incorporating
/ 14th Asia-Pacific Congress of Clinical Microbiology and Infection
CY JUN 05-08, 2013
CL Yokohama, JAPAN
SP Int Soc Chemotherapy
C1 [Fukuta, Y.; Doi, Y.; Clarke, L. G.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Muder, R. R.] VA Pittsburgh Healthcare Syst, Infect Control, Pittsburgh, PA USA.
[Agha, M. E.] Univ Pittsburgh, Med Ctr, Hilman Canc Ctr, Pittsburgh, PA USA.
[Hensler, A. M.] Univ Pittsburgh, Med Ctr Shadyside, Pittsburgh, PA USA.
[Wagener, M. M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
EM nana-yuri@hotmail.co.jp
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUN
PY 2013
VL 42
SU 2
BP S140
EP S141
PG 2
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 178KS
UT WOS:000321447400436
ER
PT J
AU Pearson, DA
Santos, CW
Aman, MG
Arnold, LE
Casat, CD
Mansour, R
Lane, DM
Loveland, KA
Bukstein, OG
Jerger, SW
Factor, P
Vanwoerden, S
Perez, E
Cleveland, LA
AF Pearson, Deborah A.
Santos, Cynthia W.
Aman, Michael G.
Arnold, L. Eugene
Casat, Charles D.
Mansour, Rosleen
Lane, David M.
Loveland, Katherine A.
Bukstein, Oscar G.
Jerger, Susan W.
Factor, Perry
Vanwoerden, Salome
Perez, Evelyn
Cleveland, Lynne A.
TI Effects of Extended Release Methylphenidate Treatment on Ratings of
Attention-Deficit/Hyperactivity Disorder (ADHD) and Associated Behavior
in Children with Autism Spectrum Disorders and ADHD Symptoms
SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
LA English
DT Article
ID PERVASIVE DEVELOPMENTAL DISORDERS; DEFICIT HYPERACTIVITY DISORDER; EARLY
INFANTILE-AUTISM; STIMULANT MEDICATION; MENTAL-RETARDATION;
PSYCHIATRIC-DISORDERS; FOLLOW-UP; TRIAL; PHARMACOTHERAPY; PREVALENCE
AB Objective: The purpose of this study was to examine the behavioral effects of four doses of psychostimulant medication, combining extended-release methylphenidate (MPH) in the morning with immediate-release MPH in the afternoon.
Method: The sample comprised 24 children (19 boys; 5 girls) who met American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient [IQ] = 85; SD = 16.8). Effects of four dose levels of MPH on parent and teacher behavioral ratings were investigated using a within-subject, crossover, placebo-controlled design.
Results: MPH treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school. Parents noted significant declines in inattentive and oppositional behavior, and improvements in social skills. No exacerbation of stereotypies was noted, and side effects were similar to those seen in typically developing children with ADHD. Dose response was primarily linear in the dose range studied.
Conclusions: The results of this study suggest that MPH formulations are efficacious and well-tolerated for children with ASD and significant ADHD symptoms.
C1 [Pearson, Deborah A.; Santos, Cynthia W.; Mansour, Rosleen; Loveland, Katherine A.; Bukstein, Oscar G.; Factor, Perry; Vanwoerden, Salome; Perez, Evelyn; Cleveland, Lynne A.] Univ Texas Houston, Sch Med, Houston, TX 77054 USA.
[Aman, Michael G.; Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA.
[Casat, Charles D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Lane, David M.] Rice Univ, Dept Psychol, Houston, TX 77251 USA.
[Jerger, Susan W.] Univ Texas Dallas, Sch Behav & Brain Sci, Dallas, TX 75230 USA.
RP Pearson, DA (reprint author), Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, 1941 East Rd, Houston, TX 77054 USA.
EM Deborah.A.Pearson@uth.tmc.edu
FU National Institute of Mental Health (NIMH) [MH072263]
FX This study was funded by grant number MH072263 from the National
Institute of Mental Health (NIMH).
NR 73
TC 10
Z9 12
U1 1
U2 32
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5463
J9 J CHILD ADOL PSYCHOP
JI J. Child Adolesc. Psychopharmacol.
PD JUN
PY 2013
VL 23
IS 5
BP 337
EP 351
DI 10.1089/cap.2012.0096
PG 15
WC Pediatrics; Pharmacology & Pharmacy; Psychiatry
SC Pediatrics; Pharmacology & Pharmacy; Psychiatry
GA 168LJ
UT WOS:000320707000006
PM 23782128
ER
PT J
AU Hartwell, KJ
Prisciandaro, JJ
Borckardt, J
Li, XB
George, MS
Brady, KT
AF Hartwell, Karen J.
Prisciandaro, James J.
Borckardt, Jeffery
Li, Xingbao
George, Mark S.
Brady, Kathleen T.
TI Real-Time fMRI in the Treatment of Nicotine Dependence: A Conceptual
Review and Pilot Studies
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE real-time fMRI; real-time fMRI feedback; neurofeedback; nicotine
dependence
ID CORTEX ACTIVITY; FUNCTIONAL MRI; ACTIVATION; SMOKERS; NEUROFEEDBACK;
BIOFEEDBACK; MODULATION; INTERFACE; RELAPSE
AB Technical advances allowing for the analysis of functional MRI (fMRI) results in real time have led to studies exploring the ability of individuals to use neural feedback signals to modify behavior and regional brain activation. The use of real-time fMRI (rtfMRI) feedback has been explored for therapeutic benefit in a number of disease states, but to our knowledge, the potential therapeutic benefit of rtfMRI feedback in the treatment of addictive disorders has not been explored. This article will provide an overview of the development of rtfMRI and discussion of its potential uses in the treatment of addictions. We also describe a series of pilot studies that highlight some of the technical challenges in developing a rtfMRI feedback paradigm for use in addictions, specifically in nicotine dependence. Because the use of rtfMRI feedback is in its infancy, the work described is focused on establishing some of the basic parameters in optimizing the rtfMRI feedback, such as the type of feedback signal, region of interest for feedback and predicting which subjects are most likely to respond well to training. While rtfMRI feedback remains an intriguing possibility for the treatment of addictions, much work remains to be done in establishing its efficacy.
C1 [Hartwell, Karen J.; Prisciandaro, James J.; Borckardt, Jeffery; Li, Xingbao; George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Hartwell, Karen J.; George, Mark S.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA.
RP Hartwell, KJ (reprint author), Med Univ S Carolina, 67 President St,MSC 861, Charleston, SC 29425 USA.
EM hartwelk@musc.edu
FU NIDA NIH HHS [R33 DA026085, R33 DA026085-04, R33 DA036085-03]
NR 45
TC 12
Z9 12
U1 2
U2 14
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD JUN
PY 2013
VL 27
IS 2
SI SI
BP 501
EP 509
DI 10.1037/a0028215
PG 9
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA 170HS
UT WOS:000320841600017
PM 22564200
ER
PT J
AU Patel, MS
Arron, MJ
Sinsky, TA
Green, EH
Baker, DW
Bowen, JL
Day, S
AF Patel, Mitesh S.
Arron, Martin J.
Sinsky, Thomas A.
Green, Eric H.
Baker, David W.
Bowen, Judith L.
Day, Susan
TI Estimating the Staffing Infrastructure for a Patient-Centered Medical
Home
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; HEALTH-CARE; GLYCEMIC
CONTROL; COST SAVINGS; INNOVATION; SERVICES; QUALITY; MODEL; MANAGEMENT
AB Background:The patient-centered medical home (PCMH) offers an innovative method of delivering primary care. However, the necessary staffing infrastructure is not well established.
Objectives: To evaluate the roles of personnel within a PCMH and to propose necessary staffing ratios and associated incremental costs to implement this model of care.
Methods: We sampled primary care clinical practices that either have successfully deployed or were in the process of implementing a PCMH practice model. We conducted targeted interviews of administrators from these practices and reviewed published literature on the personnel roles within a PCMH. Collectively, these data were compared with current staffing standards and used to inform an analytical model and sensitivity analysis.
Results: Primary care practices that successfully transitioned to a PCMH have incorporated a range of new staff and functionalities. Based on our model, we estimated that 4.25 full-time equivalents (FTEs) should be allocated to staffing personnel per 1 physician FTE. Compared with the base-case model of current staffing in the United States of 2.68 FTEs per physician FTE, this is a 59% increase. After applying sensitivity analysis for variability in staffing and compensation, the incremental staffing FTE per physician FTE was 1.57 (range 1.41-1.73) and the incremental associated cost per member per month was $4.68 (range $3.79-$6.43).
Conclusions: Our study suggests that additional staff with specific expertise and training is necessary to implement a PCMH. Further study and opportunities for funding additional staffing costs will be important for realizing the potential of the PCMH model of care.
C1 [Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Patel, Mitesh S.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Day, Susan] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Arron, Martin J.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
[Sinsky, Thomas A.] Med Associates, Dubuque, IA USA.
[Green, Eric H.] Mercy Catholic Med Ctr, Darby, PA USA.
[Baker, David W.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
[Bowen, Judith L.] Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA.
RP Patel, MS (reprint author), Univ Penn, 423 Guardian Dr,13th Fl, Philadelphia, PA 19104 USA.
EM mpatel@mail.med.upenn.edu
NR 47
TC 19
Z9 19
U1 2
U2 10
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JUN
PY 2013
VL 19
IS 6
BP 509
EP 516
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 171FO
UT WOS:000320910700005
PM 23844711
ER
PT J
AU Thiagarajan, P
Afshar-Kharghan, V
AF Thiagarajan, Perumal
Afshar-Kharghan, Vahid
TI Platelet Transfusion Therapy
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Platelet transfusion; Alloimmunization; Transfusion triggers; Pathogen
reduction
ID THROMBOTIC THROMBOCYTOPENIC PURPURA; MEMBRANE PHOSPHOLIPID ASYMMETRY;
PATHOGEN INACTIVATION; STORED PLATELETS; CROSS-MATCH; PHOSPHATIDYLSERINE
EXPOSURE; APHERESIS PLATELETS; BLEEDING DIATHESIS; BLOOD-PLATELETS;
ACUTE-LEUKEMIA
AB Platelet transfusion therapy has become an integral part of the treatment of patients with hematological and solid tumor malignancy receiving chemotherapy. Since its introduction almost 60 years ago, several advances and refinements have been introduced in the collection, storage, and administration to improve the safety and efficacy of platelet transfusion. This review summarizes the current practice and clinical approach to patients with thrombocytopenia. Existing evidence-based guidelines for appropriate platelet transfusion is reviewed.
C1 [Thiagarajan, Perumal] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA.
[Thiagarajan, Perumal] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
[Afshar-Kharghan, Vahid] MD Anderson Canc Ctr, Sect Benign Hematol, Houston, TX 77030 USA.
RP Thiagarajan, P (reprint author), Michael E DeBakey VA Med Ctr, Mail Stop 113,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM perumalt@bcm.edu
OI Thiagarajan, Perumal/0000-0003-2186-7036
FU Veterans Affairs Research Service
FX Supported by a grant from the Veterans Affairs Research Service (P.
Thiagarajan).
NR 103
TC 12
Z9 12
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2013
VL 27
IS 3
BP 629
EP +
DI 10.1016/j.hoc.2013.03.004
PG 16
WC Oncology; Hematology
SC Oncology; Hematology
GA 168XJ
UT WOS:000320740900012
PM 23714315
ER
PT J
AU Reuben, DB
Ganz, DA
Roth, CP
McCreath, HE
Ramirez, KD
Wenger, NS
AF Reuben, David B.
Ganz, David A.
Roth, Carol P.
McCreath, Heather E.
Ramirez, Karina D.
Wenger, Neil S.
TI Effect of Nurse Practitioner Comanagement on the Care of Geriatric
Conditions
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE quality improvement; practice redesign; ACOVE; geriatric conditions
ID RANDOMIZED-CONTROLLED-TRIAL; GUIDED CARE; COLLABORATIVE CARE;
HEALTH-CARE; OLDER-PATIENTS; QUALITY; MANAGEMENT; INTERVENTION; ADULTS;
DEPRESSION
AB Objectives To determine whether community-based primary care physician (PCP)-nurse practitioner (NP) comanagement implementing the Assessing Care of Vulnerable Elders (ACOVE)-2 model: (case finding, delegation of data collection, structured visit notes, physician and patient education, and linkage to community resources) can improve the quality of care for geriatric conditions. Design Case study. Setting Two community-based primary care practices. Participants Patients aged 75 and older who screened positive for at least one condition: falls, urinary incontinence (UI), dementia, and depression. Intervention The ACOVE-2 model augmented by NP comanagement of conditions. Measurements Quality of care according to medical record review using ACOVE-3 quality indicators (QIs). Individuals receiving comanagement were compared with those who received PCP care alone in the same practices. Results Of 1,084 screened individuals, 658 (61%) screened positive for more than one condition; 485 of these were randomly selected for chart review and triggered a mean of seven QIs. A NP saw 49% for comanagement. Overall, individuals received 57% of recommended care. Quality scores for all conditions (falls, 80% vs 34%; UI, 66% vs 19%; dementia, 59% vs 38%) except depression (63% vs 60%) were higher for individuals who saw a NP. In analyses adjusted for sex and age of patient, number of conditions, site, and a NP estimate of medical management style, NP comanagement remained significantly associated with receiving recommended care (P<.001), as did NP estimate of medical management style (P=.02). Conclusion NP comanagement is associated with better quality of care for geriatric conditions in community-based primary care than usual care using the ACOVE-2 model.
C1 [Reuben, David B.; Ganz, David A.; McCreath, Heather E.; Ramirez, Karina D.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA.
[Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Los Angeles, CA USA.
[Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Ganz, David A.; Roth, Carol P.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA.
[Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
RP Reuben, DB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM dreuben@mednet.ucla.edu
FU UniHealth Foundation; U.S. Department of Veterans Affairs, Veterans
Health Administration, Veterans Affairs Health Services Research &
Development Service (HSR&D) through the Veterans Affairs Greater Los
Angeles HSR&D Center of Excellence [VA CD2 08-012-1]; National Institute
on Aging [5P30AG028748]
FX This project was supported by a grant from the UniHealth Foundation to
DBR. DAG was supported by a Career Development Award from the U.S.
Department of Veterans Affairs, Veterans Health Administration, Veterans
Affairs Health Services Research & Development Service (HSR&D) through
the Veterans Affairs Greater Los Angeles HSR&D Center of Excellence
(Project VA CD2 08-012-1). Data collection and analysis was supported in
part by the University of California at Los Angeles Claude Pepper Older
Americans Independence Center funded by the National Institute on Aging
(5P30AG028748).
NR 23
TC 10
Z9 10
U1 7
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2013
VL 61
IS 6
BP 857
EP 867
DI 10.1111/jgs.12268
PG 11
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 164KD
UT WOS:000320407100001
PM 23772723
ER
PT J
AU Matsumoto, AM
AF Matsumoto, Alvin M.
TI Testosterone Administration in Older Men
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Hypogonadism; Aging; Diagnosis; Testosterone; Treatment
ID CLINICAL-PRACTICE GUIDELINE; SEX-HORMONE LEVELS; SERUM TESTOSTERONE;
ANDROGEN DEFICIENCY; ELDERLY-MEN; HYPOGONADAL MEN; HEALTHY-YOUNG; ADULT
MEN; PROSTATE; THERAPY
AB The only indication for testosterone administration in older men is testosterone replacement therapy for male hypogonadism. Compared with young hypogonadal men, the diagnosis and management of male hypogonadism in older men is more challenging. Both the clinical manifestations of androgen deficiency and low testosterone levels may be caused or modified by comorbid illnesses that occur and medications taken more frequently by older men, resulting in a greater likelihood for overdiagnosis of hypogonadism and subsequent inappropriate use of and inadequate response to testosterone treatment. It is important to use a systematic, holistic approach to the diagnosis and management of older men with hypogonadism.
C1 [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Clin Res Unit, Seattle, WA 98108 USA.
[Matsumoto, Alvin M.] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Matsumoto, AM (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 South Columbian Way S-182-GRECC, Seattle, WA 98108 USA.
EM alvin.matsumoto@va.gov
NR 32
TC 7
Z9 8
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD JUN
PY 2013
VL 42
IS 2
BP 271
EP +
DI 10.1016/j.ecl.2013.02.011
PG 17
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 168XK
UT WOS:000320741000007
PM 23702401
ER
PT J
AU Gill, SN
Duron, RM
Medina, MT
Martinez-Juarez, I
Alonso, MA
Ochoa, A
Jara-Prado, A
Machado-Salas, J
Tanaka, M
Bailey, JN
Delgado-Escueta, A
AF Gill, S. N.
Duron, R. M.
Medina, M. T.
Martinez-Juarez, I
Alonso, M. A.
Ochoa, A.
Jara-Prado, A.
Machado-Salas, J.
Tanaka, M.
Bailey, J. N.
Delgado-Escueta, A.
TI FOCAL SPIKES IN ASYMPTOMATIC MEMBERS OF JUVENILE MYOCLONIC EPILEPSY
FAMILIES WITH MUTATED EPILEPSY GENES
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 30th International Epilepsy Congress
CY JUN 23-27, 2013
CL Montreal, CANADA
SP Int Bur Epilepsy (IBE), Int League Against Epilepsy (ILAE)
C1 [Gill, S. N.; Tanaka, M.; Delgado-Escueta, A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gill, S. N.; Duron, R. M.; Tanaka, M.; Bailey, J. N.; Delgado-Escueta, A.] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Epilepsy Genet Genom Lab, Los Angeles, CA USA.
[Gill, S. N.; Duron, R. M.; Tanaka, M.; Bailey, J. N.; Delgado-Escueta, A.] VA Greater Los Angeles Healthcare Syst, Res Serv, Epilepsy Genet Genom Lab, Los Angeles, CA USA.
[Gill, S. N.; Duron, R. M.; Medina, M. T.; Martinez-Juarez, I; Alonso, M. A.; Ochoa, A.; Jara-Prado, A.; Machado-Salas, J.; Tanaka, M.; Bailey, J. N.; Delgado-Escueta, A.] Int GENESS Consortium, Los Angeles, CA USA.
[Duron, R. M.] Lucas Med Ctr, Dept Neurol, Tegucigalpa, Honduras.
[Duron, R. M.; Medina, M. T.] Natl Autonomous Univ, Dept Neurol, Tegucigalpa, Honduras.
[Martinez-Juarez, I; Alonso, M. A.; Ochoa, A.; Jara-Prado, A.] Natl Inst Neurol & Neurosurg, Dept Neurol, Mexico City, DF, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2013
VL 54
SU 3
SI SI
BP 194
EP 194
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 165GS
UT WOS:000320472000616
ER
PT J
AU Ioannou, GN
Bryson, CL
Weiss, NS
Scott, JD
Boyko, EJ
AF Ioannou, George N.
Bryson, Christopher L.
Weiss, Noel S.
Scott, John D.
Boyko, Edward J.
TI The prevalence of cirrhosis and hepatocellular carcinoma in patients
with human immunodeficiency virus infection: Are the data found in this
sample applicable to other settings? Reply
SO HEPATOLOGY
LA English
DT Letter
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA.
[Bryson, Christopher L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Div Internal Med, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
[Weiss, Noel S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Scott, John D.] Univ Washington, Div Infect Dis, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUN
PY 2013
VL 57
IS 6
BP 2545
EP 2545
DI 10.1002/hep.26171
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 162PC
UT WOS:000320276400053
PM 23197437
ER
PT J
AU Dombroski, BA
Galasko, DR
Mata, IF
Zabetian, CP
Craig, UK
Garruto, RM
Oyanagi, K
Schellenberg, GD
AF Dombroski, Beth A.
Galasko, Douglas R.
Mata, Ignacio F.
Zabetian, Cyrus P.
Craig, Ulla-Katrina
Garruto, Ralph M.
Oyanagi, Kiyomitsu
Schellenberg, Gerard D.
TI C9orf72 Hexanucleotide Repeat Expansion and Guam Amyotrophic Lateral
Sclerosis-Parkinsonism-Dementia Complex
SO JAMA NEUROLOGY
LA English
DT Article
ID KII PENINSULA; JAPAN; DISEASE; RISK; TAU; MUTATIONS; REGION; GENE; FTD;
ALS
AB Importance: High-prevalence foci of amyotrophic lateral sclerosis (ALS) and parkinsonism-dementia complex (PDC) exist in Japanese on the Kii Peninsula of Japan and in the Chamorros of Guam. Clinical and neuropathologic similarities suggest that the disease in these 2 populations may be related. Recent findings showed that some of the Kii Peninsula ALS cases had pathogenic C9orf72 repeat expansions, a genotype that causes ALS in Western populations.
Objectives: To perform genotyping among Guam residents to determine if the C9orf72 expanded repeat allele contributes to ALS-PDC in this population and to evaluate LRRK2 for mutations in the same population.
Design and Setting: Case-control series from neurodegenerative disease research programs on Guam that screened residents for ALS, PDC, and dementia.
Participants: Study participants included 24 with ALS and 22 with PDC and 43 older control subjects with normal cognition ascertained between 1956 and 2006. All but one participant were Chamorro, the indigenous people of Guam. A single individual of white race/ethnicity with ALS was ascertained on Guam during the study.
Main Outcomes and Measures: Participants were screened for C9orf72 hexanucleotide repeat length. Participants with repeat numbers in great excess of 30 were considered to have pathogenic repeat expansions. LRRK2 was screened for point mutations by DNA sequencing.
Results: We found a single individual with an expanded pathogenic hexanucleotide repeat. This individual of white race/ethnicity with ALS was living on Guam at the time of ascertainment but had been born in the United States. All Chamorro participants with ALS and PDC and control subjects had normal repeats, ranging from 2 to 17 copies. No pathogenic LRRK2 mutations were found.
Conclusions and Relevance: Unlike participants with ALS from the Kii Peninsula, C9orf72 expansions do not cause ALS-PDC in Chamorros. Likewise, LRRK2 mutations do not cause Guam ALS-PDC.
C1 [Dombroski, Beth A.; Schellenberg, Gerard D.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Garruto, Ralph M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Grad Program Biomed Anthropol, Binghamton, NY USA.
[Oyanagi, Kiyomitsu] Tokyo Metropolitan Inst Neurosci, Dept Neuropathol, Tokyo, Japan.
RP Schellenberg, GD (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Room 609B,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM gerardsc@mail.med.upenn.edu
OI Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian,
Cyrus/0000-0002-7739-4306
FU National Institute on Aging [AG14382, P01-AG-017586, R37 AG11762];
National Institute of Neurological Disorders and Stroke [R01 NS065070]
FX This work was supported by grants AG14382, P01-AG-017586, and R37
AG11762 from the National Institute on Aging and by grant R01 NS065070
from the National Institute of Neurological Disorders and Stroke.
NR 20
TC 10
Z9 11
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUN
PY 2013
VL 70
IS 6
BP 742
EP 745
DI 10.1001/jamaneurol.2013.1817
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 160PV
UT WOS:000320132600010
PM 23588498
ER
PT J
AU Jaussaud, N
Chitsaz, S
Meadows, A
Wintermark, M
Cambronero, N
Azadani, AN
Saloner, DA
Chuter, TA
Tseng, EE
AF Jaussaud, N.
Chitsaz, S.
Meadows, A.
Wintermark, M.
Cambronero, N.
Azadani, A. N.
Saloner, D. A.
Chuter, T. A.
Tseng, E. E.
TI Acute type A aortic dissection intimal tears by 64-slice computed
tomography: a role for endovascular stent-grafting?
SO JOURNAL OF CARDIOVASCULAR SURGERY
LA English
DT Article
DE Aorta; Tomography, spiral computed; Lacerations
ID INTERNATIONAL REGISTRY; SURGICAL-TREATMENT; THORACIC AORTA; MANAGEMENT;
REPAIR; ANEURYSM; OUTCOMES; DISEASE; CT; PLACEMENT
AB Aim. The goal of this study was to identify physical characteristics of primary intimal tears in patients arriving to the hospital alive with acute type A aortic dissection using 64-multislice computerized tomography (MSCT) in order to determine anatomic feasibility of endovascular stent-grafting (ESG) for future treatment.
Methods. Radiology database was screened for acute type A aortic dissection since the time of acquisition of the 64-slice CT scanner and cross-referenced with surgical database. Seventeen patients met inclusion criteria. Images were reviewed for number, location, and size of intimal tears and aortic dimensions. Potential obstacles for ESG were determined.
Results. Ascending aorta (29%) and sinotubular junction (29%) were the most frequent regions where intimal tears originated. Location of intimal tears in nearly 75% of patients was inappropriate for ESG, and 94% of patients did not have sufficient proximal or distal landing zone required for secure fixation. Only 71% of patients underwent surgical aortic dissection repair after imaging and 86% of entry tears detected on MSCT were confirmed on intraoperative documentation. Only one patient would have met all technical criteria for ESG using currently available devices.
Conclusion. Location of intimal tear, aortic valve insufficiency, aortic diameter>38mm are major factors limiting use of ESG for acute type A dissection. Available stents used to treat type B aortic dissection do not address anatomic constraints present in type A aortic dissection in the majority of cases, such that development of new devices would be required.
C1 [Jaussaud, N.; Chitsaz, S.; Cambronero, N.; Azadani, A. N.; Chuter, T. A.; Tseng, E. E.] Univ Calif San Francisco, Dept Surg, Med Ctr, Div Cardiothorac Surg, San Francisco, CA USA.
[Jaussaud, N.; Chitsaz, S.; Meadows, A.; Wintermark, M.; Cambronero, N.; Azadani, A. N.; Saloner, D. A.; Chuter, T. A.; Tseng, E. E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Meadows, A.; Wintermark, M.; Saloner, D. A.] Univ Calif San Francisco, Med Ctr, Dept Radiol, San Francisco, CA USA.
RP Tseng, EE (reprint author), UCSF Med Ctr, 500 Parnassus Ave Suite 405W Box 0118, San Francisco, CA 94143 USA.
EM Elaine.Tseng@ucsfmedctr.org
RI Chitsaz, Sam/C-4586-2008
OI Wintermark, Max/0000-0002-6726-3951
FU American Heart Association; Northern California Institute for Research
and Education; Federation Francaise de Cardiologie/Societe Frangaise de
Cardiologie, Societe Francaise de Chirurugie Thoracique et
Cardio-Vasculaire
FX This work was supported by American Heart Association, Northern
California Institute for Research and Education, and Federation
Francaise de Cardiologie/Societe Francaise de Cardiologie, Societe
Francaise de Chirurugie Thoracique et Cardio-Vasculaire.
NR 36
TC 5
Z9 5
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0021-9509
J9 J CARDIOVASC SURG
JI J. Cardiovasc. Surg.
PD JUN
PY 2013
VL 54
IS 3
BP 373
EP 381
PG 9
WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology; Surgery
GA 168YF
UT WOS:000320743200008
PM 22820738
ER
PT J
AU Rahgozar, K
Wright, E
Carrithers, LM
Carrithers, MD
AF Rahgozar, Kusha
Wright, Erik
Carrithers, Lisette M.
Carrithers, Michael D.
TI Mediation of Protection and Recovery From Experimental Autoimmune
Encephalomyelitis by Macrophages Expressing the Human Voltage-Gated
Sodium Channel NaV1.5
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Alternative activation; Experimental autoimmune encephalomyelitis;
Macrophage; Multiple sclerosis; Sodium channel
ID CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; IMMUNE SURVEILLANCE;
ARGINASE-I; INFLAMMATION; ACTIVATION; CELLS; POLARIZATION; REGENERATION;
PLASTICITY
AB Multiple sclerosis (MS) is the most common nontraumatic cause of neurologic disability in young adults. Despite treatment, progressive tissue injury leads to accumulation of disability in many patients. Here, our goal was to develop an immune-mediated strategy to promote tissue repair and clinical recovery in an MS animal model. We previously demonstrated that a variant of the voltage-gated sodium channel NaV1.5 is expressed intracellularly in human macrophages, and that it regulates cellular signaling. This channel is not expressed in mouse macrophages, which has limited the study of its functions. To overcome this obstacle, we developed a novel transgenic mouse model (C57BL6(c-fms-hSCN5A)), in which the human macrophage NaV1.5 splice variant is expressed in vivo in mouse macrophages. These mice were protected from experimental autoimmune encephalomyelitis, the mouse model of MS. During active inflammatory disease, NaV1.5-positive macrophages were found in spinal cord lesions where they formed phagocytic cell clusters; they expressed markers of alternative activation during recovery. NaV1.5-positive macrophages that were adoptively transferred into wild-type recipients with established experimental autoimmune encephalomyelitis homed to lesions and promoted recovery. These results suggest that NaV1.5-positive macrophages enhance recovery from CNS inflammatory disease and could potentially be developed as a cell-based therapy for the treatment of MS.
C1 [Carrithers, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA.
[Rahgozar, Kusha; Wright, Erik; Carrithers, Lisette M.; Carrithers, Michael D.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Carrithers, Michael D.] Univ Wisconsin, Program Cellular & Mol Pathol, Madison, WI 53706 USA.
RP Carrithers, MD (reprint author), Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, 1300 Univ Ave,Room 2679, Madison, WI 53706 USA.
EM carrithers@neurology.wisc.edu
FU VA Merit Award from the BLRD service; University of Wisconsin
FX This work was supported by a VA Merit Award from the BLR&D service to
Michael Carrithers and the University of Wisconsin.
NR 42
TC 4
Z9 4
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2013
VL 72
IS 6
BP 489
EP 504
DI 10.1097/NEN.0b013e318293eb08
PG 16
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 151IR
UT WOS:000319454400005
PM 23656992
ER
PT J
AU Holschneider, DP
Guo, YM
Wang, Z
Roch, M
Scremin, OU
AF Holschneider, Daniel P.
Guo, Yumei
Wang, Zhuo
Roch, Margareth
Scremin, Oscar U.
TI Remote Brain Network Changes after Unilateral Cortical Impact Injury and
Their Modulation by Acetylcholinesterase Inhibition
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE cholinergic; diaschisis; functional brain mapping; functional
connectivity; traumatic brain injury
ID CEREBRAL BLOOD-FLOW; CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE;
FUNCTIONAL CONNECTIVITY; MOTOR CORTEX; BASAL GANGLIA; RESTING-STATE;
RAT-BRAIN; INDICATOR FRACTIONATION; SPATIAL NORMALIZATION
AB We explored whether cerebral cortical impact injury (CCI) effects extend beyond direct lesion sites to affect remote brain networks, and whether acetylcholinesterase (AChE) inhibition elicits discrete changes in functional activation of motor circuits following CCI. Adult male rats underwent unilateral motor-sensory CCI or sham injury. Physostigmine (AChE inhibitor) or saline were administered subcutaneously continuously via implanted minipumps (1.6 micromoles/kg/day) for 3 weeks, followed by cerebral perfusion mapping during treadmill walking using [C-14]-iodoantipyrine. Quantitative autoradiographs were analyzed by statistical parametric mapping and functional connectivity (FC) analysis. CCI resulted in functional deficits in the ipsilesional basal ganglia, with increased activation contralesionally. Recruitment was also observed, especially contralesionally, of the red nucleus, superior colliculus, pedunculopontine tegmental nucleus, thalamus (ventrolateral n., central medial n.), cerebellum, and sensory cortex. FC decreased significantly within ipsi- and contralesional motor circuits and between hemispheres, but increased between midline cerebellum and select regions of the basal ganglia within each hemisphere. Physostigmine significantly increased functional brain activation in the cerebellar thalamocortical pathway (midline cerebellum -> ventrolateral thalamus -> motor cortex), subthalamic nucleus/zona incerta, and red nucleus and bilateral sensory cortex. In conclusion, CCI resulted in increased functional recruitment of contralesional motor cortex and bilateral subcortical motor regions, as well as recruitment of the cerebellar-thalamocortical circuit and contralesional sensory cortex. This phenomenon, augmented by physostigmine, may partially compensate motor deficits. FC decreased inter-hemispherically and in negative, but not positive, intra-hemispherical FC, and it was not affected by physostigmine. Circuit-based approaches into functional brain reorganization may inform future behavioral or molecular strategies to augment targeted neurorehabilitation.
C1 [Holschneider, Daniel P.; Guo, Yumei; Wang, Zhuo] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.; Guo, Yumei; Wang, Zhuo] Univ So Calif, Keck Sch Med, Dept Behav Sci, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Neurol, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.; Roch, Margareth; Scremin, Oscar U.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
RP Holschneider, DP (reprint author), Univ So Calif, Dept Psychiat & Behav Sci, 1333 San Pablo St,MCH 51A,MC9151, Los Angeles, CA 90033 USA.
EM holschne@usc.edu
FU Department of Veterans Affairs Rehabilitation Research & Development
Merit Review (VARRD) [B5089R]; VARR&D Research Career Scientist award
(OUS)
FX This study was supported by a Department of Veterans Affairs
Rehabilitation Research & Development Merit Review (VARR&D) #B5089R and
a VARR&D Research Career Scientist award (OUS).
NR 93
TC 7
Z9 7
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2013
VL 30
IS 11
BP 907
EP 919
DI 10.1089/neu.2012.2657
PG 13
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 166WD
UT WOS:000320589300002
PM 23343118
ER
PT J
AU Durazzo, TC
Abadjian, L
Kincaid, A
Bilovsky-Muniz, T
Boreta, L
Gauger, GE
AF Durazzo, Timothy C.
Abadjian, Linda
Kincaid, Adam
Bilovsky-Muniz, Tobias
Boreta, Lauren
Gauger, Grant E.
TI The Influence of Chronic Cigarette Smoking on Neurocognitive Recovery
after Mild Traumatic Brain Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE cigarette smoking; cognition; mild traumatic brain injury; recovery
ID ALCOHOL-DEPENDENT INDIVIDUALS; OXIDATIVE STRESS; NICOTINE ADDICTION;
ANTIOXIDANT STATUS; TOBACCO-SMOKE; TEENAGE GIRLS; VITAMIN-C; IN-VITRO;
HISTORY; DAMAGE
AB The majority of the approximately 1.7 million civilians in the United States who seek emergency care for traumatic brain injury (TBI) are classified as mild (MTBI). Premorbid and comorbid conditions that commonly accompany MTBI may influence neurocognitive and functional recovery. This study assessed the influence of chronic smoking and hazardous alcohol consumption on neurocognitive recovery after MTBI. A comprehensive neurocognitive battery was administered to 25 non-smoking MTBI participants (nsMTBI), 19 smoking MTBI (sMTBI) 38 +/- 22 days (assessment point 1: AP1) and 230 +/- 36 (assessment point 2: AP2) days after injury. Twenty non-smoking light drinkers served as controls (CON). At AP1, nsMTBI and sMTBI were inferior to CON on measures of auditory-verbal learning and memory; nsMTBI performed more poorly than CON on processing speed and global neurocognition, and sMTBI performed worse than CON on working memory measures; nsMTBI were inferior to sMTBI on visuospatial memory. Over the AP1-AP2 interval, nsMTBI showed significantly greater improvement than sMTBI on measures of processing speed, visuospatial learning and memory, visuospatial skills, and global neurocognition, whereas sMTBI only showed significant improvement on executive skills. At AP2, sMTBI remained inferior to CON on auditory-verbal learning and auditory-verbal memory; there were no significant differences between nsMTBI and CON or among nsMTBI and sMTBI on any domain at AP2. Hazardous alcohol consumption was not significantly associated with change in any neurocognitive domain. For sMTBI, over the AP1-AP2 interval, greater lifetime duration of smoking and pack-years were related to significantly less improvement on multiple domains. Results suggest consideration of the effects of chronic cigarette smoking is necessary to understand the potential factors influencing neurocognitive recovery after MTBI.
C1 [Durazzo, Timothy C.; Abadjian, Linda; Bilovsky-Muniz, Tobias; Boreta, Lauren; Gauger, Grant E.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Durazzo, Timothy C.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Kincaid, Adam; Gauger, Grant E.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
FU Department of Defense [W81XWII-05-2-0094]; National Institute on Drug
Abuse [DA24136]; National Institute on Alcohol and Alcoholism [AA10788]
FX This material is the result of work supported by the Department of
Defense (W81XWII-05-2-0094 to TCD and GEG), National Institute on Drug
Abuse (DA24136 to TCD), National Institute on Alcohol and Alcoholism
(AA10788 to Dieter J. Meyerhoff), and with resources and the use of
facilities at the San Francisco Veterans Affairs Medical Center, San
Francisco, CA. We thank Dr. Geoffrey Manley and Michelle Meeker for
invaluable assistance in recruitment, Hana Lee for assistance with
neurocognitive assessment, and Dr. Dieter J. Meyerhoff for providing a
portion of the neurocognitive data for control participants. We also
wish to extend our gratitude to the study participants, who made this
research possible.
NR 74
TC 5
Z9 5
U1 1
U2 10
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2013
VL 30
IS 11
BP 1013
EP 1022
DI 10.1089/neu.2012.2676
PG 10
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 166WD
UT WOS:000320589300012
PM 23421788
ER
PT J
AU Ahmed, FS
Miller, LS
AF Ahmed, Fayeza S.
Miller, L. Stephen
TI Relationship Between Theory of Mind and Functional Independence Is
Mediated by Executive Function
SO PSYCHOLOGY AND AGING
LA English
DT Article
DE theory of mind; executive function; functional independence
ID MILD COGNITIVE IMPAIRMENT; STRANGE STORIES TEST; OLDER-ADULTS;
ASPERGER-SYNDROME; FRONTOTEMPORAL DEMENTIA; INSTRUMENTAL ACTIVITIES;
ALZHEIMERS-DISEASE; INHIBITORY CONTROL; WORKING-MEMORY; MENTAL-STATE
AB Theory of mind (ToM) is the ability to comprehend another person's perspective. Although there is much literature of ToM in children, there is a limited and somewhat inconclusive amount of studies examining ToM in a geriatric population. This study examined ToM's relationship to functional independence. Two tests of ToM, tests of executive function, and a measure of functional ability were administered to cognitively intact older adults. Results showed that 1 test of ToM (Strange Stories test) significantly accounted for variance in functional ability, whereas the other did not (Faux Pas test). In addition, Strange Stories test performance was partially driven by a verbal abstraction-based executive function: proverb interpretation. A multiple mediation model was employed to examine whether executive functions explained the relationship between the Strange Stories test and functional ability. Results showed that both the combined and individual indirect effects of the executive function measures mediated the relationship. We argue that, although components of ToM are associated with functional independence, ToM does not appear to account for additional variance in functional independence beyond executive function measures.
C1 [Ahmed, Fayeza S.; Miller, L. Stephen] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
RP Ahmed, FS (reprint author), VA Puget Sound, Seattle, WA USA.
EM ahmedfs@gmail.com
NR 95
TC 2
Z9 2
U1 8
U2 32
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0882-7974
J9 PSYCHOL AGING
JI Psychol. Aging
PD JUN
PY 2013
VL 28
IS 2
BP 293
EP 303
DI 10.1037/a0031365
PG 11
WC Gerontology; Psychology, Developmental
SC Geriatrics & Gerontology; Psychology
GA 165OB
UT WOS:000320492100001
PM 23795763
ER
PT J
AU Morinelli, TA
Lee, MH
Kendall, RT
Luttrell, LM
Walker, LP
Ullian, ME
AF Morinelli, Thomas A.
Lee, Mi-Hye
Kendall, Ryan T.
Luttrell, Louis M.
Walker, Linda P.
Ullian, Michael E.
TI Angiotensin II activates NF-kappa B through AT(1A) receptor recruitment
of beta-arrestin in cultured rat vascular smooth muscle cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE angiotensin receptor; NF-kappa B; beta-arrestins; signal transduction;
vascular smooth muscle cells; cyclooxygenase-2
ID NUCLEAR-LOCALIZATION SEQUENCE; SIGNAL-TRANSDUCTION; TYROSINE KINASES;
EXPRESSION; PATHWAY; CYCLOOXYGENASE-2; IDENTIFICATION; TRANSCRIPTION;
PHOSPHORYLATION; MOLECULE
AB Activation of the angiotensin type 1A receptor (AT(1A)R) in rat aorta vascular smooth muscle cells (RASMC) results in increased synthesis of the proinflammatory enzyme cyclooxygenase-2 (COX-2). We previously showed that nuclear localization of internalized AT(1A)R results in activation of transcription of the gene for COX-2, i.e., prostaglandin-endoperoxide synthase-2. Others have suggested that ANG II stimulation of COX-2 protein synthesis is mediated by NF-kappa B. The purpose of the present study was to examine the interrelationship between AT(1A)R activation, beta-arrestin recruitment, and NF-kappa B activation in the ability of ANG II to increase COX-2 protein synthesis in RASMC. In the present study we utilized RASMC, inhibitors of the NF-kappa B pathway, beta-arrestin knockdown, radioligand binding, immunoblotting, and immunofluorescence to characterize the roles of AT(1A)R internalization, NF-kappa B activation, and beta-arrestin in ANG II-induced COX-2 synthesis. Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappa B activation, blocked ANG II-induced p65 NF-kappa B nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT(1A)R internalization without inhibiting ANG II-induced p42/44 ERK activation. Curcumin, an inhibitor of NF-kappa B-induced transcription, blocked ANG II-induced COX-2 protein expression without altering AT(1A)R internalization, ANG II-induced p65 NF-kappa B nuclear localization, or p42/44 ERK activation. Small interfering RNA-induced knockdown of beta-arrestin-1 and -2 inhibited ANG II-induced p65 NF-kappa B nuclear localization. In vascular smooth muscle cells, internalization of the activated AT(1A)R mediated by beta-arrestins activates the NF-kappa B pathway, producing nuclear localization of the transcription factor and initiation of COX-2 protein synthesis, thereby linking internalization of the receptor with the NF-kappa B pathway.
C1 [Morinelli, Thomas A.; Walker, Linda P.; Ullian, Michael E.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Lee, Mi-Hye; Kendall, Ryan T.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA.
[Luttrell, Louis M.; Ullian, Michael E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Morinelli, TA (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA.
EM morinelt@musc.edu
FU Dialysis Clinic, Incorporated; National Institute of Diabetes and
Digestive and Kidney Diseases [DK-055524]; National Center for Research
Resources [1S10 RR-027777-01]; Research Service of the Veterans Affairs
Medical Center of Charleston, SC
FX This project was supported by Dialysis Clinic, Incorporated, National
Institute of Diabetes and Digestive and Kidney Diseases Grant DK-055524
(L. M. Luttrell), National Center for Research Resources Grant 1S10
RR-027777-01 (FLIPR Tetra, L. M. Luttrell and T. A. Morinelli), and the
Research Service of the Veterans Affairs Medical Center of Charleston,
SC.
NR 33
TC 7
Z9 7
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JUN
PY 2013
VL 304
IS 12
BP C1176
EP C1186
DI 10.1152/ajpcell.00235.2012
PG 11
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 164XJ
UT WOS:000320445300009
PM 23576578
ER
PT J
AU Miller, MW
Knaub, LA
Olivera-Fragoso, LF
Keller, AC
Balasubramaniam, V
Watson, PA
Reusch, JEB
AF Miller, Matthew W.
Knaub, Leslie A.
Olivera-Fragoso, Luis F.
Keller, Amy C.
Balasubramaniam, Vivek
Watson, Peter A.
Reusch, Jane E. B.
TI Nitric oxide regulates vascular adaptive mitochondrial dynamics
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE endothelial nitric oxide synthase; vascular mitochondria
ID SMOOTH-MUSCLE-CELLS; ENDOTHELIAL-CELLS; SUPEROXIDE-DISMUTASE;
DIABETES-MELLITUS; OXIDATIVE STRESS; SKELETAL-MUSCLE;
PULMONARY-HYPERTENSION; IN-VIVO; DYSFUNCTION; SYNTHASE
AB Cardiovascular disease risk factors, such as diabetes, hypertension, dyslipidemia, obesity, and physical inactivity, are all correlated with impaired endothelial nitric oxide synthase (eNOS) function and decreased nitric oxide (NO) production. NO-mediated regulation of mitochondrial biogenesis has been established in many tissues, yet the role of eNOS in vascular mitochondrial biogenesis and dynamics is unclear. We hypothesized that genetic eNOS deletion and 3-day nitric oxide synthase (NOS) inhibition in rodents would result in impaired mitochondrial biogenesis and defunct fission/fusion and autophagy profiles within the aorta. We observed a significant, eNOS expression-dependent decrease in mitochondrial electron transport chain (ETC) protein subunits from complexes I, II, III, and V in eNOS heterozygotes and eNOS null mice compared with age-matched controls. In response to NOS inhibition with N-G-nitro-L-arginine methyl ester (L-NAME) treatment in Sprague Dawley rats, significant decreases were observed in ETC protein subunits from complexes I, III, and IV as well as voltage-dependent anion channel 1. Decreased protein content of upstream regulators of mitochondrial biogenesis, cAMP response element-binding protein and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, were observed in response to 3-day L-NAME treatment. Both genetic eNOS deletion and NOS inhibition resulted in decreased manganese superoxide dismutase protein. L-NAME treatment resulted in significant changes to mitochondrial dynamic protein profiles with decreased fusion, increased fission, and minimally perturbed autophagy. In addition, L-NAME treatment blocked mitochondrial adaptation to an exercise intervention in the aorta. These results suggest that eNOS/NO play a role in basal and adaptive mitochondrial biogenesis in the vasculature and regulation of mitochondrial turnover.
C1 [Miller, Matthew W.; Knaub, Leslie A.; Keller, Amy C.; Balasubramaniam, Vivek; Watson, Peter A.; Reusch, Jane E. B.] Univ Colorado, Aurora, CO USA.
[Miller, Matthew W.; Knaub, Leslie A.; Keller, Amy C.; Watson, Peter A.; Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Olivera-Fragoso, Luis F.] Univ Puerto Rico, San Juan, PR 00936 USA.
[Balasubramaniam, Vivek] Childrens Hosp, Aurora, CO USA.
RP Reusch, JEB (reprint author), Univ Colorado Denver, Div Endocrinol Diabet & Metab, Anschutz Med Campus,12801 E 17th Ave,MS8106, Aurora, CO 80045 USA.
EM jane.reusch@ucdenver.edu
FU National Heart, Lung, and Blood Institute [1R25-HL-103286-02]
FX This work was supported by National Heart, Lung, and Blood Institute
Grant 1R25-HL-103286-02.
NR 68
TC 23
Z9 24
U1 1
U2 27
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD JUN
PY 2013
VL 304
IS 12
BP H1624
EP H1633
DI 10.1152/ajpheart.00987.2012
PG 10
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 164XB
UT WOS:000320444300004
PM 23585138
ER
PT J
AU Merkow, RP
Bentrem, DJ
Winchester, DP
Stewart, AK
Ko, CY
Bilimoria, KY
AF Merkow, Ryan P.
Bentrem, David J.
Winchester, David P.
Stewart, Andrew K.
Ko, Clifford Y.
Bilimoria, Karl Y.
TI Effect of Including Cancer-Specific Variables on Risk-Adjusted Hospital
Surgical Quality Comparisons
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT Endocrine Cancer Parallel Session at the 65th Annual Cancer Symposium of
the Society-of-Surgical-Oncology (SSO) / Presidential Plenary Session
CY MAR 21-24, 2012
CL Orlando, FL
SP Soc Surg Oncol (SSO)
ID IMPROVEMENT PROGRAM; SURGERY; MORTALITY; SAFETY; CARE
AB Quality initiatives are increasingly focusing on the quality of oncologic surgery. However, there is concern that a lack of cancer-specific variables may make risk-adjusted hospital quality comparisons inadequate. Our objective was to assess whether hospital quality rankings for cancer surgery are influenced by the addition of cancer-specific variables to the risk-adjusted models.
Patients from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) and National Cancer Data Base (NCDB) who underwent colon or rectal resection for cancer were linked (2006-2008). Hierarchical models were developed predicting ACS NSQIP outcomes based on ACS NSQIP only vs a model using NSQIP and NCDB-derived cancer variables (e.g., stage and neoadjuvant therapy). Changes in hospital quality rankings were compared.
A total of 11,405 patients underwent colon (n = 9,678, 146 hospitals) or rectal (n = 1,727, 135 hospitals) resection for cancer (2006-2008). Hospital-level complication rates (and standard deviation) after colon surgery were 2.2 % (+/- 2.7 %) for mortality and 17.2 % (+/- 8.7 %) for serious morbidity. After rectal cancer resection, complication rates were 0.9 % (+/- 3.8 %) for mortality and 22.3 % (+/- 20.4 %) for serious morbidity. When cancer-specific variables were included in risk-adjustment, outlier agreement was very good (kappa > 0.85), and hospital odds ratio correlations were nearly identical (R > 0.98) for all outcomes assessed. Median changes in hospital rankings with the addition of the cancer-specific variables ranged from 1 to 2 after colon resection to 2-4 after rectal resection.
Addition of the available cancer-specific variables to risk-adjustment models did not affect hospital quality rankings for cancer surgery. Existing ACS NSQIP risk-adjustment variables appears to be sufficient for accurate comparisons of hospital quality.
C1 [Merkow, Ryan P.; Winchester, David P.; Stewart, Andrew K.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA.
[Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Northwestern Inst Comparat Effectiveness Res NICE, Chicago, IL 60611 USA.
[Merkow, Ryan P.] Univ Colorado Denver, Dept Surg, Aurora, CO USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
EM kbilimoria@facs.org
NR 18
TC 6
Z9 6
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD JUN
PY 2013
VL 20
IS 6
BP 1766
EP 1773
DI 10.1245/s10434-013-2867-z
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA 147LS
UT WOS:000319169100004
PM 23354565
ER
PT J
AU Win, AK
Parry, S
Parry, B
Kalady, MF
Macrae, FA
Ahnen, DJ
Young, GP
Lipton, L
Winship, I
Boussioutas, A
Young, JP
Buchanan, DD
Arnold, J
Le Marchand, L
Newcomb, PA
Haile, RW
Lindor, NM
Gallinger, S
Hopper, JL
Jenkins, MA
AF Win, Aung Ko
Parry, Susan
Parry, Bryan
Kalady, Matthew F.
Macrae, Finlay A.
Ahnen, Dennis J.
Young, Graeme P.
Lipton, Lara
Winship, Ingrid
Boussioutas, Alex
Young, Joanne P.
Buchanan, Daniel D.
Arnold, Julie
Le Marchand, Loic
Newcomb, Polly A.
Haile, Robert W.
Lindor, Noralane M.
Gallinger, Steven
Hopper, John L.
Jenkins, Mark A.
TI Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in
Mismatch Repair Gene Mutation Carriers
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID NONPOLYPOSIS COLORECTAL-CANCER; POUCH-ANAL ANASTOMOSIS; QUALITY-OF-LIFE;
LYNCH-SYNDROME; FAMILY
AB Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer.
This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan-Meier method.
During median 9 years (range 1-32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 %) were diagnosed with metachronous colon cancer (incidence 24.25, 95 % confidence interval [CI] 15.81-37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 % (95 % CI 9-31 %) at 10 years, 47 (95 % CI 31-68 %) at 20 years, and 69 % (95 % CI 45-89 %) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01-1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 % stage I, 22 % stage II, and 6 % stage III.
Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.
C1 [Win, Aung Ko; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia.
[Parry, Susan; Arnold, Julie] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand.
[Parry, Susan] Middlemore Hosp, Dept Gastroenterol, Auckland 6, New Zealand.
[Parry, Bryan] Auckland City Hosp, Colorectal Surg Unit, Auckland, New Zealand.
[Kalady, Matthew F.] Cleveland Clin, Inst Digest Dis, Dept Colorectal Surg, Cleveland, OH 44106 USA.
[Macrae, Finlay A.; Winship, Ingrid] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO 80202 USA.
[Young, Graeme P.] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA 5001, Australia.
[Lipton, Lara] Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia.
[Winship, Ingrid] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia.
[Boussioutas, Alex] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia.
[Boussioutas, Alex] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia.
[Boussioutas, Alex] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia.
[Young, Joanne P.; Buchanan, Daniel D.] Queensland Inst Med Res, Canc & Populat Studies Grp, Bancroft Ctr, Herston, Qld 4006, Australia.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
[Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ USA.
[Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Gallinger, Steven] Canc Care Ontario, Toronto, ON, Canada.
RP Win, AK (reprint author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia.
EM SParry@adhb.govt.nz
RI Jenkins, Mark/P-7803-2015
OI Jenkins, Mark/0000-0002-8964-6160; Boussioutas,
Alex/0000-0002-8109-6897; Win, Aung Ko/0000-0002-2794-5261; Buchanan,
Daniel/0000-0003-2225-6675; Winship, Ingrid/0000-0001-8535-6003
FU National Cancer Institute, National Institutes of Health under RFA
[CA-95-011]; Picchi Brothers Foundation Cancer Council Victoria Cancer
Research Scholarship, Australia
FX This work was supported by the National Cancer Institute, National
Institutes of Health under RFA #CA-95-011 and through cooperative
agreements with members of the Colon Cancer Family Registry and
Principal Investigators. Collaborating centers include Australasian
Colorectal Cancer Family Registry (U01 CA097735), Familial Colorectal
Neoplasia Collaborative Group (U01 CA074799) [USC], Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies (U01 CA074800),
Ontario Registry for Studies of Familial Colorectal Cancer (U01
CA074783), Seattle Colorectal Cancer Family Registry (U01 CA074794), and
University of Hawaii Colorectal Cancer Family Registry (U01 CA074806).
AKW is supported by the Picchi Brothers Foundation Cancer Council
Victoria Cancer Research Scholarship, Australia. MAJ is a Senior
Research Fellow and JLH is an Australia Fellow of the National Health
and Medical Research Council, Australia.
NR 24
TC 32
Z9 34
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD JUN
PY 2013
VL 20
IS 6
BP 1829
EP 1836
DI 10.1245/s10434-012-2858-5
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA 147LS
UT WOS:000319169100011
PM 23358792
ER
PT J
AU Press, MJ
Scanlon, DP
Ryan, AM
Zhu, JS
Navathe, AS
Mittler, JN
Volpp, KG
AF Press, Matthew J.
Scanlon, Dennis P.
Ryan, Andrew M.
Zhu, Jingsan
Navathe, Amol S.
Mittler, Jessica N.
Volpp, Kevin G.
TI Limits Of Readmission Rates In Measuring Hospital Quality Suggest The
Need For Added Metrics
SO HEALTH AFFAIRS
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; MORTALITY-RATES; HEALTH-CARE;
PERFORMANCE-MEASURES; TEACHING STATUS; TRIAL
AB Recent national policies use risk-standardized readmission rates to measure hospital performance on the theory that readmissions reflect dimensions of the quality of patient care that are influenced by hospitals. In this article our objective was to assess readmission rates as a hospital quality measure. First we compared quartile rankings of hospitals based on readmission rates in 2009 and 2011 to see whether hospitals maintained their relative performance or whether shifts occurred that suggested either changes in quality or random variation. Next we examined the relationship between readmission rates and several commonly used hospital quality indicators, including risk-standardized mortality rates, volume, teaching status, and process-measure performance. We found that quartile rankings fluctuated and that readmission rates for lower-performing hospitals in 2009 tended to improve by 2011, while readmission rates for higher-performing hospitals tended to worsen. Regression to the mean (a form of statistical noise) accounted for a portion of the changes in hospital performance. We also found that readmission rates were higher in teaching hospitals and were weakly correlated with the other indicators of hospital quality. Policy makers should consider augmenting the use of readmission rates with other measures of hospital performance during care transitions and should build on current efforts that take a communitywide approach to the readmissions issue.
C1 [Press, Matthew J.] Weill Cornell Med Coll, New York, NY USA.
[Scanlon, Dennis P.] Penn State Univ, Hlth Policy & Adm, Coll Hlth & Human Dev, State Coll, PA USA.
[Ryan, Andrew M.] Weill Cornell Med Coll, Div Outcomes & Effectiveness Res, New York, NY USA.
[Zhu, Jingsan] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Navathe, Amol S.] Harvard Univ, Sch Med, Boston, MA USA.
[Navathe, Amol S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Navathe, Amol S.] Harvard Vanguard Med Associates, Boston, MA USA.
[Mittler, Jessica N.] Penn State Univ, Dept Hlth Policy Adm, State Coll, PA USA.
[Volpp, Kevin G.] Philadelphia Vet Affairs Med Center, Philadelphia, PA USA.
RP Press, MJ (reprint author), Weill Cornell Med Coll, New York, NY USA.
EM map9069@med.cornell.edu
FU Commonwealth Fund; Department of Veterans Affairs Health Services
Research and Development (VA HSRD); Agency for Healthcare Research and
Quality [K01HS018546-01]
FX Some results from this study were presented at the Society of General
Internal Medicine Annual Meeting, Orlando, Florida, May 2012. This
project was funded by the Commonwealth Fund (principal investigator:
Dennis Scanlon). The authors thank the Department of Veterans Affairs
Health Services Research and Development (VA HSR&D) for the support of
Kevin Volpp. Matthew Press is supported in part by funds provided to him
as a Nanette Laitman Clinical Scholar in Public Health at Weill Cornell
Medical College. Andrew Ryan is supported by Grant No. K01HS018546-01
from the Agency for Healthcare Research and Quality. The authors also
thank Andrea Troxel of the University of Pennsylvania for statistical
advice.
NR 36
TC 24
Z9 24
U1 4
U2 13
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2013
VL 32
IS 6
BP 1083
EP 1091
DI 10.1377/hlthaff.2012.0518
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 163XV
UT WOS:000320372800010
PM 23733983
ER
PT J
AU Olfson, M
Marcus, SC
AF Olfson, Mark
Marcus, Steven C.
TI Decline In Placebo-Controlled Trial Results Suggests New Directions For
Comparative Effectiveness Research
SO HEALTH AFFAIRS
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION;
RESEARCH-AND-DEVELOPMENT; ACTIVE-CONTROL TRIALS; BIOMEDICAL-RESEARCH;
OUTCOMES; DESIGN; TRENDS; ISSUES; SIZE
AB The Affordable Care Act offers strong support for comparative effectiveness research, which entails comparisons among active treatments, to provide the foundation for evidence-based practice. Traditionally, a key form of research into the effectiveness of therapeutic treatments has been placebo-controlled trials, in which a specified treatment is compared to placebo. These trials feature high-contrast comparisons between treatments. Historical trends in placebo-controlled trials have been evaluated to help guide the comparative effectiveness research agenda. We investigated placebo-controlled trials reported in four leading medical journals between 1966 and 2010. We found that there was a significant decline in average effect size or average difference in efficacy (the ability to produce a desired effect) between the active treatment and placebo. On average, recently studied treatments offered only small benefits in efficacy over placebo. A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy.
C1 [Olfson, Mark] Columbia Univ, New York, NY 10027 USA.
[Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Marcus, Steven C.] Univ Penn, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
RP Olfson, M (reprint author), Columbia Univ, New York, NY 10027 USA.
EM mo49@columbia.edu
FU Agency for Healthcare Research and Quality [U19 HS021112]; New York
State Psychiatric Institute
FX Mark Olfson's work on this project was supported by the Agency for
Healthcare Research and Quality (Grant No. U19 HS021112) and the New
York State Psychiatric Institute. The sponsors had no role in the design
and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript. No human subjects were involved in the conduct of this
study. Steven Marcus had access to all of the extracted data in the
study and takes responsibility for the accuracy of the data analysis. A
bibliography of the 315 articles selected for review is available from
Olfson on request.
NR 48
TC 7
Z9 7
U1 1
U2 5
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2013
VL 32
IS 6
BP 1116
EP 1125
DI 10.1377/hlthaff.2012.1353
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 163XV
UT WOS:000320372800014
PM 23733987
ER
PT J
AU Morrison, P
Nikolajski, C
Zickmund, S
AF Morrison, Penelope
Nikolajski, Cara
Zickmund, Susan
TI 'When we think about risk, we think about rights': community-based
organisations' staff members' perspectives on risk, resiliency and
rights in Juiz de Fora, Brazil
SO HEALTH RISK & SOCIETY
LA English
DT Article
DE public health; risk; risk perception; young people; Brazil
ID SAO-PAULO; PROTECTIVE FACTORS; SEXUAL-BEHAVIOR; DRUG-USE; HEALTH;
ADOLESCENTS; YOUTH; CHILDREN; CONFLICT; STUDENTS
AB In this article, we draw on a qualitative case study undertaken in 2008 and 2009 of staff working at community-based organisations for at-risk youth in Juiz de Fora, Brazil, to examine staff members' perspectives of adolescent health-risk behaviours and resiliency. We use these data to explore how recent policy changes in Brazil have led to a shift in the ways in which adolescent risk taking is perceived by those working in youth services, and to suggest the influence that this has had on the way in which these entities promote resiliency among the population they serve. Specifically, we argue that Brazil's Child and Adolescent Act of 1990, a policy derived from the United Nations Convention on the Rights of the Child, has been instrumental in reframing for the community-based organisations the question of adolescent health-risk behaviours into a rights-based framework and has shifted the perceptions of those working at such organisations as to who a youth at-risk' is, why young people engage in risk taking and how best to promote resiliency. This work has implications for understanding both how risk and resiliency are constructed in different social and cultural contexts and how such concepts may change over time due to shifting socio-political climates.
C1 [Morrison, Penelope] Univ Pittsburgh, RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA 15260 USA.
[Nikolajski, Cara] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Zickmund, Susan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Morrison, P (reprint author), Univ Pittsburgh, RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA 15260 USA.
EM morrisonpk@upmc.edu
NR 62
TC 0
Z9 0
U1 1
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1369-8575
J9 HEALTH RISK SOC
JI Health Risk Soc.
PD JUN 1
PY 2013
VL 15
IS 4
BP 347
EP 362
DI 10.1080/13698575.2013.796347
PG 16
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 160DV
UT WOS:000320098100004
ER
PT J
AU Imel, ZE
Laska, K
Jakupcak, M
Simpson, TL
AF Imel, Zac E.
Laska, Kevin
Jakupcak, Matthew
Simpson, Tracy L.
TI Meta-Analysis of Dropout in Treatments for Posttraumatic Stress Disorder
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE PTSD; clinical trials; dropout; psychotherapy
ID RANDOMIZED CONTROLLED-TRIAL; EYE-MOVEMENT DESENSITIZATION; NARRATIVE
EXPOSURE THERAPY; COGNITIVE PROCESSING THERAPY; AFRICAN REFUGEE
SETTLEMENT; BONA-FIDE PSYCHOTHERAPIES; SUBSTANCE USE DISORDERS;
CHILDHOOD SEXUAL-ABUSE; PROLONGED EXPOSURE; IMAGINAL EXPOSURE
AB Objective: Many patients drop out of treatments for posttraumatic stress disorder (PTSD); some clinicians believe that trauma-focused treatments increase dropout. Method: We conducted a meta-analysis of dropout among active treatments in clinical trials for PTSD (42 studies; 17 direct comparisons). Results: The average dropout rate was 18%, but it varied significantly across studies. Group modality and greater number of sessions, but not trauma focus, predicted increased dropout. When the meta-analysis was restricted to direct comparisons of active treatments, there were no differences in dropout. Differences in trauma focus between treatments in the same study did not predict dropout. However, trauma-focused treatments resulted in higher dropout compared with present-centered therapy (PCT), a treatment originally designed as a control but now listed as a research-supported intervention for PTSD. Conclusion: Dropout varies between active interventions for PTSD across studies, but variability is primarily driven by differences between studies. There do not appear to be systematic differences across active interventions when they are directly compared in the same study. The degree of clinical attention placed on the traumatic event does not appear to be a primary cause of dropout from active treatments. However, comparisons of PCT may be an exception to this general pattern, perhaps because of a restriction of variability in trauma focus among comparisons of active treatments. More research is needed comparing trauma-focused interventions to trauma-avoidant treatments such as PCT.
C1 [Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
[Imel, Zac E.; Jakupcak, Matthew; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Laska, Kevin] Bedford VA Med Ctr, Bedford, MA USA.
RP Imel, ZE (reprint author), Univ Utah, Dept Educ Psychol, 1705 Campus Ctr Dr RM 327, Salt Lake City, UT 84112 USA.
EM zac.imel@utah.edu
OI imel, zachary/0000-0001-9645-7184
FU NCRR NIH HHS [UL1 RR025014, UL1RR025014]; NIDA NIH HHS [R34 DA034860]
NR 73
TC 54
Z9 54
U1 11
U2 46
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD JUN
PY 2013
VL 81
IS 3
BP 394
EP 404
DI 10.1037/a0031474
PG 11
WC Psychology, Clinical
SC Psychology
GA 150RA
UT WOS:000319407300003
PM 23339535
ER
PT J
AU Suswam, EA
Shacka, JJ
Walker, K
Lu, L
Li, XL
Si, Y
Zhang, XW
Zheng, L
Nabors, LB
Cao, HP
King, PH
AF Suswam, Esther A.
Shacka, John J.
Walker, Kiera
Lu, Liang
Li, Xuelin
Si, Ying
Zhang, Xiaowen
Zheng, Lei
Nabors, L. Burt
Cao, Heping
King, Peter H.
TI Mutant tristetraprolin: a potent inhibitor of malignant glioma cell
growth
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE RNA stability; VEGF; IL-6; IL-8; Post-transcriptional gene regulation
ID MESSENGER-RNA STABILITY; ACTIVATED PROTEIN-KINASE;
TUMOR-NECROSIS-FACTOR; SIGNALING PATHWAY; RICH ELEMENTS; UP-REGULATION;
BRF PROTEINS; CANCER CELLS; BINDING; HUR
AB Malignant gliomas rely on the production of certain critical growth factors including VEGF, interleukin (IL)-6 and IL-8, to fuel rapid tumor growth, angiogenesis, and treatment resistance. Post-transcriptional regulation through adenine and uridine-rich elements of the 3' untranslated region is one mechanism for upregulating these and other growth factors. In glioma cells, we have shown that the post-transcriptional machinery is optimized for growth factor upregulation secondary to overexpression of the mRNA stabilizer, HuR. The negative regulator, tristetraprolin (TTP), on the other hand, may be suppressed because of extensive phosphorylation. Here we test that possibility by analyzing the phenotypic effects of a mutated form of TTP (mt-TTP) in which 8 phosphoserine residues were converted to alanines. We observed a significantly enhanced negative effect on growth factor expression in glioma cells at the post-transcriptional and transcriptional levels. The protein became stabilized and displayed significantly increased antiproliferative effects compared to wild-type TTP. Macroautophagy was induced with both forms of TTP, but inhibition of autophagy did not affect cell viability. We conclude that glioma cells suppress TTP function through phosphorylation of critical serine residues which in turn contributes to growth factor upregulation and tumor progression.
C1 [Suswam, Esther A.; Walker, Kiera; Lu, Liang; Li, Xuelin; Si, Ying; Zheng, Lei; Nabors, L. Burt; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Shacka, John J.; Lu, Liang; Li, Xuelin; Si, Ying; King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
[Zhang, Xiaowen] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Cao, Heping] ARS, Utilizat Res Unit, So Reg Res Ctr, USDA, New Orleans, LA 70124 USA.
[King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[King, Peter H.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
RP Suswam, EA (reprint author), Univ Alabama Birmingham, Dept Neurol, 1720 2nd Ave South,WTI410C, Birmingham, AL 35294 USA.
EM easuswam@uab.edu; pking@uab.edu
FU Department of Veterans Affairs Research; National Institutes of Health
[RO1 NS064133, CA131468, NS057664]
FX Grant support: Department of Veterans Affairs Research, Merit Review
grants (PHK and JJS), National Institutes of Health grants (RO1 NS064133
to PHK, CA131468 to EAS, and NS057664 to LL). The sponsors played no
role in the design of experiments, interpretation of results, or writing
this manuscript.
NR 50
TC 11
Z9 11
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JUN
PY 2013
VL 113
IS 2
BP 195
EP 205
DI 10.1007/s11060-013-1112-8
PG 11
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 162CD
UT WOS:000320241100005
PM 23525947
ER
PT J
AU Grady, CD
Schwarz, EB
Emeremni, CA
Yabes, J
Akers, A
Zite, N
Borrero, S
AF Grady, Cynthia D.
Schwarz, Eleanor Bimla
Emeremni, Chetachi A.
Yabes, Jonathan
Akers, Aletha
Zite, Nikki
Borrero, Sonya
TI Does a History of Unintended Pregnancy Lessen the Likelihood of Desire
for Sterilization Reversal?
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID TUBAL-STERILIZATION; UNITED-STATES; FEMALE STERILIZATION; REGRET
AB Background: Unintended pregnancy has been significantly associated with subsequent female sterilization. Whether women who are sterilized after experiencing an unintended pregnancy are less likely to express desire for sterilization reversal is unknown.
Methods: This study used national, cross-sectional data collected by the 2006-2010 National Survey of Family Growth. The study sample included women ages 15-44 who were surgically sterile from a tubal sterilization at the time of interview. Multivariable logistic regression was used to examine the relationship between a history of unintended pregnancy and desire for sterilization reversal while controlling for potential confounders.
Results: In this nationally representative sample of 1,418 women who were sterile from a tubal sterilization, 78% had a history of at least one unintended pregnancy and 28% expressed a desire to have their sterilization reversed. In unadjusted analysis, having a prior unintended pregnancy was associated with higher odds of expressing desire for sterilization reversal (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.15-2.79). In adjusted analysis controlling for sociodemographic factors, unintended pregnancy was no longer significantly associated with desire for reversal (OR: 1.46; 95% CI: 0.91-2.34).
Conclusion: Among women who had undergone tubal sterilization, a prior history of unintended pregnancy did not decrease desire for sterilization reversal.
C1 [Grady, Cynthia D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Schwarz, Eleanor Bimla; Yabes, Jonathan; Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Schwarz, Eleanor Bimla] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.
[Emeremni, Chetachi A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA.
[Yabes, Jonathan; Akers, Aletha] Univ Pittsburgh, Res Ctr, Hlth Care Data Ctr, Pittsburgh, PA 15213 USA.
[Zite, Nikki] Univ Tennessee, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Borrero, S (reprint author), Univ Pittsburgh, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
EM borrerosp@upmc.edu
OI Schwarz, Eleanor Bimla/0000-0002-9912-8236
FU National Center for Research Resources; National Center For Advancing
Translational Sciences of the National Institutes of Health [2KL2
RR024154-06]
FX Dr. Borrero's effort on this project was supported by the National
Center for Research Resources and the National Center For Advancing
Translational Sciences of the National Institutes of Health through
Grant Number 2KL2 RR024154-06.
NR 20
TC 3
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2013
VL 22
IS 6
BP 501
EP 506
DI 10.1089/jwh.2012.3885
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 161BE
UT WOS:000320164600006
PM 23621776
ER
PT J
AU Chang, I
Majid, S
Saini, S
Zaman, MS
Yamamura, S
Chiyomaru, T
Shahryari, V
Fukuhara, S
Deng, GR
Dahiya, R
Tanaka, Y
AF Chang, Inik
Majid, Shahana
Saini, Sharanjot
Zaman, Mohd S.
Yamamura, Soichiro
Chiyomaru, Takeshi
Shahryari, Varahram
Fukuhara, Shinichiro
Deng, Guoren
Dahiya, Rajvir
Tanaka, Yuichiro
TI Hrk Mediates 2-Methoxyestradiol- Induced Mitochondrial Apoptotic
Signaling in Prostate Cancer Cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID BH3-ONLY PROTEINS; MEMBRANE PERMEABILIZATION; PROMOTER METHYLATION;
BCL-2 PROTEINS; GENE; BAX; INACTIVATION; EXPRESSION; TARGET;
IDENTIFICATION
AB Prostate cancer is one of the most prevalent cancers in males and ranks as the second most common cause of cancer-related deaths. 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite, is a promising anticancer agent for various types of cancers. Although 2-ME has been shown to activate c-Jun-NH2-kinase (JNK) and mitochondrial-dependent apoptotic signaling pathways, the underlying mechanisms, including downstream effectors, remain unclear. Here, we report that the human Bcl-2 homology 3 (BH3)-only protein harakiri (Hrk) is a critical effector of 2-ME-induced JNK/mitochondria-dependent apoptosis in prostate cancer cells. Hrk mRNA and protein are preferentially upregulated by 2-ME, and Hrk induction is dependent on the JNK activation of c-Jun. Hrk knockdown prevents 2-ME-mediated apoptosis by attenuating the decrease in mitochondrial membrane potential, subsequent cytochrome c (cyt c) release, and caspase activation. Involvement of the proapoptotic protein Bak in this process suggested the possible interaction between Hrk and Bak. Thus, Hrk activation by 2-ME or its overexpression displaced Bak from the complex with antiapoptotic protein Bcl-xL, whereas deletion of the Hrk BH3 domain abolished its interaction with Bcl-xL, reducing the proapoptotic function of Hrk. Finally, Hrk is also involved in the 2-ME-mediated reduction of X-linked inhibitor of apoptosis through Bak activation in prostate cancer cells. Together, our findings suggest that induction of the BH3-only protein Hrk is a critical step in 2-ME activation of the JNK-induced apoptotic pathway, targeting mitochondria by liberating proapoptotic protein Bak. (C) 2013 AACR.
C1 [Tanaka, Yuichiro] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Tanaka, Yuichiro] Univ Calif San Francisco, San Francisco, CA 94121 USA.
RP Tanaka, Y (reprint author), San Francisco VA Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM yuichiro.tanaka@ucsf.edu
FU Veterans Affairs Merit Review grant; Research Enhancement Award Program
FX This study was supported by the Veterans Affairs Merit Review grant and
Research Enhancement Award Program (Y. Tanaka).
NR 39
TC 6
Z9 7
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2013
VL 12
IS 6
BP 1049
EP 1059
DI 10.1158/1535-7163.MCT-12-1187
PG 11
WC Oncology
SC Oncology
GA 160HT
UT WOS:000320110500020
PM 23580416
ER
PT J
AU Davidson, CL
Babson, KA
Bonn-Miller, MO
Souter, T
Vannoy, S
AF Davidson, Collin L.
Babson, Kimberly A.
Bonn-Miller, Marcel O.
Souter, Tasha
Vannoy, Steven
TI The Impact of Exercise on Suicide Risk: Examining Pathways through
Depression, PTSD, and Sleep in an Inpatient Sample of Veterans
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; NATIONAL
COMORBIDITY SURVEY; LATE-LIFE DEPRESSION; PHYSICAL-ACTIVITY;
PRIMARY-CARE; MENTAL-HEALTH; MAJOR DEPRESSION; COMMUNITY SAMPLE;
OLDER-ADULTS
AB Suicide has a large public health impact. Although effective interventions exist, the many people at risk for suicide cannot access these interventions. Exercise interventions hold promise in terms of reducing suicide because of their ease of implementation. While exercise reduces depression, and reductions in depressive symptoms are linked to reduced suicidal ideation, no studies have directly linked exercise and suicide risk. The current study examined this association, including potential mediators (i.e., sleep disturbance, posttraumatic stress symptoms, and depression), in a sample of Veterans. SEM analyses revealed that exercise was directly and indirectly associated with suicide risk. Additionally, exercise was associated with fewer depressive symptoms and better sleep patterns, each of which was, in turn, related to lower suicide risk.
C1 [Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA.
[Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA.
[Babson, Kimberly A.; Souter, Tasha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA.
[Bonn-Miller, Marcel O.] Philadelphia VAMC, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA.
[Souter, Tasha] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Vannoy, Steven] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Davidson, CL (reprint author), 1055 Clermont St, Denver, CO 80220 USA.
EM collin.davidson@va.gov
OI Babson, Kimberly/0000-0002-9233-8230; Vannoy, Steven/0000-0003-3029-8306
NR 73
TC 15
Z9 15
U1 7
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2013
VL 43
IS 3
BP 279
EP 289
DI 10.1111/sltb.12014
PG 11
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 161GO
UT WOS:000320180700005
PM 23901428
ER
PT J
AU Navarro-Millan, I
Charles-Schoeman, C
Yang, S
Bathon, JM
Bridges, SL
Chen, L
Cofield, SS
Dell'Italia, LJ
Moreland, LW
O'Dell, JR
Paulus, HE
Curtis, JR
AF Navarro-Millan, Iris
Charles-Schoeman, Christina
Yang, Shuo
Bathon, Joan M.
Bridges, S. Louis, Jr.
Chen, Lang
Cofield, Stacey S.
Dell'Italia, Louis J.
Moreland, Larry W.
O'Dell, James R.
Paulus, Harold E.
Curtis, Jeffrey R.
TI Changes in Lipoproteins Associated With Methotrexate or Combination
Therapy in Early Rheumatoid Arthritis: Results From the Treatment of
Early Rheumatoid Arthritis Trial
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; HIGH-DENSITY-LIPOPROTEIN;
MYOCARDIAL-INFARCTION; LIPID PROFILES; RECEPTOR INHIBITION;
DOUBLE-BLIND; ATHEROSCLEROSIS; CHOLESTEROL; TOCILIZUMAB; DISEASE
AB Objective To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. Methods This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. Results At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Conclusion Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.
C1 [Navarro-Millan, Iris; Yang, Shuo; Bridges, S. Louis, Jr.; Chen, Lang; Cofield, Stacey S.; Dell'Italia, Louis J.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Charles-Schoeman, Christina; Paulus, Harold E.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Bathon, Joan M.] Columbia Univ, New York, NY USA.
[Dell'Italia, Louis J.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Moreland, Larry W.] Univ Pittsburgh, Pittsburgh, PA USA.
[O'Dell, James R.] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Curtis, JR (reprint author), Univ Alabama Birmingham, 510 20th St South,FOT 802D, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
FU Arthritis Foundation; NIH (National Heart, Lung, and Blood Institute)
[5K23-HL-094834]; NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) [R21-AR-057913-01A1]; Margaret J.
Miller Endowed Professor of Arthritis Research Chair at the University
of Pittsburgh; NIH [AR-053351, R01-AR-052658]; Agency for Healthcare
Research and Quality [R01-HS-018517]; Amgen
FX Supported by the Arthritis Foundation (grant to Dr. Curtis). Dr.
Charles-Schoeman's work was supported by the NIH (National Heart, Lung,
and Blood Institute grant 5K23-HL-094834 and National Institute of
Arthritis and Musculoskeletal and Skin Diseases grant
R21-AR-057913-01A1). Dr. Moreland's work was supported by the Margaret
J. Miller Endowed Professor of Arthritis Research Chair at the
University of Pittsburgh. Dr. Curtis' work was supported by the NIH
(grant AR-053351) and the Agency for Healthcare Research and Quality
(grant R01-HS-018517). The Treatment of Early Rheumatoid Arthritis
(TEAR) biorepository was funded by the NIH (grant R01-AR-052658 to Dr.
Bridges). The TEAR trial was supported by Amgen.
NR 39
TC 39
Z9 41
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JUN
PY 2013
VL 65
IS 6
BP 1430
EP 1438
DI 10.1002/art.37916
PG 9
WC Rheumatology
SC Rheumatology
GA 155IG
UT WOS:000319740600004
PM 23460074
ER
PT J
AU Wofsy, D
Hillson, JL
Diamond, B
AF Wofsy, David
Hillson, Jan L.
Diamond, Betty
TI Comparison of Alternative Primary Outcome Measures for Use in Lupus
Nephritis Clinical Trials
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID CYCLOPHOSPHAMIDE; THERAPY
AB Objective Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to gain insight into which outcome measure, if any, was best able to discern differences among treatment groups. Methods Study patients received either abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids. Using data from this trial, the following primary outcome measures at 24 and 52 weeks were compared: complete response rate, major clinical response rate, total response rate (complete plus partial response), improvement in proteinuria, improvement in estimated glomerular filtration rate, and frequency of treatment failure. Time to complete response was also evaluated. Results Complete response rate, major clinical response rate, and time to complete response were the measures that best discriminated between the abatacept groups and placebo, and the sensitivities of these 3 measures were comparable. For these measures, sample sizes of 50 patients would have been sufficient to demonstrate a statistically significant difference between treatment and control at 52 weeks. Each of the other measures also discriminated between treatment and control, but much larger group sizes would have been required to determine statistical significance. Conclusion The choice of primary outcome measure can substantially influence the ability to detect therapeutic benefit in lupus nephritis trials. This study suggests that complete response rate, major clinical response rate at 52 weeks, and time to complete response may be the most sensitive outcome measures for detecting differences among therapeutic regimens.
C1 [Wofsy, David] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hillson, Jan L.] Bristol Myers Squibb Co, Princeton, NJ USA.
[Diamond, Betty] Feinstein Inst Med Res, Manhasset, NY USA.
RP Wofsy, D (reprint author), San Francisco VA Med Ctr, Arthrit Immunol Unit 111R, 4150 Clement St, San Francisco, CA 94121 USA.
EM wofsyd@medsch.ucsf.edu
FU Rosalind Russell Medical Research Center for Arthritis at the University
of California, San Francisco
FX Supported by the Rosalind Russell Medical Research Center for Arthritis
at the University of California, San Francisco.
NR 8
TC 31
Z9 31
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JUN
PY 2013
VL 65
IS 6
BP 1586
EP 1591
DI 10.1002/art.37940
PG 6
WC Rheumatology
SC Rheumatology
GA 155IG
UT WOS:000319740600021
PM 23529285
ER
PT J
AU Bar, M
Sandmaier, BM
Inamoto, Y
Bruno, B
Hari, P
Chauncey, T
Martin, PJ
Storb, R
Maloney, DG
Storer, B
Flowers, MED
AF Bar, Merav
Sandmaier, Brenda M.
Inamoto, Yoshihiro
Bruno, Benedetto
Hari, Parameswaran
Chauncey, Thomas
Martin, Paul J.
Storb, Rainer
Maloney, David G.
Storer, Barry
Flowers, Mary E. D.
TI Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after
Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of
the Initial CD3(+) T Cell Dose
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Donor lymphocyte infusion (DLI); Hematopoietic cell transplantation
(HCT); CD3(+) T cells; Graft-versus-host disease (GVHD); Adoptive
immunotherapy for relapse after HCT
ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CHRONIC
MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; LEUKOCYTE INFUSIONS;
ADOPTIVE IMMUNOTHERAPY; CHRONIC GRAFT; MULTIPLE-MYELOMA; WORKING PARTY;
CHEMOTHERAPY
AB The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in patients with chronic myeloid leukemia but limited in patients with other hematological malignancies. In this retrospective study, we evaluated the effect of initial DLI CD3(+) cell dose on graft-versus-host disease (GVHD) and overall survival after DLI given for relapse of any hematological malignancies after allogeneic hematopoietic cell transplantation (HCT) with high- or reduced-intensity conditioning. The cohort included 225 patients. Initial DLI CD3(+) cell dose per kilogram of recipient body weight was <= 1 x 10(7) (n = 84; group A), >1.0 to <10 x 10(7) (n = 58; group B), and >= 10 x 10(7) (n = 66; group C). The initial cell dose was unknown for the remaining 17 patients. Cumulative incidence rates of GVHD at 12 months after DLI were 21%, 45%, and 55% for groups A, B, and C, respectively. Multivariate analysis showed that initial DLI CD3(+) cell >= 10 x 10(7) dose per kilogram is associated with an increased risk of GVHD after DLI (P = .03). Moreover, an initial DLI CD3(+) cell dose of 10 x 10(7) or higher did not decrease the risk of relapse and did not improve overall survival. Thus, these results support the use of less than 10 x 10(7) CD3(+) cell per kilogram as the initial cell dose of DLI for treatment of persistent or recurrent hematological malignancy after HCT. (C) 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
C1 [Bar, Merav; Sandmaier, Brenda M.; Inamoto, Yoshihiro; Chauncey, Thomas; Martin, Paul J.; Storb, Rainer; Maloney, David G.; Storer, Barry; Flowers, Mary E. D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Bar, Merav; Sandmaier, Brenda M.; Chauncey, Thomas; Martin, Paul J.; Storb, Rainer; Maloney, David G.; Flowers, Mary E. D.] Univ Washington, Dept Med, Seattle, WA USA.
[Bruno, Benedetto; Storer, Barry] Univ Turin, Turin, Italy.
[Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Storer, Barry] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Bar, M (reprint author), Fred Hutchinson Canc Res Ctr, POB 19024, Seattle, WA 98109 USA.
EM mbar@u.washington.edu
OI Hari, Parameswaran/0000-0002-8800-297X
FU National Institutes of Health [CA78902, CA018029]
FX This study was supported in part by grants CA78902 and CA018029 from the
National Institutes of Health.
NR 36
TC 26
Z9 27
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUN
PY 2013
VL 19
IS 6
BP 949
EP 957
DI 10.1016/j.bbmt.2013.03.001
PG 9
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 156TX
UT WOS:000319847900018
PM 23523892
ER
PT J
AU Gupta, H
Ramanan, B
Gupta, PK
Fang, X
Polich, A
Modrykamien, A
Schuller, D
Morrow, LE
AF Gupta, Himani
Ramanan, Bala
Gupta, Prateek K.
Fang, Xiang
Polich, Ann
Modrykamien, Ariel
Schuller, Dan
Morrow, Lee E.
TI Impact of COPD on Postoperative Outcomes Results From a National
Database
SO CHEST
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; ABDOMINAL WOUND DEHISCENCE; AFFAIRS
SURGICAL RISK; NUTRITIONAL-STATUS; NONCARDIAC SURGERY; PROGNOSTIC VALUE;
RENAL-FAILURE; OLDER-ADULTS; MORTALITY; CARE
AB Background: Although COPD affects large sections of the population, its effects on postoperative outcomes have not been rigorously studied. The objectives of this study were to describe the prevalence of COPD in patients undergoing surgery and to analyze the associations between COPD and postoperative morbidity, mortality, and hospital length of stay.
Methods: Patients with COPD who underwent surgery were identified from the National Surgical Quality Improvement Program database (2007-2008). Univariate and multivariate analyses were performed on this multicenter, prospective data set (N = 468,795).
Results: COPD was present in 22,576 patients (4.82%). These patients were more likely to be older, men, white, smokers, and taking corticosteroids and had a lower BMI (P <.0001 for each). Median length of stay was 4 days for patients with COPD vs 1 day in those without COPD (P <.0001). Thirty-day morbidity rates were 25.8% and 10.2% for patients with and without COPD, respectively (P <.0001). Thirty-day death rates were 6.7% and 1.4% for patients with and without COPD, respectively (P <.0001). After controlling for >50 comorbidities through logistic regression modeling, COPD was independently associated with higher postoperative morbidity (OR, 1.35; 95% CI, 1.30-1.40; P <.0001) and mortality (OR, 1.29; 95% CI, 1.19-1.39; P <.0001). Multivariate analyses with each individual postoperative complication as the outcome of interest showed that COPD was associated with increased risk for postoperative pneumonia, respiratory failure, myocardial infarction, cardiac arrest, sepsis, return to the operating room, and renal insufficiency or failure (P <.05 for each).
Conclusions: COPD is common among patients undergoing surgery and is associated with increased morbidity, mortality, and length of stay.
C1 [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA.
[Ramanan, Bala] Creighton Univ, Dept Surg, Omaha, NE 68178 USA.
[Fang, Xiang] Creighton Univ, Biostat Core, Omaha, NE 68178 USA.
[Polich, Ann] Creighton Univ, Dept Med, Omaha, NE 68178 USA.
[Modrykamien, Ariel; Schuller, Dan; Morrow, Lee E.] Creighton Univ, Div Pulm Crit Care & Sleep Med, Omaha, NE 68178 USA.
[Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA.
RP Gupta, PK (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA.
EM pgupta@uwhealth.org
NR 42
TC 21
Z9 23
U1 2
U2 4
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2013
VL 143
IS 6
BP 1599
EP 1606
DI 10.1378/chest.12-1499
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 159UN
UT WOS:000320072900018
PM 23287892
ER
PT J
AU Young, B
AF Young, Bessie
TI Geography and ESRD Care: What Contributes Most to Hemodialysis
Patient-Provider Visit Variation?
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID CLINICAL-PERFORMANCE TARGETS; STAGE RENAL-DISEASE; REGIONAL-VARIATIONS;
PHYSICIAN CONTACT; OUTCOMES; FREQUENCY; QUALITY
C1 [Young, Bessie] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Kidney Res Inst, Div Nephrol, Seattle, WA 98195 USA.
RP Young, B (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 111-A RDU,1660 S Columbian Way, Seattle, WA 98108 USA.
EM youngb@u.washington.edu
NR 20
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2013
VL 8
IS 6
BP 898
EP 900
DI 10.2215/CJN.03970413
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 160VZ
UT WOS:000320149900003
PM 23749447
ER
PT J
AU Olson, J
Kalina, C
Berg, D
AF Olson, Jonathan
Kalina, Carol
Berg, Daniel
TI Foam Dressing as a Suturing Model
SO DERMATOLOGIC SURGERY
LA English
DT Letter
ID FLAP MECHANICS
C1 [Olson, Jonathan; Berg, Daniel] Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA.
[Kalina, Carol] Vet Affairs Puget Sound Healthcare Syst, Dermatol Sect, Seattle, WA USA.
RP Olson, J (reprint author), Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA.
NR 5
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
J9 DERMATOL SURG
JI Dermatol. Surg.
PD JUN
PY 2013
VL 39
IS 6
BP 952
EP 953
DI 10.1111/dsu.12169
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 157ST
UT WOS:000319920100020
PM 23464974
ER
PT J
AU Sacks, H
Symonds, ME
AF Sacks, Harold
Symonds, Michael E.
TI Anatomical Locations of Human trovvn Adipose Tissue Functional Relevance
and Implications in Obesity and Type 2 Diabetes
SO DIABETES
LA English
DT Article
ID BROWN ADIPOSE; ADULT HUMANS; SKIN TEMPERATURE; ENERGY-BALANCE;
GLUCOSE-UPTAKE; COLD-EXPOSURE; FAT; THERMOGENESIS; AGE; IDENTIFICATION
AB We will review information about and present hypotheses as to the anatomy of brown adipose tissue (BAT). Why is it located where it is in humans? Its anatomical distribution is likely to confer survival value by protecting critical organs from hypothermia by adaptive thermogenesis. Ultimately, the location and function will be important when considering therapeutic strategies for preventing and treating obesity and type 2 diabetes, in which case successful interventions will need to have a significant effect on BAT function in subjects living in a thermoneutral environment. In view of the diverse locations and potential differences in responsiveness between BAT depots, it is likely that BAT will be shown to have much more subtle and thus previously overlooked functions and regulatory control mechanisms.
C1 [Sacks, Harold] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90095 USA.
[Symonds, Michael E.] Univ Nottingham, Early Life Nutr Res Unit, Acad Div Child Hlth, Sch Clin Sci,Univ Hosp, Nottingham NG7 2RD, England.
RP Sacks, H (reprint author), VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90095 USA.
EM hsacks@hotmail.com
OI Symonds, Michael/0000-0001-9649-8963
NR 50
TC 46
Z9 47
U1 0
U2 16
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JUN
PY 2013
VL 62
IS 6
BP 1783
EP 1790
DI 10.2337/db12-1430
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 156SU
UT WOS:000319845000002
PM 23704519
ER
PT J
AU Bentov, I
Damodarasamy, M
Plymate, S
Reed, MJ
AF Bentov, Itay
Damodarasamy, Mamatha
Plymate, Stephen
Reed, May J.
TI B16/F10 tumors in aged 3D collagen in vitro simulate tumor growth and
gene expression in aged mice in vivo
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE Aged; Mice; Gene expression; B16/F10 melanoma tumors; 3D collagen
ID HORMONE RECEPTOR; HUMAN-MELANOMA; CANCER; OLD; CELLS; GELS
AB Although the incidence of cancer rises with age, tumor growth is often slowed in older hosts. The B16/F10 melanoma cell line is commonly used in murine models of age-related tumor growth suppression. We wished to determine if the growth pattern and gene expression of B16/10 tumors grown in aged mice could be simulated in 3D collagen matrices derived from aged mice. Outcome measures were tumor size in vitro and gene expression of the key growth regulatory molecules: growth hormone receptor (GHR), IL-10R beta, IL-4R alpha, and IL-6. B16/F10 tumors were grown in 20-25-mo-old C57/BL6 male mice. Tumor sizes ranged from 30 to 4,910 mg in vivo. Tumors from a subset of mice were removed after euthanasia, and equivalent amounts of each tumor were placed in aged 3D collagen and grown for 5 d. Tumor sizes in aged 3D collagen correlated highly with their original tumor size in vivo. Gene expression changes noted in vivo were also maintained during tumor growth in aged 3D collagen in vitro. The relative expression of GHR was increased, IL-10R beta was unchanged, and IL-4R alpha and IL-6 were decreased in the larger tumors relative to the smaller tumors in vitro, in a pattern similar to that noted in vivo. We propose that 3D matrices from aged mice provide an in vitro model of tumor growth that correlates highly with tumor size and expression of key regulatory molecules in vivo.
C1 [Bentov, Itay] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA.
[Damodarasamy, Mamatha; Plymate, Stephen; Reed, May J.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.
[Plymate, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Reed, May J.] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
RP Reed, MJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Box 359625,325 9th Ave, Seattle, WA 98104 USA.
EM mjr@uw.edu
FU [U54 CA126540]; [R01 AG015837]; [R21 AG033391]
FX The authors thank Nathan Karres, Margaret Eugenio, and Matthew NR
Johnson for assistance with the tumor samples. This work was supported
by U54 CA126540, R01 AG015837, and R21 AG033391.
NR 23
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JUN
PY 2013
VL 49
IS 6
BP 395
EP 399
DI 10.1007/s11626-013-9623-3
PG 5
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 162QG
UT WOS:000320279500001
PM 23661088
ER
PT J
AU Ganz, PA
Kwan, L
Castellon, SA
Oppenheim, A
Bower, JE
Silverman, DHS
Cole, SW
Irwin, MR
Ancoli-Israel, S
Belin, TR
AF Ganz, Patricia A.
Kwan, Lorna
Castellon, Steven A.
Oppenheim, Amy
Bower, Julienne E.
Silverman, Daniel H. S.
Cole, Steve W.
Irwin, Michael R.
Ancoli-Israel, Sonia
Belin, Thomas R.
TI Cognitive Complaints After Breast Cancer Treatments: Examining the
Relationship With Neuropsychological Test Performance
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID STANDARD-DOSE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; WORKING-MEMORY;
SYSTEMIC CHEMOTHERAPY; VERBAL MEMORY; SURVIVORS; WOMEN; DYSFUNCTION;
SYMPTOMS; THERAPY
AB Cognitive complaints are reported frequently after breast cancer treatments. Their association with neuropsychological (NP) test performance is not well-established.
Early-stage, posttreatment breast cancer patients were enrolled in a prospective, longitudinal, cohort study prior to starting endocrine therapy. Evaluation included an NP test battery and self-report questionnaires assessing symptoms, including cognitive complaints. Multivariable regression models assessed associations among cognitive complaints, mood, treatment exposures, and NP test performance.
One hundred eighty-nine breast cancer patients, aged 2165 years, completed the evaluation; 23.3% endorsed higher memory complaints and 19.0% reported higher executive function complaints (> 1 SD above the mean for healthy control sample). Regression modeling demonstrated a statistically significant association of higher memory complaints with combined chemotherapy and radiation treatments (P .01), poorer NP verbal memory performance (P .02), and higher depressive symptoms (P < .001), controlling for age and IQ. For executive functioning complaints, multivariable modeling controlling for age, IQ, and other confounds demonstrated statistically significant associations with better NP visual memory performance (P .03) and higher depressive symptoms (P < .001), whereas combined chemotherapy and radiation treatment (P .05) approached statistical significance.
About one in five postadjuvant treatment breast cancer patients had elevated memory and/or executive function complaints that were statistically significantly associated with domain-specific NP test performances and depressive symptoms; combined chemotherapy and radiation treatment was also statistically significantly associated with memory complaints. These results and other emerging studies suggest that subjective cognitive complaints in part reflect objective NP performance, although their etiology and biology appear to be multifactorial, motivating further transdisciplinary research.
C1 [Ganz, Patricia A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA.
[Belin, Thomas R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Ganz, Patricia A.; Kwan, Lorna; Oppenheim, Amy] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA.
[Ganz, Patricia A.; Cole, Steve W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Silverman, Daniel H. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Bower, Julienne E.; Irwin, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Castellon, Steven A.; Bower, Julienne E.; Irwin, Michael R.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Bower, Julienne E.; Cole, Steve W.; Irwin, Michael R.] Univ Calif Los Angeles, Semel Inst, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90095 USA.
[Castellon, Steven A.] VA Greater Los Angeles Hlth Care Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
RP Ganz, PA (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, A2-125 CHS,Box 956900, Los Angeles, CA 90095 USA.
EM pganz@mednet.ucla.edu
RI Irwin, Michael/H-4870-2013
OI Irwin, Michael/0000-0002-1502-8431
FU National Cancer Institute [R01 CA 109650, R01-AG034588, R01-AG026364,
R01-CA119159, R01-HL079955, R01 HL095799, P30-AG028748, UL RR 033176,
R01CA112035]; Breast Cancer Research Foundation; National Institutes of
Health; Cousins Center for Psychoneuroimmunology
FX This research was supported by funding from the National Cancer
Institute R01 CA 109650 and the Breast Cancer Research Foundation (to
PAG); the National Institutes of Health and National Cancer Institute
R01-AG034588; R01-AG026364; R01-CA119159; R01-HL079955; R01 HL095799;
P30-AG028748; UL RR 033176 (to MRI), and the Cousins Center for
Psychoneuroimmunology (to MRI); the National Cancer Institute
R01CA112035 (to SA-I).
NR 51
TC 43
Z9 44
U1 1
U2 31
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD JUN
PY 2013
VL 105
IS 11
BP 791
EP 801
DI 10.1093/jnci/djt073
PG 11
WC Oncology
SC Oncology
GA 160QK
UT WOS:000320134100010
PM 23606729
ER
PT J
AU Abrahamson, EE
Foley, LM
DeKosky, ST
Hitchens, TK
Ho, C
Kochanek, PM
Ikonomovic, MD
AF Abrahamson, Eric E.
Foley, Lesley M.
DeKosky, Steven T.
Hitchens, T. Kevin
Ho, Chien
Kochanek, Patrick M.
Ikonomovic, Milos D.
TI Cerebral blood flow changes after brain injury in human amyloid-beta
knock-in mice
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE Alzheimer's disease; amyloid; arterial spin-labeling MRI; blood flow;
brain injury; statin
ID TRAUMA-INDUCED INCREASES; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE;
PRECURSOR PROTEIN; A-BETA; FUNCTIONAL HYPEREMIA; REDUCTASE INHIBITORS;
OXIDATIVE STRESS; SIMVASTATIN; ACTIVATION
AB Traumatic brain injury (TBI) is an environmental risk factor for Alzheimer's disease (AD). Increased brain concentrations of amyloid-beta (A beta) peptides and impaired cerebral blood flow (CBF) are shared pathologic features of TBI and AD and promising therapeutic targets. We used arterial spin-labeling magnetic resonance imaging to examine if CBF changes after TBI are influenced by human A beta and amenable to simvastatin therapy. CBF was measured 3 days and 3 weeks after controlled cortical impact (CCI) injury in transgenic human A beta-expressing APP(NLh/NLh) mice compared to murine A beta-expressing C57Bl/6J wild types. Compared to uninjured littermates, CBF was reduced in the cortex of the injured hemisphere in both A beta transgenics and wild types; deficits were more pronounced in the transgenic group, which exhibited injury-induced increased concentrations of human A beta. In the hemisphere contralateral to CCI, CBF levels were stable in A beta transgenic mice but increased in wild-type mice, both relative to uninjured littermates. Post-injury treatment of A beta transgenic mice with simvastatin lowered brain A beta concentrations, attenuated deficits in CBF ipsilateral to injury, restored hyperemia contralateral to injury, and reduced brain tissue loss. Future studies examining long-term effects of simvastatin therapy on CBF and chronic neurodegenerative changes after TBI are warranted.
C1 [Abrahamson, Eric E.; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Dept Biol Sci, VA Pittsburgh Healthcare Syst, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA.
[DeKosky, Steven T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA.
[DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
[Kochanek, Patrick M.] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
RP Ikonomovic, MD (reprint author), Univ Pittsburgh, Dept Neurol, BSTWR S-521,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM ikonomovicmd@upmc.edu
RI Kochanek, Patrick/D-2371-2015; Ho, Chien/O-6112-2016
OI Kochanek, Patrick/0000-0002-2627-913X; Ho, Chien/0000-0002-4094-9232
FU NIH [P50 NS30318]; National Institutes of Health [P41-EB001977]
FX Supported by NIH P50 NS30318. The Pittsburgh NMR Center for Biomedical
Research is supported by a grant from the National Institutes of Health
(P41-EB001977). We acknowledge expert technical assistance provided by
Mr. William Paljug, Mr. John Melick, and Ms. Lan Shao.
NR 37
TC 5
Z9 5
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD JUN
PY 2013
VL 33
IS 6
BP 826
EP 833
DI 10.1038/jcbfm.2013.24
PG 8
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 156KP
UT WOS:000319821100005
PM 23443172
ER
PT J
AU Basile, JN
Bloch, MJ
AF Basile, Jan N.
Bloch, Michael J.
TI Determining the Relative Antihypertensive Potency and Relative
Cardiovascular Risk Reduction Associated With Different Thiazide and
Thiazide-Type Diuretics
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
C1 [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med Geriatr, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA.
[Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA.
RP Bloch, MJ (reprint author), Univ Hlth Syst, 1500 East 2nd St,Suite 302, Reno, NV 89502 USA.
EM mbloch@aol.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2013
VL 15
IS 6
BP 359
EP 361
DI 10.1111/jch.12079
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 157MA
UT WOS:000319899000001
PM 23730981
ER
PT J
AU Naab, F
Brown, R
Heidrich, S
AF Naab, Florence
Brown, Roger
Heidrich, Susan
TI Psychosocial Health of Infertile Ghanaian Women and Their Infertility
Beliefs
SO JOURNAL OF NURSING SCHOLARSHIP
LA English
DT Article
DE Beliefs; infertility; psychosocial; women
ID REPRESENTATIONAL APPROACH; PATIENT EDUCATION; TREATMENT-SEEKING;
SOUTH-AFRICA; RESPONSES; PREVALENCE; VALIDATION; CHILDREN; STRESS; TRIAL
AB Purpose The purpose of this study was to describe infertile women's psychosocial health problems and their infertility-related beliefs and examine the relationships between their beliefs about infertility and psychosocial health problems. Design The study was a descriptive correlational cross-sectional survey. Women (N = 203) who were receiving treatment for fertility problems in two public hospitals in Ghana were recruited. Methods Participants completed a Fertility Belief Questionnaire; measures of infertility-related stress, anxiety, social isolation, perceived stigma, and depressive symptoms; and sociodemographic and infertility-related health questions. Descriptive statistics, Pearson's correlations, and hierarchical regression analyses were performed. Findings The women reported high levels of infertility-related stress, low levels of anxiety, some social isolation, low levels of perceived stigma, and high levels of depressive symptoms. Beliefs that infertility has negative consequences and that one has a poor understanding of infertility were significantly related to infertility-related stress, social isolation, and depressive symptoms. Belief that infertility could be managed by personal control was significantly related to lower levels of anxiety and perceived stigma. Beliefs about consequences, illness coherence, and personal control explained significant proportions of the variances in anxiety, stress, social isolation, perceived stigma, and depressive symptoms. Conclusions Infertile women in Ghana have psychosocial health problems that are associated with their beliefs about infertility. Clinical Relevance Findings have implications for nursing care of infertile women in Ghana.
C1 [Naab, Florence] Univ Ghana, Dept Maternal & Child Hlth, Sch Nursing, Coll Hlth Sci, Legon, Accra, Ghana.
[Brown, Roger] Univ Wisconsin, Sch Nursing, Madison, WI USA.
[Brown, Roger] Univ Wisconsin, Sch Med, Madison, WI USA.
[Brown, Roger] Univ Wisconsin, Sch Publ Hlth, Madison, WI USA.
[Heidrich, Susan] Univ Wisconsin, Madison, WI USA.
[Heidrich, Susan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Naab, F (reprint author), Univ Ghana, Dept Maternal & Child Hlth, Sch Nursing, Coll Hlth Sci, POB LG 43, Legon Boundary, Accra, Ghana.
EM florencenaab@yahoo.com
NR 41
TC 4
Z9 4
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6546
J9 J NURS SCHOLARSHIP
JI J. Nurs. Scholarsh.
PD JUN
PY 2013
VL 45
IS 2
BP 132
EP 140
DI 10.1111/jnu.12013
PG 9
WC Nursing
SC Nursing
GA 157OA
UT WOS:000319906400005
PM 23731032
ER
PT J
AU Sherry, D
Fennessy, MM
Benavente, VG
Ruppar, TM
Collins, EG
AF Sherry, Daisy
Fennessy, Michelle M.
Benavente, Viola G.
Ruppar, Todd M.
Collins, Eileen G.
TI Important Considerations When Applying for a Postdoctoral Fellowship
SO JOURNAL OF NURSING SCHOLARSHIP
LA English
DT Article
DE Postdoctoral nurse fellowship; graduate training; nurse education
ID OPPORTUNITIES; GRANTS; NINR
AB Purpose To examine important decision points that graduates should consider before applying for a postdoctoral fellowship. Methods A literature review was performed. Findings and Conclusions A synthesis of the present data on the postdoctoral fellowship, eligibility criteria, application process, and important considerations was provided. Experiential knowledge from four present postdoctoral fellows was included. The goals, advantages, and disadvantages of the fellowship were discussed. In conclusion, the postdoctoral fellowship was examined to offer important considerations in the decision to pursue this opportunity. Clinical Relevance The clinical relevance of this article is related to the training and education of nurses to become the next generation of independent, successful scholars and scientists. Postdoctoral training adds valuable contributions and quality to the field of nursing.
C1 [Sherry, Daisy] US Dept Vet Affairs, Edward Hines Jr VA Hosp, Hines, IL 60141 USA.
[Fennessy, Michelle M.] Univ Calif Davis Hlth Syst, Betty Irene Moore Sch Nursing, Sacramento, CA USA.
[Benavente, Viola G.] Boston Coll, William F Connell Sch Nursing, Chestnut Hill, MA 02167 USA.
[Ruppar, Todd M.] Univ Missouri, Sinclair Sch Nursing, Columbia, MO USA.
[Collins, Eileen G.] US Dept Vet Affairs, Dept Rehabil, Hines, IL 60141 USA.
RP Sherry, D (reprint author), US Dept Vet Affairs, Edward Hines Jr VA Hosp, 5000 S 5th Ave 151H, Hines, IL 60141 USA.
EM daisyc6@juno.com
RI Ruppar, Todd/B-8091-2015
OI Ruppar, Todd/0000-0003-0794-5544
FU U.S. Department of Veterans Affairs; Gordon & Betty Moore Foundation;
Ruth L. Kirschstein National Research Institutional Training Program;
National Institutes of Health, National Institute of Nursing Research
[T32NR007106]; John A. Hartford Foundation; Atlantic Philanthropies
Claire M. Fagin Fellowship
FX Dr. Sherry is funded by the U.S. Department of Veterans Affairs
Postdoctoral Fellowship. Dr. Fennessy is funded by a fellowship through
the Gordon & Betty Moore Foundation. Dr. Benavente is funded by a Ruth
L. Kirschstein National Research Institutional Training Program funded
by the National Institutes of Health, National Institute of Nursing
Research, T32NR007106 Biobehavioral Nursing Research Training Program
(principal investigator Dr. Carol Landis). Dr. Ruppar is funded by a
John A. Hartford Foundation and Atlantic Philanthropies Claire M. Fagin
Fellowship.
NR 21
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6546
J9 J NURS SCHOLARSHIP
JI J. Nurs. Scholarsh.
PD JUN
PY 2013
VL 45
IS 2
BP 210
EP 218
DI 10.1111/jnu.12012
PG 9
WC Nursing
SC Nursing
GA 157OA
UT WOS:000319906400014
PM 23452068
ER
PT J
AU Qiu, JY
Chen, WJ
Gao, XF
Xu, Y
Tong, HQ
Yang, M
Xiao, ZP
Yang, M
AF Qiu, Jianyin
Chen, Weijun
Gao, Xiufei
Xu, Yong
Tong, Huiqi
Yang, Min
Xiao, Zeping
Yang, Min
TI A randomized controlled trial of group cognitive behavioral therapy for
Chinese breast cancer patients with major depression
SO JOURNAL OF PSYCHOSOMATIC OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE Breast cancer; group cognitive behavioral therapy; major depression
ID WOMEN; PREVALENCE; DISORDERS; SURVIVORS; INTERVENTION; SYMPTOMS;
EFFICACY; ANXIETY
AB Background: This study aims to evaluate the effects of Group Cognitive Behavioral Therapy (GCBT) in treating major depression in Chinese women with breast cancer.
Methods: Sixty-two breast cancer patients diagnosed with major depression were randomly assigned to GCBT group (N=31) or a waiting list control group provided with an educational booklet (N=31). The primary outcome measure was the 17-Item Hamilton Depression Rating Scale (17-HAMD). The second outcome measures were Self-Rating Anxiety Scale, Functional Assessment of Cancer Therapy - Breast and Self-Esteem Scale (SES). Assessments were carried out at completion of the study and six-month afterwards.
Results: Patients in the GCBT group had a significant reduction in the 17-HAMD mean score by 9 points (p<0.001), more than any reduction among patients in the control group from baseline to the end of therapy and a significant 7 points (p<0.001) more reduction from baseline to six-month follow-up. GCBT also yielded significantly greater improvement than the control group with regard to quality of life (QoL; p<0.01) and self-esteem (p<0.05). No significant differences were found between groups on improving anxiety (p>0.05).
Conclusion: The results of this trial suggest that GCBT is effective for treating major depression, as well as for improving QoL and self-esteem in breast cancer patients.
C1 [Qiu, Jianyin; Chen, Weijun; Xu, Yong; Xiao, Zeping] Shanghai Jiao Tong Univ, Dept Clin Psychol, Shanghai Mental Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China.
[Gao, Xiufei] Shanghai Univ TCM, Longhua Hosp, Dept Breast Care, Shanghai, Peoples R China.
[Tong, Huiqi] San Francisco VA Med Ctr, Womens Clin, San Francisco, CA USA.
[Yang, Min; Yang, Min] Univ Nottingham, Dept Psychiat, Nottingham NG7 2RD, England.
RP Yang, M (reprint author), Univ Nottingham, Dept Psychiat, Univ Pk, Nottingham NG7 2RD, England.
EM Min.Yang@nottingham.ac.uk
FU WHO [WP/2006/CHN/MNH/2.4/001]
FX This study was funded by grant number WP/2006/CHN/MNH/2.4/001 from WHO.
NR 42
TC 8
Z9 10
U1 3
U2 26
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0167-482X
J9 J PSYCHOSOM OBST GYN
JI J. Psychosomat. Obstet. Gynecol.
PD JUN
PY 2013
VL 34
IS 2
BP 60
EP 67
DI 10.3109/0167482X.2013.766791
PG 8
WC Psychology, Clinical; Obstetrics & Gynecology; Psychiatry
SC Psychology; Obstetrics & Gynecology; Psychiatry
GA 155LB
UT WOS:000319748300002
PM 23646866
ER
PT J
AU Appleton, KM
Luttrell, LM
AF Appleton, Kathryn M.
Luttrell, Louis M.
TI Emergent biological properties of arrestin pathway-selective biased
agonism
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE Arrestin; functional genomics; functional selectivity; G protein-coupled
receptor; heterotrimeric G protein; pharmacology
ID PROTEIN-COUPLED RECEPTOR; PARATHYROID-HORMONE; BETA(2)-ADRENERGIC
RECEPTOR; CRYSTAL-STRUCTURE; CARDIAC MYOCYTES; LIGAND EFFICACY; IN-VIVO;
ACTIVATION; REVEALS; ALLOSTERISM
AB Our growing appreciation of the pluridimensionality of G protein-coupled receptor ( GPCR) signaling, combined with the phenomenon of orthosteric ligand "bias'', has created the possibility of drugs that selectively modulate different aspects of GPCR function for therapeutic benefit. When viewed from the short-term perspective, e.g. changes in receptor conformation, effector coupling or second messenger generation, biased ligands appear to activate a subset of the response profile produced by a conventional agonist. Yet when examined in vivo, the limited data available suggest that biased ligand effects can diverge from their conventional counterparts in ways that cannot be predicted from their in vitro efficacy profile. What is currently missing, at least with respect to G protein and arrestin pathway-selective ligands, is a rational framework for relating the in vitro efficacy of a "biased'' agonist to its in vivo actions that will enable drug screening programs to identify ligands with the desired biological effects.
C1 [Appleton, Kathryn M.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Coll Med, Dept Med, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Coll Med, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
RP Luttrell, LM (reprint author), Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 816 CSB,MSC624, Charleston, SC 29425 USA.
EM luttrell@musc.edu
FU NIDDK NIH HHS [DK64353, DK55524]
NR 34
TC 5
Z9 5
U1 0
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1079-9893
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD JUN
PY 2013
VL 33
IS 3
BP 153
EP 161
DI 10.3109/10799893.2013.769004
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 155LI
UT WOS:000319749200005
PM 23448506
ER
PT J
AU Appleton, KM
Lee, MH
Alele, C
Luttrell, DK
Peterson, YK
Luttrell, LM
AF Appleton, Kathryn M.
Lee, Mi-Hye
Alele, Christine
Luttrell, Deirdre K.
Peterson, Yuri K.
Luttrell, Louis M.
TI DISSOCIATION OF ARRESTIN-DEPENDENT SIGNALING FROM RECEPTOR
DESENSITIZATION USING FUNCTIONALLY-SELECTIVE PARATHYROID HORMONE
RECEPTOR LIGANDS
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Meeting Abstract
C1 [Appleton, Kathryn M.; Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Lee, Mi-Hye; Alele, Christine; Luttrell, Louis M.] Med Univ S Carolina, Dept Med & Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Deirdre K.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1079-9893
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD JUN
PY 2013
VL 33
IS 3
BP 184
EP 184
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 155LI
UT WOS:000319749200011
ER
PT J
AU Leonard, A
Appleton, KM
Luttrell, LM
Peterson, YK
AF Leonard, Anthony
Appleton, Kathryn M.
Luttrell, Louis M.
Peterson, Yuri K.
TI A HIGH-CONTENT, LIVE-CELL, AND REAL-TIME APPROACH TO THE QUANTITATION OF
LIGAND INDUCED B-ARRESTIN2 AND CLASS A/CLASS B GPCR MOBILIZATION
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Meeting Abstract
C1 [Leonard, Anthony; Appleton, Kathryn M.; Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Med & Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1079-9893
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD JUN
PY 2013
VL 33
IS 3
BP 199
EP 199
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 155LI
UT WOS:000319749200057
ER
PT J
AU Sripada, RK
Rauch, SAM
Tuerk, PW
Smith, E
Defever, AM
Mayer, RA
Messina, M
Venners, M
AF Sripada, Rebecca K.
Rauch, Sheila A. M.
Tuerk, Peter W.
Smith, Erin
Defever, Andrew M.
Mayer, Rebecca A.
Messina, Michael
Venners, Margaret
TI Mild Traumatic Brain Injury and Treatment Response in Prolonged Exposure
for PTSD
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS;
RANDOMIZED CONTROLLED-TRIAL; THERAPY; VETERANS; IRAQ; METAANALYSIS;
AFGHANISTAN; MECHANISMS; CLINICIAN
AB A proportion of U.S. veterans returning from Iraq and Afghanistan have experienced mild traumatic brain injury (mTBI), which is associated with increased risk for developing posttraumatic stress disorder (PTSD). Prolonged Exposure (PE) has proven effectiveness in the treatment of PTSD; however, some clinicians have reservations about using PE with individuals with a history of mTBI. We examined the impact of PE for veterans with PTSD and with or without a history of mTBI in a naturalistic sample of 51 veterans who received PE at a Veterans Health Administration PTSD clinic. We also analyzed previously collected data from a controlled trial of 22 veterans randomly assigned to PE or present centered therapy. For both sets of data, we found that PE reduced symptom levels and we also did not detect an effect for mTBI, suggesting that PE may be helpful for individuals with PTSD and a history of mTBI.
C1 [Sripada, Rebecca K.; Rauch, Sheila A. M.; Smith, Erin; Defever, Andrew M.; Mayer, Rebecca A.; Messina, Michael; Venners, Margaret] Univ Michigan, Sch Med, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA.
[Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
RP Sripada, RK (reprint author), VA Serious Mental Illness Treatment Resource & Ev, Ann Arbor, MI USA.
EM rekaufma@umich.edu
RI Rauch, Sheila/K-4450-2015
OI Rauch, Sheila/0000-0001-9686-4011; Sripada, Rebecca/0000-0002-2844-3458
NR 48
TC 14
Z9 14
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2013
VL 26
IS 3
BP 369
EP 375
DI 10.1002/jts.21813
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 157GA
UT WOS:000319882800009
PM 23696427
ER
PT J
AU Chuang, PY
Fu, J
He, JC
AF Chuang, Peter Y.
Fu, Jia
He, John C.
TI Capturing the in vivo molecular signature of the podocyte
SO KIDNEY INTERNATIONAL
LA English
DT Editorial Material
ID GLOMERULI
AB The podocyte has an essential role in glomerular function. When cultured ex vivo, podocytes do not recapitulate their in vivo phenotype. Several technical barriers have prevented isolation of podocytes from animals with sufficient yield and purity to allow genome-wide assessment of their molecular fingerprint. Boerries et al. overcame some of these barriers and characterized the transcriptome and proteome of freshly isolated podocytes. These data sets and isolation protocol are valuable resources for the podocyte research community.
C1 [Chuang, Peter Y.; He, John C.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Fu, Jia] Nanjing Univ, Sch Med, Jinling Hosp, Res Inst Nephrol, Nanjing 210008, Jiangsu, Peoples R China.
[He, John C.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA.
RP Chuang, PY (reprint author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM cijiang.he@mssm.edu
FU NIDDK NIH HHS [R01 DK088541, 5K08-DK082760, P01 DK056492, P01-DK56492,
K08 DK082760, R01 DK078897, 1R01-DK088541]
NR 9
TC 0
Z9 0
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2013
VL 83
IS 6
BP 986
EP 988
DI 10.1038/ki.2013.65
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 155ID
UT WOS:000319740300003
PM 23727999
ER
PT J
AU Bhensdadia, NM
Hunt, KJ
Lopes-Virella, MF
Tucker, JM
Mataria, MR
Alge, JL
Neely, BA
Janech, MG
Arthur, JM
AF Bhensdadia, Nishant M.
Hunt, Kelly J.
Lopes-Virella, Maria F.
Tucker, J. Michael
Mataria, Mohammad R.
Alge, Joseph L.
Neely, Benjamin A.
Janech, Michael G.
Arthur, John M.
CA Vet Affairs Diabet Trial VADT Stud
TI Urine haptoglobin levels predict early renal functional decline in
patients with type 2 diabetes
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE biological markers; chronic kidney disease; diabetes; diabetic
nephropathy; type 2 diabetes; urine
ID GELATINASE-ASSOCIATED LIPOCALIN; CLINICAL PROTEINURIA; GLUCOSE CONTROL;
BLOOD-PRESSURE; RISK-FACTORS; MICROALBUMINURIA; NEPHROPATHY;
COMPLICATIONS; INSUFFICIENCY; ALBUMINURIA
AB Diabetic nephropathy is the leading cause of end-stage renal disease. The urinary albumin to creatinine ratio is used as a predictor for the development of nephropathy but it is neither sensitive nor specific. Here we used liquid chromatography/mass spectrometry on urine of eight normoalbuminuric patients with type 2 diabetes from the VA Diabetes Trial to identify candidate markers for loss of renal function. Initial verification of seven markers (agrin, haptoglobin, mannan-binding lectin serine protease 2, LAMP-2, angiotensinogen, NGAL, and uromodulin) in the urine of an additional 30 patients showed that haptoglobin was the best predictor of early renal functional decline. We then measured this in the urine of 204 patients with type 2 diabetes who did not yet have significant kidney disease (estimated glomerular filtration rate stage 2 or better and an albumin to creatinine ratio < 300mg/g). In comparing the highest to lowest tertiles, the odds ratio for having early renal function decline was 2.70 (CI: 1.15, 6.32) using the haptoglobin to creatinine ratio compared with 2.50 (CI 1.14, 5.48) using the albumin to creatinine ratio after adjusting for treatment group and use of ACE inhibitors. Addition of the haptoglobin to creatinine ratio to a model using the albumin to creatinine ratio to predict early renal function decline resulted in improved predictive performance. Thus, the haptoglobin to creatinine ratio may be useful to predict patients with type 2 diabetes at risk of nephropathy before the development of macroalbuminuria or reduced glomerular filtration rate.
C1 [Bhensdadia, Nishant M.; Hunt, Kelly J.; Lopes-Virella, Maria F.; Tucker, J. Michael; Mataria, Mohammad R.; Alge, Joseph L.; Neely, Benjamin A.; Janech, Michael G.; Arthur, John M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.; Janech, Michael G.; Arthur, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, 829 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM arthurj@musc.edu
OI Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066;
Janech, Michael/0000-0002-3202-4811
FU Biomedical Laboratory Research and Development Program of the Department
of Veterans Affairs; NIH [R01 DK080234, UL1 RR029882, ULI RR029882];
Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development; VA Merit Review Award
FX This study was supported by a merit review award (JMA) and a career
development 2 award (MGJ) from the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs and NIH grants
R01 DK080234 and UL1 RR029882. The VADT study was sponsored by the
Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development. The contents do not necessarily represent
the views of the Department of Veterans Affairs or the United States
Government. Portions of the data were presented in abstract form at the
2012 American Society of Nephrology meeting.; Sources of support that
require acknowledgment:; VA Merit Review Award; NIH R01DK080234; ULI
RR029882
NR 41
TC 20
Z9 25
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2013
VL 83
IS 6
BP 1136
EP 1143
DI 10.1038/ki.2013.57
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 155ID
UT WOS:000319740300022
PM 23536133
ER
PT J
AU Krings, G
Ramachandran, R
Jain, D
Wu, TT
Yeh, MM
Torbenson, M
Kakar, S
AF Krings, Gregor
Ramachandran, Rageshree
Jain, Dhanpat
Wu, Tsung-Teh
Yeh, Matthew M.
Torbenson, Michael
Kakar, Sanjay
TI Immunohistochemical pitfalls and the importance of glypican 3 and
arginase in the diagnosis of scirrhous hepatocellular carcinoma
SO MODERN PATHOLOGY
LA English
DT Article
DE arginase; cholangiocarcinoma; glypican 3; scirrhous hepatocellular
carcinoma
ID TISSUE MICROARRAY ANALYSIS; LIVER-TRANSPLANTATION; INTRAHEPATIC
CHOLANGIOCARCINOMA; CYTOKERATIN-19 EXPRESSION; HEPATOCYTE PARAFFIN-1;
METASTATIC CARCINOMA; NEOPLASTIC TISSUES; ONCOFETAL PROTEIN;
NEEDLE-BIOPSY; MARKER
AB Scirrhous hepatocellular carcinoma is a rare ill-defined morphological subtype of hepatocellular carcinoma characterized by marked stromal fibrosis. This variant can be difficult to distinguish from intrahepatic cholangiocarcinoma and metastatic adenocarcinoma, especially on needle biopsies. We performed immunohistochemistry for hepatocellular and adenocarcinoma-associated markers on 20 scirrhous hepatocellular carcinoma cases and compared the results with classical hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Scirrhous hepatocellular carcinomas were significantly less likely to be HepPar-1 positive than classical hepatocellular carcinomas (26% and 74%, respectively; P<0.001) and were significantly more likely to express adenocarcinoma-associated markers such as epithelial cell adhesion molecule (63 vs 11%; P<0.001), cytokeratin 19 (26 vs 2%; P<0.001), and cytokeratin 7 (53 vs 2%; P<0.001). At least one of these adenocarcinoma-related markers was positive in 80% of scirrhous hepatocellular carcinoma cases. Glypican 3 and arginase were positive in 79% and 85% of cases of scirrhous hepatocellular carcinoma, respectively; the combined use of these two markers yielded 100% sensitivity for scirrhous hepatocellular carcinoma. In conclusion, the scirrhous morphology, absence of HepPar-1 staining, and frequent positivity with adenocarcinoma-related markers in scirrhous hepatocellular carcinoma can lead to an erroneous diagnosis of adenocarcinoma. Glypican 3 and arginase are the most reliable markers for identifying hepatocellular differentiation in this setting.
C1 [Krings, Gregor; Ramachandran, Rageshree; Kakar, Sanjay] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
[Jain, Dhanpat] Yale Univ, Dept Pathol, New Haven, CT USA.
[Wu, Tsung-Teh] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Torbenson, Michael] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
[Kakar, Sanjay] Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
RP Kakar, S (reprint author), San Francisco VA Med Ctr, Dept Anat Pathol, 4150 Clement St, San Francisco, CA 94121 USA.
EM sanjay.kakar@ucsf.edu
FU Department of Pathology, University of California, San Francisco
FX The study was funded by the Department of Pathology, University of
California, San Francisco.
NR 50
TC 18
Z9 20
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD JUN
PY 2013
VL 26
IS 6
BP 782
EP 791
DI 10.1038/modpathol.2012.243
PG 10
WC Pathology
SC Pathology
GA 156EY
UT WOS:000319805800004
PM 23348905
ER
PT J
AU Duong, TQ
AF Duong, Timothy Q.
TI Magnetic resonance imaging of perfusion-diffusion mismatch in rodent and
non-human primate stroke models
SO NEUROLOGICAL RESEARCH
LA English
DT Review
DE Magnetic resonance imaging; Perfusion-diffusion mismatch; Apparent
diffusion coefficient; Cerebral blood flow; Diffusion-weighted imaging;
Perfusion-weighted imaging; Experimental stroke model; Rodents; Oxygen
challenge; Predictive mode; Rats; Hyperperfusion; Functional magnetic
resonance imaging
ID ISCHEMIC TISSUE FATE; CEREBRAL-BLOOD-FLOW; QUANTITATIVE PREDICTION;
PLASMINOGEN ACTIVATOR; FOCAL ISCHEMIA; FUNCTIONAL MRI; BRAIN-INJURY;
RAT-BRAIN; BASE-LINE; BOLD
AB Stroke is a leading cause of death and long-term disability. Non-invasive magnetic resonance imaging (MRI) has been widely used for the early detection of ischemic stroke and the longitudinal monitoring of novel treatment strategies. Recent advances in MRI techniques have enabled improved sensitivity and specificity to detecting ischemic brain injury and monitoring functional recovery. This review describes recent progresses in the development and application of multimodal MRI and image analysis techniques to study experimental stroke in rats and non-human primates.
C1 [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA.
RP Duong, TQ (reprint author), Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NIH [R01-NS45879]; American Heart Association [EIA 0940104N, SDG
0830293N]
FX This work was supported by the NIH (R01-NS45879) and the American Heart
Association (EIA 0940104N and SDG 0830293N).
NR 46
TC 2
Z9 2
U1 0
U2 4
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 0161-6412
J9 NEUROL RES
JI Neurol. Res.
PD JUN
PY 2013
VL 35
IS 5
BP 465
EP 469
DI 10.1179/1743132813Y.0000000211
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 156IY
UT WOS:000319816500005
PM 23594679
ER
PT J
AU Beacham, BL
Deatrick, JA
AF Beacham, Barbara L.
Deatrick, Janet A.
TI Health Care Autonomy in Children with Chronic Conditions Implications
for Self-Care and Family Management
SO NURSING CLINICS OF NORTH AMERICA
LA English
DT Article
DE Child; Development; Chronic health conditions; Family management;
Self-care; Autonomy
ID CHRONIC ILLNESS; ADOLESCENT AUTONOMY; CHILDHOOD; PERSPECTIVES;
PERCEPTIONS; ADHERENCE; SUPPORT; IMPACT; STYLE
AB Health care autonomy typically occurs during late adolescence but health care providers and families often expect children with chronic health conditions to master self-care earlier. Few studies have examined the development of health care autonomy as it pertains to self-care and family management. This review links the 3 concepts and discusses the implications for families and health care providers. Case studies are provided as exemplars to highlight areas where intervention and research is needed.
C1 [Beacham, Barbara L.; Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
RP Beacham, BL (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Room 243 2Lower Claire M Fagin Hall,418 Curie Blv, Philadelphia, PA 19104 USA.
EM blynne@nursing.upenn.edu
FU National Institutes of Health, National Institute of Nursing Research
[F31NR11524, T32NR007100]; Sigma Theta Tau Xi Chapter, University of
Pennsylvania
FX This work was supported by grant nos. F31NR11524 and T32NR007100 from
the National Institutes of Health, National Institute of Nursing
Research and by a grant from the Sigma Theta Tau Xi Chapter, University
of Pennsylvania.
NR 27
TC 4
Z9 6
U1 2
U2 22
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0029-6465
J9 NURS CLIN N AM
JI Nurs. Clin. North Am.
PD JUN
PY 2013
VL 48
IS 2
BP 305
EP +
DI 10.1016/j.cnur.2013.01.010
PG 14
WC Nursing
SC Nursing
GA 158FJ
UT WOS:000319954600010
PM 23659815
ER
PT J
AU Hebert, PL
McBean, AM
O'Connor, H
Frank, B
Good, C
Maciejewski, ML
AF Hebert, Paul L.
McBean, Alexander Marshall
O'Connor, Heidi
Frank, Barbara
Good, Charles
Maciejewski, Matthew L.
TI Time until incident dementia among Medicare beneficiaries using
centrally acting or non-centrally acting ACE inhibitors
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE dementia; hypertension; centrally active; ACE inhibitor; Alzheimer's;
Medicare; pharmacoepidemiology
ID CONVERTING ENZYME-INHIBITORS; ALZHEIMERS-DISEASE; INSTRUMENTAL
VARIABLES; PRESCRIBING PREFERENCE; COGNITIVE IMPAIRMENT; PROSPECTIVE
COHORT; PROPENSITY-SCORE; ANGIOTENSIN; PERINDOPRIL; PERFORMANCE
AB Background Centrally active (CA) angiotensin-converting enzyme inhibitors (ACEIs) are able to cross the blood-brain barrier. Small observational studies and mouse models suggest that use of CA versus non-CA ACEIs is associated with a reduced incidence of Alzheimer's disease and related dementias (ADRD). Objective The aim of this research was to assess the effect of CA versus non-CA ACEI use on incident ADRD. Design This is a retrospective cohort study with a non-equivalent control group. Setting and patients This study used a national random sample of Medicare beneficiaries enrolled in Part D with an ACEI prescription. A prevalent ACEI user cohort included beneficiaries (n=107179) with an ACEI prescription prior to 30 April 2007; beneficiaries without an ACEI prescription before this date were defined as incident ACEI users (n=9840). Measurements The main outcome was time until first diagnosis of ADRD in Medicare claims. Results The unadjusted, propensity-matched and instrumental variable analyses of both the prevalent and incident ACEI user cohorts consistently showed similar time until incident ADRD in those taking CA ACEIs compared with those who took non-CA ACEIs. Limitations The limitations of this study include the use of observational data, relatively short follow-up time and claims-based measure of cognitive decline. Conclusions In this analysis of Medicare beneficiaries who were prevalent or incident users of ACEIs in 2007-2009, the use of CA ACEIs was unrelated to cognitive decline within 3years of index prescription. Continued follow-up of these patients and more sensitive measures of cognitive decline are necessary to determine whether a cognitive benefit of CA ACEIs is realized in the long term. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[McBean, Alexander Marshall; O'Connor, Heidi; Frank, Barbara; Good, Charles] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA.
[Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Dept Med, Durham, NC 27705 USA.
RP Maciejewski, ML (reprint author), Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27705 USA.
EM mlm34@duke.edu
FU Centers for Medicare and Medicaid Services (CMS) [HHSM-500-2005-00271];
VA Health Services Research and Development Service (HSR&D) Research
Career Scientist Award [RCS-10-391]
FX This project was supported by the Centers for Medicare and Medicaid
Services (CMS) contract HHSM-500-2005-00271. Dr. Maciejewski is
supported by a VA Health Services Research and Development Service
(HSR&D) Research Career Scientist Award (RCS-10-391).
NR 29
TC 6
Z9 7
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD JUN
PY 2013
VL 22
IS 6
BP 641
EP 648
DI 10.1002/pds.3449
PG 8
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 157DG
UT WOS:000319875400010
PM 23620414
ER
PT J
AU Chan, ED
Chan, MM
Chan, MM
AF Chan, Edward D.
Chan, Michael M.
Chan, Mallory M.
TI Pulse oximetry: Understanding its basic principles facilitates
appreciation of its limitations
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Pulse oximetry; Oxygen saturation; Co-oximetry; Carboxyhemoglobin;
Methemoglobin
ID DECREASED OXYGEN-SATURATION; SICKLE-CELL-DISEASE; NAIL POLISH;
HEMOGLOBIN KOLN; ANEMIA; SULFHEMOGLOBINEMIA; DESATURATION; ACCURACY;
READINGS; BLOOD
AB Pulse oximetry has revolutionized the ability to monitor oxygenation in a continuous, accurate, and non-invasive fashion. Despite its ubiquitous use, it is our impression and supported by studies that many providers do not know the basic principles behind its mechanism of function. This knowledge is important because it provides the conceptual basis of appreciating its Limitations and recognizing when pulse oximeter readings may be erroneous. In this review, we discuss how pulse oximeters are able to distinguish oxygenated hemoglobin from deoxygenated hemoglobin and how they are able to recognize oxygen saturation only from the arterial compartment of blood. Based on these principles, we discuss the various conditions that can cause spurious readings and the mechanisms underlying them. Published by Elsevier Ltd.
C1 [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
[Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Denver, CO 80206 USA.
[Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
[Chan, Michael M.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
[Chan, Mallory M.] Univ Colorado, Denver Sch Med, Aurora, CO USA.
RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
NR 55
TC 26
Z9 28
U1 8
U2 49
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2013
VL 107
IS 6
BP 789
EP 799
DI 10.1016/j.rmed.2013.02.004
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 155ZO
UT WOS:000319789700001
PM 23490227
ER
PT J
AU Chervin, RD
Chesson, AL
Benca, RM
Greenough, GP
O'Hearn, DJ
Auckley, DH
Littner, M
Mullington, JM
Malhotra, A
Berry, RB
Malhotra, RK
Schulman, DA
AF Chervin, Ronald D.
Chesson, Andrew L., Jr.
Benca, Ruth M.
Greenough, Glen P.
O'Hearn, Daniel J.
Auckley, Dennis H.
Littner, Michael
Mullington, Janet M.
Malhotra, Atul
Berry, Richard B.
Malhotra, Raman K.
Schulman, David A.
TI Organization and Structure for Sleep Medicine Programs at Academic
Institutions: Part 1-Current Challenges
SO SLEEP
LA English
DT Editorial Material
ID DISORDERS; CENTERS
C1 [Chervin, Ronald D.] Univ Michigan, Dept Neurol, Sleep Disorders Ctr, Ann Arbor, MI 48109 USA.
[Chesson, Andrew L., Jr.] Louisiana State Univ, Sch Med, Dept Neurol, Div Sleep Med, Shreveport, LA USA.
[Benca, Ruth M.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA.
[Greenough, Glen P.] Dartmouth Hitchcock Med Ctr, Sleep Disorders Ctr, Lebanon, NH 03766 USA.
[O'Hearn, Daniel J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Auckley, Dennis H.] MetroHlth Med Ctr, Div Pulm Crit Care & Sleep Med, Cleveland, OH USA.
[Auckley, Dennis H.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
[Littner, Michael] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Mullington, Janet M.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Malhotra, Atul] Brigham & Womens Hosp, Sleep Disorders Res Program, Boston, MA 02115 USA.
[Malhotra, Atul] Harvard Univ, Sch Med, Boston, MA USA.
[Berry, Richard B.] Univ Florida, Gainesville, FL USA.
[Malhotra, Raman K.] SLUcare Sleep Disorders Ctr, St Louis, MO USA.
[Schulman, David A.] Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA USA.
RP Chervin, RD (reprint author), Univ Michigan, Sleep Disorders Ctr, Michael S Aldrich Sleep Disorders Lab, C728 Med Inn Bldg,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
FU NHLBI NIH HHS [K24 HL093218, R01 HL085188, R01 HL090897]
NR 10
TC 0
Z9 0
U1 1
U2 5
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2013
VL 36
IS 6
BP 795
EP 801
DI 10.5665/sleep.2690
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 155HX
UT WOS:000319739700001
PM 23729918
ER
PT J
AU Chesson, AL
Chervin, RD
Benca, RM
Greenough, GP
O'Hearn, DJ
Auckley, DH
Littner, M
Mullington, JM
Malhotra, A
Berry, RB
Malhotra, RK
Schulman, DA
AF Chesson, Andrew L., Jr.
Chervin, Ronald D.
Benca, Ruth M.
Greenough, Glen P.
O'Hearn, Daniel J.
Auckley, Dennis H.
Littner, Michael
Mullington, Janet M.
Malhotra, Atul
Berry, Richard B.
Malhotra, Raman K.
Schulman, David A.
TI Organization and Structure for Sleep Medicine Programs at Academic
Institutions: Part 2-Goals and Strategies to Optimize Patient Care,
Education, and Discovery
SO SLEEP
LA English
DT Editorial Material
C1 [Chesson, Andrew L., Jr.] Louisiana State Univ, Sch Med, Dept Neurol, Div Sleep Med, Shreveport, LA USA.
[Chervin, Ronald D.] Univ Michigan, Dept Neurol, Sleep Disorders Ctr, Ann Arbor, MI USA.
[Benca, Ruth M.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA.
[Greenough, Glen P.] Dartmouth Hitchcock Med Ctr, Sleep Disorders Ctr, Lebanon, NH 03766 USA.
[O'Hearn, Daniel J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Auckley, Dennis H.] MetroHlth Med Ctr, Div Pulm Crit Care & Sleep Med, Cleveland, OH USA.
[Auckley, Dennis H.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
[Littner, Michael] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Mullington, Janet M.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Malhotra, Atul] Brigham & Womens Hosp, Sleep Disorders Res Program, Boston, MA 02115 USA.
[Malhotra, Atul] Harvard Univ, Sch Med, Boston, MA USA.
[Berry, Richard B.] Univ Florida, Gainesville, FL USA.
[Malhotra, Raman K.] SLUcare Sleep Disorders Ctr, St Louis, MO USA.
[Schulman, David A.] Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA USA.
RP Chesson, AL (reprint author), LSUHSC, Sch Med, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.
FU NHLBI NIH HHS [K24 HL093218, R01 HL090897, R01 HL085188]
NR 3
TC 0
Z9 0
U1 0
U2 4
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2013
VL 36
IS 6
BP 803
EP 811
DI 10.5665/sleep.2692
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 155HX
UT WOS:000319739700002
PM 23729919
ER
PT J
AU Willett, LL
Estrada, CA
Adams, M
Arora, V
Call, S
Chacko, K
Chaudhry, S
Halvorsen, AJ
Hopkins, R
McDonald, FS
AF Willett, Lisa L.
Estrada, Carlos A.
Adams, Michael
Arora, Vineet
Call, Stephanie
Chacko, Karen
Chaudhry, Saima
Halvorsen, Andrew J.
Hopkins, Robert
McDonald, Furman S.
TI Challenges with Continuity Clinic and Core Faculty Accreditation
Requirements
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID INTERNAL-MEDICINE; PROGRAM-DIRECTORS; EDUCATION
C1 [Willett, Lisa L.] Univ Alabama Birmingham, Dept Med, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
[Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Adams, Michael] Medstar Georgetown Univ Hosp, Washington, DC USA.
[Arora, Vineet] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Call, Stephanie] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA.
[Chacko, Karen] Univ Colorado, Primary Care Internal Med Residency Program, Denver, CO 80202 USA.
[Chacko, Karen] Univ Colorado, Internal Med Residency Program, Denver, CO 80202 USA.
[Chaudhry, Saima] Hofstra North Shore LIJ Sch Med, Dept Med, Internal Med Residency Program, Hempstead, NY USA.
[Halvorsen, Andrew J.] Mayo Clin, Dept Med, Internal Med Residency Off Educ Innovat, Rochester, MI USA.
[Hopkins, Robert] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Hopkins, Robert] Univ Arkansas Med Sci, Div Gen Internal Med, Little Rock, AR 72205 USA.
[McDonald, Furman S.] Mayo Clin, Dept Med, Rochester, MI USA.
[McDonald, Furman S.] Mayo Clin, Div Gen, Rochester, MI USA.
[McDonald, Furman S.] Mayo Clin, Hosp Internal Med, Rochester, MI USA.
RP Willett, LL (reprint author), Univ Alabama Birmingham, Dept Med, Div Gen Internal Med, BDB 341,1720 2nd Ave S, Birmingham, AL 35294 USA.
EM lwillett@uab.edu
OI Arora, Vineet/0000-0002-4745-7599
NR 16
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD JUN
PY 2013
VL 126
IS 6
BP 550
EP 556
DI 10.1016/j.amjmed.2013.02.008
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 146TY
UT WOS:000319116400033
PM 23684398
ER
PT J
AU Crane, C
Cornejo, A
Lyons, R
Alter, GJ
AF Crane, Curtis
Cornejo, Agustin
Lyons, Robert
Alter, Gary J.
TI Urethral Reconstruction Using a Prefabricated Pedicled Gracilis Flap
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article
DE urethral injury; urethral disruption; urethral reconstruction; pedicled
gracilis flap; Fournier reconstruction
AB This case study describes a patient who experienced an iatrogenic urethral injury because of a Fournier gangrene debridement. Because of the extent of the debridement, which resected all penile and scrotal dartos tissue, no local flaps that would typically be used to reconstruct a urethral disruption were possible. The authors chose to use a prefabricated pedicled gracilis flap to restore urethral continuity.
C1 [Crane, Curtis; Alter, Gary J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Plast Surg, San Antonio, TX 78229 USA.
[Cornejo, Agustin] Univ Texas Hlth Sci Ctr San Antonio, Dept Gen Surg, San Antonio, TX 78229 USA.
[Lyons, Robert] South Texas Vet Hlth Care Syst, Audie L Murphy Surg Serv, San Antonio, TX USA.
[Alter, Gary J.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
RP Crane, C (reprint author), Dept Plast Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM cnd51924@yahoo.com
NR 5
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-7043
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD JUN
PY 2013
VL 70
IS 6
BP 691
EP 693
DI 10.1097/SAP.0b013e3182414843
PG 3
WC Surgery
SC Surgery
GA 146DA
UT WOS:000319068200020
PM 22791063
ER
PT J
AU Wu, CW
Aronson, WJ
Terris, MK
Presti, JC
Kane, CJ
Amling, CL
Freedland, SJ
AF Wu, Chenwei
Aronson, William J.
Terris, Martha K.
Presti, Joseph C., Jr.
Kane, Christopher J.
Amling, Christopher L.
Freedland, Stephen J.
TI Diabetes predicts metastasis after radical prostatectomy in obese men:
results from the SEARCH database
SO BJU INTERNATIONAL
LA English
DT Article
DE diabetes; obesity; race; prostate cancer; metastasis
ID CANCER-SPECIFIC MORTALITY; SERUM TESTOSTERONE LEVEL; BODY-MASS INDEX;
GROWTH-FACTOR-I; PATHOLOGICAL STAGE; UNITED-STATES; SEX-HORMONES; RISK;
MELLITUS; INSULIN
AB What's known on the subject? and What does the study add? Diabetes is known to be associated with a slightly lower risk of prostate cancer. Only a limited number of studies have examined the impact of diabetes on prostate cancer outcomes, with mixed results. This study builds on our prior work showing that on the whole, diabetes is not a risk factor for progression to metastases after surgery. However, intriguingly we found a significant interaction with obesity for modifying the relationship between diabetes and progression. If confirmed in future studies, this suggests the mechanisms by which diabetes alters prostate cancer aggressiveness may differ in obese and non-obese men.
Objective To examine the association between diabetes and metastasis risk after radical prostatectomy (RP) and to determine if race or obesity modifies this relationship.
Patients and Methods Patients comprised 2058 US veterans with prostate cancer (PCa) enrolled in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database and treated with RP between 1988 and 2010.
The association of diabetes with metastasis risk or secondary treatment rates was examined using Cox proportional hazards, adjusting for preoperative and, separately, clinical and postoperative findings.
The effect modification by race (black vs white) and obesity (body mass index [BMI] 30 vs <30kg/m2) was tested via interaction terms.
Results Men with diabetes had higher BMIs and were more likely to be non-white (all P 0.001).
On multivariable analysis, diabetes was not associated with metastasis risk (P 0.45), but, among men with diabetes, longer diabetes duration was associated with higher metastasis risk (P 0.035).
When stratified by obesity, diabetes was linked with higher metastasis risk in obese but not in non-obese men (P-interaction 0.037), but there was no significant interaction with race (P-interaction 0.56).
Diabetes also predicted more aggressive secondary treatment among obese men but less aggressive treatment among non-obese men (hazard ratio 1.39 vs 0.63, P-interaction = 0.006).
Where applicable, results were similar for both pre- and postoperative models.
Conclusions Diabetes was not associated with metastasis risk overall.
Stratification by obesity yielded significant differences, with diabetes linked to a fourfold higher metastasis risk in obese men, despite predicting more aggressive secondary treatment. Longer diabetes duration was also associated with increased metastasis risk.
C1 [Wu, Chenwei; Freedland, Stephen J.] Duke Univ, Sch Med, Durham, NC USA.
[Wu, Chenwei; Freedland, Stephen J.] Duke Univ, Med Ctr, Durham VA Med Ctr, Urol Sect, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Surg, Div Urol Surg, Durham, NC 27710 USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Duke Prostate Ctr, Durham, NC USA.
[Aronson, William J.] UCLA Hlth Syst, Dept Urol, Los Angeles, CA USA.
[Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Presti, Joseph C., Jr.] Stanford Sch Med, Dept Urol, Palo Alto, CA USA.
[Presti, Joseph C., Jr.] VA Palo Alto Healthcare Syst, Urol Sect, Palo Alto, CA USA.
[Kane, Christopher J.] UC San Diego Hlth Syst, Dept Surg, Div Urol, San Diego, CA USA.
[Terris, Martha K.] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA.
[Terris, Martha K.] Charlie Norwood VA Med Ctr, Urol Sect, Augusta, GA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
RP Freedland, SJ (reprint author), DUMC 2626 Suite 475, Durham, NC 27710 USA.
EM steve.freedland@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU American Urological Association Foundation/Astellas Rising Star in
Urology Award (S.J.F.); Howard Hughes Medical Institute Medical Research
Fellows scholarship (C. W.)
FX This work was supported by the American Urological Association
Foundation/Astellas Rising Star in Urology Award (S.J.F.) and a Howard
Hughes Medical Institute Medical Research Fellows scholarship (C.W.)
NR 39
TC 7
Z9 7
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD JUN
PY 2013
VL 111
IS 8
BP E310
EP E318
DI 10.1111/j.1464-410X.2012.11687.x
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 152GW
UT WOS:000319520800006
PM 23305170
ER
PT J
AU Todoran, TM
Zile, MR
AF Todoran, Thomas M.
Zile, Michael R.
TI Neuromodulation Device Therapy for Treatment of Hypertensive Heart
Disease
SO CIRCULATION JOURNAL
LA English
DT Review
DE Baroreflex activation therapy; Hypertension; Spinal cord stimulation;
Sympathetic renal denervation; Vagal nerve stimulation
ID RENAL SYMPATHETIC DENERVATION; BAROREFLEX ACTIVATION THERAPY;
LEFT-VENTRICULAR HYPERTROPHY; DRUG-RESISTANT HYPERTENSION; LOWERS
BLOOD-PRESSURE; RHEOS PIVOTAL TRIAL; LEFT ATRIAL VOLUME; BARORECEPTOR
STIMULATION; MULTICENTER FEASIBILITY; DIASTOLIC DYSFUNCTION
AB Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity in the United States. Despite the availability of medical therapy it remains a challenge to treat. Autonomic nervous system imbalance resulting in overactivity of the sympathetic nervous system and under activity of the parasympathetic nervous system is integral in the development of hypertension and ultimately the development of HHD. Emerging data suggest that neuromodulation device therapy for treatment of HHD is promising.
C1 Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA.
Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Todoran, TM (reprint author), 25 Courtenay Dr,MSC 592, Charleston, SC 29425 USA.
EM todoran@musc.edu
FU CVRx; Medtronic
FX T.M.T. has nothing to disclose. M.R.Z. is a consultant for and receives
research funds from CVRx and Medtronic.
NR 47
TC 3
Z9 4
U1 1
U2 8
PU JAPANESE CIRCULATION SOC
PI KYOTO
PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO,
606-8305, JAPAN
SN 1346-9843
J9 CIRC J
JI Circ. J.
PD JUN
PY 2013
VL 77
IS 6
BP 1351
EP 1363
DI 10.1253/circj.CJ-13-0390
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 154CG
UT WOS:000319648500001
PM 23657125
ER
PT J
AU Zhang, Y
Harrison, JM
Nateras, OS
Chalfin, S
Duong, TQ
AF Zhang, Yi
Harrison, Joseph M.
Nateras, Oscar San Emeterio
Chalfin, Steven
Duong, Timothy Q.
TI Decreased retinal-choroidal blood flow in retinitis pigmentosa as
measured by MRI
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Retinal diseases; Magnetic resonance imaging; Electroretinography;
Retinal degeneration
ID MANGANESE-ENHANCED MRI; RAT RETINA; FUNCTIONAL MRI; MOUSE MODEL;
MORPHOLOGICAL-CHANGES; ABYSSINIAN CATS; VASCULAR LAYERS; ANATOMICAL MRI;
IN-VIVO; DEGENERATION
AB To evaluate retinal and choroidal blood flow (BF) using high-resolution magnetic resonance imaging (MRI) as well as visual function measured by the electroretinogram (ERG) in patients with retinitis pigmentosa (RP).
MRI studies were performed in 6 RP patients (29-67 years) and 5 healthy volunteers (29-64 years) on a 3-Tesla scanner with a custom-made surface coil. Quantitative BF was measured using the pseudo-continuous arterial spin-labeling technique at 0.5 x 0.8 x 6.0 mm. Full-field ERGs of all patients were recorded. Amplitudes and implicit times of standard ERGs were analyzed.
Basal BF in the posterior retinal-choroid was 142 +/- A 16 ml/100ml/min (or 1.14 +/- A 0.13 mu l/mm(2)/min) in the control group and was 70 +/- 19 ml/100ml/min (or 0.56 +/- A 0.15 mu l/mm(2)/min) in the RP group. Retinal-choroidal BF was significantly reduced by 52 +/- A 8 % in RP patients compared to controls (P < 0.05). ERG a- and b-wave amplitudes of RP patients were reduced, and b-wave implicit times were delayed. There were statistically significant correlations between a-wave amplitude and BF value (r=0.9, P < 0.05) but not between b-wave amplitude and BF value (r =0.7, P=0.2).
This study demonstrates a novel non-invasive MRI approach to measure quantitative retinal and choroidal BF in RP patients. We found that retinal-choroidal BF was markedly reduced and significantly correlated with reduced amplitudes of the a-wave of the standard combined ERG.
C1 [Zhang, Yi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Harrison, Joseph M.; Chalfin, Steven; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU Clinical Translational Science Award Pilot Grant; Translational
Technology Resource grant [UL1TR000149]; NIH/NEI [R01 EY014211,
EY018855]; Department of Veterans Affairs MERIT awards; Translational
Science Training award through the University of Texas System Graduate
Program Initiative
FX This work was supported by a Clinical Translational Science Award Pilot
Grant and a Translational Technology Resource grant (parent grant
UL1TR000149), NIH/NEI (R01 EY014211 and EY018855), and Department of
Veterans Affairs MERIT awards to TQD. YZ was supported by a
Translational Science Training award through the University of Texas
System Graduate Program Initiative.
NR 65
TC 15
Z9 16
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD JUN
PY 2013
VL 126
IS 3
BP 187
EP 197
DI 10.1007/s10633-013-9374-1
PG 11
WC Ophthalmology
SC Ophthalmology
GA 151QX
UT WOS:000319476400002
PM 23408312
ER
PT J
AU Chan, BK
Abedon, ST
Loc-Carrillo, C
AF Chan, Benjamin K.
Abedon, Stephen T.
Loc-Carrillo, Catherine
TI Phage cocktails and the future of phage therapy
SO FUTURE MICROBIOLOGY
LA English
DT Review
DE antibacterial; antibiotic resistance; bacteriophage; diversity of
bacterial; pathogen; phage cocktail; polyphage
ID ESCHERICHIA-COLI O157H7; IN-VIVO; PSEUDOMONAS-AERUGINOSA; BACTERIOPHAGE
THERAPY; PERSONALIZED MEDICINE; CAMPYLOBACTER-JEJUNI; INFLUENZA
VACCINES; BROILER-CHICKENS; HOST-RANGE; RESISTANCE
AB Viruses of bacteria, known as bacteriophages or phages, were discovered nearly 100 years ago. Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' trials predating Fleming's discovery of penicillin by approximately a decade. In this review, we consider phage therapy that can be used for treating bacterial infections in humans, domestic animals and even biocontrol in foods. Following an overview of the topic, we explore the common practice - both experimental and, in certain regions of the world, clinical - of mixing therapeutic phages into cocktails consisting of multiple virus types. We conclude with a discussion of the commercial and medical context of phage cocktails as therapeutic agents. In comparing off-the-shelf versus custom approaches, we consider the merits of a middle ground, which we deem 'modifiable'. Finally, we explore a regulatory framework for such an approach based on an influenza vaccine model.
C1 [Chan, Benjamin K.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
[Abedon, Stephen T.] Ohio State Univ, Dept Microbiol, Mansfield, OH USA.
[Loc-Carrillo, Catherine] Univ Utah, Dept Orthoped, Salt Lake City, UT 84112 USA.
[Loc-Carrillo, Catherine] US Dept Vet Affairs, Hlth Care Syst, Salt Lake City, UT USA.
RP Loc-Carrillo, C (reprint author), Univ Utah, Dept Orthoped, Salt Lake City, UT 84112 USA.
EM c.loc.carrillo@hsc.utah.edu
RI Loc Carrillo, Catherine/B-5461-2014
OI Loc Carrillo, Catherine/0000-0002-7265-1203
NR 103
TC 101
Z9 104
U1 23
U2 165
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1746-0913
EI 1746-0921
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD JUN
PY 2013
VL 8
IS 6
BP 769
EP 783
DI 10.2217/FMB.13.47
PG 15
WC Microbiology
SC Microbiology
GA 151EH
UT WOS:000319443000014
PM 23701332
ER
PT J
AU Taylor, WC
King, KE
Shegog, R
Paxton, RJ
Evans-Hudnall, GL
Rempel, DM
Chen, V
Yancey, AK
AF Taylor, Wendell C.
King, Kathryn E.
Shegog, Ross
Paxton, Raheem J.
Evans-Hudnall, Gina L.
Rempel, David M.
Chen, Vincent
Yancey, Antronette K.
TI Booster Breaks in the workplace: participants' perspectives on
health-promoting work breaks
SO HEALTH EDUCATION RESEARCH
LA English
DT Article
ID PHYSICAL-ACTIVITY INTERVENTIONS; SEDENTARY BEHAVIOR; AFRICAN-AMERICAN;
TIME; DETERMINANTS; MORTALITY; BELIEFS; OBESITY; LIFE
AB Increasing sedentary work has been associated with greater cardiovascular and metabolic risk, as well as premature mortality. Interrupting the sedentary workday with health-promoting work breaks can counter these negative health effects. To examine the potential sustainability of work-break programs, we assessed the acceptance of these breaks among participants in a Booster Break program. We analyzed qualitative responses from 35 participants across five worksites where one 15-min physical activity break was taken each workday. Two worksites completed a 1-year intervention and three worksites completed a 6-month intervention. Responses to two open-ended questions about the acceptance and feasibility of Booster Breaks were obtained from a survey administered after the intervention. Three themes for benefits and two themes for barriers were identified. The benefit themes were (i) reduced stress and promoted enjoyment, (ii) increased health awareness and facilitated behavior change, and (iii) enhanced workplace social interaction. The barrier themes were the need for (iv) greater variety in Booster Break routines and (v) greater management support. This study provides empirical support for the acceptance and feasibility of Booster Breaks during the workday. Emphasizing the benefits and minimizing the barriers are strategies that can be used to implement Booster Breaks in other workplaces.
C1 [Taylor, Wendell C.; King, Kathryn E.; Chen, Vincent] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Hlth Promot & Behav Sci, Houston, TX 77030 USA.
[Shegog, Ross] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Hlth Promot & Behav Sci, Houston, TX 77030 USA.
[Paxton, Raheem J.] Univ Texas MD Anderson Canc Ctr, Dorothy I Height Ctr Hlth Equ & Evaluat Res D CHE, Div OVP Canc Prevent & Populat Sci, Houston, TX 77030 USA.
[Evans-Hudnall, Gina L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
[Rempel, David M.] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA.
[Rempel, David M.] Univ Calif Berkeley, Ergon Program, Dept Bioengn, Richmond, CA 94804 USA.
[Yancey, Antronette K.] UCLA Fielding Sch Publ Hlth, UCLA Kaiser Permanente Ctr Hlth Equ, Dept Hlth Serv, Los Angeles, CA 90095 USA.
RP Taylor, WC (reprint author), Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Hlth Promot & Behav Sci, 7000 Fannin St,Suite 2670, Houston, TX 77030 USA.
EM Wendell.C.Taylor@uth.tmc.edu
OI Paxton, Raheem/0000-0001-9430-7051
FU NCI NIH HHS [K01 CA158000]; NINR NIH HHS [R03NR10291]
NR 40
TC 8
Z9 8
U1 2
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1153
J9 HEALTH EDUC RES
JI Health Educ. Res.
PD JUN
PY 2013
VL 28
IS 3
BP 414
EP 425
DI 10.1093/her/cyt001
PG 12
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 153YP
UT WOS:000319639000005
PM 23466367
ER
PT J
AU Schliamser, JE
Kadish, AH
Subacius, H
Shalaby, A
Schaechter, A
Levine, J
Goldberger, JJ
AF Schliamser, Jorge E.
Kadish, Alan H.
Subacius, Haris
Shalaby, Alaa
Schaechter, Andi
Levine, Joseph
Goldberger, Jeffrey J.
CA DEFINITE Investigators
TI Significance of follow-up left ventricular ejection fraction
measurements in the Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation trial (DEFINITE)
SO HEART RHYTHM
LA English
DT Article
DE Nonischemic cardiomyopathy; Implantable cardioverter-defibrillator;
Sudden cardiac death
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SUDDEN CARDIAC DEATH; DILATED
CARDIOMYOPATHY; HEART-FAILURE; RISK STRATIFICATION; VARIABILITY;
OUTCOMES
AB BACKGROUND As left ventricular ejection fraction (LVEF) may improve, worsen, or remain the same over time, patients' prognosis may also be expected to change because of the change in LVEF, among other factors. OBJECTIVE To evaluate the effect of LVEF change on outcome in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial. METHODS Patients with nonischemic cardiomyopathy with LVEF<36%, history of symptomatic heart failure, and the presence of significant ventricular ectopic activity were enrolled in the DEFINITE trial. Follow-up LVEF measurements were obtained annually in only a minority (17%) of trial participants. This study therefore evaluated survival and arrhythmic end points in patients whose LVEF was reassessed between 90 and 730 days after enrollment. RESULTS During the 90-730-day postrandomization period, 187 of 449 (42%) enrolled patients who survived at least 90 days had at least 1 follow-up LVEF measurement; these patients were younger and white; had diabetes, better 6-minute walk test results, and higher BMI; were more likely to have appropriate shocks; and had fewer deaths compared to those without follow-up LVEF measurements. Patients whose LVEF improved had reduced mortality compared to patients whose LVEF decreased (hazard ratio 0.09; 95% confidence interval 0.02-0.39; P = .001). Survival free of appropriate shocks was not significantly related to LVEF improvement during follow-up. CONCLUSIONS LVEF improvement was associated with improved survival, but not with a significant decrease in appropriate shocks. These data highlight that appropriate caution should be exercised not to extrapolate the positive effect of improved LVEF to the elimination of arrhythmic events.
C1 [Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi; Goldberger, Jeffrey J.] Northwestern Univ, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
[Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi; Goldberger, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA.
[Kadish, Alan H.] Touro Coll, Brooklyn, NY USA.
[Kadish, Alan H.] New York Med Coll, Valhalla, NY 10595 USA.
[Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Levine, Joseph] St Francis Hosp, Ctr Heart, Roslyn, NY USA.
RP Goldberger, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, 251 E Huron St,Feinberg 8-503, Chicago, IL 60611 USA.
EM j-goldberger@northwestern.edu
OI Subacius, Haris/0000-0003-4061-1220
FU St Jude Medical; Sylmar; Medtronic; Boston Scientific; Biotronik
FX DEFINITE was funded by St Jude Medical, Sylmar, CA. Dr Kadish is a
consultant for Impulse Dynamics and Backbeat Medical AK. Dr Shalaby has
received significant research support from St Jude Medical. Dr Levine is
an ad hoc consultant for St Jude Medical and Medtronic. Dr Goldberger is
Director of the Path to Improved Risk Stratification, NFP, a
not-for-profit think tank on the risk stratification for the prevention
of sudden cardiac death, which has received unrestricted educational
grants from Medtronic, Boston Scientific, and St Jude Medical. He has
received grant support and/or honoraria from Medtronic, Biotronik, and
St Jude Medical.
NR 19
TC 26
Z9 28
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD JUN
PY 2013
VL 10
IS 6
BP 838
EP 846
DI 10.1016/j.hrthm.2013.02.017
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 152BJ
UT WOS:000319504200017
PM 23422221
ER
PT J
AU Brody, AL
Mukhin, AG
La Charite, J
Ta, K
Farahi, J
Sugar, CA
Mamoun, MS
Vellios, E
Archie, M
Kozman, M
Phuong, J
Arlorio, F
Mandelkern, MA
AF Brody, Arthur L.
Mukhin, Alexey G.
La Charite, Jaime
Ta, Karen
Farahi, Judah
Sugar, Catherine A.
Mamoun, Michael S.
Vellios, Evan
Archie, Meena
Kozman, Maggie
Phuong, Jonathan
Arlorio, Franca
Mandelkern, Mark A.
TI Up-regulation of nicotinic acetylcholine receptors in menthol cigarette
smokers
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Age; nicotine dependence; nicotinic acetylcholine receptor; positron
emission tomography; tobacco
ID SMOKING-CESSATION; TOBACCO SMOKING; HUMAN-BRAIN; AFRICAN-AMERICAN;
UNITED-STATES; YOUNG-ADULTS; BINDING; ABSTINENCE; OCCUPANCY; PET
AB One-third of smokers primarily use menthol cigarettes and usage of these cigarettes leads to elevated serum nicotine levels and more difficulty quitting in standard treatment programmes. Previous brain imaging studies demonstrate that smoking (without regard to cigarette type) leads to up-regulation of beta*(2)-containing nicotinic acetylcholine receptors (nAChRs). We sought to determine if menthol cigarette usage results in greater nAChR up-regulation than non-menthol cigarette usage. Altogether, 114 participants (22 menthol cigarette smokers, 41 non-menthol cigarette smokers and 51 non-smokers) underwent positron emission tomography scanning using the alpha(4)beta*(2) nAChR radioligand 2-[F-18]fluoro-A-85380 (2-FA). In comparing menthol to non-menthol cigarette smokers, an overall test of 2-FA total volume of distribution values revealed a significant between-group difference, resulting from menthol smokers having 9-28% higher alpha(4)beta*(2) nAChR densities than non-menthol smokers across regions. In comparing the entire group of smokers to non-smokers, an overall test revealed a significant between-group difference, resulting from smokers having higher alpha(4)beta*(2) nAChR levels in all regions studied (36-42%) other than thalamus (3%). Study results demonstrate that menthol smokers have greater up-regulation of nAChRs than non-menthol smokers. This difference is presumably related to higher nicotine exposure in menthol smokers, although other mechanisms for menthol influencing receptor density are possible. These results provide additional information about the severity of menthol cigarette use and may help explain why these smokers have more trouble quitting in standard treatment programmes.
C1 [Brody, Arthur L.; Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA.
[Brody, Arthur L.; La Charite, Jaime; Ta, Karen; Mamoun, Michael S.; Vellios, Evan; Archie, Meena; Kozman, Maggie; Phuong, Jonathan; Arlorio, Franca; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA.
[Mukhin, Alexey G.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
[Farahi, Judah] VA Greater Los Angeles Healthcare Syst, Dept Radiochem, Los Angeles, CA USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM abrody@ucla.edu
FU Tobacco-Related Disease Research Program [19XT-0135]; National Institute
on Drug Abuse [R01 DA20872]; Veterans Affairs Type I Merit Review Award;
Richard Metzner Chair in Clinical Neuropharmacology; Pfizer, Inc.;
Phillip Morris, Inc.
FX This study was supported by the Tobacco-Related Disease Research Program
[A.L.B. (19XT-0135)], the National Institute on Drug Abuse [A.L.B. (R01
DA20872)] and a Veterans Affairs Type I Merit Review Award (A.L.B.), as
well as by an endowment from the Richard Metzner Chair in Clinical
Neuropharmacology (A.L.B.). The sponsors had no role in the design and
conduct of the study, collection, management, analysis and
interpretation of the data or preparation, review or approval of the
manuscript.; Drs Brody and Mandelkern were previously co-investigators
on a grant funded by Pfizer, Inc., which was unrelated to this study. Dr
Mukhin is a co-investigator on a grant from Phillip Morris, Inc., for
research unrelated to this study.
NR 57
TC 19
Z9 20
U1 0
U2 12
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2013
VL 16
IS 5
BP 957
EP 966
DI 10.1017/S1461145712001022
PG 10
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 146WW
UT WOS:000319127100003
PM 23171716
ER
PT J
AU Nair, BG
Horibe, M
Newman, SF
Wu, WY
Schwid, HA
AF Nair, Bala G.
Horibe, Mayumi
Newman, Shu-Fang
Wu, Wei-Ying
Schwid, Howard A.
TI Near real-time notification of gaps in cuff blood pressure recordings
for improved patient monitoring
SO JOURNAL OF CLINICAL MONITORING AND COMPUTING
LA English
DT Article
DE Decision support; Anesthesia information management system; Patient
monitoring; Blood pressure monitoring; Real-time reminders
ID DOCUMENTATION; PERFORMANCE; QUALITY
AB Blood pressure monitoring during anesthesia is an American Society of Anesthesiology standard. However, the anesthesia provider sometimes fails to engage the patient monitor to make periodic (generally every 3-5 min) measurements of Non-Invasive Blood Pressure (NIBP), which can lead to extended periods (> 5 min) when blood pressure is not monitored. We describe a system to automatically detect such gaps in NIBP measurement and notify clinicians in real-time to initiate measurement. We applied a decision support system called the Smart Anesthesia Messenger (SAM) to notify the anesthesia provider if NIBP measurements have not been made in the last 7 min. Notification messages were generated only if direct arterial blood pressure was not being monitored. NIBP gaps were analyzed for 9 months before and after SAM notification was initiated (12,000 cases for each period). SAM notification was able to reduce the occurrence of extended NIBP gaps > 15 min from 15.7 +/- A 4.5 to 6.7 +/- A 2.0 instances per 1,000 cases (p < 0.001). In addition, for extended gaps (> 15 min) the mean gap duration declined from 23.1 +/- A 2.0 to 18.6 +/- A 1.1 min after SAM notification was initiated (p < 0.001). However, for 7-15 min gaps, SAM notification was not effective in reducing the occurrence. The maximum gap encountered before SAM was 64 min, while it was 27 min with SAM notification. Real-time notification using SAM is an effective way to reduce both the number of instances and the duration of inadvertent, extended (> 15 min) gaps in blood pressure measurements in the operating room. However, the frequency of gaps < 15 min could not be reduced using the current configuration of SAM.
C1 [Nair, Bala G.; Schwid, Howard A.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
[Horibe, Mayumi] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA USA.
[Newman, Shu-Fang] Univ Washington, Patient Care Serv, Seattle, WA 98195 USA.
[Wu, Wei-Ying] Natl Dong Hwa Univ, Dept Appl Math, Hualien, Taiwan.
RP Nair, BG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, BB-1469 Hlth Sci Bldg,1959 NE Pacific St,Mail Box, Seattle, WA 98195 USA.
EM nairbg@uw.edu
FU Laura Cheney Patient Safety grant by the University of Washington
FX This research was supported by Laura Cheney Patient Safety grant
provided by the University of Washington. We would also like to thank
Rafael Vergara for his daily support of the SAM system.
NR 15
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1387-1307
J9 J CLIN MONIT COMPUT
JI J. Clin. Monitor. Comp.
PD JUN
PY 2013
VL 27
IS 3
BP 265
EP 271
DI 10.1007/s10877-012-9425-2
PG 7
WC Anesthesiology
SC Anesthesiology
GA 146DW
UT WOS:000319070600009
PM 23283561
ER
PT J
AU Chang, A
Bowen, JL
Buranosky, RA
Frankel, RM
Ghosh, N
Rosenblum, MJ
Thompson, S
Green, ML
AF Chang, Anna
Bowen, Judith L.
Buranosky, Raquel A.
Frankel, Richard M.
Ghosh, Nivedita
Rosenblum, Michael J.
Thompson, Sara
Green, Michael L.
TI Transforming Primary Care Training-Patient-Centered Medical Home
Entrustable Professional Activities for Internal Medicine Residents
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient-centered medical home; entrustable professional activities;
graduate medical education; internal medicine; primary care
ID TASK-FORCE; EDUCATION; ORGANIZATION; DIRECTORS; REFORM
AB The U.S. faces a critical gap between residency training and clinical practice that affects the recruitment and preparation of internal medicine residents for primary care careers. The patient-centered medical home (PCMH) represents a new clinical microsystem that is being widely promoted and implemented to improve access, quality, and sustainability in primary care practice.
We address two key questions regarding the training of internal medicine residents for practice in PCMHs. First, what are the educational implications of practice transformations to primary care home models? Second, what must we do differently to prepare internal medicine residents for their futures in PCMHs?
The 2011 Society of General Internal Medicine (SGIM) PCMH Education Summit established seven work groups to address the following topics: resident workplace competencies, teamwork, continuity of care, assessment, faculty development, 'medical home builder' tools, and policy. The output from the competency work group was foundational for the work of other groups. The work group considered several educational frameworks, including developmental milestones, competencies, and entrustable professional activities (EPAs).
The competency work group defined 25 internal medicine resident PCMH EPAs. The 2011 National Committee for Quality Assurance (NCQA) PCMH standards served as an organizing framework for EPAs.
The list of PCMH EPAs has the potential to begin to transform the education of internal medicine residents for practice and leadership in the PCMH. It will guide curriculum development, learner assessment, and clinical practice redesign for academic health centers.
C1 [Chang, Anna] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94118 USA.
[Bowen, Judith L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bowen, Judith L.] Vet Hlth Adm Off Acad Affiliat, Washington, DC USA.
[Buranosky, Raquel A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Frankel, Richard M.] Indiana Univ Sch Med, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
[Ghosh, Nivedita] Harvard Univ, Sch Med, Brigham & Womens Adv Primary Care Associates, Boston, MA USA.
[Rosenblum, Michael J.] Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA.
[Thompson, Sara] Univ Washington, Sch Med, Grp Hlth Family Med Residency, Seattle, WA USA.
[Green, Michael L.] Yale Univ, Sch Med, New Haven, CT USA.
RP Chang, A (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 3333 Calif St,Suite 380, San Francisco, CA 94118 USA.
EM anna.chang@ucsf.edu
FU Josiah Macy Jr. Foundation; United Health Foundation
FX Josiah Macy Jr. Foundation supported the Education Summit. Additional
financial support for the Summit was provided by the United Health
Foundation. The American College of Physicians, Primary Care Progress,
and the Veterans Health Administration office of Academic Affiliations
provided in-kind support.
NR 39
TC 27
Z9 28
U1 2
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
IS 6
BP 801
EP 809
DI 10.1007/s11606-012-2193-3
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 151OB
UT WOS:000319468800013
PM 22997002
ER
PT J
AU Yechoor, P
Blaustein, AS
Bakaeen, FG
Cornwell, LD
Coselli, JS
LeMaire, SA
Chu, D
AF Yechoor, Poornima
Blaustein, Alvin S.
Bakaeen, Faisal G.
Cornwell, Lorraine D.
Coselli, Joseph S.
LeMaire, Scott A.
Chu, Danny
TI The natural history of moderate aortic stenosis in a veteran population
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID CARDIOVASCULAR MORTALITY; VALVE DISEASE; PROGRESSION; MANAGEMENT; MILD
AB Objective: Our objective was to evaluate the natural history of moderate aortic stenosis in veterans-a unique patient population with significant comorbidities.
Methods: We retrospectively reviewed the records of all patients who underwent echocardiography at a single veterans affairs hospital during 2006. We identified consecutive patients who had moderate aortic stenosis as indicated by a mean transaortic gradient of 25 to 40 mm Hg, peak aortic jet velocity of 3 to 4 m/s, or aortic valve area of 1.0 to 1.5 cm(2). The primary end point was defined as survival without aortic valve replacement.
Results: Of the 104 patients (mean age, 74 +/- 10 years), 49% had diabetes, 21% had peripheral vascular disease, 21% were current smokers, 18% had chronic obstructive pulmonary disease, 60% had coronary artery disease, 89% had hypertension, and 31% had a body mass index of 30 kg/m(2) or more. Mean ejection fraction was 49% +/- 12%. During the mean follow-up period of 22 months (range, 1-67 months), 30% of patients underwent aortic valve replacement-26% for symptomatic severe aortic stenosis and 4% concomitantly with coronary artery bypass grafting as the primary indicated operation-and 61% died. Event-free survivals were 48%, 24%, and 15% at 1, 3, and 5 years, respectively.
Conclusions: Our cohort of military veteran patients had significant comorbidities. Event-free survival for such patients who have moderate aortic stenosis is significantly lower than previously reported data suggest. Within this unique group of patients, identifying factors that accelerate the progression of moderate aortic stenosis would help surgeons select patients who may benefit from early aortic valve replacement for moderate aortic stenosis.
C1 St Lukes Episcopal Hosp, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Baylor Coll Med,Div Cardiothorac Surg, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Baylor Coll Med,Div Cardiol, Houston, TX 77030 USA.
RP Chu, D (reprint author), St Lukes Episcopal Hosp, Texas Heart Inst, Baylor Coll Med, Div Cardiothorac Surg, 1 Baylor Plaza, Houston, TX 77030 USA.
EM dchumd@gmail.com
FU Michael E. DeBakey Veterans Affairs Health Services Research &
Development Center of Excellence [HFP90-020]; Baylor College of Medicine
FX Funded by the Michael E. DeBakey Veterans Affairs Health Services
Research & Development Center of Excellence (HFP90-020); internal
funding from Baylor College of Medicine.
NR 25
TC 4
Z9 4
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JUN
PY 2013
VL 145
IS 6
BP 1550
EP 1553
DI 10.1016/j.jtcvs.2012.05.013
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 146CK
UT WOS:000319066300038
PM 22664178
ER
PT J
AU Barshes, NR
Ozaki, CK
Kougias, P
Belkin, M
AF Barshes, Neal R.
Ozaki, C. Keith
Kougias, Panos
Belkin, Michael
TI A cost-effectiveness analysis of infrainguinal bypass in the absence of
great saphenous vein conduit
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID CRITICAL LIMB ISCHEMIA; INFRAPOPLITEAL ARTERIES; POLYTETRAFLUOROETHYLENE
BYPASS; TIBIAL BYPASS; SALVAGE; GRAFTS; METAANALYSIS; MULTICENTER;
MANAGEMENT; PATCH
AB Background: Good-quality great saphenous vein (GSV) is the preferred conduit for infrainguinal surgical revascularizations, but it is not available in all patients. We sought to identify the alternative conduit that would maximize cost-effectiveness in the context of infrapopliteal bypass for critical limb ischemia and nonhealing foot wounds.
Methods: A Markov model was used to create a detailed simulation of 10-year outcomes in a hypothetical Edifoligide for the Prevention of Infrainguinal Vein Graft Failure (PREVENT) III-type patient cohort undergoing infrainguinal bypass for nonhealing foot wounds. The following management options were evaluated: (1) conservative therapy (local wound care, amputation as needed); (2) primary amputation; (3) bypass with autologous alternative vein (AAV), including arm or lesser saphenous vein; (4) bypass with GSV <3 mm in diameter; (5) bypass with polytetrafluoroethylene (PTFE); (6) cryopreserved venous allograft; and (7) cryopreserved arterial allograft. Estimates of 10-year total costs were incorporated into the model. Cost-effectiveness was measured in terms of incremental United States dollars per additional year of ambulation.
Results: Bypass with AAV had the highest effectiveness as measured in median years of ambulation. After primary amputation, bypass with PTFE had the lowest total costs. With incremental cost-effectiveness ratios of $5325 and $21,228, bypass with PTFE or AAV appeared to be cost-effective alternatives to conservative therapy for nonhealing ischemic wounds. Primary amputation, GSV <3 mm, and allograft options were dominated (ie, more costly and less effective). Primary amputation was weakly dominated.
Conclusions: Bypass with PTFE or AAV appears to be a cost-effective option for the management of critical limb ischemia and nonhealing foot wounds when good-quality GSV is not available.
C1 [Barshes, Neal R.; Kougias, Panos] Baylor Coll Med, Div Vasc & Endovasc Surg, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Ozaki, C. Keith; Belkin, Michael] Brigham & Womens Hosp, Dept Surg, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
RP Barshes, NR (reprint author), Baylor Coll Med, Div Vasc & Endovasc Surg, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA.
EM nbarshes@bcm.tmc.edu
NR 25
TC 6
Z9 6
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2013
VL 57
IS 6
BP 1466
EP 1470
DI 10.1016/j.jvs.2012.11.115
PG 5
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 150KN
UT WOS:000319389400003
PM 23395205
ER
PT J
AU Gasper, WJ
Reilly, LM
Rapp, JH
Grenon, SM
Hiramoto, JS
Sobel, JD
Chuter, TAM
AF Gasper, Warren J.
Reilly, Linda M.
Rapp, Joseph H.
Grenon, S. Marlene
Hiramoto, Jade S.
Sobel, Julia D.
Chuter, Timothy A. M.
TI Assessing the anatomic applicability of the multibranched endovascular
repair of thoracoabdominal aortic aneurysm technique
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 27th Annual Meeting of the Western-Vascular-Society
CY SEP 22-25, 2012
CL Park City, UT
SP Western Vasc Soc
ID UNITED-STATES; STENT GRAFTS; EXPERIENCE
AB Background: Multibranched endovascular aneurysm repair (MBEVAR) has the potential to lower the morbidity and mortality rates of thoracoabdominal aneurysm repair, but the applicability of the technique is unknown. Our aim was to estimate the prevalence of anatomic suitability for MBEVAR.
Methods: Retrospective review of patients referred for a prospective trial of MBEVAR between November 2005 and July 2012. Anatomic suitability was assessed on three-dimensional computed tomography scan reconstructions according to the current criteria for a custom-made stent graft or a fixed, off-the-shelf stent graft in both standard (22F) and low-profile (18F) delivery systems.
Results: A total of 250 contrast-enhanced computed tomography scans were reviewed, 49 of which were excluded due to inadequate aneurysm size. Of 201 candidates for repair, 149 (74%) were men and 86 (43%) had Crawford classification type IV/paravisceral aneurysms; 109 (58%) were anatomically suitable for a single-stage repair with a custom-made, low-profile stent graft. Another 58 (29%) could have been made suitable for MBEVAR with an adjunct procedure, including angiogram with visceral or renal artery stenting (n = 23), carotid-subclavian bypass (n = 5), or iliac bypass for device insertion (n = 17), or to preserve internal iliac artery flow because of an iliac aneurysm (n = 9), or dissection (n = 8). There was no association between suitability and gender, aneurysm diameter, or type. However, women were significantly more likely to need a conduit or low-profile device (P = .003). Patients with type B aortic dissections were significantly less likely to have anatomy suitable for repair (P = .035) and more likely to require a multistage repair. Thirty-four patients would have been unsuitable for repair because of renal artery anatomy (n = 14), visceral artery anatomy (n = 4), lack of a proximal landing zone due to an arch aneurysm (n = 7), or inadequate access arteries (n = 9). The low-profile device increased the number of patients who would have been suitable for a single-stage repair by 16. The off-the-shelf graft has the advantage of a faster assessment-to-treatment time, but only 64 patients would have been suitable for a single-stage repair and another 30 could have been made suitable with an adjunct procedure.
Conclusions: Most patients would have been suitable or could have been made suitable for a thoracoabdominal stent graft using current anatomic criteria. The applicability of MBEVAR will continue to change as the experience with the technique grows and devices evolve, as evidenced by the potential reduction in iliac bypasses after the introduction of a low-profile device and the ability to treat symptomatic or urgent patients with the off-the-shelf device.
C1 [Gasper, Warren J.; Reilly, Linda M.; Hiramoto, Jade S.; Sobel, Julia D.; Chuter, Timothy A. M.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
[Rapp, Joseph H.; Grenon, S. Marlene] San Francisco VA Med Ctr, Vasc Surg Sect, San Francisco, CA USA.
RP Gasper, WJ (reprint author), Univ Calif San Francisco, Div Vasc & Endovasc Surg, 400 Parnassus Ave,Box 0222, San Francisco, CA 94143 USA.
EM Warren.Gasper@ucsf.edu
NR 23
TC 17
Z9 17
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2013
VL 57
IS 6
BP 1553
EP 1558
DI 10.1016/j.jvs.2012.12.021
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 150KN
UT WOS:000319389400017
PM 23395201
ER
PT J
AU Berry, K
Ioannou, GN
AF Berry, Kristin
Ioannou, George N.
TI Serum alpha-fetoprotein level independently predicts posttransplant
survival in patients with hepatocellular carcinoma
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LIVER-TRANSPLANTATION; CIRRHOSIS; VALIDATION; ALLOCATION
AB We aimed to determine whether combining serum alpha-fetoprotein (AFP) level with hepatocellular carcinoma (HCC) tumor burden would allow better stratification of posttransplant survival for patients with HCC undergoing liver transplantation. Adjusting for donor and recipient characteristics, we calculated the risk of posttransplant mortality associated with serum AFP level or HCC tumor burden for all first-time adult liver transplants performed in the United States between 2002 and 2011 (n=45,267). Serum AFP level, rather than tumor burden, was the tumor characteristic most strongly associated with posttransplant survival. Although recipients with HCC and a serum AFP level15 ng/mL at the time of transplantation had no excess posttransplant mortality [adjusted hazard ratio (AHR)=1.02, 95% confidence interval (CI)=0.93-1.12], patients with a serum AFP level of 16 to 65 ng/mL (AHR=1.38, 95% CI=1.23-1.54), patients with a serum AFP level of 66 to 320 ng/mL (AHR=1.65, 95% CI=1.45-1.88), and patients with a serum AFP level>320 ng/mL (AHR=2.37, 95% CI=2.06-2.73) had progressively worse posttransplant mortality in comparison with recipients without HCC. Patients with a tumor burden exceeding the Milan criteria (who are usually excluded from transplantation) had excellent posttransplant survival if their serum AFP level was 0 to 15 ng/mL (AHR=0.97, 95% CI=0.66-1.43). In contrast, patients within the Milan criteria (who are routinely considered to be transplant candidates) had poor survival if their serum AFP level was substantially elevated (for a serum AFP level66 ng/mL, AHR=1.93, 95% CI=1.74-2.15). Changes in serum AFP level while patients were on the waiting list corresponded closely to changes in posttransplant mortality. In conclusion, the absolute serum AFP level and changes in the serum AFP level strongly predict posttransplant survival independently of the tumor burden. We hope that these data, in combination with other factors, can be used to inform future studies and ongoing discussions aimed at improving the eligibility criteria for liver transplantation for patients with HCC. Liver Transpl 19:634-645, 2013. (c) 2013 AASLD.
C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, 1660 South Columbian Way,S-111 Gastro, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU Veterans Affairs Office of Research and Development; Health Resources
and Services Administration [231-00-0115]
FX This study was supported by the Research Enhancement Award Program of
the Veterans Affairs Office of Research and Development.; This research
is based on data derived from the United Network for Organ Sharing in
October 2011. This work was supported in part by Health Resources and
Services Administration contract 231-00-0115. The content is the
responsibility of the authors alone and does not necessarily reflect the
views or policies of the Department of Health and Human Services.
NR 16
TC 39
Z9 39
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2013
VL 19
IS 6
BP 634
EP 645
DI 10.1002/lt.23652
PG 12
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 152FZ
UT WOS:000319518000010
PM 23536495
ER
PT J
AU Schacht, JP
Anton, RF
Randall, PK
Li, XB
Henderson, S
Myrick, H
AF Schacht, Joseph P.
Anton, Raymond F.
Randall, Patrick K.
Li, Xingbao
Henderson, Scott
Myrick, Hugh
TI Effects of a GABA-ergic medication combination and initial alcohol
withdrawal severity on cue-elicited brain activation among
treatment-seeking alcoholics
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Alcoholism; Anticonvulsant; Craving; Neuroimaging; Relapse
ID ANTERIOR CINGULATE CORTEX; COMPULSIVE DRINKING SCALE; PREFRONTAL CORTEX;
DEPENDENT INDIVIDUALS; ABSTINENT ALCOHOLICS; ETHANOL WITHDRAWAL;
RECEPTOR FUNCTION; GENE-EXPRESSION; DOUBLE-BLIND; GABAPENTIN
AB Many studies have reported medication effects on alcohol cue-elicited brain activation or associations between such activation and subsequent drinking. However, few have combined the methodological rigor of a randomized clinical trial (RCT) with follow-up assessments to determine whether cue-elicited activation predicts relapse during treatment, the crux of alcoholism.
This study analyzed functional magnetic resonance imaging (fMRI) data from 48 alcohol-dependent subjects enrolled in a 6-week RCT of an investigational pharmacotherapy.
Subjects were randomized, based on their level of alcohol withdrawal (AW) at study entry, to receive either a combination of gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days) or two placebos. Midway through the RCT, subjects were administered an fMRI alcohol cue reactivity task.
There were no main effects of medication or initial AW status on cue-elicited activation, but these factors interacted, such that the GBP/FMZ/higher AW and placebo/lower AW groups, which had previously been shown to have relatively reduced drinking, demonstrated greater dorsal anterior cingulate cortex (dACC) activation to alcohol cues. Further analysis suggested that this finding represented differences in task-related deactivation and was associated with greater control over alcohol-related thoughts. Among study completers, regardless of medication or AW status, greater left dorsolateral prefrontal cortex (DLPFC) activation predicted more post-scan heavy drinking.
These data suggest that alterations in task-related deactivation of dACC, a component of the default mode network, may predict better alcohol treatment response, while activation of DLPFC, an area associated with selective attention, may predict relapse drinking.
C1 [Schacht, Joseph P.; Anton, Raymond F.; Randall, Patrick K.; Li, Xingbao; Henderson, Scott; Myrick, Hugh] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Myrick, Hugh] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Schacht, JP (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
EM schacht@musc.edu
FU National Institute on Alcohol Abuse and Alcoholism [T32 AA007474, K05
AA017435]; Hythiam, Inc.
FX This work was conducted under an unrestricted grant from Hythiam, Inc.
This funding source had no involvement in the study design, in the
collection, analysis, and interpretation of data, in the writing of the
paper, or in the decision to submit for publication. Drs. Schacht and
Anton are supported by grants from the National Institute on Alcohol
Abuse and Alcoholism (T32 AA007474 and K05 AA017435). Portions of this
work were presented as a poster at the 34th Annual Meeting of the
Research Society on Alcoholism (June 2011, Atlanta, GA, USA).
NR 57
TC 10
Z9 11
U1 7
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUN
PY 2013
VL 227
IS 4
BP 627
EP 637
DI 10.1007/s00213-013-2996-x
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 150XF
UT WOS:000319424200006
PM 23389755
ER
PT J
AU Doyle, PJ
Hula, WD
Hula, SNA
Stone, CA
Wambaugh, JL
Ross, KB
Schumacher, JG
AF Doyle, Patrick J.
Hula, William D.
Hula, Shannon N. Austermann
Stone, Clement A.
Wambaugh, Julie L.
Ross, Katherine B.
Schumacher, James G.
TI Self- and surrogate-reported communication functioning in aphasia
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Outcomes assessment; Self-assessment; Factor analysis; Aphasia
ID QUALITY-OF-LIFE; STROKE IMPACT SCALE; MEASUREMENT INVARIANCE; FACTORIAL
INVARIANCE; PSYCHOMETRIC EVALUATION; OUTCOME MEASURE; RASCH ANALYSIS;
CES-D; PROXY; RELIABILITY
AB To evaluate the dimensionality and measurement invariance of the aphasia communication outcome measure (ACOM), a self- and surrogate-reported measure of communicative functioning in aphasia.
Responses to a large pool of items describing communication activities were collected from 133 community-dwelling persons with aphasia of a parts per thousand yen 1 month post-onset and their associated surrogate respondents. These responses were evaluated using confirmatory and exploratory factor analysis. Chi-square difference tests of nested factor models were used to evaluate patient-surrogate measurement invariance and the equality of factor score means and variances. Association and agreement between self- and surrogate reports were examined using correlation and scatterplots of pairwise patient-surrogate differences.
Three single-factor scales (Talking, Comprehension, and Writing) approximating patient-surrogate measurement invariance were identified. The variance of patient-reported scores on the Talking and Writing scales was higher than surrogate-reported variances on these scales. Correlations between self- and surrogate reports were moderate-to-strong, but there were significant disagreements in a substantial number of individual cases.
Despite minimal bias and relatively strong association, surrogate reports of communicative functioning in aphasia are not reliable substitutes for self-reports by persons with aphasia. Furthermore, although measurement invariance is necessary for direct comparison of self- and surrogate reports, the costs of obtaining invariance in terms of scale reliability and content validity may be substantial. Development of non-invariant self- and surrogate report scales may be preferable for some applications.
C1 [Doyle, Patrick J.; Hula, William D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.
[Doyle, Patrick J.; Hula, William D.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
[Hula, Shannon N. Austermann] VA Pittsburgh Healthcare Syst, Res Serv, Pittsburgh, PA USA.
[Stone, Clement A.] Univ Pittsburgh, Dept Educ Psychol, Pittsburgh, PA USA.
[Wambaugh, Julie L.] VA Salt Lake City Healthcare Syst, Res Serv, Salt Lake City, UT USA.
[Wambaugh, Julie L.] Univ Utah, Dept Commun Sci & Disorders, Salt Lake City, UT USA.
[Ross, Katherine B.] Phoenix VA Healthcare Syst, Audiol & Speech Pathol, Phoenix, AZ USA.
[Schumacher, James G.] VA Pittsburgh Healthcare Syst, Audiol & Speech Pathol, Pittsburgh, PA USA.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.
EM william.hula@va.gov
FU VA Rehabilitation Research & Development Merit Review Award [C6098R];
Career Development Award [6210 M]; VA Pittsburgh Healthcare System
Geriatric Research Education and Clinical Center
FX This work was supported by VA Rehabilitation Research & Development
Merit Review Award C6098R, Career Development Award 6210 M, and the VA
Pittsburgh Healthcare System Geriatric Research Education and Clinical
Center. An earlier version of this work was presented at the Clinical
Aphasiology Conference, May 27, 2010, Isle of Palms, SC, USA. The
contents of this paper do not represent the views of the Department of
Veterans Affairs or the United States Government.
NR 58
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
J9 QUAL LIFE RES
JI Qual. Life Res.
PD JUN
PY 2013
VL 22
IS 5
BP 957
EP 967
DI 10.1007/s11136-012-0224-5
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 152FQ
UT WOS:000319516800004
PM 22729711
ER
PT J
AU Batki, SL
Lasher, BA
Metzler, T
Heinz, AJ
Herbst, E
Waldrop, A
Neylan, TC
Kalapatapu, R
AF Batki, S. L.
Lasher, B. A.
Metzler, T.
Heinz, A. J.
Herbst, E.
Waldrop, A.
Neylan, T. C.
Kalapatapu, R.
TI PREDICTORS OF OUTCOME IN A PILOT CONTROLLED TRIAL OF TOPIRAMATE FOR
ALCOHOL DEPENDENCE IN VETERANS WITH PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Batki, S. L.; Lasher, B. A.; Metzler, T.; Heinz, A. J.; Herbst, E.; Waldrop, A.; Neylan, T. C.; Kalapatapu, R.] San Francisco VA Med Ctr, UCSF Dept Psychiat, Addict Res Program, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 17A
EP 17A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998300026
ER
PT J
AU Santos, GM
Lasher, A
Heinz, AJ
Kalapatapu, R
Herbst, E
Metzler, T
Waldrop, A
Neylan, TC
Tarasovsky, G
Prathikanti, S
Jatlow, P
Batki, SL
AF Santos, G-M
Lasher, A.
Heinz, A. J.
Kalapatapu, R.
Herbst, E.
Metzler, T.
Waldrop, A.
Neylan, T. C.
Tarasovsky, G.
Prathikanti, S.
Jatlow, P.
Batki, S. L.
TI URINARY ETHYL GLUCURONIDE AND ETHYL SULFATE TESTING TO EVALUATE THE
EFFICACY OF TOPIRAMATE TREATMENT OF ALCOHOL DEPENDENCE IN VETERANS WITH
PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Santos, G-M; Lasher, A.; Heinz, A. J.; Kalapatapu, R.; Herbst, E.; Metzler, T.; Waldrop, A.; Neylan, T. C.; Tarasovsky, G.; Prathikanti, S.; Jatlow, P.; Batki, S. L.] San Francisco VA Med Ctr, UCSF Dept Psychiat, Addict Res Program, San Francisco, CA 94121 USA.
NR 0
TC 1
Z9 1
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 19A
EP 19A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998300036
ER
PT J
AU Wilhelm, CJ
Hashimoto, JG
Andrew, MR
Roberts, ML
Loftis, JM
Wiren, KM
AF Wilhelm, C. J.
Hashimoto, J. G.
Andrew, M. R.
Roberts, M. L.
Loftis, J. M.
Wiren, K. M.
TI PRO-INFLAMMATORY ACTIVATION FOLLOWING CHRONIC INTOXICATION IN FEMALE BUT
NOT MALE MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 171A
EP 171A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998300641
ER
PT J
AU Rasmussen, DD
Kincaid, CL
Froehlich, JC
AF Rasmussen, D. D.
Kincaid, C. L.
Froehlich, J. C.
TI PRAZOSIN DECREASES ALCOHOL DRINKING DURING WITHDRAWAL IN RATS WITH A
PROLONGED HISTORY OF VOLUNTARY HIGH ALCOHOL DRINKING AND DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 174A
EP 174A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998300656
ER
PT J
AU Rasmussen, DD
Kincaid, CL
Froehlich, JC
AF Rasmussen, D. D.
Kincaid, C. L.
Froehlich, J. C.
TI PRAZOSIN plus NALTREXONE DECREASES ALCOHOL DRINKING MORE EFFECTIVELY
THAN DOES EITHER DRUG ALONE IN P RATS WITH HISTORY OF PROLONGED ALCOHOL
DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 175A
EP 175A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998300657
ER
PT J
AU Cates, LN
Nadav, T
Crabbe, JC
Phillips, TJ
Roberts, AJ
AF Cates, L. N.
Nadav, T.
Crabbe, J. C.
Phillips, T. J.
Roberts, A. J.
TI FENOFIBRATE, BUT NOT TESAGLITAZAR, REDUCED ETHANOL DRINKING IN HIGH
DRINKING-IN-THE-DARK MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Cates, L. N.; Nadav, T.; Crabbe, J. C.; Phillips, T. J.; Roberts, A. J.] Scripps Res Inst, La Jolla, CA 92037 USA.
[Cates, L. N.; Nadav, T.; Crabbe, J. C.; Phillips, T. J.; Roberts, A. J.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Cates, L. N.; Nadav, T.; Crabbe, J. C.; Phillips, T. J.; Roberts, A. J.] Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 245A
EP 245A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998301123
ER
PT J
AU Gubner, NR
Phillips, TJ
AF Gubner, N. R.
Phillips, T. J.
TI THE EFFECT OF NICOTINE IN COMBINATION WITH ETHANOL ON THE DEVELOPMENT OF
BEHAVIORAL SENSITIZATION
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Gubner, N. R.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 248A
EP 248A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998301135
ER
PT J
AU Buck, KJ
Walter, NAR
Denmark, DL
AF Buck, K. J.
Walter, N. A. R.
Denmark, D. L.
TI SUPRAMOLECULAR ORGANIZATION OF MITOCHONDRIAL RESPIRATORY CHAIN COMPLEXES
EXHIBITS STRAIN-DEPENDENCE IN C57BL6/J AND DBA/2J MOUSE BRAIN
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 253A
EP 253A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998301153
ER
PT J
AU Simpson, TL
Stappenbeck, CA
Luterek, JA
Lehavot, K
Kaysen, DL
AF Simpson, T. L.
Stappenbeck, C. A.
Luterek, J. A.
Lehavot, K.
Kaysen, D. L.
TI AN EVENT LEVEL EVALUATION OF THE INTERPLAY BETWEEN PTSD SYMPTOMS AND
ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH COMORBID PTSD AND ALCOHOL
DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Simpson, T. L.; Stappenbeck, C. A.; Luterek, J. A.; Lehavot, K.; Kaysen, D. L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 270A
EP 270A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998301221
ER
PT J
AU Lapham, GT
Rubinsky, AD
Hawkins, EJ
Williams, EC
Kivlahan, DJ
Bradley, KA
AF Lapham, G. T.
Rubinsky, A. D.
Hawkins, E. J.
Williams, E. C.
Kivlahan, D. J.
Bradley, K. A.
TI ANNUAL ALCOHOL SCREENING MAY NOT BE NECESSARY FOR NONDRINKERS WITH
MULTIPLE PRIOR NEGATIVE SCREENS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 22-26, 2013
CL Orlando, FL
SP Res Soc Alcoholism
C1 [Lapham, G. T.; Rubinsky, A. D.; Hawkins, E. J.; Williams, E. C.; Kivlahan, D. J.; Bradley, K. A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2013
VL 37
SU 2
SI SI
BP 286A
EP 286A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 145EU
UT WOS:000318998301286
ER
PT J
AU Caplan, L
Clegg, DO
Inman, RD
AF Caplan, Liron
Clegg, Daniel O.
Inman, Robert D.
TI Ankylosing Spondylitis Clinical Registries: Principles, Practices and
Possibilities
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 10th Annual Meeting of the
SPondyloArthritis-Research-and-Treatment-Network
(SPARTAN)-Group-for-Research-and-Assessment-of-Psoriasis-and-Psoriatic-A
rthritis (GRAPPA)
CY JUL 27-28, 2012
CL Portland, OR
SP SPondyloArthritis Res & Treatment Network (SPARTAN), Grp Res & Assessment Psoriasis & Psoriat Arthrit (GRAPPA)
DE Clinical registry; Spondyloathritis; Ankylosing spondylitis
AB The need for a rigorously developed longitudinal registry of patients with spondyloarthritis (SpA) is clear and urgent. Like randomized controlled trials, registries rely on a prospective, systematic protocol-driven approach to data acquisition to assess outcomes for a prescribed cohort of patients. Registries seek to capture large numbers of patients across large geographic zones and can serve as a valuable resource for patient advocacy, patient education and support, incidence and prevalence, and broad demographic profiles. Building on 3 existing registries the Prospective Study of Outcomes in Ankylosing Spondylitis, the Program to Understand the Longterm Outcomes of Spondyloarthritis (PULSAR) and the University Health Network Spondyloarthritis Program-these registries and the Spondylitis Association of America propose to form a combined registry of North American SpA patients. The combined registry would, ideally, complement ongoing clinical goals and improve patient care.
C1 [Caplan, Liron] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA.
[Clegg, Daniel O.] Univ Utah, Sch Med, George E Whalen Salt Lake Vet Affairs Med Ctr, Salt Lake City, UT USA.
[Inman, Robert D.] Univ Toronto, Toronto, ON, Canada.
RP Clegg, DO (reprint author), Univ Utah Hlth Care, 50 North Med Dr, Salt Lake City, UT 84132 USA.
EM daniel.clegg@hsc.utah.edu
NR 1
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUN
PY 2013
VL 345
IS 6
BP 437
EP 439
DI 10.1097/MAJ.0b013e3182937335
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 151CH
UT WOS:000319437700005
PM 23841118
ER
PT J
AU Bakaeen, FG
Chu, D
Kelly, RF
Ward, HB
Jessen, ME
Chen, GJ
Petersen, NJ
Holman, WL
AF Bakaeen, Faisal G.
Chu, Danny
Kelly, Rosemary F.
Ward, Herbert B.
Jessen, Michael E.
Chen, G. John
Petersen, Nancy J.
Holman, William L.
TI Performing Coronary Artery Bypass Grafting Off-Pump May Compromise
Long-Term Survival in a Veteran Population
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT 49th Annual Meeting of the Society-of-Thoracic-Surgeons
CY JAN 26-30, 2013
CL Los Angeles, CA
SP Soc Thorac Surg
ID ON-PUMP; RANDOMIZED-TRIAL; REDUCE MORBIDITY; CARDIAC-SURGERY; OUTCOMES;
REVASCULARIZATION; MORTALITY; METAANALYSIS; STROKE; PATENCY
AB Background. There are ample data regarding the short-term outcomes of on-pump and off-pump coronary artery bypass grafting (CABG), but little is known about the long-term survival associated with these approaches.
Methods. Using the Veterans Affairs (VA) Continuous Improvement in Cardiac Surgery Program, we identified all VA patients (n = 65,097) who underwent primary isolated CABG from October 1997 to April 2011. The primary outcome measure was all-cause mortality. Age, 17 preoperative risk factors, and year of operation were used to calculate propensity scores for each patient. A greedy-match algorithm using the propensity scores matched 8,911 off-pump with 26,733 on-pump patients. Survival functions were estimated by the Kaplan-Meier method and compared by using the log-rank test.
Results. In the complete cohort, off-pump was used in 11,629 of 65,097 (17.9%) operations. For the matched cohort, the median follow-up was 6.7 years (interquartile range, 3.72 to 9.35 years). Risk-adjusted mortality did not differ significantly between the off-pump and on-pump groups at 1 year (4.67% vs 4.78%; risk ratio [RR], 0.98; 95% confidence interval [CI], 0.88 to 1.09) or 3 years (9.21% vs 8.89%; RR, 1.04; 95% CI, 0.96 to 1.12). However, risk-adjusted mortality was higher in the off-pump group at 5 years (14.47% vs 13.45%; RR, 1.08; 95% CI 1.02 to 1.15) and 10 years (25.18% vs 23.57%; RR, 1.07; 95% CI, 1.03 to 1.12). Overall, the hazard ratio for off-pump vs on-pump was 1.06 (95% CI, 1.00 to 1.13; p = 0.04).
Conclusions. Off-pump CABG may be associated with decreased long-term survival. Further studies are needed to identify the reasons behind this finding. (C) 2013 by The Society of Thoracic Surgeons
C1 Michael E DeBakey VA Med Ctr, Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX USA.
Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Div Cardiothorac Surg, Minneapolis, MN USA.
Univ Texas SW Med Ctr Dallas, Div Cardiothorac Surg, Dallas, TX 75390 USA.
Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Houston, TX USA.
Univ Alabama Birmingham, Dept Cardiothorac Surg, Birmingham, AL USA.
Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Bakaeen, FG (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77005 USA.
EM fbakaeen@bcm.edu
NR 29
TC 16
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2013
VL 95
IS 6
BP 1952
EP 1960
DI 10.1016/j.athoracsur.2013.02.064
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 149QF
UT WOS:000319335400027
PM 23647861
ER
PT J
AU Zartman, AL
Hilsabeck, RC
Guarnaccia, CA
Houtz, A
AF Zartman, Andrea L.
Hilsabeck, Robin C.
Guarnaccia, Charles A.
Houtz, Andrew
TI The Pillbox Test: An Ecological Measure of Executive Functioning and
Estimate of Medication Management Abilities
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Assessment; Executive functions; Test construction
ID COGNITIVE FUNCTION; OLDER-ADULTS; ALZHEIMERS-DISEASE; PERFORMANCE;
IMPAIRMENT; DECLINE; PREDICTORS; MEMORY; SCHIZOPHRENIA; ASSOCIATION
AB Studies indicate that executive functioning (EF) is a strong predictor of everyday function. However, assessment can be problematic as no single standardized instrument is known to measure all EF domains simultaneously. Thus, the Pillbox Test was developed as a new measure tapping four EF factors through the real-time assessment of medication management, a complex instrumental activity of daily living. The Pillbox Test showed good criterion-related validity and was effective in differentiating graduated levels of executive dysfunction between a mixed neurological group, medical control group, and healthy community control group. This test also showed good convergent validity as it correlated significantly in expected directions with established EF measures in all four of selected EF domains and the Direct Assessment of Functional Status. Finally, a receiver operator characteristic curve found a sensitivity of 75 and specificity of 87.5, suggesting that the Pillbox Test is a promising new ecological measure of EF.
C1 [Zartman, Andrea L.; Guarnaccia, Charles A.] Univ N Texas, Dept Psychol, Denton, TX 76203 USA.
[Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Hilsabeck, Robin C.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Houtz, Andrew] Cognit Solut, Ft Worth, TX USA.
RP Zartman, AL (reprint author), VA North Texas Hlth Care Syst, Mental Hlth 4500 S Lancaster Rd 116A, Dallas, TX 75216 USA.
EM andrea.zartman@va.gov
NR 64
TC 7
Z9 7
U1 3
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD JUN
PY 2013
VL 28
IS 4
BP 307
EP 319
DI 10.1093/arclin/act014
PG 13
WC Psychology, Clinical; Psychology
SC Psychology
GA 148XI
UT WOS:000319281500001
PM 23502807
ER
PT J
AU Thaler, NS
Goldstein, G
Pettegrew, JW
Luther, JF
Reynolds, CR
Allen, DN
AF Thaler, Nicholas S.
Goldstein, Gerald
Pettegrew, Jay W.
Luther, James F.
Reynolds, Cecil R.
Allen, Daniel N.
TI Developmental Aspects of Working and Associative Memory
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Learning and memory; Assessment
ID SHORT-TERM-MEMORY; TEMPORAL-LOBE; BRIEF-HISTORY; LONG-TERM
AB Developmental differences between working and long-term associative memory were evaluated through a cross-sectional age difference study based on data from a memory batterys standardization sample. The scores of 856 children and adolescents ranging from 5 to 17 years of age were compared on memory subtests that assess verbal working and long-term memory. Data were examined using curve fitting and ANOVA procedures that evaluated age group and years of age differences. The major finding was that the developmental trajectories across age differed substantially between the two memory domains. The working memory trajectory was linear until age 11, whereas the long-term memory trajectory was curvilinear with an inflection point at age 8. Both trajectories plateaued after age 11. ANOVAs produced significant interactions between tests of working and associative memory with age, supporting the view that the age trajectories had differing courses. The results are discussed in terms of neurobiological implications for the two memory systems studied.
C1 [Thaler, Nicholas S.; Allen, Daniel N.] Univ Nevada, Las Vegas, NV 89154 USA.
[Goldstein, Gerald; Luther, James F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
[Pettegrew, Jay W.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Reynolds, Cecil R.] Texas A&M Univ, College Stn, TX USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM ggold@nb.net
FU Mental Illness Research, Education, and Clinical Center (MIRECC)
VISN-IV, Pittsburgh, PA; Medical Research Service, Department of
Veterans Affairs
FX This research was supported by the Mental Illness Research, Education,
and Clinical Center (MIRECC) VISN-IV, Pittsburgh, PA, and by the Medical
Research Service, Department of Veterans Affairs.
NR 28
TC 3
Z9 3
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD JUN
PY 2013
VL 28
IS 4
BP 348
EP 355
DI 10.1093/arclin/acs114
PG 8
WC Psychology, Clinical; Psychology
SC Psychology
GA 148XI
UT WOS:000319281500004
PM 23341435
ER
PT J
AU Thase, ME
AF Thase, M. E.
TI Clustering of depressive and manic symptoms in bipolar disorder
SO BIPOLAR DISORDERS
LA English
DT Meeting Abstract
CT 10th International Conference on Bipolar Disorder of the
International-Society-for-Bipolar-Disorders
CY JUN 13-16, 2013
CL Miami Beach, FL
SP Int Soc Bipolar Disorders
DE bipolar affective disorder; depression; hypomania; mania; mixed states
C1 [Thase, M. E.] Univ Penn, Philadelphia VA Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2013
VL 15
SU 1
SI SI
BP 18
EP 18
PG 1
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 156MR
UT WOS:000319826800029
ER
PT J
AU Thase, ME
AF Thase, M. E.
TI Clinical perspective on RDoC and ROAMER utility
SO BIPOLAR DISORDERS
LA English
DT Meeting Abstract
CT 10th International Conference on Bipolar Disorder of the
International-Society-for-Bipolar-Disorders
CY JUN 13-16, 2013
CL Miami Beach, FL
SP Int Soc Bipolar Disorders
DE bipolar disorder; depression; dimensional assessment; RDOCs; ROAMER;
cognitive dysfunction; insomnia
C1 [Thase, M. E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, M. E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2013
VL 15
SU 1
SI SI
BP 37
EP 37
PG 1
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 156MR
UT WOS:000319826800079
ER
PT J
AU Valente, AJ
Yoshida, T
Izadpanah, R
Delafontaine, P
Siebenlist, U
Chandrasekar, B
AF Valente, Anthony J.
Yoshida, Tadashi
Izadpanah, Reza
Delafontaine, Patrice
Siebenlist, Ulrich
Chandrasekar, Bysani
TI Interleukin-18 enhances IL-18R/Noxl binding, and mediates
TRAF3IP2-dependent smooth muscle cell migration. Inhibition by
simvastatin
SO CELLULAR SIGNALLING
LA English
DT Article
DE Interleukin-18; TRAF3IP2; Nox1; Oxidative stress; SMC migration;
Vascular diseases
ID KAPPA-B KINASE; NADPH OXIDASE; CIKS ACT1; EXPRESSION; NOX1; ACTIVATION;
STATINS; PROTEIN; ATHEROSCLEROSIS; PROLIFERATION
AB We investigated the role of TRAF3 interacting protein 2 (TRAF3IP2), a redox-sensitive adapter protein and an upstream regulator of IKK and JNK in interleukin (IL)-18 induced smooth muscle cell migration, and the mechanism of its inhibition by simvastatin. The pleiotropic cytokine IL-18 induced human coronary artery SMC migration through the induction of TRAF3IP2. IL-18 induced Nox1-dependent ROS generation, TRAF3IP2 expression, and IKK/NF-kappa B and JNK/AP-1 activation. IL-18 induced its own expression and that of its receptor subunit IL-18R alpha. Using co-IP/IB and GST pull-down assays, we show for the first time that the subunits of the IL-18R heterodimer physically associate with Nox1 under basal conditions, and IL-18 appears to enhance their binding. Importantly, the HMG-coA reductase inhibitor simvastatin attenuated IL-18-induced TRAF3IP2 induction. These inhibitory effects were reversed by mevalonate and geranylgeranylpyrophosphate (GGPP), but not by famesylpyrophosphate (FPP). Interestingly, simvastatin, GGPP, FPP, or Rac1 inhibition did not modulate ectopically expressed TRAF3IP2. These results demonstrate that the promigratory effects of IL-18 are mediated through TRAF3IP2 in a redox-sensitive manner, and this may involve IL-18R/Nox1 physical association. Further, Simvastatin inhibits inducible, but not ectopically-xpressed TRAF3IP2. Targeting TRAF3IP2 may blunt progression of hyperplastic vascular diseases in vivo. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Yoshida, Tadashi; Izadpanah, Reza; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
[Siebenlist, Ulrich] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA.
EM bchandra@tulane.edu
FU Department of Veterans Affairs Research Career Scientist award; VA
Office of Research and Development Biomedical Laboratory Research and
Development Service Award [1I01BX000246]; NIH/NHLBI [HL-86787]; NHLBI
[HL-70241, HL-80682]
FX BC is a recipient of the Department of Veterans Affairs Research Career
Scientist award, and is supported by VA Office of Research and
Development Biomedical Laboratory Research and Development Service Award
1I01BX000246 and the NIH/NHLBI grant HL-86787. The contents of this
report do not represent the views of the Department of Veterans Affairs
or the United States Government. PD is supported by NHLBI grants
HL-70241 and HL-80682. The authors gratefully acknowledge the excellent
technical assistance of Maria Gamez.
NR 27
TC 8
Z9 9
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2013
VL 25
IS 6
BP 1447
EP 1456
DI 10.1016/j.cellsig.2013.03.007
PG 10
WC Cell Biology
SC Cell Biology
GA 147OD
UT WOS:000319176000013
PM 23541442
ER
PT J
AU Akgun, KM
Tate, JP
Pisani, M
Fried, T
Butt, AA
Gibert, CL
Huang, L
Rodriguez-Barradas, MC
Rimland, D
Justice, AC
Crothers, K
AF Akguen, Kathleen M.
Tate, Janet P.
Pisani, Margaret
Fried, Terri
Butt, Adeel A.
Gibert, Cynthia L.
Huang, Laurence
Rodriguez-Barradas, Maria C.
Rimland, David
Justice, Amy C.
Crothers, Kristina
TI Medical ICU Admission Diagnoses and Outcomes in Human Immunodeficiency
Virus-Infected and Virus-Uninfected Veterans in the Combination
Antiretroviral Era
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE 30-day mortality; comorbidity; human immunodeficiency virus; medical
ICU; Veterans Aging Cohort Study Index
ID INTENSIVE-CARE-UNIT; HIV-NEGATIVE VETERANS; CIGARETTE-SMOKING; THERAPY
ERA; HEPATITIS-C; MORTALITY; SURVIVAL; IMPACT; COHORT; RISK
AB Objectives: Human immunodeficiency virus (HIV)-infected (HIV+) patients on combination antiretroviral therapy are living longer but have increased risk for aging-associated disease which may lead to increasing critical care requirements. We compare medical ICU admission characteristics and outcomes among HIV infected and demographically similar uninfected patients (uninfected) and considered whether an index which combines routine clinical biomarkers (the Veterans Aging Cohort Study Index) predicts 30-day medical ICU mortality.
Design: Observational data analyses (Veterans Aging Cohort Study).
Setting: Eight Veterans Affairs medical centers nationwide.
Patients: HIV infected and uninfected with a medical ICU admission between 2002 and 2010.
Intervention: None.
Measurements and Main Results: Medical ICU admission was determined using bedsection (Veterans Affairs) and revenue center codes (Medicare). For Veterans Affairs admissions, we used clinical data to calculate Veterans Aging Cohort Study Index scores and multivariable logistic regression to determine factors associated with 30-day mortality. Overall, 539 of 3,620 (15%) HIV infected and 375 of 3,639 (10%) uninfected had a medical ICU admission; 72% and 78%, respectively, were Veterans Affairs based. HIV+ patients were younger at admission (p < 0.0001). Although most HIV+ patients were on antiretroviral therapy (71%) with undetectable HIV-1 RNA (54%), compared with uninfected they were more commonly admitted with respiratory diagnoses or infections (21% vs. 12%), were more likely to require mechanical ventilation (17% vs. 9%; p = 0.001), and had a higher mortality rate (18.6% vs. 11.2%, p = 0.003). Cardiovascular diagnoses were less common among HIV infected (18% vs. 29%; p < 0.0001). In logistic regression (c-statistic 0.87), a 5-point increment in Veterans Aging Cohort Study Index was associated with an odds ratio of death of 1.22 (95% confidence interval 1.14-1.30) among HIV infected and of 1.50 (95% confidence interval 1.29-1.76) among uninfected; infection/sepsis and respiratory diagnoses were also associated with mortality.
Conclusions: Medical ICU admission was frequent, 30-day mortality higher, and mechanical ventilation more common in HIV infected compared with uninfected. The Veterans Aging Cohort Study Index calculated at medical ICU admission predicted 30-day mortality for HIV infected and uninfected. As more individuals age with HIV, their requirements for medical ICU care may be greater than demographically similar uninfected individuals.
C1 [Akguen, Kathleen M.; Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT USA.
[Akguen, Kathleen M.; Tate, Janet P.; Pisani, Margaret; Fried, Terri; Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Fried, Terri] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
[Gibert, Cynthia L.] VAMC, Dept Med, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Washington, DC USA.
[Huang, Laurence] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E De Bakey VAMC, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Rimland, David] Atlanta VA, Dept Med, Decatur, GA USA.
[Rimland, David] Emory Univ, Decatur, GA USA.
[Crothers, Kristina] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
RP Akgun, KM (reprint author), VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT USA.
EM kathleen.akgun@yale.edu
RI Andrade, Hugo/M-6631-2013
OI Andrade, Hugo/0000-0001-6781-6125; Crothers,
Kristina/0000-0001-9702-0371
FU Association of Subspecialty Physicians and CHEST Foundation of the
American College of Chest Physicians T. Franklin Williams Award;
National Institutes of Health, National Heart, Lung, and Blood Institute
[K24 HL087713, R01 HL090342]; National Institute on Alcohol Abuse and
Alcoholism [5U01AA013566-05]; National Institutes of Health; ASP-ACCP;
Merck; ATS
FX Supported, in part, by Association of Subspecialty Physicians and CHEST
Foundation of the American College of Chest Physicians T. Franklin
Williams Award (KMA); National Institutes of Health, National Heart,
Lung, and Blood Institute K24 HL087713 (LH); National Institute on
Alcohol Abuse and Alcoholism 5U01AA013566-05 (AJ); and National
Institutes of Health, National Heart, Lung, and Blood Institute R01
HL090342 (KC).; Drs. Akgun, Tate, Gibert, Huang, Rodriguez-Barradas,
Rimland, Justice, and Crothers received grant support from the National
Institutes of Health. Dr. Akgun received grant support from ASP-ACCP (T
Franklin Williams Award). Dr. Butt received grant support from Merck.
Dr. Rodriguez-Barradas received support for travel from NIH. Dr. Butt
lectured for Gilead. Dr. Crothers received educational presentation
funding from ATS.
NR 48
TC 26
Z9 27
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2013
VL 41
IS 6
BP 1458
EP 1467
DI 10.1097/CCM.0b013e31827caa46
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA 148TC
UT WOS:000319269400028
PM 23507717
ER
PT J
AU Clark, BJ
Williams, A
Feemster, LMC
Bradley, KA
Macht, M
Moss, M
Burnham, EL
AF Clark, Brendan J.
Williams, Andre
Feemster, Laura M. Cecere
Bradley, Katharine A.
Macht, Madison
Moss, Marc
Burnham, Ellen L.
CA NHLBI ARDS Network Investigators
TI Alcohol Screening Scores and 90-Day Outcomes in Patients With Acute Lung
Injury
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE acute lung injury; alcohol misuse; alcohol use disorder; alcohol use
disorders identification test; unhealthy alcohol use
ID RESPIRATORY-DISTRESS-SYNDROME; DISORDERS IDENTIFICATION TEST;
MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL PATIENTS; RISK-FACTORS;
TEST AUDIT; EPITHELIAL PERMEABILITY; HOSPITAL MORTALITY;
CIGARETTE-SMOKING; CLINICAL-TRIAL
AB Objectives: The effects of excess alcohol consumption (alcohol misuse) on outcomes in patients with acute lung injury have been inconsistent, and there are no studies examining this association in the era of low tidal volume ventilation and a fluid conservative strategy. We sought to determine whether validated scores on the Alcohol Use Disorders Identification Test that correspond to past-year abstinence (zone 1), low-risk drinking (zone 2), mild to moderate alcohol misuse (zone 3), and severe alcohol misuse (zone 4) are associated with poor outcomes in patients with acute lung injury.
Design: Secondary analysis.
Setting: The Acute Respiratory Distress Syndrome Network, a consortium of 12 university centers (44 hospitals) dedicated to the conduct of multicenter clinical trials in patients with acute lung injury.
Subjects: Patients meeting consensus criteria for acute lung injury enrolled in one of three recent Acute Respiratory Distress Syndrome Network clinical trials.
Interventions: None.
Measurements and Main Results: Of 1,133 patients enrolled in one of three Acute Respiratory Distress Syndrome Network studies, 1,037 patients had an Alcohol Use Disorders Identification Test score available for analysis. Alcohol misuse was common with 70 (7%) of patients having Alcohol Use Disorders Identification Test scores in zone 3 and 129 (12%) patients in zone 4. There was a U-shaped association between validated Alcohol Use Disorders Identification Test zones and death or persistent hospitalization at 90 days (34% in zone 1, 26% in zone 2, 27% in zone 3, 36% in zone 4; p < 0.05 for comparison of zone 1 to zone 2 and zone 4 to zone 2). In a multiple logistic regression model, there was a significantly higher odds of death or persistent hospitalization in patients having Alcohol Use Disorders Identification Test zone 4 compared with those in zone 2 (adjusted odds ratio 1.70; 95% confidence interval 1.00, 2.87; p = 0.048).
Conclusions: Severe but not mild to moderate alcohol misuse is independently associated with an increased risk of death or persistent hospitalization at 90 days in acute lung injury patients.
C1 [Clark, Brendan J.; Macht, Madison; Moss, Marc; Burnham, Ellen L.] Univ Colorado Denver, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
[Williams, Andre] Natl Jewish Hlth, Dept Biostat & Bioinformat, Denver, CO USA.
[Feemster, Laura M. Cecere] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Feemster, Laura M. Cecere] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
RP Clark, BJ (reprint author), Univ Colorado Denver, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
EM brendan.clark@ucdenver.edu
FU National Institutes of Health [K24-HL-089223, R24-AA-019661-01A1, N01
HR56167]; VA HSRD fellowship [TPM 61-037]; National Heart and Lung Bloos
Institute; VA HSRD Fellowship
FX Supported, in part, by National Institutes of Health (K24-HL-089223,
R24-AA-019661-01A1) and National Institutes of Health contract N01
HR56167; VA HSR&D fellowship (TPM 61-037) to Dr. Cecere.; Dr. Clark
received grant support from the National Heart and Lung Bloos Institute.
Dr. Feemster received grant support and funding for research for this
study from the VA HSR&D Fellowship. Dr. Burnham received travel support
from NIH.
NR 58
TC 14
Z9 14
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2013
VL 41
IS 6
BP 1518
EP 1525
DI 10.1097/CCM.0b013e318287f1bb
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 148TC
UT WOS:000319269400035
PM 23538449
ER
PT J
AU Garvin, EC
Cannuscio, CC
Branas, CC
AF Garvin, Eugenia C.
Cannuscio, Carolyn C.
Branas, Charles C.
TI Greening vacant lots to reduce violent crime: a randomised controlled
trial
SO INJURY PREVENTION
LA English
DT Article
ID NEIGHBORHOOD DISORDER; COLLECTIVE EFFICACY; INNER-CITY; FEAR; HEALTH;
ENVIRONMENT; OUTCOMES; STRESS; INJURY; SPACES
AB Background Vacant lots are often overgrown with unwanted vegetation and filled with trash, making them attractive places to hide illegal guns, conduct illegal activities such as drug sales and prostitution, and engage in violent crime. There is some evidence that greening vacant lots is associated with reductions in violent crime.
Methods We performed a randomised controlled trial of vacant lot greening to test the impact of this intervention on police reported crime and residents' perceptions of safety and disorder. Greening consisted of cleaning the lots, planting grass and trees, and building a wooden fence around the perimeter. We randomly allocated two vacant lot clusters to the greening intervention or to the control status (no intervention). Administrative data were used to determine crime rates, and local resident interviews at baseline (n = 29) and at follow-up (n = 21) were used to assess perceptions of safety and disorder.
Results Unadjusted difference-in-differences estimates showed a non-significant decrease in the number of total crimes and gun assaults around greened vacant lots compared with control. People around the intervention vacant lots reported feeling significantly safer after greening compared with those living around control vacant lots (p < 0.01).
Conclusions In this study, greening was associated with reductions in certain gun crimes and improvements in residents' perceptions of safety. A larger randomised controlled trial is needed to further investigate the link between vacant lot greening and violence reduction.
C1 [Garvin, Eugenia C.] Univ Penn, Perelman Sch Med, Robert Wood Johnson Clin Scholars, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.] Univ Penn, Perelman Sch Med, VA Ctr Hlth Equ Res & Promot, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Branas, Charles C.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Garvin, EC (reprint author), Univ Penn, Perelman Sch Med, Robert Wood Johnson Clin Scholars, 13th Fl Blockley Hall,423 Gaurdian Dr, Philadelphia, PA 19104 USA.
EM eugenia.garvin@uphs.upenn.edu
FU Robert Wood Johnson Health and Society Scholars Educational Fund
FX This work was supported by a grant from the Robert Wood Johnson Health
and Society Scholars Educational Fund (no grant number). The funders
played no role in study design, data collection or data analysis.
NR 40
TC 32
Z9 32
U1 5
U2 50
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1353-8047
J9 INJURY PREV
JI Inj. Prev.
PD JUN
PY 2013
VL 19
IS 3
BP 198
EP 203
DI 10.1136/injuryprev-2012-040439
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 147YS
UT WOS:000319208700009
PM 22871378
ER
PT J
AU Schwartz, AV
Schafer, AL
Grey, A
Vittinghoff, E
Palermo, L
Lui, LYL
Wallace, RB
Cummings, SR
Black, DM
Bauer, DC
Reid, IR
AF Schwartz, Ann V.
Schafer, Anne L.
Grey, Andrew
Vittinghoff, Eric
Palermo, Lisa
Lui, Li-Yung L.
Wallace, Robert B.
Cummings, Steven R.
Black, Dennis M.
Bauer, Douglas C.
Reid, Ian R.
TI Effects of antiresorptive therapies on glucose metabolism: Results from
the FIT, HORIZON-PFT, and FREEDOM trials
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANTIRESORPTIVE THERAPY; GLUCOSE; DIABETES; WEIGHT
ID FRACTURE INTERVENTION TRIAL; POSTMENOPAUSAL OSTEOPOROTIC WOMEN; YEARLY
ZOLEDRONIC ACID; BONE TURNOVER; OLDER MEN; UNDERCARBOXYLATED
OSTEOCALCIN; BIOCHEMICAL MARKERS; VERTEBRAL FRACTURES;
INSULIN-RESISTANCE; ENERGY-METABOLISM
AB In rodent models, undercarboxylated osteocalcin (ucOC) acts as a hormone that promotes insulin sensitivity and secretion. If ucOC plays a similar role in humans, then antiresorptive therapies, which reduce ucOC levels, may increase the risk of insulin resistance and diabetes. We tested whether antiresorptive therapies result in higher fasting glucose, increased weight, or greater diabetes incidence in post hoc analyses of three randomized, placebo-controlled trials in postmenopausal women: Fracture Intervention Trial (FIT) (N=6151) of alendronate (4 years), Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial (HORIZON-PFT) (N=7113) of zoledronic acid (3 years), and Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (N=7076) of denosumab (3 years). Fasting glucose was measured annually in FIT and HORIZON in a subset of women, and every 6 months in FREEDOM in all participants. Weight was measured annually in all trials. Incident diabetes was identified from adverse event reports, initiation of diabetes medication, or elevated fasting glucose. Differences in fasting glucose changes from randomization to trial conclusion between treatment and placebo groups were not statistically significant: 0.47mg/dL in FIT, 0.20mg/dL in HORIZON-PFT, and 0.09mg/dL in FREEDOM, all p>0.6. Weight change differed between treatment and placebo groups in FIT (0.32kg, p=0.003) and FREEDOM (0.31kg, p=0.023) but not in HORIZON-PFT (0.15kg, p=0.132). In the three trials combined, diabetes occurred in 203 and 225 women assigned to treatment or placebo, respectively. Diabetes incidence was not increased in any of the treatment groups or in the pooled estimate (pooled relative risk [RR]=0.90; 95% confidence interval [CI] 0.741.10). Antiresorptive therapy does not have a clinically important effect on fasting glucose, weight, or diabetes risk in postmenopausal women. Contrary to predictions from mouse models, reduced bone turnover does not appear to play a significant role in glucose metabolism in humans.
C1 [Schwartz, Ann V.; Schafer, Anne L.; Vittinghoff, Eric; Palermo, Lisa; Black, Dennis M.; Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94107 USA.
[Schafer, Anne L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Grey, Andrew; Reid, Ian R.] Univ Auckland, Auckland 1, New Zealand.
[Lui, Li-Yung L.; Cummings, Steven R.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Wallace, Robert B.] Univ Iowa, Iowa City, IA USA.
RP Schwartz, AV (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Suite 5700, San Francisco, CA 94107 USA.
EM aschwartz@psg.ucsf.edu
FU Department of Veterans Affairs [5 IK2 CX000549-02]; Merck Co., Inc.;
Novartis Pharma; Amgen Inc.
FX ALS was supported by a career development award from the Department of
Veterans Affairs (5 IK2 CX000549-02). The clinical trials were supported
by their respective sponsors. The Fracture Intervention Trial was
sponsored by Merck & Co., Inc.; Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly Pivotal Fracture Trial (HORIZON-PFT)
was sponsored by Novartis Pharma; and the Fracture Reduction Evaluation
of Denosumab in Osteoporosis Every 6 months (FREEDOM) trial was
sponsored by Amgen Inc. This study was not financially supported by the
trial sponsors.
NR 36
TC 41
Z9 42
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2013
VL 28
IS 6
BP 1348
EP 1354
DI 10.1002/jbmr.1865
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 149VS
UT WOS:000319350100013
PM 23322676
ER
PT J
AU Hashash, JG
Nasr, JY
Francis, F
AF Hashash, J. G.
Nasr, J. Y.
Francis, Fadi
TI Gastrointestinal: Mucinous and signet cell adenocarcinoma of the
appendix
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
C1 [Hashash, J. G.; Nasr, J. Y.] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.
[Francis, Fadi] VA Pittsburgh Healthcare Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
RP Hashash, JG (reprint author), Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.
NR 0
TC 1
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD JUN
PY 2013
VL 28
IS 6
BP 903
EP 903
DI 10.1111/jgh.12226
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 149RX
UT WOS:000319339900004
PM 23692577
ER
PT J
AU de Mena, L
Samaranch, L
Coto, E
Cardo, LF
Ribacoba, R
Lorenzo-Betancor, O
Pastor, P
Wang, L
Irigoyen, J
Mata, IF
Diaz, M
Moris, G
Menendez, M
Corao, AI
Lorenzo, E
Alvarez, V
AF de Mena, Lorena
Samaranch, LLuis
Coto, Eliecer
Cardo, Lucia F.
Ribacoba, Rene
Lorenzo-Betancor, Oswaldo
Pastor, Pau
Wang, Li
Irigoyen, Jaione
Mata, Ignacio F.
Diaz, Marta
Moris, German
Menendez, Manuel
Corao, Ana I.
Lorenzo, Elena
Alvarez, Victoria
TI Mutational Screening of PARKIN Identified a 3 ' UTR Variant (rs62637702)
Associated with Parkinson's Disease
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article; Proceedings Paper
CT 11th International Symposium on VIP, PACAP and Related Peptides
CY AUG 27-31, 2013
CL Univ Pecs, Pecs, HUNGARY
HO Univ Pecs
DE Parkinson's disease; Parkin; Mutation; DNA polymorphisms; Genetic risk;
Genetics
ID ALPHA-SYNUCLEIN EXPRESSION; RISK; GENE
AB PRKN mutations have been linked to Parkinson's disease (PD). Most of the mutational screenings have focused on the coding exons. The 3' untranslated region (UTR) could also harbor functionally relevant nucleotide changes. We performed a mutational screening of PRKN in a cohort of early-onset PD patients (n = 235) from Spain. We found 16 mutations (five new): 16 patients (7 %) carried two mutations and only one mutation was found in 28 (12 %). Patients with two mutations had significantly lower mean age (30 +/- 9 years) compared to patients with one (40 +/- 7) or no mutation (42 +/- 7). We found a total of 15 nucleotide variants (three new) in the 3' UTR region. The frequency of carriers of the rare rs62637702 G allele (*94A/G) was significantly lower among the patients compared to healthy controls (n = 418) (0.03 vs. 0.004; p < 0.001), suggesting a protective role for this allele. In order to investigate the basal effect of this variant, we performed luciferase assays. No different basal activity was observed between the two alleles. In conclusion, the rs62637702 polymorphism was associated with PD. This could be a surrogate marker for disease risk, in linkage disequilibrium with other non-identified functional variant.
C1 [de Mena, Lorena; Coto, Eliecer; Cardo, Lucia F.; Diaz, Marta; Corao, Ana I.; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo, Spain.
[Samaranch, LLuis; Lorenzo-Betancor, Oswaldo; Pastor, Pau; Irigoyen, Jaione; Lorenzo, Elena] Univ Navarra, CIMA, Ctr Appl Med Res, Neurogenet Lab,Div Neurosci, E-31080 Pamplona, Spain.
[Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Cent Asturias, Asturias, Spain.
[Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Alvarez Buylla Mieres, Asturias, Spain.
[Coto, Eliecer] Univ Oviedo, Dept Med, Oviedo, Spain.
[Lorenzo-Betancor, Oswaldo; Pastor, Pau; Irigoyen, Jaione; Lorenzo, Elena] Univ Navarra, Sch Med, Clin Univ Navarra, Dept Neurol, E-31080 Pamplona, Spain.
[Wang, Li] Univ Utah, Sch Med, Dept Med, Huntsman Canc Inst, Salt Lake City, UT USA.
[Wang, Li] Univ Utah, Sch Med, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT USA.
[Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Alvarez, Victoria] Hosp Cent Asturias Maternidad, Oviedo 33006, Spain.
RP Alvarez, V (reprint author), Hosp Cent Asturias Maternidad, Oviedo 33006, Spain.
EM victoria.alvarez@sespa.princast.es
RI Pastor, Pau/C-9834-2009
OI Pastor, Pau/0000-0002-7493-8777; Moris, German/0000-0001-7608-2194;
Fernandez Mata, Ignacio/0000-0003-1198-0633
FU Spanish Fondo de Investigaciones Sanitarias-Fondos FEDER European Union
[FIS-05/008, 08/0915, 11/0093]; FICYT-Principado de Asturias; Spanish
Ministry of Science and Technology; European Social Fund; Spanish
Ministry of Education and Science [SAF2006-10126]; Fundacio La Marato de
TV3 [061131]; UTE project FIMA, Spain; Fundacion Parkinson Asturias;
Obra Social Cajastur
FX The authors thank the Fundacion Parkinson Asturias and Obra Social
Cajastur for their support. This work was supported by grants from the
Spanish Fondo de Investigaciones Sanitarias-Fondos FEDER European Union
(FIS-05/008, 08/0915, and 11/0093). LFC and LDM are predoctoral
fellowships of FICYT-Principado de Asturias. LS held a Torres Quevedo
fellowship from the Spanish Ministry of Science and Technology,
co-financed by the European Social Fund. This study was supported by a
grant from the Spanish Ministry of Education and Science (SAF2006-10126:
2006-2009), by the project 061131 from the Fundacio La Marato de TV3 and
by the UTE project FIMA, Spain to PP. We thank all participating
subjects and their relatives for their contribution to the study. We
thank Drs. Maria A. Pastor, Jose Obeso, Maria R Luquin, Maria C
Rodriguez-Oroz, and Mario Riverol for recruiting some subjects for the
study.
NR 21
TC 3
Z9 3
U1 0
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD JUN
PY 2013
VL 50
IS 2
BP 264
EP 269
DI 10.1007/s12031-012-9942-y
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 148UX
UT WOS:000319274200005
PM 23275044
ER
PT J
AU Hausmann, LRM
Gao, S
Mor, MK
Schaefer, JH
Fine, MJ
AF Hausmann, Leslie R. M.
Gao, Shasha
Mor, Maria K.
Schaefer, James H., Jr.
Fine, Michael J.
TI Understanding Racial and Ethnic Differences in Patient Experiences With
Outpatient Health Care in Veterans Affairs Medical Centers
SO MEDICAL CARE
LA English
DT Article
DE race and ethnicity; disparities; CAHPS; health care experiences;
Veterans
ID UNITED-STATES; MANAGED CARE; SATISFACTION; DISPARITIES; ASSESSMENTS;
RACE/ETHNICITY; PERCEPTIONS; PROVIDERS
AB Background: Racial and ethnic differences in patient health care experiences have not been well examined in the Veterans Affairs (VA) Healthcare System.
Objectives: To examine racial/ethnic differences in outpatient health care experiences within and between VA medical facilities.
Research Design: We assessed within-facility and between-facility racial/ethnic differences in responses to the 2010 VA Survey of Healthcare Experiences of Patients using mixed-effects multinomial regression.
Subjects: A total of 211,459 respondents (53.2%) to a random survey of outpatients from 910 VA medical facilities (71.9% non-Hispanic white, 15.1% non-Hispanic black, 6.4% Hispanic, and 6.7% Other race/ethnicity).
Measures: Negative and positive patient-reported experiences in 8 domains of health care.
Results: Between-facility effects for black race were higher for 7 domains of negative experiences [risk differences (RDs): 0.37% to 1.64%] and lower for 6 domains of positive experiences (RDs: -0.69% to -2.54%). Between-facility effects for Hispanic ethnicity were higher for 5 domains of negative experiences (RDs: 0.60%-1.34%) and lower for 5 domains of positive experiences (RDs: -1.00% to -1.88%). Hispanic ethnicity was also associated with higher within-facility rates of positive experiences for 5 domains of care (RDs: 2.97%-4.08%). Other race/ethnicity was associated with significantly higher within-facility rates of negative experiences (RDs: 2.04%-3.95%) and lower rates of positive experiences for all 8 domains (RDs: -2.05% to -4.70%).
Conclusions: In a national random sample of Veterans managed in the VA Healthcare System, we demonstrated significant within-facility and between-facility racial and ethnic differences in outpatient health care experiences, with differing patterns for each minority group.
C1 [Hausmann, Leslie R. M.; Gao, Shasha; Mor, Maria K.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hausmann, Leslie R. M.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Schaefer, James H., Jr.] Off Informat & Analyt, Dept Vet Affairs, Durham, NC USA.
RP Hausmann, LRM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM leslie.hausmann@gmail.com
FU Center for Health Equity Research and Promotion (CHERP) VISN4 Pilot
Research Program [LIP 72-051]; Veterans Affairs Health Services Research
and Development Career Development Program [RCD 06-287]
FX Supported by the Center for Health Equity Research and Promotion (CHERP)
VISN4 Pilot Research Program (LIP 72-051). L.R.M.H.'s effort was
supported by the Veterans Affairs Health Services Research and
Development Career Development Program (RCD 06-287).
NR 33
TC 14
Z9 14
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUN
PY 2013
VL 51
IS 6
BP 532
EP 539
DI 10.1097/MLR.0b013e318287d6e5
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 145VD
UT WOS:000319045800010
PM 23673395
ER
PT J
AU Kargi, AY
Merriam, GR
AF Kargi, Atil Y.
Merriam, George R.
TI Diagnosis and treatment of growth hormone deficiency in adults
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; GH REPLACEMENT THERAPY;
BONE-MINERAL DENSITY; INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK
MARKERS; PLACEBO-CONTROLLED TRIAL; INSULIN TOLERANCE-TEST; LONG-TERM
MORTALITY; BODY-MASS INDEX
AB The availability of synthetic recombinant human growth hormone (GH) in potentially unlimited quantities since the 1980s has improved understanding of the many nonstatural effects of GH on metabolism, body composition, physical and psychological function, as well as the consequences of GH deficiency in adult life. Adult GH deficiency is now recognized as a distinct if nonspecific syndrome with considerable adverse health consequences. GH replacement therapy in lower doses than those used in children can reverse many of these abnormalities and restore functional capacities toward or even to normal; if dosed appropriately, GH therapy has few adverse effects. Although some doubts remain about possible long-term risks of childhood GH therapy, most registries of adult GH replacement therapy, albeit limited in study size and duration, have not shown an increased incidence of cancers or of cardiovascular morbidity or mortality.
C1 [Kargi, Atil Y.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA.
[Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Merriam, George R.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
RP Merriam, GR (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.
EM merriam@uw.edu
FU National Institute of Aging, US National Institutes of Health
FX The authors thank P. Asberry, S. Brickle, M. Kletke and L. Smith for
their assistance with the work of the research group. The authors
gratefully acknowledge research support from the National Institute of
Aging, US National Institutes of Health, and from the facilities and
resources of the US Department of Veterans Affairs Puget Sound Health
Care System.
NR 136
TC 12
Z9 13
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5029
EI 1759-5037
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD JUN
PY 2013
VL 9
IS 6
BP 335
EP 345
DI 10.1038/nrendo.2013.77
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 149QK
UT WOS:000319335900007
PM 23629539
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Patient-level clinically meaningful improvements in activities of daily
living and pain after total hip arthroplasty: data from a large US
institutional registry
SO RHEUMATOLOGY
LA English
DT Article
DE pain; activity limitation; activities of daily living; function;
functional limitation; total hip replacement; arthroplasty; joint
replacement; outcomes; patient-reported outcomes; primary; revision
ID QUALITY-OF-LIFE; TOTAL KNEE ARTHROPLASTY; REVISION HIP; OUTCOMES;
QUESTIONNAIRE; EXPECTATIONS; PREDICTORS; RESPONSIVENESS; REPLACEMENT;
COMORBIDITY
AB Objective. To characterize patient-level clinically meaningful improvements in pain and limitation of key activities of daily living (ADLs) after primary or revision total hip arthroplasty (THA).
Methods. We analysed prospectively collected data from the Mayo Clinic Total Joint Registry to study clinically meaningful improvements in index hip pain severity and limitation in seven key ADLs (walking, climbing stairs, putting on shoes/socks, picking up objects, getting in/out of car, rising from a chair and sitting), from preoperative to 2- and 5-year post-THA.
Results. The primary THA cohort consisted of 6168 responders preoperatively, 5707 at 2 years and 3289 at 5 years postoperatively. The revision THA cohort consisted of 2063 responders preoperatively, 2682 at 2 years and 1627 at 5 years postoperatively. In the primary THA cohort, clinically meaningful pain reduction to mild or no hip pain at 2 years was reported by 94% with moderate and 91% with severe preoperative pain; respective proportions were 91% and 89% at 5-year follow-up. For revision THA, respective proportions were 84% and 77% at 2 years and 80% and 78% at 5 years. In the primary THA cohort, up to 4% with moderate and 17% with severe preoperative ADL limitation reported severe limitation in the respective activity 2 years post-primary THA; at 5 years, the respective proportions were up to 7% and 20%. Respective proportions for revision THA were up to 10% and 26% at 2 years and 13% and 30% at 5 years.
Conclusions. These comprehensive data for patient-level clinically meaningful improvements in pain and seven key ADLs can help patients set realistic goals for improvement after THA.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds, National Institutes of
Health (NIH) [1 KL2 RR024151-01]
FX This work was supported by research grants from the Mayo Clinic
Orthopedic Surgery research funds, National Institutes of Health (NIH)
Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic
Center for Clinical and Translational Research) and the resources and
use of facilities at the Birmingham VA Medical Center, Birmingham, AL,
USA.
NR 28
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUN
PY 2013
VL 52
IS 6
BP 1109
EP 1118
DI 10.1093/rheumatology/kes416
PG 10
WC Rheumatology
SC Rheumatology
GA 151KS
UT WOS:000319460000019
PM 23382362
ER
PT J
AU Sasaki, K
Anderson, E
Shankland, SJ
Nicosia, RF
AF Sasaki, Kotaro
Anderson, Eric
Shankland, Stuart J.
Nicosia, Roberto F.
TI Diffuse Proliferative Glomerulonephritis Associated With Cetuximab, an
Epidermal Growth Factor Receptor Inhibitor
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Immunoglobulin A (IgA); diffuse proliferative glomerulonephritis;
cetuximab
ID IGA NEPHROPATHY; DISEASE
AB Cetuximab is an epidermal growth factor receptor inhibitor used for advanced squamous cell carcinoma of the head and neck. We report an unusual case of diffuse proliferative and crescentic glomerulonephritis in a 67-year-old man in close temporal association with cetuximab treatment for recurrent oral squamous cell carcinoma. The patient presented with acute renal failure and nephrotic-range proteinuria. Kidney biopsy showed diffuse proliferative and focally crescentic glomerulonephritis associated with immunoglobulin A (IgA)-dominant immune-complex deposition within glomerular capillary walls and mesangium. The patient showed dramatic improvement in kidney function after discontinuation of cetuximab therapy and a short course of cyclophosphamide and steroid. The clinical outcome of this case suggests that cetuximab therapy may trigger or exacerbate IgA-mediated glomerular injury and warrants close monitoring of kidney function in patients treated with this epidermal growth factor receptor inhibitor. (c) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Sasaki, Kotaro; Nicosia, Roberto F.] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA.
[Anderson, Eric; Shankland, Stuart J.] Univ Washington, Med Ctr, Dept Nephrol, Seattle, WA 98195 USA.
[Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol Serv, Seattle, WA USA.
[Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Lab Med Serv, Seattle, WA USA.
RP Sasaki, K (reprint author), Univ Washington, Med Ctr, 1959 NE Pacific,Box 356100, Seattle, WA 98195 USA.
EM ksasaki@uw.edu
NR 9
TC 5
Z9 6
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUN
PY 2013
VL 61
IS 6
BP 988
EP 991
DI 10.1053/j.ajkd.2013.01.008
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 145FC
UT WOS:000318999200021
PM 23474009
ER
PT J
AU Alele, JD
Luttrell, LM
Hollis, BW
Luttrell, DK
Hunt, KJ
AF Alele, Jimmy D.
Luttrell, Louis M.
Hollis, Bruce W.
Luttrell, Deirdre K.
Hunt, Kelly J.
CA VADT Study Grp
TI Relationship between vitamin D status and incidence of vascular events
in the Veterans Affairs Diabetes Trial
SO ATHEROSCLEROSIS
LA English
DT Article
DE Diabetes mellitus; Cardiovascular outcomes; Epidemiology; Vitamin D;
Prospective cohort study
ID ISCHEMIC-HEART-DISEASE; SMOOTH-MUSCLE-CELLS; CARDIOVASCULAR-DISEASE;
MYOCARDIAL-INFARCTION; 25-HYDROXYVITAMIN D; D DEFICIENCY;
ENDOTHELIAL-CELLS; D INSUFFICIENCY; BLOOD-PRESSURE; RISK
AB Objective: Few studies have examined the relationship between vitamin D levels and incident cardiovascular events in large well-characterized patient cohorts. Therefore, our objective was to determine if low vitamin D levels predicted vascular complications of diabetes.
Methods: Prospective analysis of 936 veterans with type 2 diabetes (59.7 +/- 8.4 years, 96.9% male) who participated in the Veteran Affairs Diabetes Trial (VADT) was conducted. 25(OH)-vitamin D was measured a median of two years after entry and participants were subsequently followed 3.7 years. Hazard ratios (HRs) were calculated for cardiovascular endpoints in relation to 25(OH)-vitamin D quartile. For microvascular endpoints, logistic regression was used to calculate odds ratios.
Results: After adjusting for age, minority status, treatment arm and history of prior event, individuals in the lowest vitamin D quartile (i.e., 1-15.9 ng/ml) were at similar risk of MI [HR = 1.13 (95% CI: 0.53, 2.42)], CHD [HR = 0.87 (95% CI: 0.49, 1.55)], congestive heart failure [HR = 1.44 (95% CI: 0.67, 3.06)], and death from any cause [HR = 1.04 (95% CI: 0.53, 2.04)] as individuals in the highest vitamin D quartile (i.e., 29.9-77.2 ng/ml). Similarly, there were no differences in the odds associated with retinopathy or renal disease onset or progression in the lowest versus highest vitamin D quartile.
Conclusions: These data indicate that vitamin D status had no significant impact on the incidence of vascular events in a cohort of high-risk veterans with diabetes in which traditional risk factors were managed according to current treatment guidelines. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Alele, Jimmy D.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Hollis, Bruce W.; Luttrell, Deirdre K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Luttrell, Louis M.; Hunt, Kelly J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Hunt, KJ (reprint author), Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA.
EM huntke@musc.edu
FU American Heart Association [AHA0755466U]; Research Service of the
Charleston SC VA Medical Center; Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development
FX This work was supported by American Heart Association Grant-in-Aid
AHA0755466U (L.M.L.) and the Research Service of the Charleston SC VA
Medical Center. This material is based upon work supported in part by
the Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development. The funding source had no
involvement in the study design; in the collection, analysis or
interpretation of data; in the writing of the report; or in the decision
to submit the article for publication. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 35
TC 10
Z9 11
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2013
VL 228
IS 2
BP 502
EP 507
DI 10.1016/j.atherosclerosis.2013.03.024
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 145SI
UT WOS:000319037200034
PM 23608249
ER
PT J
AU Carlson, KF
Barnes, JE
Hagel, EM
Taylor, BC
Cifu, DX
Sayer, NA
AF Carlson, Kathleen F.
Barnes, Joan E.
Hagel, Emily M.
Taylor, Brent C.
Cifu, David X.
Sayer, Nina A.
TI Sensitivity and specificity of traumatic brain injury diagnosis codes in
United States Department of Veterans Affairs administrative data
SO BRAIN INJURY
LA English
DT Article
DE Clinical coding; epidemiology; ICD-9-CM; public health surveillance;
traumatic brain injury; validity
ID CASE ASCERTAINMENT; WAR VETERANS; HEAD-INJURY; VALIDITY; ACCURACY;
AFGHANISTAN; PREVALENCE; IRAQ; ADMISSIONS; SERVICES
AB Objective: To examine the validity of using International Classification of Diseases (ICD) diagnosis codes from United States Department of Veterans Affairs (VA) data to describe prevalence of traumatic brain injury (TBI) among military veterans.
Methods: VA clinicians complete a standardized TBI evaluation to determine whether veterans' deployment exposures resulted in TBI. Clinician-confirmed cases and non-cases of TBI were used as recorded on the evaluation as the criterion standard against which to evaluate three series of TBI-related ICD diagnosis codes in national VA datasets. Focusing on codes used within VA, measures of validity were calculated and correlates of discordance examined, including patient characteristics, region and time. Secondarily, it was examined whether TBI codes can differentiate mild from more severe TBI cases.
Results: Of 49 962 veterans with completed TBI evaluations, 29 534 (59%) received clinician-confirmed TBI diagnoses. Sensitivity of the VA series of codes was 70%, specificity was 82% and concordance was 75%. Concordance varied by region, but not by patient characteristics or time. Codes were not useful for distinguishing mild TBI.
Conclusion: Estimates of TBI prevalence in military veterans are important for national programme development and resource distribution. Estimates derived from ICD diagnosis codes in administrative data should take potential misclassification into account.
C1 [Carlson, Kathleen F.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA.
[Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Barnes, Joan E.; Hagel, Emily M.; Taylor, Brent C.; Sayer, Nina A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Taylor, Brent C.; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
[Cifu, David X.] Vet Hlth Adm, Phys Med & Rehabil Serv, Richmond, VA USA.
[Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA.
[Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA.
[Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA.
RP Carlson, KF (reprint author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM kathleen.carlson@va.gov
RI Taylor, Brent/A-8069-2009; Sayer, Nina/E-3249-2016
OI Taylor, Brent/0000-0002-2140-8377;
FU United States Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service [CDA
08-025]
FX This work was supported by a career development award from the United
States Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development Service (CDA 08-025). The
opinions expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. The authors report no conflicts
of interest.
NR 53
TC 8
Z9 8
U1 0
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2013
VL 27
IS 6
BP 640
EP 650
DI 10.3109/02699052.2013.771795
PG 11
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 143QO
UT WOS:000318882500002
PM 23514276
ER
PT J
AU Brandt, CP
Zvolensky, MJ
Bonn-Miller, MO
AF Brandt, Charles P.
Zvolensky, Michael J.
Bonn-Miller, Marcel O.
TI Distress Tolerance, Emotion Dysregulation, and Anxiety and Depressive
Symptoms Among HIV+ Individuals
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Emotion dysregulation; Distress tolerance; HIV; AIDS; Anxiety;
Depression
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE USE DISORDERS; QUALITY-OF-LIFE;
PANIC DISORDER; REGULATION DIFFICULTIES; TRANSMISSION RISK; NEGATIVE
AFFECT; HEALTH-STATUS; DAILY SMOKERS; SELF-REPORT
AB The current study examined the mediational effects of emotion dysregulation in terms of the relation between perceived distress tolerance and anxiety and depressive symptoms among HIV+ individuals. Participants included 176 HIV+ adults (21.6 % female, M (age) = 48.40 years, SD = 8.66). Results indicated that distress tolerance was significantly related to greater depressive and anxiety symptoms. Results also indicated that emotion dysregulation mediated this association. The observed findings were evident above and beyond the variance accounted for by CD4 T-cell count, ethnicity, gender, education level, and cannabis use status. The results are discussed in terms of the potential explanatory utility of perceived distress tolerance and emotion dysregulation in terms of psychological well-being among HIV+ individuals.
C1 [Brandt, Charles P.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA 19104 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
RP Brandt, CP (reprint author), Univ Houston, Dept Psychol, 126 Heyne Bldg, Houston, TX 77204 USA.
EM cpbrandt1@gmail.com; Marcel.Bonn-Miller@va.gov
NR 72
TC 11
Z9 11
U1 2
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD JUN
PY 2013
VL 37
IS 3
BP 446
EP 455
DI 10.1007/s10608-012-9497-9
PG 10
WC Psychology, Clinical
SC Psychology
GA 142SI
UT WOS:000318817000004
ER
PT J
AU Toro, ML
Koontz, AM
Cooper, RA
AF Toro, Maria Luisa
Koontz, Alicia M.
Cooper, Rory A.
TI The Impact of Transfer Setup on the Performance of Independent
Wheelchair Transfers
SO HUMAN FACTORS
LA English
DT Article
DE activities of daily living; accessibility standards; wheeled mobility;
wheelchair; disability
ID SPINAL-CORD-INJURY; USERS; INDIVIDUALS; SHOULDER; IMPINGEMENT;
KINEMATICS
AB Objective: The aim of this study was to determine how selected environmental factors affect transfers and to compare our results to the Americans with Disabilities Act Accessibility Guidelines (ADAAG).
Background: Few data are available to support standards development related to transfers in the built environment.
Method: Participants were 120 wheeled mobility device (WMD) users who transferred to and from a modular transfer station that consisted of a height-adjustable platform with a lateral grab bar, optional obstacle to the transfer, and an optional height-adjustable front grab bar. Maximum and minimum vertical heights of the transfer surface, maximum gap distance between the WMD and transfer surface, grab bar use, and WMD space needs were recorded.
Results: The 95th percentile lowest and highest heights attained were similar to the median WMD seat-to-floor height (56 cm). We found that 42% (47/113) could not perform a transfer with the obstacle present. Participants transferred higher when the front grab bar was added to the setup (p = .005) and higher and lower with the front grab bar than without it when the obstacle was present in the setup (p = .003 and p = .005, respectively). We found that 95% of participants performed a transfer across an 8.9-cm gap. ADAAG recommendations fall short for the height and clear-space needs of the 50th-percentile WMD users.
Conclusion: Revisions concerning transfer heights, gaps, clear spaces, and grab bar heights are necessary to make transfers more accessible to WMD users.
Application: The data will be used to revise the guidelines related to transfers and to enable designers and engineers to create an environment that is more accessible.
C1 [Toro, Maria Luisa; Koontz, Alicia M.; Cooper, Rory A.] Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA.
RP Koontz, AM (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400 151R-B, Pittsburgh, PA 15206 USA.
EM akoontz@pitt.edu
FU Department of Education (NIDRR), United States Access Board
[H133E070024, 84.133E]
FX The authors are also affiliated with the University of Pittsburgh,
Pittsburgh, Pennsylvania. Funding for this study was provided by the
Department of Education (NIDRR), United States Access Board Grant
H133E070024 and Project No. 84.133E. This material is the result of work
supported with resources and the use of facilities at the Human
Engineering Research Laboratories, VA Pittsburgh Healthcare System. The
contents do not represent the views of the Department of Veterans
Affairs or the U. S. government.
NR 29
TC 2
Z9 2
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0018-7208
J9 HUM FACTORS
JI Hum. Factors
PD JUN
PY 2013
VL 55
IS 3
BP 567
EP 580
DI 10.1177/0018720812460549
PG 14
WC Behavioral Sciences; Engineering, Industrial; Ergonomics; Psychology,
Applied; Psychology
SC Behavioral Sciences; Engineering; Psychology
GA 144MF
UT WOS:000318942900009
PM 23829031
ER
PT J
AU Graber, CJ
Madaras-Kelly, K
Jones, MM
Neuhauser, MM
Goetz, MB
AF Graber, Christopher J.
Madaras-Kelly, Karl
Jones, Makoto M.
Neuhauser, Melinda M.
Goetz, Matthew Bidwell
TI Unnecessary Antimicrobial Use in the Context of Clostridium difficile
Infection: A Call to Arms for the Veterans Affairs Antimicrobial
Stewardship Task Force
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Letter
C1 [Graber, Christopher J.; Goetz, Matthew Bidwell] Vet Affairs VA Greater Los Angeles Healthcare Sys, Infect Dis Sect, Los Angeles, CA USA.
[Graber, Christopher J.; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Madaras-Kelly, Karl] Boise VA Med Ctr, Serv Pharm, Boise, ID USA.
[Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Meridian, ID USA.
[Jones, Makoto M.] VA Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT USA.
[Jones, Makoto M.] Univ Utah, Div Epidemiol, Salt Lake City, UT USA.
[Neuhauser, Melinda M.] Dept VA Pharm Benefits Management Serv, Hines, IL USA.
RP Graber, CJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA.
EM christopher.graber@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
NR 6
TC 4
Z9 4
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN
PY 2013
VL 34
IS 6
BP 651
EP 653
DI 10.1086/670640
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 142AB
UT WOS:000318766800023
PM 23651905
ER
PT J
AU Burgio, KL
Newman, DK
Rosenberg, MT
Sampselle, C
AF Burgio, K. L.
Newman, D. K.
Rosenberg, M. T.
Sampselle, C.
TI Impact of behaviour and lifestyle on bladder health
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Review
ID URINARY-TRACT SYMPTOMS; BENIGN PROSTATIC HYPERPLASIA;
NUTRITION-EXAMINATION-SURVEY; OVERACTIVE BLADDER; CIGARETTE-SMOKING;
RISK-FACTORS; STRESS-INCONTINENCE; FLUID INTAKE; CANCER RISK; CHRONIC
CONSTIPATION
AB Bladder conditions, including UTI, UI, and bladder cancer, are highly prevalent and affect a wide range of populations. There are a variety of modifiable behavioral and lifestyle factors that influence bladder health. Some factors, such as smoking and obesity, increase the risk or severity of bladder conditions, whereas other factors, such as pelvic floor muscle exercise, are protective. Although clinical practice may be assumed to be the most appropriate ground for education on behavioral and lifestyle factors that influence bladder health, it is also crucial to extend these messages into the general population through public health interventions to reach those who have not yet developed bladder conditions and to maximize the prevention impact of these behaviors. Appropriate changes in these factors have the potential for an enormous impact on bladder health if implemented on a population-based level.
C1 [Burgio, K. L.] Dept Vet Affairs Med Ctr, Birmingham, AL USA.
[Burgio, K. L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Newman, D. K.] Univ Penn, Perelman Sch Med, Div Urol, Philadelphia, PA 19104 USA.
[Rosenberg, M. T.] Midmichigan Hlth Ctr, Jackson, MI USA.
[Sampselle, C.] Univ Michigan, Sch Nursing, Div Hlth Promot & Risk Reduct, Ann Arbor, MI 48109 USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 700 South 19th St, Birmingham, AL 35233 USA.
EM kburgio@uabmc.edu
FU Pfizer Inc.
FX Funding for two expert panel meetings on bladder health, at which this
manuscript was conceptualised, was provided by Pfizer Inc. Editorial
assistance was provided by Nicole Lodowski of Pfizer Inc and Colin P.
Mitchell, PhD, of Complete Healthcare Communications, Inc. and was
funded by Pfizer Inc.
NR 100
TC 8
Z9 8
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD JUN
PY 2013
VL 67
IS 6
BP 495
EP 504
DI 10.1111/ijcp.12143
PG 10
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 146BJ
UT WOS:000319063500005
PM 23679903
ER
PT J
AU Dellavalle, RP
AF Dellavalle, Robert P.
TI Internet dermatology resources
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Editorial Material
ID INFORMATION
C1 [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Dellavalle, RP (reprint author), 1055 Clermont St,Box 165, Denver, CO 80220 USA.
EM robert.dellavalle@ucdenver.edu
RI Dellavalle, Robert/L-2020-2013
OI Dellavalle, Robert/0000-0001-8132-088X
NR 7
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2013
VL 68
IS 6
BP 1039
EP 1039
DI 10.1016/j.jaad.2012.09.006
PG 1
WC Dermatology
SC Dermatology
GA 143ZW
UT WOS:000318909600039
PM 23680195
ER
PT J
AU Seo, YK
Mirkheshti, N
Song, CS
Kim, S
Dodds, S
Ahn, SC
Christy, B
Mendez-Meza, R
Ittmann, MM
Abboud-Werner, S
Chatterjee, B
AF Seo, Young-Kyo
Mirkheshti, Nooshin
Song, Chung S.
Kim, Soyoung
Dodds, Sherry
Ahn, Soon C.
Christy, Barbara
Mendez-Meza, Rosario
Ittmann, Michael M.
Abboud-Werner, Sherry
Chatterjee, Bandana
TI SULT2B1b Sulfotransferase: Induction by Vitamin D Receptor and Reduced
Expression in Prostate Cancer
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN HYDROXYSTEROID SULFOTRANSFERASE; ACTIVITY IN-VITRO; CHOLESTEROL
SULFOTRANSFERASE; 1,25-DIHYDROXYVITAMIN D-3; ANDROGEN RECEPTOR; BINDING
PROTEIN; CELLS; ACID; PROMOTER; ENZYMES
AB An elevated tumor tissue androgen level, which reactivates androgen receptor in recurrent prostate cancer, arises from the intratumor synthesis of 5 alpha-dihydrotestosterone through use of the precursor steroid dehydroepiandrosterone (DHEA) and is fueled by the steroidogenic enzymes 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD1), aldoketoreductase (AKR1C3), and steroid 5-alpha reductase, type 1 (SRD5A1) present in cancer tissue. Sulfotransferase 2B1b (SULT2B1b) (in short, SULT2B) is a prostate-expressed hydroxysteroid SULT that converts cholesterol, oxysterols, and DHEA to 3 beta-sulfates. DHEA metabolism involving sulfonation by SULT2B can potentially interfere with intraprostate androgen synthesis due to reduction of free DHEA pool and, thus, conversion of DHEA to androstenedione. Here we report that in prostatectomy specimens from treatment-naive patients, SULT2B expression is markedly reduced in malignant tissue (P < .001, Mann-Whitney U test) compared with robust expression in adjacent nonmalignant glands. SULT2B was detected in formalin-fixed specimens by immunohistochemistry on individual sections and tissue array. Immunoblotting of protein lysates of frozen cancer and matched benign tissue confirmed immunohistochemistry results. An in-house-developed rabbit polyclonal antibody against full-length human SULT2B was validated for specificity and used in the analyses. Ligand-activated vitamin D receptor induced the SULT2B1 promoter in vivo in mouse prostate and increased SULT2B mRNA and protein levels in vitro in prostate cancer cells. A vitamin D receptor/retinoid X receptor-alpha-bound DNA element (with a DR7 motif) mediated induction of the transfected SULT2B1 promoter in calcitriol-treated cells. SULT2B knockdown caused an increased proliferation rate of prostate cancer cells upon stimulation by DHEA. These results suggest that the tumor tissue SULT2B level may partly control prostate cancer growth, and its induction in a therapeutic setting may inhibit disease progression.
C1 [Seo, Young-Kyo; Mirkheshti, Nooshin; Song, Chung S.; Kim, Soyoung; Dodds, Sherry; Ahn, Soon C.; Christy, Barbara; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
[Mendez-Meza, Rosario; Abboud-Werner, Sherry] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA.
[Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu
FU Department of Veterans Affairs (VA) Merit Review [1I01BX000280]; VA
Senior Research Career Scientist Award; National Institute of Aging
(NIA/NIH) RO1 [AG-10486, AG-19660]; Morrison Trust Foundation; American
Cancer Research Foundation; Translational Resource Supplement, UTHSCSA
[CTSA5UL1RR025767-04]; Antibody Core, UTHSCSA [P30 CA54174]; Dan L.
Duncan Cancer Center Human Tissue Acquisition and Pathology Core, Baylor
College of Medicne [P30 CA1251230]
FX This work was supported by Department of Veterans Affairs (VA) Merit
Review 1I01BX000280 and VA Senior Research Career Scientist Award (to B.
C.), National Institute of Aging (NIA/NIH) RO1 (AG-10486 and AG-19660),
and pilot grants (Morrison Trust Foundation and American Cancer Research
Foundation). Partial support came from Translational Resource Supplement
(CTSA5UL1RR025767-04) and Antibody Core (P30 CA54174), UTHSCSA, and the
Dan L. Duncan Cancer Center Human Tissue Acquisition and Pathology Core
(P30 CA1251230), Baylor College of Medicne.
NR 43
TC 10
Z9 10
U1 0
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2013
VL 27
IS 6
BP 925
EP 939
DI 10.1210/me.2012-1369
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 147XT
UT WOS:000319205300006
PM 23579488
ER
PT J
AU Cheng, G
Alavi, A
Lim, E
Werner, TJ
Del Bello, CV
Akers, SR
AF Cheng, Gang
Alavi, Abass
Lim, Esther
Werner, Thomas J.
Del Bello, Catherine V.
Akers, Scott R.
TI Dynamic Changes of FDG Uptake and Clearance in Normal Tissues
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE FDG PET; SUV; Time course; Delayed imaging; Normal tissues
ID POINT F-18-FDG PET; POSITRON-EMISSION-TOMOGRAPHY; SOLITARY PULMONARY
NODULES; HEPATOCELLULAR-CARCINOMA; HEPATIC METASTASES;
COLORECTAL-CANCER; BREAST-CANCER; TIME; LIVER; MALIGNANCY
AB This study aims to evaluate dynamic 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake in normal tissues.
Thirty male patients underwent FDG positron emission tomography (PET)/computed tomography imaging at 1, 2, and 3 h after tracer injection. Standardized uptake values (SUV) were obtained in regions of interest of normal tissues.
The aorta (blood pool), liver, and spleen FDG activity demonstrated significantly and continuously decreased activity from 1 to 2 and 2 to 3 h, while FDG uptake in the lungs, pancreas, lymph nodes, and skeletal muscle decreased from 1 to 2 h only. In contrast, the left ventricular myocardium demonstrated two patterns of dynamic changes: myocardium with higher FDG uptake (SUVmax a parts per thousand yenaEuro parts per thousand 3.25) on the initial images had more remarkable increased activity on the delayed images, while myocardium with lower FDG uptake (SUVmax < 3.25) on the initial imaging had no increased uptake on delayed imaging. Increased FDG uptake was also observed in the bones on the delayed images. No significant changes of FDG uptake were noted in the parotid gland, thyroid gland, and prostate gland.
These findings may help nuclear medicine physicians when comparing images performed at different time points, when using FDG uptake in internal reference regions as a relative indicator of FDG uptake in a specific lesion, and when reading a delayed FDG PET imaging.
C1 [Cheng, Gang; Lim, Esther; Del Bello, Catherine V.; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Alavi, Abass; Werner, Thomas J.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com; akerssco@me.com
FU Department of Veterans Affairs (VISN 4 CPPF grant)
FX This study was supported in part by a grant from the Department of
Veterans Affairs (VISN 4 CPPF grant).
NR 28
TC 29
Z9 29
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD JUN
PY 2013
VL 15
IS 3
BP 345
EP 352
DI 10.1007/s11307-012-0600-0
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 142JZ
UT WOS:000318794800013
PM 23090853
ER
PT J
AU Taylor, JJ
Borckardt, JJ
Canterberry, M
Li, XB
Hanlon, CA
Brown, TR
George, MS
AF Taylor, Joseph J.
Borckardt, Jeffrey J.
Canterberry, Melanie
Li, Xingbao
Hanlon, Colleen A.
Brown, Truman R.
George, Mark S.
TI Naloxone-Reversible Modulation of Pain Circuitry by Left Prefrontal rTMS
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE pain modulation; rTMS; endogenous opioids; analgesia; imaging;
prefrontal cortex
ID TRANSCRANIAL MAGNETIC STIMULATION; NORMAL HUMAN CORTEX; PERIAQUEDUCTAL
GRAY; CYTOARCHITECTONIC DEFINITION; CORTICAL PROJECTIONS; ENDOGENOUS
OPIOIDS; HEALTHY-VOLUNTEERS; PLACEBO ANALGESIA; AREAS 9; DEPRESSION
AB A 20-minute session of 10 Hz repetitive transcranial magnetic stimulation (rTMS) of Brodmann Area (BA) nine of the left dorsolateral prefrontal cortex (DLPFC) can produce analgesic effects on postoperative and laboratory-induced pain. This analgesia is blocked by pretreatment with naloxone, a mu-opioid antagonist. The purpose of this sham-controlled, double-blind, crossover study was to identify the neural circuitry that underlies the analgesic effects of left DLPFC rTMS, and to examine how the function of this circuit, including midbrain and medulla, changes during opioid blockade. Fourteen healthy volunteers were randomized to receive intravenous saline or naloxone immediately before sham and real left DLPFC rTMS on the same experimental visit. One week later, each participant received the novel pretreatment but the same stimulation paradigm. Using short sessions of heat on capsaicin-sensitized skin, hot allodynia was assessed during 3 Tesla functional magnetic resonance imaging (fMRI) scanning at baseline, post-sham rTMS, and post-real rTMS. Data were analyzed using whole-brain voxel-based analysis, as well as time series extractions from anatomically-defined regions of interest representing midbrain and medulla. Consistent with previous findings, real rTMS significantly reduced hot allodynia pain ratings. This analgesia was associated with elevated blood oxygenation-level dependent (BOLD) signal in BAs 9 and 10, and diminished BOLD signal in the anterior cingulate, thalamus, midbrain, and medulla during pain. Naloxone pretreatment largely abolished rTMS-induced analgesia, as well as rTMS-induced attenuation of BOLD signal response to painful stimuli throughout pain processing regions, including midbrain and medulla. These preliminary results suggest that left DLPFC rTMS drives top-down opioidergic analgesia.
C1 [Taylor, Joseph J.; Borckardt, Jeffrey J.; Canterberry, Melanie; Li, Xingbao; Hanlon, Colleen A.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29414 USA.
[Brown, Truman R.] Med Univ S Carolina, Dept Radiol, Ctr Biomed Imaging, Charleston, SC 29414 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Taylor, JJ (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St,Room 504 North, Charleston, SC 29414 USA.
EM taylorjj@musc.edu
FU NIDA [1F30DA033748-01]; Center for Biomedical Imaging (CBI) at the
Medical University of South Carolina; [T32DA007288]; [K01DA0267756]
FX We thank Kathryn Beaver, RN and Tracey Greene, RN for their assistance
in conducting this study. JJT is funded by 1F30DA033748-01 (NIDA) and a
Grant-In-Kind from the Center for Biomedical Imaging (CBI) at the
Medical University of South Carolina. MC is funded by T32DA007288. CH is
funded by K01DA0267756. A Clinical Trail Agreement with Neuronetics
provided the TMS treatment cards used to drive laboratory owned TMS
machines in this study.
NR 50
TC 17
Z9 17
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2013
VL 38
IS 7
BP 1189
EP 1197
DI 10.1038/npp.2013.13
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 146UV
UT WOS:000319120000005
PM 23314221
ER
PT J
AU Wright, JL
Plymate, SR
Porter, MP
Gore, JL
Lin, DW
Hu, E
Zeliadt, SB
AF Wright, J. L.
Plymate, S. R.
Porter, M. P.
Gore, J. L.
Lin, D. W.
Hu, E.
Zeliadt, S. B.
TI Hyperglycemia and prostate cancer recurrence in men treated for
localized prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE hyperglycemia; biochemical recurrence; veterans' affairs
ID INSULIN-RESISTANCE; LUNG-CANCER; MORTALITY; OBESITY; VETERANS; DATABASE;
OUTCOMES; BREAST; RISK
AB BACKGROUND: Obesity is consistently linked with prostate cancer (PCa) recurrence and mortality, though the mechanism is unknown. Impaired glucose regulation, which is common among obese individuals, has been hypothesized as a potential mechanism for PCa tumor growth. In this study, we explore the relationship between serum glucose at time of treatment and risk of PCa recurrence following initial therapy.
METHODS: The study group comprised 1734 men treated with radical prostatectomy (RP) or radiation therapy (RT) for localized PCa between 2001-2010. Serum glucose levels closest to date of diagnosis were determined. PCa recurrence was determined based on PSA progression (nadir PSA + 2 for RT; PSA >= 0.2 for RP) or secondary therapy. Multivariate Cox regression was performed to determine whether glucose level was associated with biochemical recurrence after adjusting for age, race, body mass index, comorbidity, diagnosis of diabetes, Gleason Sum, PSA, treatment and treatment year.
RESULTS: Recurrence was identified in 16% of men over a mean follow-up period of 41 months (range 1-121 months). Those with elevated glucose (>= 100 mg/dl) had a 50% increased risk of recurrence (HR 1.5, 95% CI: 1.1-2.0) compared with those with a normal glucose level (< 100 mg/dl). This effect was seen in both those undergoing RP (HR 1.9, 95% CI: 1.0-3.6) and those treated with RT (HR 1.4, 95% CI: 1.0-2.0).
CONCLUSIONS: Glucose levels at the time of PCa diagnosis are an independent predictor of PCa recurrence for men undergoing treatment for localized disease.
C1 [Wright, J. L.; Porter, M. P.; Gore, J. L.; Lin, D. W.] Univ Washington, Dept Urol, Sch Med, Seattle, WA 98195 USA.
[Wright, J. L.; Porter, M. P.] VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA.
[Wright, J. L.; Gore, J. L.; Lin, D. W.; Zeliadt, S. B.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Plymate, S. R.] Univ Washington, Dept Med, Sch Med, Seattle, WA 98195 USA.
[Plymate, S. R.; Hu, E.; Zeliadt, S. B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Plymate, S. R.; Hu, E.; Zeliadt, S. B.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
RP Wright, JL (reprint author), Univ Washington, Dept Urol, Sch Med, 1959 NE Pacific,Box 356510, Seattle, WA 98195 USA.
EM jlwright@uw.edu
OI Gore, John/0000-0002-2847-5062
FU NIH from the National Cancer Institute [P50CA097186]; Fred Hutchinson
Cancer Research Center
FX This study was supported by NIH grants: P50CA097186 from the National
Cancer Institute; with additional support from the Fred Hutchinson
Cancer Research Center. This material is the result of work supported by
resources from the VA Puget Sound Health Care System, Seattle,
Washington.
NR 29
TC 13
Z9 14
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2013
VL 16
IS 2
BP 204
EP 208
DI 10.1038/pcan.2013.5
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 144UJ
UT WOS:000318965800014
PM 23459096
ER
PT J
AU Drummond, JB
Tucholski, J
Haroutunian, V
Meador-Woodruff, JH
AF Drummond, Jana B.
Tucholski, Janusz
Haroutunian, Vahram
Meador-Woodruff, James H.
TI Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in
anterior cingulate cortex in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE AMPA receptor auxiliary protein; Glutamate receptor; Trafficking;
Postmortem; Human
ID IONOTROPIC GLUTAMATE RECEPTORS; MESSENGER-RNA EXPRESSION; PREFRONTAL
CORTEX; SYNAPTIC PLASTICITY; AUXILIARY SUBUNITS; ELDERLY SCHIZOPHRENICS;
DECREASED EXPRESSION; CORNICHON PROTEINS; POSTMORTEM BRAIN;
BINDING-PROTEINS
AB The glutamate hypothesis of schizophrenia proposes that abnormal glutamatergic neurotransmission occurs in this illness, and a major contribution may involve dysregulation of the AMPA subtype of ionotropic glutamate receptor (AMPAR). Transmembrane AMPAR regulatory proteins (TARPs) form direct associations with AMPARs to modulate the trafficking and biophysical functions of these receptors, and their dysregulation may alter the localization and activity of AMPARs, thus having a potential role in the pathophysiology of schizophrenia. We performed comparative quantitative real-time PCR and Western blot analysis to measure transcript (schizophrenia, N = 25; comparison subjects, N = 25) and protein (schizophrenia, N = 36; comparison subjects, N = 33) expression of TARPs (gamma subunits 1-8) in the anterior cingulate cortex (ACC) in schizophrenia and a comparison group. TARP expression was also measured in frontal cortex of rats chronically treated with haloperidol decanoate (28.5 mg/kg every three weeks for nine months) to determine the effect of antipsychotic treatment on the expression of these molecules. We found decreased transcript expression of TARP gamma-8 in schizophrenia. At the protein level, gamma-3 and gamma-5 were increased, while gamma-4, gamma-7 and gamma-8 were decreased in schizophrenia. No changes in any of the molecules were noted in the frontal cortex of haloperidol-treated rats. TARPs are abnormally expressed at transcript and protein levels in ACC in schizophrenia, and these changes are likely due to the illness and not to the antipsychotic treatment. Alterations in the expression of TARPs may contribute to the pathophysiology of schizophrenia, and represent a potential mechanism of glutamatergic dysregulation in this illness. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Drummond, Jana B.; Tucholski, Janusz; Meador-Woodruff, James H.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA.
[Haroutunian, Vahram] James J Peters Vet Adm, Dept Psychiat, Mt Sinai Sch Med, Bronx, NY 10468 USA.
RP Drummond, JB (reprint author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, CIRC 589A,1719 6th Ave South, Birmingham, AL 35294 USA.
EM jdrummond@uab.edu
FU NIH [MH53327, MH066392]
FX Funding for this study was provided by NIH grants: MH53327 (JHMW) and
MH066392 (VH).
NR 74
TC 11
Z9 12
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2013
VL 147
IS 1
BP 32
EP 38
DI 10.1016/j.schres.2013.03.010
PG 7
WC Psychiatry
SC Psychiatry
GA 145VN
UT WOS:000319047100004
PM 23566497
ER
PT J
AU Smucny, J
Olincy, A
Eichman, LC
Lyons, E
Tregellas, JR
AF Smucny, Jason
Olincy, Ann
Eichman, Lindsay C.
Lyons, Emma
Tregellas, Jason R.
TI Early sensory processing deficits predict sensitivity to distraction in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Attention; Distraction; P50
ID P50 SUPPRESSION; REACTION-TIME; ATTENTIONAL PERFORMANCE; SUSTAINED
ATTENTION; AUDITORY MISMATCH; NEGATIVE SYMPTOMS; HIPPOCAMPAL;
PERCEPTION; ABNORMALITIES; ACTIVATION
AB Patients with schizophrenia frequently report difficulties paying attention during important tasks, because they are distracted by noise in the environment. The neurobiological mechanism underlying this problem is, however, poorly understood. The goal of this study was to determine if early sensory processing deficits contribute to sensitivity to distracting noise in schizophrenia. To that end, we examined the effect of environmentally relevant distracting noise on performance of an attention task in 19 patients with schizophrenia and 22 age and gender-matched healthy comparison subjects. Using electroencephalography, P50 auditory gating ratios also were measured in the same subjects and were examined for their relationship to noise-induced changes in performance on the attention task. Positive symptoms also were evaluated in patients. Distracting noise caused a greater increase in reaction time in patients, relative to comparison subjects, on the attention task. Higher P50 auditory gating ratios also were observed in patients. P50 gating ratio significantly correlated with the magnitude of noise-induced increase in reaction time. Noise-induced increase in reaction time was associated with delusional thoughts in patients. P50 ratios were associated with delusional thoughts and hallucinations in patients. In conclusion, the observation of noise effects on attention in patients is consistent with subjective reports from patients. The observed relationship between noise effects on reaction time and P50 auditory gating supports the hypothesis that early inhibitory processing deficits may contribute to susceptibility to distraction in the illness. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA.
[Smucny, Jason; Olincy, Ann; Eichman, Lindsay C.; Lyons, Emma; Tregellas, Jason R.] Denver VA Med Ctr, Denver, CO USA.
[Smucny, Jason; Olincy, Ann; Eichman, Lindsay C.; Lyons, Emma; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA.
RP Smucny, J (reprint author), Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA.
EM Jason.Smucny@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
OI Smucny, Jason/0000-0001-5656-7987
FU VA Biomedical Laboratory and Clinical Science Research and Development
Service; National Association for Research in Schizophrenia and
Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation
FX This research was supported by the VA Biomedical Laboratory and Clinical
Science Research and Development Service, the National Association for
Research in Schizophrenia and Affective Disorders (NARSAD) and the
Blowitz-Ridgeway Foundation.
NR 39
TC 23
Z9 23
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2013
VL 147
IS 1
BP 196
EP 200
DI 10.1016/j.schres.2013.03.025
PG 5
WC Psychiatry
SC Psychiatry
GA 145VN
UT WOS:000319047100030
PM 23590872
ER
PT J
AU Torgerson, CM
Irimia, A
Leow, AD
Bartzokis, G
Moody, TD
Jennings, RG
Alger, JR
Van Horn, JD
Altshuler, LL
AF Torgerson, Carinna M.
Irimia, Andrei
Leow, Alex D.
Bartzokis, George
Moody, Teena D.
Jennings, Robin G.
Alger, Jeffry R.
Van Horn, John Darrell
Altshuler, Lori L.
TI DTI tractography and white matter fiber tract characteristics in
euthymic bipolar I patients and healthy control subjects
SO BRAIN IMAGING AND BEHAVIOR
LA English
DT Article
DE Diffusion tensor imaging (DTI); White matter (WM); Bipolar disorder
(BD); Tractography; Tract length; Fiber density
ID DIFFUSION TENSOR TRACTOGRAPHY; MILD COGNITIVE IMPAIRMENT; AUTISM
SPECTRUM DISORDER; MAGNETIC-RESONANCE; CORPUS-CALLOSUM; UNCINATE
FASCICULUS; FRONTAL-LOBE; ABNORMALITIES; INTEGRITY; SCHIZOPHRENIA
AB With the introduction of diffusion tensor imaging (DTI), structural differences in white matter (WM) architecture between psychiatric populations and healthy controls can be systematically observed and measured. In particular, DTI-tractography can be used to assess WM characteristics over the entire extent of WM tracts and aggregated fiber bundles. Using 64-direction DTI scanning in 27 participants with bipolar disorder (BD) and 26 age-and-gender-matched healthy control subjects, we compared relative length, density, and fractional anisotrophy (FA) of WM tracts involved in emotion regulation or theorized to be important neural components in BD neuropathology. We interactively isolated 22 known white matter tracts using region-of-interest placement (TrackVis software program) and then computed relative tract length, density, and integrity. BD subjects demonstrated significantly shorter WM tracts in the genu, body and splenium of the corpus callosum compared to healthy controls. Additionally, bipolar subjects exhibited reduced fiber density in the genu and body of the corpus callosum, and in the inferior longitudinal fasciculus bilaterally. In the left uncinate fasciculus, however, BD subjects exhibited significantly greater fiber density than healthy controls. There were no significant differences between groups in WM tract FA for those tracts that began and ended in the brain. The significance of differences in tract length and fiber density in BD is discussed.
C1 [Torgerson, Carinna M.; Irimia, Andrei; Van Horn, John Darrell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA.
[Leow, Alex D.] Univ Illinois, Dept Bioengn, Dept Psychiat, Chicago, IL 60612 USA.
[Leow, Alex D.] Community Psychiat Associates, Chicago, IL 60612 USA.
[Bartzokis, George; Moody, Teena D.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Jennings, Robin G.; Altshuler, Lori L.] Univ Calif San Diego, ADCS Imaging Core, San Diego, CA 92037 USA.
[Alger, Jeffry R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
RP Torgerson, CM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, 635 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM carinnat@gmail.com
RI Irimia, Andrei/B-8275-2008; Bartzokis, George/K-2409-2013; Leow,
Alex/K-3236-2014
OI Irimia, Andrei/0000-0002-9254-9388; Leow, Alex/0000-0002-5660-8651
FU National Institute of Mental Health [R21MH086104, R21MH085944]; HF
Foundation
FX This work was supported by grants to LLA from the National Institute of
Mental Health (R21MH086104, R21MH085944) and a generous donation from
the HF Foundation.
NR 70
TC 16
Z9 16
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7557
J9 BRAIN IMAGING BEHAV
JI Brain Imaging Behav.
PD JUN
PY 2013
VL 7
IS 2
BP 129
EP 139
DI 10.1007/s11682-012-9202-3
PG 11
WC Neuroimaging
SC Neurosciences & Neurology
GA 136NY
UT WOS:000318369800004
PM 23070746
ER
PT J
AU DePalma, G
Xu, HP
Covinsky, KE
Craig, BA
Stallard, E
Thomas, J
Sands, LP
AF DePalma, Glen
Xu, Huiping
Covinsky, Kenneth E.
Craig, Bruce A.
Stallard, Eric
Thomas, Joseph, III
Sands, Laura P.
TI Hospital Readmission Among Older Adults Who Return Home With Unmet Need
for ADL Disability
SO GERONTOLOGIST
LA English
DT Article
DE Activities of daily living; Insufficient help
ID ALL-CAUSE HOSPITALIZATION; FUNCTIONAL OUTCOMES; ELDERLY-PEOPLE;
HEART-FAILURE; ACUTE-CARE; COMMUNITY; DISCHARGE; CONSEQUENCES;
ASSISTANCE; ADMISSIONS
AB Purpose: This study determined whether returning to the community from a recent hospitalization with unmetactivities of daily living (ADL) need was associated with probability of readmission. Methods: A total of 584 respondents to the 1994, 1999, and/or 2004 National Long-Term Care Surveys (NLTCS) who were hospitalized within 90 days prior to the interview and reported ADL disability at the time of the interview were considered for analysis. Medicare claims linked to the NLTCS provided information about hospital episodes, so those enrolled in Health Maintenance Organizations or Veterans Affairs Medical Centers were not included (n = 62), resulting in a total sample size of 522. ADL disability was defined as needing human help or equipment to complete the task. Unmet ADL need was defined as receiving inadequate or no help for one or more ADL disabilities. Disability that began within 90 days of the interview was considered new disability. Results: After adjusting for demographic, health, and functioning characteristics, unmet ADL need was associated with increased risk for hospital readmission (HR: 1.37, 95% CI: 1.03-1.82). Risk of readmission was greater for those with unmet need for new disabilities than those with unmet need for disabilities that were present before the index hospitalization (HR: 1.66, 95% CI: 1.01-2.73). Implications: Many older patients are discharged from the hospital with ADL disability. Those who report unmet need for new ADL disabilities after they return home from the hospital are particularly vulnerable to readmission. Patients' functional needs after discharge should be carefully evaluated and addressed.
C1 [DePalma, Glen; Craig, Bruce A.] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA.
[Xu, Huiping] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA.
[Stallard, Eric] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA.
[Thomas, Joseph, III] Purdue Univ, Coll Pharm, Ctr Aging & Life Course, Regenstrief Ctr Healthcare Engn,Ctr Hlth Outcomes, W Lafayette, IN 47907 USA.
[Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA.
[Sands, Laura P.] Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA.
RP Sands, LP (reprint author), Purdue Univ, Sch Nursing, 502 N Univ St, W Lafayette, IN 47907 USA.
EM lsands@purdue.edu
RI Sands, Laura/E-8919-2015; Craig, Bruce/D-5797-2017
OI Sands, Laura/0000-0003-2446-4486; Craig, Bruce/0000-0001-9346-467X
FU NIA NIH HHS [R01 AG034160, R01AG034160]
NR 32
TC 23
Z9 25
U1 2
U2 19
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD JUN
PY 2013
VL 53
IS 3
BP 454
EP 461
DI 10.1093/geront/gns103
PG 8
WC Gerontology
SC Geriatrics & Gerontology
GA 137UP
UT WOS:000318464000010
PM 22859438
ER
PT J
AU Leutwyler, H
Hubbard, EM
Jeste, DV
Vinogradov, S
AF Leutwyler, Heather
Hubbard, Erin M.
Jeste, Dilip V.
Vinogradov, Sophia
TI "We're Not Just Sitting on the Periphery": A Staff Perspective of
Physical Activity in Older Adults With Schizophrenia
SO GERONTOLOGIST
LA English
DT Article
DE Schizophrenia; Grounded theory
ID SERIOUS MENTAL-ILLNESS; HEALTH; EXERCISE; INTERVENTION; DISABILITY;
QUALITY; LIFE
AB Targeted physical activity interventions to improve the poor physical function of older adults with schizophrenia are necessary but currently not available. Given disordered thought processes and institutionalization, it is likely that older adults with schizophrenia have unique barriers and facilitators to physical activity. It is necessary to consider the perspective of the mental health staff about barriers and facilitators to physical activity to design a feasible intervention. Purpose of This Study: To describe the perceptions of mental health staff about barriers and facilitators to engage in physical activities that promote physical function among older adults with schizophrenia. Design and Method: We conducted qualitative interviews with 23 mental health staff that care for older adults with schizophrenia. The data were collected and analyzed with grounded theory methodology. Results: The participants were interested in promoting physical activity with older adults with schizophrenia. Facilitators and barriers to physical activity identified were mental health, role models and rewards, institutional factors, and safety. Implications: In order to design successful physical activity interventions for this population, the intervention may need to be a routine part of the mental health treatment program and patients may need incentives to participate. Staff should be educated that physical activity may provide the dual benefit of physical and mental health treatment.
C1 [Leutwyler, Heather; Hubbard, Erin M.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Jeste, Dilip V.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Leutwyler, H (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way,N631A,Box 0610, San Francisco, CA 94143 USA.
EM heather.leutwyler@nursing.ucsf.edu
FU NCRR NIH HHS [KL2RR024130]; NIMH NIH HHS [R01 MH094151]; NINR NIH HHS
[P30-NR011934-0]
NR 35
TC 13
Z9 13
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD JUN
PY 2013
VL 53
IS 3
BP 474
EP 483
DI 10.1093/geront/gns092
PG 10
WC Gerontology
SC Geriatrics & Gerontology
GA 137UP
UT WOS:000318464000012
PM 22936534
ER
PT J
AU Etingen, B
LaVela, SL
Miskevics, S
Goldstein, B
AF Etingen, Bella
LaVela, Sherri L.
Miskevics, Scott
Goldstein, Barry
TI Health Information During the H1N1 Influenza Pandemic: Did the Amount
Received Influence Infection Prevention Behaviors?
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE H1N1 influenza; Vaccine; Pandemic; Veteran; Spinal cord injuries
ID RISK PERCEPTION; VACCINE UPTAKE; NETHERLANDS; A(H1N1); PREPAREDNESS
AB In the wake of uncertainty due to the H1N1 influenza pandemic, amount and sources of H1N1-related information were examined in a cohort at high-risk for respiratory complications. Factors associated with adequate amount of information were identified. A cross-sectional mailed survey was conducted in 2010 with veterans with spinal cord injuries and disorders. Bivariate comparisons assessed adequate H1N1-realted information versus not enough and too much. Multivariate regression identified variables associated with receipt of adequate information. A greater proportion who received adequate versus not enough information received H1N1 vaccination (61.87 vs. 48.49 %, p < 0.0001). A greater proportion who received adequate versus too much information received seasonal vaccination (84.90 vs. 71.02 %, p < 0.0001) and H1N1 vaccination (61.87 vs. 42.45 %, p < 0.0001). Variables associated with greater odds of receiving adequate information included being white, a college graduate, and having VA health professionals as their primary information source. Receiving adequate information was associated with lower odds of staying home with flu/flu-like symptoms, and higher odds of H1N1 vaccine receipt and wearing a facemask. Receiving appropriate amounts of information from valid sources may impact adherence to infection control recommendations during pandemics. Findings can be used to facilitate efforts ensuring information is received by high-risk populations.
C1 [Etingen, Bella; LaVela, Sherri L.; Miskevics, Scott] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Etingen, Bella; LaVela, Sherri L.; Miskevics, Scott; Goldstein, Barry] Hines VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA.
[LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Goldstein, Barry] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Goldstein, Barry] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Etingen, B (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H, Hines, IL 60141 USA.
EM Bella.Etingen@va.gov
NR 20
TC 2
Z9 2
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD JUN
PY 2013
VL 38
IS 3
BP 443
EP 450
DI 10.1007/s10900-012-9647-8
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 136PJ
UT WOS:000318373500005
PM 23269499
ER
PT J
AU Peralta, CA
Weekley, CC
Li, YM
Shlipak, MG
AF Peralta, Carmen A.
Weekley, Cristin C.
Li, Yongmei
Shlipak, Michael G.
TI Occult chronic kidney disease among persons with hypertension in the
United States: data from the national health and nutrition surveys
1988-1994 and 1999-2002
SO JOURNAL OF HYPERTENSION
LA English
DT Article
DE albumin-to-creatinine ratio; chronic kidney disease; cystatin C;
National Health and Nutrition Examination Survey
ID GLOMERULAR-FILTRATION-RATE; HIGH BLOOD-PRESSURE; CYSTATIN-C; SERUM
CREATININE; CARDIOVASCULAR EVENTS; NHANES; NEPHROSCLEROSIS; ALBUMINURIA;
ASSOCIATION; POPULATION
AB Objectives: Hypertension guidelines recommend screening for chronic kidney disease (CKD) using serum creatinine and urine dipstick; this strategy may lead to misclassification. Persons with occult CKD [i.e. missed by creatinine but detected by cystatin C or albumin-to-creatinine ratio (ACR)] have higher risks for death, cardiovascular events, and end-stage renal disease.
Methods: We studied occult CKD prevalence among nondiabetic, hypertensive adults in National Health and Nutrition Examination Survey 1988-1994 (N = 2088) and 1999-2002 (N = 737). We defined occult CKD as estimated glomerular filtration rate by cystatin C (eGFRcys) less than 60 ml/min per 1.73 m(2) and/or ACR at least 30 mg/g among persons with eGFRcreat more than 60 ml/min per 1.73 m(2). We studied occult CKD prevalence by either marker, stratified by age, race/ethnicity, and assessed clinical predictors associated with occult CKD presence.
Results: In 1988-1994, occult CKD was prevalent among 25% of nondiabetic hypertensive persons, and it was 22% in 1999-2002. Each marker's ability to detect occult CKD varied by age and race. Cystatin C detected occult CKD among 8.9% of persons more than 65 years, and among 3.8% of whites. ACR detected occult CKD among 9.3% of persons less than 45 years, 16.6% of Blacks, and 20.6% of Mexican-Americans. In multivariate models, each decade of advancing age was associated with a higher occult CKD prevalence by cystatin C (OR 3.1, 95% CI 2.5-3.8) in 1988-1994 and 1999-2002 (OR 2.9, 1.8-4.6).
Conclusion: Current hypertension guidelines may fail to detect a large proportion of high-risk individuals with CKD who can be identified by cystatin C or ACR. Future studies are needed to evaluate targeted use of multimarker renal panels among hypertensives.
C1 [Peralta, Carmen A.; Weekley, Cristin C.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Weekley, Cristin C.; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM carmenalicia.peralta@ucsf.edu
FU National Institutes of Diabetes and Digestive and Kidney Diseases
[1K23SK082793-01]; Robert Wood Johnson Harold Amos award
FX C.A.P. is funded by the National Institutes of Diabetes and Digestive
and Kidney Diseases 1K23SK082793-01 and a Robert Wood Johnson Harold
Amos award. These funding sources had no involvement in the design or
execution of this study.
NR 23
TC 5
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2013
VL 31
IS 6
BP 1196
EP 1202
DI 10.1097/HJH.0b013e328360ae2d
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 138XC
UT WOS:000318543900020
PM 23640605
ER
PT J
AU Quinones, AR
Liang, J
Ye, W
AF Quinones, Ana R.
Liang, Jersey
Ye, Wen
TI DIFFERENCES IN DIABETES MELLITUS ONSET FOR OLDER BLACK, WHITE, AND
MEXICAN AMERICANS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Ethnic Differences; Diabetes Mellitus Incidence; Discrete-Time Survival
Analysis
ID RISK-FACTORS; HEALTH; PREVALENCE; DISEASE; ADULTS; COHORT
AB Objectives: Our research examines the differences in estimated odds of developing diabetes mellitus for White, Black, and Mexican Americans age 51 and over for a period of 11 years.
Design, Setting, and Participants: Longitudinal data came from 14,783 respondents of the Health and Retirement Study (1995-2006) who reported being diabetes-free at the first time period. Discrete-time survival models were used to analyze ethnic variations in the probability of developing diabetes.
Main Outcome Measure: Estimated odds of developing diabetes mellitus.
Results: The odds of newly diagnosed diabetes increased between 1995 and 2006, with 11% cumulative incidence for all study participants. The probability of incident diabetes among Black Americans was .01 during the period of 1995/96-1998, which increased to .03 during 1998-2000 and remained at .03 throughout subsequent periods, with cumulative incidence over the 11 years at 12%. In contrast, for Mexican Americans the probability more than doubled from .02 in 1995/96-1998 to .05 in 2004-2006, with cumulative incidence at 19%. White Americans had 11% cumulative incidence during the 11 year period.
Conclusions: Relative to White Americans, Mexican Americans had significantly elevated odds of developing diabetes throughout the 11-year period of observation even after controlling for differences in demographic, socioeconomic, and time-varying health characteristics.
C1 [Quinones, Ana R.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Quinones, Ana R.] Portland VA Med Ctr, Portland, OR USA.
[Liang, Jersey] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Ye, Wen] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
RP Quinones, AR (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA.
EM quinones@ohsu.edu
FU National Institute On Aging [F31-AG029783, R36AG031570, R01-AG015124,
R01-AG028116]
FX This research was supported by the National Institute On Aging grants
F31-AG029783 and R36AG031570 (Ana Quinones, PI), R01-AG015124 and
R01-AG028116 (Jersey Liang, PI). The content is solely the
responsibility of the author and does not necessarily represent the
official views of the National Institute on Aging or the National
Institutes of Health. We thank Joan Bennett, Xiao Xu, and Alexis Dinno.
NR 21
TC 2
Z9 2
U1 2
U2 2
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2013
VL 23
IS 3
BP 310
EP 315
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ7QV
UT WOS:000343015200007
PM 23914416
ER
PT J
AU Talbert, J
Chan, ED
AF Talbert, Janet
Chan, Edward D.
TI The association between body shape and nontuberculous mycobacterial lung
disease
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Editorial Material
DE bronchiectasis; environmental mycobacteria; Marfan syndrome;
nontuberculous mycobacteria; pectus excavatum; scoliosis
ID SHPRINTZEN-GOLDBERG SYNDROME; PULMONARY-DISEASE; MARFANS-SYNDROME; AVIUM
COMPLEX; INFECTION; MUTATIONS; TUBERCULOSIS; ANOMALIES; DOMINANT; GROWTH
C1 [Talbert, Janet] Univ Colorado Denver, Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Denver Vet Affairs Med Ctr, Denver, CO 80217 USA.
[Chan, Edward D.] Univ Colorado Denver, Dept Med, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Natl Jewish Hlth, Cell Biol Program, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA.
RP Chan, ED (reprint author), Univ Colorado Denver, Denver Vet Affairs Med Ctr, Anschutz Med Campus, Denver, CO 80217 USA.
EM chane@njhealth.org
NR 31
TC 2
Z9 2
U1 1
U2 1
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
PD JUN
PY 2013
VL 7
IS 3
BP 201
EP 204
DI 10.1586/ERS.13.23
PG 4
WC Respiratory System
SC Respiratory System
GA AI8RF
UT WOS:000337190100002
PM 23734642
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI PEGYLATED INTERFERON ALFA, NITAZOXANIDE, TELAPREVIR, RIBAVIRIN, IN
GENOTYPE 1 UNDERGOING PRIOR EXPERIENCED CHC-A RANDOMIZED PLACEBO CONTROL
CLINICAL PILOT TRIAL (INTRIGUE-C)
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
[Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A183
EP A184
DI 10.1136/gutjnl-2013-304907.417
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600311
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI RESTLESS LEG SYNDROME, (RLS) IS ASSOCIATED WITH HEPATIC ENCEPHALOPATHY
(HE) IN DECOMPENSATED CIRRHOSIS. A CLINICAL PILOT STUDY
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A182
EP A183
DI 10.1136/gutjnl-2013-304907.415
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600309
ER
PT J
AU Kern, RS
Zarate, R
Glynn, SM
Turner, LR
Smith, KM
Mitchell, SS
Becker, DR
Drake, RE
Kopelowicz, A
Tovey, W
Liberman, RP
AF Kern, Robert S.
Zarate, Roberto
Glynn, Shirley M.
Turner, Luana R.
Smith, Kellie M.
Mitchell, Sharon S.
Becker, Deborah R.
Drake, Robert E.
Kopelowicz, Alex
Tovey, Wendi
Liberman, Robert P.
TI A Demonstration Project Involving Peers as Providers of Evidence-Based,
Supported Employment Services
SO PSYCHIATRIC REHABILITATION JOURNAL
LA English
DT Article
DE peer support; supported employment; schizophrenia; psychiatric
rehabilitation
AB Objective: The present demonstration project involved development of a training program designed to teach recovering consumers employed as peer advocates how to provide evidence-based supported employment services to consumers with severe mental illness. Methods: A training curriculum was developed to teach the core competencies of the Individual Placement and Support (IPS) model of supported employment. Three peers participated in training and provided work outcome data from their caseloads. Assessments were conducted of peers' competence in implementing IPS and effectiveness in promoting job placements. Peer competency was assessed by the following: (a) a formal IPS fidelity review performed by two external reviewers to evaluate service implementation, and (b) the Kansas Employment Specialist Job Performance Evaluation, an objective measure of employment specialist attitudes and skills. Program efficacy was assessed by examining the number of job placements and corresponding tenure. Results: The fidelity review revealed that peers met IFS standards of implementation on 7 of 14 items assessing service delivery. The Kansas scale results revealed attitudes to be a relative strength and job performance competency ratings fell in the average to above average range across skill areas assessed (e.g., vocational assessment, job development). Thirty-three percent of consumers from the peers' caseloads got competitive jobs; mean tenure was 26.1 weeks. Conclusions and Implications for Practice: This demonstration project provides a starting point for future efforts aimed at expanding the role of peers as providers of evidence-based mental health services and provides a measured degree of optimism that this is a realistic, attainable goal.
C1 [Kern, Robert S.; Zarate, Roberto; Glynn, Shirley M.; Turner, Luana R.; Smith, Kellie M.; Mitchell, Sharon S.; Kopelowicz, Alex; Liberman, Robert P.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90073 USA.
[Kern, Robert S.; Glynn, Shirley M.] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Becker, Deborah R.; Drake, Robert E.] Dartmouth Coll, Dartmouth Psychiat Res Ctr, Dept Psychiat, Geisel Sch Med, Hanover, NH 03755 USA.
[Kopelowicz, Alex] San Fernando Mental Hlth Ctr, Granada Hills, CA USA.
[Tovey, Wendi] Los Angeles Cty Dept Mental Hlth, Los Angeles, CA USA.
RP Kern, RS (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd MIRECC 210 A,Bldg 210, Los Angeles, CA 90073 USA.
EM rkern@ucla.edu
OI kopelowicz, alex/0000-0002-1728-4105
FU NIMH [R01 MH082939]; VA Merit Award; Los Angeles County Department of
Mental Health
FX We thank each of the peers for their dedication and tireless effort in
working towards becoming a supported employment specialist under the IPS
model. This project was supported in part by NIMH grant R01 MH082939 and
a VA Merit Award received by R. Kern (Principal Investigator), and the
Los Angeles County Department of Mental Health. Special thanks go to
Marvin Southard, DSW who had the foresight to realize the rehabilitative
potential of persons with serious mental illnesses to recover and become
employed by his own agency to serve others with SMI using an
evidence-based, person-centered model of supported employment.
NR 40
TC 11
Z9 11
U1 4
U2 16
PU CENTER PSYCHIATRIC REHABILITATION
PI BOSTON
PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA
SN 1095-158X
EI 1559-3126
J9 PSYCHIATR REHABIL J
JI Psychiatr. Rehabil. J.
PD JUN
PY 2013
VL 36
IS 2
BP 99
EP 107
DI 10.1037/h0094987
PG 9
WC Psychiatry; Rehabilitation
SC Psychiatry; Rehabilitation
GA V36ST
UT WOS:000209231700007
PM 23750760
ER
PT J
AU Tang, XN
Liu, LP
Koike, MA
Yenari, MA
AF Tang, Xian Nan
Liu, Liping
Koike, Maya A.
Yenari, Midori A.
TI Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage
and Blood Brain Barrier Disruption After Experimental Stroke
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Article
AB Therapeutic hypothermia has shown neuroprotective promise, but whether it can be used to improve outcome in stroke has yet to be determined in patients. Recombinant tissue plasminogen activator (rt-PA) is only given to a minority of patients with acute ischemic stroke, and is not without risk, namely significant brain hemorrhage. We explored whether mild hypothermia, in combination with rt-PA, influences the safety of rt-PA. Mice were subjected to middle cerebral artery occlusion (MCAO) using a filament model, followed by 24 hours reperfusion. Two paradigms were studied. In the first paradigm, cooling and rt-PA treatment began at the same time upon reperfusion, whereas in the second paradigm, cooling began soon after ischemia onset, and rt-PA began after re-warming and upon reperfusion. Experimental groups included: tPA treatment at normothermia (37 degrees C), rt-PA treatment at hypothermia (33 degrees C), no rt-PA at normothermia, and no rt-PA treatment at hypothermia. Infarct size, neurological deficit scores, blood brain barrier (BBB) permeability, brain hemorrhage, and expression of endogenous tissue plasminogen activator (tPA) and its inhibitor, plasminogen activator inhibitor (PAI-1) were assessed. For both paradigms, hypothermia reduced infarct size and neurological deficits compared to normothermia, regardless of whether rt-PA was given. rt-PA treatment increased brain hemorrhage and BBB disruption compared to normothermia, and this was prevented by cooling. However, mortality was higher when rt-PA and cooling were administered at the same time, beginning 1-2 hours post MCAO. Endogenous tPA expression was reduced in hypothermic mice, whereas PAI-1 levels were unchanged by cooling. In the setting of rt-PA treatment, hypothermia reduces brain hemorrhage, and BBB disruption, suggesting that combination therapy with mild hypothermia and rt-PA appears safe.
C1 [Tang, Xian Nan; Liu, Liping; Koike, Maya A.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Tang, Xian Nan; Liu, Liping; Koike, Maya A.; Yenari, Midori A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA USA.
[Liu, Liping] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.
RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
FU National Institutes of Health [NS40516]; Veteran's Merit Award
FX This work was supported by grants from National Institutes of Health
(NS40516) and Veteran's Merit Award to M.Y. Grants to M.Y. were
administered by Northern California Institute for Research and
Education, and supported by resources of Veterans Affairs Medical
Center, San Francisco, California.
NR 57
TC 11
Z9 11
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD JUN 1
PY 2013
VL 3
IS 2
BP 74
EP 83
DI 10.1089/ther.2013.0010
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA V38PL
UT WOS:000209355200007
PM 23781399
ER
PT J
AU McCauley, JL
Back, SE
Brady, KT
AF McCauley, Jenna L.
Back, Sudie E.
Brady, Kathleen T.
TI Pilot of a brief, web-based educational intervention targeting safe
storage and disposal of prescription opioids
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Prescription opioid misuse; Web; Computer; Primary care; Dental
ID RANDOMIZED CONTROLLED-TRIAL; NONMEDICAL USE; NONCANCER PAIN; DRUG-ABUSE;
VALIDATION; PREVENTION; ADOLESCENTS; DEPENDENCE; DIVERSION; INTERNET
AB Prescription opioid misuse has been declared an American epidemic and a significant proportion of misused opioids are diverted from legitimate prescriptions. Patient education,regarding appropriate use and the dangers of misuse has been identified as a key intervention target. The current study presents findings from the open pilot of a patient-tailored, brief, web-based intervention designed to improve knowledge of safe medication use, storage and disposal.
Methods: Subjects were 62 treatment-seeking outpatients at two diverse outpatient health clinics (dental and pain management) who were prescribed an opioid medication. Subjects completed an online assessment of risk factors for prescription opioid misuse and the 15-minute Script Safety intervention. Knowledge and misuse behaviors were assessed at baseline, immediately post intervention (knowledge only) and at one-week and one-month follow up. Knowledge regarding safe prescription opioid use, storage and disposal improved significantly from pre to post intervention and was sustained at follow up (% correct from baseline to one-month follow up: unsafe to retain unused pills, 66.1% vs. 96.5%; unsafe to borrow pills from family/friends, 87.1% vs. 98.2%; best to store pills in cool, dry, secure location, 45.2% vs. 89.5%; not recommended to use expired medications, 75.8% vs. 96.5%; not recommended to flush all medications down the toilet, 45.2% vs. 82.5%, ps<.01). Reductions in self-reported misuse behaviors were also observed. Although preliminary, the findings highlight the potential utility of integrating brief, web-based educational interventions in community and primary health care settings. Published by Elsevier Ltd.
C1 [McCauley, Jenna L.; Back, Sudie E.; Brady, Kathleen T.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Back, Sudie E.; Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP McCauley, JL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 125 Doughty St,Suite 140, Charleston, SC 29425 USA.
EM mccaule@musc.edu
FU South Carolina Clinical & Translational Research (SCTR) Institute;
Medical University of South Carolina; NIH/NCRR [UL1RR029882-02];
National Institute on Drug Abuse [K23 DA021228]
FX This study was supported by the South Carolina Clinical & Translational
Research (SCTR) Institute, with an academic home at the Medical
University of South Carolina, NIH/NCRR Grant number UL1RR029882-02
(KTB), and grant K23 DA021228 (SEB) from the National Institute on Drug
Abuse. Funding agencies had no role in the study design, collection,
analysis or interpretation of the data, writing the manuscript, or the
decision to submit the paper for publication.
NR 35
TC 17
Z9 17
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD JUN
PY 2013
VL 38
IS 6
BP 2230
EP 2235
DI 10.1016/j.addbeh.2013.01.019
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 135YC
UT WOS:000318325600005
PM 23501140
ER
PT J
AU Feng, JQ
Clinkenbeard, EL
Yuan, BZ
White, KE
Drezner, MK
AF Feng, Jian Q.
Clinkenbeard, Erica L.
Yuan, Baozhi
White, Kenneth E.
Drezner, Marc K.
TI Osteocyte regulation of phosphate homeostasis and bone mineralization
underlies the pathophysiology of the heritable disorders of rickets and
osteomalacia
SO BONE
LA English
DT Review
DE Osteocyte; Rickets; Osteomalacia; Fibroblast growth factor-23; PHEX;
DMP1
ID DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIA;
X-LINKED HYPOPHOSPHATEMIA; HYP MICE; PEX GENE; IN-VIVO; DMP1; PHENOTYPE;
FGF23; MUTATIONS
AB Although recent studies have established that osteocytes function as secretory cells that regulate phosphate metabolism, the biomolecular mechanism(s) underlying these effects remain incompletely defined. However, investigations focusing on the pathogenesis of X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and autosomal recessive hypophosphatemic rickets (ARHR), heritable disorders characterized by abnormal renal phosphate wasting and bone mineralization, have clearly implicated FGF23 as a central factor in osteocytes underlying renal phosphate wasting, documented new molecular pathways regulating FGF23 production, and revealed complementary abnormalities in osteocytes that regulate bone mineralization. The seminal observations leading to these discoveries were the following: 1) mutations in FGF23 cause ADHR by limiting cleavage of the bioactive intact molecule, at a subtilisin-like protein convertase (SPC) site, resulting in increased circulating FGF23 levels and hypophosphatemia; 2) mutations in DMP1 cause ARHR, not only by increasing serum FGF23, albeit by enhanced production and not limited cleavage, but also by limiting production of the active DMP1 component, the C-terminal fragment, resulting in dysregulated production of Dial and beta-catenin, which contributes to impaired bone mineralization; and 3) mutations in PHEX cause XLH both by altering FGF23 proteolysis and production and causing dysregulated production of Dial and p-catenin, similar to abnormalities in ADHR and ARHR, but secondary to different central pathophysiological events. These discoveries indicate that ADHR, XLH, and ARHR represent three related heritable hypophosphatemic diseases that arise from mutations in, or dysregulation of, a single common gene product, FGF23 and, in ARHR and XLH, complimentary DMP1 and PHEX directed events that contribute to abnormal bone mineralization.
This article is part of a Special Issue entitled "The Osteocyte". (C) 2013 Elsevier Inc. All rights reserved.
C1 [Feng, Jian Q.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, Dallas, TX 75246 USA.
[Clinkenbeard, Erica L.; White, Kenneth E.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Yuan, Baozhi; Drezner, Marc K.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA.
[Yuan, Baozhi; Drezner, Marc K.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res & Educ Ctr, Madison, WI 53792 USA.
RP White, KE (reprint author), Indiana Univ Sch Med, Dept Med & Mol Genet, 975 West Walnut St,IB 130, Indianapolis, IN 46202 USA.
EM kenewhit@iu.edu; mkd@medicine.wisc.edu
FU NIH [AR27032, 2UL1TR000427, DE018486, DK063934, AR059278];
Sanofi-Genzyme
FX This work was funded by NIH grants to MK Drezner (AR27032,
2UL1TR000427), JQ Feng (DE018486), and KE White (DK063934, AR059278) and
a GRIP Award from Sanofi-Genzyme to KE White.
NR 49
TC 33
Z9 34
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2013
VL 54
IS 2
SI SI
BP 213
EP 221
DI 10.1016/j.bone.2013.01.046
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131NJ
UT WOS:000318000100006
PM 23403405
ER
PT J
AU Haritha, AT
Wood, KH
Hoef, LWV
Knight, DC
AF Haritha, Abhishek T.
Wood, Kimberly H.
Hoef, Lawrence W. Ver
Knight, David C.
TI Human trace fear conditioning: right-lateralized cortical activity
supports trace-interval processes
SO COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE fMRI; Learning; Conditioning; Trace; Prefrontal; Parietal; Emotion;
Fear; Skin conductance
ID MEDIAL PREFRONTAL CORTEX; WORKING-MEMORY MAINTENANCE; HUMAN AMYGDALA
ACTIVITY; HIPPOCAMPAL INVOLVEMENT; BRAIN ACTIVATION; FUNCTIONAL MRI;
HUMAN DELAY; AWARENESS; FMRI; ACQUISITION
AB Pavlovian conditioning requires the convergence and simultaneous activation of neural circuitry that supports conditioned stimulus (CS) and unconditioned stimulus (US) processes. However, in trace conditioning, the CS and US are separated by a period of time called the trace interval, and thus do not overlap. Therefore, determining brain regions that support associative learning by maintaining a CS representation during the trace interval is an important issue for conditioning research. Prior functional magnetic resonance imaging (fMRI) research has identified brain regions that support trace-conditioning processes. However, relatively little is known about whether this activity is specific to the trace CS, the trace interval, or both periods of time. The present study was designed to disentangle the hemodynamic response produced by the trace CS from that associated with the trace interval, in order to identify learning-related activation during these distinct components of a trace-conditioning trial. Trace-conditioned activity was observed within dorsomedial prefrontal cortex (PFC), dorsolateral PFC, insula, inferior parietal lobule (IPL), and posterior cingulate (PCC). Each of these regions showed learning-related activity during the trace CS, while trace-interval activity was only observed within a subset of these areas (i.e., dorsomedial PFC, PCC, right dorsolateral PFC, right IPL, right superior/middle temporal gyrus, and bilateral insula). Trace-interval activity was greater in right than in left dorsolateral PFC, IPL, and superior/middle temporal gyrus. These findings indicate that components of the prefrontal, cingulate, insular, and parietal cortices support trace-interval processes, as well as suggesting that a right-lateralized fronto-parietal circuit may play a unique role in trace conditioning.
C1 [Haritha, Abhishek T.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
[Wood, Kimberly H.; Knight, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA.
[Hoef, Lawrence W. Ver] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Knight, DC (reprint author), CIRC 235H,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM knightdc@uab.edu
FU University of Alabama at Birmingham Faculty Development Grant Program;
Civitan International Research Center
FX A.T.H. and K. H. W. contributed equally to this work. This research was
supported by the University of Alabama at Birmingham Faculty Development
Grant Program and the Civitan International Research Center.
NR 60
TC 6
Z9 6
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-7026
EI 1531-135X
J9 COGN AFFECT BEHAV NE
JI Cogn. Affect. Behav. Neurosci.
PD JUN
PY 2013
VL 13
IS 2
BP 225
EP 237
DI 10.3758/s13415-012-0142-6
PG 13
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 131II
UT WOS:000317986100002
PM 23263840
ER
PT J
AU Strauss, GP
Horan, WP
Kirkpatrick, B
Fischer, BA
Keller, WR
Miski, P
Buchanan, RW
Green, MF
Carpenter, WT
AF Strauss, Gregory P.
Horan, William P.
Kirkpatrick, Brian
Fischer, Bernard A.
Keller, William R.
Miski, Pinar
Buchanan, Robert W.
Green, Michael F.
Carpenter, William T., Jr.
TI Deconstructing negative symptoms of schizophrenia: Avolition-apathy and
diminished expression clusters predict clinical presentation and
functional outcome
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Negative symptoms; Avolition; Apathy; Emotion; Blunted
affect
ID DEFICIT SYNDROME SCHIZOPHRENIA; NONDEFICIT SCHIZOPHRENIA; DIFFERENTIAL
PATTERNS; ASSESSMENT INTERVIEW; FACTORIAL STRUCTURE; FLAT AFFECT; SCALE;
VALIDATION; MEDICATION; SCHEDULE
AB Background: Previous studies indicate that negative symptoms reflect a separable domain of pathology from other symptoms of schizophrenia. However, it is currently unclear whether negative symptoms themselves are multi-faceted, and whether sub-groups of patients who display unique negative symptom profiles can be identified.
Methods: A data-driven approach was used to examine the heterogeneity of negative symptom presentations in two samples: Study 1 included 199 individuals with schizophrenia assessed with a standard measure of negative symptoms and Study 2 included 169 individuals meeting criteria for deficit schizophrenia (i.e., primary and enduring negative symptoms) assessed with a specialized measure of deficit symptoms. Cluster analysis was used to determine whether different groups of patients with distinct negative symptoms profiles could be identified.
Results: Across both studies, we found evidence for two distinctive negative symptom sub-groups: one group with predominantly Avolition-Apathy (AA) symptoms and another with a predominantly Diminished Expression (DE) profile. Follow-up discriminant function analyses confirmed the validity of these groups. AA and DE negative symptom sub-groups significantly differed on clinically relevant external validators, including measures of functional outcome, premorbid adjustment, clinical course, disorganized symptoms, social cognition, sex, and ethnicity.
Conclusions: These results suggest that distinct subgroups of patients with elevated AA or DE can be identified within the broader diagnosis of schizophrenia and that these subgroups show clinically meaningful differences in presentation. Additionally, AA tends to be associated with poorer outcomes than DE, suggesting that it may be a more severe aspect of psychopathology. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Strauss, Gregory P.; Fischer, Bernard A.; Keller, William R.; Miski, Pinar; Buchanan, Robert W.; Carpenter, William T., Jr.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA.
[Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Fischer, Bernard A.; Buchanan, Robert W.; Carpenter, William T., Jr.] VA Maryland Hlth Care Syst, Vet Affairs Capital Network VISN Mental Illness R, Baltimore, MD USA.
[Kirkpatrick, Brian] Texas A&M Coll Med, Dept Psychiat, Scott & White Healthcare, Temple, TX USA.
RP Strauss, GP (reprint author), Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, POB 21247, Baltimore, MD 21228 USA.
EM gstrauss@mprc.umaryland.edu
FU NIH [MH043292, P30MH068580]; UpToDate Incorporated
FX The current studies were supported in part by NIH Grants: MH043292 (M.F.
Green PI) and P30MH068580 (W.T. Carpenter PI). Study sponsors had no
role in study design, data collection, analysis and interpretation; the
writing of the report; and in the decision to submit the paper for
publication.; Dr. Carpenter served as a consultant for Genentech, Astra
Zeneca, and Merck. Dr. Green has served as a consultant for Abbott
laboratories, Amgen, and Shire. Dr. Kirkpatrick has served as a
consultant for Sunovion, Abbott, Boehringer Ingelheim. Dr Buchanan is on
the advisory boards of Amgen, Janssen Pharmaceuticals, Inc., NuPathe,
Inc., Pfizer, and Roche, and has served as a consultant to Abbott,
Amgen, EnVivo, and Pfizer. Dr. Buchanan is also a DSMB member for Pfizer
and Otsuka. Drs. Fischer receives royalties from UpToDate Incorporated.
Drs. Strauss, Horan, Keller, Miski report no financial relationships
with commercial interests.
NR 66
TC 78
Z9 78
U1 3
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2013
VL 47
IS 6
BP 783
EP 790
DI 10.1016/j.jpsychires.2013.01.015
PG 8
WC Psychiatry
SC Psychiatry
GA 135ZH
UT WOS:000318328700012
PM 23453820
ER
PT J
AU Naylor, DE
Liu, HT
Niquet, J
Wasterlain, CG
AF Naylor, David E.
Liu, Hantao
Niquet, Jerome
Wasterlain, Claude G.
TI Rapid surface accumulation of NMDA receptors increases glutamatergic
excitation during status epilepticus
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE NMDA receptor trafficking; Status epilepticus; Epilepsy; Hippocampus;
Synaptic excitation
ID METHYL-D-ASPARTATE; SUSTAINING STATUS EPILEPTICUS; PROTEIN-KINASE-C;
LONG-TERM POTENTIATION; PROLONGED STATUS EPILEPTICUS; LIMBIC STATUS
EPILEPTICUS; GABA(A) RECEPTORS; RAT HIPPOCAMPUS; SUBUNIT COMPOSITION;
AMPA RECEPTORS
AB After 1 h of lithium-pilocarpine status epilepticus (SE), immunocytochemical labeling of NMDA receptor NR1 subunits reveals relocation of subunits from the interior to the cell surface of dentate gyrus granule cells and CA3 pyramidal cells. Simultaneously, an increase in NMDA-miniature excitatory postsynaptic currents (mEPSC) as well as an increase in NMDA receptor-mediated tonic currents is observed in hippocampal slices after SE. Mean-variance analysis of NMDA-mEPSCs estimates that the number of functional postsynaptic NMDA receptors per synapse increases 38% during SE, and antagonism by ifenprodil suggests that an increase in the surface representation of NR2B-containing NMDA receptors is responsible for the augmentation of both the phasic and tonic excitatory currents with SE. These results provide a potential mechanism for an enhancement of glutamatergic excitation that maintains SE and may contribute to excitotoxic injury during SE. Therapies that directly antagonize NMDA receptors may be a useful therapeutic strategy during refractory SE. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Naylor, David E.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Neurol, Torrance, CA 90509 USA.
[Naylor, David E.; Liu, Hantao; Niquet, Jerome; Wasterlain, Claude G.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Wasterlain, Claude G.] Univ Calif Los Angeles, Brain Res Inst, Torrance, CA 90509 USA.
[Naylor, David E.; Liu, Hantao; Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, Dept Neurol, Torrance, CA 90509 USA.
RP Naylor, DE (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Vet Adm Greater Angeles Healthcare Syst, 1000 West Carson St Bldg N-25 Neurol 432, Torrance, CA 90509 USA.
EM dnaylor@ucla.edu
FU Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center;
VA Career Development Award; NINDS [N13515]
FX Support provided by the Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center and a VA Career Development Award to D.N. and
by NINDS (N13515) to C.W.
NR 119
TC 37
Z9 38
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD JUN
PY 2013
VL 54
BP 225
EP 238
DI 10.1016/j.nbd.2012.12.015
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 132EZ
UT WOS:000318052000022
PM 23313318
ER
PT J
AU Wilson, LB
Tregellas, JR
Slason, E
Pasko, BE
Hepburn, S
Rojas, DC
AF Wilson, Lisa B.
Tregellas, Jason R.
Slason, Erin
Pasko, Bryce E.
Hepburn, Susan
Rojas, Donald C.
TI Phonological processing in first-degree relatives of individuals with
autism: An fMRI study
SO HUMAN BRAIN MAPPING
LA English
DT Review
DE functional magnetic resonance imaging (fMRI); autism spectrum disorders
(ASD); broad autism phenotype (BAP); phonology; priming; nonword
repetition
ID FUNCTIONAL MAGNETIC-RESONANCE; SUPERIOR TEMPORAL GYRUS; VOXEL-BASED
MORPHOMETRY; VERBAL WORKING-MEMORY; PERVASIVE DEVELOPMENTAL DISORDERS;
POSITRON-EMISSION-TOMOGRAPHY; VISUAL WORD RECOGNITION;
SCHOOL-AGE-CHILDREN; LANGUAGE IMPAIRMENT; SPECTRUM DISORDERS
AB Autism spectrum disorders (ASD) are complex neurodevelopmental disorders. Twin studies have provided heritability estimates as high as 90% for idiopathic ASD. Further evidence for the spectrum's heritability is provided by the presence of the broad autism phenotype (BAP) in unaffected first-degree relatives. Language ability, specifically phonological processing, is proposed to be a core BAP trait. To date, however, no functional neuroimaging investigations of phonological processing in relatives of individuals with ASD have been undertaken. We conducted a functional magnetic resonance imaging (fMRI) study in parents of children with ASD utilizing a priming task probing implicit phonological processing. In our condition that placed heavier demands on phonological recoding, parents exhibited greater hemodynamic responses than controls in a network of cortical regions involved in phonological processing. Across conditions, parents exhibited enhanced priming-induced response suppression suggesting compensatory neural processing. A nonword repetition test used in previous studies of relatives was also administered. Correlations between this measure and our functional measures also suggested compensatory processing in parents. Regions exhibiting atypical responses in parents included regions previously implicated in the spectrum's language impairments and found to exhibit structural abnormalities in a parent study. These results suggest a possible neurobiological substrate of the phonological deficits proposed to be a core BAP trait. However, these results should be considered preliminary. No previous fMRI study has investigated phonological processing in ASD, so replication is required. Furthermore, interpretation of our fMRI results is limited by the fact that the parent group failed to exhibit behavioral evidence of phonological impairments. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Wilson, Lisa B.; Tregellas, Jason R.; Slason, Erin; Pasko, Bryce E.; Hepburn, Susan; Rojas, Donald C.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Dept Psychiat, Denver, CO USA.
RP Rojas, DC (reprint author), Univ Colorado Denver, Dept Psychiat, 13001 East 17th Pl, Aurora, CO 80045 USA.
EM don.rojas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
OI Rojas, Don/0000-0001-6560-9616; Hepburn, Susan/0000-0002-8545-3804
FU Autism Speaks [2090]; Autism Speaks Weatherstone [6291]; National
Institutes of Health (NIH) [PHS R01 MH082020]; NIH/NCRR Colorado CTSI
[TL1 RR025778]; National Institute of Child Health and Human Development
(NICHHD) [HD041697]
FX Contract grant sponsor: Autism Speaks; Contract grant number: 2090;
Contract grant sponsor: Autism Speaks Weatherstone; Contract grant
number: 6291; Contract grant sponsor: National Institutes of Health
(NIH); Contract grant number: PHS R01 MH082020; Contract grant sponsor:
NIH/NCRR Colorado CTSI; Contract grant number: TL1 RR025778; Contract
grant sponsor: National Institute of Child Health and Human Development
(NICHHD); Contract grant number: HD041697.
NR 146
TC 6
Z9 7
U1 7
U2 45
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUN
PY 2013
VL 34
IS 6
BP 1447
EP 1463
DI 10.1002/hbm.22001
PG 17
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 129QA
UT WOS:000317855400016
PM 22419478
ER
PT J
AU Gong, B
Pan, Y
Vempati, P
Zhao, W
Knable, L
Ho, L
Wang, J
Sastre, M
Ono, K
Sauve, AA
Pasinetti, GM
AF Gong, Bing
Pan, Yong
Vempati, Prashant
Zhao, Wei
Knable, Lindsay
Ho, Lap
Wang, Jun
Sastre, Magdalena
Ono, Kenjiro
Sauve, Anthony A.
Pasinetti, Giulio M.
TI Nicotinamide riboside restores cognition through an upregulation of
proliferator-activated receptor-gamma coactivator 1 alpha regulated
beta-secretase 1 degradation and mitochondrial gene expression in
Alzheimer's mouse models
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Nicotinamide riboside; Alzheimer's disease; beta-secretase (BACE1);
Promotes peroxisome proliferator-activated receptor (PPAR)-gamma
coactivator 1 (PGC)-1 alpha; Ubiquitin-proteasome system; Mitochondrial
metabolism; Synaptic plasticity; Long-term potentiation
ID PERMEABILITY TRANSITION; SYNAPTIC FUNCTION; OXIDATIVE STRESS; TRANSGENIC
MICE; DISEASE; PGC-1-ALPHA; NAD(+); SIRT1; MECHANISM; DEMENTIA
AB Nicotinamide adenine dinucleotide (NAD)(+), a coenzyme involved in redox activities in the mitochondrial electron transport chain, has been identified as a key regulator of the lifespan-extending effects, and the activation of NAD(+) expression has been linked with a decrease in beta-amyloid (A beta) toxicity in Alzheimer's disease (AD). Nicotinamide riboside (NR) is a NAD(+) precursor, it promotes peroxisome proliferator-activated receptor-gamma coactivator 1 (PGC)-1 alpha expression in the brain. Evidence has shown that PGC-1 alpha is a crucial regulator of A beta generation because it affects beta-secretase (BACE1) degradation. In this study we tested the hypothesis that NR treatment in an AD mouse model could attenuate A beta toxicity through the activation of PGC-1 alpha-mediated BACE1 degradation. Using the Tg2576 AD mouse model, using in vivo behavioral analyses, biochemistry assays, small hairpin RNA (shRNA) gene silencing and electrophysiological recording, we found (1) dietary treatment of Tg2576 mice with 250 mg/kg/day of NR for 3 months significantly attenuates cognitive deterioration in Tg2576 mice and coincides with an increase in the steady-state levels of NAD(+) in the cerebral cortex; (2) application of NR to hippocampal slices (10 mu M) for 4 hours abolishes the deficits in long-term potentiation recorded in the CA1 region of Tg2576 mice; (3) NR treatment promotes PGC-1 alpha expression in the brain coinciding with enhanced degradation of BACE1 and the reduction of A beta production in Tg2576 mice. Further in vitro studies confirmed that BACE1 protein content is decreased by NR treatment in primary neuronal cultures derived from Tg2576 embryos, in which BACE1 degradation was prevented by PGC-1 alpha-shRNA gene silencing; and (4) NR treatment and PGC-1 alpha overexpression enhance BACE1 ubiquitination and proteasomal degradation. Our studies suggest that dietary treatment with NR might benefit AD cognitive function and synaptic plasticity, in part by promoting PGC-1 alpha-mediated BACE1 ubiquitination and degradation, thus preventing A beta production in the brain. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Gong, Bing; Pan, Yong; Vempati, Prashant; Zhao, Wei; Knable, Lindsay; Ho, Lap; Wang, Jun; Ono, Kenjiro; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurotherapeut, New York, NY 10029 USA.
[Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Sastre, Magdalena] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London, England.
[Sauve, Anthony A.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
FU Veterans Administration, US National Institutes of Health; Alzheimer's
Association [IIRG-08-89354]
FX The studies described here were supported in part from a grant from the
Veterans Administration by the US National Institutes of Health grants
to G. M. P. and by grant from Alzheimer's Association (IIRG-08-89354) to
B. G. The authors thank Dr Ottavio Arancio (Columbia University) for his
advice on the reported electrophysiological recording and thank Ms.
Amanda Bilski for assisting in preparation of the manuscript.
NR 34
TC 53
Z9 54
U1 2
U2 50
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUN
PY 2013
VL 34
IS 6
BP 1581
EP 1588
DI 10.1016/j.neurobiolaging.2012.12.005
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 123UQ
UT WOS:000317417100008
PM 23312803
ER
PT J
AU Gilkeson, GS
Mashmoushi, AK
Ruiz, P
Caza, TN
Perl, A
Oates, JC
AF Gilkeson, Gary S.
Mashmoushi, Ahmad K.
Ruiz, Phillip
Caza, Tiffany N.
Perl, Andras
Oates, Jim C.
TI Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic
Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in
Murine Lupus Nephritis
SO PLOS ONE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; SUPEROXIDE-PRODUCTION; OXIDATIVE
STRESS; REDOX REGULATION; GENETIC-ANALYSIS; MICE; ERYTHEMATOSUS; CELLS;
TETRAHYDROBIOPTERIN; INHIBITION
AB Systemic lupus erythematosus, in both animal models and in humans, is characterized by autoantibody production followed by immune complex deposition in target tissues. Ensuing target organ damage is modulated by reactive intermediates, including reactive nitrogen and oxygen species, through as of now incompletely understood mechanisms. Endothelial nitric oxide synthase is known to impact vascular reactivity; however its impact on reactive intermediate production and inflammatory renal disease is less well defined. In this study, we assessed the impact of endothelial nitric oxide synthase (eNOS) on disease in lupus prone MRL/lpr mice. Mice lacking eNOS developed earlier more severe disease with decreased survival. eNOS deficient mice died sooner and developed significantly more glomerular crescents, necrosis, inflammatory infiltrates and vasculitis, indicating a role for eNOS in modulating these renal lesions. Immune complex deposition was similar between groups, indicating the impact of eNOS is distal to antibody/complement glomerular deposition. Urinary nitric oxide production was decreased in the eNOS deficient mice, while proteinuria was increased. Urinary monocyte chemotactic protein-1 was also increased in the knockout mice. CD4+ T cells from MRL/lpr mice demonstrated mitochondrial hyperpolarization, increased nitric oxide and superoxide production and increased calcium flux compared to B6 control mice. Deficiency of eNOS resulted in decreased nitric oxide and mitochondrial calcium levels but had no effect on mitochondrial hyperpolarization. Renal cortices from MRL/lpr mice that are eNOS deficient demonstrated increased superoxide production, which was blocked by both nitric oxide synthase and NADPH oxidase inhibitors. These studies thus demonstrate a key role for eNOS in modulating renal disease in lupus prone MRL/lpr mice. The impact appears to be mediated by effects on superoxide production in the kidney, impacting downstream mediators such as monocyte chemotactic protein-1. These results suggest that modulation of eNOS may be a novel therapeutic approach to treating lupus nephritis.
C1 [Gilkeson, Gary S.; Mashmoushi, Ahmad K.; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA.
[Ruiz, Phillip] Univ Miami, Miller Sch Med, Dept Surg & Pathol, Transplant Labs & Immunopathol, Miami, FL 33136 USA.
[Caza, Tiffany N.; Perl, Andras] SUNY Upstate Med Univ, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA.
RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
EM oatesjc@musc.edu
OI Perl, Andras/0000-0002-5017-1348
FU Medical University of SC Clinical and Translational Science Award (NIH)
[UL1TR000062]; National Institutes of Health [R01-AR045476,
T32-GM008716, AI048079, AI072648]; Alliance for Lupus Research; Central
New York Community Foundation
FX This work was supported by the Medical University of SC Clinical and
Translational Science Award (NIH grant UL1TR000062) and National
Institutes of Health grant numbers R01-AR045476 and T32-GM008716. This
work was supported in part by grants AI048079 and AI072648 from the
National Institutes of Health, the Alliance for Lupus Research, and the
Central New York Community Foundation
(http://grants.nih.gov/grants/oer.htm). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 43
TC 9
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e64650
DI 10.1371/journal.pone.0064650
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900072
PM 23741359
ER
PT J
AU Sun, Q
Gao, WT
Loughran, P
Shapiro, R
Fan, J
Billiar, TR
Scott, MJ
AF Sun, Qian
Gao, Wentao
Loughran, Patricia
Shapiro, Rick
Fan, Jie
Billiar, Timothy R.
Scott, Melanie J.
TI Caspase 1 Activation Is Protective against Hepatocyte Cell Death by
Up-regulating Beclin 1 Protein and Mitochondrial Autophagy in the
Setting of Redox Stress
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HEMORRHAGIC-SHOCK; REPERFUSION INJURY; RAT HEPATOCYTES; NITRIC-OXIDE;
IN-VIVO; HYPOXIA; LIVER; DYSFUNCTION; MOUSE; INFLAMMATION
AB Caspase 1 activation can be induced by oxidative stress, which leads to the release of the proinflammatory cytokines IL1 beta and IL18 in myeloid cells and a potentially damaging inflammatory response. However, little is known about the role of caspase 1 in non-immune cells, such as hepatocytes, that express and activate the inflammasome but do not produce a significant amount of IL1 beta/IL18. Here we demonstrate that caspase 1 activation protects against cell death after redox stress induced by hypoxia/reoxygenation in hepatocytes. Mechanistically, we show that caspase 1 reduces mitochondrial respiration and reactive oxygen species by increasing mitochondrial autophagy and subsequent clearance of mitochondria in hepatocytes after hypoxia/reoxygenation. Caspase 1 increases autophagic flux through up-regulating autophagy initiator beclin 1 during redox stress and is an important cell survival factor in hepatocytes. We find that during hemorrhagic shock with resuscitation, an in vivo mouse model associated with severe hepatic redox stress, caspase 1 activation is also protective against liver injury and excessive oxidative stress through the up-regulation of beclin 1. Our findings suggest an alternative role for caspase 1 activation in promoting adaptive responses to oxidative stress and, more specifically, in limiting reactive oxygen species production and damage in cells and tissues where IL1 beta/IL18 are not highly expressed.
C1 [Sun, Qian; Gao, Wentao; Loughran, Patricia; Shapiro, Rick; Fan, Jie; Billiar, Timothy R.; Scott, Melanie J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Sun, Qian] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.
[Loughran, Patricia] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA.
[Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
RP Scott, MJ (reprint author), Univ Pittsburgh, Dept Surg, NW607 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.
EM scottm@upmc.edu
RI Sun, Qian/E-8130-2015
OI Sun, Qian/0000-0002-1121-5344
FU National Institutes of Health [R01-HL-079669, P50-GM053789]; Surgical
Infection Society
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01-HL-079669 (to J. F.) and P50-GM053789 (to T. R. B.).
This work was also supported by the Surgical Infection Society (to M.
S.).
NR 42
TC 26
Z9 26
U1 1
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 31
PY 2013
VL 288
IS 22
BP 15947
EP 15958
DI 10.1074/jbc.M112.426791
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 156LA
UT WOS:000319822300047
PM 23589298
ER
PT J
AU Bandyopadhyay, M
Kono, M
Rohrer, B
AF Bandyopadhyay, Mausumi
Kono, Masahiro
Rohrer, Baerbel
TI Explant cultures of Rpe65(-/-) mouse retina: a model to investigate cone
opsin trafficking
SO MOLECULAR VISION
LA English
DT Article
ID NEUROTROPHIN RECEPTOR TRKB; ORGAN-CULTURE; PHARMACOLOGICAL MANIPULATION;
TEMPORAL EXPRESSION; 9-CIS-RETINOIC ACID; INVERSE AGONISTS; CELL-DEATH;
RD MOUSE; RHODOPSIN; PHOTORECEPTOR
AB Purpose: In the absence of 11-cis retinal (e.g., Rpe65(-/-)), the chromophore for all pigments, cone opsins are mislocalized in vivo. Using the systemic application of 11-cis retinal, appropriate protein localization can be promoted. Here, we asked whether explant cultures of Rpe65(-/-) mouse retina are amenable to screening retinoids for their ability to promote opsin trafficking.
Methods: Retina-retinal pigment epithelium (RPE) cultures were prepared from 7-day-old Rpe65(-/-) Rho(-/-) or wild-type pups and cultured for 11 days. Explants were treated with retinoids throughout this period. Ultraviolet (UV)-opsin trafficking was analyzed by immunohistochemistry and quantitative image analysis, while its messenger RNA expression was examined by quantitative real-time PCR, and the interaction of retinoids with UV-opsin was probed in transducing-activation assays.
Results: In wild-type explant cultures, UV-opsin was restricted to the outer segments, whereas in those derived from Rpe65(-/-) Rho(-/-) mice, opsin trafficking was impaired. In Rpe65(-/-) Rho(-/-) explants, administration of 11-cis retinal, 11-cis retinol or retinoic acid (RA) reversed the opsin trafficking phenotype. RA analogs designed to act by binding to the retinoic acid receptor or the retinoid X-receptor, however, had no effect. RA was shown to interact with the UV-cone opsin, demonstrated by its ability to effect ligand-dependent activation of transducin by UV-cone opsin. All compounds tested increased cone opsin messenger RNA expression.
Conclusions: Cone-opsin trafficking defects were replicated in Rpe65(-/-) Rho(-/-) retina-RPE cultures, and were reversed by 11-cis retinal treatment. Comparing the effects of different retinoids on their ability to promote UV-opsin trafficking to outer segments confirmed the critical role of agents that bind in the retinoid binding pocket. Retinoids that act as transcription factors, however, were ineffective. Thus, organ cultures may be a powerful low-throughput screening tool to identify novel compounds to promote cone survival.
C1 [Bandyopadhyay, Mausumi; Kono, Masahiro; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health from the Extramural Research Facilities
Program of the National Center for Research Resources [C06 RR015455];
National Institutes of Health [R01EY04939, R01EY019515]; Hope for
Vision, Washington, DC; Research to Prevent Blindness (RPB), Inc., New
York, NY
FX We thank Dr. Rosalie Crouch for helpful discussions, Patrice Goletz for
expert assistance on the transducin assays and Dr. Luanna Bartholomew
for critical review. The animal studies were conducted in a facility
constructed with support from the National Institutes of Health through
a grant (C06 RR015455) from the Extramural Research Facilities Program
of the National Center for Research Resources. This work was supported
in part by the National Institutes of Health (R01EY04939, BR and
R01EY019515, MK); Hope for Vision, Washington, DC (BR); and an
unrestricted grant to MUSC from Research to Prevent Blindness (RPB),
Inc., New York, NY. BR is a RPB Olga Keith Wiess Scholar.
NR 53
TC 3
Z9 3
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 29
PY 2013
VL 19
BP 1149
EP 1157
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 158QW
UT WOS:000319988400006
PM 23734084
ER
PT J
AU Hoy, JL
Haeger, PA
Constable, JRL
Arias, RJ
McCallum, R
Kyweriga, M
Davis, L
Schnell, E
Wehr, M
Castillo, PE
Washbourne, P
AF Hoy, Jennifer L.
Haeger, Paola A.
Constable, John R. L.
Arias, Renee J.
McCallum, Raluca
Kyweriga, Michael
Davis, Lawrence
Schnell, Eric
Wehr, Michael
Castillo, Pablo E.
Washbourne, Philip
TI Neuroligin1 Drives Synaptic and Behavioral Maturation through
Intracellular Interactions
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MORRIS WATER MAZE; AUTISM SPECTRUM DISORDERS; D-ASPARTATE RECEPTORS;
NMDA RECEPTORS; GLUTAMATERGIC SYNAPSES; INHIBITORY SYNAPSES; OBJECT
RECOGNITION; BURST STIMULATION; MOUSE MODEL; MICE
AB In vitro studies suggest that the intracellular C terminus of Neuroligin1 (NL1) could play a central role in the maturation of excitatory synapses. However, it is unknown how this activity affects synapses in vivo, and whether it may impact the development of complex behaviors. To determine how NL1 influences the state of glutamatergic synapses in vivo, we compared the synaptic and behavioral phenotypes of mice overexpressing a full-length version of NL1 (NL1FL) with mice overexpressing a version missing part of the intracellular domain (NL1 Delta C). We show that overexpression of full-length NL1 yielded an increase in the proportion of synapses with mature characteristics and impaired learning and flexibility. In contrast, the overexpression of NL1 Delta C increased the number of excitatory postsynaptic structures and led to enhanced flexibility in mnemonic and social behaviors. Transient overexpression of NL1FL revealed that elevated levels are not necessary to maintain synaptic and behavioral states altered earlier in development. In contrast, overexpression of NL1FL in the fully mature adult was able to impair normal learning behavior after 1 month of expression. These results provide the first evidence that NL1 significantly impacts key developmental processes that permanently shape circuit function and behavior, as well as the function of fully developed neural circuits. Overall, these manipulations of NL1 function illuminate the significance of NL1 intracellular signaling in vivo, and enhance our understanding of the factors that gate the maturation of glutamatergic synapses and complex behavior. This has significant implications for our ability to address disorders such as autism spectrum disorders.
C1 [Hoy, Jennifer L.; Constable, John R. L.; Arias, Renee J.; McCallum, Raluca; Kyweriga, Michael; Wehr, Michael; Washbourne, Philip] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
[Haeger, Paola A.; Castillo, Pablo E.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.
[Schnell, Eric] Portland VA Med Ctr, Portland, OR 97239 USA.
[Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Davis, Lawrence] Univ Oregon, Dept Phys, Eugene, OR 97403 USA.
RP Washbourne, P (reprint author), 1254 Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
EM pwash@uoneuro.uoregon.edu
RI Kyweriga, Michael/H-3226-2013
OI Kyweriga, Michael/0000-0003-3511-6292; Schnell, Eric/0000-0002-5623-5015
FU National Institute of Neurological Disorders and Stroke [R01 NS065795];
Autism Speaks [1368]; National Institute of Mental Health [R01
MH081935]; American Psychological Association [DPN T32 MH18882-22];
National Science Foundation [GK-12]; Oregon Center for Optics;
Biomedical Sciences Chile; Becas Chile
FX This work was supported by National Institute of Neurological Disorders
and Stroke R01 NS065795 and Autism Speaks 1368 to P.W., by National
Institute of Mental Health R01 MH081935 to P.E.C., the American
Psychological Association DPN T32 MH18882-22 to J.L.H, National Science
Foundation GK-12 program to L.D., and the Oregon Center for Optics to
J.L.H. and L.D.P.A.H. is a PEW Latin American Fellow in the Biomedical
Sciences and Becas Chile recipient. We thank Keith Beadle for
establishing the immunolabeling technique in thinly sectioned brain
tissue; Sheryl Moy (University of North Carolina) for excellent guidance
in conducting the appropriate behavioral tests and initial
characterization of our transgenic mice, and providing critical feedback
on this manuscript; Cris Niell and Victoria Herman for providing
comments on previous versions of this manuscript; Gary Westbrook (OHSU)
for generously providing his lab's reagents and support; Miriam Deutsch
(University of Oregon Physics Department) for providing lab support for
extended data analysis techniques; Shawn Brown and Sebastien Valverde
for technical assistance in preparation of synaptosomal fractions and
Western blot generation; and Sebastien Valverde and Leah Deblander for
additional assistance in training mice in the water maze and social
tasks.
NR 77
TC 5
Z9 5
U1 0
U2 10
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 29
PY 2013
VL 33
IS 22
BP 9364
EP 9384
DI 10.1523/JNEUROSCI.4660-12.2013
PG 21
WC Neurosciences
SC Neurosciences & Neurology
GA 152XV
UT WOS:000319566300014
PM 23719805
ER
PT J
AU Guyenet, SJ
Nguyen, HT
Hwang, BH
Schwartz, MW
Baskin, DG
Thaler, JP
AF Guyenet, Stephan J.
Nguyen, Hong T.
Hwang, Bang H.
Schwartz, Michael W.
Baskin, Denis G.
Thaler, Joshua P.
TI High-fat diet feeding causes rapid, non-apoptotic cleavage of caspase-3
in astrocytes
SO BRAIN RESEARCH
LA English
DT Article
DE Glia; Astrocytes; Apoptosis; Obesity; Neuron injury; Hypothalamus
ID POSTNATAL EXCITOTOXIC DAMAGE; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC
BRAIN-INJURY; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; CELL-DEATH;
KAPPA-B; ACTIVATION; OBESITY; MICE
AB Astrocytes respond to multiple forms of central nervous system (CNS) injury by entering a reactive state characterized by morphological changes and a specific pattern of altered protein expression. Termed astrogliosis, this response has been shown to strongly influence the injury response and functional recovery of CNS tissues. This pattern of CNS inflammation and injury associated with astrogliosis has recently been found to occur in the energy homeostasis centers of the hypothalamus during diet-induced obesity (DIO) in rodent models, but the characterization of the astrocyte response remains incomplete. Here, we report that astrocytes in the mediobasal hypothalamus respond robustly and rapidly to purified high-fat diet (HFD) feeding by cleaving caspase-3, a protease whose cleavage is often associated with apoptosis. Although obesity develops in HFD-fed rats by day 14, caspase-3 cleavage occurs by day 3, prior to the development of obesity, suggesting the possibility that it could play a causal role in the hypothalamic neuropathology and fat gain observed in DIO. Caspase-3 cleavage is not associated with an increase in the rate of apoptosis, as determined by TUNEL staining, suggesting it plays a non-apoptotic role analogous to the response to excitotoxic neuron injury. Our results indicate that astrocytes in the mediobasal hypothalamus respond rapidly and robustly to HFD feeding, activating caspase-3 in the absence of apoptosis, a process that has the potential to influence the course of DIO. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.] Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, Seattle, WA 98109 USA.
[Hwang, Bang H.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev, Seattle, WA 98108 USA.
RP Thaler, JP (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, 850 Republican St,Box 358055, Seattle, WA 98109 USA.
EM guyenet@uw.edu; hongtng@uw.edu; bhhwang@uw.edu; mschwart@uw.edu;
baskindg@uw.edu; jpthaler@uw.edu
FU National Institutes of Health (NIH) [T32DK007247, F32DK091989, DK088872,
DK017047, P30DK017047, DK068384, DK083042, DK052989]; Department of
Veterans Affairs Senior Research Career Scientist Award at the Veterans
Affairs Puget Sound Health Care System; Biomedical Research Core
Programs Cellular and Molecular Imaging Core of the University of
Washington NIH/NIDDK Diabetes Research Center
FX This work was supported by a National Institutes of Health (NIH)
Fellowship Training Program Award (T32DK007247), an NIH National
Research Service Award (F32DK091989) to S.G., an NIH Career Development
Award (DK088872), an NIH-funded Diabetes Research Center Pilot and
Feasibility award (DK017047) to J.T., the NIH-funded University of
Washington Nutrition Obesity Research Center and Diabetes Research
Center (Grant P30DK017047 to D.B.), and NIH Grants DK068384, DK083042,
and DK052989 to M.S.; This work was also supported by resources from the
Office of Research and Development, Medical Research Service, Department
of Veterans Affairs, including the Merit Review Research Program and the
Research Enhancement Award Program. D.B. is the recipient of a
Department of Veterans Affairs Senior Research Career Scientist Award at
the Veterans Affairs Puget Sound Health Care System. Additional support
came from the Biomedical Research Core Programs Cellular and Molecular
Imaging Core of the University of Washington NIH/NIDDK Diabetes Research
Center.
NR 36
TC 11
Z9 12
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 28
PY 2013
VL 1512
BP 97
EP 105
DI 10.1016/j.brainres.2013.03.033
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 160AG
UT WOS:000320087800010
PM 23548599
ER
PT J
AU Hirata, H
Ueno, K
Nakajima, K
Tabatabai, ZL
Hinoda, Y
Ishii, N
Dahiya, R
AF Hirata, H.
Ueno, K.
Nakajima, K.
Tabatabai, Z. L.
Hinoda, Y.
Ishii, N.
Dahiya, R.
TI Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in
renal cancer cells
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Genistein; miR-1260b; RCC; Dkk2; sFRP1; Smad4; real-time RT-PCR; MTS
assay; invasion assay; apoptosis; FACS; western blot; 3 ' UTR luciferase
assay; TOPflash
ID BETA-CATENIN; TUMOR-SUPPRESSOR; CARCINOMA; THERAPY; EXPRESSION;
DIAGNOSIS
AB Background: Wnt-signalling has an important role in renal cancer and it is modulated by genistein in other cancers. Recently, microRNAs (miRNAs) have emerged as new regulators of gene expression. Thus, we focused on miRNAs to examine the regulatory mechanism of genistein on the Wnt-signalling pathway in renal cell carcinoma (RCC).
Methods: Initially, we investigated the effect of genistein on Wnt-signalling (TOPflash reporter assay (TCF reporter assays)) in renal cancer cells, and using microarray identified candidate miRNAs whose expression was decreased by genistein. We performed functional analyses and investigated the relationship between miRNA expression and renal cancer patient outcomes. We also did 3'UTR luciferase assays to look at direct miRNA regulation of Wnt-signalling-related genes.
Results: Genistein promoted apoptosis while inhibiting RCC cell proliferation and invasion. Genistein also decreased TCF reporter activity in RCC cells. We found that miR-1260b was highly expressed and significantly downregulated by genistein in RCC cells. The expression of miR-1260b was significantly higher in renal cancer tissues compared with normal, and significantly related to overall shorter survival. In addition, miR-1260b promoted renal cancer cell proliferation and invasion in RCC cells. The 3'UTR luciferase activity of target genes (sFRP1, Dkk2, Smad4) was significantly decreased and their protein expression significantly upregulated in miR-1260b inhibitor-transfected renal cancer cells.
Conclusion: Our data suggest that genistein inhibited Wnt-signalling by regulating miR-1260b expression in renal cancer cells.
C1 [Hirata, H.; Ueno, K.; Dahiya, R.] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Hirata, H.; Ueno, K.; Tabatabai, Z. L.; Dahiya, R.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Nakajima, K.; Ishii, N.] Toho Univ, Fac Med, Dept Urol, Tokyo, Japan.
[Tabatabai, Z. L.] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Hinoda, Y.] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123]; VA Merit
Review; VA Program Project; Yamada Science Foundation
FX We thank Dr Roger Erickson for his support and assistance with the
preparation of the manuscript. This study was supported by National
Center for Research Resources of the National Institutes of Health
through Grant Number RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123,
VA Merit Review, VA Program Project (PI: R Dahiya) and Yamada Science
Foundation.
NR 26
TC 31
Z9 34
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 28
PY 2013
VL 108
IS 10
BP 2070
EP 2078
DI 10.1038/bjc.2013.173
PG 9
WC Oncology
SC Oncology
GA 152WE
UT WOS:000319561300021
PM 23591200
ER
PT J
AU Walter, LC
Fung, KZ
Kirby, KA
Shi, Y
Espaldon, R
O'Brien, S
Freedland, SJ
Powell, AA
Hoffman, RM
AF Walter, Louise C.
Fung, Kathy Z.
Kirby, Katharine A.
Shi, Ying
Espaldon, Roxanne
O'Brien, Sarah
Freedland, Stephen J.
Powell, Adam A.
Hoffman, Richard M.
TI Five-Year Downstream Outcomes Following Prostate-Specific Antigen
Screening in Older Men
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SERVICES TASK-FORCE; UNITED-STATES; RADICAL PROSTATECTOMY; CANCER
MORTALITY; RANDOMIZED-TRIAL; MEDICARE; RECOMMENDATION; POPULATION;
BIOPSY; LUNG
AB Importance: Despite ongoing controversies surrounding prostate-specific antigen (PSA) screening, many men 65 years or older undergo screening. However, few data exist that quantify the chain of events following screening in clinical practice to better inform decisions.
Objective: To quantify 5-year downstream outcomes following a PSA screening result exceeding 4.0 ng/mL in older men.
Design and Setting: Longitudinal cohort study in the national Veterans Affairs health care system.
Participants: In total, 295 645 men 65 years or older who underwent PSA screening in the Veterans Affairs health care system in 2003 and were followed up for 5 years using national Veterans Affairs and Medicare data.
Main Outcome Measures: Among men whose index screening PSA level exceeded 4.0 ng/mL, we determined the number who underwent prostate biopsy, were diagnosed as having prostate cancer, were treated for prostate cancer, and were treated for prostate cancer and were alive at 5 years according to baseline characteristics. Biopsy and treatment complications were also assessed.
Results: In total, 25 208 men (8.5%) had an index PSA level exceeding 4.0 ng/mL. During the 5-year follow-up period, 8313 men (33.0%) underwent at least 1 prostate biopsy, and 5220 men (62.8%) who underwent prostate biopsy were diagnosed as having prostate cancer, of whom 4284 (82.1%) were treated for prostate cancer. Performance of prostate biopsy decreased with advancing age and worsening comorbidity (P < .001), whereas the percentage treated for biopsy-detected cancer exceeded 75% even among men 85 years or older, those with a Charlson-Deyo Comorbidity Index of 3 or higher, and those having low-risk cancer. Among men with biopsy-detected cancer, the risk of death from non-prostate cancer causes increased with advancing age and worsening comorbidity (P < .001). In total, 468 men (5.6%) had complications within 7 days after prostate biopsy. Complications of prostate cancer treatment included new urinary incontinence in 584 men (13.6%) and new erectile dysfunction 588 men (13.7%).
Conclusions and Relevance: Performance of prostate biopsy is uncommon in older men with abnormal screening PSA levels and decreases with advancing age and worsening comorbidity. However, once cancer is detected on biopsy, most men undergo immediate treatment regardless of advancing age, worsening comorbidity, or low-risk cancer. Understanding downstream outcomes in clinical practice should better inform individualized decisions among older men considering PSA screening.
C1 [Walter, Louise C.; Fung, Kathy Z.; Kirby, Katharine A.; Shi, Ying; Espaldon, Roxanne; O'Brien, Sarah] San Francisco Vet Affairs VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Walter, Louise C.; Fung, Kathy Z.; Kirby, Katharine A.; Shi, Ying; Espaldon, Roxanne; O'Brien, Sarah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Freedland, Stephen J.] Duke Univ, Durham VA Med Ctr, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Duke Prostate Ctr, Durham, NC USA.
[Powell, Adam A.] Univ Minnesota, Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Powell, Adam A.] Univ Minnesota, Dept Med, Minneapolis, MN USA.
[Hoffman, Richard M.] Univ New Mexico, New Mexico VA Hlth Care Syst, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA.
RP Walter, LC (reprint author), San Francisco VA Med Ctr, Div Geriatr, Mail Code 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM Louise.Walter@ucsf.edu
FU National Cancer Institute at the National Institutes of Health [R01
CA134425]; National Institute on Aging at the National Institutes of
Health [K24AG041180]; Veterans Affairs Career Development Award Program
[CDA 08-024]; New Mexico Veterans Affairs Health Care System
FX This work was supported by grant R01 CA134425 from the National Cancer
Institute at the National Institutes of Health (Drs Walter, Freedland,
Powell, and Hoffman), by grant K24AG041180 from the National Institute
on Aging at the National Institutes of Health (Dr Walter), by grant CDA
08-024 from the Veterans Affairs Career Development Award Program (Dr
Powell), and by the New Mexico Veterans Affairs Health Care System (Dr
Hoffman).
NR 49
TC 12
Z9 15
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 27
PY 2013
VL 173
IS 10
BP 866
EP 873
DI 10.1001/jamainternmed.2013.323
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159KR
UT WOS:000320044800007
PM 23588999
ER
PT J
AU Liang, ST
Cuevas, G
Tizani, S
Salas, T
Liu, HJ
Li, BJ
Habib, SL
AF Liang, Sitai
Cuevas, Gabriela
Tizani, Shaza
Salas, Tiffanie
Liu, Huijuan
Li, Baojie
Habib, Samy L.
TI Novel mechanism of regulation of fibrosis in kidney tumor with tuberous
sclerosis
SO MOLECULAR CANCER
LA English
DT Article
DE Angiomyolipoma; Fibrosis; alpha-SMA; YY1 and TSC
ID REPAIR ENZYME OGG1; TSC2 GAP ACTIVITY; 3-KINASE/AKT PATHWAY; COMPLEX;
GENE; ANGIOMYOLIPOMAS; EXPRESSION; RAT; LYMPHANGIOLEIOMYOMATOSIS;
PHOSPHORYLATION
AB Background: Deficiency in tuberin results in activation the mTOR pathway and leads to accumulation of cell matrix proteins. The mechanisms by which tuberin regulates fibrosis in kidney angiomyolipomas (AMLs) of tuberous sclerosis patients are not fully known.
Method: In the present study, we investigated the potential role of tuberin/mTOR pathway in the regulation of cell fibrosis in AML cells and kidney tumor tissue from tuberous sclerosis complex (TSC) patients.
Results: AML cells treated with rapamycin shows a significant decrease in mRNA and protein expression as well as in promoter transcriptional activity of alpha-smooth muscle actin (alpha-SMA) compared to untreated cells. In addition, cells treated with rapamycin significantly decreased the protein expression of the transcription factor YY1. Rapamycin treatment also results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells. Moreover, cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the alpha SMA promoter element in nuclear extracts of AML cells. Kidney angiomyolipoma tissues from TSC patients showed lower levels of tuberin and higher levels of phospho-p70S6K that resulted in higher levels of mRNA and protein of alpha SMA expression compared to control kidney tissues. In addition, most of the alpha-SMA staining was identified in the smooth muscle cells of AML tissues. YY1 was also significantly increased in tumor tissue of AMLs compared to control kidney tissue suggesting that YY1 plays a major role in the regulation of alpha SMA.
Conclusions: These data comprise the first report to provide one mechanism whereby rapamycin might inhibit the cell fibrosis in kidney tumor of TSC patients.
C1 [Habib, Samy L.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA.
[Liu, Huijuan; Li, Baojie] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
[Liang, Sitai; Cuevas, Gabriela; Tizani, Shaza; Salas, Tiffanie; Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
RP Habib, SL (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA.
EM habib@uthscsa.edu
FU American Heart Association; American Diabetes Association; Merit Review
Award from South Texas Veterans Healthcare System
FX This work was supported in part by grants from the American Heart
Association, American Diabetes Association and Merit Review Award from
South Texas Veterans Healthcare System (to S.L.H.).
NR 30
TC 2
Z9 2
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 25
PY 2013
VL 12
AR 49
DI 10.1186/1476-4598-12-49
PG 11
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 163IG
UT WOS:000320328900001
PM 23705901
ER
PT J
AU Teerlink, JR
Metra, M
AF Teerlink, John R.
Metra, Marco
CA RELAX-AHF Investigators
TI Not time to RELAX in acute heart failure Reply
SO LANCET
LA English
DT Letter
ID SERELAXIN; TRIAL; AHF
C1 [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 25
PY 2013
VL 381
IS 9880
BP 1813
EP 1814
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 151EO
UT WOS:000319443700021
PM 23706796
ER
PT J
AU Kampa-Schittenhelm, KM
Heinrich, MC
Akmut, F
Rasp, KH
Illing, B
Dohner, H
Dohner, K
Schittenhelm, MM
AF Kampa-Schittenhelm, Kerstin Maria
Heinrich, Michael Charles
Akmut, Figen
Rasp, Katharina Henriette
Illing, Barbara
Doehner, Hartmut
Doehner, Konstanze
Schittenhelm, Marcus Matthias
TI Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor
NVP-BGT226 in acute leukemia
SO MOLECULAR CANCER
LA English
DT Article
DE Leukemia; PI3K; AKT; NVP-BEZ235; NVP-BGT226
ID ACUTE MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; ACUTE
LYMPHOBLASTIC-LEUKEMIA; C-KIT; TYROSINE KINASE; PATHWAY ACTIVATION;
THERAPEUTIC TARGET; MAMMALIAN TARGET; ADULT PATIENTS; CANCER CELLS
AB Background: Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT pathway are uncommon. In some cases, constitutive AKT activation can be linked to gain-of-function tyrosine kinase (TK) mutations upstream of the PI3K/AKT pathway. Inhibitors of the PI3K/AKT pathway are attractive candidates for cancer drug development, but so far clinical efficacy of PI3K inhibitors against various neoplasms has been moderate. Furthermore, specific MTORC1 inhibitors, acting downstream of AKT, have the disadvantage of activating AKT via feed-back mechanisms. We now evaluated the antitumor efficacy of NVP-BGT226, a novel dual pan-PI3K and MTORC1/2 inhibitor, in acute leukemia.
Methods: Native leukemia blasts were stained to analyze for AKT phosphorylation levels on a flow cytometer. Efficacy of NVP-BGT226 in comparison to a second dual inhibitor, NVP-BEZ235, was determined with regard to cellular proliferation, autophagy, cell cycle regulation and induction of apoptosis in in vitro and ex vivo cellular assays as well as on the protein level. An isogenic AKT-autoactivated Ba/F3 model, different human leukemia cell lines as well as native leukemia patient blasts were studied. Isobologram analyses were set up to calculate for (super) additive or antagonistic effects of two agents.
Results: We show, that phosphorylation of AKT is frequently augmented in acute leukemia. NVP-BGT226 as well as NVP-BEZ235 profoundly and globally suppress AKT signaling pathways, which translates into potent antiproliferative effects. Furthermore, NVP-BGT226 has potent proapoptotic effects in vitro as well as in ex vivo native blasts. Surprisingly and in contrast, NVP-BEZ235 leads to a profound G1/G0 arrest preventing significant induction of apoptosis. Combination with TK inhibitors, which are currently been tested in the treatment of acute leukemia subtypes, overcomes cell cycle arrest and results in (super) additive proapoptotic effects for NVP-BGT226 - but also for NVP-BEZ235. Importantly, mononuclear donor cells show lower phospho-AKT expression levels and consequently, relative insensitivity towards dual PI3K-MTORC1/2 inhibition.
Conclusions: Our data suggest a favorable antileukemic profile for NVP-BGT226 compared to NVP-BEZ235 - which provides a strong rationale for clinical evaluation of the dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
C1 [Kampa-Schittenhelm, Kerstin Maria; Akmut, Figen; Rasp, Katharina Henriette; Illing, Barbara; Schittenhelm, Marcus Matthias] Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, D-72076 Tubingen, Germany.
[Heinrich, Michael Charles] Portland VA Med Ctr, Portland, OR USA.
[Heinrich, Michael Charles] OHSU Knight Canc Inst, Portland, OR USA.
[Doehner, Hartmut; Doehner, Konstanze] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.
RP Schittenhelm, MM (reprint author), Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Otfried Muller Str 10, D-72076 Tubingen, Germany.
EM marcus.schittenhelm@med.uni-tuebingen.de
FU Deutsche Forschungsgemeinschaft; University of Tubingen; Deutsche
Krebshilfe Foundation; fortune-Program of the Tubingen Medical Faculty
[1490-0-0, 11836-0-0]; IZKF Program of the Medical Faculty Tubingen;
Jose Carreras Scholarship Program; Ludwig Hiermaier Foundation of the
Comprehensive Cancer Center Tubingen; Department of Veterans Affairs;
Leukemia and Lymphoma Society; GIST Cancer Research Fund; Life Raft
Group
FX We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publishing Fund of the University of Tubingen.; In part by the
Deutsche Krebshilfe Foundation (MMS, KKS), the fortune-Program of the
Tubingen Medical Faculty (Nr. 1490-0-0, MMS and 11836-0-0, KMK), the
IZKF Program of the Medical Faculty Tubingen (MMS) and the Jose Carreras
Scholarship Program (KKS), the Ludwig Hiermaier Foundation of the
Comprehensive Cancer Center Tubingen (MMS), a Merit Review Grant from
the Department of Veterans Affairs (MCH) and a grant from the Leukemia
and Lymphoma Society (MCH), GIST Cancer Research Fund (MCH) and the Life
Raft Group (MCH).
NR 56
TC 21
Z9 22
U1 1
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 24
PY 2013
VL 12
AR 46
DI 10.1186/1476-4598-12-46
PG 18
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 168SA
UT WOS:000320724800001
PM 23705826
ER
PT J
AU Gardiner, D
Lalezari, J
Lawitz, E
DiMicco, M
Ghalib, R
Reddy, KR
Chang, KM
Sulkowski, M
O' Marro, S
Anderson, J
He, B
Kansra, V
McPhee, F
Wind-Rotolo, M
Grasela, D
Selby, M
Korman, AJ
Lowy, I
AF Gardiner, David
Lalezari, Jay
Lawitz, Eric
DiMicco, Michael
Ghalib, Rheem
Reddy, K. Rajender
Chang, Kyong-Mi
Sulkowski, Mark
O' Marro, Steven
Anderson, Jeffrey
He, Bing
Kansra, Vikram
McPhee, Fiona
Wind-Rotolo, Megan
Grasela, Dennis
Selby, Mark
Korman, Alan J.
Lowy, Israel
TI A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558,
a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in
Patients with Chronic Hepatitis C Virus Infection
SO PLOS ONE
LA English
DT Article
ID T-CELL EXHAUSTION; CHRONIC VIRAL-INFECTION; IMMUNE-RESPONSES; FUNCTIONAL
RESTORATION; UP-REGULATION; PHASE-I; B-VIRUS; BLOCKADE; EXPRESSION;
SAFETY
AB Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of several chronic viral infections, including human hepatitis C virus (HCV). The antiviral potential of BMS-936558 (MDX-1106) - a fully human anti-PD-1 monoclonal immunoglobulin-G4 that blocks ligand binding - was explored in a proof-of-concept, placebo-controlled single-ascending-dose study in patients (N = 54) with chronic HCV infection. Interferon-alfa treatment-experienced patients (n = 42) were randomized 5:1 to receive a single infusion of BMS-936558 (0.03, 0.1, 0.3, 1.0, 3.0 mg/kg [n = 5 each] or 10 mg/kg [n = 10]) or of placebo (n = 7). An additional 12 HCV treatment naive patients were randomized to receive 10 mg/kg BMS-936558 (n = 10) or placebo (n = 2). Patients were followed for 85 days post-dose. Five patients who received BMS-936558 (0.1 [n = 1] or 10 mg/kg) and one placebo patient achieved the primary study endpoint of a reduction in HCV RNA >= 0.5 log(10) IU/mL on at least 2 consecutive visits; 3 (10 mg/kg) achieved a >4 log(10) reduction. Two patients (10 mg/kg) achieved HCV RNA below the lower limit of quantitation (25 IU/mL), one of whom (a prior null-responder) remained RNA-undetectable 1 year post-study. Transient reductions in CD4(+), CD8(+) and CD19(+) cells, including both naive and memory CD4(+) and CD8(+) subsets, were observed at Day 2 without evidence of immune deficit. No clinically relevant changes in immunoglobulin subsets or treatment-related trends in circulating cytokines were noted. BMS-936558 exhibited dose-related exposure increases, with a half-life of 20-24 days. BMS-936558 was mostly well tolerated. One patient (10 mg/kg) experienced an asymptomatic grade 4 ALT elevation coincident with the onset of a 4-log viral load reduction. Six patients exhibited immune-related adverse events of mild-to-moderate intensity, including two cases of hyperthyroidism consistent with autoimmune thyroiditis. Further investigation of PD-1 pathway blockade in chronic viral disease is warranted.
C1 [Gardiner, David; Anderson, Jeffrey; He, Bing; Grasela, Dennis] Bristol Myers Squibb Co, Pennington, NJ USA.
[Lalezari, Jay] Quest Clin Res, San Francisco, CA USA.
[Lawitz, Eric] Alamo Med Res, San Antonio, TX USA.
[DiMicco, Michael] Adv Clin Res Inst, Anaheim, CA USA.
[Ghalib, Rheem] Methodist Hosp, Liver Inst, Dallas, TX USA.
[Reddy, K. Rajender; Chang, Kyong-Mi] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Chang, Kyong-Mi] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Sulkowski, Mark] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[O' Marro, Steven] Springfield Clin Infect Dis, Springfield, IL USA.
[Kansra, Vikram; Wind-Rotolo, Megan] Bristol Myers Squibb Co, Princeton, NJ USA.
[McPhee, Fiona] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Selby, Mark; Korman, Alan J.] Bristol Myers Squibb Co, Milpitas, CA USA.
[Lowy, Israel] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
RP Gardiner, D (reprint author), Bristol Myers Squibb Co, Pennington, NJ USA.
EM david.gardiner@bms.com
FU Bristol-Myers Squibb
FX This study was wholly funded by Medarex, now Bristol-Myers Squibb. The
funders, Medarex (now BMS), had a primary role in study design, in
collaboration with clinical investigators and health authorities. In
addition, Medarex had a primary role in the data collection and
analysis, decision to publish, and publication of the manuscript.
NR 50
TC 54
Z9 58
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e63818
DI 10.1371/journal.pone.0063818
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700065
PM 23717490
ER
PT J
AU Thompson, G
Wang, SR
Bercovitch, R
Bolaris, M
Van Den Akker, D
Taylor, S
Lopez, R
Catanzaro, A
Cadena, J
Chin-Hong, P
Spellberg, B
AF Thompson, George, III
Wang, Sharon
Bercovitch, Robert
Bolaris, Michael
Van Den Akker, Dane
Taylor, Sandra
Lopez, Rodrigo
Catanzaro, Antonio
Cadena, Jose
Chin-Hong, Peter
Spellberg, Brad
TI Routine CSF Analysis in Coccidioidomycosis Is Not Required
SO PLOS ONE
LA English
DT Article
ID MENINGITIS; PULMONARY; THERAPY; DISEASE
AB Although routinely done, there has been no evaluation of the utility of performing routine cerebrospinal fluid (CSF) examination in patients with active coccidioidomycosis and high complement fixation (IgG) antibody titers or other risk factors for disseminated infection. In our review 100% of patients diagnosed with coccidioidal meningitis had at least one sign or symptom consistent with infection of the central nervous system, headache was present in 100% of those with meningitis, while no patients without signs/symptoms of CNS infection were found to have coccidioidal meningitis, irrespective of antibody titers or other risk factors. Thus routine lumbar puncture may be unnecessary for patients with coccidioidomycosis who lack suggestive clinical symptoms.
C1 [Thompson, George, III] Univ Calif Davis, Dept Med Microbiol & Immunol, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
[Thompson, George, III; Wang, Sharon] Univ Calif Davis, Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA.
[Bercovitch, Robert; Catanzaro, Antonio] Univ Calif San Diego, Dept Internal Med, Div Pulm & Crit Care Med, San Diego, CA 92103 USA.
[Bolaris, Michael] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Pediat Infect Dis, Torrance, CA 90509 USA.
[Van Den Akker, Dane; Spellberg, Brad] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Gen Internal Med, Torrance, CA 90509 USA.
[Taylor, Sandra] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA.
[Lopez, Rodrigo; Cadena, Jose] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Cadena, Jose] South Texas Vet Hlth Care Syst, Dept Internal Med, San Antonio, TX USA.
[Chin-Hong, Peter] Univ Calif San Francisco, Dept Interal Med, Div Infect Dis, San Francisco, CA 94143 USA.
[Spellberg, Brad] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Thompson, G (reprint author), Univ Calif Davis, Dept Med Microbiol & Immunol, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
EM grthompson@ucdavis.edu; bspellberg@LABioMed.org
FU Pfizer; National Center for Advancing Translational Sciences (NCATS),
National Institutes of Health (NIH) [UL1 TR000002]
FX Funding for this study was generously provided by Pfizer. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; We wish to thank Stuart
Cohen MD for helpful comments during the writing of this manuscript and
we thank the research staff at each of the sites for invaluable
assistance. "The project described was supported by the National Center
for Advancing Translational Sciences (NCATS), National Institutes of
Health (NIH), through grant #UL1 TR000002.''
NR 15
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e64249
DI 10.1371/journal.pone.0064249
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700124
PM 23717579
ER
PT J
AU Gandy, S
Heppner, FL
AF Gandy, Sam
Heppner, Frank L.
TI Microglia as Dynamic and Essential Components of the Amyloid Hypothesis
SO NEURON
LA English
DT Editorial Material
ID ONSET ALZHEIMERS-DISEASE; PATHOLOGY; VARIANTS; MICE
C1 [Gandy, Sam] Icahn Sch Med, New York, NY 10029 USA.
[Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10029 USA.
[Heppner, Frank L.] Charite, Dept Neuropathol, D-10117 Berlin, Germany.
RP Gandy, S (reprint author), Icahn Sch Med, New York, NY 10029 USA.
EM samuel.gandy@mssm.edu; frank.heppner@charite.de
FU NIA NIH HHS [P50 AG005138, R34 AG049649, U01 AG046170]
NR 15
TC 28
Z9 28
U1 1
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD MAY 22
PY 2013
VL 78
IS 4
BP 575
EP 577
DI 10.1016/j.neuron.2013.05.007
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA 151WN
UT WOS:000319491200001
PM 23719156
ER
PT J
AU Marcum, ZA
Sevick, MA
Handler, SM
AF Marcum, Zachary A.
Sevick, Mary Ann
Handler, Steven M.
TI Medication Nonadherence A Diagnosable and Treatable Medical Condition
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID ADHERENCE
C1 [Marcum, Zachary A.; Handler, Steven M.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 5th Ave,Ste 500, Pittsburgh, PA 15213 USA.
EM zam12@pitt.edu
OI Handler, Steven/0000-0002-3940-3224
FU AHRQ HHS [R01HS018721, R01 HS018721]; NIA NIH HHS [P30 AG024827, K07
AG033174, K07AG033174, P30AG024827]; NIDDK NIH HHS [R01-DK100492, R01
DK100492]; NINR NIH HHS [R01 NR010135, K24 NR012226, 2R01-NR010135,
K24-NR012226]
NR 7
TC 43
Z9 43
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 22
PY 2013
VL 309
IS 20
BP 2105
EP 2106
DI 10.1001/jama.2013.4638
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148FU
UT WOS:000319229600024
PM 23695479
ER
PT J
AU Bauman, WA
Spungen, AM
Collins, JF
Raisch, DW
Ho, C
Deitrick, GA
Nemchausky, BA
Goetz, LL
Park, JS
Schwartz, M
Merritt, JL
Jayawardena, V
Sandford, P
Sabharwal, S
Holmes, SA
Nasar, F
Sasaki, R
Punj, V
Zachow, KF
Chua, WC
Thomas, MD
Trincher, RC
AF Bauman, William A.
Spungen, Ann M.
Collins, Joseph F.
Raisch, Dennis W.
Ho, Chester
Deitrick, George A.
Nemchausky, Bernard A.
Goetz, Lance L.
Park, Jai S.
Schwartz, Michael
Merritt, John L.
Jayawardena, Vidya
Sandford, Paul
Sabharwal, Sunil
Holmes, Sally A.
Nasar, Fahima
Sasaki, Roy
Punj, Vandana
Zachow, Karin F.
Chua, Walter C.
Thomas, MaryKutty D.
Trincher, Rose C.
TI The Effect of Oxandrolone on the Healing of Chronic Pressure Ulcers in
Persons With Spinal Cord Injury A Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SURGICAL PATIENTS; NUTRITIONAL-STATUS; STATUS CLASSIFICATION; BURN
INJURY; MALNUTRITION; TESTOSTERONE; CYTOKINES; WEIGHT; INFECTION;
RESIDENTS
AB Background: Anabolic steroids have been reported to improve wound healing.
Objective: To determine whether oxandrolone increases the percentage of target pressure ulcers (TPUs) that heal compared with placebo and whether healed ulcers remain closed 8 weeks after treatment.
Design: Parallel-group, placebo-controlled, randomized trial conducted from 1 August 2005 to 30 November 2008. Patients, clinical care providers, study personnel, and statisticians were blinded to treatment assignment. (ClinicalTrials.gov: NCT00101361)
Setting: 16 inpatient spinal cord injury (SCI) services at Veterans Affairs medical centers.
Patients: 1900 prescreened, 779 screened, and 212 randomly assigned inpatients with SCI and stage III or IV TPUs.
Intervention: Oxandrolone, 20 mg/d (n = 108), or placebo (n = 104) until the TPU healed or 24 weeks.
Measurements: The primary outcome was healed TPUs. The secondary outcome was the percentage of TPUs that remained healed at 8-week follow-up.
Results: 24.1% (95% CI, 16.0% to 32.1%) of TPUs in oxandrolone recipients and 29.8% (CI, 21.0% to 38.6%) in placebo recipients healed (difference, -5.7 percentage points [CI, -17.5 to 6.8 percentage points]; P = 0.40). At 8-week follow-up, 16.7% (CI, 9.6% to 23.7%) of oxandrolone recipients and 15.4% (CI, 8.5% to 22.3%) of placebo recipients retained a healed TPU (difference, 1.3 percentage points [CI, -8.8 to 11.2 percentage points]; P = 0.70). No serious adverse events were related to oxandrolone. Liver enzyme levels were elevated in 32.4% (CI, 23.6% to 41.2%) of oxandrolone recipients and 2.9% (CI, 0.0% to 6.1%) of placebo recipients (P < 0.001).
Limitations: Selection of severe wounds may have reduced treatment response. Approximately one third of patients did not complete the study in the treatment and placebo groups. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between the groups.
Conclusion: Oxandrolone showed no benefit over placebo for improving healing or the percentage of TPUs that remained closed after 8 weeks of treatment.
C1 James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Med Spinal Cord Injury & Res Serv, Bronx, NY 10468 USA.
Mt Sinai Sch Med, New York, NY USA.
Perry Point Vet Affairs Med Ctr, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Perry Point, MD USA.
Univ New Mexico, Vet Affairs Cooperat Study Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87131 USA.
Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA.
Univ Calgary, Calgary, AB, Canada.
Vet Affairs North Texas Hlth Care Syst, Dallas, TX USA.
Virginia Commonwealth Univ, Richmond, VA USA.
St Louis Vet Affairs Med Ctr, Spinal Cord Injury Serv, St Louis, MO 63125 USA.
Univ S Florida, James A Haley Vet Hosp, Tampa, FL USA.
Univ S Florida, Coll Med, Tampa, FL USA.
Hunter H McGuire Vet Affairs Med Ctr, Richmond, VA USA.
Tufts Univ, Sch Med, Boston, MA 02111 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA.
Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA.
Stanford Sch Med, Stanford, CA USA.
Miami Vet Affairs Healthcare Syst, Spinal Cord Injury Serv, Miami, FL USA.
Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA.
Charlie Norwood Vet Affairs Med Ctr, Augusta, GA 30904 USA.
Georgia Hlth Sci Univ, Augusta, GA USA.
RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Suite 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU By the Veterans Affairs Clinical Science Research and Development
Service, Cooperative Study [535]; Rehabilitation Research and
Development, National Center of Excellence for the Medical Consequences
of Spinal Cord Injury [B2648C, B4162C, B9212C]; Department of Veterans
Affairs, Spinal Cord Injury Services
FX Grant Support: By the Veterans Affairs Clinical Science Research and
Development Service, Cooperative Study #535; Rehabilitation Research and
Development, National Center of Excellence for the Medical Consequences
of Spinal Cord Injury (B2648C, B4162C, and B9212C); and Department of
Veterans Affairs, Spinal Cord Injury Services.
NR 51
TC 7
Z9 8
U1 1
U2 12
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 21
PY 2013
VL 158
IS 10
BP 718
EP 726
DI 10.7326/0003-4819-158-10-201305210-00006
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154HY
UT WOS:000319666200014
PM 23689765
ER
PT J
AU Liang, HY
Hussey, SE
Sanchez-Avila, A
Tantiwong, P
Musi, N
AF Liang, Hanyu
Hussey, Sophie E.
Sanchez-Avila, Alicia
Tantiwong, Puntip
Musi, Nicolas
TI Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human
Muscle
SO PLOS ONE
LA English
DT Article
ID LPS-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM STRESS; TYPE-2 DIABETIC
SUBJECTS; HUMAN SKELETAL-MUSCLE; ADIPOSE-TISSUE; RESISTANCE; GLUCOSE;
SENSITIVITY; ENDOTOXEMIA; OBESITY
AB Accumulating evidence from animal studies suggest that chronic elevation of circulating intestinal-generated lipopolysaccharide (LPS) (i.e., metabolic endotoxemia) could play a role in the pathogenesis of insulin resistance. However, the effect of LPS in human muscle is unclear. Moreover, it is unknown whether blockade/down regulation of toll-like receptor (TLR) 4 can prevent the effect of LPS on insulin action and glucose metabolism in human muscle cells. In the present study we compared plasma LPS concentration in insulin resistant [obese non-diabetic and obese type 2 diabetic (T2DM)] subjects versus lean individuals. In addition, we employed a primary human skeletal muscle cell culture system to investigate the effect of LPS on glucose metabolism and whether these effects are mediated via TLR4. Obese non-diabetic and T2DM subjects had significantly elevated plasma LPS and LPS binding protein (LBP) concentrations. Plasma LPS (r = -0.46, P = 0.005) and LBP (r = -0.49, P = 0.005) concentrations negatively correlated with muscle insulin sensitivity (M). In human myotubes, LPS increased JNK phosphorylation and MCP-1 and IL-6 gene expression. This inflammatory response led to reduced insulin-stimulated IRS-1, Akt and AS160 phosphorylation and impaired glucose transport. Both pharmacologic blockade of TLR4 with TAK-242, and TLR4 gene silencing, suppressed the inflammatory response and insulin resistance caused by LPS in human muscle cells. Taken together, these findings suggest that elevations in plasma LPS concentration found in obese and T2DM subjects could play a role in the pathogenesis of insulin resistance and that antagonists of TLR4 may improve insulin action in these individuals.
C1 [Liang, Hanyu; Hussey, Sophie E.; Sanchez-Avila, Alicia; Tantiwong, Puntip; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
[Liang, Hanyu; Hussey, Sophie E.; Tantiwong, Puntip; Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA.
[Liang, Hanyu; Hussey, Sophie E.; Tantiwong, Puntip; Musi, Nicolas] Texas Diabet Inst, San Antonio, TX USA.
RP Musi, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
EM musi@uthscsa.edu
FU National Institutes of Health [RO1-DK80157, RO1- DK089229, TR000149,
1F32DK095565-01A1]; American Diabetes Association
FX This work was supported by grants from the National Institutes of Health
(RO1-DK80157 and RO1- DK089229 to N.M., TR000149 to UTHSCSA, and
1F32DK095565-01A1 to S.H.) and the American Diabetes Association. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 39
TC 26
Z9 27
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63983
DI 10.1371/journal.pone.0063983
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200098
PM 23704966
ER
PT J
AU Mu, XX
Lin, S
Yang, JH
Chen, C
Chen, Y
Herzig, MC
Washburn, K
Halff, GA
Walter, CA
Sun, BC
Sun, LZ
AF Mu, Xiaoxin
Lin, Shu
Yang, Junhua
Chen, Chen
Chen, Yun
Herzig, Maryanne C.
Washburn, Kenneth
Halff, Glenn A.
Walter, Christi A.
Sun, Beicheng
Sun, Lu-Zhe
TI TGF-beta Signaling Is Often Attenuated during Hepatotumorigenesis, but
Is Retained for the Malignancy of Hepatocellular Carcinoma Cells
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; PLASMA TRANSFORMING GROWTH-FACTOR-BETA-1;
RECEPTOR-TYPE-II; TUMOR-SUPPRESSOR; HUMAN CANCER; EXPRESSION; LIVER;
INHIBITOR; SURVIVAL; PROTEIN
AB The role of transforming growth factor-beta (TGF-beta) signaling in hepatocarcinogenesis remains controversial. We aimed to reveal TGF-beta signaling status in human and murine tissues of hepatocellular carcinoma (HCC) and the mechanisms that mediate TGF-beta's role in regulating HCC malignancy. Here, TGF-beta pathway component expression and activation in human and murine HCC tissues were measured with quantitative RT-PCR and Western blotting assays. The role of TGF-beta receptor and Smad signaling in the growth and survival of several HCC cell lines was determined with several in vitro and in vivo approaches. We found that TGF-beta receptor II (T beta RII) expression was downregulated in two different HCC patient cohorts. Consistently, Smad3 phosphorylation was also downregulated in HCC tissues in comparison to that in adjacent normal tissues. Interestingly, many HCC cell lines were sensitive to TGF-beta and growth-inhibited by exogenous TGF-beta. However, stable knockdown of T beta RII inhibited cell growth on plastic and in soft agar, and induced apoptosis resulting in suppressed subcutaneous tumor growth and metastatic potential in vivo. Furthermore, knockdown of Smad4 also led to a significant inhibition of growth on plastic and in soft agar with concomitant increase of apoptosis, PTEN expression, and reduced nuclear accumulation of linker region-phosphorylated Smad3. Taken together, TGF-beta signaling pathway plays a dichotomous role in hepatocellular carcinogenesis. It appears to suppress HCC development, but is retained for HCC cell survival and malignancy. Furthermore, Smad4 can mediate both growth inhibitory activity induced by exogenous TGF-beta and the survival activity induced by autocrine TGF-beta revealing a delicate selection of the two opposing activities of TGF-beta during HCC evolution.
C1 [Mu, Xiaoxin; Chen, Chen; Chen, Yun; Sun, Beicheng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.
[Mu, Xiaoxin; Lin, Shu; Yang, Junhua; Herzig, Maryanne C.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Washburn, Kenneth; Halff, Glenn A.] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Canc Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.] Audie Murphy Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Sun, BC (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.
EM sunbc@njmu.edu.cn; sunl@uthscsa.edu
RI Lin, Shu/C-3790-2013; Washburn, William/Q-5677-2016
FU NIH [R01CA75253, R01CA79683]; Cancer Therapy and Research Center at the
University of Texas Health Science Center at San Antonio (UTHSCSA)
through the NCI Cancer Center Support Grant [2 P30 CA054174-17];
National Science Foundation for Distinguished Young Scholars of China
Grant [81225017]
FX This work was supported in part by NIH Grants R01CA75253 and R01CA79683,
the Cancer Therapy and Research Center at the University of Texas Health
Science Center at San Antonio (UTHSCSA) through the NCI Cancer Center
Support Grant 2 P30 CA054174-17, and the National Science Foundation for
Distinguished Young Scholars of China Grant No.81225017. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 43
TC 14
Z9 15
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63436
DI 10.1371/journal.pone.0063436
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200038
PM 23704908
ER
PT J
AU Johnson, EM
Traver, KL
Hoffman, SW
Harrison, CR
Herman, JP
AF Johnson, Erica M.
Traver, Kyle L.
Hoffman, Stuart W.
Harrison, Catherine R.
Herman, James P.
TI Environmental enrichment protects against functional deficits caused by
traumatic brain injury
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE environmental enrichment; traumatic brain injury; morris water maze;
controlled cortical impact; sensory neglect
ID EARLY-ONSET STIMULATION; ADULT-RAT; COGNITIVE FUNCTION; PREFRONTAL
CORTEX; DENTATE GYRUS; RECOVERY; MICE; EXPRESSION; PLASTICITY; INCREASES
AB Environmental enrichment (EE) increases cortical weight, neuronal density, dendritic branching, and angiogenesis, all of which may be critical for functional recovery following insult. Our study was designed to determine possible benefits of pre-exposure to EE in preventing functional deficits following traumatic brain injury (TBI) to the prefrontal cortex. To examine the benefit of EE, adult male rats were placed in an enriched environment for 15 days. Enrichment was provided through social interaction, exercise, olfactory stimulation, and new objects/toys to explore. Following enrichment, experimental and age-matched controls were subjected to a moderate medial prefrontal cortex injury via controlled cortical impact (CCI). After 1 week recovery, animals were behaviorally tested to assess memory, anxiety, and sensory neglect. Lesion-induced deficits in spatial memory [Morris water maze (MWM)] were significantly attenuated in EE pre-exposed rats 18-21 days following injury. In addition, TBI-induced sensory neglect was significantly reduced in EE rats relative to non-enriched animals. No differences in anxiety-like behavior on the elevated plus maze (EPM) were detected. The behavioral data suggest that EE is neuroprotective when applied prior to TBI, resulting in improved recovery following injury.
C1 [Johnson, Erica M.; Herman, James P.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
[Johnson, Erica M.; Traver, Kyle L.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA.
[Hoffman, Stuart W.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA.
[Harrison, Catherine R.] FAA, Washington, DC USA.
RP Johnson, EM (reprint author), USAF, Res Lab, 711th Human Performance Wing,2510 5th St, Wright Patterson AFB, OH 45433 USA.
EM erica.johnson.7@us.af.mil
RI Herman, James/D-4960-2015
OI Herman, James/0000-0003-3571-2406
FU Air Force Research Laboratory, Wright Patterson Air Force Base; Defense
and Veterans Brain Injury Center
FX This research was sponsored by the Air Force Research Laboratory, Wright
Patterson Air Force Base, and was funded in part by the Defense and
Veterans Brain Injury Center. The authors wish to thank Mr. Chuck
Goodyear for his invaluable assistance with statistical analysis, the
animal research support team for their excellent assistance with
enrichment housing and behavioral testing and the University of
Cincinnati Neuroscience graduate program for their generous support.
NR 51
TC 20
Z9 22
U1 4
U2 19
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD MAY 21
PY 2013
VL 7
AR 44
DI 10.3389/fnbeh.2013.00044
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 148NV
UT WOS:000319252700001
PM 23734108
ER
PT J
AU Hoffecker, BM
Raffield, LM
Kamen, DL
Nowling, TK
AF Hoffecker, Brett M.
Raffield, Laura M.
Kamen, Diane L.
Nowling, Tamara K.
TI Systemic Lupus Erythematosus and Vitamin D Deficiency Are Associated
with Shorter Telomere Length among African Americans: A Case-Control
Study
SO PLOS ONE
LA English
DT Article
ID DISEASE-ACTIVITY; IMMUNE-SYSTEM; REVISED CRITERIA; CELLS;
MANIFESTATIONS; CLASSIFICATION; AUTOIMMUNITY; POPULATION; PREVALENCE;
ANTIBODIES
AB Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that disproportionately affects African American females. The causes of SLE are unknown but postulated to be a combination of genetic predisposition and environmental triggers. Vitamin D deficiency is one of the possible environmental triggers. In this study we evaluated relationships between vitamin D status, cellular aging (telomere length) and anti-telomere antibodies among African American Gullah women with SLE. The study population included African American female SLE patients and unaffected controls from the Sea Island region of South Carolina. Serum 25-hydroxyvitamin D levels were measured using a nonchromatographic radioimmunoassay. Telomere length was measured in genomic DNA of peripheral blood mononuclear cells (PBMCs) by monochrome multiplex quantitative PCR. Anti-telomere antibody levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients with SLE had significantly shorter telomeres and higher anti-telomere antibody titers compared to age-and gender-matched unaffected controls. There was a positive correlation between anti-telomere antibody levels and disease activity among patients and a significant correlation of shorter telomeres with lower 25-hydroxyvitamin D levels in both patients and controls. In follow-up examination of a subset of the patients, the patients who remained vitamin D deficient tended to have shorter telomeres than those patients whose 25-hydroxyvitamin D levels were repleted. Increasing 25-hydroxyvitamin D levels in African American patients with SLE may be beneficial in maintaining telomere length and preventing cellular aging. Moreover, anti-telomere antibody levels may be a promising biomarker of SLE status and disease activity.
C1 [Hoffecker, Brett M.; Raffield, Laura M.; Kamen, Diane L.; Nowling, Tamara K.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Nowling, Tamara K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
RP Kamen, DL (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
EM kamend@musc.edu; nowling@musc.edu
FU Medical Research Service, Veterans Affairs Medical Center [BX000115];
National Institutes of Health (NIH) [AR053376, K23 AR052364]; South
Carolina Clinical & Translational Research (SCTR) Institute; Medical
University of South Carolina, (NIH/NCRR) [UL1 RR029882]; NIAMS [P60
AR062755]
FX This work was supported by VA Merit Review grant BX000115 from the
Medical Research Service, Veterans Affairs Medical Center and National
Institutes of Health (NIH) grant AR053376 awarded to TKN, NIH grant K23
AR052364 awarded to DLK and by the South Carolina Clinical &
Translational Research (SCTR) Institute, with an academic home at the
Medical University of South Carolina, (NIH/NCRR UL1 RR029882), and NIAMS
grant P60 AR062755 (DLK). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 41
TC 8
Z9 9
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2013
VL 8
IS 6
AR UNSP e63725
DI 10.1371/journal.pone.0063725
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 158JQ
UT WOS:000319966400028
PM 23700431
ER
PT J
AU Fischer, MJ
Ho, PM
McDermott, K
Lowy, E
Parikh, CR
AF Fischer, Michael J.
Ho, P. Michael
McDermott, Kelly
Lowy, Elliott
Parikh, Chirag R.
TI Chronic kidney disease is associated with adverse outcomes among elderly
patients taking clopidogrel after hospitalization for acute coronary
syndrome
SO BMC NEPHROLOGY
LA English
DT Article
DE Kidney disease; Myocardial infarction; Hospitalization; Bleeding
ID ACUTE MYOCARDIAL-INFARCTION; CHRONIC RENAL-INSUFFICIENCY; ST-SEGMENT
ELEVATION; ANTIPLATELET THERAPY; STENT IMPLANTATION; PLATELET-FUNCTION;
ELUTING STENTS; MEDICATION USE; BLEEDING-TIME; SHORT-TERM
AB Background: Chronic kidney disease (CKD) is associated with worse outcomes among patients with acute coronary syndrome (ACS). Less is known about the impact of CKD on longitudinal outcomes among clopidogrel treated patients following ACS.
Methods: Using a retrospective cohort design, we identified patients hospitalized with ACS between 10/1/2005 and 1/10/10 at Department of Veterans Affairs (VA) facilities and who were discharged on clopidogrel. Using outpatient serum creatinine values, estimated glomerular filtration rate [eGFR (1.73 ml/min/m(2))] was calculated using the CKD-EPI equation. The association between eGFR and mortality, hospitalization for acute myocardial infarction (AMI), and major bleeding were examined using Cox proportional hazards models.
Results: Among 7413 patients hospitalized with ACS and discharged taking clopidogrel, 34.5% had eGFR 30-60 and 11.6% had eGFR < 30. During 1-year follow-up after hospital discharge, 10% of the cohort died, 18% were hospitalized for AMI, and 4% had a major bleeding event. Compared to those with eGFR > = 60, individuals with eGFR 30-60 (HR 1.45; 95% CI: 1.18-1.76) and < 30 (HR 2.48; 95% CI: 1.97-3.13) had a significantly higher risk of death. A progressive increased risk of AMI hospitalization was associated with declining eGFR: HR 1.20; 95% CI: 1.04-1.37 for eGFR 30-60 and HR 1.47; 95% CI: 1.22-1.78 for eGFR < 30. eGFR < 30 was independently associated with over a 2-fold increased risk in major bleeding (HR 2.09; 95% CI: 1.40-3.12) compared with eGFR > = 60.
Conclusion: Lower levels of kidney function were associated with higher rates of death, AMI hospitalization, and major bleeding among patients taking clopidogrel after hospitalization for ACS.
C1 [Fischer, Michael J.] Jesse Brown VAMC Univ Illinois Med Ctr, Chicago, IL USA.
[Fischer, Michael J.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
[McDermott, Kelly] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA.
[Lowy, Elliott] Univ Washington, VA Puget Sound Healthcare System, Seattle, WA 98195 USA.
[Parikh, Chirag R.] Yale Univ, Clin Epidemiol Res Ctr, West Haven VA, New Haven, CT USA.
[Parikh, Chirag R.] Yale Univ, Dept Med, Program Appl Translat Res, New Haven, CT 06520 USA.
RP Fischer, MJ (reprint author), Jesse Brown VAMC Univ Illinois Med Ctr, Chicago, IL USA.
EM fischerm@uic.edu
FU Ischemic Heart Disease (IHD) Quality Enhancement Research Initiative
(QUERI); Department of Veterans Affairs; Office of Research and
Development; Health Services Research and Development Service (HSRD);
Career Development Award; National Institutes of Health (NIH), National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[K24DK090203]
FX Funding support was provided by the Ischemic Heart Disease (IHD) Quality
Enhancement Research Initiative (QUERI). The authors also received
support from the Department of Veterans Affairs, Office of Research and
Development, Health Services Research and Development Service (HSR&D),
Career Development Award (MJF, PMH), and the National Institutes of
Health (NIH), National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), K24DK090203 (CRP). The views expressed in this article
are those of the authors and do not necessarily represent the views of
the Department of Veterans Affairs or Health Services Research and
Development Service.
NR 50
TC 8
Z9 9
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD MAY 20
PY 2013
VL 14
AR 107
DI 10.1186/1471-2369-14-107
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 154IA
UT WOS:000319666400001
PM 23688069
ER
PT J
AU Alumkal, JJ
Slottke, R
Mori, M
Schwartzman, J
Graff, JN
Beer, TM
Ryan, CW
Koop, DR
Cherala, G
Munar, M
Flamiatos, JF
Gao, L
Tucker, E
AF Alumkal, Joshi J.
Slottke, Rachel
Mori, Motomi
Schwartzman, Jacob
Graff, Julie Nicole
Beer, Tomasz M.
Ryan, Christopher W.
Koop, Dennis R.
Cherala, Ganesh
Munar, Myrna
Flamiatos, Jason Frederick
Gao, Lina
Tucker, Erin
TI Sulforaphane treatment in men with recurrent prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5017
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601618
ER
PT J
AU Bach, P
Zauderer, MG
Gucalp, A
Epstein, AS
Norton, L
Seidman, AD
Caroline, A
Grigorenko, A
Bartashnik, A
Wagner, I
Keesing, J
Kohn, M
Hsiao, F
Megerian, M
Stevens, RJ
Malin, J
Whitney, J
Kris, MG
AF Bach, Peter
Zauderer, Marjorie Glass
Gucalp, Ayca
Epstein, Andrew S.
Norton, Larry
Seidman, Andrew David
Caroline, Aryeh
Grigorenko, Alexander
Bartashnik, Aleksandra
Wagner, Isaac
Keesing, Jeffrey
Kohn, Martin
Hsiao, Franny
Megerian, Mark
Stevens, Rick J.
Malin, Jennifer
Whitney, John
Kris, Mark G.
TI Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision
making
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
IBM Corp, Yorktown Hts, NY USA.
IBM Corp, Dublin, Ireland.
IBM Corp, Rochester, MN 55901 USA.
IBM Corp, Monkton, VT USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Wellpoint Inc, Albany, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 18
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6508
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602228
ER
PT J
AU Heinrich, MC
Fletcher, JA
Anjum, R
Serrano-Garcia, C
Vodala, S
Bauer, S
Town, A
Zhu, MJ
Ning, YY
Eilers, G
Griffith, D
Patterson, J
McKinley, A
Wang, FY
Garner, AP
Rivera, VM
AF Heinrich, Michael C.
Fletcher, Jonathan A.
Anjum, Rana
Serrano-Garcia, Cesar
Vodala, Sadanand
Bauer, Sebastian
Town, Ajia
Zhu, Meijun
Ning, Yaoyu
Eilers, Grant
Griffith, Diana
Patterson, Janice
McKinley, Arin
Wang, Frank Y.
Garner, Andrew P.
Rivera, Victor M.
TI Use of ponatinib to inhibit kinase mutations associated with
drug-resistant gastrointestinal stromal tumors (GIST).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
ARIAD Pharmaceut Inc, Cambridge, MA USA.
Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10509
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600280
ER
PT J
AU Matsumoto, AM
Getzenberg, RH
Coss, C
Hancock, ML
Si, XM
Dalton, JT
Steiner, MS
AF Matsumoto, Alvin M.
Getzenberg, Robert H.
Coss, Christopher
Hancock, Michael L.
Si, Xuemei
Dalton, James T.
Steiner, Mitchell S.
TI The free hormone hypothesis: Correlation of decreases in PSA with free
testosterone rather than total testosterone in men with advanced
prostate cancer treated with GTx-758.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, GRECC, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
GTx Inc, Memphis, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16015
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604207
ER
PT J
AU De Waal, EM
Liang, HY
Pierce, A
Hamilton, RT
Buffenstein, R
Chaudhuri, AR
AF De Waal, Eric M.
Liang, Hanyu
Pierce, Anson
Hamilton, Ryan T.
Buffenstein, Rochelle
Chaudhuri, Asish R.
TI Elevated protein carbonylation and oxidative stress do not affect
protein structure and function in the long-living naked-mole rat: A
proteomic approach
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Naked-mole rat; Peroxiredoxin 1; Triosephosphate isomerase; Protein
carbonylation; Oxidative stress
ID AGE-RELATED-CHANGES; 2-CYS PEROXIREDOXIN; TRIOSEPHOSPHATE ISOMERASE;
CRYSTAL-STRUCTURE; LONGEVITY; RODENT; ERYTHROCYTES; DISEASE
AB The 'oxidative stress theory of aging' predicts that aging is primarily regulated by progressive accumulation of oxidized macromolecules that cause deleterious effects to cellular homeostasis and induces a decline in physiological function. However, our reports on the detection of higher level of oxidized protein carbonyls in the soluble cellular fractions of long-living rodent naked-mole rats (NMRs, lifespan similar to 30 yrs) compared to short-lived mice (lifespan similar to 3.5 yrs) apparently contradicts a key tenet of the oxidative theory. As oxidation often inactivates enzyme function and induces higher-order soluble oligomers, we performed a comprehensive study to measure global protein carbonyl level in different tissues of age-matched NMRs and mice to determine if the traditional concept of oxidation mediated impairment of function and induction of higher-order structures of proteins are upheld in the NMRs. We made three intriguing observations with NMRs proteins: (1) protein carbonyl is significantly elevated across different tissues despite of its exceptional longevity, (2) enzyme function is restored despite of experiencing higher level of protein carbonylation, and (3) enzymes show lesser sensitivity to form higher-order non-reducible oligomers compared to short-living mouse proteins in response to oxidative stress. These observations were made based on the global analysis of protein carbonyl and identification of two heavily carbonylated proteins in the kidney, triosephosphate isomerase (TPI) and cytosolic peroxiredoxin (Prdx1). These un-expected intriguing observations thus strongly suggest that oxidative modification may not be the only criteria for impairment of protein and enzyme function; cellular environment is likely be the critical determining factor in this process and may be the underlying mechanism for exceptional longevity of NMR. (C) 2013 Elsevier Inc. All rights reserved.
C1 [De Waal, Eric M.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
[Liang, Hanyu] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
[Pierce, Anson] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
[Buffenstein, Rochelle; Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Hamilton, Ryan T.; Buffenstein, Rochelle] South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Chaudhuri, Asish R.] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Hamilton, Ryan T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chaudhuria@uthscsa.edu
FU National Institutes of Health/National Institute on Aging [K07 AG025063
04]; NIH/NIA [RO1AG-022891]
FX This work was supported by the National Institutes of Health/National
Institute on Aging pilot Grants K07 AG025063 04 (to A.C.) and from an
NIH/NIA RO1AG-022891 (to R.B.). The following funding sources had no
involvement in the interpretation, representation or publication of the
work other providing the funding necessary.
NR 20
TC 9
Z9 9
U1 0
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 17
PY 2013
VL 434
IS 4
BP 815
EP 819
DI 10.1016/j.bbrc.2013.04.019
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 161SI
UT WOS:000320213200020
PM 23618867
ER
PT J
AU Le Grand, JN
Bon, K
Fraichard, A
Zhang, JH
Jouvenot, M
Risold, PY
Boyer-Guittaut, M
Delage-Mourroux, R
AF Le Grand, Jaclyn Nicole
Bon, Karine
Fraichard, Annick
Zhang, Jianhua
Jouvenot, Michele
Risold, Pierre-Yves
Boyer-Guittaut, Michael
Delage-Mourroux, Regis
TI Specific Distribution of the Autophagic Protein GABARAPL1/GEC1 in the
Developing and Adult Mouse Brain and Identification of Neuronal
Populations Expressing GABARAPL1/GEC1
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; GABA(A) RECEPTOR; MESSENGER-RNAS;
PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; IN-VIVO; GEC1; MICE; DEGRADATION;
INTERACTS
AB Macroautophagy is a highly conserved cellular degradation process, regulated by autophagy-related (atg) factors, in which a double membrane autophagosome engulfs cytoplasmic components to target them for degradation. In yeast, the Atg8 protein is indispensable for autophagosome formation. In mammals, this is complicated by the presence of six Atg8 homologues grouped into the GABARAP and MAP1LC3 subfamilies. Although these proteins share a high similarity, their transcript expression, regulation and protein interactions differ, suggesting they may display individual properties and specific functions. GABARAPL1/GEC1 is a member of the GABARAP subfamily and its mRNA is the most highly expressed Atg8 homologue in the central nervous system. Consequently, we performed an in depth study of GABARAPL1 distribution in the developing and adult murine brain. Our results show that GABARAPL1 brain expression is visible as early as embryonic day 11 and progressively increases to a maximum level in the adult. Immunohistochemical staining was detected in both fibers and immature neurons in embryos but was restrained to neurons in adult tissue. By E17, intense punctate-like structures were visible and these accumulated in cortical primary neurons treated with the autophagosome/lysosome fusion inhibitor Bafilomycin A1 (Baf A1), suggesting that they represent autophagosomes. Finally, GABARAPL1 expression was particularly intense in motoneurons in the embryo and in neurons involved in somatomotor and neuroendocrine functions in the adult, particularly in the substantia nigra pars compacta, a region affected in Parkinson's disease. Our study of cerebral GABARAPL1 protein expression provides insight into its role in the development and homeostasis of the mouse brain.
C1 [Le Grand, Jaclyn Nicole; Bon, Karine; Fraichard, Annick; Jouvenot, Michele; Risold, Pierre-Yves; Boyer-Guittaut, Michael; Delage-Mourroux, Regis] Univ Franche Comte, UFR Sci & Tech, Estrogenes Express Gen & Pathol Syst Nerveux Cent, Lab Biochim,SFR IBCT FED 4234, F-25030 Besancon, Doubs, France.
[Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA.
RP Delage-Mourroux, R (reprint author), Univ Franche Comte, UFR Sci & Tech, Estrogenes Express Gen & Pathol Syst Nerveux Cent, Lab Biochim,SFR IBCT FED 4234, F-25030 Besancon, Doubs, France.
EM regis.delage-mourroux@univ-fcomte.fr
FU Ministere de l'Enseignement Superieur et de la Recherche (MESR); VA
merit award; [NIHR01-NS064090]
FX JNLG is supported by a fellowship from the Ministere de l'Enseignement
Superieur et de la Recherche (MESR) and Dr. JZ was supported by
NIHR01-NS064090 and a VA merit award. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 43
TC 7
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2013
VL 8
IS 5
AR e63133
DI 10.1371/journal.pone.0063133
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145XK
UT WOS:000319052700021
PM 23690988
ER
PT J
AU Seay, K
Qi, XH
Zheng, JH
Zhang, C
Chen, K
Dutta, M
Deneroff, K
Ochsenbauer, C
Kappes, JC
Littman, DR
Goldstein, H
AF Seay, Kieran
Qi, Xiaohua
Zheng, Jian Hua
Zhang, Cong
Chen, Ken
Dutta, Monica
Deneroff, Kathryn
Ochsenbauer, Christina
Kappes, John C.
Littman, Dan R.
Goldstein, Harris
TI Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1
Expression: A New Model for Investigating HIV-1 Transmission and
Treatment Efficacy
SO PLOS ONE
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; LENTIVIRAL-VECTORS; MOUSE MODEL;
RAG2(-/-)GAMMA(-/-)(C) MICE; GENE-TRANSFER; INFECTION; REPLICATION;
ANTIBODY; VIVO; LYMPHOCYTES
AB Mice cannot be used to evaluate HIV-1 therapeutics and vaccines because they are not infectible by HIV-1 due to structural differences between several human and mouse proteins required for HIV-1 entry and replication including CD4, CCR5 and cyclin T1. We overcame this limitation by constructing mice with CD4 enhancer/promoter-regulated human CD4, CCR5 and cyclin T1 genes integrated as tightly linked transgenes (hCD4/R5/cT1 mice) promoting their efficient co-transmission and enabling the murine CD4-expressing cells to support HIV-1 entry and Tat-mediated LTR transcription. All of the hCD4/R5/ cT1 mice developed disseminated infection of tissues that included the spleen, small intestine, lymph nodes and lungs after intravenous injection with an HIV-1 infectious molecular clone (HIV-IMC) expressing Renilla reniformis luciferase (LucR). Furthermore, localized infection of cervical-vaginal mucosal leukocytes developed after intravaginal inoculation of hCD4/R5/ cT1 mice with the LucR-expressing HIV-IMC. hCD4/R5/cT1 mice reproducibly developed in vivo infection after inoculation with LucR-expressing HIV-IMC which could be bioluminescently quantified and visualized with a high sensitivity and specificity which enabled them to be used to evaluate the efficacy of HIV-1 therapeutics. Treatment with highly active anti-retroviral therapy or one dose of VRC01, a broadly neutralizing anti-HIV-1 antibody, almost completed inhibited acute systemic HIV-1 infection of the hCD4/R5/cT1 mice. hCD4/R5/cT1 mice could also be used to evaluate the capacity of therapies delivered by gene therapy to inhibit in vivo HIV infection. VRC01 secreted in vivo by primary B cells transduced with a VRC01-encoding lentivirus transplanted into hCD4/R5/cT1 mice markedly inhibited infection after intravenous challenge with LucR-expressing HIV-IMC. The reproducible infection of CD4/R5/cT1 mice with LucR-expressing HIV-IMC after intravenous or mucosal inoculation combined with the availability of LucR-expressing HIV-IMC expressing transmitted/ founder and clade A/E and C Envs will provide researchers with a highly accessible pre-clinical in vivo HIV-1-infection model to study HIV-1 acquisition, treatment, and prevention.
C1 [Seay, Kieran; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
[Qi, Xiaohua; Zheng, Jian Hua; Zhang, Cong; Dutta, Monica; Deneroff, Kathryn; Goldstein, Harris] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
[Chen, Ken] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA.
[Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA.
[Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY USA.
[Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY USA.
RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
EM harris.goldstein@einstein.yu.edu
FU National Institutes of Health (National Institute of Drug Abuse)
[R01-DA-033788]; National Institutes of Health (National Institute of
Allergy and Infectious Diseases) [R01-AI065309]; National Institutes of
Health (Einstein-Montefiore Center for AIDS Research) [AI51519]; Charles
Michael Chair in Autoimmune Diseases; NIH-funded AIDS training grant
[T32-AI007501]; VHA Merit Review Award; NIH Center for HIV-1/AIDS
Vaccine Immunology (CHAVI) [UO1-AI067854]; UAB Center for AIDS Research
[P30-AI-27767]; [U01-GM-094665]; [U54-GM-094662]; [P30-CA-013330]
FX The construct expressing VRC01 was a kind gift of Dr. John Mascola
(VRC/NIAID/NIH) which was used to generate VRC01 antibody in the
Einstein Macromolecular Therapeutics Facility (supported by
U01-GM-094665, U54-GM-094662 and P30-CA-013330) by Man K. Chan. The
following reagents were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl cells,
pT4B and pCCR-5.; This work was supported by the National Institutes of
Health (National Institute of Drug Abuse R01-DA-033788, National
Institute of Allergy and Infectious Diseases R01-AI065309 and the
Einstein-Montefiore Center for AIDS Research AI51519). HG was supported
by the Charles Michael Chair in Autoimmune Diseases, KS by an NIH-funded
AIDS training grant, T32-AI007501 and JCK by a VHA Merit Review Award.
Work by JCK and CO was supported by the NIH Center for HIV-1/AIDS
Vaccine Immunology (CHAVI), UO1-AI067854; and the UAB Center for AIDS
Research (P30-AI-27767). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 48
TC 14
Z9 14
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2013
VL 8
IS 5
AR e63537
DI 10.1371/journal.pone.0063537
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145XK
UT WOS:000319052700042
PM 23691059
ER
PT J
AU Deyo, RA
Smith, DHM
Johnson, ES
Tillotson, CJ
Donovan, M
Yang, XH
Petrik, A
Morasco, BJ
Dobscha, SK
AF Deyo, Richard A.
Smith, David H. M.
Johnson, Eric S.
Tillotson, Carrie J.
Donovan, Marilee
Yang, Xiuhai
Petrik, Amanda
Morasco, Benjamin J.
Dobscha, Steven K.
TI Prescription Opioids for Back Pain and Use of Medications for Erectile
Dysfunction
SO SPINE
LA English
DT Article
DE opioids; low back pain; erectile dysfunction; sexual dysfunction
ID CHRONIC NONCANCER PAIN; UNITED-STATES; ORAL OPIOIDS; ASSOCIATION;
HYPOGONADISM; TRENDS; MEN; EPIDEMIOLOGY; METAANALYSIS; PREVALENCE
AB Study Design. Cross-sectional analysis of electronic medical and pharmacy records.
Objective. To examine associations between use of medication for erectile dysfunction or testosterone replacement and use of opioid therapy, patient age, depression, and smoking status.
Summary of Background Data. Males with chronic pain may experience erectile dysfunction related to depression, smoking, age, or opioid-related hypogonadism. The prevalence of this problem in back pain populations and the relative importance of several risk factors are unknown.
Methods. We examined electronic pharmacy and medical records for males with back pain in a large group model health maintenance organization during 2004. Relevant prescriptions were considered for 6 months before and after the index visit. Results. There were 11,327 males with a diagnosis of back pain. Males who received medications for erectile dysfunction or testosterone replacement (n = 909) were significantly older than those who did not and had greater comorbidity, depression, smoking, and use of sedative-hypnotics. In logistic regressions, the long-term use of opioids was associated with greater use of medications for erectile dysfunction or testosterone replacement compared with no opioid use (odds ratio, 1.45; 95% confidence interval, 1.12-1.87, P < 0.01). Age, comorbidity, depression, and use of sedative-hypnotics were also independently associated with the use of medications for erectile dysfunction or testosterone replacement. Patients prescribed daily opioid doses of 120 mg of morphine-equivalents or more had greater use of medication for erectile dysfunction or testosterone replacement than patients without opioid use (odds ratio, 1.58; 95% confidence interval, 1.03-2.43), even with adjustment for the duration of opioid therapy.
Conclusion. Dose and duration of opioid use, as well as age, comorbidity, depression, and use of sedative-hypnotics, were associated with evidence of erectile dysfunction. These findings may be important in the process of decision making for the long-term use of opioids.
C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Family Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Publ Hlth, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Prevent Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Kaiser Ctr Hlth Res, Portland, OR USA.
[Smith, David H. M.; Johnson, Eric S.; Donovan, Marilee; Yang, Xiuhai; Petrik, Amanda] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Portland, OR USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM deyor@ohsu.edu
FU NIH/NCRR
FX NIH/NCRR grant funds were received to support this work.
NR 38
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD MAY 15
PY 2013
VL 38
IS 11
BP 909
EP 915
DI 10.1097/BRS.0b013e3182830482
PG 7
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 144CD
UT WOS:000318916300015
PM 23459134
ER
PT J
AU Womack, JA
Goulet, JL
Gibert, C
Brandt, CA
Skanderson, M
Gulanski, B
Rimland, D
Rodriguez-Barradas, MC
Tate, J
Yin, MT
Justice, AC
AF Womack, Julie A.
Goulet, Joseph L.
Gibert, Cynthia
Brandt, Cynthia A.
Skanderson, Melissa
Gulanski, Barbara
Rimland, David
Rodriguez-Barradas, Maria C.
Tate, Janet
Yin, Michael T.
Justice, Amy C.
CA Vet Aging Cohort Study Project
TI Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; frailty; fragility fractures; Veterans
ID BONE-MINERAL DENSITY; ALCOHOL INTAKE; OLDER-ADULTS; RISK-FACTORS;
ELDERLY-MEN; FALLS; WOMEN; INFLAMMATION; MORTALITY; INDEX
AB Background. The Veterans Aging Cohort Study (VACS) Index is associated with all-cause mortality in individuals infected with human immunodeficiency virus (HIV). It is also associated with markers of inflammation and may thus reflect physiologic frailty. This analysis explores the association between physiologic frailty, as assessed by the VACS Index, and fragility fracture.
Methods. HIV-infected men from VACS were included. We identified hip, vertebral, and upper arm fractures using ICD-9-CM codes. We used Cox regression models to assess fragility fracture risk factors including the VACS Index, its components (age, hepatitis C status, FIB-4 score, estimated glomerular filtration rate, hemoglobin, HIV RNA, CD4 count), and previously identified risk factors for fragility fractures.
Results. We included 40 115 HIV-infected male Veterans. They experienced 588 first fragility fractures over 6.0 +/- 3.9 years. The VACS Index score (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.11-1.19), white race (HR, 1.92; 95% CI, 1.63-2.28), body mass index (HR, 0.94; 95% CI, .92-.96), alcohol-related diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27), and protease inhibitor use (HR, 1.25; 95% CI, 1.04-1.50) were associated with fracture risk. Components of the VACS Index score most strongly associated with fracture risk were age (HR, 1.40; 95% CI, 1.27-1.54), log HIV RNA (HR, 0.91; 95% CI, .88-.94), and hemoglobin level (HR, 0.82; 95% CI, .78-.86).
Conclusions. Frailty, as measured by the VACS Index, is an important predictor of fragility fractures among HIV-infected male Veterans.
C1 [Womack, Julie A.] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
[Goulet, Joseph L.; Brandt, Cynthia A.; Skanderson, Melissa; Gulanski, Barbara; Tate, Janet; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Goulet, Joseph L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06536 USA.
[Gibert, Cynthia] George Washington Univ, Vet Affairs Med Ctr, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Dept Med, Washington, DC USA.
[Brandt, Cynthia A.] Yale Univ, Yale Ctr Med Informat, New Haven, CT 06536 USA.
[Gulanski, Barbara; Justice, Amy C.] Yale Univ, Dept Internal Med, Sect Gen Internal Med, New Haven, CT 06536 USA.
[Rimland, David] Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Med Serv, Michael E De Bakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Yin, Michael T.] Columbia Univ, Dept Med, Med Ctr, Div Infect Dis, New York, NY USA.
RP Womack, JA (reprint author), Yale Univ, Sch Nursing, 100 Church St South, New Haven, CT 06536 USA.
EM julie.womack@yale.edu
OI Goulet, Joseph/0000-0002-0842-804X
FU Veterans Administration Office, Academic Affiliations, Information
Research and Development Medical Informatics Fellowship Program;
National Institute of Nursing Research of the National Institutes of
Health [1K01NR013437-01]; CTSA Grant from the National Center for
Research Resources, component of the National Institutes of Health [UL1
RR024139]; National Center for Advancing Translational Science,
component of the National Institutes of Health; National Institute on
Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA Public Health Strategic
Health Core Group; NIH roadmap for Medical Research
FX This work was supported by the Veterans Administration Office, Academic
Affiliations, Information Research and Development Medical Informatics
Fellowship Program; the National Institute of Nursing Research of the
National Institutes of Health (grant number 1K01NR013437-01); CTSA Grant
Number UL1 RR024139 from the National Center for Research Resources and
the National Center for Advancing Translational Science, components of
the National Institutes of Health, and NIH roadmap for Medical Research;
the Veterans Aging Cohort Study funded by the National Institute on
Alcohol Abuse and Alcoholism (U10 AA 13566) and VHA Public Health
Strategic Health Core Group.
NR 40
TC 42
Z9 42
U1 3
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2013
VL 56
IS 10
BP 1498
EP 1504
DI 10.1093/cid/cit056
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 140EF
UT WOS:000318636500024
PM 23378285
ER
PT J
AU Sun, HY
Munoz, P
Torre-Cisneros, J
Aguado, JM
Lattes, R
Montejo, M
Garcia-Reyne, A
Bouza, E
Valerio, M
Lara, R
John, GT
Bruno, D
Singh, N
AF Sun, Hsin-Yun
Munoz, Patricia
Torre-Cisneros, Julian
Aguado, Jose M.
Lattes, Roberta
Montejo, Miguel
Garcia-Reyne, Ana
Bouza, Emilio
Valerio, Maricela
Lara, Rosario
John, George T.
Bruno, Didier
Singh, Nina
TI Mycobacterium Tuberculosis-Associated Immune Reconstitution Syndrome in
Solid-Organ Transplant Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Immune reconstitution syndrome; Mycobacterium tuberculosis; Solid-organ
transplant recipients
ID CRYPTOCOCCUS-NEOFORMANS INFECTION; T-CELL RESPONSES; CLINICAL
CHARACTERISTICS; PULMONARY TUBERCULOSIS; INFLAMMATORY SYNDROME;
RISK-FACTORS; THERAPY; DISEASE
AB Background. Incidence, characteristics, and risk factors for tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.
Methods. Patients are composed of 64 consecutive SOT recipients with TB followed for 12 months. IRS was defined based on previously proposed criteria.
Results. IRS developed in 14% (9/64) of the patients, a median of 47 days after the use of anti-TB therapy. Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6.11; 95% confidence interval [CI], 1.08-34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.93-34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74-27) were associated with a higher risk of IRS. The presence of more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors conferred a 19-fold increase in the risk of IRS (P=0.01). Mortality at 1 year after diagnosis was 33.3% in patients with IRS and 17.2% in those without IRS (P=0.31).
Conclusions. IRS was documented in 14% of the SOT recipients with TB. We determined clinically identifiable factors that may be useful in assessing the risk of tuberculosis-associated posttransplantation IRS.
C1 [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan.
[Munoz, Patricia; Bouza, Emilio; Valerio, Maricela] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Dept Med, Madrid, Spain.
[Torre-Cisneros, Julian; Lara, Rosario] Univ Cordoba, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Cordoba, Spain.
[Aguado, Jose M.; Garcia-Reyne, Ana] Hosp 12 Octubre, E-28041 Madrid, Spain.
[Lattes, Roberta] Inst Nefrol, Infect Dis Sect, Dept Transplantat, Buenos Aires, DF, Argentina.
[Montejo, Miguel] Hosp Univ Cruces, Bilbao, Spain.
[John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
[Bruno, Didier] Hosp Univ Fdn Favaloro, Dept Internal Med, Buenos Aires, DF, Argentina.
[Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
RP Sun, HY (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM hy.jamie.sun@gmail.com
RI Montejo, Jose Miguel/E-1755-2012; Munoz, Patricia/E-9431-2017
OI Munoz, Patricia/0000-0001-5706-5583; Bruno, Didier/0000-0002-9540-2269;
bouza, emilio/0000-0001-6967-9267; SUN, HSIN-YUN/0000-0003-0074-7721
FU Ministerio de Economia y Competitividad, Instituto de Salud Carlos III;
European Development Regional Fund "A way to achieve Europe," Spanish
Network for the Research in Infectious Diseases [REIPI RD06/0008,
RD12/0015]; Instituto de Salud Carlos III (Rio Hortega) [CN09130]
FX The Spanish investigators are supported by Ministerio de Economia y
Competitividad, Instituto de Salud Carlos III-cofinanced by the European
Development Regional Fund "A way to achieve Europe," Spanish Network for
the Research in Infectious Diseases (REIPI RD06/0008 and RD12/0015).
A.G.-R. was supported by a grant from Instituto de Salud Carlos III (Rio
Hortega grant no. CN09130).
NR 33
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 15
PY 2013
VL 95
IS 9
BP 1173
EP 1181
DI 10.1097/TP.0b013e31828719c8
PG 9
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 141ZF
UT WOS:000318764500018
PM 23435454
ER
PT J
AU Beverly, LJ
Howell, LA
Hernandez-Corbacho, M
Casson, L
Chipuk, JE
Siskind, LJ
AF Beverly, Levi J.
Howell, Lauren A.
Hernandez-Corbacho, Maria
Casson, Lavona
Chipuk, Jerry E.
Siskind, Leah J.
TI BAK activation is necessary and sufficient to drive ceramide
synthase-dependent ceramide accumulation following inhibition of
BCL2-like proteins
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE ABT-263; ABT-737; apoptosis; BCL2; ceramide; haematology; leukaemia;
sphingolipid
ID BCL-2 FAMILY INHIBITOR; CELL LUNG-CANCER; SPHINGOLIPID METABOLISM;
ANTIAPOPTOTIC BCL-2; INDUCED APOPTOSIS; DRUG-RESISTANCE; BH3 DOMAINS;
ABT-737; MCL-1; CHANNELS
AB Determining mechanistic details about how drugs kill cancer cells is critical for predicting which cancers will respond to given therapeutic regimens and for identifying effective combinations of drugs that more potently kill cancer cells while sparing normal cells. The BCL2 family of proteins and bioactive sphingolipids are intricately linked during apoptotic cell death. In fact, many chemotherapeutic drugs are known to cause accumulation of the pro-apoptotic sphingolipid ceramide; however, the mechanism by which this occurs is not completely understood. In the present study we demonstrate that direct inhibition of antiapoptotic BCL2 proteins with ABT-263 is sufficient to induce C-16-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells. ABT-263 activates CerS (ceramide synthase) activity only in cells expressing BAK or in cells capable of activating BAK. Importantly, recombinant BAK is sufficient to increase in vitro CerS activity in microsomes purified from Bak-KO (knockout) cells and activated BAK more potently activates CerS than inactive BAK. Likewise, ABT-263 addition to wild-type, but not Bak-deficient, microsomes increases CerS in vitro activity. Furthermore, we present a feed-forward model by which BAK activation of CerS by chemotherapeutic drugs leads to elevated ceramide levels that result in synergistic channel formation by ceramide (or one of its metabolites) and BAX/BAK.
C1 [Beverly, Levi J.; Casson, Lavona] Univ Louisville, James Graham Brown Canc Ctr, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA.
[Howell, Lauren A.; Siskind, Leah J.] South Carolina Coll Pharm, Med Sch South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Hernandez-Corbacho, Maria] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.
[Chipuk, Jerry E.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
[Siskind, Leah J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Beverly, LJ (reprint author), Univ Louisville, James Graham Brown Canc Ctr, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA.
EM levi.beverly@louisville.edu; siskind@musc.edu
OI Chipuk, Jerry Edward/0000-0002-1337-842X
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
NIH (National Institutes of Health) [R01DK093462]; Cancer Center Support
Grant [P30 CA138313]; NIH/NCRR (National Center for Research Resources)
COBRE (Centers of Biomedical Research Excellence) in Lipidomics and
Pathobiology [P20 RR17677]; NIH, Molecular Targets COBRE
[8P20GM103482-10]; Wendy Will Case Cancer Fund [GB220413]; Kosair
Pediatric Cancer Research Program award; James Graham Brown Cancer
Center, NIH [CA157740]; March of Dimes Foundation [5-FY11-74]
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases of the NIH (National Institutes of Health)
[grant number R01DK093462 (to L.J.S.)], the Lipidomics Shared Resource
of the Hollings Cancer Center at the Medical University of South
Carolina supported by a Cancer Center Support Grant [grant number P30
CA138313], pilot project from the NIH/NCRR (National Center for Research
Resources) COBRE (Centers of Biomedical Research Excellence) in
Lipidomics and Pathobiology [grant number P20 RR17677 (to L.J.S)]; NIH,
Molecular Targets COBRE [grant number 8P20GM103482-10 (to L.J.B.)], the
Wendy Will Case Cancer Fund [grant number GB220413 (to L.J.B.)], a
Kosair Pediatric Cancer Research Program award (to L.J.B.) the James
Graham Brown Cancer Center, NIH R01 [grant number CA157740 (to J.E.C.)]
and the March of Dimes Foundation [grant number 5-FY11-74 (to J.E.C.)].
NR 49
TC 27
Z9 27
U1 1
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD MAY 15
PY 2013
VL 452
BP 111
EP 119
DI 10.1042/BJ20130147
PN 1
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 137RS
UT WOS:000318455700011
PM 23480852
ER
PT J
AU Calkins, ME
Ray, A
Gur, RC
Freedman, R
Green, MF
Greenwood, TA
Light, GA
Nuechterlein, KH
Olincy, A
Radant, AD
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, C
Swerdlow, NR
Tsuang, DW
Tsuang, MT
Turetsky, BI
Braff, DL
Lazzeroni, LC
Gur, RE
AF Calkins, Monica E.
Ray, Amrita
Gur, Ruben C.
Freedman, Robert
Green, Michael F.
Greenwood, Tiffany A.
Light, Gregory A.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine
Swerdlow, Neal R.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Braff, David L.
Lazzeroni, Laura C.
Gur, Raquel E.
TI Sex Differences in Familiality Effects on Neurocognitive Performance in
Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Endophenotype; genetics; heritability; neurocognition; schizophrenia;
sex differences
ID 1ST-DEGREE RELATIVES; COGNITIVE DEFICITS; HERITABILITY; ENDOPHENOTYPES;
CONSORTIUM; GENETICS; IMPAIRMENTS; VALIDATION; SIBLINGS; FAMILIES
AB Background: Numerous studies have documented that patients with schizophrenia show neurocognitive impairments, which are also heritable in schizophrenia families. In view of these findings, the current investigation tested the hypothesis that neurocognitive performance of schizophrenia probands can predict the neurocognitive performance of their unaffected family members.
Methods: Participants (n = 1967; schizophrenia = 369; first-degree relatives = 1072; community comparison subjects = 526) in the Consortium on the Genetics of Schizophrenia were administered the Penn Computerized Neurocognitive Battery.
Results: Consistent with prior work, probands showed significant neurocognitive impairment, and neurocognitive ability was significantly heritable across domains. On average, unaffected relatives did not differ from community comparison subjects in their neurocognitive performance. However, in six of seven domains, proband scores predicted the performance of their unaffected siblings. Male, but not female, proband performance was predictive of their unaffected relatives' (siblings and mothers) performance, most consistently in face memory and spatial processing.
Conclusions: Using a novel approach in which individual probands are paired with their respective unaffected relatives within each family, we found that male proband performance predicted both sister and brother performance, an effect that was most powerfully observed for face memory and spatial processing. Results suggest that the familial transmission of sexually dimorphic neurocognitive domains, in which a particular sex tends to show a performance advantage over the other, may not itself be sex specific in schizophrenia families.
C1 [Calkins, Monica E.; Gur, Ruben C.; Turetsky, Bruce I.; Gur, Raquel E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Ray, Amrita; Tsuang, Debby W.; Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA.
[Ray, Amrita; Tsuang, Debby W.; Lazzeroni, Laura C.] Stanford Univ, Dept Behav Sci, Stanford, CA 94305 USA.
[Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA.
[Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA.
[Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
Vet Affairs San Diego Healthcare Syst, Vet Integrated Serv Network Mental Illness Res Ed, San Diego, CA USA.
[Radant, Allen D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Radant, Allen D.] US Dept Vet Affairs, Vet Integrated Serv Network Mental Illness Res Ed, Seattle, WA USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div,Dept Psychiat,Sch Med, Boston, MA 02115 USA.
[Siever, Larry J.; Silverman, Jeremy M.] SUNY Upstate Med Univ, Med Genet Res Program, Syracuse, NY 13210 USA.
[Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Siever, Larry J.] James J Peters Vet Affairs, Bronx, NY USA.
[Siever, Larry J.] Vet Integrated Serv Network Mental Illness Res Ed, Bronx, NY USA.
[Green, Michael F.; Sugar, Catherine] US Dept Vet Affairs, Vet Integrated Serv Network Mental Illness Res Ed, Los Angeles, CA USA.
RP Calkins, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, Schizophrenia Res Ctr, 3600 Spruce St, Philadelphia, PA 19104 USA.
EM mcalkins@upenn.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920
FU National Institute of Mental Health [R01 MH086735, R01 MH65571, R01
MH42228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01
MH65578, R01 MH65558, K08 MH79364]; Neuropsychiatry Postdoctoral
traineeship [MH19112]; Scottish Rite Schizophrenia Research Fellowship;
Abbott Laboratories; Amgen; Cypress; Lundbeck; Teva; Otsuka; Sunovion;
Janssen Scientific Affairs; Genentech; AstraZeneca; Pfizer
Pharmaceuticals; La Roche; Bristol-Myers
FX This study was supported by National Institute of Mental Health Grants
R01 MH086735, R01 MH65571, R01 MH42228, R01 MH65588, R01 MH65562, R01
MH65707, R01 MH65554, R01 MH65578, R01 MH65558, and K08 MH79364; a
Neuropsychiatry Postdoctoral traineeship (MH19112); and a Scottish Rite
Schizophrenia Research Fellowship.; Dr. Michael F. Green reports having
received consulting fees from Abbott Laboratories, Amgen, Cypress,
Lundbeck, and Teva. He has received speaking fees from Otsuka and
Sunovion. Dr. Gregory A. Light has received compensation for one-time
participation in a scientific advisory board meeting for Astellas Inc.
Dr. Keith H. Nuechterlein reports research grant funding from Janssen
Scientific Affairs and Genentech and consulting fees from Genentech and
Otsuka. Dr. Neal R. Swerdlow was a consultant to Neurocrine, Inc. Dr.
Bruce I. Turetsky reports unrelated research grant support from
AstraZeneca and Pfizer Pharmaceuticals and consulting fees from La Roche
and Bristol-Myers. Dr. Laura C Lazzeroni is named as an inventor on a
pharmacogenetic patent application that is being pursued by Stanford
University. All other authors report no biomedical financial interests
or potential conflicts of interest.
NR 33
TC 11
Z9 11
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2013
VL 73
IS 10
BP 976
EP 984
DI 10.1016/j.biopsych.2012.12.021
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 137SV
UT WOS:000318458600007
PM 23395246
ER
PT J
AU Sharma, A
Schwartz, SM
Mendez, E
AF Sharma, Arun
Schwartz, Stephen M.
Mendez, Eduardo
TI Hospital volume is associated with survival but not multimodality
therapy in Medicare patients with advanced head and neck cancer
SO CANCER
LA English
DT Article
DE head and neck neoplasms; survival; radiotherapy; chemoradiotherapy;
cisplatin
ID LOCALLY ADVANCED HEAD; SQUAMOUS-CELL CARCINOMA; STAGE LARYNGEAL-CANCER;
COMORBIDITY INDEX; CHEMOTHERAPY; RADIOTHERAPY; IMPACT; FACILITIES;
MORTALITY; RESECTION
AB BACKGROUND: Given the complexity of management of advanced head and neck squamous cell carcinoma (HNSCC), this study hypothesized that high hospital volume would be associated with receiving National Comprehensive Cancer Network (NCCN) guideline therapy and improved survival in patients with advanced HNSCC. METHODS: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify patients with advanced HNSCC. Treatment modalities and survival were determined using Medicare data. Hospital volume was determined by the number of patients with HNSCC treated at each hospital. RESULTS: There were 1195 patients with advanced HNSCC who met inclusion criteria. In multivariable analyses, high hospital volume was not associated with receiving multimodality therapy per NCCN guidelines (odds ratio = 1.02, 95% confidence interval = 0.66-1.60), but showed a nearly significant inverse association with survival in a model adjusted for National Cancer Institutedesignated cancer center status, age, sex, race, socioeconomic status, marital status, comorbidity, year of diagnosis, tumor site, and tumor stage (hazard ratio = 0.85, 95% confidence interval = 0.69-1.04). CONCLUSIONS: Medicare patients with advanced HNSCC treated at high-volume hospitals were not more likely to receive NCCN guideline therapy, but had nearly statistically significant better survival, when compared with patients treated at low-volume hospitals. These results suggest that features of high-volume hospitals other than delivery of NCCN guideline therapy influence survival. Cancer 2013. (c) 2013 American Cancer Society.
C1 [Sharma, Arun; Mendez, Eduardo] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Schwartz, Stephen M.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA.
[Schwartz, Stephen M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
RP Mendez, E (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave,North Mailstop D4-100, Seattle, WA 98109 USA.
EM edmendez@u.washington.edu
OI Schwartz, Stephen/0000-0001-7499-8502
FU National Institute on Deafness and Other Communication Disorders Grant
[2T32DC000018]; National Cancer Institute [N01-PC-35142]; National
Center for Research Resources Grant [5KL2RR025015]; Intuitive Surgical,
Inc.
FX This work was funded by National Institute on Deafness and Other
Communication Disorders Grant 2T32DC000018; National Cancer Institute
Contract N01-PC-35142; and National Center for Research Resources Grant
5KL2RR025015.; Dr. Mendez has received speaking fees/honoraria from
Intuitive Surgical, Inc. All other authors made no disclosures.
NR 29
TC 14
Z9 14
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2013
VL 119
IS 10
BP 1845
EP 1852
DI 10.1002/cncr.27976
PG 8
WC Oncology
SC Oncology
GA 138JT
UT WOS:000318505500014
PM 23456789
ER
PT J
AU Parekh, VV
Wu, L
Boyd, KL
Williams, JA
Gaddy, JA
Olivares-Villagomez, D
Cover, TL
Zong, WX
Zhang, JH
Van Kaer, L
AF Parekh, Vrajesh V.
Wu, Lan
Boyd, Kelli L.
Williams, Janice A.
Gaddy, Jennifer A.
Olivares-Villagomez, Danyvid
Cover, Timothy L.
Zong, Wei-Xing
Zhang, Jianhua
Van Kaer, Luc
TI Impaired Autophagy, Defective T Cell Homeostasis, and a Wasting Syndrome
in Mice with a T Cell-Specific Deletion of Vps34
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NKT CELLS; MAMMALIAN-CELLS; KINASE VPS34; DEATH; EXPRESSION; ANTIGEN;
PROLIFERATION; INFLAMMATION; LYMPHOCYTES; METABOLISM
AB Autophagy plays a critical role in multiple aspects of the immune system, including the development and function of T lymphocytes. In mammalian cells, the class III PI3K vacuolar protein sorting (Vps) 34 is thought to play a critical role in autophagy. However, recent studies have cast doubt on the role of Vps34 in autophagy, at least in certain cell types. To study the effects of Vps34 on autophagy in T lymphocytes, we generated mice that selectively lack Vps34 in the T cell lineage. Vps34 ablation in T cells caused profound defects in autophagic flux, resulting in accumulation of cellular organelles and apoptosis. These animals exhibited normal intrathymic development of conventional T cells, but they were profoundly impaired in the intrathymic development of invariant NKT cells. In peripheral organs, T cell-specific ablation of Vps34 had a profound impact on T cell homeostasis and function. Furthermore, aged animals developed an inflammatory wasting syndrome characterized by weight loss, intestinal inflammation, and anemia. Consistent with this phenotype, Vps34 was required for the peripheral maintenance and function of CD4(+)Foxp3(+) regulatory T cells. Collectively, our study reveals a critical role for Vps34 in autophagy and for the peripheral homeostasis and function of T lymphocytes.
C1 [Parekh, Vrajesh V.; Wu, Lan; Boyd, Kelli L.; Olivares-Villagomez, Danyvid; Cover, Timothy L.; Van Kaer, Luc] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
[Williams, Janice A.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
[Gaddy, Jennifer A.; Cover, Timothy L.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
[Cover, Timothy L.] Vet Affairs Tennessee Valley Healthcare Sys, Nashville, TN 37232 USA.
[Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.
[Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
RP Parekh, VV (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Med Ctr North, 21st Ave South Garland Ave,Room AA 5206, Nashville, TN 37232 USA.
EM vrajesh.v.parekh@vanderbilt.edu; luc.van.kaer@vanderbilt.edu
RI Van Kaer, Luc/H-1033-2015; Cover, Timothy/I-3814-2015
OI Van Kaer, Luc/0000-0001-5275-2309; Cover, Timothy/0000-0001-8503-002X;
Zhang, Jianhua/0000-0002-2128-9574
FU National Institutes of Health [AI070305, HL089667, DK081536, CA129536,
GM97355, NS064090, P30DK058404]; Veterans Affairs merit award;
Vanderbilt Digestive Diseases Research Center; National Multiple
Sclerosis Society of America
FX This work was supported by National Institutes of Health Grants AI070305
(to L. V. K.), HL089667 (to L. V. K.), DK081536 (to L. W. and L. V. K.),
CA129536 (to W.-X.Z), GM97355 (to W.-X.Z.), and NS064090 (to J.Z.), a
Veterans Affairs merit award (to J.Z.), the Vanderbilt Digestive
Diseases Research Center (supported by National Institutes of Health
Grant P30DK058404), and a postdoctoral fellowship from the National
Multiple Sclerosis Society of America (to V.V.P.).
NR 53
TC 36
Z9 37
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2013
VL 190
IS 10
BP 5086
EP 5101
DI 10.4049/jimmunol.1202071
PG 16
WC Immunology
SC Immunology
GA 138YB
UT WOS:000318546700020
PM 23596309
ER
PT J
AU Xu, P
Wen, Z
Shi, X
Li, Y
Fan, L
Xiang, M
Li, A
Scott, MJ
Xiao, G
Li, S
Billiar, TR
Wilson, MA
Fan, J
AF Xu, Peng
Wen, Zongmei
Shi, Xueyin
Li, Yuehua
Fan, Liyan
Xiang, Meng
Li, Aijun
Scott, Melanie J.
Xiao, Guozhi
Li, Song
Billiar, Timothy R.
Wilson, Mark A.
Fan, Jie
TI Hemorrhagic Shock Augments Nlrp3 Inflammasome Activation in the Lung
through Impaired Pyrin Induction
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FAMILIAL MEDITERRANEAN FEVER; RESPIRATORY-DISTRESS-SYNDROME; MULTIPLE
ORGAN FAILURE; SEVERE BLUNT TRAUMA; PULMONARY INFLAMMATION;
GENE-EXPRESSION; INTERLEUKIN-10; CYTOKINE; INJURY; MEDIATORS
AB Hemorrhagic shock (HS) promotes the development of systemic inflammatory response syndrome and organ injury by activating and priming the innate immune system for an exaggerated inflammatory response through, as of yet, unclear mechanisms. IL-1 beta also plays an important role in the development of post-HS systemic inflammatory response syndrome and active IL-1 beta production is tightly controlled by the inflammasome. Pyrin, a protein of 781 aa with pyrin domain at the N-terminal, negatively regulates inflammasome activation through interaction with nucleotide-binding oligomerization domain-like receptor protein (NLRP). Expression of pyrin can be induced by LPS and cytokines, and IL-10 is a known potent inducer of pyrin expression in macrophages. In the current study, we tested the hypothesis that HS downregulates IL-10 and therefore decreases pyrin expression to promote inflammasome activation and subsequent IL-1 beta processing and secretion in the lungs. Our results show that LPS, while activating Nlrp3 inflammasome in the lungs, also induced pyrin expression, which in turn suppressed inflammasome activation. More importantly, LPS-mediated upregulation of IL-10 enhanced pyrin expression, which serves, particularly in later phases, as a potent negative-feedback mechanism regulating inflammasome activation. However, HS-mediated suppression of IL-10 expression in alveolar macrophages attenuated the upregulation of pyrin in alveolar macrophages and lung endothelial cells and thereby significantly enhanced inflammasome activation and IL-1 beta secretion in the lungs. This study demonstrates a novel mechanism by which HS suppresses negative-feedback regulation of Nlrp3 inflammasome to enhance IL-1 beta secretion in response to subsequent LPS challenge and so primes for inflammation.
C1 [Xu, Peng; Wen, Zongmei; Li, Yuehua; Xiang, Meng; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA.
[Xu, Peng; Wen, Zongmei; Shi, Xueyin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China.
[Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA 15213 USA.
[Xiang, Meng] Fudan Univ, Dept Physiol & Pathophysiol, Shanghai Med Coll, Shanghai 200032, Peoples R China.
[Li, Aijun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200003, Peoples R China.
[Xiao, Guozhi] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
[Li, Song] Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
[Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA.
RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Bldg 1,2W109 151L U,Univ Dr C, Pittsburgh, PA 15240 USA.
EM shixueyin1128@yahoo.com.cn; jif7@pitt.edu
FU National Institutes of Health [R01-HL-079669]; National Institutes of
Health Center Grant [P50-GM-53789]; Veterans Affairs Merit Award; 12th
five-year key project grant of the People's Liberation Army [BWS12J027]
FX This work was supported by the National Institutes of Health Grant
R01-HL-079669 (to M. A. W. and J.F.), National Institutes of Health
Center Grant P50-GM-53789 (to T. R. B. and J.F.), a Veterans Affairs
Merit Award (to J.F.), and the 12th five-year key project grant of the
People's Liberation Army BWS12J027 (to X.S.).
NR 48
TC 17
Z9 19
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2013
VL 190
IS 10
BP 5247
EP 5255
DI 10.4049/jimmunol.1203182
PG 9
WC Immunology
SC Immunology
GA 138YB
UT WOS:000318546700036
PM 23585683
ER
PT J
AU Lang, JS
Scherzer, R
Weekley, CC
Tien, PC
Grunfeld, C
Shlipak, MG
AF Lang, Joshua
Scherzer, Rebecca
Weekley, Cristin C.
Tien, Phyllis C.
Grunfeld, Carl
Shlipak, Michael G.
TI Serum albumin and short-term risk for mortality and cardiovascular
disease among HIV-infected veterans
SO AIDS
LA English
DT Article
DE albumin; cardiovascular disease; end-stage renal disease; glomerular
filtration rate; kidney
ID INFLAMMATION; PROGRESSION; SURVIVAL; MARKERS; ASSOCIATION; PREDICTOR;
VIRUS; WOMEN
AB Objective: We examined the short-term and long-term associations of serum albumin with mortality and cardiovascular disease among HIV-infected veterans.
Design: Retrospective cohort analysis using a national database of US veterans with HIV infection.
Methods: This analysis evaluated all HIV-infected veterans in the Department of Veterans Affairs HIV Clinical Case Registry (CCR), a national database consisting of demographic, clinical, laboratory, pharmaceutical, and viral status data. There were 25 522 patients enrolled between 1986 and 2007. We evaluated the associations of baseline and time-updated serum albumin levels with all-cause mortality, atherosclerotic cardiovascular disease, and heart failure by multivariate proportional hazards models.
Results: Over 21 years, there were 10 869 deaths; the cumulative mortality was 73.2 per 1000 person-years. After multivariate adjustment for covariates measured at baseline, the lowest category of serum albumin (<2.5 g/dl) was associated with a higher mortality risk compared with the highest category (>4 g/dl; hazard ratio 3.00; 2.67-3.37). When analyzed as a time-dependent model, the association strengthened substantially (15.1; 14.0-16.4). Findings were similar for atherosclerotic cardiovascular disease and heart failure. We stratified the baseline mortality model by year of follow-up and found that albumin was more strongly associated with deaths that occurred within 1 year of baseline (9.29; 7.85-11.0) than in the second (1.66; 1.18-2.33) or third (1.22; 0.77-1.96) year after measurement.
Conclusion: Among ambulatory HIV-infected patients, lower serum albumin levels are strongly predictive of mortality risk, particularly within 1 year. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1339-1343
C1 [Lang, Joshua] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA.
[Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Weekley, Cristin C.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA.
EM michael.shlipak@ucsf.edu
FU [1R03AG034871-01]
FX 1R03AG034871-01: 'Kidney Disease, Antiretroviral Therapy and
Cardiovascular Events in HIV-Infection' (principal investigator, M. G.
S.), which was administered by the Northern California Institute for
Research and Education, and with resources of the Veterans Affairs
Medical Center, San Francisco, CA, USA.
NR 16
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2013
VL 27
IS 8
BP 1339
EP 1343
DI 10.1097/QAD.0b013e32835f1dd6
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133RG
UT WOS:000318156400017
PM 23343914
ER
PT J
AU Huang, SL
Du, F
Shih, YYI
Shen, Q
Gonzalez-Lima, F
Duong, TQ
AF Huang, Shiliang
Du, Fang
Shih, Yen-Yu I.
Shen, Qiang
Gonzalez-Lima, F.
Duong, Timothy Q.
TI Methylene blue potentiates stimulus-evoked fMRI responses and cerebral
oxygen consumption during normoxia and hypoxia
SO NEUROIMAGE
LA English
DT Article
DE fMRI; BOLD; CBF; Perfusion; Oxidative metabolism; Arterial spin
labeling; Cerebral metabolic rate of oxygen; Forepaw stimulation
ID RAT FOREPAW STIMULATION; FUNCTIONAL MRI; BLOOD-FLOW; QUANTITATIVE
PERFUSION; ANESTHETIZED RATS; DIFFUSION; BOLD; NEUROPROTECTION; MEMORY;
CBF
AB Methylene blue USP (MB) at low doses has metabolic-enhancing and antioxidant properties and exhibits experimental neurotherapeutic benefits, but little is known about its in vivo effects on cerebral blood flow (CBF), functional evoked responses, and the associated changes in cerebral metabolic rate of oxygen (CMRO2). This study used magnetic resonance imaging (MRI) to evaluate the in vivo effects of a single intravenous MB therapeutic dose (0.5 mg/kg) on basal CBF, blood oxygenation level-dependent (BOLD) and CBF responses to hypercapnic (5% CO2 in air) inhalation, as well as changes in BOLD, CBF, and CMRO2 during forepaw stimulation in the rat brain. MB did not have significant effects on arterial oxygen saturation, heart rate and fMRI responses to hypercapnia. However, MB significantly potentiated forepaw-evoked BOLD and CBF changes under normoxia. To further evaluate in vivo effects of MB under metabolic stress conditions, MRI measurements were also made under mild hypoxia (15% O-2). Hypoxia per se increased evoked functional MRI responses. MB under hypoxia further potentiated forepaw-evoked BOLD, CBF and oxygen consumption responses relative to normoxia. These findings provide insights into MB's effects on cerebral hemodynamics in vivo and could help to optimize treatments in neurological diseases with mitochondrial dysfunction and oxidative stress. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Huang, Shiliang; Du, Fang; Shih, Yen-Yu I.; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
[Gonzalez-Lima, F.] Univ Texas Austin, Dept Pharmacol & Toxicol, Austin, TX 78712 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Shen, Qiang/B-8784-2008
OI Shen, Qiang/0000-0002-4287-3403; Shih, Yen-Yu Ian/0000-0001-6529-911X;
Gonzalez-Lima, Francisco/0000-0001-9856-0775
FU Translational Technology Resource grant via the Clinical Translational
Science Award (CTSA) [NIH 8UL1TR000149]; NIH/NEI [R01 EY014211,
EY018855]; NIH/NINDS [R01-NS45879]
FX This work was supported in part by a Translational Technology Resource
grant via the Clinical Translational Science Award (CTSA, parent grant
NIH 8UL1TR000149), the NIH/NEI (R01 EY014211 and EY018855), NIH/NINDS
(R01-NS45879). TQD holds the Stanley I Glickman, MD, Endowed Chair in
Ophthalmic Research. We thank Dr. Shaohau Yang and Dr. Ailing Lin for
the helpful discussion in various phases of the project
NR 46
TC 13
Z9 13
U1 1
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2013
VL 72
BP 237
EP 242
DI 10.1016/j.neuroimage.2013.01.027
PG 6
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 120JO
UT WOS:000317166800023
PM 23357077
ER
PT J
AU van der Meer, P
Postmus, D
Ponikowski, P
Cleland, JG
O'Connor, CM
Cotter, G
Metra, M
Davison, BA
Givertz, MM
Mansoor, GA
Teerlink, JR
Massie, BM
Hillege, HL
Voors, AA
AF van der Meer, Peter
Postmus, Douwe
Ponikowski, Piotr
Cleland, John G.
O'Connor, Christopher M.
Cotter, Gad
Metra, Marco
Davison, Beth A.
Givertz, Michael M.
Mansoor, George A.
Teerlink, John R.
Massie, Barry M.
Hillege, Hans L.
Voors, Adriaan A.
TI The Predictive Value of Short-Term Changes in Hemoglobin Concentration
in Patients Presenting With Acute Decompensated Heart Failure
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE acute heart failure; hemoglobin; outcome
ID RENAL DYSFUNCTION; ENDOGENOUS ERYTHROPOIETIN; ANEMIA; MORTALITY;
ROLOFYLLINE; PREVALENCE; SURVIVAL; ASSOCIATION; ANTAGONIST; REGISTRY
AB Objectives The study sought to investigate the clinical correlates and prognostic role of anemia and changes in hemoglobin in patients hospitalized for acute decompensated heart failure (AHF).
Background Anemia is related to a poor outcome in patients with heart failure. In addition, an increase in hemoglobin during hospitalization might be a sign of effective decongestion and therefore related to improved outcome.
Methods This is a post hoc analysis of the PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) study in 1,969 patients with AHF and mild to moderate impaired renal function. Hemoglobin levels were measured daily for the first 4 days and at day 7. The endpoint was 180-day all-cause mortality.
Results Anemia at baseline was observed in 50.3% of the patients. During follow-up, 359 patients (18.2%) died. Hemoglobin increased in 69.1% and was associated with a better renal function at baseline and more weight loss, but was associated with a deterioration of renal function (p = 0.01), whereas total dose diuretics was lower in patients with hemoconcentration (p < 0.01). Interaction analysis showed that greater weight loss and better baseline renal function were associated with a more rapid increase in hemoglobin concentration (p < 0.01 for both). The absolute change in hemoglobin (g/dl) independently predicted outcome (hazard ratio: 0.66; 95% confidence interval: 0.51 to 0.86; p = 0.002), whereas baseline hemoglobin levels did not.
Conclusions Patients with AHF and preserved renal function are decongested better, as shown by an increase in hemoglobin. A rapid increase in hemoglobin during the first week is independently associated with a favorable outcome, despite a slight decrease in renal function. (C) 2013 by the American College of Cardiology Foundation
C1 [van der Meer, Peter; Postmus, Douwe; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands.
[Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland.
[Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mansoor, George A.] Merck Res Labs, Rahway, NJ USA.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Voors, AA (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Postmus,
Douwe/0000-0002-9458-7038; Metra, Marco/0000-0001-6691-8568; Davison,
Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016
FU Vifor Pharma; Amgen, Inc.; Merck; Abbott; Amgen; Biogen Idec; Corthera;
Cytokinetics; Johnson Johnson/Scios; Novartis; Relypsa; Solvay
FX Dr. Ponikowski has received honoraria from Merck; consulting fees from
Vifor Pharma and Amgen, Inc., honoraria from Vifor Pharma; and
travel/accommodation expenses covered by Vifor Pharma and Amgen, Inc.
Dr. Cleland was on the Steering Committee for the study; served on the
advisory board for MSD; and received payments for both. Dr. O'Connor is
a consultant to Merck and Amgen. Dr. Davison and Dr. Cotter are
employees of Momentum Research Inc, which was contracted to perform work
on the project by Merck. Drs. Metra and Massie have received honoraria
and reimbursements from NovaCardia, sponsors of the study, and from
Merck, which purchased the rights to rolofylline after completion of the
PROTECT pilot study. Dr. Givertz has received institutional research
support and served on a scientific Advisory Board for Merck. Dr. Mansoor
is an employee of Merck. Dr. Teerlink has received research funds and
consulting fees from Merck, the makers of rolofylline for the conduct of
this study and has also received research funds and consulting fees from
Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics, Johnson &
Johnson/Scios, Novartis, Relypsa, and Solvay for research in related
areas. Dr. Voors has received speaker and consultancy fees from Merck.
All other authors have reported that they have no relationships relevant
to the contents of this paper to report.
NR 23
TC 56
Z9 57
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 14
PY 2013
VL 61
IS 19
BP 1973
EP 1981
DI 10.1016/j.jacc.2012.12.050
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 144AB
UT WOS:000318910300007
PM 23500313
ER
PT J
AU Allison, TA
Sudore, RL
AF Allison, Theresa A.
Sudore, Rebecca L.
TI Disregard of Patients' Preferences Is a Medical Error
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID ADVANCE CARE
C1 [Allison, Theresa A.; Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Allison, Theresa A.; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA.
[Allison, Theresa A.] Univ Calif San Francisco, Div Geriatr, Dept Family & Community Med, San Francisco, CA 94143 USA.
RP Allison, TA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,POB 181-G, San Francisco, CA 94941 USA.
EM Theresa.Allison@UCSF.edu
NR 9
TC 11
Z9 11
U1 1
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 13
PY 2013
VL 173
IS 9
BP 787
EP 788
DI 10.1001/jamainternmed.2013.203
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159JN
UT WOS:000320041800018
PM 23545699
ER
PT J
AU Kerlikowske, K
Zhu, WW
Hubbard, RA
Geller, B
Dittus, K
Braithwaite, D
Wernli, KJ
Miglioretti, DL
O'Meara, ES
AF Kerlikowske, Karla
Zhu, Weiwei
Hubbard, Rebecca A.
Geller, Berta
Dittus, Kim
Braithwaite, Dejana
Wernli, Karen J.
Miglioretti, Diana L.
O'Meara, Ellen S.
CA Breast Canc Surveillance Consorti
TI Outcomes of Screening Mammography by Frequency, Breast Density, and
Postmenopausal Hormone Therapy
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID FALSE-POSITIVE RECALL; SERVICES TASK-FORCE; REPLACEMENT THERAPY; CANCER
RISK; TUMOR CHARACTERISTICS; WOMEN; ASSOCIATION; BENEFITS; COHORT;
REPRODUCIBILITY
AB Importance: Controversy exists about the frequency women should undergo screening mammography and whether screening interval should vary according to risk factors beyond age.
Objective: To compare the benefits and harms of screening mammography frequencies according to age, breast density, and postmenopausal hormone therapy (HT) use.
Design: Prospective cohort.
Setting: Data collected January 1994 to December 2008 from mammography facilities in community practice that participate in the Breast Cancer Surveillance Consortium (BCSC) mammography registries.
Participants: Data were collected prospectively on 11 474 women with breast cancer and 922 624 without breast cancer who underwent mammography at facilities that participate in the BCSC.
Main Outcomes and Measures: We used logistic regression to calculate the odds of advanced stage (IIb, III, or IV) and large tumors (> 20 mm in diameter) and 10-year cumulative probability of a false-positive mammography result by screening frequency, age, breast density, and HT use. The main predictor was screening mammography interval.
Results: Mammography biennially vs annually for women aged 50 to 74 years does not increase risk of tumors with advanced stage or large size regardless of women's breast density or HT use. Among women aged 40 to 49 years with extremely dense breasts, biennial mammography vs annual is associated with increased risk of advanced-stage cancer (odds ratio [OR], 1.89; 95% CI, 1.06-3.39) and large tumors (OR, 2.39; 95% CI, 1.37-4.18). Cumulative probability of a false-positive mammography result was high among women undergoing annual mammography with extremely dense breasts who were either aged 40 to 49 years (65.5%) or used estrogen plus progestogen (65.8%) and was lower among women aged 50 to 74 years who underwent biennial or triennial mammography with scattered fibroglandular densities (30.7% and 21.9%, respectively) or fatty breasts (17.4% and 12.1%, respectively).
Conclusions and Relevance: Women aged 50 to 74 years, even those with high breast density or HT use, who undergo biennial screening mammography have similar risk of advanced-stage disease and lower cumulative risk of false-positive results than those who undergo annual mammography. Whendeciding whether to undergo mammography, women aged 40 to 49 years who have extremely dense breasts should be informed that annual mammography may minimize their risk of advancedstage disease but the cumulative risk of false-positive results is high.
C1 [Kerlikowske, Karla; Braithwaite, Dejana] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA.
[Zhu, Weiwei; Hubbard, Rebecca A.; Wernli, Karen J.; Miglioretti, Diana L.; O'Meara, Ellen S.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[O'Meara, Ellen S.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Geller, Berta] Univ Vermont, Coll Med, Dept Family Med, Burlington, VT 05405 USA.
[Geller, Berta] Univ Vermont, Coll Med, Dept Radiol, Burlington, VT 05405 USA.
[Dittus, Kim] Univ Vermont, Coll Med, Dept Med Oncol, Burlington, VT 05405 USA.
[Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA.
RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,Mailing Code 111A1, San Francisco, CA 94121 USA.
EM Karla.Kerlikowske@ucsf.edu
FU National Cancer Institute-funded Breast Cancer Surveillance Consortium
cooperative agreement [U01CA63740, U01CA86076, U01CA86082, U01CA63736,
U01CA70013, U01CA69976, U01CA63731, U01CA70040]; National Cancer
Institute [RC2CA148577, R03CA150007, P01 CA107584]
FX This work was supported by the National Cancer Institute-funded Breast
Cancer Surveillance Consortium cooperative agreement (grants U01CA63740,
U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731,
U01CA70040) and the National Cancer Institute-funded grants RC2CA148577,
R03CA150007, and P01 CA107584. The collection of cancer data used in
this study was supported in part by several state public health
departments and cancer registries throughout the United States For a
full description of these sources, please see
http://breastscreening.cancer.gov/work/acknowledgement.html.
NR 38
TC 59
Z9 60
U1 0
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 13
PY 2013
VL 173
IS 9
BP 807
EP 816
DI 10.1001/jamainternmed.2013.307
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159JN
UT WOS:000320041800023
PM 23552817
ER
PT J
AU Russo, SB
Tidhar, R
Futerman, AH
Cowart, LA
AF Russo, Sarah Brice
Tidhar, Rotem
Futerman, Anthony H.
Cowart, L. Ashley
TI Myristate-derived d16:0 Sphingolipids Constitute a Cardiac Sphingolipid
Pool with Distinct Synthetic Routes and Functional Properties
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MAMMALIAN SERINE-PALMITOYLTRANSFERASE; TANDEM MASS-SPECTROMETRY;
CERAMIDE SYNTHASES; CELL-DEATH; ACYL-CHAIN; SPHINGOSINE 1-PHOSPHATE;
DIABETIC CARDIOMYOPATHY; HEART-FAILURE; LONG-CHAIN; RAT-BRAIN
AB The enzyme serine palmitoyltransferase (SPT) catalyzes the formation of the sphingoid base "backbone" from which all sphingolipids are derived. Previous studies have shown that inhibition of SPT ameliorates pathological cardiac outcomes in models of lipid overload, but the metabolites responsible for these phenotypes remain unidentified. Recent in vitro studies have shown that incorporation of the novel subunit SPTLC3 broadens the substrate specificity of SPT, allowing utilization of myristoyl-coenzyme A (CoA) in addition to its canonical substrate palmitoyl-CoA. However, the relevance of these findings in vivo has yet to be determined. The present study sought to determine whether myristate-derived d16 sphingolipids are represented among myocardial sphingolipids and, if so, whether their function and metabolic routes were distinct from those of palmitate-derived d18 sphingolipids. Data showed that d16: 0 sphingoid bases occurred in more than one-third of total dihydrosphingosine and dihydroceramides in myocardium, and a diet high in saturated fat promoted their de novo production. Intriguingly, d16-ceramides demonstrated highly limited N-acyl chain diversity, and in vitro enzyme activity assays showed that these bases were utilized preferentially to canonical bases by CerS1. Functional differences between myristate- and palmitate-derived sphingolipids were observed in that, unlike d18 sphingolipids and SPTLC2, d16 sphingolipids and SPTLC3 did not appear to contribute to myristate-induced autophagy, whereas only d16 sphingolipids promoted cell death and cleavage of poly(ADPribose) polymerase in cardiomyocytes. Thus, these results reveal a previously unappreciated component of cardiac sphingolipids with functional differences from canonical sphingolipids.
C1 [Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA.
[Tidhar, Rotem; Futerman, Anthony H.] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
[Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
RP Cowart, LA (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC509, Charleston, SC 29403 USA.
EM cowartl@musc.edu
OI Futerman, Anthony/0000-0003-0013-0115
FU National Institutes of Health (NIH), NIDDK [F30DK092125]; NIH [P30
CA138313, P20 RR017677]; NIH COBRE in Lipidomics and Pathobiology at
MUSC; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health (NIH), NIDDK, Grant F30DK092125 (to S. B. R.); NIH Grant P30
CA138313 (Lipidomics Shared Resource, Hollings Cancer Center, Medical
University of South Carolina (MUSC)); NIH Grant P20 RR017677 (Lipidomics
Core in the South Carolina Lipidomics and Pathobiology Centers of
Biomedical Research Excellence (COBRE), Department of Biochemistry,
MUSC); and the NIH COBRE in Lipidomics and Pathobiology at MUSC (to L.
A. C.). This work was also supported by a Merit Award from the
Department of Veterans Affairs (to L. A. C.).
NR 63
TC 16
Z9 16
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 10
PY 2013
VL 288
IS 19
BP 13397
EP 13409
DI 10.1074/jbc.M112.428185
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 143EV
UT WOS:000318850300025
PM 23530041
ER
PT J
AU Qin, WP
Sun, L
Cao, J
Peng, YZ
Collier, L
Wu, Y
Creasey, G
Li, JH
Qin, YW
Jarvis, J
Bauman, WA
Zaidi, M
Cardozo, C
AF Qin, Weiping
Sun, Li
Cao, Jay
Peng, Yuanzhen
Collier, Lauren
Wu, Yong
Creasey, Graham
Li, Jianhua
Qin, Yiwen
Jarvis, Jonathan
Bauman, William A.
Zaidi, Mone
Cardozo, Christopher
TI The Central Nervous System (CNS)-independent Anti-bone-resorptive
Activity of Muscle Contraction and the Underlying Molecular and Cellular
Signatures
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SPINAL-CORD-INJURY; GENE-EXPRESSION; C-FOS; CELLS; DIFFERENTIATION;
IMMOBILIZATION; DISEASE; OSTEOCLASTOGENESIS; STIMULATION; NANDROLONE
AB Muscle and bone work as a functional unit. Cellular and molecular mechanisms underlying effects of muscle activity on bone mass are largely unknown. Spinal cord injury (SCI) causes muscle paralysis and extensive sublesional bone loss and disrupts neural connections between the central nervous system (CNS) and bone. Muscle contraction elicited by electrical stimulation (ES) of nerves partially protects against SCI-related bone loss. Thus, application of ES after SCI provides an opportunity to study the effects of muscle activity on bone and roles of the CNS in this interaction, as well as the underlying mechanisms. Using a rat model of SCI, the effects on bone of ES-induced muscle contraction were characterized. The SCI-mediated increase in serum C-terminal telopeptide of type I collagen (CTX) was completely reversed by ES. In ex vivo bone marrow cell cultures, SCI increased the number of osteoclasts and their expression of mRNA for several osteoclast differentiation markers, whereas ES significantly reduced these changes; SCI decreased osteoblast numbers, but increased expression in these cells of receptor activator of NF-kappa B ligand (RANKL) mRNA, whereas ES increased expression of osteoprotegerin (OPG) and the OPG/RANKL ratio. A microarray analysis revealed that ES partially reversed SCI-induced alterations in expression of genes involved in signaling through Wnt, FSH, parathyroid hormone (PTH), oxytocin, and calcineurin/nuclear factor of activated T-cells (NFAT) pathways. ES mitigated SCI-mediated increases in mRNA levels for the Wnt inhibitors DKK1, sFRP2, and sclerostin in ex vivo cultured osteoblasts. Our results demonstrate an anti-bone-resorptive activity of muscle contraction by ES that develops rapidly and is independent of the CNS. The pathways involved, particularly Wnt signaling, suggest future strategies to minimize bone loss after immobilization.
C1 [Qin, Weiping; Sun, Li; Peng, Yuanzhen; Li, Jianhua; Bauman, William A.; Zaidi, Mone; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
[Sun, Li; Li, Jianhua; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
[Qin, Weiping; Peng, Yuanzhen; Collier, Lauren; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA.
[Cao, Jay] Res Serv, USDA, Human Nutr Res Ctr, Grand Forks, ND 58201 USA.
[Creasey, Graham] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
[Creasey, Graham] Stanford Univ, Palo Alto, CA 94304 USA.
[Qin, Yiwen] Chapin Sch, New York, NY 10028 USA.
[Jarvis, Jonathan] Liverpool John Moores Univ, Sch Sport & Exercise Sci, Liverpool L3 3AF, Merseyside, England.
RP Qin, WP (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences SCI, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM weiping.qin@mssm.edu; Chris.cardozo@mssm.edu
FU United States Veterans Health Administration, Rehabilitation Research
and Development Service [B4162C, B4055X, B3347K]; United States
Department of Defense [SC090504]; National Institutes of Health
[AG23176, DK80459]; European Commission [QLG5-CT-2001-02191]
FX This work was supported by the United States Veterans Health
Administration, Rehabilitation Research and Development Service Grants
B4162C (to W. A. B.) and B4055X and B3347K (to C. C.), the United States
Department of Defense Grant SC090504 (to W. Q.), National Institutes of
Health Grants AG23176 and DK80459 (to M. Z.), and European Commission
Project RISE Grant QLG5-CT-2001-02191 (to J. J.).
NR 62
TC 21
Z9 21
U1 1
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 10
PY 2013
VL 288
IS 19
BP 13511
EP 13521
DI 10.1074/jbc.M113.454892
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 143EV
UT WOS:000318850300035
PM 23530032
ER
PT J
AU Bhargava, R
Janssen, W
Altmann, C
Andres-Hernando, A
Okamura, K
Vandivier, RW
Ahuja, N
Faubel, S
AF Bhargava, Rhea
Janssen, William
Altmann, Christopher
Andres-Hernando, Ana
Okamura, Kayo
Vandivier, R. William
Ahuja, Nilesh
Faubel, Sarah
TI Intratracheal IL-6 Protects against Lung Inflammation in Direct, but Not
Indirect, Causes of Acute Lung Injury in Mice
SO PLOS ONE
LA English
DT Article
ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY;
CRITICALLY-ILL PATIENTS; RESPIRATORY-DISTRESS-SYNDROME;
BILATERAL-NEPHRECTOMY; ALVEOLAR MACROPHAGES; MECHANICAL VENTILATION;
PERSISTENT ELEVATION; CARDIAC-SURGERY
AB Introduction: Serum and bronchoalveolar fluid IL-6 are increased in patients with acute respiratory distress syndrome (ARDS) and predict prolonged mechanical ventilation and poor outcomes, although the role of intra-alveolar IL-6 in indirect lung injury is unknown. We investigated the role of endogenous and exogenous intra-alveolar IL-6 in AKI-mediated lung injury (indirect lung injury), intraperitoneal (IP) endotoxin administration (indirect lung injury) and, for comparison, intratracheal (IT) endotoxin administration (direct lung injury) with the hypothesis that IL-6 would exert a pro-inflammatory effect in these causes of acute lung inflammation.
Methods: Bronchoalveolar cytokines (IL-6, CXCL1, TNF-alpha, IL-1 beta, and IL-10), BAL fluid neutrophils, lung inflammation (lung cytokines, MPO activity [ a biochemical marker of neutrophil infiltration]), and serum cytokines were determined in adult male C57Bl/ 6 mice with no intervention or 4 hours after ischemic AKI (22 minutes of renal pedicle clamping), IP endotoxin (10 mu g), or IT endotoxin (80 mu g) with and without intratracheal (IT) IL-6 (25 ng or 200 ng) treatment.
Results: Lung inflammation was similar after AKI, IP endotoxin, and IT endotoxin. BAL fluid IL-6 was markedly increased after IT endotoxin, and not increased after AKI or IP endotoxin. Unexpectedly, IT IL-6 exerted an anti-inflammatory effect in healthy mice characterized by reduced BAL fluid cytokines. IT IL-6 also exerted an anti-inflammatory effect in IT endotoxin characterized by reduced BAL fluid cytokines and lung inflammation; IT IL-6 had no effect on lung inflammation in AKI or IP endotoxin.
Conclusion: IL-6 exerts an anti-inflammatory effect in direct lung injury from IT endotoxin, yet has no role in the pathogenesis or treatment of indirect lung injury from AKI or IP endotoxin. Since intra-alveolar inflammation is important in the pathogenesis of direct, but not indirect, causes of lung inflammation, IT anti-inflammatory treatments may have a role in direct, but not indirect, causes of ARDS.
C1 [Bhargava, Rhea; Altmann, Christopher; Andres-Hernando, Ana; Okamura, Kayo; Ahuja, Nilesh] Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
[Janssen, William] Natl Jewish Hlth, Dept Med, Div Pulm Med, Denver, CO USA.
[Vandivier, R. William] Univ Colorado Denver, Div Pulm Med, Dept Med, Aurora, CO USA.
[Faubel, Sarah] Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
[Faubel, Sarah] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
RP Faubel, S (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
EM Sarah.Faubel@ucdenver.edu
FU United States National Institutes of Health (NIH); NHLBI [R01 HL095363];
NIH [HL109517]; AHA Postdoctoral Fellowship
FX This work was supported by United States National Institutes of Health
(NIH) funding from NHLBI: R01 HL095363 to S.F., NIH HL109517, and AHA
Postdoctoral Fellowship to A.A.-H. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 17
Z9 21
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2013
VL 8
IS 5
AR e61405
DI 10.1371/journal.pone.0061405
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145YI
UT WOS:000319055600011
PM 23667439
ER
PT J
AU Lewis, KB
Hughes, RJ
Epstein, MS
Josephson, NC
Kempton, CL
Kessler, CM
Key, NS
Howard, TE
Kruse-Jarres, R
Lusher, JM
Walsh, CE
Watts, RG
Ettinger, RA
Pratt, KP
AF Lewis, Kenneth B.
Hughes, Richard J.
Epstein, Melinda S.
Josephson, Neil C.
Kempton, Christine L.
Kessler, Craig M.
Key, Nigel S.
Howard, Tom E.
Kruse-Jarres, Rebecca
Lusher, Jeanne M.
Walsh, Christopher E.
Watts, Raymond G.
Ettinger, Ruth A.
Pratt, Kathleen P.
CA PATH Personalized Alternative
TI Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII
Characterized by Surface Plasmon Resonance
SO PLOS ONE
LA English
DT Article
ID FACTOR-VIII ANTIBODIES; HUMAN/PORCINE FACTOR-VIII;
VON-WILLEBRAND-FACTOR; FAB-ARM EXCHANGE; HEMOPHILIA-A; BETHESDA ASSAY;
IGG4 ANTIBODIES; B-CELL; MONOCLONAL-ANTIBODIES; INHIBITOR ANTIBODIES
AB Evidence of antibody isotype/ subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed "inhibitors''. A sensitive, high-information-content surface plasmon resonance (SPR) assay has been developed to quantify IgG subtype distributions and the domain specificity of anti-drug antibodies. Plasma samples from 22 subjects with an alloor auto-immune reaction to FVIII were analyzed. Pre-analytical treatment protocols were developed to minimize nonspecific binding and specific matrix interference due to von Willebrand factor-FVIII interactions. The dynamic range for IgG quantification was 0.2-5 mu g/ml (similar to 1-33 nM), allowing characterization of inhibitor-positive samples. Subtype-specific monoclonal antibodies were used to quantify the IgG subtype distribution of FVIII-specific antibodies. Most samples obtained from multiply-infused inhibitor subjects contained IgG(4) antibodies. Several distinct phenotypes were assigned based on the IgG subtype distribution: IgG(1), IgG(4), IgG(1) & IgG(4), and IgG(1), IgG(2) & IgG(4). An IgG(1)-only response was found in mild/moderate HA subjects during early FVIII infusions, and analysis of serial samples followed antibody class switching as several subjects' immune responses developed. Competition studies utilizing a recombinant FVIII-C2 domain indicated 40-80% of FVIII-specific antibodies in most samples were directed against this domain.
C1 [Lewis, Kenneth B.; Josephson, Neil C.; Ettinger, Ruth A.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
[Hughes, Richard J.; Epstein, Melinda S.; Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Josephson, Neil C.; Pratt, Kathleen P.] Univ Washington, Div Hematol, Seattle, WA 98195 USA.
[Kempton, Christine L.] Emory Univ, Atlanta, GA 30322 USA.
[Kessler, Craig M.] Georgetown Univ, Washington, DC USA.
[Key, Nigel S.] Univ N Carolina, Chapel Hill, NC USA.
[Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Howard, Tom E.] USC, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA.
[Kruse-Jarres, Rebecca] Tulane Univ, New Orleans, LA 70118 USA.
[Lusher, Jeanne M.] Wayne State Univ, Detroit, MI USA.
[Walsh, Christopher E.] Mt Sinai Sch Med, New York, NY USA.
[Watts, Raymond G.] Univ Alabama Birmingham, Birmingham, AL USA.
RP Pratt, KP (reprint author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
EM KathleenP@psbc.org
FU NHLBI [1RC2 HL101851]; Bayer HealthCare LLC
FX Major support for this work was from NHLBI 1RC2 HL101851: "Mechanisms of
Race-Based Differences in Factor VIII Immunogenicity in Hemophilia A"
(PIs TE Howard and KP Pratt). Minor support for this work was from: 1.
Unrestricted research support was received under a CSL Behring
Foundation Hemophilia grant: "Do Non-Synonymous Single Nucleotide
Polymorphisms in Factor VIII Lead to T-Cell Responses and Subsequent
Inhibitor Development in Black Hemophilia A Patients?" (PI: KP Pratt),
funder: CSL Behring Foundation for Research and Advancement of Patient
Health, http://www.cslbehringfoundation.com/.2. Unrestricted research
support was received from a Bayer Healthcare LLC grant: "Repository for
Human HLA-restricted T-Cell Clones" (PI: KP Pratt), funder: Bayer
HealthCare LLC, http://grants-contributions.bayerweb.com/en/home/index.
php, 800 Dwight Way, Berkeley, California 94710. These funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.; The authors have the following
interests. Dr's. Pratt and Lewis are inventors on a patent describing
the SPR methodology described in this study. Dr. Pratt received travel
support from GE Health Sciences to present preliminary SPR studies at
the 2011 DiPia meeting in Boston, Massachusetts. This study was partly
funded by Bayer HealthCare LLC. The authors thank Dr. Jason Schuman (GE
Health Sciences) for technical advice and Bill Church (Green Mountain
Antibodies, Burlington, Vermont) for donations of monoclonal antibodies.
Drs. Lewis and Pratt are inventors on the following patent:
International Patent Application No. PCT/US2012/61/553, 660, Title:
Antibody Response Phenotyping, Filed: October 31, 2012, Inventors:
Kathleen Pratt, PhD; Kenneth Lewis, PhD. There are no further patents,
products in development or marketed products to declare. This does not
alter the authors' adherence to all the PLOS ONE policies on sharing
data and materials, as detailed online in the guide for authors.
NR 43
TC 6
Z9 6
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2013
VL 8
IS 5
AR e61120
DI 10.1371/journal.pone.0061120
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145YI
UT WOS:000319055600009
PM 23667433
ER
PT J
AU Raitt, MH
AF Raitt, Merritt H.
TI Reducing Shocks and Improving Outcomes With Implantable Defibrillators
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID CARDIOVERTER-DEFIBRILLATORS; HEART-FAILURE; THERAPY; MORTALITY
C1 [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA.
[Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD,3710 SW US Vet Rd, Portland, OR 97239 USA.
EM merritt.raitt@va.gov
OI Raitt, Merritt/0000-0001-5638-7732
NR 13
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 8
PY 2013
VL 309
IS 18
BP 1937
EP 1938
DI 10.1001/jama.2013.5561
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138AZ
UT WOS:000318481900029
PM 23652525
ER
PT J
AU Yomogida, K
Wu, SL
Baravati, B
Avendano, C
Caldwell, T
Maniaci, B
Zhu, Y
Chu, CQ
AF Yomogida, Kentaro
Wu, Shili
Baravati, Bobby
Avendano, Camilo
Caldwell, Tom
Maniaci, Brian
Zhu, Yong
Chu, Cong-Qiu
TI Cell penetrating recombinant Foxp3 protein enhances Treg function and
ameliorates arthritis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Foxp3; T regulatory cells; Arthritis
ID REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; AUTOIMMUNITY;
ACTIVATION; GENERATION; EXPRESSION; TOLERANCE; ALLERGY; CD25
AB Foxp3 is the master transcription factor for T regulatory (Treg) cell differentiation and function. This study aimed to test the therapeutic potential of cell penetrating recombinant Foxp3 protein in arthritis. Recombinant Foxp3 protein was fused to a cell penetrating polyarginine (Foxp3-11R) tag to facilitate intracellular transduction. In vitro Foxp3-11R treated CD4(+) T cells showed a 50% increase in suppressive function compared with control protein treated cells. Severity of arthritis in Foxp3-11R treated mice was significantly reduced compared with those treated with a control protein. CD4(+) T cells of lymph nodes and spleen from Foxp3-11R treated mice showed increased levels of Foxp3 expression compared with those of a control protein treated. These results demonstrated that Foxp3-11R can enhance T cell suppressive function and ameliorate experimental arthritis and suggest that cell penetrating recombinant Foxp3 is a potentially useful agent in therapy of arthritis. Published by Elsevier Inc.
C1 [Yomogida, Kentaro; Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Yomogida, Kentaro; Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR 97239 USA.
[Wu, Shili; Baravati, Bobby; Avendano, Camilo; Caldwell, Tom; Maniaci, Brian; Zhu, Yong] VivoScript Inc, Costa Mesa, CA 92626 USA.
RP Chu, CQ (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA.
EM chuc@ohsu.edu
FU NIH [AR055254]; Portland VA Medical Center
FX This work was supported by a grant from NIH to CQC (AR055254) and
Portland VA Medical Center to CQC.
NR 24
TC 3
Z9 3
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 3
PY 2013
VL 434
IS 2
BP 263
EP 267
DI 10.1016/j.bbrc.2013.02.114
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 146NW
UT WOS:000319098800014
PM 23541572
ER
PT J
AU Joseph, K
Kulik, L
Coughlin, B
Kunchithapautham, K
Bandyopadhyay, M
Thiel, S
Thielens, NM
Holers, VM
Rohrer, B
AF Joseph, Kusumam
Kulik, Liudmila
Coughlin, Beth
Kunchithapautham, Kannan
Bandyopadhyay, Mausumi
Thiel, Steffen
Thielens, Nicole M.
Holers, V. Michael
Rohrer, Baerbel
TI Oxidative Stress Sensitizes Retinal Pigmented Epithelial (RPE) Cells to
Complement-mediated Injury in a Natural Antibody-, Lectin Pathway-, and
Phospholipid Epitope-dependent Manner
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INDUCED CHOROIDAL NEOVASCULARIZATION; LIPID-PEROXIDATION PRODUCTS;
MACULAR DEGENERATION AMD; MEMBRANE-ATTACK-COMPLEX; MANNOSE-BINDING
LECTIN; FACTOR-H; ISCHEMIA/REPERFUSION INJURY; SERINE-PROTEASE;
ALTERNATIVE PATHWAY; REPERFUSION INJURY
AB Uncontrolled activation of the alternative complement pathway (AP) is thought to be associated with age-related macular degeneration. Previously, we have shown that in retinal pigmented epithelial (RPE) monolayers, oxidative stress reduced complement inhibition on the cell surface, resulting in sublytic complement activation and loss of transepithelial resistance (TER), but the potential ligand and pathway involved are unknown. ARPE-19 cells were grown as monolayers on transwell plates, and sublytic complement activation was induced with H2O2 and normal human serum. TER deteriorated rapidly in H2O2-exposed monolayers upon adding normal human serum. Although the effect required AP activation, AP was not sufficient, because elimination of MASP, but not C1q, prevented TER reduction. Reconstitution experiments to unravel essential components of the lectin pathway (LP) showed that both ficolin and mannan-binding lectin can activate the LP through natural IgM antibodies (IgM-C2) that recognize phospholipid cell surface modifications on oxidatively stressed RPE cells. The same epitopes were found on human primary embryonic RPE monolayers. Likewise, mouse laser-induced choroidal neovascularization, an injury that involves LP activation, could be increased in antibody-deficient rag1(-/-) mice using the phospholipid-specific IgM-C2. In summary, using a combination of depletion and reconstitution strategies, we have shown that the LP is required to initiate the complement cascade following natural antibody recognition of neoepitopes, which is then further amplified by the AP. LP activation is triggered by IgM bound to phospholipids. Taken together, we have defined novel mechanisms of complement activation in oxidatively stressed RPE, linking molecular events involved in age-related macular degeneration, including the presence of natural antibodies and neoepitopes.
C1 [Joseph, Kusumam; Coughlin, Beth; Kunchithapautham, Kannan; Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Kulik, Liudmila; Holers, V. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA.
[Thiel, Steffen] Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.
[Thielens, Nicole M.] Univ Grenoble 1, CNRS, Inst Biol Struct, UMR 5075 CEA, F-38027 Grenoble 1, France.
[Rohrer, Baerbel] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health Grant [R01EY019320, C06 RR015455];
Department of Veterans Affairs Grant [I01 RX000444]; Foundation Fighting
Blindness; Research to Prevent Blindness, Inc. (New York)
FX This work was supported, in whole or in part, by National Institutes of
Health Grant R01EY019320. This work was also supported by Department of
Veterans Affairs Grant I01 RX000444, Foundation Fighting Blindness, and
an unrestricted grant to the Medical University of South Carolina from
Research to Prevent Blindness, Inc. (New York). Animal studies were
conducted in a facility constructed with support from National
Institutes of Health Grant C06 RR015455.
NR 69
TC 19
Z9 20
U1 5
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 12753
EP 12765
DI 10.1074/jbc.M112.421891
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100032
PM 23493397
ER
PT J
AU Donnelly, BF
Needham, PG
Snyder, AC
Roy, A
Khadem, S
Brodsky, JL
Subramanya, AR
AF Donnelly, Bridget F.
Needham, Patrick G.
Snyder, Avin C.
Roy, Ankita
Khadem, Shaheen
Brodsky, Jeffrey L.
Subramanya, Arohan R.
TI Hsp70 and Hsp90 Multichaperone Complexes Sequentially Regulate
Thiazide-sensitive Cotransporter Endoplasmic Reticulum-associated
Degradation and Biogenesis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; NA-CL COTRANSPORTER; HEAT-SHOCK
PROTEINS; CHAPERONE MACHINERY; QUALITY-CONTROL; MOLECULAR CHAPERONES;
GITELMANS-SYNDROME; MUTATIONS; CHIP; CFTR
AB The thiazide-sensitive NaCl cotransporter (NCC) is the primary mediator of salt reabsorption in the distal convoluted tubule and is a key determinant of the blood pressure set point. Given its complex topology, NCC is inefficiently processed and prone to endoplasmic reticulum (ER)-associated degradation (ERAD), although the mechanisms governing this process remain obscure. Here, we identify factors that impact the ER quality control of NCC. Analyses of NCC immunoprecipitates revealed that the cotransporter formed complexes with the core chaperones Hsp90, Hsp70, and Hsp40. Disruption of Hsp90 function accelerated NCC degradation, suggesting that Hsp90 promotes NCC folding. In addition, two cochaperones, the C terminus of Hsp70-interacting protein (CHIP) and the Hsp70/Hsp90 organizer protein, were associated with NCC. Although CHIP, an E3 ubiquitin ligase, promoted NCC ubiquitination and ERAD, the Hsp70/Hsp90 organizer protein stabilized NCC turnover, indicating that these two proteins differentially remodel the core chaperone systems to favor cotransporter degradation and biogenesis, respectively. Adjusting the folding environment in mammalian cells via reduced temperature enhanced NCC biosynthetic trafficking, increased Hsp90-NCC interaction, and diminished binding to Hsp70. In contrast, cotransporters harboring disease-causing mutations that impair NCC biogenesis failed to escape ERAD as efficiently as the wild type protein when cells were incubated at a lower temperature. Instead, these mutants interacted more strongly with Hsp70, Hsp40, and CHIP, consistent with a role for the Hsp70/Hsp40 system in selecting misfolded NCC for ERAD. Collectively, these observations indicate that Hsp70 and Hsp90 comprise two functionally distinct ER quality control checkpoints that sequentially monitor NCC biogenesis.
C1 [Needham, Patrick G.; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA.
[Donnelly, Bridget F.; Snyder, Avin C.; Roy, Ankita; Khadem, Shaheen; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA.
[Khadem, Shaheen; Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
RP Subramanya, AR (reprint author), 3550 Terrace St,S832 Scaife Hall, Pittsburgh, PA 15261 USA.
EM ars129@pitt.edu
FU National Institutes of Health [DK79307, GM75061]; U.S. Dept. of Veterans
Affairs; James A. Shaver Fund of the American Heart Association
[10BGIA3890010]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK79307 (to the Pittsburgh Center for Kidney Research,
Model Organisms Core) and GM75061 (to J. L. B.). This work was also
supported by a Mid-Level Career Development Award from the U.S. Dept. of
Veterans Affairs (to A. R. S.) and Grant 10BGIA3890010 from the James A.
Shaver Fund of the American Heart Association (to A. R. S.).
NR 52
TC 14
Z9 14
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 13124
EP 13135
DI 10.1074/jbc.M113.455394
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100062
PM 23482560
ER
PT J
AU Ramos, AD
Diaz, A
Nellore, A
Delgado, RN
Park, KY
Gonzales-Roybal, G
Oldham, MC
Song, JS
Lim, DA
AF Ramos, Alexander D.
Diaz, Aaron
Nellore, Abhinav
Delgado, Ryan N.
Park, Ki-Youb
Gonzales-Roybal, Gabriel
Oldham, Michael C.
Song, Jun S.
Lim, Daniel A.
TI Integration of Genome-wide Approaches Identifies lncRNAs of Adult Neural
Stem Cells and Their Progeny In Vivo
SO CELL STEM CELL
LA English
DT Article
ID LONG NONCODING RNAS; RETINAL DEVELOPMENT; GENE-EXPRESSION; MOUSE-BRAIN;
CHROMATIN; DIFFERENTIATION; REVEALS; NEUROGENESIS; LINCRNAS; LINEAGE
AB Long noncoding RNAs (lncRNAs) have been described in cell lines and various whole tissues, but lncRNA analysis of development in vivo is limited. Here, we comprehensively analyze lncRNA expression for the adult mouse subventricular zone neural stem cell lineage. We utilize complementary genome-wide techniques including RNA-seq, RNA CaptureSeq, and ChIP-seq to associate specific lncRNAs with neural cell types, developmental processes, and human disease states. By integrating data from chromatin state maps, custom microarrays, and FACS purification of the subventricular zone lineage, we stringently identify lncRNAs with potential roles in adult neurogenesis. shRNA-mediated knockdown of two such lncRNAs, Six3os and Dlx1as, indicate roles for lncRNAs in the glial-neuronal lineage specification of multipotent adult stem cells. Our data and workflow thus provide a uniquely coherent in vivo lncRNA analysis and form the foundation of a user-friendly online resource for the study of lncRNAs in development and disease.
C1 [Ramos, Alexander D.; Delgado, Ryan N.; Park, Ki-Youb; Gonzales-Roybal, Gabriel; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Ramos, Alexander D.; Delgado, Ryan N.; Park, Ki-Youb; Gonzales-Roybal, Gabriel; Oldham, Michael C.; Song, Jun S.; Lim, Daniel A.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
[Ramos, Alexander D.; Delgado, Ryan N.] Univ Calif San Francisco, Med Scientist Training Program, Biomed Sci Grad Program, San Francisco, CA 94143 USA.
[Diaz, Aaron; Nellore, Abhinav; Song, Jun S.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Oldham, Michael C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Song, Jun S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
[Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM limd@neurosurg.ucsf.edu
OI Lim, Daniel/0000-0001-7221-3425
FU NIH [DP2-OD006505-01, R01CA163336]; VA [1I01 BX000252-01]; Sontag
Foundation; Sandler Foundation; NIH GMS [K12-GM081266]; California
Institute for Regenerative Medicine (CIRM); UCSF Program for
Breakthrough Biomedical Research; MSTP [2T32GM007618-34]
FX This project was supported by NIH DP2-OD006505-01, VA 1I01 BX000252-01,
and the Sontag Foundation to D.A.L., NIH R01CA163336 and the Sontag
Foundation to J.S.S., the UCSF Program for Breakthrough Biomedical
Research, which is funded in part by the Sandler Foundation, to M.C.O.,
NIH GMS K12-GM081266 to G.G.-R., a training grant from the California
Institute for Regenerative Medicine (CIRM) to A.D.R., MSTP training
grant 2T32GM007618-34 to A.D.R. and R.N.D, and facilities and resources
provided by the San Francisco Veterans Affairs Medical Center.
NR 55
TC 87
Z9 94
U1 3
U2 39
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 2
PY 2013
VL 12
IS 5
BP 616
EP 628
DI 10.1016/j.stem.2013.03.003
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VE
UT WOS:000329569600016
PM 23583100
ER
PT J
AU Van Daele, CM
De Meyer, T
De Buyzere, ML
Gillebert, TC
Denil, SLIJ
Bekaert, S
Chirinos, JA
Segers, P
De Backer, GG
De Bacquer, D
Rietzschel, ER
AF Van Daele, Caroline M.
De Meyer, Tim
De Buyzere, Marc L.
Gillebert, Thierry C.
Denil, Simon L. I. J.
Bekaert, Sofie
Chirinos, Julio A.
Segers, Patrick
De Backer, Guy G.
De Bacquer, Dirk
Rietzschel, Ernst R.
CA Asklepios Investigators
TI Addition of a Novel, Protective Family History Category Allows Better
Profiling of Cardiovascular Risk and Atherosclerotic Burden in the
General Population. The Asklepios Study
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; MIDDLE-AGED ADULTS; LOW-DENSITY-LIPOPROTEIN;
INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; PARENTAL-HISTORY; STROKE;
HEALTH; STATEMENT; MEDICINE
AB Objectives: Whereas the importance of family history (FH) is widely recognized in cardiovascular risk assessment, its full potential could be underutilized, when applied with its current simple guidelines-based definition (cFH): presence of premature cardiovascular disease (CVD) in a first-degree relative. We tested the added value of a new, extended family history definition (eFH), also taking into account later onset of disease, second-degree relatives and number of affected relatives, on profiling cardiovascular risk and atherosclerotic burden in the general population.
Design: longitudinal population study.
Setting: random, representative population sample from Erpe-Mere and Nieuwerkerken (Belgium, primary care).
Subjects: 2524 male/female volunteers, aged 35-55 years, free from overt CVD.
Main outcome measures: Subjects were extensively phenotyped including presence of atherosclerosis (ultrasound) and a newly developed FH questionnaire (4 generations).
Results: Compared to cFH, eFH was superior in predicting an adverse risk profile (glycemic state, elevated blood pressure, lipid abnormalities, presence of metabolic syndrome components) and presence of atherosclerosis (all age & sex-adjusted p<0.05). Unlike cFH, eFH remained a significant predictor of subclinical atherosclerosis after adjusting for confounders. Most relations with eFH were not graded but showed clear informational breakpoints, with absence of CVD (including late onset) in any first-degree relative being a negative predictor of atherosclerosis, and a particularly interesting phenotype for further study.
Conclusions: A novel, extended FH definition is superior to the conventional definition in profiling cardiovascular risk and atherosclerotic burden in the general population. There remain clear opportunities to refine and increase the performance and informational content of this simple, readily-available inexpensive tool.
C1 [Van Daele, Caroline M.; De Buyzere, Marc L.; Gillebert, Thierry C.; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium.
[De Meyer, Tim; Denil, Simon L. I. J.] Univ Ghent, Fac Biosci Engn, Dept Math Modelling Stat & Bioinformat, B-9000 Ghent, Belgium.
[Bekaert, Sofie] Ghent Univ Hosp, Clin Res Ctr Ghent, Bimetra, Ghent, Belgium.
[Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA.
[Segers, Patrick] Univ Ghent, Inst Biomed Technol IbiTech, B-9000 Ghent, Belgium.
[De Backer, Guy G.; De Bacquer, Dirk; Rietzschel, Ernst R.] Univ Ghent, Fac Med & Hlth Sci, Dept Publ Hlth, B-9000 Ghent, Belgium.
RP Van Daele, CM (reprint author), Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium.
EM Caroline.Vandaele@UGent.be
OI Gillebert, Thierry/0000-0002-3832-919X
FU Fund for Scientific Research - Flanders (FWO) [G042703, G083810N]
FX The Asklepios Study is supported by the Fund for Scientific Research -
Flanders (FWO research grants G042703 and G083810N). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 52
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2013
VL 8
IS 5
AR e63185
DI 10.1371/journal.pone.0063185
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175AF
UT WOS:000321200500058
PM 23658806
ER
PT J
AU Colt, HG
Murgu, SD
Korst, RJ
Slatore, CG
Unger, M
Quadrelli, S
AF Colt, Henri G.
Murgu, Septimiu D.
Korst, Robert J.
Slatore, Christopher G.
Unger, Michael
Quadrelli, Silvia
TI Follow-up and Surveillance of the Patient With Lung Cancer After
Curative-Intent Therapy Diagnosis and Management of Lung Cancer, 3rd ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines
SO CHEST
LA English
DT Article
ID QUALITY-OF-LIFE; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; SOMATOSTATIN
RECEPTOR SCINTIGRAPHY; BRONCHIAL CARCINOID-TUMORS; SQUAMOUS-CELL
CARCINOMA; BRONCHOSCOPIC TREATMENT; NEUROENDOCRINE TUMORS; COMPLETE
RESECTION; PROGNOSTIC-FACTORS; RADIATION-THERAPY
AB Background: These guidelines are an update of the evidence-based recommendations for follow-up and surveillance of patients after curative-intent therapy for lung cancer. Particular updates pertain to whether imaging studies, health-related quality-of-life (HRQOL) measures, tumor markers, and bronchoscopy improve outcomes after curative-intent therapy.
Methods: Meta-analysis of Observational Studies in Epidemiology guidelines were followed for this systematic review, including published studies on posttreatment outcomes in patients who received curative-intent therapy since the previous American College of Chest Physicians subject review. Four population, intervention, comparison, and outcome questions were formulated to guide the review. The MEDLINE and CINAHL databases were searched from June 1, 2005, to July 8, 2011, to ensure overlap with the search strategies used previously.
Results: A total of 3,412 citations from MEDLINE and 431 from CINAHL were identified. Only 303 were relevant. Seventy-six of the 303 articles were deemed eligible on the basis of predefined inclusion criteria after full-text review, but only 34 provided data pertaining directly to the subject of the questions formulated to guide this review. In patients undergoing curative-intent surgical resection of non-small cell lung cancer, chest CT imaging performed at designated time intervals after resection is suggested for detecting recurrence. It is recommended that treating physicians who are able to incorporate the patient's clinical findings into decision-making processes be included in follow-up and surveillance strategies. The use of validated HRQOL instruments at baseline and during follow-up is recommended. Biomarker testing during surveillance outside clinical trials is not suggested. Surveillance bronchoscopy is suggested for patients with early central airway squamous cell carcinoma treated by curative-intent photodynamic therapy and for patients with intraluminal bronchial carcinoid tumor who have undergone curative-intent bronchoscopic treatment with Nd:YAG laser or electrocautery.
Conclusions: There is a paucity of well-designed prospective studies specifically targeting follow-up and surveillance modalities aimed at improving survival or QOL after curative-intent therapy. Additional research is warranted to clarify which curative-intent treatment modalities affect HRQOL the most and to identify patients who are at the most risk for recurrence or impaired QOL after treatment. Further evidence is needed to determine how the frequency and duration of surveillance programs that include imaging studies, QOL measurements, tumor markers, or bronchoscopy affect patient morbidity, survival, HRQOL, and health-care costs.
C1 [Colt, Henri G.] Univ Calif Irvine, Div Pulm & Crit Care Med, Irvine, CA USA.
[Murgu, Septimiu D.] Univ Chicago, Div Pulm & Crit Care Med, Chicago, IL 60637 USA.
[Korst, Robert J.] Valley Hosp, Valley Hlth Syst, Daniel & Gloria Blumenthal Canc Ctr, Paramus, NJ USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR 97201 USA.
[Unger, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Quadrelli, Silvia] Buenos Aires British Hosp, Buenos Aires, DF, Argentina.
RP Colt, HG (reprint author), 422 Glenneyre, Laguna Beach, CA 92651 USA.
EM hcolt@uci.edu
OI Slatore, Christopher/0000-0003-0958-8122
FU Lung Cancer Research Foundation; Boehringer Ingelheim Pharmaceuticals,
Inc.
FX The overall process for the development of these guidelines, including
matters pertaining to funding and conflicts of interest, are described
in the methodology article. 1 The development of this guideline was
supported primarily by the American College of Chest Physicians. The
lung cancer guidelines conference was supported in part by a grant from
the Lung Cancer Research Foundation. The publication and dissemination
of the guidelines was supported in part by a 2009 independent
educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. COI
grids reflecting the conflicts of interest that were current as of the
date of the conference and voting are posted in the online supplementary
materials.
NR 94
TC 24
Z9 24
U1 2
U2 11
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
SU S
BP E437
EP E454
DI 10.1378/chest.12-2365
PG 18
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AB1HL
UT WOS:000331542000020
PM 23649451
ER
PT J
AU Fadi, GH
Meaghan, B
Xing, DQ
Akash, K
Chen, YF
Alexander, S
Suzanne, O
AF Fadi, Hage G.
Meaghan, Bowling
Xing Dongqi
Akash, Kapadia
Chen Yu-Fai
Alexander, Szalai
Suzanne, Oparil
TI Estrogen Ameliorates Vascular Inflammation in Young but not Aged Mice
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE vascular injury; vascular inflammation; estrogen; aging
C1 [Fadi, Hage G.; Meaghan, Bowling; Xing Dongqi; Akash, Kapadia; Chen Yu-Fai; Alexander, Szalai; Suzanne, Oparil] Univ Alabama Birmingham, Birmingham, AL USA.
[Fadi, Hage G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400102
ER
PT J
AU Fadi, GH
Maricica, P
Xing, DQ
Rob, H
Guo, YY
Chen, YF
AF Fadi, Hage G.
Maricica, Pacurari
Xing Dongqi
Rob, Hilgers
Guo YuanYuan
Chen Yiu-Fai
TI Endothelial Cell Transfusion in Nephrectomized Rats Ameliorates
Endothelial Dysfunction by Increasing eNOS Activity
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE Endothelial Cells; Endothelial Dysfunction; Chronic Kidney Disease;
Nitric Oxide Synthase
C1 [Fadi, Hage G.; Maricica, Pacurari; Xing Dongqi; Rob, Hilgers; Guo YuanYuan; Chen Yiu-Fai] Univ Alabama Birmingham, Birmingham, AL USA.
[Fadi, Hage G.; Guo YuanYuan] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400094
ER
PT J
AU Oscar, R
Rene, AO
Joan, HF
Shuko, L
Robert, JC
AF Oscar, Rivera
Rene, Oliveros A.
Joan, Finch H.
Shuko, Lee
Robert, Chilton J.
TI Central Aortic Pulse Pressure, a Better Predictor of Vascular Aging
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE Central Pulse Pressure; Aging
C1 [Oscar, Rivera; Rene, Oliveros A.; Shuko, Lee; Robert, Chilton J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Rene, Oliveros A.; Joan, Finch H.; Shuko, Lee; Robert, Chilton J.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400047
ER
PT J
AU La Fountaine, MF
Bauman, WA
AF La Fountaine, Michael F.
Bauman, William A.
TI Use of Phase-rectified Signal Averaging to Examine Autonomic Dysfunction
After Concussive Head Trauma
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [La Fountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA.
[Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 217
BP 40
EP 40
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469700119
ER
PT J
AU Ingram, KH
Thalacker-Mercer, A
Garvey, WT
AF Ingram, Katherine H.
Thalacker-Mercer, Anna
Garvey, W. Timothy
TI Amino Acids and Insulin Sensitivity in Non-Obese, Obese, and Type 2
Diabetic Patients
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Ingram, Katherine H.] Kennesaw State Univ, Kennesaw, GA USA.
[Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 1886
BP 427
EP 428
PG 2
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469703229
ER
PT J
AU DiPiro, ND
Bowden, MG
Embry, AE
Perry, LA
Morgan, PJ
Gregory, CM
AF DiPiro, Nicole D.
Bowden, Mark G.
Embry, Aaron E.
Perry, Lindsay A.
Morgan, Patrick J.
Gregory, Chris M.
TI A Short-term, High-intensity Multimodal Exercise Program Improves
Strength and Function After Incomplete SCI
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [DiPiro, Nicole D.; Embry, Aaron E.; Perry, Lindsay A.; Morgan, Patrick J.] MUSC, Charleston, SC USA.
[Bowden, Mark G.; Gregory, Chris M.] MUSC, Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2767
BP 652
EP 652
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469705129
ER
PT J
AU Riegel, B
Hanlon, AL
Zhang, XM
Fleck, D
Sayers, SL
Goldberg, LR
Weintraub, WS
AF Riegel, Barbara
Hanlon, Alexandra L.
Zhang, Xuemei
Fleck, Desiree
Sayers, Steven L.
Goldberg, Lee R.
Weintraub, William S.
TI What is the best measure of daytime sleepiness in adults with heart
failure?
SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
LA English
DT Article
DE Heart failure; screening; sleep disorders; outcomes
ID APNEA PATIENTS; SCALE; QUALITY; POPULATION; CONSEQUENCES; DEPRIVATION;
SENSITIVITY; PERFORMANCE; PREVALENCE; VIGILANCE
AB Purpose: To identify the best screening measure of daytime sleepiness in adults with heart failure (HF).
Data sources: A total of 280 adults with HF completed the Epworth Sleepiness Scale, the Stanford Sleepiness Scale, and a single Likert item measuring daytime sleepiness. The sensitivity and specificity of these self-report measures were assessed in relation to a measure of daytime dysfunction from poor sleep quality.
Conclusions: Only 16% of the sample reported significant daytime dysfunction because of poor sleep quality. Those reporting daytime dysfunction were likely to be younger (p < .001), to be unmarried (p = .002), to have New York Heart Association (NYHA) functional class IV HF (p = .015), and to report low income (p = .006) and fewer hours of sleep (p = .015). The measure of daytime sleepiness that was most sensitive to daytime dysfunction was a single Likert item measured on a 10-point (1-10) scale. Patients with a score >= 4 were 2.4 times more likely to have daytime dysfunction than those with a score <4.
Implications for practice: Complaints of daytime dysfunction because of poor sleep are not common in adults with HF. Routine use of a single question about daytime sleepiness can help nurse practitioners to identify those HF patients with significant sleep issues that may require further screening.
C1 [Riegel, Barbara; Hanlon, Alexandra L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Zhang, Xuemei] Childrens Hosp Philadelphia Westat BDMC, Philadelphia, PA USA.
[Fleck, Desiree] Univ Penn, Sch Nursing, Childrens Hosp Penn, Philadelphia, PA 19104 USA.
[Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Weintraub, William S.] Christiana Care Ctr Outcomes Res Christiana Care, Newark, DE USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
Veterans Affairs Medical Center, VISN 4 Mental Illness Research,
Education, and Clinical Center (MIREC)
FX This work was funded by a grant from the National Heart, Lung & Blood
Institute (RO1 HL084394-01A1) and by the Philadelphia Veterans Affairs
Medical Center, VISN 4 Mental Illness Research, Education, and Clinical
Center (MIREC).
NR 47
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2327-6886
EI 2327-6924
J9 J AM ASSOC NURSE PRA
JI J. Am. Assoc. Nurs. Pract.
PD MAY
PY 2013
VL 25
IS 5
BP 272
EP 279
DI 10.1111/j.1745-7599.2012.00784.x
PG 8
WC Health Care Sciences & Services; Nursing
SC Health Care Sciences & Services; Nursing
GA 296GM
UT WOS:000330173200006
PM 24170569
ER
PT J
AU Wyte-Lake, T
Tran, K
Bowman, CC
Needleman, J
Dobalian, A
AF Wyte-Lake, Tamar
Tran, Kim
Bowman, Candice C.
Needleman, Jack
Dobalian, Aram
TI A Systematic Review of Strategies to Address the Clinical Nursing
Faculty Shortage
SO JOURNAL OF NURSING EDUCATION
LA English
DT Review
ID EDUCATION; PARTNERSHIP; WORKFORCE
AB This systematic review provides a comprehensive assessment of models used to expand the ranks of clinical nursing faculty. Nursing faculty shortages constrict the pipeline for educating nurses and make addressing the projected nursing shortage more difficult. Schools of nursing have denied admission to qualified applicants, citing insufficient numbers of nursing faculty as one major reason. Using key search terms in PubMed (R) and CINAHL (R), we identified 14 peer-reviewed articles published between 1980 and 2010 about models for expanding clinical faculty. Partnership models (n = 11) and expanded use of faculty resources (n = 9) were the most common strategies. Few (n = 8) studies assessed program efficacy. A need was identified for studies to assess the effect of alternative models on educational capacity and student performance and to examine the sub-components of academic-practice partnerships and other innovative approaches to understand the essential factors necessary to implement successful programs.
C1 [Wyte-Lake, Tamar; Tran, Kim; Bowman, Candice C.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Study Healthcare Provider, Sepulveda, CA 91343 USA.
[Needleman, Jack] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Dobalian, Aram] Vet Emergency Management Evaluat Ctr, North Hills, CA USA.
RP Wyte-Lake, T (reprint author), VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Study Healthcare Provider, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
EM Tamar.wyte@va.gov
RI Needleman, Jack/I-5461-2013
OI Needleman, Jack/0000-0002-2875-0589
FU Robert Wood Johnson Foundation [64104]; Department of Veterans Affairs,
Veterans Health Administration, Office of Academic Affiliations [XVA
65-010]; Veterans Health Administration Health Service Research
Postdoctoral Fellowship program
FX This article is based on work supported by the Robert Wood Johnson
Foundation (Project 64104) and the Department of Veterans Affairs,
Veterans Health Administration, Office of Academic Affiliations (Project
XVA 65-010). Dr. Tran receives support from the Veterans Health
Administration Health Service Research Postdoctoral Fellowship program.
The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Robert Wood Johnson
Foundation, the Department of Veterans Affairs, or the United States
government.
NR 26
TC 11
Z9 11
U1 1
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0148-4834
EI 1938-2421
J9 J NURS EDUC
JI J. Nurs. Educ.
PD MAY
PY 2013
VL 52
IS 5
BP 245
EP U15
DI 10.3928/01484834-20130213-02
PG 12
WC Nursing
SC Nursing
GA 273RJ
UT WOS:000328553700002
PM 23402282
ER
PT J
AU Bolkan, CR
Bonner, LM
Campbell, DG
Lanto, A
Zivin, K
Chaney, E
Rubenstein, LV
AF Bolkan, Cory R.
Bonner, Laura M.
Campbell, Duncan G.
Lanto, Andy
Zivin, Kara
Chaney, Edmund
Rubenstein, Lisa V.
TI Family Involvement, Medication Adherence, and Depression Outcomes Among
Patients in Veterans Affairs Primary Care
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SERIOUS MENTAL-ILLNESS; SOCIAL SUPPORT;
QUALITY IMPROVEMENT; HEALTH; SCHIZOPHRENIA; METAANALYSIS; INDIVIDUALS;
HEART; TRIAL
AB Objective: Family involvement and social support are associated with recovery from mental disorders. This project explored how family involvement in health care and social support among depressed veterans in primary care related to medication adherence and depression outcomes. Methods: During a longitudinal telephone survey, 761 Veterans Affairs (VA) primary care patients (mean age=60 years) with probable major depression were asked about depression symptoms, self-reported health, medication adherence, social support, family involvement with care, and satisfaction with clinicians' efforts to involve the patients' families in their care. Follow-up interviews at seven and 18 months assessed depression severity and medication adherence. Results: Most participants lived with others (71%) and reported moderately high social support. Most participants (62%) reported being very likely to discuss treatment of a major medical condition with family, but 64% reported that VA providers had not involved the participants' family in their care within the prior six months. In multivariate regression analyses, lower depression severity and better medication adherence over time were significantly linked to higher satisfaction with limited efforts by clinicians to involve families in care. Neither social support nor the extent of family involvement by itself was associated with outcomes. Conclusions: The results suggested a link between patient satisfaction with family involvement by clinicians and clinical outcomes among depressed veterans. In addition, clinician responsiveness to patient wishes may be more important than the amount of family involvement per se. Further research is needed to clarify when and how clinicians should involve a patient's family in depression treatment in primary care.
C1 [Bolkan, Cory R.] Washington State Univ, Dept Human Dev, Vancouver, WA 98686 USA.
[Bonner, Laura M.] Vet Affairs VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Bonner, Laura M.] Hlth Serv Res & Dev Northwest Ctr Excellence, Seattle, WA USA.
[Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA.
[Lanto, Andy; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA.
[Zivin, Kara] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, Ann Arbor, MI USA.
[Zivin, Kara] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Chaney, Edmund] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Bolkan, CR (reprint author), Washington State Univ, Dept Human Dev, 14204 Salmon Creek Ave, Vancouver, WA 98686 USA.
EM bolkan@vancouver.wsu.edu
FU Veterans Affairs (VA) Health Services Research and Development Service;
VA Mental Health Quality Enhancement Research Initiative [MHI 99-375,
MNT 01-027, MHQ 10-06]
FX Funding was provided by the Veterans Affairs (VA) Health Services
Research and Development Service and the VA Mental Health Quality
Enhancement Research Initiative (MHI 99-375, MNT 01-027, and MHQ 10-06).
The authors acknowledge the contributions of the many study
participants, without whom this work would not have been possible. The
views expressed herein are those of the authors and do not necessarily
represent the views of the VA and other affiliated institutions.
NR 34
TC 12
Z9 13
U1 1
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD MAY
PY 2013
VL 64
IS 5
BP 472
EP 478
DI 10.1176/appi.ps.201200160
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255WI
UT WOS:000327270400019
PM 23370463
ER
PT J
AU Nahas, Z
Short, B
Burns, C
Archer, M
Schmidt, M
Prudic, J
Nobler, MS
Devanand, DP
Fitzsimons, L
Lisanby, SH
Payne, N
Perera, T
George, MS
Sackeim, HA
AF Nahas, Ziad
Short, Baron
Burns, Carol
Archer, Melanie
Schmidt, Matthew
Prudic, Joan
Nobler, Mitchell S.
Devanand, D. P.
Fitzsimons, Linda
Lisanby, Sarah H.
Payne, Nancy
Perera, Tarique
George, Mark S.
Sackeim, Harold A.
TI A Feasibility Study of a New Method for Electrically Producing Seizures
in Man: Focal Electrically Administered Seizure Therapy [FEAST]
SO BRAIN STIMULATION
LA English
DT Article
DE ECT; FEAST; Depression; Seizure
ID TRANSCRANIAL MAGNETIC STIMULATION; ELECTROCONVULSIVE-THERAPY; ELECTRODE
PLACEMENT; PERIPHERAL-NERVE; MOTOR CORTEX; STIMULUS-INTENSITY; COIL
STIMULATION; ECT; EFFICACY; MECHANISMS
AB Background: Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe major depression, but with significant risk of adverse cognitive effects. Unidirectional electrical stimulation with a novel electrode placement and geometry (Focal Electrically Administered Seizure Therapy (FEAST)) has been proposed as a means to initiate seizures in prefrontal cortex prior to secondary generalization. As such, it may have fewer cognitive side effects than traditional ECT. We report on its first human clinical application.
Method: Seventeen unmedicated depressed adults (5 men; 3 bipolar disorder; age 53 +/- 16 years) were recruited after being referred for ECT. Open-label FEAST was administered with a modified spECTrum 5000Q device and a traditional ECT dosing regimen until patients clinically responded. Clinical and cognitive assessments were obtained at baseline, and end of course. Time to orientation recovery, a predictor of long-term amnestic effects, was assessed at each treatment. Nonresponders to FEAST were transitioned to conventional ECT.
Results: One patient withdrew from the study after a single titration session. After the course of FEAST (median 10 sessions), there was a 46.1 +/- 35.5% improvement in Hamilton Rating Scale for Depression (HRSD24) scores compared to baseline (33.1 +/- 6.8, 16.8 +/- 10.9; P < 0.0001). Eight of 16 patients met response criteria (50% decrease in HRSD24) and 5/16 met remission criteria (HRSD24 < 10). Patients achieved full re-orientation (4 of 5 items) in 5.5 +/- 6.4 min (median = 3.6), timed from when their eyes first opened after treatment.
Conclusion: In this feasibility study, FEAST produced clinically meaningful antidepressant improvement, with relatively short time to reorientation. Our preliminary work first in primates and now depressed adults demonstrates that FEAST is feasible, safe, well-tolerated and, if efficacy can be optimized, has potential to replace traditional Ea. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Nahas, Ziad] Amer Univ Beirut, Dept Psychiat, Beirut, Lebanon.
[Nahas, Ziad; Short, Baron; Burns, Carol; Archer, Melanie; Schmidt, Matthew; George, Mark S.] Med Univ S Carolina, Charleston, SC USA.
[Prudic, Joan; Devanand, D. P.; Fitzsimons, Linda; Perera, Tarique; Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY 10027 USA.
[Nobler, Mitchell S.] New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USA.
[Lisanby, Sarah H.] Duke Univ Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA.
[Payne, Nancy] NYU, New York, NY 10003 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Nahas, Z (reprint author), Amer Univ Beirut, Beirut, Lebanon.
EM zn17@aub.edu.lb
NR 46
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY
PY 2013
VL 6
IS 3
BP 403
EP 408
DI 10.1016/j.brs.2013.03.004
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 234VF
UT WOS:000325671700026
PM 23518262
ER
PT J
AU Karlin, BE
Agarwal, M
AF Karlin, Bradley E.
Agarwal, Madhulika
TI Achieving the Promise of Evidence-Based Psychotherapies for
Posttraumatic Stress Disorder and Other Mental Health Conditions for
Veterans
SO PSYCHOLOGICAL SCIENCE IN THE PUBLIC INTEREST
LA English
DT Editorial Material
ID COGNITIVE-BEHAVIORAL THERAPY; PROCESSING THERAPY; DISSEMINATION;
OUTCOMES
C1 [Karlin, Bradley E.; Agarwal, Madhulika] US Dept Vet Affairs, Cent Off, Washington, DC 20420 USA.
RP Karlin, BE (reprint author), US Dept Vet Affairs, Cent Off, 810 Vermont Ave, Washington, DC 20420 USA.
EM bradley.karlin2@va.gov
NR 16
TC 9
Z9 9
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1529-1006
J9 PSYCHOL SCI PUBL INT
JI Psychol. Sci. Public Interest
PD MAY
PY 2013
VL 14
IS 2
BP 62
EP 64
DI 10.1177/1529100613484706
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA 217ZQ
UT WOS:000324402500001
PM 26173291
ER
PT J
AU Bodhankar, S
Offner, H
AF Bodhankar, Sheetal
Offner, Halina
TI PD-1 interaction with PD-L1 but not PD-L2 on B cells mediates protective
effects of estrogen against EAE
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bodhankar, Sheetal; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bodhankar, Sheetal; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5176
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107037
ER
PT J
AU Bodhankar, S
Chen, YX
Murphy, S
Offner, H
AF Bodhankar, Sheetal
Chen, Yingxin
Murphy, Stephanie
Offner, Halina
TI Opposing roles of PD-1 and PD-L in modulating CNS inflammation and
infarct volume following experimental stroke in mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bodhankar, Sheetal; Chen, Yingxin; Murphy, Stephanie; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bodhankar, Sheetal; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1012
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100014
ER
PT J
AU Brandon, D
Williams, S
Zhang, X
AF Brandon, Danielle
Williams, Sarah
Zhang, Xian
TI Fli-1 transcription factor is involved in cytokine production in spleen
cells upon Toll-like receptor stimulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Brandon, Danielle; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1218
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100217
ER
PT J
AU Ding, YN
Hsu, HC
Li, J
Yang, P
Zajac, A
Mountz, J
AF Ding, Yanna
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Zajac, Allan
Mountz, John
TI IL-21 promotes autoreactive germinal center development in BXD2 mice
partially by regulating T-FR
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Ding, Yanna; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Zajac, Allan; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4116
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104185
ER
PT J
AU Dugan, J
Griffiths, E
Snow, P
Rosenzweig, H
Carr, D
Rosenbaum, J
Davey, M
AF Dugan, Jae
Griffiths, Eric
Snow, Paige
Rosenzweig, Holly
Carr, Daniel
Rosenbaum, Jim
Davey, Michael
TI Nucleotide-binding and oligomerization domain 2 (NOD2) knock-in mice
carrying a mutation associated with Blau syndrome show reduced amounts
of NOD2 protein and decreased muramyl dipeptide (MDP)-induced
inflammatory responses
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Dugan, Jae; Griffiths, Eric; Snow, Paige; Carr, Daniel; Davey, Michael] Portland VA Med Ctr, Portland, OR USA.
[Dugan, Jae; Rosenzweig, Holly; Carr, Daniel; Rosenbaum, Jim; Davey, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Rosenzweig, Holly; Davey, Michael] Oregon Hlth & Sci Univ, MMI, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1254
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987101003
ER
PT J
AU Karam, E
Williams, S
Zhang, J
AF Karam, Eva
Williams, Sarah
Zhang, John
TI Fli-1 transcription factor regulates inflammatory mediators in
endothelial cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Karam, Eva; Zhang, John] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 11516
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108077
ER
PT J
AU Li, H
Hsu, HC
Wu, Q
Yang, PA
Cua, D
Mountz, J
AF Li, Hao
Hsu, Hui-Chen
Wu, Qi
Yang, PingAr
Cua, Daniel
Mountz, John
TI IL-23 controls autoimmunity by maintaining the integrity of marginal
zone barrier that clears apoptotic bodies
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Li, Hao; Hsu, Hui-Chen; Wu, Qi; Yang, PingAr; Mountz, John] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Cua, Daniel] Merck Res Labs, Palo Alto, CA USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4178
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104246
ER
PT J
AU Li, H
Wu, Q
Yang, PA
Li, J
Fu, YX
Mountz, J
Hsu, HC
AF Li, Hao
Wu, Qi
Yang, PingAr
Li, Jun
Fu, YangXin
Mountz, John
Hsu, Hui-Chen
TI Increased type I interferon disrupts marginal zone barrier integrity via
dissociation of lymphotoxin-expressing B cells and marginal zone
macrophages in systemic autoimmunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Li, Hao; Wu, Qi; Yang, PingAr; Li, Jun; Mountz, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Fu, YangXin] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4160
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104228
ER
PT J
AU Li, J
Hsu, HC
Yang, PA
Wu, Q
Spalding, D
Mountz, J
AF Li, Jun
Hsu, Hui-Chen
Yang, PingAr
Wu, Qi
Spalding, David
Mountz, John
TI Fucosylation is a hallmark of inflammatory macrophages and a novel
therapeutic target in rheumatoid arthritis (P5137)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Spalding, David; Mountz, John] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Hsu, Hui-Chen; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 13710
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106248
ER
PT J
AU Nowling, T
Richard, E
Zhang, J
Siskind, L
AF Nowling, Tamara
Richard, Erin
Zhang, John
Siskind, Leah
TI Reducing Fli1 levels in the MRL/lpr lupus prone mouse model impacts T
cell activation and cytokine production
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Nowling, Tamara; Zhang, John; Siskind, Leah] Ralph H Johnson VAMC, Charleston, SC USA.
[Nowling, Tamara; Richard, Erin; Zhang, John; Siskind, Leah] Med Univ S Carolina, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4115
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104184
ER
PT J
AU Offner, H
Chen, YX
Murphy, S
Bodhankar, S
AF Offner, Halina
Chen, Yingxin
Murphy, Stephanie
Bodhankar, Sheetal
TI IL-10-producing B cells limit CNS inflammation and infarct volume after
experimental stroke in mice (P1090)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Offner, Halina; Chen, Yingxin; Murphy, Stephanie; Bodhankar, Sheetal] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Offner, Halina; Bodhankar, Sheetal] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100090
ER
PT J
AU Qiao, F
Zhang, LX
Yang, XF
Hua, YP
Narang, A
Holers, M
Kulik, L
Song, HB
Tomlinson, S
AF Qiao, Fei
Zhang, Lixia
Yang, Xiaofeng
Hua, Yunpeng
Narang, Aarti
Holers, Michael
Kulik, Liudmila
Song, Hongbin
Tomlinson, Stephen
TI Role of pathogenic natural antibodies and complement in a murine model
of spinal cord injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Qiao, Fei; Zhang, Lixia; Yang, Xiaofeng; Hua, Yunpeng; Narang, Aarti; Tomlinson, Stephen] Med Univ S Carolina, Charleston, SC 29425 USA.
[Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Holers, Michael; Kulik, Liudmila] Univ Colorado, Dept Med & Immunol, Denver, CO 80202 USA.
[Song, Hongbin] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4051
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104120
ER
PT J
AU Richard, ML
Nowling, T
Zhang, X
AF Richard, Mara Lennard
Nowling, Tamara
Zhang, Xian
TI Fli-1 drives transcription from the MCP-1 gene promoter, which may
provide a novel mechanism for cytokine and chemokine activation.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Richard, Mara Lennard; Nowling, Tamara; Zhang, Xian] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Nowling, Tamara; Zhang, Xian] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 11514
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108073
ER
PT J
AU Salinthone, S
Wilkinson, A
Carr, D
AF Salinthone, Sonemany
Wilkinson, Amelia
Carr, Daniel
TI Dimethyl fumarate stimulates cyclic AMP production and suppresses
production of pro-inflammatory mediators in immune cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Salinthone, Sonemany; Wilkinson, Amelia; Carr, Daniel] Portland VA Med Ctr, Portland, OR USA.
[Salinthone, Sonemany; Carr, Daniel] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5143
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107004
ER
PT J
AU Sato, S
Williams, S
Zhang, X
AF Sato, Shuzo
Williams, Sarah
Zhang, Xian
TI Fli-1 transcription factor affects inflammatory cell infiltration into
the kidneys independent of autoantibodies
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Sato, Shuzo; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4150
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104218
ER
PT J
AU Sztokman, N
Zhang, X
AF Sztokman, Nicole
Zhang, Xian
TI Transcription factor Fli-1 is involved in regulation of inflammatory
mediator production and ECM remodeling in primary dermal fibroblasts
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Sztokman, Nicole; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zhang, Xian] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5088
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106200
ER
PT J
AU Yates, C
Rodrigues, M
Wells, A
AF Yates, Cecelia
Rodrigues, Melanie
Wells, Alan
TI Co-transplantation of mesenchymal stem cell and fibroblast reduces
inflammation and corrects defective dermal remodeling
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Yates, Cecelia] Univ Pittsburgh SON, Pittsburgh, PA USA.
[Yates, Cecelia; Rodrigues, Melanie; Wells, Alan] Univ Pittsburgh SOM, Pittsburgh, PA USA.
[Yates, Cecelia; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA.
[Yates, Cecelia; Wells, Alan] VA Pittsburgh Healthcare Syst, Pathol, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5062
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106174
ER
PT J
AU Rosen, PL
Palmer, JN
O'Malley, BW
Cohen, NA
AF Rosen, Philip L.
Palmer, James N.
O'Malley, Bert W., Jr.
Cohen, Noam A.
TI Surfactants in the management of rhinopathologies
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; CITRIC ACID/ZWITTERIONIC SURFACTANT; BACTERIAL
BIOFILMS; CHRONIC RHINOSINUSITIS; STAPHYLOCOCCUS-AUREUS; TOPICAL
TOBRAMYCIN; IRRIGATION BOTTLE; ANIMAL-MODEL; SHEEP MODEL; IN-VITRO
AB Background: Surfactants are a class of amphiphilic surface active compounds that show several unique physical properties at liquid-liquid or liquid-solid surface interfaces including the ability to increase the solubility of substances, lower the surface tension of a liquid, and decrease friction between two mediums. Because of these unique physical properties several in vitro, ex vivo, and human trials have examined the role of surfactants as stand-alone or adjunct therapy in recalcitrant chronic rhinosinusitis (CRS).
Methods: A review of the literature was performed.
Results: The data from three different surfactants have been examined in this review: citric acid zwitterionic surfactant (CAZS; Medtronic ENT, Jacksonville FL), Johnson's Baby Shampoo (Johnson & Johnson, New Brunswick NJ), and SinuSurf (NeilMed Pharmaceuticals, Santa Rosa, CA). Dilute surfactant therapy shows in vitro antimicrobial effects with modest inhibition of bacterial biofilm formation. In patients with CRS, surfactants may improve symptoms, most likely through its mucolytic effects. In addition, surfactants have several distinct potential benefits including their ability to improve an irrigant's penetration of the nonoperated sinus and their synergistic effects with antibiotics. However, surfactants potential for nasal irritation and possible transient ciliotoxicity may limit their use.
Conclusion: Recent data suggest a possible therapeutic role of surfactants in treating rhinopathologies associated with mucostasis. Further investigation, including a standardization of surfactant formulations, is warranted to further elucidate the potential benefits and drawbacks of this therapy.
C1 [Rosen, Philip L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Palmer, James N.; O'Malley, Bert W., Jr.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Dept Otolaryngol, Surg Serv, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM noam.cohen@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
NR 25
TC 6
Z9 8
U1 2
U2 7
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAY-JUN
PY 2013
VL 27
IS 3
BP 177
EP 180
DI 10.2500/ajra.2013.27.3873
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 193HF
UT WOS:000322549000007
PM 23710951
ER
PT J
AU Gillis, JL
Selth, LA
Centenera, MM
Townley, SL
Sun, SH
Plymate, SR
Tilley, WD
Butler, LM
AF Gillis, Joanna L.
Selth, Luke A.
Centenera, Margaret M.
Townley, Scott L.
Sun, Shihua
Plymate, Stephen R.
Tilley, Wayne D.
Butler, Lisa M.
TI Constitutively-active androgen receptor variants function independently
of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
SO ONCOTARGET
LA English
DT Article
DE Androgen receptor; variant; HSP90; HSP90 inhibitor; prostate cancer
ID HEAT-SHOCK-PROTEIN; REFRACTORY PROSTATE-CANCER; SPLICE VARIANTS;
NUCLEAR-LOCALIZATION; BINDING DOMAIN; PROGRESSION; MUTATIONS; GROWTH;
THERAPY; COMPLEX
AB The development of lethal, castration resistant prostate cancer is associated with adaptive changes to the androgen receptor (AR), including the emergence of mutant receptors and truncated, constitutively active AR variants. AR relies on the molecular chaperone HSP90 for its function in both normal and malignant prostate cells, but the requirement for HSP90 in environments with aberrant AR expression is largely unknown. Here, we investigated the efficacy of three HSP90 inhibitors, 17-AAG, HSP990 and AUY922, against clinically-relevant AR missense mutants and truncated variants. HSP90 inhibition effectively suppressed the signaling of wild-type AR and all AR missense mutants tested. By contrast, two truncated AR variants, AR-V7 and ARv567es, exhibited marked resistance to HSP90 inhibitors. Supporting this observation, nuclear localization of the truncated AR variants was not affected by HSP90 inhibition and AR variant: HSP90 complexes could not be detected in prostate cancer cells. Interestingly, HSP90 inhibition resulted in accumulation of AR-V7 and ARv567es in both cell lines and human tumor explants. Despite the apparent independence of AR variants from HSP90 and their treatment-associated induction, the growth of cell lines with endogenous or enforced expression of AR-V7 or ARv567es remained highly sensitive to AUY922. This study demonstrates that functional AR variant signaling does not confer resistance to HSP90 inhibition, yields insight into the interaction between AR and HSP90 and provides further impetus for the clinical application of HSP90 inhibitors in advanced prostate cancer.
C1 [Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia.
[Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Univ Adelaide, Adelaide Prostate Canc Res Ctr, Adelaide, SA, Australia.
[Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Hanson Inst, Adelaide, SA, Australia.
[Sun, Shihua; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA USA.
RP Butler, LM (reprint author), Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia.
EM lisa.butler@adelaide.edu.au
FU Prostate Cancer Foundation; Prostate Cancer Foundation of
Australia/Cancer Australia [YI 0810, YI 0412, 627229]; Royal Adelaide
Hospital Research Committee; National Health and Medical Research
Council of Australia [627185, 290456, 614296]; Pacific NW Prostate
Cancer SPORE [P50 CA97186]; Veterans Affairs Research Program; Prostate
Cancer Foundation of Australia [2011/0452]
FX No potential conflicts of interest were disclosed by the authors. This
work was supported by Young Investigator Awards from the Prostate Cancer
Foundation (the Foundation 14 award; L. A. S.) and the Prostate Cancer
Foundation of Australia/Cancer Australia (L. A. S., YI 0810; M. M. C.,
YI 0412) and grants from the Prostate Cancer Foundation of
Australia/Cancer Australia (ID 627229 to L. M. B. and W. D. T.), the
Royal Adelaide Hospital Research Committee (L. M. B. and M. M. C.), the
National Health and Medical Research Council of Australia (ID 627185 to
W. D. T. and L. M. B.), the Pacific NW Prostate Cancer SPORE (ID P50
CA97186 to S. R. P.) and the Veterans Affairs Research Program (S. R.
P.). The Adelaide Prostate Cancer Research Centre is supported by an
establishment grant from the Prostate Cancer Foundation of Australia (ID
2011/0452). The Australian Prostate Cancer BioResource is supported by
the National Health and Medical Research Council of Australia (enabling
grants 290456 and 614296) and Prostate Cancer Foundation of Australia.
L. M. B. holds a senior research fellowship from the Cancer Council of
South Australia.
NR 48
TC 14
Z9 15
U1 1
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY
PY 2013
VL 4
IS 5
BP 691
EP 704
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 193RU
UT WOS:000322580000006
PM 23674566
ER
PT J
AU Kang, SH
Cho, JH
Park, SH
Toothaker, R
Cho, SA
AF Kang, Sang-Hwan
Cho, Jin Hyun
Park, Sang-Hun
Toothaker, Randall
Cho, Sung-Am
TI Comparison of Osseointegration Between Laser-Etched and
Magnesium-Incorporated Oxidized Implants in the Rabbit Femur
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE histomorphometric analysis; laser-etched; magnesium-incorporated oxided
implant; removal torque
ID TREATED TITANIUM IMPLANTS; SURFACE-PROPERTIES; REMOVAL TORQUE; BONE
RESPONSE; ROUGHNESS; HYDROXYAPATITE; ALLOY
AB Purpose: To compare the osseointegration of a laser-etched (LE) implant with a magnesium-incorporated oxidized (MgO) implant, evaluating their ability to enhance the bond strength between a titanium substrate and rabbit femur. Materials and Methods: Two type of dental implants, LE (test, commercially pure [CP] titanium grade 4) and MgO (control, CP titanium grade 4) (length, 8 mm; diameter, 3.3 mm), were evaluated for the surface characteristics using a field emission scanning electron microscope (FE-SEM), an energy dispersive spectrometer (EDS), and an optical three-dimensional profiling system. After that, two types of dental implants were implanted at the right and left distal femoral metaphysis of 10 adult rabbits weighing approximately 3.0 kg. After 6 weeks, histomorphometric analysis, removal torque tests, and surface analysis of the torque-tested implants were performed. Results: After surgery, the LE group showed thick bonelike materials within the pores observed using FE-SEM (magnifications x500 and x900). The mean removal torque was 40.72 +/- 13.3 Ncm for the test (LE) implant and 22.26 +/- 6.4 Ncm for the control (MgO) implant, respectively (P = .041). The mean bone-implant contact in the three best consecutive threads in the cortical region was 63.35% +/- 16.44% in the LE group and 51.63% +/- 5.09% in the MgO. Conclusions: In the beginning stage of cancellous bone healing, biomechanical properties of the LE implant could influence a more favorable bone response than that of MgO.
C1 [Toothaker, Randall] Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
[Toothaker, Randall] Nebraska Western Iowa Hlth Care Syst, Dent Serv NWIHCS, US Dept Vet Affairs, Dent Lab Serv, Omaha, NE USA.
EM sungamcho@gmail.com
FU Kyungpook National University Research Fund
FX This research was supported by Kyungpook National University Research
Fund, 2011. The authors reported no conflicts of interest related to
this study.
NR 21
TC 2
Z9 2
U1 0
U2 5
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 775
EP 781
DI 10.11607/jomi.2448
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 186XE
UT WOS:000322078500022
PM 23748308
ER
PT J
AU Gonzalez, SD
Xu, C
Ramirez, ME
Zavala, JM
Armas, R
Contreras, SA
Contreras, J
Dassori, A
Leach, RJ
Flores, D
Jerez, A
Raventos, H
Ontiveros, A
Nicolini, H
Escamilla, M
AF Gonzalez, S. D.
Xu, C.
Ramirez, M. E.
Zavala, J. M.
Armas, R.
Contreras, S. A.
Contreras, J.
Dassori, A.
Leach, R. J.
Flores, D.
Jerez, A.
Raventos, H.
Ontiveros, A.
Nicolini, H.
Escamilla, M.
TI Family-based association of an ANK3 haplotype with bipolar disorder in
Latino populations
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Letter
ID GENOME-WIDE ASSOCIATION; VARIANTS; CACNA1C
C1 [Gonzalez, S. D.; Xu, C.; Ramirez, M. E.; Zavala, J. M.; Escamilla, M.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Psychiat, El Paso, TX USA.
[Gonzalez, S. D.; Xu, C.; Ramirez, M. E.; Zavala, J. M.; Escamilla, M.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Neurosci, El Paso, TX USA.
[Armas, R.] Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA USA.
[Contreras, S. A.; Dassori, A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Contreras, J.; Raventos, H.] Univ Costa Rica, Ctr Invest Biol Celular & Mol, San Jose, Costa Rica.
[Contreras, J.; Raventos, H.] Univ Costa Rica, Escuela Biol, San Jose, Costa Rica.
[Dassori, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Leach, R. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Flores, D.] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Ctr Harbor, Torrance, CA 90509 USA.
[Jerez, A.] Ctr Int Trastornos Afectivos & Conducta Adictiva, Guatemala City, Guatemala.
[Ontiveros, A.] Inst Informac & Invest Salud Mental AC, Monterrey, Mexico.
[Nicolini, H.] SC, Grp Estudios Med & Familiares Carracci, Mexico City, DF, Mexico.
RP Gonzalez, SD (reprint author), Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Psychiat, El Paso, TX USA.
EM m.escamilla@ttuhsc.edu
OI Raventos, Henriette/0000-0001-9423-8308; Nicolini,
Humberto/0000-0003-2494-0067
NR 10
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD MAY
PY 2013
VL 3
AR e265
DI 10.1038/tp.2013.40
PG 2
WC Psychiatry
SC Psychiatry
GA 174VJ
UT WOS:000321184400011
PM 23715300
ER
PT J
AU Antiel, RM
Reed, DA
Van Arendonk, KJ
Wightman, SC
Hall, DE
Porterfield, JR
Horvath, KD
Terhune, KP
Tarpley, JL
Farley, DR
AF Antiel, Ryan M.
Reed, Darcy A.
Van Arendonk, Kyle J.
Wightman, Sean C.
Hall, Daniel E.
Porterfield, John R.
Horvath, Karen D.
Terhune, Kyla P.
Tarpley, John L.
Farley, David R.
TI Effects of Duty Hour Restrictions on Core Competencies, Education,
Quality of Life, and Burnout Among General Surgery Interns
SO JAMA SURGERY
LA English
DT Article
ID HOURS ENHANCING SLEEP; 80-HOUR WORK WEEK; AMERICAN SURGEONS; PROGRAM
DIRECTORS; OPERATIVE EXPERIENCE; RESIDENTS; MEDICINE; SUPERVISION;
ATTRITION; HEALTH
AB Objective: To measure the implications of the new Accreditation Council for Graduate Medical Education duty hour regulations for education, well-being, and burnout.
Design: Longitudinal study.
Setting: Eleven university-based general surgery residency programs from July 2011 to May 2012.
Participants: Two hundred thirteen surgical interns.
Main Outcome Measures: Perceptions of the impact of the new duty hours on various aspects of surgical training, including the 6 Accreditation Council for Graduate Medical Education core competencies, were measured on 3-point scales. Quality of life, burnout, balance between personal and professional life, and career satisfaction were measured using validated instruments.
Results: Half of all interns felt that the duty hour changes have decreased the coordination of patient care (53%), their ability to achieve continuity with hospitalized patients (70%), and their time spent in the operating room (57%). Less than half (44%) of interns believed that the new standards have decreased resident fatigue. In longitudinal analysis, residents' beliefs had significantly changed in 2 categories: less likely to believe that practice-based learning and improvement had improved and more likely to report no change to resident fatigue (P < .01, chi(2) tests). The majority (82%) of residents reported a neutral or good overall quality of life. Compared with the normal US population, 50 interns (32%) were 0.5 SD less than the mean on the 8-item Short Form Health Survey mental quality of life score. Approximately one-third of interns demonstrated weekly symptoms of emotional exhaustion (28%) or depersonalization (28%) or reported that their personal-professional balance was either "very poor" or "not great" (32%). Although many interns (67%) reported that they daily or weekly reflect on their satisfaction from being a surgeon, 1 in 7 considered giving up their career as a surgeon on at least a weekly basis.
Conclusions: The first cohort of surgical interns to train under the new regulations report decreased continuity with patients, coordination of patient care, and time spent in the operating room. Furthermore, suboptimal quality of life, burnout, and thoughts of giving up surgery were common, even under the new paradigm of reduced work hours.
C1 [Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Rochester, MN 55905 USA.
[Antiel, Ryan M.; Farley, David R.] Mayo Clin, Dept Surg, Rochester, MN 55905 USA.
[Van Arendonk, Kyle J.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Wightman, Sean C.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
[Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Porterfield, John R.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA.
[Horvath, Karen D.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Terhune, Kyla P.; Tarpley, John L.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
RP Farley, DR (reprint author), Mayo Clin, Dept Surg, 200 1st St SW, Rochester, MN 55905 USA.
EM farley.david@mayo.edu
OI Hall, Daniel/0000-0001-6382-0522
NR 42
TC 51
Z9 51
U1 1
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6254
J9 JAMA SURG
JI JAMA Surg.
PD MAY
PY 2013
VL 148
IS 5
BP 448
EP 455
DI 10.1001/jamasurg.2013.1368
PG 8
WC Surgery
SC Surgery
GA 163IU
UT WOS:000320330300013
PM 23325404
ER
PT J
AU Pandey, GS
Yanover, C
Howard, TE
Sauna, ZE
AF Pandey, Gouri Shankar
Yanover, Chen
Howard, Tom E.
Sauna, Zuben E.
TI Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the
Development of Inhibitory AntiFactor VIII Antibodies during the
Treatment of Hemophilia A: A Computational Assessment
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID T-CELL RESPONSES; MILD HEMOPHILIA; KINETIC STABILITY; COMPLEXES;
BINDING; FVIII; PREVENTION; MOLECULES; MUTATION; EPITOPE
AB The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide polymorphisms (ns-SNPs) in the F8 gene occur as six haplotypes in the human population (denoted H1 to H6) of which H3 and H4 have been associated with an increased risk of developing anti-drug antibodies. There is evidence that CD4+ T-cell response is essential for the development of anti-drug antibodies and such a response requires the presentation of the peptides by the MHC-class-II (MHC-II) molecules of the patient. We measured the binding and half-life of peptide-MHC-II complexes using synthetic peptides from regions of the Factor VIII protein where ns-SNPs occur and showed that these wild type peptides form stable complexes with six common MHC-II alleles, representing 46.5% of the North American population. Next, we compared the affinities computed by NetMHCIIpan, a neural network-based algorithm for MHC-II peptide binding prediction, to the experimentally measured values and concluded that these are in good agreement (area under the ROC-curve of 0.778 to 0.972 for the six MHC-II variants). Using a computational binding predictor, we were able to expand our analysis to (a) include all wild type peptides spanning each polymorphic position; and (b) consider more MHC-II variants, thus allowing for a better estimation of the risk for clinical manifestation of anti-drug antibodies in the entire population (or a specific sub-population). Analysis of these computational data confirmed that peptides which have the wild type sequence at positions where the polymorphisms associated with haplotypes H3, H4 and H5 occur bind MHC-II proteins significantly more than a negative control. Taken together, the experimental and computational results suggest that wild type peptides from polymorphic regions of FVIII constitute potential T-cell epitopes and thus could explain the increased incidence of anti-drug antibodies in hemophilia A patients with haplotypes H3 and H4.
C1 [Pandey, Gouri Shankar; Sauna, Zuben E.] US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
[Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA.
RP Pandey, GS (reprint author), US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
EM zuben.sauna@fda.hhs.gov
RI Yanover, Chen/A-3754-2012
OI Yanover, Chen/0000-0003-3663-4286
FU Food and Drug Administration's Modernization of Science program;
National Heart, Lung and Blood Institute, NIH [1RC2-HL101851, HL-71130,
HL-72533]; Bayer Healthcare Corporation, Bayer Haemophilia Awards
Program; Baxter Healthcare Corporation; Clinical Translational Science
Institute at the University of Southern California's Keck School of
Medicine
FX This work was supported by the Food and Drug Administration's
Modernization of Science program to ZES. Research conducted in the
laboratory of TEH is funded by grants from the National Heart, Lung and
Blood Institute, NIH (1RC2-HL101851, HL-71130 and HL-72533) as well as
from Bayer Healthcare Corporation, Bayer Haemophilia Awards Program,
Baxter Healthcare Corporation, and the Clinical Translational Science
Institute at the University of Southern California's Keck School of
Medicine. The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript.
NR 30
TC 9
Z9 9
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD MAY
PY 2013
VL 9
IS 5
AR e1003066
DI 10.1371/journal.pcbi.1003066
PG 11
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 159FX
UT WOS:000320032100027
PM 23696725
ER
PT J
AU Donovan, DM
Ingalsbe, MH
Benbow, J
Daley, DC
AF Donovan, Dennis M.
Ingalsbe, Michelle H.
Benbow, James
Daley, Dennis C.
TI 12-Step Interventions and Mutual Support Programs for Substance Use
Disorders: An Overview
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Review
DE 12-Step; mutual support; self-help; recovery activities
ID SELF-HELP GROUPS; ALCOHOLICS-ANONYMOUS PARTICIPATION; DUALLY DIAGNOSED
PERSONS; ONE-YEAR OUTCOMES; GROUP INVOLVEMENT; FACILITATING INVOLVEMENT;
ADDICTION TREATMENT; INITIAL VALIDATION; SOCIAL NETWORKS; ABUSE
TREATMENT
AB Social workers and other behavioral health professionals are likely to encounter individuals with substance use disorders in a variety of practice settings outside of specialty treatment. 12-Step mutual support programs represent readily available, no cost community-based resources for such individuals; however, practitioners are often unfamiliar with such programs. The present article provides a brief overview of 12-Step programs, the positive substance use and psychosocial outcomes associated with active 12-Step involvement, and approaches ranging from ones that can be utilized by social workers in any practice setting to those developed for specialty treatment programs to facilitate engagement in 12-Step meetings and recovery activities. The goal is to familiarize social workers with 12-Step approaches so that they are better able to make informed referrals that match clients to mutual support groups that best meet the individual's needs and maximize the likelihood of engagement and positive outcomes.
C1 [Donovan, Dennis M.; Ingalsbe, Michelle H.] Univ Washington, Alcohol & Drug Abuse Inst, Seattle, WA 98105 USA.
[Donovan, Dennis M.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98105 USA.
[Benbow, James] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Daley, Dennis C.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA.
RP Donovan, DM (reprint author), Univ Washington, Alcohol & Drug Abuse Inst, 1107 NE 45th St,Suite 120, Seattle, WA 98105 USA.
EM ddonovan@u.washington.edu
FU NIDA NIH HHS [U10 DA020036, U10 DA013714]
NR 122
TC 10
Z9 10
U1 5
U2 28
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1937-1918
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD MAY 1
PY 2013
VL 28
IS 3-4
SI SI
BP 313
EP 332
DI 10.1080/19371918.2013.774663
PG 20
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA 161GI
UT WOS:000320180100013
PM 23731422
ER
PT J
AU Brady, KT
Haynes, LF
Hartwell, KJ
Killeen, TK
AF Brady, Kathleen T.
Haynes, Louise F.
Hartwell, Karen J.
Killeen, Therese K.
TI Substance Use Disorders and Anxiety: A Treatment Challenge for Social
Workers
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Article
DE Anxiety; substance use disorders; comorbidity; treatment
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY;
PLACEBO-CONTROLLED TRIAL; COMORBIDITY SURVEY REPLICATION;
COCAINE-DEPENDENT INDIVIDUALS; RANDOMIZED CONTROLLED-TRIAL;
MENTAL-HEALTH PROBLEMS; DSM-IV DISORDERS; ALCOHOL DEPENDENCE; PANIC
DISORDER
AB Converging evidence from epidemiologic and treatment studies indicate that anxiety disorders and substance use disorders commonly co-occur, and the interaction is multifaceted and variable. Epidemiological studies and investigations within clinical substance abuse populations have found an association between anxiety disorders and substance use disorders. Specific anxiety disorders including generalized anxiety disorder, panic disorder, and post traumatic stress disorder have all been associated with substance use. The association with obsessive-compulsive disorder is less robust, and some research has found a negative association. The risk of nicotine dependence is significantly higher among individuals with an anxiety disorder, and conversely, smoking has been found to be associated with trait anxiety and anxiety disorders. A review of the current literature and the relationship between specific anxiety disorders and alcohol and substance use disorders is discussed in detail. This article, written for social workers in a variety of practice settings, reviews the prevalence, diagnostic, and treatment issues at the interface of substance use disorders and anxiety disorders.
C1 [Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, Charleston, SC 29425 USA.
[Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Haynes, Louise F.] Med Univ S Carolina, Div Neurosci, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Killeen, Therese K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Brady, KT (reprint author), Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA.
EM bradyk@musc.ed
FU NIDA NIH HHS [U10 DA013727]
NR 94
TC 1
Z9 2
U1 8
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1937-1918
EI 1937-190X
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD MAY 1
PY 2013
VL 28
IS 3-4
SI SI
BP 407
EP 423
DI 10.1080/19371918.2013.774675
PG 17
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA 161GI
UT WOS:000320180100019
PM 23731428
ER
PT J
AU Brennan-Minnella, AM
Shen, Y
El-Benna, J
Swanson, RA
AF Brennan-Minnella, A. M.
Shen, Y.
El-Benna, J.
Swanson, R. A.
TI Phosphoinositide 3-kinase couples NMDA receptors to superoxide release
in excitotoxic neuronal death (vol 4, e580, 2013)
SO CELL DEATH & DISEASE
LA English
DT Correction
C1 [Brennan-Minnella, A. M.; Shen, Y.; Swanson, R. A.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[El-Benna, J.] Univ Paris Diderot, Fac Med, INSERM U773,CRB3, Lab Excellence Inflamex, Paris, France.
RP Brennan-Minnella, AM (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM angela.brennan@ucsf.edu
NR 1
TC 2
Z9 2
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2013
VL 4
AR e624
DI 10.1038/cddis.2013.164
PG 1
WC Cell Biology
SC Cell Biology
GA 156LR
UT WOS:000319824100013
ER
PT J
AU Kim, AI
Han, SH
Tran, DT
Sullivan, P
Lassman, C
Raman, S
Zimmerman, P
Chin, EE
AF Kim, Andrew I.
Han, Steven-Huy
Doan-Trang Tran
Sullivan, Peggy
Lassman, Charles
Raman, Steve
Zimmerman, Peter
Chin, Eva E.
TI Abdominal imaging can misdiagnose submassive hepatic necrosis as
cirrhosis in acute liver failure
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE cirrhosis; computed tomography; fulminant hepatic failure;
transplantation; ultrasound
ID TOMOGRAPHY; SURVIVAL; DISEASE; CT
AB Patients with acute liver failure (ALF) can be listed status I for liver transplantation (LT) whereas patients with cirrhosis must follow the MELD scoring system. Liver imaging can mistakenly diagnose submassive hepatic necrosis in ALF as cirrhosis. The purpose of our study was to assess the accuracy of ultrasound (US) and computed tomography (CT) in distinguishing cirrhosis from ALF. All patients listed for ALF and transplanted during the study period were included. Controls were age- and gender-matched cirrhotic patients who underwent LT during the same period. Abdominal US or CT scans obtained on all patients were independently reviewed by three blinded abdominal radiologists. Explants from all patients were reviewed by two blinded pathologists, and histological diagnosis was correlated with radiological diagnosis. Forty-one patients with ALF and 42 patients with cirrhosis were analyzed. Univariate and multivariate analyses both revealed overall accuracy of 85% for ultrasound and 93% for CT. US and CT scans both provide high levels of accuracy in terms of discriminating ALF from cirrhosis but measures taken to determine whether a patient has ALF vs. cirrhosis needs to approach 100% accuracy. Thus, imaging studies alone should not definitively diagnosis one etiology of liver failure over the other.
C1 [Kim, Andrew I.; Doan-Trang Tran] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastroenterol, Los Angeles, CA 90095 USA.
[Kim, Andrew I.; Han, Steven-Huy] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Han, Steven-Huy] Univ Calif Los Angeles, David Geffen Sch Med, Pfleger Liver Inst, Los Angeles, CA 90095 USA.
[Sullivan, Peggy; Lassman, Charles] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
[Raman, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Zimmerman, Peter; Chin, Eva E.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA 90073 USA.
[Zimmerman, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Chin, EE (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eva.chin@va.gov
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAY-JUN
PY 2013
VL 27
IS 3
BP E339
EP E345
DI 10.1111/ctr.12123
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 156OT
UT WOS:000319832700023
PM 23647426
ER
PT J
AU Jensen, MK
Bartz, TM
Mukamal, KJ
Djousse, L
Kizer, JR
Tracy, RP
Zieman, SJ
Rimm, EB
Sscovick, DS
Shlipak, M
Ix, JH
AF Jensen, Majken K.
Bartz, Traci M.
Mukamal, Kenneth J.
Djousse, Luc
Kizer, Jorge R.
Tracy, Russell P.
Zieman, Susan J.
Rimm, Eric B.
Siscovick, David S.
Shlipak, Michael
Ix, Joachim H.
TI Fetuin-A, Type 2 Diabetes, and Risk of Cardiovascular Disease in Older
Adults The Cardiovascular Health Study
SO DIABETES CARE
LA English
DT Article
ID ALPHA(2)-HEREMANS-SCHMID GLYCOPROTEIN/FETUIN-A; RECEPTOR TYROSINE
KINASE; INSULIN-RESISTANCE; ASSOCIATION; INHIBITOR; SERUM;
CALCIFICATION; MORTALITY; DIALYSIS; MELLITUS
AB OBJECTIVE-Fetuin-A, a hepatic secretory protein that simultaneously inhibits arterial calcification and insulin action, is associated with type 2 diabetes, but its association with cardiovascular disease (CVD) is uncertain. Preliminary studies suggest that the association of fetuin-A with CVD might differ among individuals with or without type 2 diabetes.
RESEARCH DESIGN AND METHODS-This was a prospective study of 3,810 community-living individuals older than 65 years (511 with type 2 diabetes) and free of CVD in 1992 when fetuin-A levels were measured. Participants were followed-up for incident CVD through June 2008.
RESULTS-Mean age was 75 years, and 61% were women; 1,456 participants had an incident CVD event (248 among individuals with type 2 diabetes). The association of fetuin-A with CVD was modified by type 2 diabetes (P interaction = 0.02). Higher fetuin-A was associated with lower CVD risk among persons without type 2 diabetes [hazard ratio per SD 0.1 g/L higher fetuin-A, 0.93 (95% Cl, 0.88-0.99)], whereas a trend in the opposite direction was observed among individuals with type 2 diabetes, although it was not statistically significant [1.07 (0.93 1.22)]. Among individuals without type 2 diabetes, similar effect modification was observed by obesity and insulin resistance. Consistently, higher fetuin-A was associated with lower CVD risk only in the subgroups without obesity or with HOMA-IR below the median [0.91 (0.85-0.97) and 0.87 (0.79-0.95), respectively].
CONCLUSIONS-The association of fetuin-A with risk of CVD differs among elderly individuals with and without insulin resistance or type 2 diabetes.
C1 [Jensen, Majken K.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Bartz, Traci M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Djousse, Luc] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Aging, Boston, MA USA.
[Djousse, Luc] Boston Vet Affairs Healthcare Syst, Boston, MA USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY 10467 USA.
[Tracy, Russell P.] Univ Vermont, Colchester Res Facil, Dept Pathol, Colchester, VT USA.
[Zieman, Susan J.] NIA, NIH, Bethesda, MD 20892 USA.
[Rimm, Eric B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA.
[Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Shlipak, Michael] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA.
RP Jensen, MK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM mkjensen@hsph.harvard.edu
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL094555]; NHLBI
[N01 HC-85079, N01 HC-85080, N01 HC-85081, N01 HC-85082, N01 HC-85083,
N01 HC-85084, N01 HC-85085, N01HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01 HC-75150, N01 HC-54133, N01-HC85239, U01 HL080295]
FX The study was supported by a National Heart, Lung, and Blood Institute
(NHLBI) grant (R01 HL094555). The CHS was supported by contract numbers
N01 HC-85079 through N01HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01 HC-75150, N01 HC-54133, and N01-HC85239, and grant number
U01 HL080295 from the NHLBI, with additional contributions from the
National Institute of Neurologic Disorders and Stroke. This material is
the result of work supported with resources of the VA San Diego
Healthcare System.
NR 31
TC 41
Z9 43
U1 1
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1222
EP 1228
DI 10.2337/dc12-1591
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100026
PM 23250801
ER
PT J
AU Hayashi, T
Boyko, EJ
Sato, KK
McNeely, MJ
Leonetti, DL
Kahn, SE
Fujimoto, WY
AF Hayashi, Tomoshige
Boyko, Edward J.
Sato, Kyoko Kogawa
McNeely, Marguerite J.
Leonetti, Donna L.
Kahn, Steven E.
Fujimoto, Wilfred Y.
TI Patterns of Insulin Concentration During the OGTT Predict the Risk of
Type 2 Diabetes in Japanese Americans
SO DIABETES CARE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL DYSFUNCTION; FASTING GLUCOSE;
RESISTANCE; SENSITIVITY; SECRETION; CLAMP; MODEL; MEN
AB OBJECTIVE-To examine whether the patterns of insulin concentration during the oral glucose tolerance test (OGTT) predict type 2 diabetes.
RESEARCH DESIGN AND METHODS-We followed 400 nondiabetic Japanese Americans for 10-11 years. Insulin concentrations at 30, 60, and 120 min during a 2-h 75-g OGTT at baseline were used to derive the following possible patterns of insulin: pattern 1 (30-min peak, higher insulin level at 60 than at 120 min), pattern 2 (30-min peak, lower or equal level at 60 vs. 120 min), pattern 3 (60-min peak); pattern 4 (120-mm peak, lower level at 30 than at 60 min), and pattern 5 (120-min peak, equal or higher level at 30 vs. 60 mm). Insulin sensitivity was estimated by homeostasis model assessment of insulin resistance (HOMA-IR) and Matsuda index. Insulin secretion was estimated by the insulinogenic index (IGI) [Delta insulin/Delta glucose (30-0 min)] and disposition index (IGI/HOMA-IR).
RESULTS-There were 86 incident cases of type 2 diabetes. The cumulative incidence was 3.2, 9.8, 15.4, 47.8, and 37.5% for patterns 1, 2, 3, 4, and 5, respectively. Compared with pattern 1, patterns 4 and 5, characterized by a lasting late insulin response, were associated with significantly less insulin sensitivity as measured by the Matsuda index and lower early insulin response by the disposition index. The multiple-adjusted odds ratios of type 2 diabetes were 12.55 (95% Cl 4.79-32.89) for pattern 4 and 8.34(2.38-29.27) for patterns compared with patterns 1 and 2. This association was independent of insulin secretion and sensitivity.
CONCLUSIONS-The patterns of insulin concentration during an OGTT strongly predict the development of type 2 diabetes.
C1 [Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Hayashi, Tomoshige; Sato, Kyoko Kogawa] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan.
[Boyko, Edward J.; McNeely, Marguerite J.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA.
[Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
[Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Boyko, EJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
EM eboyko@u.washington.edu
RI Hayashi, Tomoshige/N-8508-2015
OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X
FU National Institutes of Health [DK-31170, HL-49293, DK-02654]; Japanese
Ministry of Education, Science, Sports, and Culture [23390177]; King
County Japanese-American community
FX This work was supported by National Institutes of Health grants
DK-31170, HL-49293, and DK-02654; facilities and services were provided
by the Diabetes and Endocrinology Research Center (DK-17047), Clinical
Nutrition Research Unit (DK-35816), and the General Clinical Research
Center (RR-00037) at the University of Washington. T.H. was supported in
part by a research grant from the Japanese Ministry of Education,
Science, Sports, and Culture (23390177). VA Puget Sound Health Care
System provided support for the participation of E.J.B. and S.E.K.; The
authors gratefully acknowledge the skilled assistance of staff members,
especially Jane B. Shofer of the Center for Studies in Demography and
Ecology, University of Washington. The authors are grateful to the King
County Japanese-American community for their support and cooperation.
NR 20
TC 12
Z9 12
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1229
EP 1235
DI 10.2337/dc12-0246
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100027
PM 23275353
ER
PT J
AU Clapp, JD
Grubaugh, AL
Allen, JG
Mahoney, J
Oldham, JM
Fowler, JC
Ellis, T
Elhai, JD
Frueh, BC
AF Clapp, Joshua D.
Grubaugh, Anouk L.
Allen, Jon G.
Mahoney, Jane
Oldham, John M.
Fowler, J. Christopher
Ellis, Tom
Elhai, Jon D.
Frueh, B. Christopher
TI Modeling Trajectory of Depressive Symptoms Among Psychiatric Inpatients:
A Latent Growth Curve Approach
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID LENGTH-OF-STAY; INVENTORY-II; DECREASING LENGTH; HOSPITAL STAY;
UNITED-STATES; CARE; PSYCHOTHERAPY; OUTCOMES; ANTIDEPRESSANTS; DISORDERS
AB Objective: Changes in the parameters of inpatient psychiatric care have inspired a sizable literature exploring correlates of prolonged intervention as well as symptom change over varying lengths of hospitalization. However, existing data offer limited insight regarding the nature of symptom change over time. Objectives of this longitudinal research were to (1) model the trajectory of depressive symptoms within an inpatient psychiatric sample, (2) identify characteristics associated with unique patterns of change, and (3) evaluate the magnitude of expected gains using objective clinical benchmarks.
Method: Participants included 1,084 psychiatric inpatients treated between April 2008 and December 2010. Latent growth curve modeling was used to determine the trajectory of Beck Depression Inventory II depressive symptoms in response to treatment. Age, gender, trauma history, prior hospitalization, and DSM-IV diagnoses were examined as potential moderators of recovery.
Results: Results indicate a nonlinear model of recovery, with symptom reductions greatest following admission and slowing gradually over time. Female gender, probable trauma exposure, prior psychiatric hospitalization, and primary depressive diagnosis were associated with more severe trajectories. Diagnosis of alcohol/substance use, by contrast, was associated with more moderate trajectories. Objective benchmarks occurred relatively consistently across patient groups, with clinically significant change occurring between 2-4 weeks after admission.
Conclusions: The nonlinear trajectory of recovery observed in these data provides insight regarding the dynamics of inpatient recovery. Across all patient groups, symptom reduction was most dramatic in the initial week of hospitalization. However, notable improvement continued for several weeks after admission. Results suggest that timelines for adequate inpatient care are largely contingent on program-specific goals.
C1 [Clapp, Joshua D.; Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Clapp, Joshua D.] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA.
[Allen, Jon G.; Mahoney, Jane; Oldham, John M.; Fowler, J. Christopher; Ellis, Tom] Menninger Clin, Houston, TX USA.
[Allen, Jon G.; Mahoney, Jane; Oldham, John M.; Fowler, J. Christopher; Ellis, Tom] Baylor Coll Med, Houston, TX 77030 USA.
[Ellis, Tom] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA.
[Ellis, Tom] Univ Toledo, Dept Psychiat, Toledo, OH 43606 USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
RP Clapp, JD (reprint author), Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA.
EM jclapp@uwyo.edu
OI Ellis, Thomas/0000-0002-4496-5280
FU Menninger Foundation; McNair Medical Institute; National Institute of
Mental Health (NIMH); NIMH [T32 MH18869]
FX This research was supported in part by funding from the Menninger
Foundation, the McNair Medical Institute, and the National Institute of
Mental Health (NIMH). Dr Frueh is a McNair Scholar. Dr Clapp was a
NIMH-sponsored intern at the Medical University of South Carolina (T32
MH18869) during the development of this project.
NR 55
TC 12
Z9 12
U1 1
U2 10
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2013
VL 74
IS 5
BP 492
EP 499
DI 10.4088/JCP.12m07842
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 157IW
UT WOS:000319890800005
PM 23759452
ER
PT J
AU Doran, KM
Ragins, KT
Gross, CP
Zerger, S
AF Doran, Kelly M.
Ragins, Kyle T.
Gross, Cary P.
Zerger, Suzanne
TI Medical Respite Programs for Homeless Patients: A Systematic Review
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Review
DE Respite care; aftercare; subacute care; homeless people;
hospitalization; patient discharge
ID SHELTER-BASED CONVALESCENCE; CASE-MANAGEMENT PROGRAM; LENGTH-OF-STAY;
ADULTS; CARE; INTERVENTIONS; QUALITY; COSTS
AB Medical respite programs provide care to homeless patients who are too sick to be on the streets or in a traditional shelter, but not sick enough to warrant inpatient hospitalization. They are designed to improve the health of homeless patients while also decreasing costly hospital use. Although there is increasing interest in implementing respite programs, there has been no prior systematic review of their effectiveness. We conducted a comprehensive search for studies of medical respite program outcomes in multiple biomedical and sociological databases, and the grey literature. Thirteen articles met inclusion criteria. The articles were heterogeneous in methods, study quality, inclusion of a comparison group, and outcomes examined. Available evidence showed that medical respite programs reduced future hospital admissions, inpatient days, and hospital readmissions. They also resulted in improved housing outcomes. Results for emergency department use and costs were mixed but promising. Future research utilizing adequate comparison groups is needed.
C1 [Doran, Kelly M.; Gross, Cary P.] Yale Univ, Sch Med YU SOM, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT 06520 USA.
[Zerger, Suzanne] Ctr Social Innovat, Needham, MA USA.
RP Doran, KM (reprint author), Yale Univ, Sch Med YU SOM, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
EM kelly.doran@yale.edu
NR 27
TC 11
Z9 11
U1 0
U2 10
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2013
VL 24
IS 2
BP 499
EP 524
PG 26
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 153VU
UT WOS:000319631400008
PM 23728025
ER
PT J
AU Stineman, MG
Zhang, GY
Kurichi, JE
Zhang, Z
Streim, JE
Pan, Q
Xie, DW
AF Stineman, Margaret G.
Zhang, Guangyu
Kurichi, Jibby E.
Zhang, Zi
Streim, Joel E.
Pan, Qiang
Xie, Dawei
TI Prognosis for Functional Deterioration and Functional Improvement in
Late Life Among Community-Dwelling Persons
SO PM&R
LA English
DT Article
ID OLDER-PEOPLE; LIMITATION PATHWAYS; ELDERLY-PEOPLE; HEALTH; DISABILITY;
REHABILITATION; INDEPENDENCE; TRANSITIONS; VALIDATION; MORTALITY
AB Objective: To examine how health-related, socioeconomic, and environmental factors combine to influence the onset of activity of daily living (ADL) limitations or prognosis for death or further functional deterioration or improvement among elderly people.
Design: A national representative sample with 2-year follow-up.
Setting: Community-dwelling people.
Participants: Included were 9447 persons (>= 70 years of age) in the United States from the Second Longitudinal Study of Aging who were interviewed in 1994, 1995, or 1996.
Methods: Self- or proxy-reported health conditions, ADLs expressed as 5 stages describing severity and pattern of limitations, and other baseline characteristics were obtained. A multinomial logistic regression model was used to predict stage transitions. Because of incomplete follow-up (17.7% of baseline sample), primary analyses were determined by multiple imputation to address potential bias associated with loss to follow-up.
Main Outcome Measurement: ADL stage transitions in 2 years (death, deteriorated, stable, and improved ADL function).
Results: In the imputed-case analysis, the percentages for those who died, deteriorated, were stable, and improved were 12.6%, 32.7%, 48.4%, and 6.2%, respectively. Persons at a mild stage of ADL limitation were most likely to deteriorate further. Persons at advanced stages were most likely to die. Married people and high school graduates had a lower likelihood of deterioration. The risk of mortality and functional deterioration increased with age. Certain conditions, such as diabetes, were associated both with mortality and functional deterioration; other conditions, such as cancer, were associated with mortality only, and arthritis was associated only with functional deterioration.
Conclusions: Although overlap occurs, different clinical traits are associated with mortality, functional deterioration, and functional improvement. ADL stages might aid physical medicine and rehabilitation clinicians and researchers in developing and monitoring disability management strategies targeted to maintaining and enhancing self-care among community-dwelling older people.
C1 [Stineman, Margaret G.; Kurichi, Jibby E.; Zhang, Zi; Pan, Qiang; Xie, Dawei] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
[Zhang, Guangyu] Univ Maryland, Dept Epidemiol & Biostat, College Pk, MD 20742 USA.
[Streim, Joel E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network VISN 4, Philadelphia, PA USA.
RP Stineman, MG (reprint author), 423 Guardian Dr,904 Blockley Hall, Philadelphia, PA 19104 USA.
EM mstinema@exchange.upenn.edu
FU nonprofit/government agencies, NIA [R01 AG032420-01A1]
FX grant support for research from nonprofit/government agencies, NIA,
grant (#R01 AG032420-01A1)
NR 46
TC 11
Z9 11
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2013
VL 5
IS 5
BP 360
EP 371
DI 10.1016/j.pmrj.2013.02.008
PG 12
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 156SO
UT WOS:000319844400002
PM 23454447
ER
PT J
AU Lehavot, K
Der-Martirosian, C
Simpson, TL
Sadler, AG
Washington, DL
AF Lehavot, Keren
Der-Martirosian, Claudia
Simpson, Tracy L.
Sadler, Anne G.
Washington, Donna L.
TI Barriers to Care for Women Veterans With Posttraumatic Stress Disorder
and Depressive Symptoms
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE women veterans; posttraumatic stress disorder; depression; barriers to
care; health care
ID HEALTH ADMINISTRATION PATIENTS; FEMALE VETERANS; RANDOMIZED-TRIAL;
MEDICAL ILLNESS; SERVICE USE; VA; AFFAIRS; IRAQ; AFGHANISTAN; PTSD
AB As the number of women veterans continues to rise, an issue of concern is whether those with mental health symptoms experience disproportionate barriers to care. The purpose of this study was to examine unmet medical needs and barriers to health care among women veterans who screened positive for lifetime posttraumatic stress disorder (PTSD), current depressive symptoms, both or neither. Using the National Survey of Women Veterans dataset (N = 3,593), we compared women veterans corresponding to these 4 groups on whether they had unmet medical needs in the past year, reasons for unmet needs, and barriers to using VA care for those not currently doing so. The majority of women veterans who screened positive for both PTSD and depressive symptoms had unmet medical care needs in the prior 12 months (59%), compared to 30% of women with PTSD symptoms only, 18% of those with depressive symptoms only, and 16% of women with neither set of symptoms. Among those reporting unmet medical needs (n = 840), those with both PTSD and depressive symptoms were more likely than the other groups to identify affordability as a reason for going without or delaying care. Among women veterans not using VA health care (n = 1,677), women with both PTSD and depressive symptoms were more likely to report not knowing if they were eligible for VA benefits and were less likely to have health insurance to cover care outside of the VA. These data highlight specific areas of vulnerability of women veterans with comorbid PTSD and depressive symptoms and identify areas of concern as VA and other health facilities work to ensure equitable access to care.
C1 [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Der-Martirosian, Claudia; Washington, Donna L.] Ctr Excellence Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv Res & Dev, Sepulveda, CA USA.
[Simpson, Tracy L.] Univ Washington, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98195 USA.
[Sadler, Anne G.] Univ Iowa, Carver Coll Med, Iowa City VA Med Ctr, Iowa City, IA 52242 USA.
[Sadler, Anne G.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA.
[Washington, Donna L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
RP Lehavot, K (reprint author), 1660 S Columbian Way S-116-POC, Seattle, WA 98108 USA.
EM klehavot@uw.edu
NR 46
TC 6
Z9 6
U1 1
U2 12
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 203
EP 212
DI 10.1037/a0031596
PG 10
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300009
PM 23730964
ER
PT J
AU Simpson, TL
Balsam, KF
Cochran, BN
Lehavot, K
Gold, SD
AF Simpson, Tracy L.
Balsam, Kimberly F.
Cochran, Bryan N.
Lehavot, Keren
Gold, Sari D.
TI Veterans Administration Health Care Utilization Among Sexual Minority
Veterans
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veterans; health care utilization; lesbian; gay; bisexual
ID HATE-CRIME VICTIMIZATION; BEHAVIORAL-MODEL; BISEXUAL ADULTS;
STRESS-DISORDER; PTSD CHECKLIST; SERVICES USE; ACCESS; GAY; WOMEN;
PREVALENCE
AB According to recent census reports, nearly a million veterans have a same-sex partner, yet little is known about them or their use of Veterans Health Care Administration (VHA) services. Gay, lesbian, and bisexual (GLB) veterans recruited from the community (N = 356) completed an on-line survey to assess their rates of VHA utilization and whether they experience specific barriers to accessing VHA services. Andersen's model of health care utilization was adapted to provide an analytic and conceptual framework. Overall, 45.5% reported lifetime VHA utilization and 28.7% reported past-year VHA utilization. Lifetime VHA health care utilization was predicted by positive service connection, positive screen for both posttraumatic stress disorder (PTSD) and depression, and history of at least one interpersonal trauma during military service related to respondent's GLB status. Past-year VHA health care utilization was predicted by female gender, positive service connection, positive screen for both PTSD and depression, lower physical functioning, a history of military interpersonal trauma related to GLB status, and no history of stressful experiences initiated by the military to investigate or punish GLB status. Rates of VHA utilization by GLB veterans in this sample are comparable to those reported by VHA Central Office for all veterans. Of those who utilized VHA services, 33% reported open communication about their sexual orientation with VHA providers. Twenty-five percent of all participants reported avoiding at least one VHA service because of concerns about stigma. Stigma and lack of communication between GLB veterans and their providers about sexual orientation are areas of concern for VHA.
C1 [Simpson, Tracy L.; Lehavot, Keren; Gold, Sari D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Simpson, Tracy L.; Lehavot, Keren; Gold, Sari D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Balsam, Kimberly F.] Univ Washington, Dept Social Work, Seattle, WA 98195 USA.
[Cochran, Bryan N.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA.
RP Simpson, TL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM tracy.simpson@va.gov
NR 45
TC 16
Z9 16
U1 4
U2 24
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 223
EP 232
DI 10.1037/a0031281
PG 10
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300011
PM 23730965
ER
PT J
AU Wyatt, GE
Gomez, CA
Hamilton, AB
Valencia-Garcia, D
Gant, LM
Graham, CE
AF Wyatt, Gail E.
Gomez, Cynthia A.
Hamilton, Alison B.
Valencia-Garcia, Dellanira
Gant, Larry M.
Graham, Charles E.
TI The Intersection of Gender and Ethnicity in HIV Risk, Interventions, and
Prevention New Frontiers for Psychology
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE HIV; gender; ethnicity; sociocultural; intersectionality
ID AFRICAN-AMERICANS; POSITIVE WOMEN; UNITED-STATES; PUBLIC-HEALTH;
IMMUNODEFICIENCY SYNDROME; SAN-FRANCISCO; SEXUAL-ABUSE; SELF-ESTEEM;
BLACK-MEN; AIDS
AB This article articulates a contextualized understanding of gender and ethnicity as interacting social determinants of HIV risk and acquisition, with special focus on African Americans and Hispanics/Latinos-2 ethnic groups currently at most risk for HIV/AIDS acquisition in the United States. First, sex and gender are defined. Second, a conceptual model of gender, ethnicity, and HIV risk and resilience is presented. Third, a historical backdrop of gender and ethnic disparities is provided, with attention to key moments in history when notions of the intersections between gender, ethnicity, and HIV have taken important shifts. Finally, new frontiers in psychology are presented, with recommendations as to how psychology as a discipline can better incorporate considerations of gender and ethnicity as not only HIV risk factors but also as potential avenues of resilience in ethnic families and communities. Throughout the article, we promulgate the notion of a syndemic intersectional approach, which provides a critical framework for understanding and building the conditions that create and sustain overall community health by locating gendered lived experiences and expectations within the layered conceptual model ranging from the biological self to broader societal structures that define and constrain personal decisions, behaviors, actions, resources, and consequences. For ethnic individuals and populations, health disparities, stress and depression, substance abuse, and violence and trauma are of considerable concern, especially with regard to HIV risk, infection, and treatment. The conceptual model poses new frontiers for psychology in HIV policy, research, interventions, and training.
C1 [Wyatt, Gail E.; Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Gomez, Cynthia A.; Valencia-Garcia, Dellanira] San Francisco State Univ, Hlth Equ Inst, San Francisco, CA USA.
[Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gant, Larry M.; Graham, Charles E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
RP Wyatt, GE (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,38-232 NPI,Box 175919, Los Angeles, CA 90024 USA.
EM gwyatt@mednet.ucla.edu
NR 108
TC 12
Z9 13
U1 7
U2 27
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
J9 AM PSYCHOL
JI Am. Psychol.
PD MAY-JUN
PY 2013
VL 68
IS 4
SI SI
BP 247
EP 260
DI 10.1037/a0032744
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA 146FS
UT WOS:000319075900005
PM 23688092
ER
PT J
AU Ko, DT
Wijeysundera, HC
Jackevicius, CA
Yousef, A
Wang, J
Tu, JV
AF Ko, Dennis T.
Wijeysundera, Harindra C.
Jackevicius, Cynthia A.
Yousef, Altayyeb
Wang, Julie
Tu, Jack V.
TI Diabetes Mellitus and Cardiovascular Events in Older Patients With
Myocardial Infarction Prescribed Intensive-Dose and Moderate-Dose
Statins
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE acute coronary syndrome; intensive-dose statins; new-onset diabetes
mellitus
ID ACUTE CORONARY SYNDROMES; MORTALITY PREDICTION RULES; HEART-DISEASE
MORTALITY; LIPID-LOWERING THERAPY; ELDERLY-PATIENTS; ADMINISTRATIVE
DATA; METAANALYSIS; ONTARIO; RISK; ASSOCIATION
AB Background-Practice guidelines recommend intensive-dose statins for patients with acute coronary syndrome, but recent data about the risk of new-onset diabetes mellitus have raised concerns about its use. Our main objective was to evaluate the association between intensive statin therapy and new-onset diabetes mellitus in patients with myocardial infarction and to evaluate the association of intensive statin therapy with long-term adverse clinical outcomes.
Methods and Results-A propensity score-matched cohort was created consisting of 17 080 patients with myocardial infarction aged >65 years old, hospitalized in Ontario, Canada, from 2004 to 2010. Clinical outcomes were compared in patients prescribed intensive-dose versus moderate-dose statins at hospital discharge. At 5 years, 13.6% of patients receiving intensive-dose statins and 13.0% of patients receiving moderate-dose statins had new-onset diabetes, which was not significantly different (P=0.19). By contrast, the 5-year rate of death or acute coronary syndrome was significantly lower at 44.8% in the intensive-dose statin group compared with 46.5% in the moderate-dose group (P=0.044). The reduction in combined clinical outcome was driven mainly by a significantly lower rate of acute coronary syndrome (P=0.039) associated with intensive-dose statins. No significant difference in mortality rates (34.8% in both groups) was observed between the treatment groups during the study period (P=0.89).
Conclusions-In older patients with myocardial infarction, we found intensive-dose statin therapy to be effective in reducing repeat hospitalization for acute coronary syndrome. The rate of new-onset diabetes mellitus at long term was not significantly different between intensive-dose and moderate-dose statins.
C1 [Ko, Dennis T.; Wijeysundera, Harindra C.; Jackevicius, Cynthia A.; Yousef, Altayyeb; Wang, Julie; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Ko, Dennis T.; Wijeysundera, Harindra C.; Tu, Jack V.] Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Toronto, ON M4N 3M5, Canada.
[Ko, Dennis T.; Wijeysundera, Harindra C.; Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA USA.
[Jackevicius, Cynthia A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Ko, DT (reprint author), Inst Clin Evaluat Sci G1 06, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM dennis.ko@ices.on.ca
OI Ko, Dennis/0000-0001-6840-8051
FU Institute for Clinical Evaluative Sciences; Ontario Ministry of Health
and Long-Term Care; Canadian Institutes of Health Research [102487];
Canada Research Chair in Health Services Research; Heart and Stroke
Foundation of Ontario
FX This study was supported by the Institute for Clinical Evaluative
Sciences, which is funded by an annual grant from the Ontario Ministry
of Health and Long-Term Care. The opinions, results and conclusions
reported in this article are those of the authors and are independent
from the funding sources. No endorsement by the Institute for Clinical
Evaluative Sciences or the Ontario Ministry of Health and Long-term Care
is intended or should be inferred.; The analysis of this study was
supported by a Canadian Institutes of Health Research operating grant
MOP (102487). Dr Ko is supported by a Canadian Institutes of Health
Research New Investigator Award. Dr Tu is supported by a Canada Research
Chair in Health Services Research and a Career Investigator Award from
the Heart and Stroke Foundation of Ontario.
NR 32
TC 20
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2013
VL 6
IS 3
BP 315
EP 322
DI 10.1161/CIRCOUTCOMES.111.000015
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 150LS
UT WOS:000319392600013
PM 23674307
ER
PT J
AU Berge, EM
Bowles, DW
Flaig, TW
Lam, ET
Jimeno, A
AF Berge, E. M.
Bowles, D. W.
Flaig, T. W.
Lam, E. T.
Jimeno, A.
TI TIVOZANIB: PRACTICAL IMPLICATIONS FOR RENAL CELL CARCINOMA AND OTHER
SOLID TUMORS
SO DRUGS OF TODAY
LA English
DT Article
DE Tivozanib; VEGFR-1 (FLT-1) inhibitors; VEGFR-2 (FLK-1/KDR) inhibitors;
VEGFR-3 (FLT-4) inhibitors; TIVO
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-III TRIAL;
ANTITUMOR-ACTIVITY; DOUBLE-BLIND; LUNG-CANCER; RETROSPECTIVE ANALYSIS;
SELECTIVE INHIBITOR; AXITINIB AG-013736; 1ST-LINE TREATMENT
AB Tivozanib is a recently developed, small-molecule tyrosine kinase inhibitor with specific affinity for the vascular endothelial growth factor receptor (VEGFR) family of kinases. Given known relevance of VHL (Von Hippel-Lindau disease tumor suppressor) deregulation in the clear cell variant of renal cell carcinoma, renal cell carcinoma remains an area of interest and subject of recent registration trials with this approach. TIVO-1, a phase III study evaluating tivozanib versus sorafenib in the first-line setting, met its primary endpoint of progression-free survival (11.9 months for tivozanib vs. 9.1 months for sorafenib), with a manageable toxicity profile, leading to formal consideration of regulatory approval in this setting. This review focuses on the preclinical development, pharmacokinetics and early clinical activity of tivozanib in renal cell carcinoma and other solid tumors.
C1 [Berge, E. M.; Bowles, D. W.; Flaig, T. W.; Lam, E. T.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA.
[Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jimeno, A (reprint author), Univ Colorado, Sch Med, Div Med Oncol, 12801 East 17th Ave,MS 8117, Aurora, CO 80045 USA.
EM antonio.jimeno@ucdenver.edu
FU Novartis; GlaxoSmithKline; Pfizer; Bayer/Onyx; Genentech; Bristol-Myers
Squibb; Argos; Exelixis
FX T. Flaig sits on the advisory board of GTx, and has acted as a
consultant for sanofi-aventis. he has received clinical trial funding
from Novartis, GlaxoSmithKline, Pfizer, Bayer/Onyx and Genentech. E. Lam
has received research funding from Bristol-Myers Squibb, Argos,
Genentech and Exelixis. The other authors state no conflicts of
interest.
NR 78
TC 5
Z9 5
U1 0
U2 4
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD MAY
PY 2013
VL 49
IS 5
BP 303
EP 315
DI 10.1358/dot.2013.49.5.1960218
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 155PC
UT WOS:000319759400002
PM 23724410
ER
PT J
AU Rice, TR
Sher, L
AF Rice, T. R.
Sher, L.
TI Killing in combat and suicide risk
SO EUROPEAN PSYCHIATRY
LA English
DT Letter
DE Suicide; Epidemiology; Suicide risk assessment; Veterans; Military
combat; Aggression
ID MENTAL-HEALTH SYMPTOMS; WAR VETERANS; IMPACT
C1 [Rice, T. R.; Sher, L.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Sher, L.] James P Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM Timothy.Rice@mssm.edu
NR 9
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD MAY
PY 2013
VL 28
IS 4
BP 261
EP 261
DI 10.1016/j.eurpsy.2012.10.001
PG 1
WC Psychiatry
SC Psychiatry
GA 152RL
UT WOS:000319548700010
PM 23182848
ER
PT J
AU Hamilton, JR
Parvataneni, R
Stuart, SE
Chren, MM
AF Hamilton, Jeffrey R.
Parvataneni, Rupa
Stuart, Sarah E.
Chren, Mary-Margaret
TI Rerecurrence 5 Years After Treatment of Recurrent Cutaneous Basal Cell
and Squamous Cell Carcinoma
SO JAMA DERMATOLOGY
LA English
DT Letter
ID MOHS MICROGRAPHIC SURGERY
C1 [Hamilton, Jeffrey R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
[Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, Mt Zion Canc Res Bldg,2340 Sutter St,Room N412,Ma, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
FU NIAMS NIH HHS [K24 AR052667, R01 AR054983]
NR 5
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2013
VL 149
IS 5
BP 616
EP 618
PG 4
WC Dermatology
SC Dermatology
GA 154JV
UT WOS:000319672100026
PM 23677098
ER
PT J
AU Kaji, I
Akiba, Y
Kaunitz, JD
AF Kaji, I.
Akiba, Y.
Kaunitz, J. D.
TI DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Involvement of gut
chemosensing in the regulation of mucosal barrier function and defense
mechanisms
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 12th International Symposium on Digestive Physiology of Pigs
CY MAY 29-JUN 01, 2012
CL Keystone, CO
DE anion secretion; bicarbonate; duodenum; enteroendocrine cells;
glucagon-like peptides; serotonin
ID DUODENAL ENTEROENDOCRINE CELLS; INTESTINAL EPITHELIUM; BICARBONATE
SECRETION; ENDOCRINE-CELLS; RAT DUODENUM; PEPTIDASE-IV; BLOOD-FLOW;
RECEPTOR; GUSTDUCIN; RELEASE
AB Meal ingestion is followed by release of numerous hormones from enteroendocrine cells interspersed among the epithelial cells lining the intestine. Recently, the de-orphanization of G protein-coupled receptor (GPCR)-type nutrient receptors, expressed on the apical membranes of enteroendocrine cells, has suggested a plausible mechanism whereby luminal nutrients trigger the release of gut hormones. Activation of nutrient receptors triggers intracellular signaling mechanisms that promote exocytosis of hormone-containing granules into the submucosal space. Hormones released by foregut enteroendocrine cells include the glucagon-like peptides (GLP) affecting glycemic control (GLP-1) and releasing proproliferative, hypertrophy-inducing growth factors (GLP-2). The foregut mucosa, being exposed to pulses of concentrated HCl, is protected by a system of defense mechanisms, which includes epithelial bicarbonate and mucus secretion and augmentation of mucosal blood flow. We have reported that luminal co-perfusion of AA with nucleotides in anesthetized rats releases GLP-2 into the portal vein, associated with increased bicarbonate and mucus secretion and mucosal blood flow. The GLP-2 increases bicarbonate secretion via release of vasoactive intestinal peptide (VIP) from myenteric nerves. Luminal bile acids also release gut hormones due to activation of the bile-acid receptor known as G Protein-Coupled Receptor (GPR) 131, G Protein Bile Acid Receptor (GPBAR) 1, or Takeda G Protein-Coupled Receptor (TGR) 5, also expressed on enteroendocrine cells. The GLP are metabolized by dipeptidyl peptidase IV (DPPIV), an enzyme of particular interest to pharmaceutical, because its inhibition increases plasma concentrations of GLP-1 to treat diabetes. We have also reported that DPPIV inhibition enhances the secretory effects of nutrient-evoked GLP-2. Understanding the release mechanism and the metabolic pathways of gut hormones is of potential utility to the formulation of feedstuff additives that, by increasing nutrient absorption due to increased mucosal mass, can increase yields.
C1 [Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Brentwood Biomed Res, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Kaji, I.] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA 90095 USA.
EM jake@ucla.edu
FU Lucta S.A. (Barcelona, Spain); American Society of Animal Science;
Journal of Animal Science; Japan Society for the Promotion of Science;
Ajinomoto, Japan; Department of Veterans Affairs; NIH-NIDDK [R01
DK54221]
FX Based on a presentation at the preconference symposium titled "Gut
Chemosensing: Integrating nutrition, gut function and metabolism in
pigs" preceding the 12th International Symposium on Digestive Physiology
of Pigs in Keystone, Colorado, May 29-June 1, 2012, with publication
sponsored by Lucta S.A. (Barcelona, Spain), the American Society of
Animal Science, and the Journal of Animal Science.; We thank Bea Palileo
for her assistance with manuscript preparation. Supported by funding
from a Grant-in-Aid for Japan Society for the Promotion of Science
Fellow (I. Kaji), a research grant from Ajinomoto, Japan (Y. Akiba),
Department of Veterans Affairs Merit Review Award (J.D. Kaunitz), and
NIH-NIDDK R01 DK54221 (J.D. Kaunitz).
NR 32
TC 6
Z9 7
U1 0
U2 18
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA
SN 0021-8812
EI 1525-3163
J9 J ANIM SCI
JI J. Anim. Sci.
PD MAY
PY 2013
VL 91
IS 5
BP 1957
EP 1962
DI 10.2527/jas.2012-5941
PG 6
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 154TA
UT WOS:000319697600004
PM 23345558
ER
PT J
AU Johansen, KL
AF Johansen, Kirsten L.
TI Obesity and Body Composition for Transplant Wait-List
Candidacy-Challenging or Maintaining the BMI Limits?
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID MASS INDEX; RENAL-TRANSPLANTATION; WEIGHT; ASSOCIATIONS; RECIPIENTS;
MORTALITY; OUTCOMES; IMPACT; GRAFT
AB Most kidney transplantation programs have a maximum body mass index (BMI) above which they will not place a patient on the active waiting list. However, obesity is common among patients with end-stage renal disease (ESRD), and weight loss is difficult, resulting in many patients being denied the opportunity to be considered for a transplant. BMI limits are in place because of data that outcomes are worse among obese transplant recipients than among those with lower BMI. However, the data to suggest that patient and graft survival are affected by obesity are not consistent, and obese patients with ESRD have better survival after kidney transplantation compared with remaining on dialysis. Therefore, it is important to carefully examine the question of BMI limits to ensure that we are achieving the right balance and making the best use of donated kidneys. (C) 2013 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Johansen, KL (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM kirsten.johansen@ucsf.edu
FU National Institutes of Health [N01-DK-7-0005]
FX This work was supported in part by National Institutes of Health
contract N01-DK-7-0005. The interpretation and reporting of the data
presented here are the responsibility of the authors and in no way
should be seen as an official policy or interpretation of the U.S.
government.
NR 14
TC 5
Z9 5
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAY
PY 2013
VL 23
IS 3
BP 207
EP 209
DI 10.1053/j.jrn.2013.02.005
PG 3
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA 147XF
UT WOS:000319203500014
PM 23611548
ER
PT J
AU Mattsson, N
Andreasson, U
Persson, S
Carrillo, MC
Collins, S
Chalbot, S
Cutler, N
Dufour-Rainfray, D
Fagan, AM
Heegaard, NHH
Hsiung, GYR
Hyman, B
Iqbal, K
Lachno, DR
Lleo, A
Lewczuk, P
Molinuevo, JL
Parchi, P
Regeniter, A
Rissman, R
Rosenmann, H
Sancesario, G
Schroder, J
Shaw, LM
Teunissen, CE
Trojanowski, JQ
Vanderstichele, H
Vandijck, M
Verbeek, MM
Zetterberg, H
Blennow, K
Kaser, SA
AF Mattsson, Niklas
Andreasson, Ulf
Persson, Staffan
Carrillo, Maria C.
Collins, Steven
Chalbot, Sonia
Cutler, Neal
Dufour-Rainfray, Diane
Fagan, Anne M.
Heegaard, Niels H. H.
Hsiung, Ging-Yuek Robin
Hyman, Bradley
Iqbal, Khalid
Lachno, D. Richard
Lleo, Alberto
Lewczuk, Piotr
Molinuevo, Jose L.
Parchi, Piero
Regeniter, Axel
Rissman, Robert
Rosenmann, Hanna
Sancesario, Giuseppe
Schroeder, Johannes
Shaw, Leslie M.
Teunissen, Charlotte E.
Trojanowski, John Q.
Vanderstichele, Hugo
Vandijck, Manu
Verbeek, Marcel M.
Zetterberg, Henrik
Blennow, Kaj
Kaeser, Stephan A.
CA Alzheimers Assoc QC Program
TI CSF biomarker variability in the Alzheimer's Association quality control
program
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Cerebrospinal fluid; Biomarkers; External
assurance; Quality control; Proficiency testing
ID CEREBROSPINAL-FLUID BIOMARKERS; NEUROCHEMICAL DEMENTIA DIAGNOSTICS; MILD
COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; DISEASE; TAU; RECOMMENDATIONS;
WORKGROUPS; GUIDELINES
AB Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1-42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories.
Methods: Data from the first nine rounds of the Alzheimer's Association quality control program was used to define the extent and sources of analytical variability. In each round, three CSF samples prepared at the Clinical Neurochemistry Laboratory (Molndal, Sweden) were analyzed by single-analyte enzyme-linked immunosorbent assay (ELISA), a multiplexing xMAP assay, or an immunoassay with electrochemoluminescence detection.
Results: A total of 84 laboratories participated. Coefficients of variation (CVs) between laboratories were around 20% to 30%; within-run CVs, less than 5% to 10%; and longitudinal within-laboratory CVs, 5% to 19%. Interestingly, longitudinal within-laboratory CV differed between biomarkers at individual laboratories, suggesting that a component of it was assay dependent. Variability between kit lots and between laboratories both had a major influence on amyloid beta 1-42 measurements, but for total tau and phosphorylated tau, between-kit lot effects were much less than between-laboratory effects. Despite the measurement variability, the between-laboratory consistency in classification of samples (using prehoc-derived cutoffs for AD) was high (>90% in 15 of 18 samples for ELISA and in 12 of 18 samples for xMAP).
Conclusions: The overall variability remains too high to allow assignment of universal biomarker cutoff values for a specific intended use. Each laboratory must ensure longitudinal stability in its measurements and use internally qualified cutoff levels. Further standardization of laboratory procedures and improvement of kit performance will likely increase the usefulness of CSF AD biomarkers for researchers and clinicians. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Mattsson, Niklas; Andreasson, Ulf; Persson, Staffan; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad,Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Molndal, Sweden.
[Mattsson, Niklas] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA.
[Carrillo, Maria C.] Alzheinzers Assoc, Chicago, IL USA.
[Collins, Steven] Univ Melbourne, Dept Pathol, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
[Chalbot, Sonia; Iqbal, Khalid] New York State Inst Basic Res, Staten Isl, NY USA.
[Cutler, Neal] Worldwide Clin Trials, Beverly Hills, CA USA.
[Dufour-Rainfray, Diane] CHRU Tours, Nucl Med Lab, Tours, France.
[Dufour-Rainfray, Diane] Univ Tours, Val Loire Univ, PRES Ctr, Tours, France.
[Dufour-Rainfray, Diane] Univ Tours, Val Loire Univ, PRES Ctr, UMR INSERM Imagerie & Cerveau U930, Tours, France.
[Fagan, Anne M.] Washington Univ, St Louis, MO USA.
[Heegaard, Niels H. H.] Statens Serum Inst, Dept Clin Biochem Immunol & Genet, DK-2300 Copenhagen, Denmark.
[Hsiung, Ging-Yuek Robin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Hyman, Bradley] MassGen Inst Neurodegenerat Dis, Charlestown, MA USA.
[Lachno, D. Richard] Eli Lilly & Co, Windlesham, Surrey, England.
[Lleo, Alberto] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Lewczuk, Piotr] Univ Klinikum Erlangen, Erlangen, Germany.
[Molinuevo, Jose L.] ICN Hosp Clin & Univ, Neurol Serv, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain.
[Molinuevo, Jose L.] Pasqual Maragall Fdn, Barcelona, Spain.
[Parchi, Piero] Univ Bologna, Inst Neurol Sci, Bologna, Italy.
[Parchi, Piero] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
[Regeniter, Axel] Univ Basel Hosp, CH-4031 Basel, Switzerland.
[Rissman, Robert] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Rosenmann, Hanna] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel.
[Sancesario, Giuseppe] Univ Roma Tor Vergata, Gen Hosp, Rome, Italy.
[Schroeder, Johannes] Univ Klinikum Heidelberg, Sekt Gerontopsychiat, Heidelberg, Germany.
[Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Philadelphia, PA 19104 USA.
[Teunissen, Charlotte E.] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, Amsterdam, Netherlands.
[Vanderstichele, Hugo] ADx NeuroSci, Ghent, Belgium.
[Vandijck, Manu] Innogenet Nv, Ghent, Belgium.
[Verbeek, Marcel M.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain, Dept Neurol, NL-6525 ED Nijmegen, Netherlands.
[Verbeek, Marcel M.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain, Dept Lab Med, NL-6525 ED Nijmegen, Netherlands.
[Zetterberg, Henrik] UCL, Inst Neurol, London, England.
[Kaeser, Stephan A.] Univ Tubingen, Tubingen, Germany.
RP Mattsson, N (reprint author), Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad,Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Molndal, Sweden.
EM niklas.mattsson@neuro.gu.se
RI Otto, Markus/F-4304-2015; Verbeek, Marcel/D-1971-2010; Vecsei,
Laszlo/B-2066-2010; Parchi, Piero/L-9833-2015; Chiasserini,
Davide/K-7074-2016
OI Otto, Markus/0000-0003-4273-4267; Vecsei, Laszlo/0000-0001-8037-3672;
Parchi, Piero/0000-0002-9444-9524; Chiasserini,
Davide/0000-0002-1169-3258; Collins, Steven/0000-0002-5245-6611;
Molinuevo, Jose Luis/0000-0003-0485-6001; Kummer,
Markus/0000-0002-0993-2918
FU NIA NIH HHS [P01 AG026276, P50 AG005131, P50 AG005134, P50 AG005681]
NR 28
TC 120
Z9 122
U1 6
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 251
EP 261
DI 10.1016/j.jalz.2013.01.010
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400001
PM 23622690
ER
PT J
AU Royall, DR
Palmer, RF
AF Royall, Donald R.
Palmer, Raymond F.
TI Alzheimer's disease pathology does not mediate the association between
depressive symptoms and subsequent cognitive decline
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Aging; Alzheimer's disease; Depression; Longitudinal; Neuropathology
ID OLDER PERSONS; MISSING DATA; RISK-FACTOR; DEMENTIA; IMPAIRMENT;
CRITERIA; PLAQUES; TANGLES; WORK; AD
AB Background: Depressive symptoms in nondemented individuals appear to hasten the progression from mild cognitive impairment to clinical Alzheimer's disease (AD) and double the risk of incident AD. However, the mechanism(s) by which depression might affect this risk has not been well established. The purpose of this analysis was to test the hypothesis that AD pathology mediates depression's apparent effect on the risk of dementia conversion using longitudinally collected psychometric testing and autopsy data from the Honolulu-Asia Aging Study.
Methods: Latent factor variables representing AD, cortical Lewy body (CLB), and ischemic neuropathology were tested as potential mediators of the association between the Center for Epidemiological Studies depression scale (CES-D) score and the 10-year prospective rate of cognitive decline, adjusted for baseline cognition, age, education, total number of medications, and brain weight at autopsy.
Results: CES-D scores, neurofibrillary tangle counts, CLB counts, and ischemic lesions each made significant independent contributions to cognitive decline. However, CES-D scores were not significantly associated with any pathological variable; thus the pathological variables were not mediators of the effect of CES-D scores on cognitive decline.
Conclusions: Subsyndromal depressive symptoms are significantly associated with subsequent cognitive decline. Although the effect is relatively modest, it is stronger than that of amyloid-related neuropathologies and independent of that of neurofibrillary tangles, cortical Lewy bodies, and ischemic lesions. Our results argue against the role of AD-related neuropathology as a mediator of depression's effect on cognitive decline, but cannot rule out a significant mediation effect in a subset of cases, perhaps with more severe baseline depressive symptoms. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Royall, Donald R.] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, South Texas Vet Hlth Syst, San Antonio, TX 78284 USA.
RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
EM royall@uthscsa.edu
FU National Institute of Neurological Disorders and Stroke (National
Institutes of Health, USA) [NSO48123-01]; Julia and Van Buren Parr
professorship in Aging and Geriatric Psychiatry; NINDS [NS048123-01,
N01-AG-4-2149]; National Institute on Aging [U01 AG0 19349]
FX HAAS data were provided by Lon R. White, the HAAS Principal
Investigator, but the HAAS staff were not further involved in the
analysis or interpretation of the data. This work was funded by National
Institute of Neurological Disorders and Stroke (National Institutes of
Health, USA), grant number NSO48123-01. HAAS neuropathological data were
entirely generated by a team of 4 expert neuropathologists under the
leadership of Dr. William Markesbery (deceased), with the oversight of
Lon R. White, the HAAS Principal Investigator. Other members of the team
were Dr. John Hardman (deceased), Dr. James Nelson (retired), and Dr.
Daron Davis (who left the study for a clinical practice in 2001). D.R.R.
and R.F.P. were funded by the Julia and Van Buren Parr professorship in
Aging and Geriatric Psychiatry. The authors accept full responsibility
for all analyses, results, and interpretations.; This work has been
supported by NINDS R21 Grant NS048123-01, contract N01-AG-4-2149, and
grant U01 AG0 19349 from the National Institute on Aging.
NR 33
TC 15
Z9 15
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 318
EP 325
DI 10.1016/j.jalz.2011.11.009
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400009
PM 23154050
ER
PT J
AU Grill, JD
Karlawish, J
Elashoff, D
Vickrey, BG
AF Grill, Joshua D.
Karlawish, Jason
Elashoff, David
Vickrey, Barbara G.
TI Risk disclosure and preclinical Alzheimer's disease clinical trial
enrollment
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Preclinical; Prevention; Predementia; Recruitment;
Risk; Clinical trial
ID GENETIC RISK; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL
INSTITUTE; RECOMMENDATIONS; CHALLENGES
AB To identify the facilitators and barriers to preclinical Alzheimer's disease (AD) clinical trial recruitment, 50 cognitively normal participants were interviewed after being randomized to one of two hypothetical AD risk scenarios: (1) the general age-related risk for AD, or (2) being at 50% increased risk for AD. Participants provided uncued barriers and facilitators to the hypothetical decision of whether they would enroll. Thirteen themes of facilitators and five themes of barriers were identified. The most common barrier was fear related to taking study drug. Those randomized to being at increased risk for AD more frequently cited lowering personal risk as a facilitator (P = .01) and less frequently cited time as a barrier to enrollment (P = .02). These results suggest potential challenges to preclinical AD clinical trial recruitment and that disclosing risk information may enhance enrollment. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Grill, Joshua D.; Elashoff, David] Univ Calif Los Angeles, Mary Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
[Grill, Joshua D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Karlawish, Jason] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Penn Memory Ctr, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Penn Ctr Bioeth, Philadelphia, PA 19104 USA.
[Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Grill, JD (reprint author), Univ Calif Los Angeles, Mary Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
EM jgrill@mednet.ucla.edu
FU NIA [AG016570]; Sidell Kagan Foundation; Marian S. Ware Alzheimer
Program
FX This work was supported by NIA AG016570 and the Sidell Kagan Foundation.
Dr. J.K. is supported by the Marian S. Ware Alzheimer Program. The
authors are grateful to the volunteer participants who made this work
possible and to Dr. Po H. Lu who participated in the cutting-and-sorting
analyses.
NR 14
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 356
EP 359
DI 10.1016/j.jalz.2012.03.001
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400014
PM 23141383
ER
PT J
AU Vielma, SA
Klein, RL
Levingston, CA
Young, MRI
AF Vielma, Silvana A.
Klein, Richard L.
Levingston, Corinne A.
Young, M. Rita I.
TI Premalignant Lesions Skew Spleen Cell Responses to Immune Modulation by
Adipocytes
SO ANTICANCER RESEARCH
LA English
DT Article
DE Adipocytes; cytokines; immune regulation; inflammation; premalignant
lesion cells
ID REGULATORY T-CELLS; CANCER-RISK; INSULIN-RESISTANCE; BREAST-CANCER;
OBESITY; CYTOKINES; LEPTIN; INFLAMMATION; ADIPOKINES; DIFFERENTIATION
AB Obesity can promote a chronic inflammatory state and is associated with an increased risk for cancer. Since adipocytes can produce mediators that can regulate conventional immune cells, this study sought to determine if the presence of premalignant oral lesions would skew how immune cells respond to adipocyte-derived mediators to create an environment that may be more favorable for their progression toward cancer. While media conditioned by adipocytes stimulated normal spleen cell production of the T helper (Th) type-1 cytokines interleukin (IL)-2, interferon-gamma (IFN-gamma), IL-12 and granulocyte-monocyte colony-stimulating factor (GM CSF), media from premalignant lesion cells either blocked or had no added affect on the adipocyte-stimulated Th1 cytokine production. In contrast, media conditioned by premalignant lesion cells exacerbated adipocyte-stimulated spleen cell production of the Th2 cytokines IL-10 and IL-13, although it did not further enhance the adipocyte-stimulated spleen cell production of IL-4 and TGF-beta. The premalignant lesion environment also heightened the adipocyte-stimulated spleen cell production of the inflammatory mediators IL 1 alpha, IL-1 beta, IL-6 and IL-9, although it did not further increase the adipocyte-stimulated production of tumor necrosis factor-alpha (TNF-alpha). IL 17 production was unaffected by the adipocyte-derived mediators, but was synergistically triggered by adding media from premalignant lesion cells. These stimulatory effects on spleen cell production of Th2 and inflammatory mediators were not induced in the absence of media conditioned by adipocytes. In contrast, media conditioned by adipocytes did not stimulate production of predominantly monocyte-derived chemokine C-X-C motif ligand (CXCL)9, chemokine C-C motif ligand (CCL)3 or CCL4, although it stimulated production of CCL2 and the predominantly T cell-derived chemokine CCL5, which was the only chemokine whose production was further increased by media from premalignant lesions. These results suggest that the responsiveness of spleen cells to adipocyte-derived mediators is influenced by mediators from premalignant lesion cells to favor conventional immune cell production of a Th2 and inflammatory cytokines.
C1 [Vielma, Silvana A.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Dept Hematol Oncol, Charleston, SC 29425 USA.
[Vielma, Silvana A.] Univ Los Andes, Dept Clin Microbiol & Parasitol, Merida, Venezuela.
[Klein, Richard L.; Levingston, Corinne A.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM Rita.Young@va.gov
FU Biomedical Laboratory of the Department of Veterans Affairs; Department
of Veterans Affairs; National Institute of Health [I01-CX000100, R01
CA128837, R01 DE018268]
FX This work was supported by the Biomedical Laboratory and Clinical
Sciences Programs of the Department of Veterans Affairs. and by grants
from the National Institute of Health awarded to M. Rita I. Young
(I01-CX000100, R01 CA128837 and R01 DE018268).
NR 45
TC 2
Z9 2
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD MAY
PY 2013
VL 33
IS 5
BP 1809
EP 1818
PG 10
WC Oncology
SC Oncology
GA 148GR
UT WOS:000319233100004
PM 23645725
ER
PT J
AU Leak, RK
Zhang, LL
Stetler, RA
Weng, ZF
Li, PY
Atkins, GB
Gao, YQ
Chen, J
AF Leak, Rehana K.
Zhang, Lili
Stetler, R. Anne
Weng, Zhongfang
Li, Peiying
Atkins, G. Brandon
Gao, Yanqin
Chen, Jun
TI HSP27 Protects the Blood-Brain Barrier Against Ischemia-Induced Loss of
Integrity
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article
DE Endothelial cell; heat shock protein; HSP25; HSPB1; microvessel; stroke;
tight junction; vascular
ID HEAT-SHOCK-PROTEIN; FOCAL CEREBRAL-ISCHEMIA; MONOCYTE CHEMOATTRACTANT
PROTEIN-1; INTRACEREBRAL HEMORRHAGE; CYTOCHROME-C; CELL-DEATH;
ISCHEMIA/REPERFUSION INJURY; MOLECULAR CHAPERONES; NEURONAL INJURY;
PRECURSOR CELLS
AB Loss of integrity of the blood-brain barrier (BBB) in stroke victims initiates a devastating cascade of events including extravasation of blood-borne molecules, water, and inflammatory cells deep into brain parenchyma. Thus, it is important to identify mechanisms by which BBB integrity can be maintained in the face of ischemic injury in experimental stroke. We previously demonstrated that the phylogenetically conserved small heat shock protein 27 (HSP27) protects against transient middle cerebral artery occlusion (tMCAO). Here we show that HSP27 transgenic overexpression also maintains the integrity of the BBB in mice subjected to tMCAO. Extravasation of endogenous IgG antibodies and exogenous FITC-albumin into the brain following tMCAO was reduced in transgenic mice, as was total brain water content. HSP27 overexpression abolished the appearance of TUNEL-positive profiles in microvessel walls. Transgenics also exhibited less loss of microvessel proteins following tMCAO. Notably, primary endothelial cell cultures were rescued from oxygen-glucose deprivation (OGD) by lentiviral HSP27 overexpression according to four viability assays, supporting a direct effect on this cell type. Finally, HSP27 overexpression reduced the appearance of neutrophils in the brain and inhibited the secretion of five cytokines. These findings reveal a novel role for HSP27 in attenuating ischemia/reperfusion injury - the maintenance of BBB integrity. Endogenous upregulation of HSP27 after ischemia in wild-type animals may exert similar protective functions and warrants further investigation. Exogenous enhancement of HSP27 by rational drug design may lead to future therapies against a host of injuries, including but not limited to a harmful breach in brain vasculature.
C1 [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA.
[Atkins, G. Brandon] Case Western Reserve Univ, Case Cardiovasc Res Inst, Dept Med, Sch Med, Cleveland, OH 44106 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, S507 Biomed Sci Tower, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU Mylan School of Pharmacy at Duquesne University; VA Merit Review grant;
National Institutes of Neurological Disorders and Stroke [NS043802,
NS045048, NS036736, NS056118]; Chinese Natural Science Foundation
[30670642, 30870794, 81020108021]; VA Research Career Scientist Award;
RK Mellon Endowed Chair from UPMC
FX RKL and LZ contributed equally to this work. RKL, LZ, RAS,
ZW, and PL performed the experiments and analyzed the data. RKL wrote
the manuscript. JC and YG designed the experiments, analyzed the data,
and helped write the manuscript. GBA contributed new research reagents.
The authors acknowledge the administrative assistance of Pat Strickler,
Deb Wilson, Mary Caruso, and Jackie Farrer. RKL was supported by a
startup from the Mylan School of Pharmacy at Duquesne University. JC was
supported by VA Merit Review grant and National Institutes of
Neurological Disorders and Stroke grants NS043802, NS045048, NS036736,
and NS056118. YG was supported by Chinese Natural Science Foundation
grants 30670642, 30870794, and 81020108021. JC is a recipient of the VA
Research Career Scientist Award and the RK Mellon Endowed Chair from
UPMC.
NR 61
TC 6
Z9 7
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1871-5273
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD MAY
PY 2013
VL 12
IS 3
BP 325
EP 337
PG 13
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 145CE
UT WOS:000318990800006
PM 23469858
ER
PT J
AU Brown-Guion, SY
Youngerman, SM
Hernandez-Tejada, MA
Dismuke, CE
Egede, LE
AF Brown-Guion, Stephanie Y.
Youngerman, Stephanie M.
Hernandez-Tejada, Melba A.
Dismuke, Clara E.
Egede, Leonard E.
TI Racial/Ethnic, Regional, and Rural/Urban Differences in Receipt of
Diabetes Education
SO DIABETES EDUCATOR
LA English
DT Article
ID CARE; INTERVENTION; METAANALYSIS; PERCEPTIONS; ADULTS
AB Purpose
The objective of this study is to examine the differences in receipt of diabetes education according to risk factors that are associated with the disease, including race/ethnicity, region, and rural/urban location.
Methods
National data from the 2007 Medical Expenditure Panel Survey (MEPS) were analyzed to examine likelihood of receipt of diabetes education in terms of race, urban/rural location, and region.
Results
Of 1747 adults with type 2 diabetes, 65.6% were white, 15% black, and 19.4% other. In addition, 49.3% were male, 50.6% female; 46.9% were under age 64; 39.8% had more than high school; 34.1% were from low-income households, 35.1% middle income, and 30.8% high income; 39.5% lived in the South while other regions were equally represented; 80.6% lived in rural areas; 63.7% did not receive any type 2 diabetes education. Patients in the South were least likely to receive education (67.5% did not). Logistic regression demonstrated that being black (odds ratio [OR] = 1.38, 95% confidence interval [CI], 1.03-1.84) and living in an urban area (OR = 1.40, 95% CI, 1.00-1.97) were associated with a higher likelihood of receiving diabetes education. By contrast, being 65 or older was associated with lower probability of receiving education (OR = 0.59, 95% CI, 0.40-0.87), as was lack of insurance (OR = 0.54, 95% CI, 0.33-0.88)
Conclusions
Being black independently increased likelihood of receiving diabetes education, but living in rural areas, being uninsured, and living in the South reduced chances one would receive this helpful information. Therefore, further research should examine benefits of leveraging technology such as telemedicine to improve delivery of diabetes education to those living in rural areas.
C1 [Brown-Guion, Stephanie Y.; Hernandez-Tejada, Melba A.; Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Youngerman, Stephanie M.; Dismuke, Clara E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
NR 27
TC 4
Z9 4
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD MAY-JUN
PY 2013
VL 39
IS 3
BP 327
EP 334
DI 10.1177/0145721713480002
PG 8
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA 148DR
UT WOS:000319223600005
PM 23482514
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI How to Catch a Suspicious Bleeding Site in Flagrante
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Gastrointestinal bleeding; Gastrointestinal endoscopy; Geometric
probability; Medical decision analysis; Outcome research; Probability
theory
AB In search for a source of gastrointestinal bleeding, endoscopy frequently reveals mucosal lesions of questionable dignity.
To investigate the probability of ascertaining conclusive evidence for gastrointestinal bleeding from a suspicious mucosal lesion through a single or multiple consecutive endoscopies.
A mathematical model is developed to estimate the probability of successful diagnosis of a bleeding gastrointestinal lesion associated with single or multiple endoscopies.
The probability of a successful confirmation through endoscopy depends on the length of time that signs of recent bleed persist at the site of the mucosal lesion and on the number of repeat endoscopies that one is willing to invest in confirmation. Assuming persistence of endoscopic evidence for 6-12 hours after the initial bleeding, a single endoscopy is associated with a 22 %-38 % chance of observing a suspicious site with clear evidence of bleeding. Using potentially up to 2 additional repeat endoscopies can raise such chances to 52 %-76 %.
The rates of success may provide useful guidance in scheduling endoscopies for the work-up of gastrointestinal bleeding and decision making about the utility of repeat endoscopy in instances of suspicious but inconclusive mucosal lesions.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 6
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2013
VL 58
IS 5
BP 1194
EP 1197
DI 10.1007/s10620-012-2488-6
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 149VU
UT WOS:000319350300009
PM 23179160
ER
PT J
AU Surti, B
Spiegel, B
Ippoliti, A
Vasiliauskas, EA
Simpson, P
Shih, DQ
Targan, SR
McGovern, DPB
Melmed, GY
AF Surti, Bijal
Spiegel, Brennan
Ippoliti, Andrew
Vasiliauskas, Eric A.
Simpson, Peter
Shih, David Q.
Targan, Stephan R.
McGovern, Dermot P. B.
Melmed, Gil Y.
TI Assessing Health Status in Inflammatory Bowel Disease Using a Novel
Single-Item Numeric Rating Scale
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Health
related quality of life; Patient reported outcome
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CROHNS-DISEASE;
RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; PHYSICIANS PERSPECTIVES;
ULCERATIVE-COLITIS; ACTIVITY INDEX; PATIENT; PERCEPTIONS
AB Current instruments used to measure disease activity and health-related quality of life in patients with Crohn's disease (CD) and ulcerative colitis (UC) are often cumbersome, time-consuming, and expensive; although used in clinical trials, they are not convenient for clinical practice. A numeric rating scale (NRS) is a quick, inexpensive, and convenient patient-reported outcome that can capture the patient's overall perception of health.
The aim of this study was to assess the validity, reliability, and responsiveness of an NRS and evaluate its use in clinical practice in patients with CD and UC.
We prospectively evaluated patient-reported NRS scores and measured correlations between NRS and a range of severity measures, including physician-reported NRS, Crohn's disease activity index (CDAI), Harvey-Bradshaw index (HBI), inflammatory bowel disease questionnaire (IBDQ), and C-reactive protein (CRP) in patients with CD. Subsequently, we evaluated the correlation between the NRS and standard measures of health status (HBI or simple colitis clinical activity index [SCCAI]) and laboratory tests (sedimentation rate [ESR], CRP, and fecal calprotectin) in patients with CD and UC.
The patient-reported NRS showed excellent correlation with CDAI (R (2) = 0.59, p < 0.0001), IBDQ (R (2) = 0.66, p < 0.0001), and HBI (R (2) = 0.32, p < 0.0001) in patients with CD. The NRS showed poor, but statistically significant correlation with SCCAI (R (2) = 0.25, p < 0.0001) in patients with UC. The NRS did not correlate with CRP, ESR, or calprotectin. The NRS was reliable and responsive to change.
The NRS is a valid, reliable, and responsive measure that may be useful to evaluate patients with CD and possibly UC.
C1 [Surti, Bijal; Ippoliti, Andrew; Vasiliauskas, Eric A.; Simpson, Peter; Shih, David Q.; Targan, Stephan R.; McGovern, Dermot P. B.; Melmed, Gil Y.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA.
[Surti, Bijal; Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA.
[Spiegel, Brennan] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Outcomes Res, Digest Dis Res Ctr, Los Angeles, CA USA.
RP Melmed, GY (reprint author), Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, 8635 W 3rd St 960 Wv, Los Angeles, CA 90048 USA.
EM Gil.Melmed@cshs.org
FU Centocor, Inc.; USPHS [PO1DK046763, DK062413]; Cedars-Sinai F. Widjaja
Foundation Inflammatory Bowel and Immunobiology Research Institute;
Helmsley Foundation; European Union; Crohn's and Colitis Foundation of
America; Feintech Family Chair in IBD; Joshua L. and Lisa Z. Greer Chair
in IBD Genetics
FX This study was funded in part by an unrestricted Investigator-Initiated
grant from Centocor, Inc. The authors gratefully acknowledge Dr Fasiha
Kanwal and Dr Ron Hays (UCLA) for methodologic input and Dr Patricio
Ibanez (Cedars-Sinai) for assistance with patient recruitment. IBD
Research at Cedars-Sinai that contributed to this study is supported by
USPHS grant PO1DK046763, DK062413 and the Cedars-Sinai F. Widjaja
Foundation Inflammatory Bowel and Immunobiology Research Institute
Research Funds. Project investigators are support by The Helmsley
Foundation, The European Union and the Crohn's and Colitis Foundation of
America (D.P.B.M.), The Feintech Family Chair in IBD (S.R.T.), The
Joshua L. and Lisa Z. Greer Chair in IBD Genetics (D.P.B.M.).
NR 51
TC 5
Z9 5
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2013
VL 58
IS 5
BP 1313
EP 1321
DI 10.1007/s10620-012-2500-1
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 149VU
UT WOS:000319350300025
PM 23250673
ER
PT J
AU Milfred-Laforest, SK
Chow, SL
Didomenico, RJ
Dracup, K
Ensor, CR
Gattis-Stough, W
Heywood, JT
Lindenfeld, J
Page, RL
Patterson, JH
Vardeny, O
Massie, BM
AF Milfred-Laforest, Sherry K.
Chow, Sheryl L.
Didomenico, Robert J.
Dracup, Kathleen
Ensor, Christopher R.
Gattis-Stough, Wendy
Heywood, J. Thomas
Lindenfeld, Joann
Page, Robert L.
Patterson, J. Herbert
Vardeny, Orly
Massie, Barry M.
TI Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the
Heart Failure Society of America and American College of Clinical
Pharmacy Cardiology Practice and Research Network
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; clinical pharmacist; multidisciplinary team; heart
transplant
ID UNITED-STATES HOSPITALS; ADVERSE DRUG-REACTIONS; INPATIENT MEDICATION
RECONCILIATION; VENTRICULAR ASSIST DEVICE; PRESCRIBER ORDER ENTRY;
INTENSIVE-CARE-UNIT; PHARMACEUTICAL CARE; CARDIOVASCULAR-DISEASE;
TRANSPLANT RECIPIENT; MANAGEMENT PROGRAM
AB Background: Heart failure (BF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a "perfect storm" of factors that predispose patients to medication errors.
Methods and Results: The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary BF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e.g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause readmissions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable.
Conclusions: Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.
C1 [Milfred-Laforest, Sherry K.] Louis Stokes Cleveland VA Med Ctr, Dept Pharm, Cleveland, OH USA.
[Chow, Sheryl L.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
[Didomenico, Robert J.] Univ Illinois, Coll Pharm, Chicago, IL USA.
[Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Ensor, Christopher R.] Univ Pittsburgh, Coll Pharm, Pittsburgh, PA USA.
[Gattis-Stough, Wendy] Campbell Univ, Coll Pharm & Hlth Sci, Dept Clin Res, Buies Creek, NC 27506 USA.
[Heywood, J. Thomas] Scripps Clin, Dept Med, La Jolla, CA 92037 USA.
[Lindenfeld, Joann] Univ Colorado Denver, Dept Med, Div Cardiol, Heart Transplantat Program, Aurora, CO USA.
[Page, Robert L.] Univ Colorado Denver, Sch Pharm, Aurora, CO USA.
[Page, Robert L.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Patterson, J. Herbert] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA.
[Vardeny, Orly] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
[Vardeny, Orly] Univ Wisconsin, Sch Med, Madison, WI USA.
[Massie, Barry M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chow, SL (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM schow@westernu.edu; barry.massie@va.gov
RI Stough, Wendy/R-4287-2016
OI Stough, Wendy/0000-0001-8290-1205; DiDomenico,
Robert/0000-0002-9374-8012
FU Medtronic; Gambro; St. Jude; Zensun; Otsuka; Novartis; Amgen
FX J. Thomas Heywood has received speaking honoraria from Actelion,
Medtronic, St Jude, and Thoratec; is a consultant for Actelion,
Medtronic, and Thoratec; and has received research grants from Medtronic
and Gambro and fellowship support from St. Jude. JoAnn Lindenfeld is a
consultant for St Jude, Boston Scientific, and Abbott and has received a
research grant from Zensun. J. Herbert Patterson has received speaking
honoraria from Otsuka, is a consultant for Otsuka and Novartis, and has
received research grants from Otsuka, Novartis, and Amgen. All of the
other authors report no potential conflict of interest.
NR 136
TC 8
Z9 9
U1 2
U2 15
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD MAY
PY 2013
VL 19
IS 5
BP 354
EP 369
DI 10.1016/j.cardfail.2013.02.002
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 148LQ
UT WOS:000319246500009
PM 23663818
ER
PT J
AU Bahraini, N
Brenner, LA
AF Bahraini, Nazanin
Brenner, Lisa A.
TI Screening for TBI and Persistent Symptoms Provides Opportunities for
Prevention and Intervention
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Editorial Material
ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MALE VIETNAM
VETERANS; WAR-ZONE STRESSORS; FEMALE; SOLDIERS
C1 [Bahraini, Nazanin; Brenner, Lisa A.] VA VISN Mental Illness Res Educ & Clin Ctr MIRECC, Denver, CO USA.
[Bahraini, Nazanin; Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Psychiat, Aurora, CO USA.
[Bahraini, Nazanin] Univ Colorado, Denver Sch Med, Dept Neurol, Aurora, CO USA.
[Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA.
RP Brenner, LA (reprint author), Denver VA Med Ctr, VISN MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA.
EM lisa.brenner@va.gov
NR 22
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 223
EP 226
DI 10.1097/HTR.0b013e318291dab7
PG 4
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 149PS
UT WOS:000319334000010
PM 23661075
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI CBCT FINDINGS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
ID INCIDENTAL FINDINGS; PREDICT; RISK
C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2013
VL 144
IS 5
BP 466
EP +
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 147RM
UT WOS:000319184700005
PM 23633690
ER
PT J
AU Ullrich, PM
Lincoln, RK
Tackett, MJ
Miskevics, S
Smith, BM
Weaver, FM
AF Ullrich, Philip M.
Lincoln, Randi K.
Tackett, M. Jan
Miskevics, Scott
Smith, Bridget M.
Weaver, Frances M.
TI Pain, Depression, and Health Care Utilization Over Time After Spinal
Cord Injury
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE spinal cord injury; pain; depression; health care
ID PHYSICAL-DISABILITIES; COGNITIVE DISTORTION; VETERANS; ANXIETY; PEOPLE;
MANAGEMENT; SYMPTOMS; RISK; BIAS; USA
AB Objective: The aim of this research was to examine comorbid pain and depression after spinal cord injury (SCI) in terms of: frequency, longitudinal course, and associations with medical conditions and use of SCI specialty care. Method: Three consecutive standardized annual psychological evaluations were reviewed for 286 persons with SCI receiving care at an SCI specialty care center. Chart abstraction included medical and demographic information, a depression scale, and a pain scale. Administrative databases were used to collect SCI specialty care utilization data. Participants were categorized as having elevated pain, elevated depression, both elevated pain and depression, or neither elevated, using cut-off scores on the pain and depression scales. ANOVA and repeated measures ANOVA were used to compare study groups. Results: Approximately 20% of the sample showed both elevated pain and depression at Year 1. Persons with elevated pain and depression showed higher scores on those measures than did persons with either pain or depression alone. Pain scores tended to be stable over time. Depression scores tended to improve over 3 years, but persons with elevated pain and depression showed less improvement on depression scores than did persons with depression alone. Persons with pain and depression tended to utilize more SCI specialty care. Conclusions: Pain and depression are often comorbid after SCI. This comorbidity is associated with higher pain and depression severity, more persistent pain and depression over time, and more use of SCI specialty care. Comorbid pain and depression should be anticipated among persons with SCI and addressed in care plans.
C1 [Ullrich, Philip M.; Lincoln, Randi K.; Tackett, M. Jan] VA Puget Sound Healthcare Syst, Spinal Cord Injury & Disorders Serv, Dept Vet Affairs, Seattle, WA USA.
[Ullrich, Philip M.; Lincoln, Randi K.; Tackett, M. Jan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Miskevics, Scott] Spinal Cord Injury Qual Enhancement Res Initiat, Dept Vet Affairs, Hines, IL USA.
[Miskevics, Scott] Edward Hines Jr Dept Vet Affairs Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Dept Vet Affairs, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Spinal Cord Injury Qual Enhancement Res Initiat, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Ctr Management Complex Chron Care, Edward Hines Jr Dept Vet Affairs Hosp, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Chicago, IL 60611 USA.
RP Ullrich, PM (reprint author), 128 NAT,1660 S Columbian Way, Seattle, WA 98108 USA.
EM philip.ullrich@va.gov
NR 55
TC 10
Z9 10
U1 1
U2 15
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD MAY
PY 2013
VL 58
IS 2
BP 158
EP 165
DI 10.1037/a0032047
PG 8
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 150DH
UT WOS:000319369900005
PM 23713727
ER
PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Sexual Dysfunction and Quality of Life in Patients on Maintenance
Dialysis
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID MALE HEMODIALYSIS-PATIENTS; ERECTILE DYSFUNCTION; SILDENAFIL TREATMENT;
DEPRESSION; WOMEN; ASSOCIATION; VARDENAFIL; MANAGEMENT; PAIN
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
NR 18
TC 4
Z9 4
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAY-JUN
PY 2013
VL 26
IS 3
BP 278
EP 280
DI 10.1111/sdi.12068
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 146DL
UT WOS:000319069300009
PM 23458106
ER
PT J
AU Fung, CH
Martin, JL
Igodan, U
Jouldjian, S
Alessi, C
AF Fung, Constance H.
Martin, Jennifer L.
Igodan, Uyi
Jouldjian, Stella
Alessi, Cathy
TI The association between difficulty using positive airway pressure
equipment and adherence to therapy: a pilot study
SO SLEEP AND BREATHING
LA English
DT Article
DE Sleep-disordered breathing; Therapy; Patient compliance; Patient outcome
assessment
ID OBSTRUCTIVE SLEEP-APNEA; PRIMARY-CARE PATIENTS; CPAP ADHERENCE; HEALTH;
OUTCOMES; ADULTS
AB Little is known about the ease of use of positive airway pressure (PAP) equipment and whether PAP equipment usability is associated with adherence. This pilot project aims to determine whether perceived difficulty with the mechanics of using PAP equipment is associated with nonadherence.
Within a larger study of insomnia treatments, we screened (via telephone interview) 148 adults for sleep apnea/prior PAP use and asked them to describe the degree of difficulty putting on their PAP mask, adjusting their mask straps, turning dials/pushing PAP machine buttons, disconnecting tubing, and removing the machine's water chamber (five items; five-point Likert-like scale) and to report their PAP use (0 versus a parts per thousand yen1 days in the past week).
Mean age of participants was 66.7 years (SD 7.0). Thirty respondents (20.3 %) reported at least "some difficulty" with at least one aspect of PAP equipment usability, and 15 respondents (10.1 %) reported at least "quite a lot of difficulty" with one or more aspects of PAP equipment usability. Of the participants, 43.9 % reported not using PAP equipment at all during the past week. Participants (73.3 %) with substantial PAP equipment difficulty (at least quite a lot of difficulty) versus 40.6 % without substantial difficulty reported zero nights of PAP use in the past week (chi-square 5.86, p = .015).
Difficulty using PAP equipment is associated with PAP nonadherence. Studies are needed to confirm these findings and to identify determinants of poor usability. If findings are confirmed, strategies could be developed to improve PAP usability, which may improve adherence.
C1 [Fung, Constance H.; Martin, Jennifer L.; Igodan, Uyi; Jouldjian, Stella; Alessi, Cathy] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC 11E, North Hills, CA 91343 USA.
[Fung, Constance H.; Martin, Jennifer L.; Alessi, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Fung, CH (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM constance.h.fung@gmail.com
FU Department of Veterans Affairs Advanced Geriatrics Fellowship Program,
Veterans Administration Health Services Research and Development [Alessi
IIR 08-295]; American Federation for Aging Research; John A. Hartford
Foundation; Centers of Excellence National Program; Veterans
Administration Greater Los Angeles Geriatric Research, Education and
Clinical Center
FX This study was supported by the Department of Veterans Affairs Advanced
Geriatrics Fellowship Program, Veterans Administration Health Services
Research and Development (Alessi IIR 08-295); American Federation for
Aging Research, The John A. Hartford Foundation, the Centers of
Excellence National Program; and Veterans Administration Greater Los
Angeles Geriatric Research, Education and Clinical Center. The authors
thank our project manager, Karen Josephson, the study coordinators,
Terry Vandenberg and Sergio Martinez, and our research staff who
assisted with the telephone interviews, Ana Grigorian, Jessica Bautista,
and Rebecca Saia. All work was completed at VA Greater Los Angeles
Healthcare System.
NR 32
TC 4
Z9 4
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
J9 SLEEP BREATH
JI Sleep Breath.
PD MAY
PY 2013
VL 17
IS 2
BP 853
EP 859
DI 10.1007/s11325-012-0779-y
PG 7
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA 146FR
UT WOS:000319075800062
PM 23149875
ER
PT J
AU Kim, JI
Kim, J
Jang, HS
Noh, MR
Lipschutz, JH
Park, KM
AF Kim, Jee In
Kim, Jinu
Jang, Hee-Seong
Noh, Mi Ra
Lipschutz, Joshua H.
Park, Kwon Moo
TI Reduction of oxidative stress during recovery accelerates normalization
of primary cilia length that is altered after ischemic injury in murine
kidneys
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE primary cilia; reactive oxygen species; ERK; ischemia; ROS
ID INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; RENAL CILIA; URETERAL
OBSTRUCTION; MOUSE; MICE; REPERFUSION; PROGRESSION; PREVENTION; FLAGELLA
AB The primary cilium is a microtubule-based nonmotile organelle that extends from the surface of cells, including renal tubular cells. Here, we investigated the alteration of primary cilium length during epithelial cell injury and repair, following ischemia/reperfusion (I/R) insult, and the role of reactive oxygen species in this alteration. Thirty minutes of bilateral renal ischemia induced severe renal tubular cell damage and an increase of plasma creatinine (PCr) concentration. Between 8 and 16 days following the ischemia, the increased PCr returned to normal range, although without complete histological restoration. Compared with the primary cilium length in normal kidney tubule cells, the length was shortened 4 h and 1 day following ischemia, increased over normal 8 days after ischemia, and then returned to near normal 16 days following ischemia. In the urine of I/R-subjected mice, acetylated tubulin was detected. The cilium length of proliferating cells was shorter than that in nonproliferating cells. Mature cells had shorter cilia than differentiating cells. Treatment with Mn(III) tetrakis(1-methyl-4-pyridyl) porphyrin (MnTMPyP), an antioxidant, during the recovery of damaged kidneys accelerated normalization of cilia length concomitant with a decrease of oxidative stress and morphological recovery in the kidney. In the Madin-Darby canine kidney (MDCK) cells, H2O2 treatment caused released ciliary fragment into medium, and MnTMPyP inhibited the deciliation. The ERK inhibitor U0126 inhibited elongation of cilia in normal and MDCK cells recovering from H2O2 stress. Taken together, our results suggest that primary cilia length reflects cell proliferation and the length of primary cilium is regulated, at least, in part, by reactive oxygen species through ERK.
C1 [Kim, Jee In; Kim, Jinu; Jang, Hee-Seong; Noh, Mi Ra; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu, South Korea.
[Kim, Jee In; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Taegu, South Korea.
[Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, Dept Anat, 101 Dongindong 2Ga, Junggu 700422, Daegu, South Korea.
EM kmpark@knu.ac.kr
OI Jang, Hee-Seong/0000-0002-9620-351X
FU Kyungpook National University Research Fund; National Research
Foundation; Korean Government [NRF-2011-220-E00001]; Korean Health
Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
[A111366]
FX This research was supported by the Kyungpook National University
Research Fund 2012, a National Research Foundation Grant funded by the
Korean Government (NRF-2011-220-E00001 to K. M. Park), and the Korean
Health Technology R&D Project, Ministry of Health & Welfare, Republic of
Korea (A111366 to K. M. Park).
NR 35
TC 6
Z9 6
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAY
PY 2013
VL 304
IS 10
BP F1283
EP F1294
DI 10.1152/ajprenal.00427.2012
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 144UM
UT WOS:000318966100007
PM 23515720
ER
PT J
AU Jensen, KP
Kranzler, HR
Stein, MB
Gelernter, J
AF Jensen, Kevin P.
Kranzler, Henry R.
Stein, Murray B.
Gelernter, Joel
TI The Effects of a Predicted MAP2K5 Microrna Target Site SNP on Risk for
Anxiety and Depressive Disorders
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE anxiety; depression; genetics; microRNA; GWAS
C1 [Jensen, Kevin P.; Gelernter, Joel] Yale Univ Sch Med, Dept Psychiat, West Haven, CT USA.
[Jensen, Kevin P.; Gelernter, Joel] VA CT Hlth Care Ctr, West Haven, CT USA.
[Kranzler, Henry R.] Univ Penn Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Gelernter, Joel] Yale Univ Sch Med, Dept Genet, West Haven, CT USA.
[Gelernter, Joel] Yale Univ Sch Med, Dept Neurobiol, West Haven, CT USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 208
BP 67S
EP 67S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800209
ER
PT J
AU Aranovich, G
McClure, SM
Shanbhag, H
Roach, BJ
Mathalon, DH
AF Aranovich, Gabriel
McClure, Samuel M.
Shanbhag, Harshad
Roach, Brian J.
Mathalon, Daniel H.
TI Neural Correlates of Delay Discounting for Monetary Rewards in Chronic
Cigarette Smokers
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Discounting; Medial Prefrontal Cortex; DLPFC; Ventral Striatum;
Addiction
C1 [Aranovich, Gabriel; Shanbhag, Harshad; Roach, Brian J.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Aranovich, Gabriel; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[McClure, Samuel M.] Stanford Univ, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 404
BP 130S
EP 130S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800400
ER
PT J
AU Hazlett, EA
Fernandez, N
Sasso, S
Mascitelli, KA
New, AS
Goodman, M
AF Hazlett, Erin A.
Fernandez, Nicolas
Sasso, Scott
Mascitelli, Kathryn A.
New, Antonia S.
Goodman, Marianne
TI Larger Startle-Eyeblink Amplitude During Unpleasant Pictures = Greater
Severity of Suicidal Behavior: A Promising Endophenotype For RDOC
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE affective startle eyeblink; suicide; emotion regulation;
psychophysiology; suicidal behavior
C1 [Hazlett, Erin A.; New, Antonia S.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Hazlett, Erin A.; Fernandez, Nicolas; Sasso, Scott; Mascitelli, Kathryn A.; New, Antonia S.; Goodman, Marianne] James J Peters VAMC, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 512
BP 162S
EP 162S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800500
ER
PT J
AU Perez-Rodriguez, MM
New, AS
Yuan, QP
Zhou, ZF
Hodgkinson, C
Goodman, M
Koenigsberg, HW
Goldstein, KE
Goldman, D
Siever, LJ
Hazlett, EA
AF Perez-Rodriguez, M. Mercedes
New, Antonia S.
Yuan, Qiaoping
Zhou, Zhifeng
Hodgkinson, Colin
Goodman, Manrianne
Koenigsberg, Harold W.
Goldstein, Kim E.
Goldman, David
Siever, Larry J.
Hazlett, Erin A.
TI Impaired Extinction of Amygdala Response to Unpleasant Pictures in
Borderline Personality Disorder Associated with BDNF genotype
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE BDNF; habituation; emotional processing; amygdala; borderline
personality disorder
C1 [Perez-Rodriguez, M. Mercedes; New, Antonia S.; Goodman, Manrianne; Koenigsberg, Harold W.; Goldstein, Kim E.; Siever, Larry J.; Hazlett, Erin A.] Mt Sinai Sch Med, New York, NY USA.
[Perez-Rodriguez, M. Mercedes; New, Antonia S.; Goodman, Manrianne; Siever, Larry J.; Hazlett, Erin A.] James J Peters VAMC, Mirecc, Bronx, NY USA.
[Yuan, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Rockville, MD 20852 USA.
[Koenigsberg, Harold W.] James J Peters VAMC, Mhcc, Bronx, NY USA.
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 629
BP 200S
EP 200S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800617
ER
PT J
AU Marder, SR
AF Marder, Stephen R.
TI Glutamate-Related Treatment Strategies in Schizophrenia Patients
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Glutamate; Neurocognition; Negative Symptoms
C1 [Marder, Stephen R.] Univ Calif Los Angeles, VA Greater LA Hlth Care Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 706
BP 225S
EP 226S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801016
ER
PT J
AU Hay, RA
Roach, BJ
Attygalle, SS
Cadenhead, K
Carrion, R
Bachman, P
Johannesen, J
Duncan, E
Belger, A
Niznikiewicz, M
McCarley, RW
Light, G
Pillay, N
Addington, J
Cannon, T
Cornblatt, B
McGlashan, T
Perkins, D
Seidman, L
Tsuang, M
Walker, E
Woods, S
Donkers, F
Mathalon, DH
AF Hay, Rachel A.
Roach, Brian J.
Attygalle, Suneth S.
Cadenhead, Kristin
Carrion, Ricardo
Bachman, Peter
Johannesen, Jason
Duncan, Erica
Belger, Aysenil
Niznikiewicz, Margaret
McCarley, Robert W.
Light, Gregory
Pillay, Neelan
Addington, Jean
Cannon, Tyrone
Cornblatt, Barbara
McGlashan, Thomas
Perkins, Diana
Seidman, Larry
Tsuang, Ming
Walker, Elaine
Woods, Scott
Donkers, Franc
Mathalon, Daniel H.
CA NAPLS Consortium
TI Mismatch Negativity Abnormalities Are Associated with Poorer Functioning
in Youth at Clinical High Risk for Psychosis: Evidence from the NAPLS
Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Mismatch negativity; Schizophrenia; Social Function; Prodrome; High Risk
C1 [Hay, Rachel A.; Roach, Brian J.; Attygalle, Suneth S.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hay, Rachel A.; Roach, Brian J.; Attygalle, Suneth S.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cadenhead, Kristin; Light, Gregory; Tsuang, Ming] Univ Calif San Diego, San Diego, CA 92103 USA.
[Carrion, Ricardo; Cornblatt, Barbara] Zucker Hillside Hosp, New York, NY USA.
[Bachman, Peter] Univ Calif Los Angeles, Los Angeles, CA USA.
[Johannesen, Jason; Cannon, Tyrone; McGlashan, Thomas; Woods, Scott] Yale Univ, New Haven, CT USA.
[Duncan, Erica; Walker, Elaine] Emory Univ, Atlanta, GA 30322 USA.
[Duncan, Erica] Atlanta VAMC, Atlanta, GA USA.
[Belger, Aysenil; Perkins, Diana; Donkers, Franc] Univ N Carolina, Chapel Hill, NC USA.
[Niznikiewicz, Margaret; McCarley, Robert W.; Seidman, Larry] Harvard Univ, Boston, MA 02115 USA.
[Pillay, Neelan; Addington, Jean] Univ Calgary, Calgary, AB, Canada.
RI Donkers, Franc/H-2391-2013
OI Donkers, Franc/0000-0002-8252-0426
NR 0
TC 1
Z9 1
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 850
BP 272S
EP 272S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801160
ER
PT J
AU Vinogradov, S
AF Vinogradov, Sophia
TI Heterogeneity in Cognitive Improvement After Intensive Cognitive
Training in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; cognition; cortical plasticity; cognitive training
C1 [Vinogradov, Sophia] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 857
BP 274S
EP 274S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801167
ER
PT J
AU Perez-Rodriguez, MM
Shen, PH
Bevilacqua, L
Yuang, QP
Zhou, ZF
Hodgkinson, C
Ripoll, L
Goodman, M
Koenigsberg, H
Goldman, D
Siever, LJ
New, AS
AF Perez-Rodriguez, M. Mercedes
Shen, Pei-Hong
Bevilacqua, Laura
Yuang, Qiaoping
Zhou, Zhifeng
Hodgkinson, Colin
Ripoll, Luis
Goodman, Marianne
Koenigsberg, Harold
Goldman, David
Siever, Larry J.
New, Antonia S.
TI Oxytocin Gene Variants Modulate Core Dimensions of Borderline
Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Oxytocin; Single Nucleotide Polymorphism; Empathy; Impulsivity;
Aggression
C1 [Perez-Rodriguez, M. Mercedes; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold; Siever, Larry J.; New, Antonia S.] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA.
[Perez-Rodriguez, M. Mercedes; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold; Siever, Larry J.; New, Antonia S.] James J Peters VAMC, MIRECC, New York, NY USA.
[Shen, Pei-Hong; Bevilacqua, Laura; Yuang, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Lab Neurogenet, NIH, Rockville, MD 20852 USA.
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
NR 0
TC 0
Z9 0
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 891
BP 285S
EP 285S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801201
ER
PT J
AU Yao, JK
Dougherty, GG
Reddy, RD
Montrose, DM
Matson, WR
Kaddurah-Daouk, R
Keshavan, M
AF Yao, Jeffrey K.
Dougherty, George G.
Reddy, Ravinder D.
Montrose, Debra M.
Matson, Wayne R.
Kaddurah-Daouk, Rima
Keshavan, Matcheri
TI Interactions between Purine Metabolites and Monoamine Neurotransmitters
in First-Episode Psychosis
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Schizophrenia; First-episode psychosis; Purine catabolism; Monoamine
neurotransmitters
C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Montrose, Debra M.; Keshavan, Matcheri] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA.
[Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
[Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
[Keshavan, Matcheri] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 913
BP 291S
EP 291S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801221
ER
PT J
AU Palzes, V
AF Palzes, Vanessa
TI Predictions Break Down Between Motor Plans and Their Consequences in
Schizophrneia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Schizophrenia; ERP; Corollary discharge; Prediction error
C1 [Palzes, Vanessa] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 931
BP 297S
EP 297S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801239
ER
PT J
AU Fryer, SL
Woods, SW
Kiehl, KA
Calhoun, VD
Pearlson, GD
Roach, BJ
Ford, JM
McGlashan, TH
Mathalon, DH
AF Fryer, Susanna L.
Woods, Scott W.
Kiehl, Kent A.
Calhoun, Vince D.
Pearlson, Godfrey D.
Roach, Brian J.
Ford, Judith M.
McGlashan, Thomas H.
Mathalon, Daniel H.
TI Youth at Clinical High-Risk for Psychosis Fail to Suppress Default Mode
Regions During Task Performance
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE psychosis prodrome; ultra high-risk; schizophrenia; default mode
network; working memory
C1 [Fryer, Susanna L.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fryer, Susanna L.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Woods, Scott W.; Calhoun, Vince D.; Pearlson, Godfrey D.; Ford, Judith M.; McGlashan, Thomas H.; Mathalon, Daniel H.] Yale Univ, New Haven, CT USA.
[Kiehl, Kent A.; Calhoun, Vince D.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Kiehl, Kent A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
[Pearlson, Godfrey D.] Olin Neuropsychiat Res Ctr, Inst Living, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 941
BP 301S
EP 301S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801249
ER
PT J
AU Storage, S
Mandelkern, M
Phuong, J
Kozman, M
Brody, A
AF Storage, Steven
Mandelkern, Mark
Phuong, Jonathan
Kozman, Maggie
Brody, Arthur
TI Relationship Between Harm Avoidance and Nicotinic Acetylcholine Receptor
Density
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Tobacco Dependence; Harm Avoidance; Positron Emission Tomography;
Nicotinic Acetylcholine Receptor; Temperament and Character Inventory
C1 [Storage, Steven] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Mandelkern, Mark] VA Greater Los Angeles Healthcare Syst, Nucl Med, Los Angeles, CA USA.
[Phuong, Jonathan; Kozman, Maggie] VA Greater Los Angeles Healthcare Syst, Res, Los Angeles, CA USA.
[Brody, Arthur] Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 964
BP 308S
EP 308S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801272
ER
PT J
AU Sonnenberg, A
Lee, BY
AF Sonnenberg, Amnon
Lee, Brent Y.
TI Birth-Cohort Analysis of Colorectal Cancer Incidence in the United
States
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
ID MORTALITY; TRENDS; ULCER
C1 [Sonnenberg, Amnon; Lee, Brent Y.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 4
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAY
PY 2013
VL 11
IS 5
BP 582
EP 583
DI 10.1016/j.cgh.2013.01.022
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 140UX
UT WOS:000318682600030
PM 23376795
ER
PT J
AU Friedlander, AH
Chang, TI
Aghazadehsanai, N
Berenji, GR
Harada, ND
Garrett, NR
AF Friedlander, A. H.
Chang, T. I.
Aghazadehsanai, N.
Berenji, G. R.
Harada, N. D.
Garrett, N. R.
TI Panoramic images of white and black post-menopausal females evidencing
carotid calcifications are at high risk of comorbid osteopenia of the
femoral neck
SO DENTOMAXILLOFACIAL RADIOLOGY
LA English
DT Article
DE atherosclerosis; panoramic images; osteopenia; fractures
ID BONE-MINERAL DENSITY; SERVICES TASK-FORCE; ARTERY CALCIFICATIONS; HIP
FRACTURE; OLDER WOMEN; OSTEOPOROSIS; RADIOGRAPHY; POPULATION; MORTALITY;
ATHEROMA
AB Objectives: Femoral neck fractures in older females resulting from decreased bone mineral density (BMD; osteopenia) are associated with increased morbidity and mortality. Bone mineralization inhibition is probably controlled by proteins which also foster vascular calcification. Therefore, we evaluated the relationship between calcified carotid artery plaque (CCAP) on panoramic images and BMD on dual energy X-ray absorptiometry (DXA) bone scans.
Methods: Images and hospital records identified by dentists defined two study groups (20 white females and 24 black females) having CCAP and an incidentally obtained bone scan. Ethnically matched (age +/- 7 years, body mass index +/- 3 units) control groups with panoramic images devoid of CCAP and accompanying DXA scan were likewise constituted. A physician determined the BMD on the DXA.
Results: Females with CCAP had significantly (p = 0.03) poorer BMD at the femoral neck than those without CCAP. Although mean femoral neck BMD was significantly lower (p = 0.009) for white than for black females, there was no significant interaction between race and CCAP (p = 0.80).
Conclusion: We observed a significant inverse association between the CCAP on panoramic images and femoral neck BMD in post-menopausal white females.
C1 [Friedlander, A. H.; Chang, T. I.; Berenji, G. R.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
[Friedlander, A. H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, A. H.; Chang, T. I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Aghazadehsanai, N.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA USA.
[Berenji, G. R.; Harada, N. D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Harada, N. D.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Garrett, N. R.] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
FU Research Facilities Improvement Program from the National Center for
Research Resources, National Institutes of Health [C06 RR-14529-01]
FX Elements of this investigation were conducted in a facility constructed
with support from Research Facilities Improvement Program Grant Number
C06 RR-14529-01 from the National Center for Research Resources,
National Institutes of Health.
NR 31
TC 5
Z9 6
U1 0
U2 5
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0250-832X
J9 DENTOMAXILLOFAC RAD
JI Dentomaxillofac. Radiol.
PD MAY
PY 2013
VL 42
IS 5
AR 20120195
DI 10.1259/dmfr.20120195
PG 6
WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
GA 146NY
UT WOS:000319099000001
PM 23571481
ER
PT J
AU Gukovsky, I
Li, N
Todoric, J
Gukovskaya, A
Karin, M
AF Gukovsky, Ilya
Li, Ning
Todoric, Jelena
Gukovskaya, Anna
Karin, Michael
TI Inflammation, Autophagy, and Obesity: Common Features in the
Pathogenesis of Pancreatitis and Pancreatic Cancer
SO GASTROENTEROLOGY
LA English
DT Review
DE Pancreatic Acinar Cell; Cytokines; Neutrophil; Pancreatic Ductal
Adenocarcinoma; K-Ras
ID NF-KAPPA-B; CERULEIN-INDUCED PANCREATITIS; TUMOR-NECROSIS-FACTOR;
PROTEIN-KINASE-C; ACINAR-CELLS; INSULIN-RESISTANCE; DEFICIENT MICE;
TRYPSINOGEN ACTIVATION; DUCTAL ADENOCARCINOMA; SIGNALING PATHWAYS
AB Inflammation and autophagy are cellular defense mechanisms. When these processes are deregulated (deficient or overactivated) they produce pathologic effects, such as oxidative stress, metabolic impairments, and cell death. Unresolved inflammation and disrupted regulation of autophagy are common features of pancreatitis and pancreatic cancer. Furthermore, obesity, a risk factor for pancreatitis and pancreatic cancer, promotes inflammation and inhibits or deregulates autophagy, creating an environment that facilitates the induction and progression of pancreatic diseases. However, little is known about how inflammation, autophagy, and obesity interact to promote exocrine pancreatic disorders. We review the roles of inflammation and autophagy, and their deregulation by obesity, in pancreatic diseases. We discuss the connections among disordered pathways and important areas for future research.
C1 [Gukovsky, Ilya; Gukovskaya, Anna] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gukovsky, Ilya; Gukovskaya, Anna] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Li, Ning; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Li, Ning; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Todoric, Jelena] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
RP Gukovskaya, A (reprint author), Univ Calif Los Angeles, Dept Vet Affairs, Los Angeles, CA 90073 USA.
EM agukovsk@ucla.edu
FU Department of Veterans Affairs; National Institutes of Health [DK59936];
Pancreatic Cancer Research Lustgarten Foundation grant [RFP-B-007];
Erwin Schrodinger Fellowship of the Austrian Science Fund [J 3233];
[P01 CA163200]; [AA19730]; [AI043477]; [CA163798]; [P50 AA011999];
[R03CA167120]
FX Our research was supported by the Department of Veterans Affairs and
National Institutes of Health grants DK59936, and, in part, P01 CA163200
(A.G.), AA19730 (I.G.), AI043477 (M.K.), CA163798 (M.K.), P50 AA011999
(A.G, I.G, Pilot Project to M.K.), and R03CA167120 (N.L.), by a
Pancreatic Cancer Research Lustgarten Foundation grant RFP-B-007 (M.K.),
and the Erwin Schrodinger Fellowship J 3233 of the Austrian Science Fund
(J.T.).
NR 201
TC 74
Z9 78
U1 4
U2 52
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 6
BP 1199
EP +
DI 10.1053/j.gastro.2013.02.007
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 144AE
UT WOS:000318910600006
PM 23622129
ER
PT J
AU Dobscha, SK
Corson, K
Helmer, DA
Bair, MJ
Denneson, LM
Brandt, C
Beane, A
Ganzini, L
AF Dobscha, Steven K.
Corson, Kathryn
Helmer, Drew A.
Bair, Matthew J.
Denneson, Lauren M.
Brandt, Cynthia
Beane, Anna
Ganzini, Linda
TI Brief assessment for suicidal ideation in OEF/OIF veterans with positive
depression screens
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Depression; Screening; Suicide; Veterans
ID PRIMARY-CARE; RISK; PHYSICIAN; SEVERITY; VALIDITY; RACE; IRAQ
AB Objectives: We describe processes, rates, and patient and system correlates of brief structured assessments (BSAs) for suicidal ideation among Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans with positive depression screens.
Methods: Electronic Veterans Affairs (VA) medical record and Department of Defense data were used to identify individual-level and BSA-process variables for 1662 OEF/OIF veterans at three VA Medical Centers.
Results: Overall, 1349/1662 (81%) veterans received BSAs for suicidal ideation within 1 month of depression screening; 94% of BSAs were conducted within 1 day. Stratified analyses revealed significant intersite differences in veteran demographics, instruments used, clinical setting and staff performing assessments, and correlates of assessment completion. At two sites, men were more likely to be assessed than women [odds ratio (OR)=2.15 (95% confidence interval {CI}=1.06-4.38) and 3.14 (CI=1.27-7.76)]. In a combined model adjusted for intrasite correlation, assessment was less likely during months 8-12 and 13-18 of the study period [OR=0.39 (CI=0.28-0.54) and OR=0.48 (95% CI=0.35-0.68), respectively] and more likely to occur among veterans receiving depression or posttraumatic stress disorder diagnoses on the day of depression screening [OR=1.83 (CI=1.36-2.46) and OR=1.50 (CI=1.13-1.98), respectively].
Conclusions: Most veterans with positive depression screens receive timely BSAs for suicidal ideation. Processes used for brief assessment for suicidal ideation vary substantially across VA settings. Published by Elsevier Inc.
C1 [Dobscha, Steven K.; Corson, Kathryn; Denneson, Lauren M.; Beane, Anna; Ganzini, Linda] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR USA.
[Dobscha, Steven K.; Corson, Kathryn; Denneson, Lauren M.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Helmer, Drew A.] VA New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, E Orange, NJ USA.
[Helmer, Drew A.] Baylor Coll Med, Houston, TX 77030 USA.
[Bair, Matthew J.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
[Brandt, Cynthia] West Haven Vet Affairs Med Ctr, West Haven, CT USA.
RP Dobscha, SK (reprint author), Portland VA Med Ctr, POB 1034 P3MHADM, Portland, OR 97207 USA.
EM steven.dobscha@va.gov
FU Department of Veterans Affairs, Veterans Health Administration; Health
Services Research and Development Service Project [DHI-08-096]
FX We gratefully acknowledge Jonathon Duckart, M. P. S.; Kathryn Dickinson,
M. P. H.; Ashley McComb, B. S.; Jose Perez, B. S.; and Megan
Crutchfield, M. P. H., for assistance with collecting and organizing
data and reviewing medical records. This material is based upon work
supported by the Department of Veterans Affairs, Veterans Health
Administration, and Health Services Research and Development Service
Project DHI-08-096. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 33
TC 5
Z9 5
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2013
VL 35
IS 3
BP 272
EP 278
DI 10.1016/j.genhosppsych.2012.12.001
PG 7
WC Psychiatry
SC Psychiatry
GA 145DZ
UT WOS:000318995800010
PM 23351524
ER
PT J
AU Hall, TO
Wan, JY
Mata, IF
Kerr, KF
Snapinn, KW
Samii, A
Roberts, JW
Agarwal, P
Zabetian, CP
Edwards, KL
AF Hall, Taryn O.
Wan, Jia Y.
Mata, Ignacio F.
Kerr, Kathleen F.
Snapinn, Katherine W.
Samii, Ali
Roberts, John W.
Agarwal, Pinky
Zabetian, Cyrus P.
Edwards, Karen L.
TI Risk prediction for complex diseases: application to Parkinson disease
SO GENETICS IN MEDICINE
LA English
DT Article
DE genetics; Parkinson disease; risk prediction
ID GENOME-WIDE ASSOCIATION; VPS35 MUTATIONS; CANCER RISK; IDENTIFICATION;
POLYMORPHISMS; SPECIFICITY; SENSITIVITY; LIMITATIONS; POPULATION;
VARIANTS
AB Purpose: The aim of this study was to evaluate the risk of Parkinson disease using clinical and demographic data alone and when combined with information from genes associated with Parkinson disease.
Methods: A total of 1,967 participants in the dbGAP NeuroGenetics Research Consortium data set were included. Single-nucleotide polymorphisms associated with Parkinson disease at a genome-wide significance level in previous genome-wide association studies were included in risk prediction. Risk allele scores were calculated as the weighted count of the minor alleles. Five models were constructed. Discriminatory capability was evaluated using the area under the curve.
Results: Both family history and genetic risk scores increased risk for Parkinson disease. Although the fullest model, which included both family history and genetic risk information, resulted in the highest area under the curve, there were no significant differences between models using family history alone and those using genetic information alone.
Conclusion: Adding genome-wide association study-derived genotypes, family history information, or both to standard demographic risk factors for Parkinson disease resulted in an improvement in discriminatory capacity. In the full model, the contributions of genotype data and family history information to discriminatory capacity were similar, and both were statistically significant. This suggests that there is limited overlap between genetic risk factors identified through genome-wide association study and unmeasured susceptibility variants captured by family history. Our results are similar to those of studies of other complex diseases and indicate that genetic risk prediction for Parkinson disease requires identification of additional genetic risk factors and/or better methods for risk prediction in order to achieve a degree of risk prediction that is clinically useful.
C1 [Hall, Taryn O.; Edwards, Karen L.] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
[Wan, Jia Y.; Snapinn, Katherine W.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mata, Ignacio F.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Mata, Ignacio F.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Kerr, Kathleen F.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Agarwal, Pinky] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA.
RP Edwards, KL (reprint author), Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
EM keddy@uw.edu
RI Kerr, Kathleen/A-2893-2013
OI Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian,
Cyrus/0000-0002-7739-4306
FU Department of Veterans Affairs [1I01BX000531]; National Institutes of
Health [P50 NS062684, R01 NS065070, R01 NS036960]
FX This work was supported by funding from the Department of Veterans
Affairs (1I01BX000531) and the National Institutes of Health (P50
NS062684, R01 NS065070, R01 NS036960).
NR 34
TC 7
Z9 7
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD MAY
PY 2013
VL 15
IS 5
BP 361
EP 367
DI 10.1038/gim.2012.109
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 143SN
UT WOS:000318888600007
PM 23222663
ER
PT J
AU Osguthorpe, JD
AF Osguthorpe, John David
TI Pathophysiology of and potential new therapies for allergic rhinitis
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Review
DE T-helper lymphocyte; IgE; eosinophil; mast cell; humanized monoclonal
antibody; cytokine; chemokine
ID HYGIENE HYPOTHESIS; NASAL POLYPOSIS; IMMUNOTHERAPY; INFLAMMATION;
DISEASE; ASTHMA; IGE; RHINOSINUSITIS; MECHANISMS; DISORDERS
AB Background Advancement in laboratory techniques in the past decade, coupled with clinical studies, has afforded a better understanding of the genetic and molecular mechanisms underlying allergy. Methods The literature on the pathophysiology of allergic rhinitis, systemic and local, was reviewed, with emphasis on the last 3 years. Results The basis in allergic rhinitis for the T-lymphocyte helper 2 cell and associated cytokine bias, and the ameliorating effects of T-regulatory lymphocytes and their cytokines, is summarized. New or currently under development pharmacotherapeutic agents are briefly presented. Conclusion Much of the molecular basis for the manifestations of allergy can now be explained, and may afford strategies to interrupt the development of disease or ameliorate such already present.
C1 [Osguthorpe, John David] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
RP Osguthorpe, JD (reprint author), Ralph Johnson VA Med Ctr, Surg Serv 112, 109 Bee St, Charleston, SC 29401 USA.
EM osguthjd@musc.edu
NR 57
TC 8
Z9 9
U1 2
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD MAY
PY 2013
VL 3
IS 5
BP 384
EP 392
DI 10.1002/alr.21120
PG 9
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 146ET
UT WOS:000319073200008
PM 23193028
ER
PT J
AU Thurman, JM
Kulik, L
Orth, H
Wong, M
Renner, B
Sargsyan, SA
Mitchell, LM
Hourcade, DE
Hannan, JP
Kovacs, JM
Coughlin, B
Woodell, AS
Pickering, MC
Rohrer, B
Holers, VM
AF Thurman, Joshua M.
Kulik, Liudmila
Orth, Heather
Wong, Maria
Renner, Brandon
Sargsyan, Siranush A.
Mitchell, Lynne M.
Hourcade, Dennis E.
Hannan, Jonathan P.
Kovacs, James M.
Coughlin, Beth
Woodell, Alex S.
Pickering, Matthew C.
Rohrer, Baerbel
Holers, V. Michael
TI Detection of complement activation using monoclonal antibodies against
C3d
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SITE-DIRECTED MUTAGENESIS; RECEPTOR-TYPE 2; FACTOR-H; MACULAR
DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CHOROIDAL
NEOVASCULARIZATION; ACQUIRED-IMMUNITY; PROTEIN BETA-1H; MICE DEFICIENT;
FLUID-PHASE
AB During complement activation the C3 protein is cleaved, and C3 activation fragments are covalently fixed to tissues. Tissue-bound C3 fragments are a durable biomarker of tissue inflammation, and these fragments have been exploited as addressable binding ligands for targeted therapeutics and diagnostic agents. We have generated cross-reactive murine monoclonal antibodies against human and mouse C3d, the final C3 degradation fragment generated during complement activation. We developed 3 monoclonal antibodies (3d8b, 3d9a, and 3d29) that preferentially bind to the iC3b, C3dg, and C3d fragments in solution, but do not bind to intact C3 or C3b. The same 3 clones also bind to tissue-bound C3 activation fragments when injected systemically. Using mouse models of renal and ocular disease, we confirmed that, following systemic injection, the antibodies accumulated at sites of C3 fragment deposition within the glomerulus, the renal tubulointerstitium, and the posterior pole of the eye. To detect antibodies bound within the eye, we used optical imaging and observed accumulation of the antibodies within retinal lesions in a model of choroidal neovascularization (CNV). Our results demonstrate that imaging methods that use these antibodies may provide a sensitive means of detecting and monitoring complement activation-associated tissue inflammation.
C1 [Thurman, Joshua M.; Kulik, Liudmila; Orth, Heather; Wong, Maria; Renner, Brandon; Sargsyan, Siranush A.; Hannan, Jonathan P.; Kovacs, James M.; Holers, V. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
[Mitchell, Lynne M.; Hourcade, Dennis E.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
[Coughlin, Beth; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Woodell, Alex S.; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC USA.
[Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London SW7 2AZ, England.
[Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
RP Thurman, JM (reprint author), Univ Colorado Denver, Sch Med, Div Nephrol & Hypertens, B-115,POB 6511, Aurora, CO 80045 USA.
EM Joshua.Thurman@ucdenver.edu
OI Hannan, Jonathan/0000-0003-3318-2341; Pickering,
Matthew/0000-0002-1153-0192
FU Alexion Pharmaceuticals, Inc.; Beckman Initiative for Macular Research;
KIDNEEDS Foundation; NIH [R01 AR51749, R01 DK076690, R01 AI051436]
FX Joshua M. Thurman and V. Michael Holers are paid consultants for Alexion
Pharmaceuticals, Inc. A patent application has been filed for the
monoclonal antibodies described in this manuscript.; We thank Shaun
Bevers at the University of Colorado Biophysics Core for technical
assistance. This work was supported in part by the Beckman Initiative
for Macular Research (to V.M. Holers), the KIDNEEDS Foundation (to J.M.
Thurman), NIH grants R01 AR51749 (to V.M. Holers), R01 DK076690 (to J.M.
Thurman), and R01 AI051436 (to D.E. Hourcade), and a sponsored research
agreement with Alexion Pharmaceuticals, Inc.
NR 48
TC 18
Z9 18
U1 0
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2218
EP 2230
DI 10.1172/JCI65861
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100040
PM 23619360
ER
PT J
AU Li, N
Wu, XF
Holzer, RG
Lee, JH
Todoric, J
Park, EJ
Ogata, H
Gukovskaya, AS
Gukovsky, I
Pizzo, DP
VandenBerg, S
Tarin, D
Atay, C
Arkan, MC
Deerinck, TJ
Moscat, J
Diaz-Meco, M
Dawson, D
Erkan, M
Kleeff, J
Karin, M
AF Li, Ning
Wu, Xuefeng
Holzer, Ryan G.
Lee, Jun-Hee
Todoric, Jelena
Park, Eek-Joong
Ogata, Hisanobu
Gukovskaya, Anna S.
Gukovsky, Ilya
Pizzo, Donald P.
VandenBerg, Scott
Tarin, David
Atay, Cigdem
Arkan, Melek C.
Deerinck, Thomas J.
Moscat, Jorge
Diaz-Meco, Maria
Dawson, David
Erkan, Mert
Kleeff, Joerg
Karin, Michael
TI Loss of acinar cell IKK alpha triggers spontaneous pancreatitis in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; UNFOLDED PROTEIN RESPONSE;
TRYPSINOGEN ACTIVATION; OXIDATIVE STRESS; AUTOPHAGY; P62; CANCER;
INFLAMMATION; MOUSE
AB Chronic pancreatitis is an inflammatory disease that causes progressive destruction of pancreatic acinar cells and, ultimately, loss of pancreatic function. We investigated the role of I kappa B kinase alpha (IKK alpha) in pancreatic homeostasis. Pancreas-specific ablation of IKK alpha (Ikk alpha(Delta pan)) caused spontaneous and progressive acinar cell vacuolization and death, interstitial fibrosis, inflammation, and circulatory release of pancreatic enzymes, clinical signs resembling those of human chronic pancreatitis. Loss of pancreatic IKK alpha causes defective autophagic protein degradation, leading to accumulation of p62-mediated protein aggregates and enhanced oxidative and ER stress in acinar cells, but none of these effects is related to NF-kappa B. Pancreas-specific p62 ablation prevented ER and oxidative stresses and attenuated pancreatitis in Ikk alpha(Delta pan) mice, suggesting that cellular stress induced by p62 aggregates promotes development of pancreatitis. Importantly, downregulation of IKK alpha and accumulation of p62 aggregates were also observed in chronic human pancreatitis. Our studies demonstrate that IKK alpha, which may control autophagic protein degradation through its interaction with ATG16L2, plays a critical role in maintaining pancreatic acinar cell homeostasis, whose dysregulation promotes pancreatitis through p62 aggregate accumulation.
C1 [Li, Ning; Wu, Xuefeng; Holzer, Ryan G.; Lee, Jun-Hee; Todoric, Jelena; Park, Eek-Joong; Ogata, Hisanobu; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Li, Ning; Wu, Xuefeng; Holzer, Ryan G.; Lee, Jun-Hee; Todoric, Jelena; Park, Eek-Joong; Ogata, Hisanobu; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Todoric, Jelena] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
[Gukovskaya, Anna S.; Gukovsky, Ilya] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gukovskaya, Anna S.; Gukovsky, Ilya] Univ Calif Los Angeles, Los Angeles, CA USA.
[Pizzo, Donald P.; VandenBerg, Scott; Tarin, David] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
[Atay, Cigdem; Arkan, Melek C.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany.
[Deerinck, Thomas J.] Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA.
[Moscat, Jorge; Diaz-Meco, Maria] Sanford Burnham Med Res Inst, La Jolla, CA USA.
[Dawson, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Erkan, Mert; Kleeff, Joerg] Tech Univ Munich, Klinikum Rechts Isar, Dept Gen Surg, D-80290 Munich, Germany.
RP Karin, M (reprint author), Univ Calif San Diego, 9500 Gilman Dr,Mail Code 0723,Leichtag Bldg,Room, La Jolla, CA 92093 USA.
EM karinoffice@ucsd.edu
RI Kleeff, Jorg/B-2124-2009; Dawson, David/I-5917-2014
OI Kleeff, Jorg/0000-0003-3432-6669;
FU NIH [P50 AA011999, AI043477, CA163798, CA167120]; Pancreatic Cancer
Research Lustgarten Foundation grant [RFP-B-007]; Susan G. Komen for the
Cure [KG111506]; Austrian Science Fund's Erwin Schroedinger Fellowship
[J 3233]
FX This work was supported by NIH grants P50 AA011999 (Pilot Project to M.
Karin), AI043477 (to M. Karin), CA163798 (to M. Karin), and CA167120 (to
N. Li) and by Pancreatic Cancer Research Lustgarten Foundation grant
RFP-B-007 (to M. Karin). X. Wu was supported by a postdoctoral
fellowship from Susan G. Komen for the Cure (KG111506). J. Todoric was
supported by the Austrian Science Fund's Erwin Schroedinger Fellowship
(Project# J 3233). We thank S.L. Gonias, D. Brenner, M. Erkan, J.
Kleeff, and F.R. Greten for help in procuring human pancreatitis samples
and for helpful advice; J. Xiao for technical assistance; and M.G.
Farquhar and M. Niwa for helpful discussions regarding lysosomes and ER
stress, respectively. We also thank Santa Cruz Biotechnology Inc. and
Cell Signaling for antibody samples.
NR 62
TC 33
Z9 35
U1 1
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2231
EP 2243
DI 10.1172/JCI64498
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100041
PM 23563314
ER
PT J
AU Chuang, PY
Menon, MC
He, JC
AF Chuang, Peter Y.
Menon, Madhav C.
He, John C.
TI Molecular targets for treatment of kidney fibrosis
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE Kidney; Fibrosis; HIPK2; Signaling pathways; Treatment
ID GROWTH-FACTOR-BETA; NF-KAPPA-B; RENAL INTERSTITIAL FIBROSIS; PROXIMAL
TUBULAR CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; SUBTOTALLY
NEPHRECTOMIZED RATS; INDUCED COLLAGEN EXPRESSION;
GLOMERULAR-FILTRATION-RATE; MATRIX GENE-EXPRESSION; TGF-BETA
AB Renal fibrosis is the culmination of processes driven by signaling pathways involving transforming growth factor-beta family of cytokines, connective-tissue growth factor, nuclear factor kappa B, Wnt/beta-catenin, Notch, and other growth factors. Many studies in experimental animal models have directly targeted these pathways and demonstrated efficacy in mitigating renal fibrosis. However, only a small fraction of these approaches have been attempted in human and even fewer have been successfully translated to clinical use for patient with kidney diseases. Drugs with proven efficacy for treatment of kidney diseases and tissue fibrosis exert some of their effects by interfering with components of these pathways. This review considers key molecular mediators of renal fibrosis and their potential as targets for treatment of renal fibrosis.
C1 [Chuang, Peter Y.; Menon, Madhav C.; He, John C.] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA.
[He, John C.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Chuang, PY (reprint author), Mt Sinai Sch Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM peter.chuang@mssm.edu
FU NIH [1R01DK078897, 1R01DK088541-01A1, 5K08DK082760]; Veterans Affairs
Merit Review Award [1I01BX000345]
FX Due to space limitations, the authors could not individually acknowledge
work of many investigators in the field of renal fibrosis. We have cited
articles that review multiple publications on a topic and we encourage
the readers to use them as sources for further study. JCH is supported
by NIH 1R01DK078897 and 1R01DK088541-01A1 and a Veterans Affairs Merit
Review Award 1I01BX000345; PYC is supported by NIH 5K08DK082760.
NR 136
TC 30
Z9 34
U1 3
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD MAY
PY 2013
VL 91
IS 5
BP 549
EP 559
DI 10.1007/s00109-012-0983-z
PG 11
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 140XT
UT WOS:000318690500003
PM 23179685
ER
PT J
AU Ellis, C
Grubaugh, AL
Egede, LE
AF Ellis, Charles
Grubaugh, Anouk L.
Egede, Leonard E.
TI Factors Associated with SF-12 Physical and Mental Health Quality of Life
Scores in Adults with Stroke
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Disability; stroke; quality of life
ID EAST MELBOURNE STROKE; SURVIVORS; DETERMINANTS; DEPRESSION; RECOVERY;
VALIDITY; IMPACT; RELIABILITY; POSTSTROKE
AB Background: Studies of poststroke quality of life (QOL) have not consistently identified which factors are most likely to independently influence the physical and mental aspects of QOL. In this study, we sought to identify which sociodemographic, comorbid disease conditions, and disability factors independently influenced the physical and mental aspects of poststroke QOL. Methods: We completed a cross-sectional study of 666 US adults with a history of stroke from the 2007 Medical Expenditure Panel Survey (MEPS). We used sequentially built multiple linear regression models to identify sociodemographic, comorbidity, and stroke-related disability factors that independently affected short form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. STATA software (version 10; StataCorp LP, College Station, TX) was used to perform the analysis to account for the complex survey design of the MEPS. Results: In fully adjusted models using a nationally representative sample of US adults, being non-Hispanic black (beta = 3.58), 45 to 64 years of age (beta = -3.48), 65 years of age or older (beta = -2.90), married (beta = -3.50), middle (beta = 2.78) and high income (beta = 3.73), or having hypertension (beta = -2.25), cardiovascular disease (beta = -2.05), arthritis (beta = -4.49), depression (beta = -2.98), physical limitations (beta = -7.60), social limitations (beta = -4.12), and a need for assistance with instrumental activities of daily living (beta = -4.49) were independently correlated with PCS scores. Being 45 to 64 years of age (beta = 3.96), depressed (beta = -15.92), or having social limitations (beta = -3.62) were independently correlated with MCS scores. Conclusions: Sociodemographic, comorbidity, and stroke-related disability factors have differential effect on physical and mental aspects of QOL in poststroke patients.
C1 [Ellis, Charles; Grubaugh, Anouk L.; Egede, Leonard E.] Med Univ S Carolina, Vet Affairs Ctr Dis Prevent & Hlth Intervent Dive, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Ellis, Charles] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
RP Ellis, C (reprint author), Med Univ S Carolina, Coll Hlth Profess, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM ellisc@musc.edu
FU South Carolina HSRD [REA 08-261]; Veterans Health Administration Health
Services Research and Development program [07-012-3, 07-015-2]
FX Supported by the use of facilities at the Charleston, South Carolina
HSR&D-funded Center for Disease Prevention and Health Interventions for
Diverse Populations (REA 08-261). Dr Ellis is supported by a career
development award (CDA # 07-012-3) from the Veterans Health
Administration Health Services Research and Development program. Dr
Grubaugh is supported by a career development award (CDA2 # 07-015-2)
from the Veterans Health Administration Health Services Research and
Development program.
NR 36
TC 11
Z9 13
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY
PY 2013
VL 22
IS 4
BP 309
EP 317
DI 10.1016/j.jstrokecerebrovasdis.2011.09.007
PG 9
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 144BX
UT WOS:000318915500005
PM 22005038
ER
PT J
AU Nadkarni, NK
Studenski, SA
Perera, S
Rosano, C
Aizenstein, HJ
Brach, JS
Van Swearingen, JM
AF Nadkarni, Neelesh K.
Studenski, Stephanie A.
Perera, Subashan
Rosano, Caterina
Aizenstein, Howard J.
Brach, Jennifer S.
Van Swearingen, Jessie M.
TI White Matter Hyperintensities, Exercise, and Improvement in Gait Speed:
Does Type of Gait Rehabilitation Matter?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE gait; rehabilitation; white matter hyperintensities; subcortical
vascular disease; tracts
ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; CARDIOVASCULAR HEALTH;
COGNITIVE FUNCTION; ELDERLY-PEOPLE; BRAIN; ABNORMALITIES; LESIONS; MRI;
DEMENTIA
AB Objectives To examine whether white matter hyperintensities (WMHs) on brain magnetic resonance imaging (MRI) in tracts in older adults with mobility impairment are linked to outcomes of gait rehabilitation interventions. Design Twelve-week randomized controlled single-blind trial. Setting University-based mobility research laboratory. Participants Ambulatory adults aged 65 and older with mobility impairment. Intervention A conventional gait intervention focusing on walking, endurance, balance, and strength (WEBS, n=21) and a task-oriented intervention focused on timing and coordination of gait (TC, n=23). Measurements Self-paced gait speed was measured over an instrumented walkway before and after the intervention, and WMH and brain volumes were quantified on preintervention brain MRI using an automated segmentation process. A white matter tract atlas was overlaid on the segmented images to measure tract WMH volumes, and WMH volumes were normalized to total brain volume. Aggregate WMH volumes in all white matter tracts and individual WMH volumes in specific longitudinal tracts (superior longitudinal fasciculus, inferior longitudinal fasciculus, and fronto-occipital fasciculus) and the cingulum were measured. Results Gait speed gains in the TC group were of the same magnitude, independent of WMH volume measures in all except the cingulum, but in the WEBS group, gain in gait speed was smaller with greater overall tract WMH volumes (P<.001) and with greater WMH volume in the three longitudinal tracts (P<.001 to .02). Conclusion Gains in gait speed with two types of gait rehabilitation are associated with individual differences in WMHs. Task-oriented therapy that targets timing and coordination of gait may particularly benefit older adults with WMHs in brain tracts that influence gait and cognition.
C1 [Nadkarni, Neelesh K.; Studenski, Stephanie A.; Perera, Subashan] Univ Pittsburgh, Dept Med, Div Geriatr Med & Gerontol, Pittsburgh, PA 15213 USA.
[Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Rosano, Caterina] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Aizenstein, Howard J.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Brach, Jennifer S.; Van Swearingen, Jessie M.] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15213 USA.
RP Nadkarni, NK (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med & Gerontol, Suite 500,3471 5th Ave,Kaufman Med Bldg, Pittsburgh, PA 15213 USA.
EM nkn3@pitt.edu
RI Perera, Subashan/D-7603-2014
OI Rosano, Caterina/0000-0002-0909-1506; Rosano,
Caterina/0000-0002-4271-6010
FU Pittsburgh Claude D. Pepper Older American's Independence Center [P30
AG024827]; Ortho Biotech; Lilly; Merck
FX This study was supported by Pittsburgh Claude D. Pepper Older American's
Independence Center Grant P30 AG024827. We appreciate the assistance of
Rebecca L. MacCloud for providing the figure inserts for the brain
tracts.; None of the authors have any financial, personal, or potential
conflict of interest with the material presented in this article.
Subhashan Perera and Stephanie A. Studenski have received past research
grants and funding from Ortho Biotech, Lilly, and Merck.
NR 58
TC 11
Z9 11
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2013
VL 61
IS 5
BP 686
EP 693
DI 10.1111/jgs.12211
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 145GB
UT WOS:000319002100002
PM 23590257
ER
PT J
AU Milfred-LaForest, SK
Chow, SL
DiDomenico, RJ
Dracup, K
Ensor, CR
Gattis-Stough, W
Heywood, JT
Lindenfeld, J
Page, RL
Patterson, JH
Vardeny, O
Massie, BM
AF Milfred-LaForest, Sherry K.
Chow, Sheryl L.
DiDomenico, Robert J.
Dracup, Kathleen
Ensor, Christopher R.
Gattis-Stough, Wendy
Heywood, J. Thomas
Lindenfeld, JoAnn
Page, Robert L., II
Patterson, J. Herbert
Vardeny, Orly
Massie, Barry M.
TI Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the
Heart Failure Society of America and American College of Clinical
Pharmacy Cardiology Practice and Research Network
SO PHARMACOTHERAPY
LA English
DT Article
DE heart failure; clinical pharmacist; multidisciplinary team; heart
transplant
ID UNITED-STATES HOSPITALS; ADVERSE DRUG-REACTIONS; INPATIENT MEDICATION
RECONCILIATION; VENTRICULAR ASSIST DEVICE; PRESCRIBER ORDER ENTRY;
INTENSIVE-CARE-UNIT; TRANSPLANT RECIPIENT; PHARMACEUTICAL CARE;
MANAGEMENT PROGRAM; CARDIOVASCULAR-DISEASE
AB Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a "perfect storm" of factors that predispose patients to medication errors. The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary HF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e. g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause read-missions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable. Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.
C1 [Milfred-LaForest, Sherry K.] Louis Stokes Cleveland VA Med Ctr, Dept Pharm, Cleveland, OH USA.
[Chow, Sheryl L.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
[DiDomenico, Robert J.] Univ Illinois, Coll Pharm, Chicago, IL USA.
[Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Ensor, Christopher R.] Univ Pittsburgh, Coll Pharm, Pittsburgh, PA USA.
[Gattis-Stough, Wendy] Campbell Univ, Coll Pharm & Hlth Sci, Dept Clin Res, Buies Creek, NC 27506 USA.
[Heywood, J. Thomas] Scripps Clin, Dept Med, La Jolla, CA 92037 USA.
[Lindenfeld, JoAnn] Univ Colorado Denver, Heart Transplantat Program, Dept Med, Div Cardiol, Aurora, CO USA.
[Page, Robert L., II] Univ Colorado Denver, Sch Pharm, Dept Med, Div Cardiol, Aurora, CO USA.
[Page, Robert L., II] Univ Colorado Denver, Sch Med, Dept Med, Div Cardiol, Aurora, CO USA.
[Patterson, J. Herbert] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA.
[Vardeny, Orly] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
[Vardeny, Orly] Univ Wisconsin, Sch Med, Madison, WI USA.
[Massie, Barry M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chow, SL (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM schow@westernu.edu; barry.massie@va.gov
OI DiDomenico, Robert/0000-0002-9374-8012
FU Medtronic; Gambro; St. Jude; Zensun; Otsuka; Novartis; Amgen
FX Robert J. DiDomenico is a consultant for F. Hoffman LaRoche. J. Thomas
Heywood has received speaking honoraria from Actelion, Medtronic, St
Jude, and Thoratec; is a consultant for Actelion, Medtronic, and
Thoratec; and has received research grants from Medtronic and Gambro and
fellowship support from St. Jude. JoAnn Lindenfeld is a consultant for
St Jude, Boston Scientific, and Abbott and has received a research grant
from Zensun. J. Herbert Patterson has received speaking honoraria from
Otsuka, is a consultant for Otsuka and Novartis, and has received
research grants from Otsuka, Novartis, and Amgen. All of the other
authors report no potential conflict of interest.
NR 135
TC 11
Z9 11
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD MAY
PY 2013
VL 33
IS 5
BP 529
EP 548
DI 10.1002/phar.1295
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137MB
UT WOS:000318438900115
PM 23649813
ER
PT J
AU Kapur, VK
Wilsdon, AG
Au, D
Avdalovic, M
Enright, P
Fan, VS
Hansel, NN
Heckbert, SR
Jiang, R
Krishnan, JA
Mukamal, K
Yende, S
Barr, RG
AF Kapur, Vishesh K.
Wilsdon, Anthony G.
Au, David
Avdalovic, Mark
Enright, Paul
Fan, Vincent S.
Hansel, Nadia N.
Heckbert, Susan R.
Jiang, Rui
Krishnan, Jerry A.
Mukamal, Kenneth
Yende, Sachin
Barr, R. Graham
TI Obesity Is Associated With a Lower Resting Oxygen Saturation in the
Ambulatory Elderly: Results From the Cardiovascular Health Study
SO RESPIRATORY CARE
LA English
DT Article
DE pulse oximetry; oxygen; obesity; body mass index; waist circumference;
hypoxemia; pulmonary function test
ID OLDER-ADULTS
AB BACKGROUND: The contribution of obesity to hypoxemia has not been reported in a community-based study. Our hypothesis was that increasing obesity would be independently associated with lower S-pO2 in an ambulatory elderly population. METHODS: The Cardiovascular Health Study ascertained resting S-pO2 in 2,252 subjects over age 64. We used multiple linear regression to estimate the association of body mass index (BMI) with S-pO2 and to adjust for potentially confounding factors. Covariates including age, sex, race, smoking, airway obstruction (based on spirometry), self reported diagnosis of emphysema, asthma, heart failure, and left ventricular function (by echocardiography) were evaluated. RESULTS: Among 2,252 subjects the mean and median S-pO2 were 97.6% and 98.0% respectively; 5% of subjects had S-pO2 values below 95%. BMI was negatively correlated with S-pO2 (Spearman R = -0.27, P < .001). The mean difference in S-pO2 between the lowest and highest BMI categories (< 25 kg/m(2) and >= 35 kg/m(2)) was 1.33% (95% CI 0.89-1.78%). In multivariable linear regression analysis, S-pO2 was significantly inversely associated with BMI (1.4% per 10 units of BMI, 95% CI 1.2-1.6, for whites/others, and 0.87% per 10 units of BMI, 95% CI 0.47-1.27, for African Americans). CONCLUSIONS: We found a narrow distribution of S-pO2 values in a community-based sample of ambulatory elderly. Obesity was a strong independent contributor to a low S-pO2 with effects comparable to or greater than other factors clinically associated with lower S-pO2.
C1 [Kapur, Vishesh K.; Au, David; Fan, Vincent S.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Wilsdon, Anthony G.] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98104 USA.
[Au, David; Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA.
[Avdalovic, Mark] Univ Calif Davis, Sch Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA.
[Enright, Paul] Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA.
[Hansel, Nadia N.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
[Jiang, Rui; Barr, R. Graham] Columbia Univ, Med Ctr, Dept Epidemiol, Dept Med, New York, NY USA.
[Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
[Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA.
RP Kapur, VK (reprint author), Univ Washington, Div Pulm & Crit Care Med, Box 359803,325 9th Ave, Seattle, WA 98104 USA.
RI Kapur, Vishesh/K-1054-2014
OI Kapur, Vishesh/0000-0002-5417-1097
FU National Institutes of Health [N01-HC-85239, N01-HC-85079, N01-HC-85080,
N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085,
N01-HC-85086, N01-HC-35129, N01 HC-15103, N01-HC-55222, N01-HC-75150,
N01-HC-45133]; National Heart, Lung, and Blood Institute [HL080295];
National Institute of Neurological Disorders and Stroke; National
Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058]
FX This research was partly supported by National Institutes of Health
grants N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129,
N01 HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, National Heart,
Lung, and Blood Institute grant HL080295, the National Institute of
Neurological Disorders and Stroke, and National Institute on Aging
grants AG-023629, AG-15928, AG-20098, and AG-027058. The Cardiovascular
Health Study principal investigators and institutions are listed at
http://www.chs-nhlbi.org/pi.htm.
NR 14
TC 3
Z9 3
U1 0
U2 3
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD MAY
PY 2013
VL 58
IS 5
BP 831
EP 837
DI 10.4187/respcare.02008
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 141UA
UT WOS:000318750800014
PM 23107018
ER
PT J
AU Frei, CR
Juday, TR
Jones, X
Labreche, MJ
Koeller, JM
Hebden, T
Seekins, DW
Oramasionwu, CU
Bollinger, M
Copeland, LA
Teshome, B
Mortensen, EM
AF Frei, C. R.
Juday, T. R.
Jones, X.
Labreche, M. J.
Koeller, J. M.
Hebden, T.
Seekins, D. W.
Oramasionwu, C. U.
Bollinger, M.
Copeland, L. A.
Teshome, B.
Mortensen, E. M.
TI COMPARATIVE VALUE OF FOUR MEASURES OF RETENTION IN EXPERT CARE IN
PREDICTING CLINICAL OUTCOMES AND HEALTH CARE UTILIZATION IN HIV PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Frei, C. R.; Koeller, J. M.; Teshome, B.] Univ Texas Austin, San Antonio, TX USA.
[Frei, C. R.; Koeller, J. M.; Teshome, B.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Juday, T. R.; Hebden, T.; Seekins, D. W.] Bristol Myers Squibb Co, Plainsboro, NJ USA.
[Jones, X.; Bollinger, M.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT Res Program, San Antonio, TX USA.
[Labreche, M. J.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Oramasionwu, C. U.] Univ N Carolina, Chapel Hill, NC USA.
[Copeland, L. A.] Scott & White Healthcare, Ctr Appl Hlth Res, Cent Texas Vet Hlth Care Syst, Temple, TX USA.
[Mortensen, E. M.] VA North Texas Hlth Care Syst, Dallas, TX 75390 USA.
[Mortensen, E. M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A184
EP A185
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916401455
ER
PT J
AU Sansgiry, S
Naik, AD
Brown, AC
Latini, DM
AF Sansgiry, S.
Naik, A. D.
Brown, A. C.
Latini, D. M.
TI QUALITY OF LIFE AMONG DIABETES PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Sansgiry, S.; Naik, A. D.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Brown, A. C.] Michael E DeBakey VA Med Ctr, VA HSR&D Ctr Excellence, Houston, TX USA.
[Latini, D. M.] San Francisco VA Med Ctr, Baylor Coll Med, Scott Dept Urol, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A196
EP A196
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916401515
ER
PT J
AU Tang, Y
Gellad, WF
Men, A
Donohue, JM
AF Tang, Y.
Gellad, W. F.
Men, A.
Donohue, J. M.
TI REGIONAL VARIATION IN USE OF GENERIC DRUGS AND MEDICARE PRESCRIPTION
DRUG COST SHARING
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Tang, Y.; Gellad, W. F.; Men, A.; Donohue, J. M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gellad, W. F.] RAND, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A248
EP A248
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916402243
ER
PT J
AU Potenza, MN
Brody, AL
AF Potenza, Marc N.
Brody, Arthur L.
TI Commentary on Boileau etal. (2013): Distinguishing D2/D3 dopaminergic
contributions to addictions
SO ADDICTION
LA English
DT Editorial Material
DE [11C]-(+)-PHNO; [11C]-raclopride; addiction; D2; D3 dopamine; gambling;
striatum
ID POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR; PET; IMPULSIVITY; RELEASE; PRE
C1 [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Potenza, Marc N.] Yale Univ, Sch Med, Dept Child Study, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Brody, Arthur L.] Univ Calif Los Angeles, Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA.
[Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90095 USA.
RP Potenza, MN (reprint author), Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
EM abrody@ucla.edu
FU CSRD VA [I01 CX000412]; NIDA NIH HHS [P20 DA027844, R01 DA20872, R01
DA020872]
NR 19
TC 4
Z9 4
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAY
PY 2013
VL 108
IS 5
BP 964
EP 965
DI 10.1111/add.12119
PG 2
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 127IK
UT WOS:000317691600023
PM 23587083
ER
PT J
AU Yan, TJ
Escarce, JJ
Liang, LJ
Longstreth, WT
Merkin, SS
Ovbiagele, B
Vassar, SD
Seeman, T
Sarkisian, C
Brown, AF
AF Yan, Tingjian
Escarce, Jose J.
Liang, Li-Jung
Longstreth, W. T., Jr.
Merkin, Sharon Stein
Ovbiagele, Bruce
Vassar, Stefanie D.
Seeman, Teresa
Sarkisian, Catherine
Brown, Arleen F.
TI Exploring psychosocial pathways between neighbourhood characteristics
and stroke in older adults: the cardiovascular health study
SO AGE AND AGEING
LA English
DT Article
DE neighbourhood; psychosocial factors; stroke; older adults
ID SOCIAL-ISOLATION; ISCHEMIC-STROKE; SOCIOECONOMIC-STATUS; DEPRESSIVE
SYMPTOMS; DISEASE; RISK; POPULATION; OUTCOMES; SUPPORT
AB Objectives: to investigate whether psychosocial pathways mediate the association between neighbourhood socioeconomic disadvantage and stroke.
Methods: prospective cohort study with a follow-up of 11.5 years.
Setting: the Cardiovascular Health Study, a longitudinal population-based cohort study of older adults >= 65 years.
Measurements: the primary outcome was adjudicated incident ischaemic stroke. Neighbourhood socioeconomic status (NSES) was measured using a composite of six census-tract variables. Psychosocial factors were assessed with standard measures for depression, social support and social networks.
Results: of the 3,834 white participants with no prior stroke, 548 had an incident ischaemic stroke over the 11.5-year follow-up. Among whites, the incident stroke hazard ratio (HR) associated with living in the lowest relative to highest NSES quartile was 1.32 (95% CI = 1.01-1.73), in models adjusted for individual SES. Additional adjustment for psychosocial factors had a minimal effect on hazard of incident stroke (HR = 1.31, CI = 1.00-1.71). Associations between NSES and stroke incidence were not found among African-Americans (n = 785) in either partially or fully adjusted models.
Conclusions: psychosocial factors played a minimal role in mediating the effect of NSES on stroke incidence among white older adults.
C1 [Yan, Tingjian] Cedars Sinai Med Ctr, Dept Resource & Outcomes Management, Los Angeles, CA 90048 USA.
[Escarce, Jose J.; Liang, Li-Jung; Brown, Arleen F.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Merkin, Sharon Stein; Seeman, Teresa; Sarkisian, Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Ovbiagele, Bruce] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Sarkisian, Catherine] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Brown, AF (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
EM abrown@mednet.ucla.edu
FU American Heart Association Pharmaceutical Roundtable -Spina Outcomes
Research Center [0875135N, 0875133N, N01-HC-85239, N01-HC-85079,
N01-HC-85086, N01-HC-35129, N01HC-15103, N01 HC-55222, N01-HC-75150,
N01-HC-45133]; National Heart, Lung, and Blood Institute [U01 HL080295];
NIH/National Center for Advancing Clinical and Translational Science
(NCATS)/UCLA Clinical and Translational Science Institute [UL1TR000124]
FX This work was supported by the American Heart Association Pharmaceutical
Roundtable -Spina Outcomes Research Center #0875135N and #0875133N as
well as by contract numbers N01-HC-85239, N01-HC-85079 through
N01-HC-85086, N01-HC-35129, N01HC-15103, N01 HC-55222, N01-HC-75150,
N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung,
and Blood Institute, with additional contribution from the National
Institute of Neurological Disorders and Stroke. A full list of principal
CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm. A.F.B. was also supported by the
NIH/National Center for Advancing Clinical and Translational Science
(NCATS)/UCLA Clinical and Translational Science Institute, grant #
UL1TR000124.
NR 25
TC 3
Z9 3
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
EI 1468-2834
J9 AGE AGEING
JI Age Ageing
PD MAY
PY 2013
VL 42
IS 3
BP 391
EP 397
DI 10.1093/ageing/afs179
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 139AE
UT WOS:000318552800021
PM 23264005
ER
PT J
AU Sonnenberg, A
Boardman, CR
AF Sonnenberg, Amnon
Boardman, Charles R.
TI When Cure Becomes Worse Than the Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID IRRITABLE-BOWEL-SYNDROME; SURGERY
C1 [Sonnenberg, Amnon; Boardman, Charles R.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI ,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2013
VL 108
IS 5
BP 854
EP 855
DI 10.1038/ajg.2013.18
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 141FE
UT WOS:000318710200029
PM 23644967
ER
PT J
AU Evans, ME
Kralovic, SM
Simbartl, LA
Obrosky, DS
Hammond, MC
Goldstein, B
Evans, CT
Roselle, GA
Jain, R
AF Evans, Martin E.
Kralovic, Stephen M.
Simbartl, Loretta A.
Obrosky, D. Scott
Hammond, Margaret C.
Goldstein, Barry
Evans, Charlesnika T.
Roselle, Gary A.
Jain, Rajiv
TI Prevention of methicillin-resistant Staphylococcus aureus infections in
spinal cord injury units
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE MRSA
ID ACUTE REHABILITATION UNIT; COLONIZATION; VETERANS; EPIDEMIOLOGY;
ORGANISMS
AB Background: Methicillin-resistant Staphylococcus aureus (MRSA) health care-associated infections (HAIs) are a concern in the 22 acute care Veterans Affairs (VA) spinal cord injury units where patients with unique rehabilitation and medical needs and a high risk of infection are treated.
Methods: A bundle was implemented in VA spinal cord injury units consisting of nasal surveillance for MRSA on admission/in-hospital transfer/discharge, contact precautions for patients colonized or infected with MRSA, an emphasis on hand hygiene, and an institutional culture change where infection control became everyone's responsibility.
Results: From October 2007, through June 2011, there were 51,627 admissions/transfers/discharges and 816,254 patient-days of care in VA spinal cord injury units. The percentage of patients screened increased to >95.0%. The mean admission MRSA prevalence was 38.6% +/- 19.1%. Monthly HAI rates declined 81% from 1.217 per 1,000 patient-days to 0.237 per 1,000 patient-days (P < .001). Bloodstream infections declined by 100% (P = .002), skin and soft-tissue infections by 60% (P = .007), and urinary tract infections by 33% (P = .07).
Conclusion: Universal surveillance, contact precautions, hand hygiene, and an institutional culture change was associated with significant declines in MRSA HAIs in a setting with a high prevalence of MRSA colonization and a high risk for infection.
C1 [Evans, Martin E.] Vet Hlth Adm, Dept Vet Affairs, MRSA MDRO Program Off, Washington, DC USA.
[Evans, Martin E.; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Vet Hlth Adm, Dept Vet Affairs, Natl Infect Dis Serv, Washington, DC USA.
[Evans, Martin E.; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.; Jain, Rajiv] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Washington, DC USA.
[Evans, Martin E.] Lexington VA Med Ctr, Lexington, KY USA.
[Evans, Martin E.] Univ Kentucky, Coll Med, Lexington, KY USA.
[Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Cincinnati VA Med Ctr, Cincinnati, OH USA.
[Kralovic, Stephen M.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Obrosky, D. Scott] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hammond, Margaret C.; Goldstein, Barry] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Spinal Cord Injury Disorders Serv, Washington, DC USA.
[Hammond, Margaret C.; Goldstein, Barry] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Spinal Cord Injury Disorders Serv, Seattle, WA USA.
[Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Spinal Cord Injury Qual Enhancement Res Initia, Hines, IL 60141 USA.
[Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Evans, ME (reprint author), VHA MDRO Program, 11I-CDD,1101 Vet Dr, Lexington, KY 40502 USA.
EM Martin.Evans@va.gov
FU Department of Veterans Affairs, Office of Research and Development,
Health Services Research and Development Service, Quality Enhancement
Research Initiative [RRP 09-163]
FX The authors thank Meredith Ambrose, MHA, and Kathleen J. Risa, MSN,
CRNP, CIC, for coordinating rollout of the Initiative and collecting
data along with providing MRSA education to all involved with the
Veterans Health Administration MRSA Prevention Initiative; Marta L.
Render, MD, and Ron W. Freyberg, MS, for managing the inpatient
evaluation center; and the clinical staff of the Veterans Affairs spinal
cord injury units, MRSA prevention coordinators, infection
preventionists, infectious diseases specialists, and clinical laboratory
personnel at each facility for their hard work and dedication toward
improving the health care of America's veterans. This study was
supported in part by the Department of Veterans Affairs, Office of
Research and Development, Health Services Research and Development
Service, Quality Enhancement Research Initiative (RRP 09-163).
NR 14
TC 9
Z9 9
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAY
PY 2013
VL 41
IS 5
BP 422
EP 426
DI 10.1016/j.ajic.2012.06.006
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 139UU
UT WOS:000318611200009
PM 23149087
ER
PT J
AU Hoffmire, CA
Piegari, RI
Bossarte, RM
AF Hoffmire, Claire A.
Piegari, Rebecca I.
Bossarte, Robert M.
TI Misclassification of veteran status on Washington state death
certificates for suicides from 1999 to 2008
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE Death certificates; Population surveillance; Public health surveillance;
Suicide; Veterans
ID REPORTING SYSTEM; MORTALITY; RISK
C1 [Hoffmire, Claire A.; Piegari, Rebecca I.; Bossarte, Robert M.] US Dept Vet Affairs, Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA.
RP Hoffmire, CA (reprint author), US Dept Vet Affairs, Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM Claire.Hoffmire@va.gov
NR 9
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD MAY
PY 2013
VL 23
IS 5
BP 298
EP 300
DI 10.1016/j.annepidem.2013.03.007
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 140OL
UT WOS:000318664700012
PM 23621996
ER
PT J
AU Luo, NL
Chung, BH
Wang, XD
Klein, RL
Tang, CK
Garvey, WT
Fu, YC
AF Luo, Nanlan
Chung, B. Hong
Wang, Xiangdong
Klein, Richard L.
Tang, Chao-Ke
Garvey, W. Timothy
Fu, Yuchang
TI Enhanced adiponectin actions by overexpression of adiponectin receptor 1
in macrophages
SO ATHEROSCLEROSIS
LA English
DT Article
DE Adiponectin receptor; Macrophage foam cells; Metabolic syndrome
ID MONOCYTE-DERIVED MACROPHAGES; PIMA INDIAN POPULATION;
INSULIN-RESISTANCE; LIPID-ACCUMULATION; ADIPOSE-TISSUE; CIRCULATING
ADIPONECTIN; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME;
SKELETAL-MUSCLE; PROTEIN ACRP30
AB Objective: Adiponectin is one of several important, metabolically active cytokines secreted from adipose tissue. Epidemiologic studies have associated low circulating levels of this adipokine with multiple metabolic disorders including obesity, insulin resistance, type II diabetes, and cardiovascular disease. To investigate how enhanced adiponectin-mediated changes in metabolism in vivo, we generated transgenic mice which specifically overexpress the gene coding for adiponectin receptor 1 (AdipoR1) in mouse macrophages using the human scavenger receptor A-I gene (SR-AI) enhancer/promoter. We found that macrophage-specific AdipoR1 transgenic mice (AdR1-TG) presented reduced whole body weight, fat accumulation and liver steatosis when these transgenic mice were fed with a high fat diet. Moreover, these macrophage AdR1-TG mice exhibited enhanced whole-body glucose tolerance and insulin sensitivity with reduced proinflammatory cytokines, MCP-1 and TNF-alpha, both in the serum and in the insulin target metabolic tissues. Additional studies demonstrated that these macrophage AdR1-TG animals exhibited reduced macrophage foam cell formation in the arterial wall when these transgenic mice were crossed with a low-density lipoprotein receptor (Ldlr) deficient mouse model.
Conclusions: These results suggest that AdipoR1 overexpressed in macrophages can physiologically modulate metabolic activities in vivo by enhancing adiponectin actions in distal metabolically active tissues. The AdipoR1 modified macrophages provide unique interactions with the residented tissues/cells, suggesting a novel role of macrophage adiponectin receptor in improving metabolic disorders in vivo. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Luo, Nanlan; Chung, B. Hong; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Wang, Xiangdong] Shandong Univ, Inst Cell Biol, Jinan 250012, Peoples R China.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Tang, Chao-Ke] Univ S China, Inst Cardiovasc Res, Hengyang 421001, Peoples R China.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Fu, YC (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Shelby Bldg 1213,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM yfu@uab.edu
FU American Diabetes Association [1-07-RA-49]; UAB Diabetes Research and
Training Center; NIH [DK-083562]
FX We thank Dr. Chris Glass (University of California at San Diego) for
kindly providing the plasmid vector containing the human scavenger
receptor A-I gene (SR-AI) enhancer/promoter. We are grateful to the UAB
Diabetes Research and Training Center for providing outstanding core
services (NIH P30 DK-56336); especially the helpful technical assistance
on en face artery dissections from Ms. Melissa Sammy and Dr. Scott
Ballinger in the core facility. This work was supported by grants from
American Diabetes Association (1-07-RA-49) and the UAB Diabetes Research
and Training Center to YF, and grant from NIH (DK-083562) to TG.
NR 51
TC 15
Z9 15
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2013
VL 228
IS 1
BP 124
EP 135
DI 10.1016/j.atherosclerosis.2013.02.026
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 139FJ
UT WOS:000318567000019
PM 23510830
ER
PT J
AU Sher, L
AF Sher, Leo
TI High and low testosterone levels may be associated with suicidal
behavior in young and older men, respectively
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 5
TC 7
Z9 7
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD MAY
PY 2013
VL 47
IS 5
BP 492
EP 493
DI 10.1177/0004867412463976
PG 2
WC Psychiatry
SC Psychiatry
GA 139GW
UT WOS:000318571000021
PM 23047955
ER
PT J
AU Won, JS
Kim, J
Paintlia, MK
Singh, I
Singh, AK
AF Won, Je-Seong
Kim, Jinsu
Paintlia, Manjeet Kaur
Singh, Inderjit
Singh, Avtar K.
TI Role of endogenous psychosine accumulation in oligodendrocyte
differentiation and survival: Implication for Krabbe disease
SO BRAIN RESEARCH
LA English
DT Article
DE Krabbe disease; Psychosine; Oligodendrocyte; Differentiation;
Peroxisome; Myelin
ID TANDEM MASS-SPECTROMETRY; TWITCHER MOUSE; GALACTOSYLSPHINGOSINE
PSYCHOSINE; PROGENITOR CELLS; GLIAL-CELLS; FATTY-ACIDS; PEROXISOMES;
BRAIN; BIOSYNTHESIS; ACTIVATION
AB Krabbe disease is a lethal, demyelinating condition caused by genetic deficiency of galactocerebrosidase (GALC) and resultant accumulation of its cytotoxic substrate, psychosine (galactosylsphingosine), primarily in oligodendrocytes (OLs). Psychosine is generated by galactosylation of sphingosine by UDP-galactose:ceramide galactosyltransferase (CGT), a galactosylceramide synthesizing enzyme which is primarily expressed in OLs. The expression of CGT and the synthesis of galactosyl-sphingolipids are associated with the terminal differentiation of OL, but little is known about the participation of endogenous psychosine accumulation in OL differentiation under GALC deficient conditions. In this study, we report that accumulation of endogenous psychosine under GALC deficient Krabbe conditions impedes OL differentiation process both by decreasing the expression of myelin lipids and protein and by inducing the cell death. of maturating OLs. The psychosine pathology under GALC deficient conditions involves participation of secretory phospholipase A(2) (sPLA(2)) activation and increase in its metabolites, as evidenced by attenuation of psychosine-induced pathology by treatment with pharmacological inhibitor of sPLA(2) 7,7-dimethyleicosadienoic acid (DEDA). These observations suggest for potential therapeutic efficacy of sPLA(2) inhibitor in Krabbe disease. Published by Elsevier B.V.
C1 [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Kim, Jinsu; Paintlia, Manjeet Kaur; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA.
RP Singh, AK (reprint author), Ralph H Johnson Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC USA.
EM Avtar.Singh@va.gov
FU National Institutes of Health (NIH) [NS064195]; NIH; Veterans
Administration (VA) [NS022576, NS037766, BX001072]
FX This work was supported by a National Institutes of Health (NIH) Grant
(NS064195) and supported, in part, by grants from NIH and Veterans
Administration (VA) Grant (NS022576, NS037766, and BX001072). We also
acknowledge Ms. Joyce Bryan and Ms. Chara Williams for their help in
procurement of animals and supplies.
NR 31
TC 16
Z9 16
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 1
PY 2013
VL 1508
BP 44
EP 52
DI 10.1016/j.brainres.2013.02.024
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 141UE
UT WOS:000318751200005
PM 23438514
ER
PT J
AU Herrin, MA
Feemster, LC
Crothers, K
Uman, JE
Bryson, CL
Au, DH
AF Herrin, Melissa A.
Feemster, Laura Cecere
Crothers, Kristina
Uman, Jane E.
Bryson, Chris L.
Au, David H.
TI Combination Antihypertensive Therapy Among Patients With COPD
SO CHEST
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; CONGESTIVE-HEART-FAILURE; LIPID-LOWERING
TREATMENT; CALCIUM-CHANNEL BLOCKER; ATTACK TRIAL ALLHAT;
RANDOMIZED-TRIAL; BLOOD-PRESSURE; CARDIOVASCULAR MORBIDITY; PHARMACY
RECORDS; BETA-BLOCKERS
AB Background: COPD and hypertension both increase the risk of congestive heart failure (CHF). Current clinical trials do not inform the selection of combination antihypertensive therapy among patients with COPD. We performed a comparative effectiveness study to investigate whether choice of dual agent antihypertensive therapy is associated with risk of hospitalization for CHF among patients with these two conditions.
Methods: We identified a cohort of 7,104 patients with COPD and hypertension receiving care within Veterans Administration hospitals between January 2001 and December 2006, with follow-up through April 2009. We included only patients prescribed two antitypertensive medications. We used Cox proportional hazard models for statistical analysis.
Results: Compared with beta-blockers plus an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, patients prescribed a thiazide diuretic plus a beta-blocker (adjusted hazard ratio [HR], 0.49; 95% CI, 0.32-0.75), a thiazide plus an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (adjusted HR, 0.50; 95% CI, 0.35-0.71), and a thiazide plus a calcium channel blocker (adjusted HR, 0.55; 95% CI, 0.35-0.88) had a significantly lower risk of hospitalization for CHF. After stratification by history of CHF, we found that this association was isolated to patients without a history of CHF. Adjustment for patient characteristics and comorbidities had a small effect on risk of hospitalization. Choice of antihypertensive medication combination had no significant association with risk of COPD exacerbation.
Conclusions: Among patients with comorbid hypertension and COPD requiring two antitypertensive agents, combination therapy that includes a thiazide diuretic was associated with a significantly lower risk of hospitalization for CHF among patients without a history of CHF.
C1 [Herrin, Melissa A.; Feemster, Laura Cecere; Uman, Jane E.; Bryson, Chris L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Feemster, Laura Cecere; Crothers, Kristina; Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA.
[Bryson, Chris L.] Univ Washington, Sch Med, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.
RP Herrin, MA (reprint author), 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA.
EM herrinmelissa@gmail.com
OI Crothers, Kristina/0000-0001-9702-0371
FU Department of Veterans Affairs, Health Services Research and
Development; American Lung Association [CI-51755N]; Veterans Affairs
Health Services Research and Development fellowship [TPM 61-037]; Gilead
FX This material is based on work supported by the Department of Veterans
Affairs, Health Services Research and Development, and American Lung
Association Grant CI-51755N. Dr Feemster is supported by a Veterans
Affairs Health Services Research and Development fellowship (TPM
61-037).; The authors have reported to CHEST the following conflicts of
interest: Drs Bryson and Au are coinvestigators on a grant from Gilead
for work unrelated to this manuscript. Dr Au is a research consultant
for Robert Bosch LLC. Mss Herrin and Uman and Drs Feemster and Crothers
have reported that no potential conflicts of interest exist with any
companies/organizations whose products or services may be discussed in
this article.
NR 33
TC 4
Z9 4
U1 1
U2 3
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
BP 1312
EP 1320
DI 10.1378/chest.12-1770
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 137TS
UT WOS:000318461700022
PM 23287970
ER
PT J
AU Rao, MK
Morris, CD
O'Malley, JP
Davis, MM
Mori, M
Anderson, S
AF Rao, Maya K.
Morris, Cynthia D.
O'Malley, Jean P.
Davis, Melinda M.
Mori, Motomi
Anderson, Sharon
TI Documentation and Management of CKD in Rural Primary Care
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; UNITED-STATES;
BLOOD-PRESSURE; RENAL-DISEASE; NEPHROLOGY CARE; ESTIMATED GFR; HEALTH;
MORTALITY; ACCESS
AB Background and objectives Recognition of CKD by primary care practitioners is essential in rural communities where nephrology access is limited. This study determined the prevalence of undocumented CKD in patients cared for in rural primary care practices and evaluated characteristics associated with undocumented CKD as well as CKD management.
Design, setting, participants, & measurements A retrospective cohort study, conducted within the Oregon Rural Practice Based Research Network, consisted of 865 CKD patients with serum creatinine >= 1.5 mg/dl in males and >= 1.3 mg/dl in females and an estimated GFR<60 ml/min per 1.73 m(2). Documentation of a CKD diagnosis and laboratory values were abstracted by chart review.
Results Of CKD patients, 51.9% had no documentation of CKD. Undocumented CKD occurred more frequently in female patients (adjusted odds ratio=2.93, 95% confidence interval=2.04, 4.21). The association of serum creatinine reporting versus automating reporting of estimated GFR on CKD documentation was dependent on patient sex, years of practitioner experience, and practitioner clinical training. Hypertensive patients with documented CKD were more likely to have a BP medication change than patients with undocumented CKD (odds ratio=2.07, 95% confidence interval=1.15, 3.73). Only 2 of 449 patients with undocumented CKD were comanaged with a nephrologist compared with 20% of patients with documented CKD (odds ratio=53.20, 95% confidence interval=14.90, 189.90).
Conclusions Undocumented CKD in a rural primary care setting is frequent, particularly in female patients. Depending on practitioner characteristics, automatic reporting of estimated GFR might improve documentation of CKD in this population.
C1 [Rao, Maya K.; Anderson, Sharon] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.
[Morris, Cynthia D.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[O'Malley, Jean P.; Mori, Motomi] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA.
[Davis, Melinda M.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
[Davis, Melinda M.] Oregon Hlth & Sci Univ, Oregon Rural Practice Based Res Network, Portland, OR 97201 USA.
[Anderson, Sharon] Portland VA Med Ctr, Dept Med, Portland, OR USA.
RP Rao, MK (reprint author), Columbia Univ, Med Ctr, Div Nephrol, 622 West 168th St,PH 4, New York, NY 10032 USA.
EM mr2971@columbia.edu
FU Medical Research Foundation of Oregon Early Clinical Investigator Grant;
National Kidney Foundation; Oregon Clinical and Translational Research
Institute Grant [1 UL 1 RRO2414001]; National Institutes of Health [T32
DK 067864]
FX This research was supported by a Medical Research Foundation of Oregon
Early Clinical Investigator Grant (to M.K.R), a National Kidney
Foundation Research Fellowship (to M.K.R), Oregon Clinical and
Translational Research Institute Grant 1 UL 1 RRO2414001 (to C.D.M.),
and National Institutes of Health Grant T32 DK 067864 (to S.A.).
NR 36
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 8
IS 5
BP 739
EP 748
DI 10.2215/CJN.02410312
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 138TB
UT WOS:000318531800008
PM 23371962
ER
PT J
AU Dean, JP
Sprenger, CC
Wan, JX
Haugk, K
Ellis, WJ
Lin, DW
Corman, JM
Dalkin, BL
Mostaghel, E
Nelson, PS
Cohen, P
Montgomery, B
Plymate, SR
AF Dean, James P.
Sprenger, Cynthia C.
Wan, Junxiang
Haugk, Kathleen
Ellis, William J.
Lin, Daniel W.
Corman, John M.
Dalkin, Bruce L.
Mostaghel, Elahe
Nelson, Peter S.
Cohen, Pinchas
Montgomery, Bruce
Plymate, Stephen R.
TI Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR
Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer
Trial: Effects of Obesity and Androgen Deprivation
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID FACTOR RECEPTOR ANTIBODY; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE;
PHASE-II; GLUCOSE-HOMEOSTASIS; TARGETED THERAPY; HORMONE-THERAPY;
RESISTANCE; DOCETAXEL; EFFICACY
AB Context: Prostate cancer patients at increased risk for relapse after prostatectomy were treated in a neoadjuvant study with androgen deprivation therapy (ADT) in combination with cixutumumab, an inhibitory fully human monoclonal antibody against IGF receptor 1 (IGF-IR).
Objective: A clinical trial with prospective collection of serum and tissue was designed to test the potential clinical efficacy of neoadjuvant IGF-IR blockade combined with ADT in these patients. The effect of body mass index (BMI) on response of IGF-IR/insulin components to IGF-IR blockade was also examined.
Design: Eligibility for the trial required the presence of high-risk prostate adenocarcinoma. Treatment consisted of bicalutamide, goserelin, and cixutumumab for 13 weeks before prostatectomy. Here we report on an analysis of serum samples from 29 enrolled patients. Changes in IGF and glucose homeostasis pathways were compared to control samples from patients in a concurrent clinical trial of neoadjuvant ADT alone.
Results: Significant increases were seen in GH (P = .001), IGF-I (P < .0001), IGF-II (P = .003), IGF binding protein (IGFBP)-3 (P < .0001), C-peptide (P = .0038), and insulin (P = .05) compared to patients treated with ADT alone. IGFBP-1 levels were significantly lower in the cixutumumab plus ADT cohort (P = .001). No significant changes in blood glucose were evident. Patients with BMIs in the normal range had significantly higher GH (P < .05) and IGFBP-1 (P < 0.5) levels compared to overweight and obese patients.
Conclusions: Patients with IGF-IR blockade in combination with ADT demonstrated significant changes in IGF and glucose homeostasis pathway factors compared to patients receiving ADT alone. In the patients receiving combination therapy, patients with normal BMI had serum levels of glucose homeostasis components similar to individuals in the ADT-alone cohort, whereas patients with overweight and obese BMIs had serum levels that differed from the ADT cohort.
C1 [Dean, James P.; Mostaghel, Elahe; Nelson, Peter S.; Montgomery, Bruce] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.
[Dean, James P.; Sprenger, Cynthia C.; Mostaghel, Elahe; Nelson, Peter S.; Montgomery, Bruce; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Wan, Junxiang; Cohen, Pinchas] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Haugk, Kathleen; Plymate, Stephen R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Ellis, William J.; Lin, Daniel W.; Corman, John M.; Dalkin, Bruce L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Corman, John M.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
RP Plymate, SR (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.
EM splymate@u.washington.edu
FU National Cancer Institute Pacific Northwest Prostate Cancer Specialized
Program of Research Excellence (SPORE) [2 P50 CA 097186-06 Project 4];
Department of Veterans Affairs; Department of Defense Prostate Cancer
Research Program [W81XWH-07-1-0159]; University of California Los
Angeles Prostate Cancer SPORE [P50 CA92131]; [PO1 CA85859]
FX This clinical trial was supported by the National Cancer Institute
Pacific Northwest Prostate Cancer Specialized Program of Research
Excellence (SPORE) (2 P50 CA 097186-06 Project 4), PO1 CA85859, and the
Department of Veterans Affairs (to S.R.P.). Laboratory data analyses
were supported by Department of Defense Prostate Cancer Research Program
(W81XWH-07-1-0159; to J.P.D.), PO1 CA85859 and the Department of
Veterans Affairs (to S.R.P.), and the University of California Los
Angeles Prostate Cancer SPORE (P50 CA92131).
NR 46
TC 10
Z9 10
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2013
VL 98
IS 5
BP E820
EP E828
DI 10.1210/jc.2012-3856
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 140WX
UT WOS:000318688200002
PM 23533230
ER
PT J
AU Carbone, K
AF Carbone, Kathryn
TI Untitled
SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING
LA English
DT Editorial Material
C1 James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Carbone, K (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM Kathryn.Carbone@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0361-929X
J9 MCN-AM J MATERN-CHIL
JI MCN-Am. J. Matern.-Child Nurs.
PD MAY-JUN
PY 2013
VL 38
IS 3
BP 135
EP 135
PG 1
WC Nursing
SC Nursing
GA 140WA
UT WOS:000318685800003
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI Carotid artery calcifications are a risk indicator for both myocardial
infarction and stroke
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Letter
C1 [Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 4
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAY
PY 2013
VL 115
IS 5
BP 700
EP 700
DI 10.1016/j.oooo.2013.02.003
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 139PL
UT WOS:000318595700034
PM 23601227
ER
PT J
AU Elderon, L
Whooley, MA
AF Elderon, Larkin
Whooley, Mary A.
TI Depression and Cardiovascular Disease
SO PROGRESS IN CARDIOVASCULAR DISEASES
LA English
DT Review
DE Cardiovascular disease; Major depressive disorder; Health-related
behaviors; Diagnosis; Treatment
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; RANDOMIZED-CONTROLLED-TRIAL;
QUALITY IMPROVEMENT STRATEGIES; SEROTONIN REUPTAKE INHIBITORS;
PLACEBO-CONTROLLED TRIAL; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY;
INFLAMMATORY MARKERS; MAJOR DEPRESSION
C1 [Elderon, Larkin] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Epidemiol, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Biostat, San Francisco, CA 94121 USA.
[Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Whooley, MA (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM mary.whooley@ucsf.edu
OI Elderon, Larkin/0000-0002-9620-7756
NR 136
TC 42
Z9 43
U1 5
U2 29
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-0620
J9 PROG CARDIOVASC DIS
JI Prog. Cardiovasc. Dis.
PD MAY-JUN
PY 2013
VL 55
IS 6
BP 511
EP 523
DI 10.1016/j.pcad.2013.03.010
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 140OO
UT WOS:000318665000002
PM 23621961
ER
PT J
AU Edmondson, D
Cohen, BE
AF Edmondson, Donald
Cohen, Beth E.
TI Posttraumatic Stress Disorder and Cardiovascular Disease
SO PROGRESS IN CARDIOVASCULAR DISEASES
LA English
DT Review
DE Posttraumatic stress disorder; Cardiovascular disease; Myocardial
infarction; Acute coronary syndrome; Stroke; Psychosocial risk factors
ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN;
MYOCARDIAL-INFARCTION PATIENTS; NATIONAL COMORBIDITY SURVEY;
QUALITY-OF-LIFE; BREAST-CANCER; MENTAL-DISORDERS; SLEEP DISTURBANCES;
HEALTH BEHAVIORS
C1 [Edmondson, Donald] Columbia Univ, Med Ctr, Dept Med, Ctr Behav Cardiovasc Hlth, New York, NY 10032 USA.
[Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Edmondson, D (reprint author), Columbia Univ, Med Ctr, 622W 168th St,PH9-317, New York, NY 10032 USA.
EM dee2109@columbia.edu
RI Edmondson, Donald/G-7486-2016
FU National Institutes of Health, Bethesda, Maryland, United States
[HL-088117, CA-156709]; Columbia University's CTSA from the National
Institutes of Health, Bethesda, Maryland, United States [UL1RR024156];
National Institutes of Health, Bethesda, MD, USA [K23 HL 094765]
FX This work was supported by grants HL-088117 and CA-156709, and in part
by Columbia University's CTSA grant No.UL1RR024156, from the National
Institutes of Health, Bethesda, Maryland, United States. Dr. Cohen was
supported by grant K23 HL 094765 from the National Institutes of Health,
Bethesda, MD, USA. Its contents are solely the responsibility of the
authors and do not necessarily represent the official view of the
National Center for Research Resources or the National Institutes of
Health.
NR 104
TC 33
Z9 33
U1 8
U2 20
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-0620
J9 PROG CARDIOVASC DIS
JI Prog. Cardiovasc. Dis.
PD MAY-JUN
PY 2013
VL 55
IS 6
BP 548
EP 556
DI 10.1016/j.pcad.2013.03.004
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 140OO
UT WOS:000318665000005
PM 23621964
ER
PT J
AU Dong, QX
Wang, DH
Bandyopadhyay, A
Gao, H
Gorena, KM
Hildreth, K
Rebel, VI
Walter, CA
Huang, CJ
Sun, LZ
AF Dong, Qiaoxiang
Wang, Danhan
Bandyopadhyay, Abhik
Gao, Hui
Gorena, Karla M.
Hildreth, Kim
Rebel, Vivienne I.
Walter, Christi A.
Huang, Changjiang
Sun, Lu-Zhe
TI Mammospheres from murine mammary stem cell-enriched basal cells: Clonal
characteristics and repopulating potential
SO STEM CELL RESEARCH
LA English
DT Article
ID NEUROSPHERE ASSAY; NEURAL STEM; GLAND; POPULATION; PROGENITOR
AB Identification of murine mammary stem cells (MaSCs) has been attempted with various in vitro and in vivo assays. While, the in vivo repopulation assay remains as the most definitive assay for MaSC detection, it is expensive, time-consuming, and technically challenging. The in vitro mammosphere assay was considered unreliable because of major concerns about its clonal origin. In the current study, co-culture experiments with mammary cells from fluorescent protein transgenic mice and time-lapse video microscopy revealed that >90% mammospheres formed from sorted basal epithelial-enriched cells were of clonal origin in terms of stem cell. These basal-cell derived mammospheres were further distinguished morphologically in a 3-dimensional extracellular matrix culture and functionally in the in vivo repopulation assay. Transplant of single mammospheres or the resultant 3-dimensional solid structures into gland-free mammary fat pads yielded a 70% success rate of multilineage mammary gland reconstitution. Thus, this in vitro sphere formation and differentiation assay is a reliable alternative to the in vivo repopulation assay for the study of MaSCs. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Dong, Qiaoxiang; Bandyopadhyay, Abhik; Hildreth, Kim; Rebel, Vivienne I.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78299 USA.
[Dong, Qiaoxiang; Wang, Danhan; Gao, Hui; Huang, Changjiang; Sun, Lu-Zhe] Wenzhou Med Coll, Sch Environm Sci & Publ Hlth, Univ Town, Wenzhou, Peoples R China.
[Bandyopadhyay, Abhik; Rebel, Vivienne I.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78299 USA.
[Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78299 USA.
[Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Dong, QX (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78299 USA.
EM dongq2@uthscsa.edu; sunl@uthscsa.edu
RI Huang, Changjiang/F-2644-2010; Dong, Qiaoxiang/F-1918-2010
OI Dong, Qiaoxiang/0000-0003-4003-7919
FU NIH [R01CA75253, R01ES022057]; Bank of America Shelby Rae Tengg
Foundation; Mary Kay Foundation [082-12]; Cancer Therapy and Research
Center at University of Texas Health Science Center at San Antonio
through the NCI Cancer Center [2P30CA054174-17]
FX This work was supported in part by funding from NIH Grants R01CA75253
and R01ES022057, the Bank of America Shelby Rae Tengg Foundation, the
Mary Kay Foundation (#082-12), and the Cancer Therapy and Research
Center at University of Texas Health Science Center at San Antonio
through the NCI Cancer Center Support Grant 2P30CA054174-17 to the flow
cytometry core facility. We thank Dr. John Stingl for his kind
instruction in establishing the in vitro and in vivo assays in our
laboratory. We also thank Dr. Rong Li for the use of the Nikon
BioStation-IM.
NR 17
TC 10
Z9 11
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2013
VL 10
IS 3
BP 396
EP 404
DI 10.1016/j.scr.2013.01.007
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 135ZY
UT WOS:000318330400012
PM 23466563
ER
PT J
AU Peyko, V
Cohen, V
Jellinek-Cohen, SP
Pearl-Davis, M
AF Peyko, Vincent
Cohen, Victor
Jellinek-Cohen, Samantha P.
Pearl-Davis, Michelle
TI Evaluation and treatment of accidental autoinjection of epinephrine
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID ADRENALINE; INJECTION; ISCHEMIA
AB Purpose. A case of accidental autoinjection. of epinephrine is described.
Summary. A 47-year-old man arrived at the emergency department after accidental injection of epinephrine with an autoinjector into his left thumb. His vital signs were stable at admission. The patient was allergic to nuts and thought he may have eaten something containing a pine nut, The patient reported feeling itching in his throat but had no shortness of breath or swollen tongue. He tried to self-administer an epinephrine injection, but it did not inject. While he was checking the device, it accidently injected into his left thumb pad. A review of systems revealed throat discomfort, a tingling sensation of the tongue, and a left-thumb puncture with pain. Physical examination of the left thumb pad revealed a pale, cool thumb with diminished capillary refill and punctuate black discoloration at the site of injection. Topical nitroglycerin paste was applied but had no effect, so terbutaline was ordered. The terbutaline injection was prepared as a 1:1 preparation of terbutaline sulfate 1 mg/mL and 0.9% sodium chloride injection. The immediate effects were the return of color from pale white to red and observable perfusion to the area within seconds. After 20 minutes, the red color remained, with observable perfusion and warmth, in addition to complete neurosensory function. Sixty minutes after terbutaline administration, the patient was discharged home.
Conclusion. A 47-year-old man who accidentally injected himself in the thumb with an epinephrine autoinjector was successfully treated with subcutaneous terbutaline. The treatment had an immediate effect, including revascularization and resolution of pain.
C1 [Peyko, Vincent] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Peyko, Vincent] Maimonides Hosp, Dept Pharmaceut Serv, Brooklyn, NY 11219 USA.
[Cohen, Victor] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA.
[Jellinek-Cohen, Samantha P.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.
[Pearl-Davis, Michelle] Maimonides Hosp, Dept Emergency Med, Brooklyn, NY 11219 USA.
RP Jellinek-Cohen, SP (reprint author), St Johns Univ, Coll Pharm & Hlth Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.
EM jellines@stjohns.edu
NR 15
TC 3
Z9 3
U1 0
U2 3
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2013
VL 70
IS 9
BP 778
EP 781
DI 10.2146/ajhp120316
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137WQ
UT WOS:000318469300010
PM 23592360
ER
PT J
AU Stroupe, KT
Smith, BM
Hogan, TP
St Andre, JR
Gellad, WF
Weiner, S
Lee, TA
Burk, M
Cunningham, F
Piette, JD
Rogers, TJ
Huo, ZP
Weaver, FM
AF Stroupe, Kevin T.
Smith, Bridget M.
Hogan, Timothy P.
St Andre, Justin R.
Gellad, Walid F.
Weiner, Saul
Lee, Todd A.
Burk, Muriel
Cunningham, Francesca
Piette, John D.
Rogers, Thea J.
Huo, Zhiping
Weaver, Frances M.
TI Medication acquisition across systems of care and patient-provider
communication among older veterans
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID HEALTH-CARE; HEART-FAILURE; ADULTS; DISCREPANCIES; HYPERTENSION;
INFORMATION; OUTCOMES; COSTS
AB Purpose. The results of a survey assessing Medicare Part D enrollment, the use of pharmacotherapies for chronic diseases, and other medication-use issues in a population of elderly military veterans are presented.
Methods. Medicare-eligible (i.e., >= 65 years of age) patients with documented recent service use at a single Veterans Affairs (VA) medical center were targeted for a mail survey. Women were oversampled (20%) to ensure an adequate sample size; the sample was weighted to adjust for this oversampling. Usable survey data were received from 458 survey respondents.
Results. Nearly all respondents (93.2%) reported having one or more chronic conditions; of those, 93.3% reported regular use of multiple drug therapies, and 30.1% reported using medications prescribed by both VA and non-VA providers for the same chronic condition. About half of the survey respondents reported at least one office visit with a non-VA physician during the previous year, and 55.8% reported obtaining medications from non-VA pharmacies. More than half (54.1%) of the respondents reported non-VA medication coverage, with 21.2% indicating they were enrolled in Medicare Part D. Among the respondents who reported obtaining medications from non-VA pharmacies, substantial proportions reported discussing those medications with VA physicians never (38.4%) or infrequently (15.7%).
Conclusion. Although large proportions of Medicare-eligible veterans take multiple medications and use non-VA health care services and pharmacies, many do not discuss medications obtained outside the VA system with VA physicians, suggesting that increased efforts to enhance provider patient communication and medication reconciliation across VA and non-VA systems of care may be warranted.
C1 [Stroupe, Kevin T.; Smith, Bridget M.] Edward Hines Jr VA Vet Affairs Hosp, Ctr Management Complex Chron Care CMC3, Hines, IL USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Natl eHlth QUERI Coordinating Ctr, eHlth Qual Enhancement Res Initiat QUERI, Bedford, MA USA.
[St Andre, Justin R.] Hlth Res & Educ Trust, Chicago, IL USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Lee, Todd A.] Univ Illinois, Chicago, IL USA.
[Cunningham, Francesca] Edward Hines Jr VA Hosp, VA Pharm Benefit Management Strateg Healthcare Gr, Hines, IL 60141 USA.
[Piette, John D.] Univ Michigan, Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
RP Stroupe, KT (reprint author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, 5000 South 5th Ave 151H, Hines, IL 60141 USA.
EM kevin.stroupe@va.gov
FU Office of Research and Development, Veterans Health Administration,
Department of Veterans Affairs; Center for Management of Complex Chronic
Care, Edward Hines, Jr. VA Hospital; VA Health Services Research and
Development [PPO 09-396]
FX Supported in part by the Office of Research and Development, Veterans
Health Administration, Department of Veterans Affairs; the Center for
Management of Complex Chronic Care, Edward Hines, Jr. VA Hospital; and
VA Health Services Research and Development grant PPO 09-396.
NR 31
TC 6
Z9 6
U1 0
U2 7
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2013
VL 70
IS 9
BP 804
EP 813
DI 10.2146/ajhp120222
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137WQ
UT WOS:000318469300013
PM 23592363
ER
PT J
AU Glasgow, JM
Yano, EM
Kaboli, PJ
AF Glasgow, Justin M.
Yano, Elizabeth M.
Kaboli, Peter J.
TI Impacts of Organizational Context on Quality Improvement
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE quality improvement; data mining; organizational characteristics;
Veterans Affairs
ID OF-THE-LITERATURE; PATIENT SAFETY; HEALTH-CARE; MODEL; COLLABORATIVES;
HOSPITALS; SUCCESS
AB Variation in how hospitals perform on similar quality improvement (QI) efforts argues for a need to understand how different organizational characteristics affect QI performance. The objective of this study was to use data-mining methods to evaluate relationships between measures of organizational characteristics and hospital QI performance. Organizational characteristics were extracted from 2 surveys and analyzed in 3 separate decision-tree models.The decision trees did not find any predictive associations in this sample of 100 hospitals participating in a national QI collaborative. Further model review identified that measures of QI Experience were associated with an ability to make improvements, whereas measures of Staffing and Culture were associated with an ability to sustain improvements. A key area for future research is to understand the challenges faced as QI teams transition from improving care to sustaining quality and to ascertain what organizational characteristics can best overcome those challenges.
C1 [Glasgow, Justin M.; Kaboli, Peter J.] Iowa City VA Healthcare Syst, Iowa City, IA 52246 USA.
[Glasgow, Justin M.] Univ Iowa, Inst Clin & Translat Sci, Iowa City, IA USA.
[Yano, Elizabeth M.] VA Greater Los Angeles, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Kaboli, Peter J.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
RP Glasgow, JM (reprint author), Iowa City VA Healthcare Syst, 601 Highway 6 West,Mailstop 152, Iowa City, IA 52246 USA.
EM justin.glasgow@va.gov
FU University of Iowa Institute for Clinical and Translational Science
[5TL1 RR024981-03]; Department of Veterans Affairs; Veterans Health
Administration; Health Services Research and Development (HSR&D) Service
through the Comprehensive Access and Delivery Research and Evaluation
(CADRE) Center [HFP 04-149]; Veterans Administration (VA) HSR&D Research
Career Scientist Award [RCS 05-195]; VA HSRD; VA Office of Quality and
Performance
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The work
reported here was supported by a TL1 award from the University of Iowa
Institute for Clinical and Translational Science (5TL1 RR024981-03) and
the Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development (HSR&D) Service through the
Comprehensive Access and Delivery Research and Evaluation (CADRE) Center
(HFP 04-149). Dr Yano's effort was funded by a Veterans Administration
(VA) HSR&D Research Career Scientist Award (RCS 05-195). The VA Clinical
Practice Organizational Survey was cosponsored by VA HSR&D and the VA
Office of Quality and Performance.
NR 29
TC 4
Z9 4
U1 3
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 196
EP 205
DI 10.1177/1062860612456730
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 136QY
UT WOS:000318379700002
PM 22942122
ER
PT J
AU Greenwood, TA
Swerdlow, NR
Gur, RE
Cadenhead, KS
Calkins, ME
Dobie, DJ
Freedman, R
Green, MF
Gur, RC
Lazzeroni, LC
Nuechterlein, KH
Olincy, A
Radant, AD
Ray, A
Schork, NJ
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, CA
Tsuang, DW
Tsuang, MT
Turetsky, BI
Light, GA
Braff, DL
AF Greenwood, Tiffany A.
Swerdlow, Neal R.
Gur, Raquel E.
Cadenhead, Kristin S.
Calkins, Monica E.
Dobie, Dorcas J.
Freedman, Robert
Green, Michael F.
Gur, Ruben C.
Lazzeroni, Laura C.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Ray, Amrita
Schork, Nicholas J.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine A.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Light, Gregory A.
Braff, David L.
TI Genome-Wide Linkage Analyses of 12 Endophenotypes for Schizophrenia From
the Consortium on the Genetics of Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID SUSCEPTIBILITY LOCUS; PREPULSE INHIBITION; CANDIDATE GENES;
WORKING-MEMORY; FOLLOW-UP; ANTISACCADE PERFORMANCE; CHROMOSOME-15 LOCUS;
POTENTIAL LINKAGE; COMPLEX DISEASES; ASSOCIATION
AB Objective: The Consortium on the Genetics of Schizophrenia has undertaken a large multisite study to characterize 12 neurophysiological and neurocognitive endophenotypic measures as a step toward understanding the complex genetic basis of schizophrenia. The authors previously demonstrated the heritability of these endophenotypes; in the present study, genetic linkage was evaluated.
Method: Each family consisted of a proband with schizophrenia, at least one unaffected sibling, and both parents. A total of 1,286 participants from 296 families were genotyped in two phases, and 1,004 individuals were also assessed for the endophenotypes. Linkage analyses of the 6,055 single-nucleotide polymorphisms that were successfully assayed, 5,760 of which were common to both phases, were conducted using both variance components and pedigree-wide regression methods.
Results: Linkage analyses of the 12 endophenotypes collectively identified one region meeting genome-wide significance criteria, with a LOD (log of odds) score of 4.0 on chromosome 3p14 for the antisaccade task, and another region on 1p36 nearly meeting genome-wide significance, with a LOD score of 3.5. for emotion recognition. Chromosomal regions meeting genome-wide suggestive criteria with LOD scores >2.2 were identified for spatial processing (2p25 and 16q23), sensorimotor dexterity (2q24 and 2q32), prepulse inhibition (5p15), the California Verbal. Learning Test (8q24), the degraded-stimulus Continuous Performance Test (10q26), face memory (10q26 and 12p12), and the Letter-Number Span (14q23).
Conclusions: Twelve regions meeting genome-wide significant and suggestive criteria for previously identified heritable, schizophrenia-related endophenotypes were observed, and several genes of potential neurobiological interest were identified. Replication and further genomic Studies are needed to assess the biological significance of these results. (Am J Psychiatry 2013; 170:521-532)
C1 [Greenwood, Tiffany A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
Scripps Translat Sci Inst, La Jolla, CA USA.
Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA.
Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
James J Peters VA Med Ctr, New York, NY USA.
Univ Calif Los Angeles, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90024 USA.
Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA.
VA San Diego Healthcare Syst, VISN 22, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Greenwood, TA (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
EM tgreenwood@ucsd.edu; dbraff@ucsd.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920
FU Brain Plasticity; Genentech; Janssen Scientific Affairs; Lundbeck
Pharmaceuticals; AstraZeneca; Pfizer; Bristol-Myers Squibb; Hoffman-La
Roche; NIMH [R01-MH-065588, R01-MH-065562, R01-MH-065707, R01-MH-065554,
R01-MH-065578, R01-MH-065558, R01-MH-86135, K01-MH-087889]; NIH
[HNSN268200782096C]
FX Dr. Swerdlow has served as a consultant to Neurocrine. Dr. Green has
served as a consultant to Abbott Laboratories, Amgen, Biogen, Mnemosyne,
Roche, and Shire. Dr. Nuechterlein has received research grant support
from Brain Plasticity, Genentech, and Janssen Scientific Affairs and has
served as a consultant to Genentech and Otsuka. Dr. Olincy has received
research grant support from Lundbeck Pharmaceuticals. Dr. Turetsky has
received research grant support from AstraZeneca and Pfizer and
consulting fees from Bristol-Myers Squibb and Hoffman-La Roche. Dr.
Light has participated in a scientific advisory board meeting for
Astellas. All other authors report no financial relationships with
commercial interests.; Supported by NIMH grants R01-MH-065588,
R01-MH-065562, R01-MH-065707, R01-MH-065554, R01-MH-065578,
R01-MH-065558, R01-MH-86135, and K01-MH-087889. Genotyping services were
provided by the Center for Inherited Disease Research (CIDR). CIDR is
fully funded through a federal contract from NIH to Johns Hopkins
University (contract number HNSN268200782096C).
NR 93
TC 54
Z9 56
U1 3
U2 24
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2013
VL 170
IS 5
BP 521
EP 532
DI 10.1176/appi.ajp.2012.12020186
PG 12
WC Psychiatry
SC Psychiatry
GA 135XO
UT WOS:000318324200013
PM 23511790
ER
PT J
AU Gros, DF
Milanak, ME
Brady, KT
Back, SE
AF Gros, Daniel F.
Milanak, Melissa E.
Brady, Kathleen T.
Back, Sudie E.
TI Frequency and Severity of Comorbid Mood and Anxiety Disorders in
Prescription Opioid Dependence
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID SUBSTANCE USE DISORDERS; PTSD; ABUSERS; INDEX
AB Background and Objectives: Comorbid substance use disorders and mood and anxiety disorders are associated with more severe psychiatric symptoms, social and occupational impairment, and economic burden. To date, the majority of research has focused on comorbidity in illicit drug users, rather than prescription drug users. To address this gap in the literature, the present cross-sectional study investigated the clinical profiles of individuals with prescription opioid dependence with or without comorbid mood and anxiety disorders.
Methods: Ninety individuals with prescription opioid use were recruited to participate in the study procedures. All participants completed a structured clinical interview and series of self-report measures.
Results and Conclusions: Of the 85 individuals with prescription opioid dependence, 47.1% (n = 40) were diagnosed with a comorbid mood or anxiety disorder. The findings showed that individuals with prescription opioid dependence and comorbid mood and anxiety disorders demonstrated significantly more severe alcohol use, psychiatric symptoms, and sleep impairment than individuals without comorbidity.
Scientific Significance: The findings highlight the frequency and severity of co-occurring mood and anxiety disorders in individuals with prescription opioid dependence and suggest that integrated interventions are needed to address these growing problems.
C1 [Gros, Daniel F.; Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Gros, Daniel F.; Milanak, Melissa E.; Brady, Kathleen T.; Back, Sudie E.] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU NIDA NIH HHS [K23 DA021228, K24 DA00435]
NR 22
TC 8
Z9 8
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 261
EP 265
DI 10.1111/j.1521-0391.2012.12008.x
PG 5
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200013
PM 23617869
ER
PT J
AU Chakravorty, S
Grandner, MA
Kranzler, HR
Mavandadi, S
Kling, MA
Perlis, ML
Oslin, DW
AF Chakravorty, Subhajit
Grandner, Michael A.
Kranzler, Henry R.
Mavandadi, Shahrzad
Kling, Mitchel A.
Perlis, Michael L.
Oslin, David W.
TI Insomnia in Alcohol Dependence: Predictors of Symptoms in a Sample of
Veterans Referred from Primary Care
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID NATIONAL EPIDEMIOLOGIC SURVEY; DRUG-USE DISORDERS; SLEEP DISTURBANCES;
SUICIDAL IDEATION; UNITED-STATES; DSM-IV; COOCCURRENCE; COMORBIDITY;
POPULATION; PREVALENCE
AB Objective: Patients with alcohol dependence presenting for treatment may have multiple associated co-morbid conditions and limited social supports, which complicate treatment. Each of these factors has been independently associated with complaints of insomnia. In this preliminary study, we investigated the relations between insomnia complaints and socio-demographic factors and psychiatric comorbidity in treatment-seeking patients with alcohol dependence.
Method: We conducted a retrospective chart review on 84 consecutive patients referred to the Behavioral Health Laboratory of the Philadelphia Veterans Affairs Medical Center for evaluation of psychiatric and substance use disorders. Patients met DSM-IV diagnostic criteria for alcohol dependence and completed a series of self-assessments of sleep. Univariate and multivariable analyses were used to examine the relations amongst the variables of interest.
Results: In multivariable models, Sleep Latency was significantly greater in individuals without partners (p = .01), those with psychiatric disorders (p = .03) and smokers (p = .01), with a nonsignificant trend for those with past-year suicidal ideation. No significant predictor of Wake Time After Sleep Onset was seen. Poor Sleep Quality was predicted by younger age (OR = .93 [.88, .98], p = .004) and the presence of a psychiatric disorder (OR = 20.80 [4, 102], p = .0002), with a non-significant trend for suicidal ideation.
Conclusions: Insomnia symptoms in treatment-seeking alcohol dependent patients should prompt consideration of the individuals' psychiatric and psychosocial features.
C1 [Chakravorty, Subhajit; Kranzler, Henry R.; Mavandadi, Shahrzad; Kling, Mitchel A.; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, MIRECC VISN 4, Philadelphia, PA 19104 USA.
[Chakravorty, Subhajit; Grandner, Michael A.; Kranzler, Henry R.; Mavandadi, Shahrzad; Kling, Mitchel A.; Perlis, Michael L.; Oslin, David W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Chakravorty, S (reprint author), Philadelphia Vet Affairs Med Ctr, MIRECC, 2nd Floor,Postal Code 116,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM subhajit.chakravorty@uphs.upenn.edu
OI Kling, Mitchel/0000-0002-2232-1409
FU NHLBI NIH HHS [T32 HL007713, 5T32HL007713, K23 HL110216]; NIEHS NIH HHS
[R21 ES022931]
NR 31
TC 8
Z9 8
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 266
EP 270
DI 10.1111/j.1521-0391.2012.12009.x
PG 5
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200014
PM 23617870
ER
PT J
AU Harrington, AT
Clarridge, JE
AF Harrington, Amanda T.
Clarridge, Jill E., III
TI Impact of identification of Streptococcus dysgalactiae subspecies
equisimilis from throat cultures in an adult population
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Pharyngitis; Streptococcus dysgalactiae subspecies equisimilis; Throat
culture
ID BETA-HEMOLYTIC STREPTOCOCCI; GROUP-C STREPTOCOCCI; LANCEFIELD GROUP-C;
ACUTE RHEUMATIC-FEVER; ACUTE PHARYNGITIS; GROUP-A; OUTBREAK;
GLOMERULONEPHRITIS; INFECTION; ANGINOSUS
AB Streptococcus dysgalactiae subspecies equisimilis (SDSE) are isolated from the throat of patients with pharyngitis, although the clinical significance remains debated. We sought to determine the incidence and association with pharyngitis of SDSE in an adult veteran population. Organisms were phenotypically identified to subspecies and Lancefield group, with selective 16S rRNA gene sequencing. From 833 throat cultures, the overall frequency of SDSE was 3.4% (64% group C and 36% group G) as compared to 8.6% for S. pyogenes (GAS). SDSE was described as a large colony in only 29% of the original culture evaluations by bench technologists, and clinical symptoms were similar for GAS and SDSE. Laboratory algorithms that are limited to identification of only GAS or are based on Lancefield group or visual identification of "large-colony type" beta hemolytic Lancefield group C and G streptococci may be missing or misidentifying SDSE along with Anginosus group streptococci. Published by Elsevier Inc.
C1 [Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Seattle, WA 98108 USA.
RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
EM jill.clarridge@va.gov
NR 29
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD MAY
PY 2013
VL 76
IS 1
BP 20
EP 23
DI 10.1016/j.diagmicrobio.2013.02.029
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 135YF
UT WOS:000318325900005
PM 23537788
ER
PT J
AU Camus, M
Jensen, DM
Ohning, GV
Kovacs, TO
Ghassemi, KA
Jutabha, R
Machicado, GA
Dulai, GS
Hines, OJ
AF Camus, M.
Jensen, D. M.
Ohning, G. V.
Kovacs, T. O.
Ghassemi, K. A.
Jutabha, R.
Machicado, G. A.
Dulai, G. S.
Hines, O. J.
TI Severe upper gastrointestinal hemorrhage from linear gastric ulcers in
large hiatal hernias: a large prospective case series of Cameron ulcers
SO ENDOSCOPY
LA English
DT Editorial Material
ID DIAGNOSIS; ANEMIA
AB We report a case series of all consecutive patients hospitalized in our two tertiary referral medical centers over the past 17 years for Cameron ulcers causing severe upper gastrointestinal hemorrhage (GIH) or severe obscure GIH. Cameron ulcers were diagnosed in 25 of the 3960 screened patients with severe upper GIH or severe obscure GIH (0.6%). Of these, 21 patients had a prospective follow-up (median time 20.4 months [interquartile range: 8.5-31.8]). Patients were more often elderly women with chronic anemia, always had large hiatal hernias, and were usually referred for obscure GIH. Twelve of the 21 patients (57%) were referred for surgery while being treated with high-dose proton pump inhibitors (PPIs). The other 9 patients (43 %) continued PPIs without any rebleeding during the follow-up. Cameron ulcers in large hiatal hernias are an uncommon cause of severe upper GIH. The choice of medical vs. surgical therapy should be individualized.
C1 [Camus, M.; Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Ghassemi, K. A.; Jutabha, R.; Machicado, G. A.; Dulai, G. S.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Hemostasis Res Grp, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Ghassemi, K. A.; Jutabha, R.; Machicado, G. A.; Dulai, G. S.] Univ Calif Los Angeles, Ronald Reagan Med Ctr, Div Digest Dis, Los Angeles, CA USA.
[Camus, M.] Univ Paris 07, Dept Gastroenterol, Lariboisiere Hosp, APHP, F-75221 Paris 05, France.
[Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Machicado, G. A.; Dulai, G. S.] Vet Affairs Greater Los Angeles Healthcare, Div Digest Dis, Los Angeles, CA USA.
[Hines, O. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Camus, M (reprint author), Lariboisiere Hosp, APHP, Dept Gastroenterol, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM marine.camus@gmail.com
FU NIDDK NIH HHS [P30 DK041301]
NR 9
TC 2
Z9 3
U1 0
U2 5
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
J9 ENDOSCOPY
JI Endoscopy
PD MAY
PY 2013
VL 45
IS 5
BP 397
EP 400
DI 10.1055/s-0032-1326294
PG 4
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 131VY
UT WOS:000318026600010
PM 23616128
ER
PT J
AU Saha, S
Korthuis, PT
Cohn, JA
Sharp, VL
Moore, RD
Beach, MC
AF Saha, Somnath
Korthuis, P. Todd
Cohn, Jonathan A.
Sharp, Victoria L.
Moore, Richard D.
Beach, Mary Catherine
TI Primary Care Provider Cultural Competence and Racial Disparities in HIV
Care and Outcomes
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE culture; ethnic groups; HIV
ID PATIENT-PHYSICIAN RELATIONSHIP; ACTIVE ANTIRETROVIRAL THERAPY;
SELF-REPORTED ADHERENCE; HEALTH-CARE; UNITED-STATES; MEDICATION
ADHERENCE; INFECTED ADULTS; QUALITY; COMMUNICATION; MORTALITY
AB Health professional organizations have advocated for increasing the "cultural competence" (CC) of healthcare providers, to reduce racial and ethnic disparities in patient care. It is unclear whether provider CC is associated with more equitable care.
To evaluate whether provider CC is associated with quality of care and outcomes for patients with HIV/AIDS.
Survey of 45 providers and 437 patients at four urban HIV clinics in the U.S.
Providers' self-rated CC was measured using a novel, 20-item instrument. Outcome measures included patients' receipt of antiretroviral (ARV) therapy, self-efficacy in managing medication regimens, complete 3-day ARV adherence, and viral suppression.
Providers' mean age was 44 years; 56 % were women, and 64 % were white. Patients' mean age was 45; 67 % were men, and 77 % were nonwhite. Minority patients whose providers scored in the middle or highest third on self-rated CC were more likely than those with providers in the lowest third to be on ARVs, have high self-efficacy, and report complete ARV adherence. Racial disparities were observed in receipt of ARVs (adjusted OR, 95 % CI for white vs. nonwhite: 6.21, 1.50-25.7), self-efficacy (3.77, 1.24-11.4), and viral suppression (13.0, 3.43-49.0) among patients of low CC providers, but not among patients of moderate and high CC providers (receipt of ARVs: 0.71, 0.32-1.61; self-efficacy: 1.14, 0.59-2.22; viral suppression: 1.20, 0.60-2.42).
Provider CC was associated with the quality and equity of HIV care. These findings suggest that enhancing provider CC may reduce racial disparities in healthcare quality and outcomes.
C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
[Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA.
[Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sahas@ohsu.edu
FU Health Resources and Services Administration; Agency for Healthcare
Research and Quality [AHRQ 290-01-0012, K08 HS013903-05]; Department of
Veterans Affairs; Generalist Physician Faculty Scholar awards from the
Robert Wood Johnson Foundation; National Institute on Drug Abuse [K23
DA019809]
FX This research was supported by a contract from the Health Resources and
Services Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). Representatives of both funding agencies
were involved in the design of the study, but not in its conduct; in
collection, management, analysis, or interpretation of the data; or in
preparation, review, or approval of the manuscript. Drs. Saha, Moore,
and Beach had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the
data analysis. Dr. Saha was supported by the Department of Veterans
Affairs. Dr. Beach was supported by the Agency for Healthcare Research
and Quality (K08 HS013903-05), and both Drs. Saha and Beach were
supported by Generalist Physician Faculty Scholar awards from the Robert
Wood Johnson Foundation. Dr. Korthuis was supported by the National
Institute on Drug Abuse (K23 DA019809). The views expressed in this
article are those of the authors, and no official endorsement by the
Agency for Healthcare Research and Quality, the Department of Veterans
Affairs, or the U.S. Department of Health and Human Services is intended
or should be inferred.
NR 53
TC 18
Z9 18
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 622
EP 629
DI 10.1007/s11606-012-2298-8
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900008
PM 23307396
ER
PT J
AU Marshall, R
Beach, MC
Saha, S
Mori, T
Loveless, MO
Hibbard, JH
Cohn, JA
Sharp, VL
Korthuis, PT
AF Marshall, Rebecca
Beach, Mary Catherine
Saha, Somnath
Mori, Tomi
Loveless, Mark O.
Hibbard, Judith H.
Cohn, Jonathan A.
Sharp, Victoria L.
Korthuis, P. Todd
TI Patient Activation and Improved Outcomes in HIV-Infected Patients
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient activation; HIV; self-efficacy; medication adherence; patient
outcomes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY ADHERENCE;
SELF-MANAGEMENT; MEDICATION ADHERENCE; REPORTED ADHERENCE; CHRONIC
DISEASE; UNITED-STATES; MEASURE PAM; VIRAL LOAD; HEALTH
AB The Patient Activation Measure (PAM) assesses several important concepts in chronic care management, including self-efficacy for positive health behaviors. In HIV-infected populations, better self-efficacy for medication management is associated with improved adherence to antiretroviral medications (ARVs), which is critically important for controlling symptoms and slowing disease progression.
To determine 1) characteristics associated with patient activation and 2) associations between patient activation and outcomes in HIV-infected patients.
Cross-sectional survey.
433 patients receiving care in four HIV clinics.
An interviewer conducted face-to-face interviews with patients following their HIV clinic visit. Survey data were supplemented with medical record abstraction to obtain most recent CD4 counts, HIV viral load and antiretroviral medications.
Patient activation was measured using the 13-item PAM (possible range 0-100). Outcomes included CD4 cell count > 200 cells/mL(3), HIV-1 RNA < 400 copies/mL (viral suppression), and patient-reported adherence.
Overall, patient activation was high (mean PAM = 72.3 [SD 16.5, range 34.7-100]). Activation was lower among those without vs. with a high school degree (68.0 vs. 74.0, p < .001), and greater depression (77.6 lowest, 70.2 middle, 68.1 highest tertile, p < .001). There was no association between patient activation and age, race, gender, problematic alcohol use, illicit drug use, or social status. In multivariable models, every 5-point increase in PAM was associated with greater odds of CD4 count > 200 cells/mL(3) (aOR 1.10 [95 % CI 1.01, 1.21]), adherence (aOR 1.18 [95 % CI 1.09, 1.29]) and viral suppression (aOR 1.08 [95 % CI 1.00, 1.17]). The association between PAM and viral suppression was mediated through adherence.
Higher patient activation was associated with more favorable HIV outcomes. Interventions to improve patient activation should be developed and tested for their ability to improve HIV outcomes.
C1 [Marshall, Rebecca] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
[Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA.
[Saha, Somnath; Mori, Tomi; Loveless, Mark O.; Hibbard, Judith H.; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Hibbard, Judith H.] Univ Oregon, Dept Planning Publ Policy & Management, Eugene, OR 97403 USA.
[Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA.
RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA.
EM korthuis@ohsu.edu
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institutes of
Health, National Institute on Drug Abuse [K23DA019809]; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards; Department of
Veterans Affairs
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). Dr. Korthuis' time was supported by the
National Institutes of Health, National Institute on Drug Abuse
(K23DA019809). Dr. Beach was supported by the Agency for Healthcare
Research and Quality (K08 HS013903-05), and both Dr. Beach and Dr. Saha
were supported by Robert Wood Johnson Generalist Physician Faculty
Scholars Awards. Dr. Saha is supported by the Department of Veterans
Affairs. The contents of the publication are solely the responsibility
of the authors and do not necessarily represent the views of the funding
agencies or the U.S. government.
NR 41
TC 26
Z9 27
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 668
EP 674
DI 10.1007/s11606-012-2307-y
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900014
PM 23288378
ER
PT J
AU Bryson, CL
Au, DH
Maciejewski, ML
Piette, JD
Fihn, SD
Jackson, GL
Perkins, M
Wong, ES
Yano, EM
Liu, CF
AF Bryson, Chris L.
Au, David H.
Maciejewski, Matthew L.
Piette, John D.
Fihn, Stephan D.
Jackson, George L.
Perkins, Mark
Wong, Edwin S.
Yano, Elizabeth M.
Liu, Chuan-Fen
TI Wide Clinic-Level Variation in Adherence to Oral Diabetes Medications in
the VA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE pharmacoepidemiology; health services research; diabetes; veterans;
primary care
ID MYOCARDIAL-INFARCTION; SELF-CARE; MANAGEMENT; IMPROVEMENT
AB While there has been extensive research into patient-specific predictors of medication adherence and patient-specific interventions to improve adherence, there has been little examination of variation in clinic-level medication adherence.
We examined the clinic-level variation of oral hypoglycemic agent (OHA) medication adherence among patients with diabetes treated in the Department of Veterans Affairs (VA) primary care clinics. We hypothesized that there would be systematic variation in clinic-level adherence measures, and that adherence within organizationally-affiliated clinics, such as those sharing local management and support, would be more highly correlated than adherence between unaffiliated clinics.
Retrospective cohort study.
VA hospital and VA community-based primary care clinics in the contiguous 48 states.
444,418 patients with diabetes treated with OHAs and seen in 158 hospital-based clinics and 401 affiliated community primary care clinics during fiscal years 2006 and 2007.
Refill-based medication adherence to OHA.
Adjusting for patient characteristics, the proportion of patients adherent to OHAs ranged from 57 % to 81 % across clinics. Adherence between organizationally affiliated clinics was high (Pearson Correlation = 0.82), and adherence between unaffiliated clinics was low (Pearson Correlation = 0.04).
The proportion of patients adherent to OHAs varied widely across VA primary care clinics. Clinic-level adherence was highly correlated to other clinics in the same organizational unit. Further research should identify which factors common to affiliated clinics influence medication adherence.
C1 [Bryson, Chris L.; Au, David H.; Perkins, Mark; Wong, Edwin S.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA.
[Bryson, Chris L.; Au, David H.; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA.
[Maciejewski, Matthew L.; Jackson, George L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.; Jackson, George L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
[Piette, John D.] VA Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Piette, John D.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Fihn, Stephan D.] Univ Washington, Dept Vet Affairs, Off Analyt & Business Intelligence, Seattle, WA 98195 USA.
[Wong, Edwin S.; Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Yano, Elizabeth M.] Los Angeles VA, Ctr Study Healthcare Provider Behav, Los Angeles, VA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
[Bryson, Chris L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
RP Bryson, CL (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Christopher.Bryson@va.gov
FU Department of Veterans Affairs, Health Services Research and Development
[IIR 07-068-2]; VA Career Development Award [03-177]; VA Health Services
Research and Development Postdoctoral Fellowship [TPP 61-024]; Bosch
Inc.; Gilead Sciences; Takeda Pharmaceuticals; Novartis; Surgical Review
Corporation
FX This research was supported by an Investigator Initiated Research Award
(IIR 07-068-2) from the Department of Veterans Affairs, Health Services
Research and Development. Dr. Bryson was supported by VA Career
Development Award 03-177. Dr. Jackson was supported for a portion of
this project by a VA Career Development Award. Dr. Piette is a VA Senior
Research Career Scientist; Dr. Maciejewski and Dr. Yano are VA Research
Career Scientists. Dr. Wong was supported by VA Health Services Research
and Development Postdoctoral Fellowship TPP 61-024. An earlier version
of this manuscript was presented as a poster at the Society of General
Internal Medicine 32nd Annual Meeting in Miami, FL in 2009. Dr. Bryson
takes responsibility for the integrity of the data and the accuracy of
the data analysis. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs.; All authors are federal employees for
the Department of Veterans Affairs. Dr. Au has received consultation
funds from Bosch Inc. and a grant from Gilead Sciences. Dr. Maciejewski
has received consultation funds from Takeda Pharmaceuticals, Novartis
and the Surgical Review Corporation. Dr. Maciejewski also owns stock in
Amgen.
NR 27
TC 5
Z9 5
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 698
EP 705
DI 10.1007/s11606-012-2331-y
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900018
PM 23371383
ER
PT J
AU Jubelt, LE
AF Jubelt, Lindsay E.
TI Capsule Commentary on Melzer et.al., Missing Potential Opportunities to
Reduce Repeat COPD Exacerbations
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Jubelt, Lindsay E.] Univ Penn, Perelman Sch Med, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
[Jubelt, Lindsay E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Jubelt, Lindsay E.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Jubelt, LE (reprint author), Univ Penn, Perelman Sch Med, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
EM ljubelt@upenn.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 708
EP 708
DI 10.1007/s11606-012-2299-7
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900021
PM 23288376
ER
PT J
AU Bryan, T
Snyder, E
AF Bryan, Teresa
Snyder, Erin
TI The Clinical Breast Exam: A Skill that Should Not Be Abandoned
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE clinical breast exam; women's health; medical education; simulation
ID SIGNIFICANT NUMBER; SCREENING-PROGRAM; NORMAL MAMMOGRAM; WOMEN PRESENT;
CANCER EVEN; PERFORMANCE; SYMPTOMS; PATIENT; TRIAL
AB The clinical breast exam (CBE) is an important tool in the care of women. However, the utility of the screening CBE has been called into question. This article discusses the importance of the CBE as a physical diagnosis tool. Recommendations regarding screening with CBE are reviewed, and evidence surrounding breast cancer screening using CBE is briefly summarized. Clinicians should strive to provide high quality CBEs as part of the general clinical exam for women, particularly those who present with breast complaints, and for patients who choose to have CBE screening. In conclusion, there is a role for the CBE in the care of women, and clinicians should be proficient at performing these exams. Simulation teaching technologies are now available at Department of Veteran Affairs (VA) facilities to enable clinicians to improve their CBE skills.
C1 [Bryan, Teresa; Snyder, Erin] Univ Alabama Birmingham, Med Sch Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Bryan, T (reprint author), Univ Alabama Birmingham, Med Sch Birmingham, Birmingham Vet Affairs Med Ctr, FOT 720 1720 2nd Ave South, Birmingham, AL 35294 USA.
EM Teresa.bryan@va.gov
NR 28
TC 8
Z9 8
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 719
EP 722
DI 10.1007/s11606-013-2373-9
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900025
PM 23435772
ER
PT J
AU Huetsch, JC
Uman, JE
Udris, EM
Au, DH
AF Huetsch, John C.
Uman, Jane E.
Udris, Edmunds M.
Au, David H.
TI Predictors of Adherence to Inhaled Medications among Veterans with COPD
(vol 27, pg 1506, 2012)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Correction
C1 [Huetsch, John C.; Uman, Jane E.; Udris, Edmunds M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Huetsch, John C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Huetsch, JC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 743
EP 747
DI 10.1007/s11606-013-2377-5
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900032
ER
PT J
AU Kara, A
McQuillan, P
Dhaliwal, G
AF Kara, Areeba
McQuillan, Patrick
Dhaliwal, Gurpreet
TI A multifaceted case
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID POSTSURGICAL GOUT; HYPERURICEMIA; RISK; PRESENTATIONS; POPULATION;
PREVALENCE; MANAGEMENT; HEALTH; US
C1 [Kara, Areeba; McQuillan, Patrick] Indiana Univ Hlth Phys, Dept Inpatient Med, Indianapolis, IN 46202 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Kara, A (reprint author), Indiana Univ Hlth Phys, Dept Inpatient Med, 1633 N Capitol Ave, Indianapolis, IN 46202 USA.
EM akara@iuhealth.org
NR 22
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY
PY 2013
VL 8
IS 5
BP 267
EP 270
DI 10.1002/jhm.2043
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 139ZS
UT WOS:000318624400007
PM 23606357
ER
PT J
AU Davidson, CL
Wingate, LR
AF Davidson, Collin L.
Wingate, LaRicka R.
TI The glass half-full or a hopeful outlook: Which explains more variance
in interpersonal suicide risk in a psychotherapy clinic sample?
SO JOURNAL OF POSITIVE PSYCHOLOGY
LA English
DT Article
DE positive psychology; optimism; hope; suicide; interpersonal
psychological theory
ID COPING SELF-EFFICACY; DISPOSITIONAL OPTIMISM; DEPRESSIVE SYMPTOMS;
SOCIAL SUPPORT; PSYCHOLOGICAL ADJUSTMENT; POSTPARTUM DEPRESSION;
INDIVIDUAL-DIFFERENCES; COLLEGE-STUDENTS; BREAST-CANCER; TRAIT ANXIETY
AB Recent research has suggested that constructs in the field of positive psychology may be important for understanding suicide risk. Specifically, both hope theory and dispositional optimism have been linked to lower levels of suicidal ideation and interpersonal suicide risk. Despite these encouraging findings, no study has investigated the relationships between hope, optimism, and suicide risk in a clinical sample. The current study aimed to address this gap and to determine if hope or optimism was more important for understanding suicide risk as operationalized by the interpersonal-psychological theory and suicidal ideation. Results of hierarchical regression analyses revealed that both hope and optimism predicted lower levels of burdensomeness and thwarted belongingness, but were not significant predictors of suicidal ideation. Further, results revealed that when both hope and optimism were entered into a hierarchical regression in the final step, only optimism remained significant. Theoretical and clinical implications of these findings are discussed.
C1 [Davidson, Collin L.] Denver VA Med Ctr, Denver, CO 80220 USA.
[Wingate, LaRicka R.] Oklahoma State Univ, Stillwater, OK 74078 USA.
RP Davidson, CL (reprint author), Denver VA Med Ctr, AVA VISN 19 MIRECC,1055 Clermont St, Denver, CO 80220 USA.
EM collin.davidson@okstate.edu
NR 63
TC 4
Z9 4
U1 0
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1743-9760
J9 J POSIT PSYCHOL
JI J. Posit. Psychol.
PD MAY 1
PY 2013
VL 8
IS 3
BP 263
EP 272
DI 10.1080/17439760.2013.787446
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA 135MA
UT WOS:000318291000008
ER
PT J
AU Roshanravan, B
Robinson-Cohen, C
Patel, KV
Ayers, E
Littman, AJ
de Boer, IH
Ikizler, TA
Himmelfarb, J
Katzel, LI
Kestenbaum, B
Seliger, S
AF Roshanravan, Baback
Robinson-Cohen, Cassianne
Patel, Kushang V.
Ayers, Ernest
Littman, Alyson J.
de Boer, Ian H.
Ikizler, T. Alp
Himmelfarb, Jonathan
Katzel, Leslie I.
Kestenbaum, Bryan
Seliger, Stephen
TI Association between Physical Performance and All-Cause Mortality in CKD
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; FUNCTIONING OLDER-ADULTS; CHRONIC-RENAL-FAILURE;
INSULIN-RESISTANCE; BODY-COMPOSITION; CYSTATIN-C; CARDIOVASCULAR HEALTH;
HEMODIALYSIS-PATIENTS; COGNITIVE IMPAIRMENT; ENERGY-METABOLISM
AB In older adults, measurements of physical performance assess physical function and associate with mortality and disability. Muscle wasting and diminished physical performance often accompany CKD, resembling physiologic aging, but whether physical performance associates with clinical outcome in CKD is unknown. We evaluated 385 ambulatory, stroke-free participants with stage 2-4 CKD enrolled in clinic-based cohorts at the University of Washington and University of Maryland and Veterans Affairs Maryland Healthcare systems. We compared handgrip strength, usual gait speed, timed up and go (TUAG), and 6-minute walking distance with normative values and constructed Cox proportional hazards models and receiver operating characteristic curves to test associations with all-cause mortality. Mean age was 61 years and the mean estimated GFR was 41 ml/min per 1.73 m(2). Measures of lower extremity performance were at least 30% lower than predicted, but handgrip strength was relatively preserved. Fifty deaths occurred during the median 3-year follow-up period. After adjustment, each 0.1-m/s decrement in gait speed associated with a 26% higher risk for death, and each 1-second longer TUAG associated with an 8% higher risk for death. On the basis of the receiver operating characteristic analysis, gait speed and TUAG more strongly predicted 3-year mortality than kidney function or commonly measured serum biomarkers. Adding gait speed to a model that included estimated GFR significantly improved the prediction of 3-year mortality. In summary, impaired physical performance of the lower extremities is common in CKD and strongly associates with all-cause mortality. J Am Soc Nephrol 24: 822-830, 2013. doi: 10.1681/ASN.2012070702
C1 [Roshanravan, Baback; Ayers, Ernest; de Boer, Ian H.; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Dept Med, Kidney Res Inst, Div Nephrol, Seattle, WA 98104 USA.
[Robinson-Cohen, Cassianne; Littman, Alyson J.] Univ Washington, Dept Epidemiol, Kidney Res Inst, Seattle, WA 98104 USA.
[Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA.
[Littman, Alyson J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN USA.
[Katzel, Leslie I.] Univ Maryland, Sch Med, Div Geriatr, Baltimore, MD 21201 USA.
[Seliger, Stephen] Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA.
RP Roshanravan, B (reprint author), Univ Washington, Dept Med, Kidney Res Inst, Div Nephrol, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM broshanr@u.washington.edu
OI Robinson-Cohen, Cassianne/0000-0003-4783-7046
FU National Institutes of Health [R01-HL070938, K23-DK063079]; Kidney
Research Institute; National Institute of Diabetes and Digestive and
Kidney Diseases [T32-DK007467-28, F32-K093235]; National Institute on
Aging Claude D. Pepper Older Americans Independence Center
[P30-AG028747]; Department of Veterans Affairs; Baltimore VAMC Geriatric
Research Education and Clinical Center; Northwest Kidney Center
Foundation; VA Rehabilitation Research and Development Career
Development Award [6982]; VA Puget Sound Health Care System, Seattle,
Washington; VA Maryland Healthcare System, Baltimore, Maryland
FX This work was supported by grants from the National Institutes of Health
(R01-HL070938 to J.H. and B.K. and K23-DK063079 to S.S.), the Kidney
Research Institute, the National Institute of Diabetes and Digestive and
Kidney Diseases (T32-DK007467-28 and F32-K093235 to B.R.), the VA
Rehabilitation R&D Merit Review (to S.S. and L.K.), the National
Institute on Aging Claude D. Pepper Older Americans Independence Center
(P30-AG028747), the Department of Veterans Affairs, and the Baltimore
VAMC Geriatric Research Education and Clinical Center, as well as an
unrestricted grant from the Northwest Kidney Center Foundation. A.J.L.
was supported by a VA Rehabilitation Research and Development Career
Development Award (#6982). This study is the result of work supported by
resources from the VA Puget Sound Health Care System, Seattle,
Washington, and the VA Maryland Healthcare System, Baltimore, Maryland.
NR 41
TC 58
Z9 60
U1 4
U2 12
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 24
IS 5
BP 822
EP 830
DI 10.1681/ASN.2012070702
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 134JZ
UT WOS:000318207800016
PM 23599380
ER
PT J
AU Thames, AD
Hinkin, CH
Byrd, DA
Bilder, RM
Duff, KJ
Mindt, MR
Arentoft, A
Streiff, V
AF Thames, April D.
Hinkin, Charles H.
Byrd, Desiree A.
Bilder, Robert M.
Duff, Kimberley J.
Mindt, Monica Rivera
Arentoft, Alyssa
Streiff, Vanessa
TI Effects of Stereotype Threat, Perceived Discrimination, and Examiner
Race on Neuropsychological Performance: Simple as Black and White?
SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
LA English
DT Article
DE Stereotype threat; Performance anxiety; Neuropsychology; Perceived
discrimination; Examiner-examinee racial discordance; Ethnicity
ID WOMENS MATH PERFORMANCE; PICTURE-VOCABULARY TEST; AFRICAN-AMERICAN;
RACIAL-DISCRIMINATION; TESTS; GAP; INTERVIEWER; PREVALENCE; MECHANISMS;
EDUCATION
AB The purpose of the current study was to examine the predictive roles of stereotype threat and perceived discrimination and the mediating role of examiner-examinee racial discordance on neuropsychological performance in a non-clinical sample of African American and Caucasian individuals. Ninety-two African American (n = 45) and Caucasian (n = 47) adults were randomly assigned to either a stereotype threat or non-threat condition. Within each condition, participants were randomly assigned to either a same race or different race examiner. All participants underwent neuropsychological testing and completed a measure of perceived discrimination. African Americans in the stereotype threat condition performed significantly worse on global NP (Mz = .30, 95% confidence interval [CI] [-0.07, -0.67] than African Americans in the non-threat condition (Mz = 0.09, CI [0.15, 0.33]. African Americans who reported high levels of perceived discrimination performed significantly worse on memory tests when tested by an examiner of a different race, Mz = -1.19, 95% CI [-1.78, -.54], than African Americans who were tested by an examiner of the same race, Mz = 0.24, 95% CI [-0.24, 0.72]. The current study underscores the importance of considering the role of contextual variables in neuropsychological performance, as these variables may obscure the validity of results among certain racial/ethnic groups.
C1 [Thames, April D.; Hinkin, Charles H.; Bilder, Robert M.; Arentoft, Alyssa] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Hinkin, Charles H.; Arentoft, Alyssa; Streiff, Vanessa] Greater Los Angeles VA Healthcare Syst, Dept Psychol, Los Angeles, CA USA.
[Byrd, Desiree A.; Mindt, Monica Rivera] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA.
[Duff, Kimberley J.] Cerritos Coll, Dept Psychol, Norwalk, CA USA.
[Mindt, Monica Rivera] Fordham Univ, Dept Psychol, New York, NY 10023 USA.
RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza C8-746, Los Angeles, CA 90095 USA.
EM athames@mednet.ucla.edu
RI Thames, April/K-1964-2014; Bilder, Robert/A-8894-2008
OI Thames, April/0000-0001-8414-7189; Bilder, Robert/0000-0001-5085-7852;
Arentoft, Alyssa/0000-0002-4235-4638
FU National Academy of Neuropsychology
FX We acknowledge the following funding source: National Academy of
Neuropsychology (PI: A. Thames). We also thank Ms. Myra Irani, Fredrica
Hendrix, and Natalie Arbid for their assistance with data collection.
The authors report no conflicts of interest.
NR 60
TC 10
Z9 10
U1 1
U2 28
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1355-6177
J9 J INT NEUROPSYCH SOC
JI J. Int. Neuropsychol. Soc.
PD MAY
PY 2013
VL 19
IS 5
BP 583
EP 593
DI 10.1017/S1355617713000076
PG 11
WC Clinical Neurology; Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 136OB
UT WOS:000318370100010
PM 23388089
ER
PT J
AU Kuna, ST
Reboussin, DM
Borradaile, KE
Sanders, MH
Millman, RP
Zammit, G
Newman, AB
Wadden, TA
Jakicic, JM
Wing, RR
Pi-Sunyer, FX
Foster, GD
AF Kuna, Samuel T.
Reboussin, David M.
Borradaile, Kelley E.
Sanders, Mark H.
Millman, Richard P.
Zammit, Gary
Newman, Anne B.
Wadden, Thomas A.
Jakicic, John M.
Wing, Rena R.
Pi-Sunyer, F. Xavier
Foster, Gary D.
CA Look AHEAD Res Grp
TI Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in
Obese Patients with Type 2 Diabetes
SO SLEEP
LA English
DT Article
DE Apnea-hypopnea index; polysomnogram
ID RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; POSITIVE AIRWAY
PRESSURE; LOW ENERGY DIET; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE;
HEART HEALTH; RISK-FACTORS; FOLLOW-UP; EXERCISE
AB Study Objectives: To examine whether the initial benefit of weight loss on obstructive sleep apnea (OSA) severity at 1 year is maintained at 4 years.
Design: Randomized controlled trial with follow-up at 1, 2, and 4 years.
Setting: 4 Look AHEAD clinical centers.
Participants: Two hundred sixty-four obese adults with type 2 diabetes and OSA.
Interventions: Intensive lifestyle intervention with a behavioral weight loss program or diabetes support and education.
Measurements: Change in apnea-hypopnea index on polysomnogram.
Results: The intensive lifestyle intervention group's mean weight loss was 10.7 +/- 0.7 (standard error), 7.4 +/- 0.7, and 5.2 +/- 0.7 kg at 1, 2, and 4 years respectively, compared to a less than 1-kg weight loss for the control group at each time (P < 0.001). Apnea-hypopnea index difference between groups was 9.7 +/- 2.0, 8.0 +/- 2.0, and 7.7 +/- 2.3 events/h at 1, 2 and 4 years respectively (P < 0.001). Change in apnea-hypopnea index over time was related to the amount of weight loss (P < 0.0001) and intervention, independent of weight loss (P = 0.001). Remission of OSA at 4 years was 5 times more common with intensive lifestyle intervention (20.7%) than diabetes support and education (3.6%).
Conclusions: Among obese adults with type 2 diabetes and OSA, intensive lifestyle intervention produced greater reductions in weight and apnea-hypopnea index over a 4 year period than did diabetes support and education. Beneficial effects of intensive lifestyle intervention on apnea-hypopnea index at 1 year persisted at 4 years, despite an almost 50% weight regain. Effect of intensive lifestyle intervention on apnea-hypopnea index was largely, but not entirely, due to weight loss.
C1 [Kuna, Samuel T.; Wadden, Thomas A.] Univ Penn, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Borradaile, Kelley E.; Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA.
[Sanders, Mark H.; Newman, Anne B.; Jakicic, John M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Millman, Richard P.; Wing, Rena R.] Brown Univ, Providence, RI 02912 USA.
[Zammit, Gary] Clinilabs, New York, NY USA.
[Pi-Sunyer, F. Xavier] Columbia Univ, New York, NY USA.
RP Kuna, ST (reprint author), Philadelphia VA Med Ctr 111P, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM skuna@mail.med.upenn.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institutes of Health NHLBI [HL070301]; National Institutes of
Health NIDDK [DK60426, DK56992, DK057135]; NIH; CDC; USDA; Robert Wood
Johnson Foundation; Nutrisystem American Beverage Association;
Novo-Nordisk; JennyCraig; Philips Respironics; Abbott; Actelion; Ancile;
Apnex; Arena; Aventis; Cephalon Inc; CHDI; Elan; Epic; Evotec; Forest;
Galderma; Glaxo Smith Kline; H. Lundbeck A/S; King; Merck and Co.;
National Institute of Health (NIH); Neurim; Neurocrine Biosciences;
Neurogen; Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics;
Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor; Shire;
Somaxon; Takeda Pharmaceuticals North America; Targacept; Thymon;
Transcept; UCB Pharma; Vanda; Wyeth-Ayerst Research; NutriSystem
FX This study was supported by the National Institutes of Health NHLBI
grant HL070301 and NIDDK grants DK60426, DK56992, and DK057135; This was
not an industry supported study. Dr. Foster serves on the Scientific
Advisory Board of Con Agra Foods, Nutrisystem, Tate, Lyle and United
Health Group. He has received grants from NIH, CDC, USDA, Robert Wood
Johnson Foundation, Nutrisystem American Beverage Association and
Novo-Nordisk. Dr. Jakicic is a member of Free & Clear Scientific
Advisory Board, has grants or grants pending from BodyMedia, Inc., and
receives payment for lectures by JennyCraig. Dr. Kuna receives grant
support from Philips Respironics. Dr. Sanders is Editor-in-Chief and
Editor for UpToDate (R); Field Editor for Sleep Medicine and Deputy
Editor for the journal SLEEP. He serves as a consultant to Philips
Respironics. Dr. Zammit is a consultant for Actelion, Alexza, Arena,
Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly,
Evotec, Forest, Glaxo Smith Kline, Jazz Pharmaceuticals, King
Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon,
Pfizer, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire,
Somnus, Takeda Pharmaceuticals, Vela, and Wyeth-Ayerst Research. He also
provides expert testimony for Acorda and has received grants or has
grants pending from Abbott, Actelion, Ancile, Apnex, Arena, Aventis,
Cephalon Inc, CHDI, Elan, Epic, Evotec, Forest, Galderma, Glaxo Smith
Kline, H. Lundbeck A/S, King, Merck and Co., National Institute of
Health (NIH), Neurim, Neurocrine Biosciences, Neurogen, Organon, Orphan
Medical, Otsuka, Pfizer, Predix, Respironics, Sanofi-Aventis,
Sanofi-Synthelabo, Schering-Plough, Sepracor, Shire, Somaxon, Takeda
Pharmaceuticals North America, Targacept, Thymon, Transcept, UCB Pharma,
Predix, Vanda, and Wyeth-Ayerst Research. Dr. Zammit has received
payment for lectures from Neurocrine Biosciences, King Pharmaceuticals,
McNeil, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda
Pharmaceuticals, Vela Pharmaceuticals, and Wyeth-Ayerst Research. Dr.
Wadden has received grant support from NutriSystem and serves on the
advisory boards of Novo Nordisk, Orexigen and Vivus. Dr. Millman has
served as a consultant for Johnson and Johnson Business Development. The
other authors have indicated no financial conflicts of interest.
NR 41
TC 52
Z9 55
U1 1
U2 11
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD MAY 1
PY 2013
VL 36
IS 5
BP 641
EP 649
DI 10.5665/sleep.2618
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 137AL
UT WOS:000318406600006
PM 23633746
ER
PT J
AU Estrella, MM
Abraham, AG
Jing, YZ
Parekh, RS
Tien, PC
Merenstein, D
Pearce, CL
Anastos, K
Cohen, MH
Dehovitz, JA
Gange, SJ
AF Estrella, Michelle M.
Abraham, Alison G.
Jing, Yuezhou
Parekh, Rulan S.
Tien, Phyllis C.
Merenstein, Dan
Pearce, Celeste Leigh
Anastos, Kathryn
Cohen, Mardge H.
Dehovitz, Jack A.
Gange, Stephen J.
TI Antiretroviral-Treated HIV-Infected Women Have Similar Long-Term Kidney
Function Trajectories as HIV-Uninfected Women
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; INTERAGENCY HIV;
RENAL-FUNCTION; TENOFOVIR; THERAPY; NEPHROPATHY; DISEASE; SAFETY; COHORT
AB Natural history studies suggest increased risk for kidney function decline with HIV infection, but few studies have made comparisons with HIV-uninfected women. We examined whether HIV infection treated with highly active antiretroviral therapy (HAART) remains associated with faster kidney function decline in the Women's Interagency HIV Study. HIV-infected women initiating HAART with (n = 105) or without (n = 373) tenofovir (TDF) were matched to HIV-uninfected women on calendar and length of follow-up, age, systolic blood pressure, hepatitis C antibody serostatus, and diabetes history. Linear mixed models were used to evaluate differences in annual estimated glomerular filtration rate (eGFR). Person-visits were 4,741 and 11,512 for the TDF-treated and non-TDF-treated analyses, respectively. Mean baseline eGFRs were higher among women initiated on TDF-containing HAART and lower among those on TDF-sparing HAART compared to their respective HIV-uninfected matches (p < 0.05 for both). HIV-infected women had annual rates of eGFR changes similar to HIV-uninfected matches (p-interaction >0.05 for both). Adjusting for baseline eGFR, mean eGFRs at 1 and 3 years of follow-up among women initiated on TDF-containing HAART were lower than their uninfected matches (-4.98 and -4.26ml/min/1.73 m(2), respectively; p < 0.05 for both). Mean eGFR of women initiated on TDF-sparing HAART was lower versus uninfected matches at 5 years (-2.19ml/min/1.73 m(2), p = 0.03). HAART-treated HIV-infected women had lower mean eGFRs at follow-up but experienced rates of annual eGFR decline similar to HIV-uninfected women. Tenofovir use in HIV-infected women with normal kidney function did not accelerate long-term kidney function decline relative to HIV-uninfected women.
C1 [Estrella, Michelle M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Abraham, Alison G.; Jing, Yuezhou; Parekh, Rulan S.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Parekh, Rulan S.] Univ Toronto, Div Nephrol, Toronto, ON, Canada.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Merenstein, Dan] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA.
[Pearce, Celeste Leigh] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Anastos, Kathryn] Stroger Hosp, Montefiore Med Ctr, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Dehovitz, Jack A.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
RP Estrella, MM (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, 1830 East Monument St,Suite 416, Baltimore, MD 21205 USA.
EM mestrel1@jhmi.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development [UO1-HD-32632]; National Cancer Institute; National
Institute on Drug Abuse; National Institute on Deafness and Other
Communication Disorders; National Center for Research Resources
(UCSF-CTSI grant) [UL1 RR024131]; NIH-NIDDK grant [K23DK081317]
FX Data in this article were collected by the Women's Interagency HIV Study
(WIHS) Collaborative Study Group with centers (Principal Investigators)
at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY
(Howard Minkoff); Washington, DC, Metropolitan Consortium (Mary Young);
The Connie Wofsy Study Consortium of Northern California (Ruth
Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data
Coordinating Center (Stephen Gange). The WIHS is funded by the National
Institute of Allergy and Infectious Diseases (UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and
UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (UO1-HD-32632). The study is cofunded
by the National Cancer Institute, the National Institute on Drug Abuse,
and the National Institute on Deafness and Other Communication
Disorders. Funding is also provided by the National Center for Research
Resources (UCSF-CTSI grant UL1 RR024131). The contents of this
publication are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health. M.M.E. is supported by NIH-NIDDK grant K23DK081317.
NR 20
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 755
EP 760
DI 10.1089/aid.2012.0248
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200003
PM 23273313
ER
PT J
AU Thilen, SR
Bryson, CL
Reid, RJ
Wijeysundera, DN
Weaver, EM
Treggiari, MM
AF Thilen, Stephan R.
Bryson, Christopher L.
Reid, Robert J.
Wijeysundera, Duminda N.
Weaver, Edward M.
Treggiari, Miriam M.
TI Patterns of Preoperative Consultation and Surgical Specialty in an
Integrated Healthcare System
SO ANESTHESIOLOGY
LA English
DT Article
ID MAJOR NONCARDIAC SURGERY; MEDICAL CONSULTATION; PERIOPERATIVE MEDICINE;
MANAGED CARE; INTERNISTS; INDEX; WASTE; COST
AB Background: Many patients scheduled for elective surgery are referred for a preoperative medical consultation. Only limited data are available on factors associated with preoperative consultations. The authors hypothesized that surgical specialty contributes to variation in referrals for preoperative consultations.
Methods: This is a cohort study using data from Group Health Cooperative, an integrated healthcare system. The authors included 13,673 patients undergoing a variety of common procedures-primarily low-risk surgeries-representing six surgical specialties, in 2005-2006. The authors identified consultations by family physicians, general internists, pulmonologists, or cardiologists in the 42 days preceding surgery. Multivariable logistic regression was used to estimate the association between surgical specialty and consultation, adjusting for potential confounders including the revised cardiac risk index, age, gender, Deyo comorbidity index, number of prescription medications, and 11 medication classes.
Results: The authors found that 3,063 (22%) of all patients had preoperative consultations, with significant variation by surgical specialty. Patients having ophthalmologic, orthopedic, or urologic surgery were more likely to have consultations compared with those having general surgery-adjusted odds ratios (95% CI) of 3.8 (3.3-4.2), 1.5 (1.3-1.7), and 2.3 (1.8-2.8), respectively. Preoperative consultations were more common in patients with lower revised cardiac risk scores.
Conclusion: There is substantial practice variation among surgical specialties with regard to the use of preoperative consultations in this integrated healthcare system. Given the large number of consultations provided for patients with low cardiac risk and for patients presenting for low-risk surgeries, their indications, the financial burden, and cost-effectiveness of consultations deserve further study.
C1 [Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Reid, Robert J.] Grp Hlth Res Inst, Seattle, WA USA.
[Thilen, Stephan R.; Treggiari, Miriam M.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
RP Thilen, SR (reprint author), 325 9th Ave,Box 359724, Seattle, WA 98104 USA.
EM sthilen@uw.edu
OI Wijeysundera, Duminda/0000-0002-5897-8605
FU National Institutes of Health, Bethesda, Maryland [T32GM086270]; U.S.
Department of Veterans Affairs, Office of Research and Development,
Health Services Research and Development Center of Excellence; VA Puget
Sound Health Care Systems, Seattle, Washington; Canadian Institutes of
Health Research (Ottawa, Ontario, Canada); Department of Anesthesia at
the University of Toronto, Toronto, Ontario, Canada; Group Health
Research Institute, Seattle, Washington
FX Supported by grant T32GM086270, National Institutes of Health, Bethesda,
Maryland (to Dr. Thilen). This material is based on work supported by
the U.S. Department of Veterans Affairs, Office of Research and
Development, Health Services Research and Development Center of
Excellence; VA Puget Sound Health Care Systems, Seattle, Washington.
Supported by a Clinician Scientist Award from the Canadian Institutes of
Health Research (Ottawa, Ontario, Canada), and a Merit Award from the
Department of Anesthesia at the University of Toronto, Toronto, Ontario,
Canada (to Dr. Wijeysundera). The authors were also supported by Group
Health Research Institute, Seattle, Washington, who waived part of the
indirect costs. Without this support this project may not have been
possible. Meetings at which work has been presented: Preliminary data
were presented at the 5th annual meeting of the Society for
Perioperative Assessment and Quality Improvement, March 3, 2011, Miami
Beach, Florida, and at the annual meeting of the American Society of
Anesthesiologists, October 16, 2011, Chicago, Illinois.
NR 30
TC 9
Z9 10
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAY
PY 2013
VL 118
IS 5
BP 1028
EP 1037
DI 10.1097/ALN.0b013e31828ea68a
PG 10
WC Anesthesiology
SC Anesthesiology
GA 131BA
UT WOS:000317964300008
PM 23503373
ER
PT J
AU Ovrutsky, AR
Chan, ED
Kartalija, M
Bai, XY
Jackson, M
Gibbs, S
Falkinham, JO
Iseman, MD
Reynolds, PR
McDonnell, G
Thomas, V
AF Ovrutsky, Alida R.
Chan, Edward D.
Kartalija, Marinka
Bai, Xiyuan
Jackson, Mary
Gibbs, Sara
Falkinham, Joseph O., III
Iseman, Michael D.
Reynolds, Paul R.
McDonnell, Gerald
Thomas, Vincent
TI Cooccurrence of Free-Living Amoebae and Nontuberculous Mycobacteria in
Hospital Water Networks, and Preferential Growth of Mycobacterium avium
in Acanthamoeba lenticulata
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID DRINKING-WATER; MOLECULAR-IDENTIFICATION; DISINFECTION TREATMENTS;
DISTRIBUTION-SYSTEMS; RESISTING BACTERIA; INFECTIONS; KERATITIS; HEALTH;
BIODIVERSITY; ENDOSYMBIONT
AB The incidence of lung and other diseases due to nontuberculous mycobacteria (NTM) is increasing. NTM sources include potable water, especially in households where NTM populate pipes, taps, and showerheads. NTM share habitats with free-living amoebae (FLA) and can grow in FLA as parasites or as endosymbionts. FLA containing NTM may form cysts that protect mycobacteria from disinfectants and antibiotics. We first assessed the presence of FLA and NTM in water and biofilm samples collected from a hospital, confirming the high prevalence of NTM and FLA in potable water systems, particularly in biofilms. Acanthamoeba spp. (genotype T4) were mainly recovered (8/17), followed by Hartmannella vermiformis (7/17) as well as one isolate closely related to the genus Flamella and one isolate only distantly related to previously described species. Concerning mycobacteria, Mycobacterium gordonae was the most frequently found isolate (9/17), followed by Mycobacterium peregrinum (4/17), Mycobacterium chelonae (2/17), Mycobacterium mucogenicum (1/17), and Mycobacterium avium (1/17). The propensity of Mycobacterium avium hospital isolate H87 and M. avium collection strain 104 to survive and replicate within various FLA was also evaluated, demonstrating survival of both strains in all amoebal species tested but high replication rates only in Acanthamoeba lenticulata. As A. lenticulata was frequently recovered from environmental samples, including drinking water samples, these results could have important consequences for the ecology of M. avium in drinking water networks and the epidemiology of disease due to this species.
C1 [Ovrutsky, Alida R.; Chan, Edward D.; Kartalija, Marinka; Bai, Xiyuan; Iseman, Michael D.; Reynolds, Paul R.] Natl Jewish Hlth, Denver, CO USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Jackson, Mary; Gibbs, Sara] Colorado State Univ, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.
[Ovrutsky, Alida R.; Chan, Edward D.; Bai, Xiyuan; Iseman, Michael D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA.
[Kartalija, Marinka; Iseman, Michael D.] Univ Colorado, Div Infect Dis, Denver, CO 80202 USA.
[Falkinham, Joseph O., III] Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA.
[McDonnell, Gerald; Thomas, Vincent] STERIS Corp, Paris, France.
RP Thomas, V (reprint author), STERIS Corp, Paris, France.
EM chane@njhealth.org; vincethom2009@yahoo.fr
RI Jackson, Mary/D-5345-2017; Thomas, Vincent/A-8941-2012
OI Jackson, Mary/0000-0002-9212-0258; Thomas, Vincent/0000-0003-4034-9525
FU National Institutes of Health/National Institute of Allergy and
Infectious Diseases [AI089718]
FX This work was supported in part by National Institutes of
Health/National Institute of Allergy and Infectious Diseases grant
AI089718.
NR 46
TC 30
Z9 32
U1 1
U2 33
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD MAY
PY 2013
VL 79
IS 10
BP 3185
EP 3192
DI 10.1128/AEM.03823-12
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 132AJ
UT WOS:000318039800006
PM 23475613
ER
PT J
AU Bowden, MG
Behrman, AL
Neptune, RR
Gregory, CM
Kautz, SA
AF Bowden, Mark G.
Behrman, Andrea L.
Neptune, Richard R.
Gregory, Chris M.
Kautz, Steven A.
TI Locomotor Rehabilitation of Individuals With Chronic Stroke: Difference
Between Responders and Nonresponders
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Hemiparesis; Rehabilitation; Stroke; Walking
ID RANDOMIZED CONTROLLED-TRIAL; BODY-WEIGHT SUPPORT; DYNAMIC GAIT INDEX;
TREADMILL; WALKING; POSTSTROKE; RECOVERY; PERFORMANCE; SURVIVORS; SCALE
AB Objectives: To identify the clinical measures associated with improved walking speed after locomotor rehabilitation in individuals poststroke and how those who respond with clinically meaningful changes in walking speed differ from those with smaller speed increases.
Design: A single group pre-post intervention study. Participants were stratified on the basis of a walking speed change of greater than (responders) or less than (nonresponders) .16m/s. Paired sample t tests were run to assess changes in each group, and correlations were run between the change in each variable and change in walking speed.
Setting: Outpatient interdisciplinary rehabilitation research center.
Participants: Hemiparetic subjects (N=27) (17 left hemiparesis; 19 men; age: 58.74 +/- 12.97y; 22.70 +/- 16.38mo poststroke).
Intervention: A 12-week locomotor intervention incorporating training on a treadmill with body weight support and manual trainers accompanied by training overground walking.
Main Outcome Measures: Measures of motor control, balance, functional walking ability, and endurance were collected at pre- and postintervention assessments.
Results: Eighteen responders and 9 nonresponders differed by age (responders=63.6y, nonresponders=49.0y, P=.001) and the lower extremity Fugl-Meyer Assessment score (responders=24.7, nonresponders=19.9, P=.003). Responders demonstrated an average improvement of .27m/s in walking speed as well as significant gains in all variables except daily step activity and paretic step ratio. Conversely, nonresponders demonstrated statistically significant improvements only in walking speed and endurance. However, the walking speed increase of .10m/s was not clinically meaningful. Change in walking speed was negatively correlated with changes in motor control in the nonresponder group, implying that walking speed phis may have been accomplished via compensatory mechanisms.
Conclusions: This study is a step toward discerning the underlying factors contributing to improved walking performance. Archives of Physical Medicine and Rehabilitation 2013;94:856-62 (C) 2013 by the American Congress of Rehabilitation Medicine
C1 [Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA.
[Behrman, Andrea L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA.
[Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
RP Bowden, MG (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM bowdenm@musc.edu
OI Kautz, Steven/0000-0003-3151-8235
FU VA Merit Review [B3983-R]; VA Center of Excellence [F2182C]; VA Career
Development Award [B7177]; National Institutes of Health - National
Center for Medical and Rehabilitation Research (NICHD) [K12 HD055929];
National Institute for Neurological Disorders Stroke
FX Supported by VA Merit Review (grant no. B3983-R); VA Center of
Excellence (grant no. F2182C) (Brain Rehabilitation Research Center); VA
Career Development Award (Phase I): B7177; and K12 HD055929 National
Institutes of Health - National Center for Medical and Rehabilitation
Research (NICHD) and National Institute for Neurological Disorders &
Stroke.
NR 46
TC 26
Z9 27
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAY
PY 2013
VL 94
IS 5
BP 856
EP 862
DI 10.1016/j.apmr.2012.11.032
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 134HX
UT WOS:000318202100009
PM 23220082
ER
PT J
AU Ibrahim, SA
Hanusa, BH
Hannon, MJ
Kresevic, D
Long, J
Kwoh, CK
AF Ibrahim, Said A.
Hanusa, Barbara H.
Hannon, Michael J.
Kresevic, Denise
Long, Judith
Kwoh, C. Kent
TI Willingness and Access to Joint Replacement Among African American
Patients With Knee Osteoarthritis: A Randomized, Controlled Intervention
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TOTAL HIP-ARTHROPLASTY; ETHNIC-DIFFERENCES; RACIAL DISPARITIES; PROBLEM
DRINKERS; UNITED-STATES; ARTHRITIS; PREVALENCE; SURGERY; CARE;
EXPECTATIONS
AB Objective African American patients are significantly less likely to undergo knee replacement for the management of knee osteoarthritis (OA). Racial difference in preference (willingness) has emerged as a key factor. This study was undertaken to examine the efficacy of a patient-centered educational intervention on patient willingness and the likelihood of receiving a referral to an orthopedic clinic. Methods A total of 639 African American patients with moderate-to-severe knee OA from 3 Veterans Affairs primary care clinics were enrolled in a randomized, controlled trial with a 2 x 2 factorial design. Patients were shown a knee OA decision-aid video with or without brief counseling. The main outcome measures were change in patient willingness and receipt of a referral to an orthopedic clinic. Also assessed were whether patients discussed knee pain with their primary care provider or saw an orthopedic surgeon within 12 months of the intervention. Results At baseline, 67% of the participants were definitely/probably willing to consider knee replacement, with no difference among the groups. The intervention increased patient willingness (75%) in all groups at 1 month. For those who received the decision aid intervention alone, the gains were sustained for up to 3 months. By 12 months postintervention, patients who received any intervention were more likely to report engaging their provider in a discussion about knee pain (92% versus 85%), to receive a referral to an orthopedic surgeon (18% versus 13%), and for those with a referral, to attend an orthopedic consult (61% versus 50%). Conclusion An educational intervention significantly increased the willingness of African American patients to consider knee replacement. It also improved the likelihood of patientprovider discussion about knee pain and access to surgical evaluation.
C1 [Ibrahim, Said A.; Long, Judith] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Ibrahim, Said A.; Long, Judith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hanusa, Barbara H.; Hannon, Michael J.; Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hannon, Michael J.; Kwoh, C. Kent] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Kresevic, Denise] Univ Hosp Case Med Ctr, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Kresevic, Denise] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Ibrahim, SA (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr Annex, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM said.ibrahim2@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research and Development
Service [IIR 05-234-2]; NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) [1K24-AR-055259-01]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research and Development Service (grant IIR 05-234-2 to Dr. Ibrahim).
Dr. Ibrahim's work also was supported by the NIH (National Institute of
Arthritis and Musculoskeletal and Skin Diseases grant
1K24-AR-055259-01).
NR 43
TC 12
Z9 12
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD MAY
PY 2013
VL 65
IS 5
BP 1253
EP 1261
DI 10.1002/art.37899
PG 9
WC Rheumatology
SC Rheumatology
GA 133WC
UT WOS:000318170600015
PM 23613362
ER
PT J
AU Riddle, DL
Singh, JA
Harmsen, WS
Schleck, CD
Lewallen, DG
AF Riddle, Daniel L.
Singh, Jasvinder A.
Harmsen, William S.
Schleck, Cathy D.
Lewallen, David G.
TI Clinically Important Body Weight Gain Following Knee Arthroplasty: A
Five-Year Comparative Cohort Study
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID ROCHESTER EPIDEMIOLOGY PROJECT; TOTAL HIP-ARTHROPLASTY; UNITED-STATES;
RISK-FACTORS; OBESITY; ADULTS; POPULATION; OSTEOARTHRITIS; REPLACEMENT;
HEALTH
AB Objective The impact of knee arthroplasty on body weight has not been fully explored. Clinically important weight gain following knee arthroplasty would pose potentially important health risks. Methods We used one of the largest US-based knee arthroplasty registries and a population-based control sample from the same geographic region to determine whether knee arthroplasty increases the risk of clinically important weight gain of 5% of baseline body weight over a 5-year postoperative period. Results Of the persons in the knee arthroplasty sample, 30.0% gained 5% of baseline body weight 5 years following surgery as compared to 19.7% of the control sample. The multivariable-adjusted (age, sex, body mass index, education, comorbidity, and presurgical weight change) odds ratio (OR) was 1.6 (95% confidence interval [95% CI] 1.22.2) in persons with knee arthroplasty as compared to the control sample. Additional arthroplasty procedures during followup further increased the risk for weight gain (OR 2.1, 95% CI 1.43.1) relative to the control sample. Specifically, among patients with knee arthroplasty, younger patients and those who lost greater amounts of weight in the 5-year preoperative period were at greater risk for clinically important weight gain. Conclusion Patients who undergo knee arthroplasty are at an increased risk of clinically important weight gain following surgery. The findings potentially have broad implications to multiple members of the health care team. Future research should develop weight loss/maintenance interventions particularly for younger patients who have lost a substantial amount of weight prior to surgery, as they are most at risk for substantial postsurgical weight gain.
C1 [Riddle, Daniel L.] Virginia Commonwealth Univ, Richmond, VA 23298 USA.
[Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Harmsen, William S.; Schleck, Cathy D.; Lewallen, David G.] Mayo Clin, Rochester, MN USA.
RP Riddle, DL (reprint author), Virginia Commonwealth Univ, Dept Phys Therapy, POB 980224, Richmond, VA 23298 USA.
EM dlriddle@vcu.edu
OI singh, jasvinder/0000-0003-3485-0006
FU Virginia Commonwealth University Presidential Research Initiative
Program; URL; Savient; Novartis; Takeda; Allergan; Ardea; Osteotech;
Zimmer
FX Supported by a grant from the Virginia Commonwealth University
Presidential Research Initiative Program.; Dr. Riddle has received
honoraria (less than $10,000) for his role as Deputy Editor of Physical
Therapy. Dr. Singh has received consultant fees, speaking fees, and/or
honoraria (less than $10,000 each) from URL, Savient, and Novartis, and
(more than $10,000 each) from Takeda, Allergan, and Ardea, and has
received investigator-initiated grants from Takeda and Savient. Dr.
Lewallen has received consultant fees, speaking fees, and/or honoraria
(less than $10,000 each) from Osteotech and Zimmer, and receives fees
and royalties from Zimmer for hip and knee implants.
NR 49
TC 10
Z9 10
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 669
EP 677
DI 10.1002/acr.21880
PG 9
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700002
PM 23203539
ER
PT J
AU Schmajuk, G
Yazdany, J
AF Schmajuk, Gabriela
Yazdany, Jinoos
TI Underestimation of the Reliability of Codes for Rheumatoid Arthritis
Within Administrative Data: Comment on the Article by Ng et al
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
ID VETERANS
C1 [Schmajuk, Gabriela; Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Schmajuk, Gabriela] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Schmajuk, G (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 3
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 835
EP 836
DI 10.1002/acr.21911
PG 2
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700028
PM 23212977
ER
PT J
AU Ng, B
Aslam, F
Yu, HJ
AF Ng, Bernard
Aslam, Fawad
Yu, Hong-Jen
TI Underestimation of the Reliability of Codes for Rheumatoid Arthritis
Within Administrative Data: Comment on the Article by Ng et al Reply
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
ID DATABASES; DIAGNOSIS; ACCURACY
C1 [Ng, Bernard; Yu, Hong-Jen] Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA.
[Ng, Bernard; Aslam, Fawad] Baylor Coll Med, Houston, TX 77030 USA.
RP Ng, B (reprint author), Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 836
EP 838
DI 10.1002/acr.21906
PG 3
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700029
PM 23212929
ER
PT J
AU Zhan, HC
Cardozo, C
Raza, A
AF Zhan, Huichun
Cardozo, Christopher
Raza, Azra
TI MicroRNAs in myeloproliferative neoplasms
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Review
DE microRNA; myeloproliferative neoplasm; polycythaemia vera; essential
thrombocythaemia; myelofibrosis
ID HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA;
ESSENTIAL THROMBOCYTHEMIA; V617F MUTATION; C-MYB; MEGAKARYOCYTIC
DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; MICROPROCESSOR COMPLEX;
NORMAL ERYTHROPOIESIS
AB The chronic myeloproliferative neoplasms (MPN), including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are clonal stem cell disorders characterized by dysregulated haematopoietic stem cell expansion and production of red cells, white cells and platelets alone or in combination. An acquired mutation JAK2V617F can be found in all three disorders and shows many of the phenotypic abnormalities of the diseases in murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 1824 nucleotide single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. There is growing evidence that miRNAs regulate haematopoiesis in both haematopoietic stem cells and committed progenitor cells. Here, we review the field of miRNA biology and its regulatory roles in normal haematopoiesis with an emphasis on miRNA deregulations in MPNs. Continued research into how miRNAs impact JAK2V617F clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
C1 [Zhan, Huichun; Cardozo, Christopher] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Zhan, Huichun; Raza, Azra] Columbia Univ, Med Ctr, New York, NY USA.
[Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA.
RP Zhan, HC (reprint author), James J Peters VA Med Ctr, 3F-12,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM Huichun.Zhan@va.gov
FU Veterans Affairs (VA) Career Development Award [10959632]; VA
Rehabilitation Research and Development Service Center [B9212-C]
FX Huichun Zhan is currently supported by Veterans Affairs (VA) Career
Development Award Grant 10959632 and VA Rehabilitation Research and
Development Service Center Grant B9212-C. We are grateful to Dr Jerry L.
Spivak from Johns Hopkins University for his valuable advice and
critical review during the preparation of the manuscript. We thank Dr
Haoyi Zheng from New York University Medical Center for his
indispensable help in editing the manuscript. We thank Dr Naomi Galili
from Columbia University Medical Center for reviewing the manuscript.
NR 136
TC 17
Z9 18
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAY
PY 2013
VL 161
IS 4
BP 471
EP 483
DI 10.1111/bjh.12276
PG 13
WC Hematology
SC Hematology
GA 133WT
UT WOS:000318172300004
PM 23432162
ER
PT J
AU Meek, TH
Wisse, BE
Thaler, JP
Guyenet, SJ
Matsen, ME
Fischer, JD
Taborsky, GJ
Schwartz, MW
Morton, GJ
AF Meek, Thomas H.
Wisse, Brent E.
Thaler, Joshua P.
Guyenet, Stephan J.
Matsen, Miles E.
Fischer, Jonathan D.
Taborsky, Gerald J., Jr.
Schwartz, Michael W.
Morton, Gregory J.
TI BDNF Action in the Brain Attenuates Diabetic Hyperglycemia via
Insulin-Independent Inhibition of Hepatic Glucose Production
SO DIABETES
LA English
DT Article
ID NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; ENERGY-BALANCE; MESSENGER-RNA;
FOOD-INTAKE; LEPTIN; MICE; RATS; RESISTANCE; OBESITY
AB Recent evidence suggests that central leptin administration fully normalizes hyperglycemia in a rodent model of uncontrolled insulin-deficient diabetes by reducing hepatic glucose production (HGP) and by increasing glucose uptake. The current studies were undertaken to determine whether brain-derived neurotrophic factor (BDNF) action in the brain lowers blood glucose in uncontrolled insulin-deficient diabetes and to investigate the mechanisms mediating this effect. Adult male rats implanted with cannulas to either the lateral cerebral ventricle or the ventromedial hypothalamic nucleus (VMN) received either vehicle or sizeptozotocin to induce uncontrolled insulin-deficient diabetes. Three days later, animals received daily intracerebroventricular or intra-VMN injections of either BDNF or its vehicle. We found that repeated daily intracerebroventricular administration of BDNF attenuated diabetic hyperglycemia independent of changes in food intake. Instead, using tracer dilution techniques during a basal clamp, we found that BDNF lowered blood glucose levels by potently suppressing HGP, without affecting tissue glucose uptake, an effect associated with normalization of both plasma glucagon levels and hepatic expression of gluconeogenic genes. Moreover, BDNF microinjection directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-deficient diabetes, but this effect was modest compared with intracerebroventricular administration. We conclude that central nervous system BDNF attenuates diabetic hyperglycemia via an insulin-independent mechanism. This action of BDNF likely involves the VMN and is associated with inhibition of glucagon secretion and a decrease in the rate of HGP. Diabetes 62:1512-1518, 2013
C1 [Meek, Thomas H.; Wisse, Brent E.; Thaler, Joshua P.; Guyenet, Stephan J.; Matsen, Miles E.; Fischer, Jonathan D.; Schwartz, Michael W.; Morton, Gregory J.] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA.
[Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Med Ctr, Seattle, WA USA.
RP Morton, GJ (reprint author), Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA.
EM gjmorton@u.washington.edu
FU National Institutes of Health [DK089053, DK083042, DK050154-13];
Nutrition Obesity Research Center (NORC) [DK035816]; University of
Washington (Seattle, Washington) [T32 DK0007247]; Perkins Coie; American
Heart Association Scientist Development Grant
FX This work was supported by National Institutes of Health grants DK089053
(G.J.M.), DK083042 (M.W.S.), and DK050154-13 (G.J.T.); by the Nutrition
Obesity Research Center (NORC, DK035816) and the Diabetes and Metabolism
Training Grant (T32 DK0007247) at the University of Washington (Seattle,
Washington); by research funding from Perkins Coie; and by an American
Heart Association Scientist Development Grant (G.J.M.). No other
potential conflicts of interest relevant to this article were reported.
NR 25
TC 17
Z9 17
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1512
EP 1518
DI 10.2337/db12-0837
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700030
PM 23274899
ER
PT J
AU Zraika, S
Koh, DS
Barrow, BM
Lu, B
Kahn, SE
Andrikopoulos, S
AF Zraika, Sakeneh
Koh, Duk-Su
Barrow, Breanne M.
Lu, Bao
Kahn, Steven E.
Andrikopoulos, Sofianos
TI Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory
Dysfunction by Maintaining Calcium Influx
SO DIABETES
LA English
DT Article
ID PANCREATIC BETA-CELLS; NEUTRAL ENDOPEPTIDASE ACTIVITY; C57BL/6J MICE;
MOUSE MODELS; GLUCOSE; ACIDS; INHIBITION; PALMITATE; PATHWAY; ISLETS
AB Neprilysin contributes to free fatty acid (FFA)-induced cellular dysfunction in nonislet tissues in type 2 diabetes. Here, we show for the first time that with prolonged FFA exposure, islet neprilysin is upregulated and this is associated with reduced insulin pre-mRNA and ATP levels, oxidative/nitrative stress, impaired potassium and calcium channel activities, and decreased glucose-stimulated insulin secretion (GSLS). Genetic ablation of neprilysin specifically protects against FFA-induced impairment of calcium influx and GSIS in vitro and in vivo but does not ameliorate other FFA-induced defects. Importantly, adenoviral overexpression of neprilysin in islets cultured without FFA reproduces the defects in both calcium influx and GSIS, suggesting that upregulation of neprilysin per se mediates insulin secretory dysfunction and that the mechanism for protection conferred by neprilysin deletion involves prevention of reduced calcium influx. Our findings highlight the critical nature of calcium signaling for normal insulin secretion and suggest that interventions to inhibit neprilysin may improve beta-cell function in obese humans with type 2 diabetes. Diabetes 62:1593-1601, 2013
C1 [Zraika, Sakeneh; Barrow, Breanne M.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Zraika, Sakeneh; Barrow, Breanne M.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
[Koh, Duk-Su] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Lu, Bao] Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp, Boston, MA 02115 USA.
[Andrikopoulos, Sofianos] Univ Melbourne, Heidelberg Repatriat Hosp, Dept Med, Heidelberg, Vic, Australia.
RP Zraika, S (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
EM zraikas@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002
FU National Institutes of Health (NIH) [DK-080945]; Department of Veterans
Affairs, VA Puget Sound Health Care System; Diabetes Australia Research
Trust; National Health and Medical Research Council (NHMRC) of
Australia; NIH [DK-017047]; NHMRC of Australia
FX This study was supported by National Institutes of Health (NIH) Grant
DK-080945 (to S.Z.), the Department of Veterans Affairs, VA Puget Sound
Health Care System, the Diabetes Australia Research Trust, and the
National Health and Medical Research Council (NHMRC) of Australia.
Calcium influx and rubidium efflux studies as well as histological
studies were performed at the University of Washington's Diabetes
Research Center Cell Function Analysis Core and Cellular and Molecular
Imaging Core, respectively, both of which are supported by NIH Grant
DK-017047. S.A. was the recipient of a Career Development Award from the
NHMRC of Australia.
NR 48
TC 5
Z9 5
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1593
EP 1601
DI 10.2337/db11-1593
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700038
PM 23328128
ER
PT J
AU Raman, SB
Nguyen, MH
Cheng, SJ
Badrane, H
Iczkowski, KA
Wegener, M
Gaffen, SL
Mitchell, AP
Clancy, CJ
AF Raman, Suresh B.
Nguyen, M. Hong
Cheng, Shaoji
Badrane, Hassan
Iczkowski, Kenneth A.
Wegener, Marilyn
Gaffen, Sarah L.
Mitchell, Aaron P.
Clancy, Cornelius J.
TI A Competitive Infection Model of Hematogenously Disseminated Candidiasis
in Mice Redefines the Role of Candida albicans IRS4 in Pathogenesis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MIXED INFECTIONS; HYPHAL FORMATION; ALBICANS; VIRULENCE; CASPOFUNGIN;
BLOOD; HOMEOSTASIS; EXPRESSION; RESISTANCE; MUTATIONS
AB Candida albicans IRS4 encodes a protein that regulates phosphatidylinositol-(4,5)-bisphosphate, which was shown to contribute to hematogenously disseminated candidiasis (DC) after several days in the standard mouse model. Our objective was to more accurately define the temporal contributions of IRS4 to pathogenesis. During competition assays in vitro, an irs4-null (Delta irs4) mutant exhibited wild-type fitness. In DC experiments, mice were infected intravenously with the Delta irs4 mutant, strain CAI-12 (1 x 10(5) CFU), or a mixture of the strains (0.5 x 10(5) CFU each). In single-strain infections, quantitative PCR revealed reduced Delta irs4 mutant burdens within kidneys at days 1, 4, and 7 but not 6 h. In competitive infections, the Delta irs4 mutant was outcompeted by CAI-12 in each mouse at >= 6 h (competitive indices, P <= 0.0001). At 4 and 7 days, the Delta irs4 mutant burdens during competitive infections were significantly lower than those during single-strain infections (P = 0.01 and P < 0.001, respectively), suggesting increased susceptibility to inflammatory responses. Phagocytic infiltration of kidneys in response to CAI-12 or competitive infections was significantly greater than that in response to Delta irs4 mutant infection at days 1 and 4 (P < 0.001), and the Delta irs4 mutant was more susceptible to phagocytosis and killing by human polymorphonuclear cells (P = 0.01 and P = 0.006, respectively) and mouse macrophages in vitro (P = 0.04 and P = 0.01, respectively). Therefore, IRS4 contributes to tissue invasion at early stages of DC and mediates resistance to phagocytosis as DC progresses. Microarray analysis revealed remarkably similar gene expression by the Delta irs4 mutant and reference strain CAI-12 within blood, suggesting that IRS4 is not significantly involved in the hematogenous stage of disease. A competitive DC model detects attenuated virulence that is not evident with the standard model.
C1 [Raman, Suresh B.; Nguyen, M. Hong; Cheng, Shaoji; Badrane, Hassan; Gaffen, Sarah L.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
[Wegener, Marilyn; Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Iczkowski, Kenneth A.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA.
[Mitchell, Aaron P.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
EM cjc76@pitt.edu
OI Mitchell, Aaron/0000-0002-0868-4000
FU NIDCR NIH HHS [R01 DE022550]
NR 31
TC 4
Z9 5
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2013
VL 81
IS 5
BP 1430
EP 1438
DI 10.1128/IAI.00743-12
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 126AE
UT WOS:000317582700006
PM 23429534
ER
PT J
AU Bower, JE
Ganz, PA
Irwin, MR
Castellon, S
Arevalo, J
Cole, SW
AF Bower, Julienne E.
Ganz, Patricia A.
Irwin, Michael R.
Castellon, Steven
Arevalo, Jesusa
Cole, Steven W.
TI Cytokine Genetic Variations and Fatigue Among Patients With Breast
Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; QUALITY-OF-LIFE; INFLAMMATORY
BIOMARKERS; BEHAVIORAL SYMPTOMS; PERSISTENT FATIGUE; SLEEP DISTURBANCE;
SURVIVORS; POLYMORPHISMS; DEPRESSION
AB Purpose
Fatigue is a common adverse effect of cancer treatment and may persist for years after treatment completion. However, risk factors for post-treatment fatigue have not been determined. On the basis of studies suggesting an inflammatory basis for fatigue, this study tested the hypothesis that expression-regulating polymorphisms in proinflammatory cytokine genes would predict post-treatment fatigue in breast cancer survivors.
Patients and Methods
Women diagnosed with early-stage breast cancer (n = 171) completed questionnaires to assess fatigue and other behavioral symptoms (ie, depressive symptoms, memory complaints, sleep disturbance) and provided blood for genotyping within 3 months after primary treatment. Genomic DNA was extracted from peripheral-blood leukocytes and assayed for single nucleotide polymorphisms (SNPs) in the promoter regions of three cytokine genes: ILB -511 C>T (rs16944), IL6 -174 G > C (rs1800795), and TNF -308 G > A (rs1800629). An additive genetic risk score was computed by summing the number of high-expression alleles (zero, one, or two) across all three polymorphisms.
Results
The genetic risk index was significantly associated with fatigue; as the number of high-expression alleles increased, so did self-reported fatigue severity (P = .002). Analyses of individual SNPs showed that TNF -308 and IL6 - 174 were independently associated with fatigue (P = .032). The genetic risk index was also associated with depressive symptoms (P = .007) and memory complaints (P = .016).
Conclusion
These findings further implicate inflammatory processes as contributors to cancer-related fatigue and suggest a new strategy for identifying and treating patients at risk for this symptom based on genetic variants in proinflammatory cytokine genes. J Clin Oncol 31: 1656-1661. (C) 2013 by American Society of Clinical Oncology
C1 [Bower, Julienne E.; Ganz, Patricia A.; Irwin, Michael R.; Castellon, Steven; Arevalo, Jesusa; Cole, Steven W.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Castellon, Steven] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Bower, JE (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall, Los Angeles, CA 90095 USA.
EM jbower@ucla.edu
RI Irwin, Michael/H-4870-2013
OI Irwin, Michael/0000-0002-1502-8431
FU National Institutes of Health [R01-CA109650, R01-CA116778, R01-AG034588,
R01-AG026364, R01-CA160245-01, R01-CA119159, R01-HL095799,
R01-DA032922-01, P30-AG028748]; Cousins Center for
Psychoneuroimmunology; Breast Cancer Research Foundation
FX Supported by National Institutes of Health Grants No. R01-CA109650
(P.A.G.), R01-CA116778 (S.W.C.), R01-AG034588, R01-AG026364,
R01-CA160245-01, R01-CA119159, R01-HL095799, R01-DA032922-01, and
P30-AG028748 (M.I.); the Cousins Center for Psychoneuroimmunology; and
the Breast Cancer Research Foundation.
NR 59
TC 44
Z9 45
U1 1
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1656
EP +
DI 10.1200/JCO.2012.46.2143
PG 7
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200013
PM 23530106
ER
PT J
AU Pierre, JF
Heneghan, AF
Feliciano, RP
Shanmuganayagam, D
Roenneburg, DA
Krueger, CG
Reed, JD
Kudsk, KA
AF Pierre, Joseph F.
Heneghan, Aaron F.
Feliciano, Rodrigo P.
Shanmuganayagam, Dhanansayan
Roenneburg, Drew A.
Krueger, Christian G.
Reed, Jess D.
Kudsk, Kenneth A.
TI Cranberry Proanthocyanidins Improve the Gut Mucous Layer Morphology and
Function in Mice Receiving Elemental Enteral Nutrition
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE enteral nutrition; proanthocyanidins; goblet cells; mucin; cytokines
ID RECURRENT ULCERATIVE-COLITIS; TOTAL PARENTERAL-NUTRITION; MUCOSAL
IMMUNITY; LYMPHOID-TISSUE; HOST-DEFENSE; GRAPE SEEDS; MUC2 MUCIN; RATS;
POLYPHENOLS; PROCYANIDINS
AB Background: Lamina propria Th2 cytokines, interleukin (IL)-4 and IL-13, stimulate goblet cell (GC) proliferation and MUC2 production, which protect the intestinal mucosa. Elemental enteral nutrition (EEN) reduces tissue IL-4 and impairs barrier function. Proanthocyanidins (PACs) stimulate oral mucin levels. We hypothesized that adding PAC to EEN would maintain Th2-without stimulating Th1-cytokines and preserve luminal MUC2 vs EEN alone. Materials and Methods: Seventy mice were randomized to 5 diet groups-standard chow, intragastric EEN, or EEN with lowPAC, midPAC (50 mg), or highPAC (100 mg PAC/kg BW)-for 5 days, starting 2 days after gastric cannulation. Ileal tissue was analyzed for histomorphology and the cytokines IL-4, IL-13, IL-1 beta, IL-6, and TNF-alpha by enzyme-linked immunosorbent assay. MUC2 was measured in intestinal washes. Results: EEN lowered IL-13 (P < .05) compared with standard chow, whereas IL-4 was not significant (P < .07). LowPAC and midPAC increased IL-13 (P < .05), whereas highPAC increased both IL-4 and IL-13 (P < .05) compared with EEN. All EEN diets reduced (P < .05) crypt depth compared with the chow group. Compared with standard chow, GC numbers and luminal MUC2 were reduced with EEN (P < .05). These effects were attenuated (P < .05) with midPAC and highPAC. No changes were observed in tissue Th1 cytokines. Conclusions: Adding PACs to EEN reverses impaired intestinal barrier function following EEN by improving the gut mucous layer and function through increased GC size and number as well as levels of MUC2 and ileal IL-4 and IL-13. (JPEN J Parenter Enteral Nutr. 2013;37:401-409)
C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Roenneburg, Drew A.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53792 USA.
[Pierre, Joseph F.; Feliciano, Rodrigo P.; Shanmuganayagam, Dhanansayan; Krueger, Christian G.; Reed, Jess D.] Univ Wisconsin, Dept Anim Sci, Madison, WI 53792 USA.
[Feliciano, Rodrigo P.] Univ Wisconsin, Dept Food Sci, Madison, WI 53792 USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Ctr Clin Sci, G5-341 600 Highland Ave, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
OI Feliciano, Rodrigo/0000-0002-8116-997X
FU Biomedical Laboratory Research & Development Service of the VA Office of
Research and Development [I01BX001672]; National Institutes of Health
(NIH) [R01 GM53439]; Reed Research Group; Fundacao para a Ciencia e a
Tecnologia, Portugal [SFRH/BD/73067/2010]
FX The project described was supported by award number I01BX001672 from the
Biomedical Laboratory Research & Development Service of the VA Office of
Research and Development. The research was also supported by a National
Institutes of Health (NIH) grant (R01 GM53439) and by the Reed Research
Group.; Rodrigo P. Feliciano is recipient of a BD fellowship
(SFRH/BD/73067/2010) from Fundacao para a Ciencia e a Tecnologia,
Portugal. We would like to thank Jennifer J. Meudt and Michael P. Shea
for their technical assistance and Dr Martha Vestling for her assistance
with mass spectrometry.
NR 58
TC 13
Z9 13
U1 1
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD MAY
PY 2013
VL 37
IS 3
BP 401
EP 409
DI 10.1177/0148607112463076
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 131IW
UT WOS:000317987600015
PM 23064255
ER
PT J
AU Hookway, LA
Fuhr, P
Frazier, M
AF Hookway, Larry Allen
Fuhr, Patti
Frazier, Marcela
TI Use of Ready-Made Spectacles to Meet Visual Needs in a Low-Resource
Adult Population
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE humanitarian eye care; vision correction; presbyopia; refractive error;
readers; functional vision; spectacles; vision; uncorrected refractive
error; visual impairment; blindness
ID WILLINGNESS-TO-PAY; UNCORRECTED PRESBYOPIA; REFRACTIVE ERROR; RURAL
TANZANIA; EYE DISEASE; IMPAIRMENT; CARE; COUNTRIES; BLINDNESS; PACIFIC
AB Purpose. In affluent societies, distance and near vision problems are typically corrected with custom-made eyeglasses. Many persons in less affluent areas do not have the resources for such. The purpose of this study was to assess the use of less expensive ready-made (RM) bifocals and readers to correct distance and near refractive error and presbyopia in an outreach clinic in Nicaragua.
Methods. This is a retrospective review of records of all patients older than 34 years who presented for an eye examination in an outreach clinic in Granada, Nicaragua, in 2010. A visual satisfaction questionnaire had been administered to patients before they were examined and after RM plus sphere bifocals or plus sphere reading spectacles were dispensed. The main outcome measures included pre- and post-distance and near visual acuities, vision satisfaction and difficulty ratings, and perceived cost and willingness to pay for replacement rating.
Results. Ready-made plus sphere spectacles (bifocals or single-vision readers) were dispensed to 95.4% of those examined. The remaining 4.6% required custom prescriptions because of astigmatism, myopia, or anisometropia. The RM bifocals were very well accepted, with high visual satisfaction ratings with the bifocals improving from a presenting value of 11 to 89.4% at distance and from 6.6 to 89.4% at near. Percentage of patients achieving visual acuity of 20/40 or better improved from 60 to 84.5% at distance and from 44 to 97% at near. Percentage achieving functionally good near vision (20/40 or better) improved from 38 to 97% with RM readers. Patients reporting highest satisfaction with near vision improved from 6.3 to 86.6%. Patients indicated that, on average, they would be willing to pay US$ 18.39 to replace the bifocals and US$ 16.67 to replace the readers.
Conclusions. Ready-made bifocals and RM single-vision readers may be an acceptable and affordable alternative for many patients with hyperopia and/or presbyopia where access to custom-made eyeglasses is difficult. (Optom Vis Sci 2013; 90: 494-500)
C1 [Hookway, Larry Allen] NOVA Southeastern Coll Optometry, Ft Lauderdale, FL USA.
[Fuhr, Patti; Frazier, Marcela] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
[Fuhr, Patti] Birmingham VA Med Ctr, Blind Rehabil Ctr, Birmingham, AL USA.
RP Hookway, LA (reprint author), 320 W Walton St,POB 270, Willard, OH 44890 USA.
EM larryhookway@gmail.com
NR 29
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2013
VL 90
IS 5
BP 494
EP 500
DI 10.1097/OPX.0b013e31828dedf6
PG 7
WC Ophthalmology
SC Ophthalmology
GA 131TW
UT WOS:000318020300015
PM 23584487
ER
PT J
AU Winters-Stone, KM
Dobek, J
Nail, LM
Bennett, JA
Leo, MC
Torgrimson-Ojerio, B
Luoh, SW
Schwartz, A
AF Winters-Stone, K. M.
Dobek, J.
Nail, L. M.
Bennett, J. A.
Leo, M. C.
Torgrimson-Ojerio, B.
Luoh, S. -W.
Schwartz, A.
TI Impact plus resistance training improves bone health and body
composition in prematurely menopausal breast cancer survivors: a
randomized controlled trial
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Chemotherapy; Neoplasm; Obesity; Osteoporosis; Physical activity
ID MINERAL DENSITY; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; OVARIAN
FAILURE; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; FRACTURE RISK;
WEIGHT-GAIN; EXERCISE; ESTROGEN
AB Our randomized controlled trial in prematurely menopausal breast cancer survivors showed that impact + resistance training prevented increases in percentage of body fat compared with controls and also improved BMD at the hip and prevented BMD loss at the spine among exercise-trained women who were menopausal for > 1 year.
Cancer treatment-related menopause worsens bone health and body composition in breast cancer survivors (BCS). We investigated whether impact + resistance training could improve bone mineral density (BMD), reduce bone turnover, build muscle, and decrease fat mass in BCS with premature menopause.
We conducted a randomized controlled trial in 71 BCS (mean age, 46.5 years) within 5 years of treatment-related menopause. Women were randomly assigned to one of two groups: (1) impact + resistance training (prevent osteoporosis with impact + resistance (POWIR)) or (2) exercise placebo (FLEX) 3x/week for 1 year. Outcomes were hip and spine BMD (in grams per square centimeter) and body composition (percent body fat (%BF) and lean and fat mass (in kilograms)) by DXA and bone turnover markers (serum osteocalcin (in nanograms per milliliter) and urinary deoxypryrodinoline (in nanomoles per milliliter).
There were no significant group x time interactions for bone outcomes when using an intent-to-treat approach on the full sample. In analyses restricted to BCS who were menopausal for a parts per thousand yen1 year, POWIR increased BMD at the hip and slowed BMD loss at the spine compared with FLEX (femoral neck-POWIR, 0.004 +/- 0.093 g/cm(2) vs. FLEX, -0.010 +/- 0.089 g/cm(2); p < 0.01; spine-POWIR, -0.003 +/- 0.114 g/cm(2) vs. FLEX, -0.020 +/- 0.110 g/cm(2); p = 0.03). POWIR prevented increases in %BF (POWIR, 0.01 % vs. FLEX, 1.3 %; p < 0.04). Women with attendance to POWIR at a parts per thousand yen64 % had better improvements in %BF than women attending less often (p < 0.03).
Impact + resistance training may effectively combat bone loss and worsening body composition from premature menopause in BCS.
C1 [Winters-Stone, K. M.; Dobek, J.; Nail, L. M.; Bennett, J. A.; Torgrimson-Ojerio, B.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.
[Dobek, J.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
[Winters-Stone, K. M.; Nail, L. M.; Bennett, J. A.] Oregon Hlth & Sci Univ, Knight Canc Ctr, Portland, OR 97239 USA.
[Luoh, S. -W.] Portland VA Med Ctr, Portland, OR USA.
[Leo, M. C.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Schwartz, A.] Idaho State Univ, Pocatello, ID 83209 USA.
[Winters-Stone, K. M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Winters-Stone, KM (reprint author), Oregon Hlth & Sci Univ, 3455 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM wintersk@ohsu.edu
FU American Cancer Society Research Scholar Grant [RSGPB-06-092-01-CPPB]
FX Funding was provided by an American Cancer Society Research Scholar
Grant (RSGPB-06-092-01-CPPB). We thank the Oregon State Cancer Registry
for their assistance with recruitment; Thera-band, Inc. for providing
elastic exercise bands; and our research assistants, exercise trainers,
and participants.
NR 45
TC 26
Z9 27
U1 2
U2 38
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2013
VL 24
IS 5
BP 1637
EP 1646
DI 10.1007/s00198-012-2143-2
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 135HV
UT WOS:000318280100011
PM 22996743
ER
PT J
AU Ahluwalia, SC
Levin, JR
Lorenz, KA
Gordon, HS
AF Ahluwalia, Sangeeta C.
Levin, Jennifer R.
Lorenz, Karl A.
Gordon, Howard S.
TI "There's no cure for this condition": How physicians discuss advance
care planning in heart failure
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Communication; Qualitative; Advance care planning; Heart failure
ID BREAKING-BAD-NEWS; LIFE-SUSTAINING TREATMENT; COMMUNICATION-SKILLS;
OF-LIFE; SIMULATED INTERVIEWS; MEDICAL-STUDENTS; RANDOMIZED-TRIAL;
CANCER CARE; PREFERENCES; END
AB Objective: To evaluate the extent to which physicians engage in recommended elements of advance care planning (ACP) communication during outpatient clinic visits with heart failure (HF) patients.
Methods: We conducted a qualitative content analysis of 71 audio-recorded and transcribed outpatient visits with 52 patients >= 65 years recently hospitalized for HF and their physicians (n = 44).
Results: We identified 25 instances of ACP-related communication over 15 of the 71 visits: in 17 instances, physicians explained the nature of HF but only once was the life-limiting potential of HF Mentioned. Physicians discussed goals of care in 6 instances but elicited their patients' preferences in only 2 of those instances. Finally, physicians encouraged documentation of preferences in 2 instances.
Conclusions: Despite recommendations for early ACP with HF patients, physicians rarely engaged in fundamental elements of ACP discussions during outpatient visits. We suggest a stepwise approach to supporting the process of ACP communication in practice.
Practice implications: Given the importance of ACP in helping patients plan for their future care, outpatient clinicians should be helped to incorporate these discussions in the routine care of their HF patients. Using a simple heuristic might help physicians engage in fundamental elements of ACP during busy outpatient visits. Published by Elsevier Ireland Ltd.
C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA.
[Ahluwalia, Sangeeta C.; Levin, Jennifer R.; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90064 USA.
[Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gordon, Howard S.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
[Gordon, Howard S.] VA Ctr Management Complex Chron Care, Chicago, IL USA.
[Gordon, Howard S.] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA.
RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA.
EM sangeeta.ahluwalia@va.gov
RI Gordon, Howard/E-4420-2010
OI Gordon, Howard/0000-0002-6712-5954
FU VA Health Services Research and Development (HSR&D), Department of
Veterans Affairs [ECV-02-254]; Office of Academic Affiliation's VA
Associated Health Postdoctoral Fellowship Program at the VA Greater Los
Angeles HSR&D Center of Excellence
FX Supported in part by grant ECV-02-254 from VA Health Services Research
and Development (HSR&D), Department of Veterans Affairs. Dr. Ahluwalia
is supported by an Office of Academic Affiliation's VA Associated Health
Postdoctoral Fellowship Program at the VA Greater Los Angeles HSR&D
Center of Excellence.
NR 45
TC 9
Z9 9
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD MAY
PY 2013
VL 91
IS 2
BP 200
EP 205
DI 10.1016/j.pec.2012.12.016
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 136AA
UT WOS:000318330600011
PM 23369373
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Medical and psychological comorbidity predicts poor pain outcomes after
total knee arthroplasty
SO RHEUMATOLOGY
LA English
DT Article
DE pain; function; functional limitation; total knee replacement; primary;
arthroplasty; joint replacement; outcomes; patient-reported outcomes
ID TOTAL HIP-ARTHROPLASTY; UNITED-STATES; REVISION HIP; REPLACEMENT; AGE;
LIMITATION; MORBIDITY; IMPACT; INDEX; TKA
AB Objective. To study comorbidity correlates of moderate to severe pain after total knee arthroplasty (TKA).
Methods. We analysed prospectively collected Total Joint Registry data to examine whether medical (heart disease, peripheral vascular disease, renal disease, chronic obstructive pulmonary disease, diabetes and CTD) and psychological (anxiety and depression) comorbidity is associated with moderate to severe pain after primary or revision TKA. Multivariable-adjusted logistic regression simultaneously adjusted for all comorbidities, age, sex, BMI, underlying diagnosis, American Society of Anesthesiologist (ASA) class, distance from medical centre and implant fixation (only for primary TKA) was used to analyse primary and revision TKA separately.
Results. The primary TKA cohort consisted of 7139 and 4234 TKAs (response rates 65% and 57%) and the revision TKA cohort consisted of 1533 and 881 TKAs at 2 and 5 years (response rates 57% and 48%), respectively. In the primary TKA cohort, anxiety was associated with 1.4 higher odds (95% CI 1.0, 2.0) of moderate to severe index knee pain at 2 years; at 5 years, heart disease (OR 1.7; 95% CI 1.1, 2.6), depression (OR 1.7; 95% CI 1.1, 2.5) and anxiety (OR 1.9; 95% CI 1.2, 3.1) were significantly associated with moderate to severe pain. For revision TKA, CTD (OR 0.5; 95% CI 0.2, 0.9) and depression (OR 1.8; 95% CI 1.1, 3.1) were significantly associated with moderate to severe pain.
Conclusion. This study identified medical and psychological comorbidity risk factors for moderate to severe pain after primary and revision TKA. This information can be used to provide realistic outcome expectations for patients before undergoing primary or revision TKA.
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Agency for Health Quality and the Research Center for Education and
Research on Therapeutics (CERTs); Mayo Clinic; National Institutes of
Health (NIH) (Mayo Clinic Center for Clinical and Translational
Research) [1 KL2 RR024151-01]; DePuy; Stryker; Biomet; Zimmer; Takeda;
Savient; URL Pharmaceuticals; Ardea; Allergan; Regeneron; Novartis;
National Institute of Aging; National Cancer Institute; Pipeline
Biomedical
FX The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the US government. J.A.S. is supported by grants from the
Agency for Health Quality and the Research Center for Education and
Research on Therapeutics (CERTs), the National Institute of Aging and
the National Cancer Institute.; This material is the result of work
supported with research grants from Mayo Clinic Orthopedic Surgery
research funds, National Institutes of Health (NIH) Clinical
Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for
Clinical and Translational Research) and the resources and use of
facilities at the Birmingham VA Medical Center, Birmingham, AL, USA.;
D.G.L. has received royalties from Zimmer, has been a paid consultant
and owns stock in Pipeline Biomedical and his institution has received
research funds from DePuy, Stryker, Biomet and Zimmer. J.A.S. has
received research and travel grants from Takeda and Savient and
consultant fees from URL Pharmaceuticals, Savient, Takeda, Ardea,
Allergan, Regeneron and Novartis.
NR 36
TC 39
Z9 41
U1 2
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAY
PY 2013
VL 52
IS 5
BP 916
EP 923
DI 10.1093/rheumatology/kes402
PG 8
WC Rheumatology
SC Rheumatology
GA 133CG
UT WOS:000318114400025
PM 23325037
ER
PT J
AU Ventura, J
Reise, SP
Keefe, RSE
Hurford, IM
Wood, RC
Bilder, RM
AF Ventura, Joseph
Reise, Steven P.
Keefe, Richard S. E.
Hurford, Irene M.
Wood, Rachel C.
Bilder, Robert M.
TI The Cognitive Assessment Interview (CAI): Reliability and Validity of a
Brief Interview-Based Measure of Cognition
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; functional outcome; functional capacity; symptoms;
informant ratings; neurocognition
ID PSYCHIATRIC RATING-SCALE; FUNCTIONAL-CAPACITY; QUALITY-ASSURANCE;
SCHIZOPHRENIA; PERFORMANCE; IMPAIRMENT; VALIDATION; PREDICTION;
SYMPTOMS; SELF
AB Objective: To obtain Food and Drug Administration approval for the treatment of cognitive impairments associated with schizophrenia, a drug will need to demonstrate benefits beyond those that may be documented on objective cognitive tests. Interview-based measures of cognition such as the Cognitive Assessment Interview (CAI) are candidate coprimary outcome measures. Methods: Psychiatrically stable schizophrenia outpatients (n = 150) were studied using the CM to obtain information about cognitive functioning from both the patient and an informant. Patients also received objective assessments of neurocognition, functional capacity, functional outcome, and symptoms, at baseline and 1 month later. Results: The CAI had good internal consistency (Cronbach's alpha = .92) and good test-retest reliability (r = .83). The CM was moderately correlated with objective neurocognitive test scores (r's = .39 to -.41) and moderately correlated with social functioning (r = -.38), work functioning (r = -.48), and overall functional outcome (r = -.49). The correlations of CAI scores with external validity indicators did not differ significantly by source of information (patient alone ratings were valid). Overall functional outcome correlated more strongly with patient CM scores (r = -.50) than with objective neurocognitive test scores (r = .29) or functional capacity (r = .29). Conclusions: Field testing of the CM produced reliable ratings of cognitive functioning that were correlated with functional outcome. Patient ratings alone yielded scores with reliability and validity values appropriate for use in clinical trials. The CM appears to provide useful complementary information and possesses practical advantages for rating cognitive functioning including an interview-based method of administration, brief assessment time (15 min for the patient assessment), little or no practice effects, and ease of scoring.
C1 [Ventura, Joseph; Wood, Rachel C.; Bilder, Robert M.] Univ Calif Los Angeles, Dept Psychiat, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Reise, Steven P.; Bilder, Robert M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Keefe, Richard S. E.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
[Hurford, Irene M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Hurford, Irene M.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA.
RP Ventura, J (reprint author), Univ Calif Los Angeles, Dept Psychiat, 300 Med Plaza,Room 2243, Los Angeles, CA 90095 USA.
EM jventura@ucla.edu
RI Bilder, Robert/A-8894-2008
OI Bilder, Robert/0000-0001-5085-7852
FU Pfizer, Inc.; National Institute of Mental Health (NIMH) [1R21MH073971,
MH37705, P50 MH066286]; Consortium for Neuropsychiatric Phonemics
[UL1-DE019580, RL1LM009833]
FX This research was supported by an investigator initiated grant from
Pfizer, Inc. and from an National Institute of Mental Health (NIMH)
grant 1R21MH073971 that were awarded to J.V., PhD. This research was
also supported in part by NIMH Grants MH37705 (P.I.: Keith H.
Nuechterlein, PhD), P50 MH066286 (P.I.: Keith H. Nuechterlein, PhD), and
the Consortium for Neuropsychiatric Phonemics UL1-DE019580, RL1LM009833
(PI: R.M.B., PhD).
NR 39
TC 14
Z9 14
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 583
EP 591
DI 10.1093/schbul/sbs001
PG 9
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200018
PM 22328641
ER
PT J
AU Harvey, PO
Zaki, J
Lee, J
Ochsner, K
Green, MF
AF Harvey, Philippe-Olivier
Zaki, Jamil
Lee, Junghee
Ochsner, Kevin
Green, Michael F.
TI Neural Substrates of Empathic Accuracy in People With Schizophrenia
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE social cognition; empathic accuracy; emotional expressivity;
schizophrenia; functional imaging
ID SOCIAL COGNITION; MAJOR DEPRESSION; BASES; MIND; ATTRIBUTION;
PERCEPTION; EMOTION; EXPRESSIVITY; CIRCUITRY; FEELINGS
AB Introduction: Empathic deficits in schizophrenia may lead to social dysfunction, but previous studies of schizophrenia have not modeled empathy through paradigms that (1) present participants with naturalistic social stimuli and (2) link brain activity to "accuracy" about inferring other's emotional states. This study addressed this gap by investigating the neural correlates of empathic accuracy (EA) in schizophrenia. Methods: Fifteen schizophrenia patients and 15 controls were scanned while continuously rating the affective state of another person shown in a series of videos (ie, targets). These ratings were compared with targets' own self-rated affect, and EA was defined as the correlation between participants' ratings and targets' self-ratings. Targets' self-reported emotional expressivity also was measured. We searched for brain regions whose activity tracked parametrically with (1) perceivers' EA and (2) targets' expressivity. Results: Patients showed reduced EA compared with controls. The left precuneus, left middle frontal gyms, and bilateral thalamus were significantly more correlated with EA in controls compared with patients. High expressivity in targets was associated with better EA in controls but not in patients. High expressivity was associated with increased brain activity in a large set of regions in controls (eg, fusiform gyrus, medial prefrontal cortex) but not in patients. Discussion: These results use a naturalistic performance measure to confirm that schizophrenic patients demonstrate impaired ability to understand others' internal states. They provide novel evidence about a potential mechanism for this impairment: schizophrenic patients failed to capitalize on targets' emotional expressivity and also demonstrate reduced neural sensitivity to targets' affective cues.
C1 [Harvey, Philippe-Olivier] Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada.
[Zaki, Jamil] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Lee, Junghee; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Lee, Junghee; Green, Michael F.] Healthcare Ctr Syst, VA Greater Los Angeles, Los Angeles, CA USA.
[Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
RP Harvey, PO (reprint author), Douglas Mental Hlth Univ Inst, 6875 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada.
EM philippe-olivier.harvey@douglas.mcgill.ca
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU Desert Pacific Mental Illness Research, Education, and Clinical Center;
UCLA Brain Mapping Center; Canadian Institutes of Health Research; Brain
Mapping Medical Research Organization; Brain Mapping Support Foundation;
Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda
R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation; Tamkin Foundation; Jennifer Jones-Simon; Capital Group
Companies Charitable Foundation; Robson Family; Northstar Fund;
[MH043292]
FX This work was supported by pilot grants from the Desert Pacific Mental
Illness Research, Education, and Clinical Center and the UCLA Brain
Mapping Center. This work was also supported by grant MH043292 to Dr
M.F.G. Poorang Nori assisted in data collection. Dr P.O.H. is supported
by a postdoctoral fellowship from the Canadian Institutes of Health
Research.; For generous support of the UCLA Brain Mapping Center, we
also thank the Brain Mapping Medical Research Organization, Brain
Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson
Foundation, William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer
Jones-Simon, Capital Group Companies Charitable Foundation, Robson
Family, and Northstar Fund. Financial Disclosures: The authors have no
financial disclosure to report. The authors have declared that there are
no conflicts of interest in relation to the subject of this study.
NR 56
TC 19
Z9 19
U1 1
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 617
EP 628
DI 10.1093/schbul/sbs042
PG 12
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200022
PM 22451493
ER
PT J
AU Lee, J
Kern, RS
Harvey, PO
Horan, WP
Kee, KS
Ochsner, K
Penn, DL
Green, MF
AF Lee, Junghee
Kern, Robert S.
Harvey, Philippe-Olivier
Horan, William P.
Kee, Kimmy S.
Ochsner, Kevin
Penn, David L.
Green, Michael F.
TI An Intact Social Cognitive Process in Schizophrenia: Situational Context
Effects on Perception of Facial Affect
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; contextual modulation; facial affect processing; social
cognition
ID PREFRONTAL CORTEX; SURPRISED FACES; EMOTION; EXPRESSIONS; TASK;
ORGANIZATION; SPECTRUM; AMYGDALA; FMRI
AB Background: Impaired facial affect recognition is the most consistent social cognitive finding in schizophrenia. Although social situations provide powerful constraints on our perception, little is known about how situational context modulates facial affect recognition in schizophrenia. Methods: Study 1 was a single-site study with 34 schizophrenia patients and 22 healthy controls. Study 2 was a 2-site study with 68 schizophrenia patients and 28 controls. Both studies administered a Situational Context Facial Affect Recognition Task with 2 conditions: a situational context condition and a no-context condition. For the situational context condition, a briefly shown face was preceded by a sentence describing either a fear- or surprise-inducing event. In the no-context condition, a face was presented without a sentence. For both conditions, subjects rated how fearful or surprised the face appeared on a 9-point Likert scale. Results: For the situational context condition of study 1, both patients and controls rated faces as more afraid when they were paired with fear-inducing sentences and as more surprised when they were paired with surprise-inducing sentences. The degree of modulation was comparable across groups. For the no-context condition, patients rated faces comparably to controls. The findings of study 2 replicated those from study 1. Conclusions: Despite previous abnormalities in other types of context paradigms, this study found intact situational context processing in schizophrenia, suggesting that patients benefit from situational context when interpreting ambiguous facial expression. This area of relative social cognitive strength in schizophrenia has implications for social cognitive training programs.
C1 [Lee, Junghee; Kern, Robert S.; Harvey, Philippe-Olivier; Horan, William P.; Kee, Kimmy S.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Lee, Junghee; Kern, Robert S.; Harvey, Philippe-Olivier; Horan, William P.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
[Harvey, Philippe-Olivier] McGill Univ, Douglas Mental Heath Univ Inst, Montreal, PQ, Canada.
[Kee, Kimmy S.] Calif State Univ, Dept Psychol, Camarillo, CA USA.
[Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
[Penn, David L.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA.
RP Lee, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 300 Med Plaza Room 2261, Los Angeles, CA 90095 USA.
EM jungheelee@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU National Institutes of Mental Health [MH043292, MH087618]
FX National Institutes of Mental Health (MH043292 and MH087618 to PI:
M.F.G., PhD).
NR 36
TC 11
Z9 11
U1 4
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 640
EP 647
DI 10.1093/schbul/sbs063
PG 8
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200024
PM 22532704
ER
PT J
AU Ahluwalia, SC
Leos, RL
Goebel, JR
Asch, SM
Lorenz, KA
AF Ahluwalia, Sangeeta C.
Leos, Rosana L.
Goebel, Joy R.
Asch, Steven M.
Lorenz, Karl A.
TI Provider Approaches to Palliative Dyspnea Assessment: Implications for
Informatics-Based Clinical Tools
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE dyspnea; qualitative research; electronic health records; clinical
informatics; palliative care; user-computer interface
ID PHYSICIAN ORDER ENTRY; QUALITY-OF-LIFE; UNITED-STATES;
RESPIRATORY-DISEASES; CONSENSUS STATEMENT; ANXIETY DISORDERS;
PRIMARY-CARE; LUNG-CANCER; MANAGEMENT; BREATHLESSNESS
AB Aim: To understand provider practices around dyspnea assessment to inform the development of an electronic medical record (EMR)-based dyspnea assessment module in an inpatient palliative care consultation template. Design: Qualitative analysis of palliative care provider interviews. Results: Three themes emerged: (1) integration of patient self-report of breathlessness with a clinical observation of dyspnea; (2) identification of patients for dyspnea assessment based on perceived patient need; and (3) variability in preferences for and use of existing severity scales for dyspnea. Conclusions: The assessment approaches described by providers underscore the challenge of developing an informatics tool that supports the natural clinical experience and facilitates standardized care. The complexity of the dyspnea assessment process and variation in provider practices necessitate a level of flexibility and choice to be built into a computer-based tool.
C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA.
[Ahluwalia, Sangeeta C.; Asch, Steven M.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
[Ahluwalia, Sangeeta C.; Leos, Rosana L.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA.
[Goebel, Joy R.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, Steven M.] Vet Adm Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Asch, Steven M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA.
EM sangeeta.c.ahluwalia@gmail.com
FU Department of Veterans Affairs Comprehensive End-of-Life Care
Initiative, Office of Patient Care Services; Office of Academic
Affiliation's VA Associated Health Postdoctoral Fellowship Program at
the VA Greater Los Angeles HSR&D Center of Excellence
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Department of Veterans Affairs Comprehensive
End-of-Life Care Initiative, Office of Patient Care Services. Dr
Ahluwalia was supported by an Office of Academic Affiliation's VA
Associated Health Postdoctoral Fellowship Program at the VA Greater Los
Angeles HSR&D Center of Excellence.
NR 64
TC 1
Z9 1
U1 1
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD MAY
PY 2013
VL 30
IS 3
BP 231
EP 238
DI 10.1177/1049909112448922
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 127CW
UT WOS:000317674300002
PM 22669935
ER
PT J
AU Schell, JO
O'Hare, AM
AF Schell, Jane O.
O'Hare, Ann M.
TI Illness trajectories and their relevance to the care of adults with
kidney disease
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE communication; experience of illness; kidney disease; patient-centered;
trajectory
ID STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; DECISION-MAKING; LAST YEAR;
OF-LIFE; FUNCTIONAL DECLINE; CANCER-PATIENTS; OLDER-ADULTS; END;
OUTCOMES
AB Purpose of review
Existing practice guidelines for chronic kidney disease advocate a stage-based approach to management, in which treatment recommendations are based largely on the severity of kidney disease, and future risk for adverse health outcomes. However, the course of kidney disease can vary widely among patients with similar levels of kidney function, and each patient will experience their illness in unique ways.
Recent findings
We summarize recent studies of patterns of kidney function over time among patients with chronic kidney disease, and discuss these findings in the context of relevant conceptual models of illness and communication. Although knowledge of disease severity can provide useful information on life expectancy and risk for future health events, an understanding of each patient's illness trajectory and their unique experience of illness is essential in supporting patient-centered care for patients with kidney disease. This information can be helpful in setting realistic expectations for the future, in communicating about prognosis and in aligning treatment decisions with each patient's goals and preferences.
Summary
We here explain how an understanding of illness trajectories may be useful in predicting and guiding care and decision-making in patients with kidney disease. We highlight the importance of competing disease trajectories, the heterogeneity in renal function trajectories among patients with kidney disease, and the variability in these trajectories over time in individual patients. We discuss how individual disease trajectories can shape each patient's experience of illness. Finally, we explain how an understanding of an individual patient's illness trajectory and experience of illness may be useful in guiding discussions about prognosis and treatment decisions and in supporting a patient-centered approach to care.
C1 [Schell, Jane O.] Univ Pittsburgh, Sch Med, Sect Palliat Care & Med Eth, UPMC, Pittsburgh, PA USA.
[Schell, Jane O.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, UPMC, Pittsburgh, PA USA.
[O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA.
[O'Hare, Ann M.] Univ Washington, Seattle, WA 98195 USA.
RP Schell, JO (reprint author), UPMC Montefiore, Suite 933W,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM schelljo@upmc.edu
FU National Institute on Aging; Centers for Disease Control; Department of
Veterans Affairs
FX A.M.O. receives research funding from the National Institute on Aging,
the Centers for Disease Control and the Department of Veterans Affairs
and royalties from UpToDate. These funding sources had no role in this
work. J.O.S. has no conflicts of interest to declare.
NR 45
TC 10
Z9 10
U1 4
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD MAY
PY 2013
VL 22
IS 3
BP 316
EP 324
DI 10.1097/MNH.0b013e32835ffaaf
PG 9
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 126YK
UT WOS:000317658800010
PM 23518464
ER
PT J
AU Sharma, S
Zhu, L
Davoodi, M
Harris-White, M
Lee, JM
St John, M
Salgia, R
Dubinett, S
AF Sharma, Sherven
Zhu, Li
Davoodi, Michael
Harris-White, Marni
Lee, Jay M.
St John, Maie
Salgia, Ravi
Dubinett, Steven
TI TLR3 agonists and proinflammatory antitumor activities
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Editorial Material
DE cancer; immune suppression; immune therapy; TLR3 agonists
ID TOLL-LIKE RECEPTOR-3; POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID;
POLYINOSINIC-POLYCYTIDYLIC ACID; CANCER-CELLS; DENDRITIC CELLS; I
INTERFERONS; APOPTOSIS; TRIAL
AB Although tumor growth leads to inflammatory responses, the immune system develops tolerance to cancer. One way to break host tolerance to tumors is to activate key immune effector activities. Toward this end, various adjuvants are under investigation in an effort to harness the immune system to overcome tolerance to tumor-associated self-antigens. There is enthusiasm for the use of specific ligands for toll-like receptor 3 (TLR3) that play a key role in the innate immune system. TLR3 agonists serve as immune adjuvants because they potently induce innate immune responses by activating dendritic cell ( DC) maturation and inflammatory cytokine secretion. These activities facilitate the bridge between the innate and adaptive immune systems promoting the expansion of cytotoxic T lymphocytes (CTL) that destroy cancer cells. TLR3 agonists either alone or in combination with tumor antigens have shown success in terms of enhancing immune responses and eliciting antitumor activity in preclinical models. However, TLR3 agonists can also impact regulatory cells that dampen immune responses. Thus, immune strategies that utilize TLR3 agonists should consider the relative induction of suppressive as well as beneficial antitumor immune activities. Herein, we summarize the TLR3 agonists that will hopefully come to clinical fruition.
C1 [Sharma, Sherven; Zhu, Li; Davoodi, Michael; Lee, Jay M.; St John, Maie; Dubinett, Steven] Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Lung Canc Res Program, Los Angeles, CA 90024 USA.
[Sharma, Sherven; Lee, Jay M.; St John, Maie; Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Sharma, Sherven; Zhu, Li; Davoodi, Michael; Harris-White, Marni; Dubinett, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA.
[Salgia, Ravi] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Lung Canc Program,Div Pulm & Crit Care Med,Mol Ge, Los Angeles, CA 90024 USA.
EM ssharma@mednet.ucla.edu
FU NCATS NIH HHS [UL1 TR000124, UL1TR000124]; NCI NIH HHS [R01 CA126944,
R01 CA95686, P50 CA090388, P50 CA90388, R01 CA085686]; NIDCR NIH HHS
[K23 DE021193]
NR 17
TC 6
Z9 6
U1 0
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD MAY
PY 2013
VL 17
IS 5
BP 481
EP 483
DI 10.1517/14728222.2013.781585
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 130RA
UT WOS:000317935400002
PM 23506058
ER
PT J
AU Kashyap, PC
Marcobal, A
Ursell, LK
Larauche, M
Duboc, H
Earle, KA
Sonnenburg, ED
Ferreyra, JA
Higginbottom, SK
Million, M
Tache, Y
Pasricha, PJ
Knight, R
Farrugia, G
Sonnenburg, JL
AF Kashyap, Purna C.
Marcobal, Angela
Ursell, Luke K.
Larauche, Muriel
Duboc, Henri
Earle, Kristen A.
Sonnenburg, Erica D.
Ferreyra, Jessica A.
Higginbottom, Steven K.
Million, Mulugeta
Tache, Yvette
Pasricha, Pankaj J.
Knight, Rob
Farrugia, Gianrico
Sonnenburg, Justin L.
TI Complex Interactions Among Diet, Gastrointestinal Transit, and Gut
Microbiota in Humanized Mice
SO GASTROENTEROLOGY
LA English
DT Article
DE Dietary Carbohydrates; Microbiome; Metabolomics; Serotonin
ID INTESTINE; HEALTH; INFLAMMATION; DISORDERS; SEROTONIN; BACTERIA;
DISEASE; SYSTEM; TRACT; FIBER
AB BACKGROUND & AIMS: Diet has major effects on the intestinal microbiota, but the exact mechanisms that alter complex microbial communities have been difficult to elucidate. In addition to the direct influence that diet exerts on microbes, changes in microbiota composition and function can alter host functions such as gastrointestinal (GI) transit time, which in turn can further affect the microbiota. METHODS: We investigated the relationships among diet, GI motility, and the intestinal microbiota using mice that are germ-free (GF) or humanized (ex-GF mice colonized with human fecal microbiota). RESULTS: Analysis of gut motility revealed that humanized mice fed a standard polysaccharide-rich diet had faster GI transit and increased colonic contractility compared with GF mice. Humanized mice with faster transit due to administration of polyethylene glycol or a nonfermentable cellulose-based diet had similar changes in gut microbiota composition, indicating that diet can modify GI transit, which then affects the composition of the microbial community. However, altered transit in mice fed a diet of fermentable fructooligosaccharide indicates that diet can change gut microbial function, which can affect GI transit. CONCLUSIONS: Based on studies in humanized mice, diet can affect GI transit through microbiota-dependent or microbiota-independent pathways, depending on the type of dietary change. The effect of the microbiota on transit largely depends on the amount and type (fermentable vs nonfermentable) of polysaccharides present in the diet. These results have implications for disorders that affect GI transit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.
C1 [Kashyap, Purna C.; Marcobal, Angela; Earle, Kristen A.; Sonnenburg, Erica D.; Ferreyra, Jessica A.; Higginbottom, Steven K.; Sonnenburg, Justin L.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
[Pasricha, Pankaj J.] Stanford Univ, Sch Med, Dept Gastroenterol & Hepatol, Stanford, CA 94305 USA.
[Kashyap, Purna C.; Farrugia, Gianrico] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA.
[Ursell, Luke K.; Million, Mulugeta; Knight, Rob] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Knight, Rob] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
RP Sonnenburg, JL (reprint author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 299 Campus Dr,Fairchild Bldg D315, Stanford, CA 94305 USA.
EM jsonnenburg@stanford.edu
RI Knight, Rob/D-1299-2010
OI Larauche, Muriel/0000-0003-3320-3675
FU National Institutes of Health [R01DK085025]; Digestive Diseases Center
[DK-41301, K01 DK088937]
FX Supported by National Institutes of Health grant R01DK085025 (to
J.L.S.), Digestive Diseases Center grant DK-41301 (Animal Models Core;
to Y.T., M. M.) and K01 DK088937 (M.L.).
NR 32
TC 90
Z9 92
U1 15
U2 123
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 5
BP 967
EP 977
DI 10.1053/j.gastro.2013.01.047
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 129BR
UT WOS:000317813900026
PM 23380084
ER
PT J
AU Schmitz, M
AF Schmitz, Martha
TI The Case: Treating Jared Through Seeking Safety
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
C1 Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Schmitz, M (reprint author), Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM Martha.schmitz@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 490
EP 493
DI 10.1002/jclp.21985
PG 4
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100006
PM 23564554
ER
PT J
AU Landes, SJ
Garovoy, ND
Burkman, KM
AF Landes, Sara J.
Garovoy, Natara D.
Burkman, Kristine M.
TI Treating Complex Trauma Among Veterans: Three Stage-Based Treatment
Models
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE complex trauma; Veterans; treatment; dialectical behavior therapy; STAIR
narrative therapy; seeking safety
ID THERAPY; PTSD
AB This article addresses the issue of complex trauma in veterans and treatments for symptom presentations resulting from complex trauma exposure. While various definitions have been proposed for complex trauma, the clinical issues related to it are relevant for veterans as they are at risk for cumulative trauma exposures such as multiple combat deployments and military sexual trauma. Several treatments were either developed to address and/or implemented with complex trauma. This article discusses three of these treatments that share a stage-based approach, focusing on the present (e.g., skills training and psychoeducation), which can then be followed, if needed, with a past-focused (e.g., exposure-based) treatment: Dialectical Behavior Therapy (Linehan, 1993), Seeking Safety (Najavits, 2002), Skills Training in Affective and Interpersonal Regulation (STAIR) Narrative Therapy (Cloitre, Cohen, & Koenen, 2006). This article also discusses what is currently being done to address symptom presentations resulting from complex trauma exposure and challenges and possible solutions to implementing this care.
C1 [Landes, Sara J.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA.
[Garovoy, Natara D.] VA Palo Alto Hlth Care Syst, Womens Prevent Outreach & Educ Ctr, Menlo Pk, CA 94025 USA.
[Burkman, Kristine M.] San Francisco VA Med Ctr, PTSD Res Program, San Francisco, CA USA.
RP Landes, SJ (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM sara.landes@va.gov
OI Landes, Sara/0000-0001-8515-2465
NR 10
TC 2
Z9 2
U1 1
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 523
EP 533
DI 10.1002/jclp.21988
PG 11
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100011
PM 23529776
ER
PT J
AU Chren, MM
Linos, E
Torres, JS
Stuart, SE
Parvataneni, R
Boscardin, WJ
AF Chren, Mary-Margaret
Linos, Eleni
Torres, Jeanette S.
Stuart, Sarah E.
Parvataneni, Rupa
Boscardin, W. John
TI Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell
Carcinoma and Squamous Cell Carcinoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID MOHS MICROGRAPHIC SURGERY; NONMELANOMA SKIN-CANCER; SURGICAL EXCISION;
COST-EFFECTIVENESS; PRIVATE-PRACTICE; FACE; VALIDITY
AB For most cutaneous basal cell and squamous cell carcinomas (nonnnelanoma skin cancers (NMSCs)), data are insufficient to permit evidence-based choices among treatments. To compare tumor recurrence after treatments, we conducted a prospective cohort study of consecutive patients with primary NMSCs treated with the most common treatments, in two practices in 1999-2000. Recurrence was determined from medical records by observers blinded to treatment type. Follow-up was available for 1,174 patients with 1,488 tumors (93.8%) at median 7.4 years; of these tumors, 24.3% (N=361) were treated with destruction with electrodessication/curettage, 38.3% (N=571) with excision, and 37.4% (N=556) with histologically guided serial excision (Mohs surgery). The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3% (2.3, 4.4). Unadjusted recurrence rates did not differ after treatments: 4.9% (2.3, 7.4) after destruction, 3.5% (1.8, 5.2) after excision, and 2.1% (0.6, 3.5) after Mohs surgery (P=0.26), and no difference was seen after adjustment for risk factors. In tumors treated only with excision or Mohs surgery, the hazard of recurrence was not significantly different, even after adjustment for propensity for treatment with Mohs surgery. These data indicate that common treatments for NMSCs were at least 95% effective, and further studies are needed to guide therapeutic choices for different clinical subgroups.
C1 [Chren, Mary-Margaret; Linos, Eleni; Stuart, Sarah E.; Parvataneni, Rupa] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret; Torres, Jeanette S.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Chren, MM (reprint author), Zion Canc Res Bldg,2340 Sutter St,Room N412,Box 0, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
RI Linos, Eleni/C-4392-2014
OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health [R01 AR 054983, K02 AR02203, K24
AR052667]; Investigator-Initiated Research Grants [IIRs 97010-2 and
04-043-3]; Health Services Research Enhancement Award Program (REAP) of
the Health Services Research; Development Service of the Department of
Veterans Affairs
FX This work was supported by grants from the National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of
Health (R01 AR 054983, K02 AR02203, and K24 AR052667), and by
Investigator-Initiated Research Grants (IIRs 97010-2 and 04-043-3) and
the Health Services Research Enhancement Award Program (REAP) of the
Health Services Research and Development Service of the Department of
Veterans Affairs.
NR 29
TC 50
Z9 51
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
IS 5
BP 1188
EP 1196
DI 10.1038/jid.2012.403
PG 9
WC Dermatology
SC Dermatology
GA 127KV
UT WOS:000317698800014
PM 23190903
ER
PT J
AU Ang, C
Anyanwu, C
Werth, V
AF Ang, C.
Anyanwu, C.
Werth, V.
TI Mechanic's hands are predictive of reduced lung diffusion capacity and
interstitial lung disease in patients with dermatomyositis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Ang, C.; Anyanwu, C.; Werth, V.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Ang, C.; Anyanwu, C.; Werth, V.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Ang, C.] Changi Gen Hosp, Dept Dermatol, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1121
BP S190
EP S190
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901410
ER
PT J
AU Anyanwu, CO
Propert, KJ
Werth, VP
AF Anyanwu, C. O.
Propert, K. J.
Werth, V. P.
TI Determination of cutaneous dermatomyositis severity using the cutaneous
dermatomyositis disease area and severity index
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Anyanwu, C. O.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
[Anyanwu, C. O.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Propert, K. J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 216
BP S36
EP S36
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900216
ER
PT J
AU Chang, YC
Propert, KJ
Werth, VP
AF Chang, Y. C.
Propert, K. J.
Werth, V. P.
TI The limitations in measuring improvement in disease activity in patients
with mild cutaneous lupus erythematosus
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Chang, Y. C.; Werth, V. P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Chang, Y. C.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Propert, K. J.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 190
BP S32
EP S32
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900190
ER
PT J
AU Chang, YC
Propert, KJ
Sirignano, S
Chong, B
Werth, VP
AF Chang, Y. C.
Propert, K. J.
Sirignano, S.
Chong, B.
Werth, V. P.
TI Disease flare and progression in cutaneous lupus erythematosus: A
longitudinal study of CLE
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Chang, Y. C.; Werth, V. P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Chang, Y. C.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Propert, K. J.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Sirignano, S.; Chong, B.] UT Southwestern, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 189
BP S32
EP S32
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900189
ER
PT J
AU Katiyar, SK
Prasad, R
AF Katiyar, S. K.
Prasad, R.
TI Prostaglandin E2 promotes UV radiation-induced immune suppression via
DNA hypermethylation
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Katiyar, S. K.; Prasad, R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1243
BP S211
EP S211
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901532
ER
PT J
AU Rubina, S
Camp, WL
Hermann, J
Cantrell, W
Cantor, AB
Athar, M
Elmets, CA
AF Rubina, S.
Camp, W. L.
Hermann, J.
Cantrell, W.
Cantor, A. B.
Athar, M.
Elmets, C. A.
TI Tanning beds use and skin cancer biomarkers - a pilot study
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Rubina, S.; Camp, W. L.; Hermann, J.; Cantrell, W.; Athar, M.; Elmets, C. A.] UAB, Birmingham, AL USA.
[Athar, M.; Elmets, C. A.] UAB, SDRC, Birmingham, AL USA.
[Cantor, A. B.] UAB, Div Prevent Med, Birmingham, AL USA.
[Elmets, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1289
BP S219
EP S219
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901578
ER
PT J
AU Timares, L
Nasti, T
Cochran, B
Jaleel, T
Yusuf, N
Elmets, CA
AF Timares, L.
Nasti, T.
Cochran, B.
Jaleel, T.
Yusuf, N.
Elmets, C. A.
TI A new mouse model for studying the development of melanomas
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Timares, L.; Nasti, T.; Cochran, B.; Jaleel, T.; Yusuf, N.; Elmets, C. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Timares, L.; Yusuf, N.; Elmets, C. A.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL USA.
[Elmets, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1400
BP S238
EP S238
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901688
ER
PT J
AU Vaid, M
Katiyar, SK
AF Vaid, M.
Katiyar, S. K.
TI Proanthocyanidins inhibit invasive potential of human melanoma cells by
targeting beta-catenin signaling
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Vaid, M.; Katiyar, S. K.] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1323
BP S225
EP S225
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901613
ER
PT J
AU Wehner, MR
Linos, E
Parvataneni, R
Stuart, SE
Boscardin, WJ
Chren, M
AF Wehner, M. R.
Linos, E.
Parvataneni, R.
Stuart, S. E.
Boscardin, W. J.
Chren, M.
TI Risk of subsequent non-melanoma skin cancers in patients with prior
non-melanoma skin cancer
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Wehner, M. R.; Linos, E.; Parvataneni, R.; Stuart, S. E.; Boscardin, W. J.; Chren, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wehner, M. R.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Chren, M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RI Linos, Eleni/C-4392-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 547
BP S93
EP S93
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900544
ER
PT J
AU Ikonomidis, JS
Ivey, CR
Wheeler, JB
Akerman, AW
Rice, A
Patel, RK
Stroud, RE
Shah, AA
Hughes, CG
Ferrari, G
Mukherjee, R
Jones, JA
AF Ikonomidis, John S.
Ivey, Charlotte R.
Wheeler, Jason B.
Akerman, Adam W.
Rice, Allison
Patel, Risha K.
Stroud, Robert E.
Shah, Asad A.
Hughes, Chad G.
Ferrari, Giovanni
Mukherjee, Rupak
Jones, Jeffrey A.
TI Plasma biomarkers for distinguishing etiologic subtypes of thoracic
aortic aneurysm disease
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID MATRIX METALLOPROTEINASES; ENDOGENOUS INHIBITORS; DILATATION; VALVES;
MATRIX-METALLOPROTEINASE-9; NORMALIZATION; EXPRESSION; MICRORNAS; SIZE
AB Background: Thoracic aortic aneurysms (TAAs) develop through an asymptomatic process resulting in gross dilation that progresses to rupture if left undetected and untreated. If detected, patients with TAA are followed over time until the risk of rupture outweighs the risk of surgical repair. Current methodologies for tracking TAA size are limited to expensive computed tomography or magnetic resonance imaging because no acceptable population screening tools are currently available. Previous studies from this laboratory and others have identified differential protein profiles for the matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs), in ascending TAA tissue from patients with bicuspid aortic valves (BAVs), versus patients with idiopathic degenerative disease and a tricuspid aortic valve (TAV). In addition, altered microRNA (miR) expression levels have also been reported in TAAs compared with normal aortic tissue. The objective of our study was to identify circulating factors within plasma that could serve as potential biomarkers for distinguishing etiologic subtypes of aneurysm disease.
Methods: Ascending TAA tissue and plasma specimens were obtained from patients with BAV (n = 21) and TAV (n = 21) at the time of surgical resection. The protein abundance of key MMPs (1, 2, 3, 8, and 9), TIMPs (1, 2, 3, and 4), and miRs (1, 21, 29a, 133a, 143, and 145) was examined using a multianalyte protein profiling system or by quantitative polymerase chain reaction, respectively. Results were compared with normal aortic tissue and plasma obtained from patients without aortic disease (n = 10).
Results: Significant (P <. 05) differences in standardized miR-1 and miR-21 abundance between BAV and TAV aortic tissue samples and different tissue and plasma profiles of analyte differences from normal aorta where observed between the BAV and TAV groups. Linear regression analysis revealed significant linear relationships in plasma and tissue measurements only for MMP-8 and TIMP-1, TIMP-3, and TIMP-4 (P <. 05). Receiver operator curve analysis revealed specific cassettes of analytes predictive of TAA disease. Relative to normal aorta, BAV proteolytic balance was significantly increased for MMP-1, MMP-2, and MMP-7, and for decreased MMP-8 and MMP-9. In contrast, TAV proteolytic balance relative to normal aorta was significantly increased only for MMP-1 and decreased for MMP-8 and MMP-9.
Conclusions: Taken together, these unique data demonstrate differential plasma profiles of MMPs, TIMPs, and miRs in ascending TAA specimens from patients with BAV and TAV. These results suggest that circulating biomarkers may form the foundation for a broader platform of biomarkers capable of detecting the presence of TAA using a simple blood test and may also be useful in personalized strategies to distinguish between etiologic subtypes of TAAs in patients with aneurysm disease. (J Thorac Cardiovasc Surg 2013; 145:1326-33)
C1 [Ikonomidis, John S.; Ivey, Charlotte R.; Wheeler, Jason B.; Akerman, Adam W.; Rice, Allison; Patel, Risha K.; Stroud, Robert E.; Mukherjee, Rupak; Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Shah, Asad A.; Hughes, Chad G.] Duke Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, Durham, NC USA.
[Ferrari, Giovanni] Univ Penn, Sch Med, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA.
[Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
RP Ikonomidis, JS (reprint author), Med Univ S Carolina, 25 Courtenay Dr,Suite 7030, Charleston, SC 29425 USA.
EM ikonomij@musc.edu
FU National Institutes of Health/National Institute on Aging [AG036954];
National Institutes of Health/National Heart, Lung, and Blood Institute
[HL102121]; Veterans Affairs Merit Award [1 I01 BX000904-01]
FX This study was supported by the following grants: National Institutes of
Health/National Institute on Aging No. AG036954, National Institutes of
Health/National Heart, Lung, and Blood Institute No. HL102121, and
Veterans Affairs Merit Award No. 1 I01 BX000904-01.
NR 20
TC 20
Z9 21
U1 0
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAY
PY 2013
VL 145
IS 5
BP 1326
EP 1333
DI 10.1016/j.jtcvs.2012.12.027
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 129LJ
UT WOS:000317840600029
PM 23312977
ER
PT J
AU Backhus, LM
Hayanga, AJ
Au, D
Zeliadt, SB
AF Backhus, Leah M.
Hayanga, Awori J.
Au, David
Zeliadt, Steven B.
TI The Effect of Provider Density on Lung Cancer Survival Among Blacks and
Whites in the United States
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung cancer; Racial disparities; Provider density
ID PROSTATE-CANCER; GEOGRAPHIC ACCESS; NORTHERN ENGLAND; HEALTH-CARE;
TRAVEL-TIME; BREAST; DISPARITIES; MORTALITY; SURGERY; RACE
AB Introduction: Lung cancer mortality rates may vary with access to specialty providers and local resources. We sought to examine the effect of access to care, using density of lung cancer care providers, on lung cancer mortality among blacks and whites in the United States.
Methods: We examined U.S. county-level data for age-adjusted lung cancer mortality rates from 2003 to 2007. Our primary independent variable was per capita number of thoracic oncologic providers, adjusting for county-level smoking rates, socioeconomic status, and other geographic factors. Data were obtained from 2009 Area Resource File, National Center for Health Statistics, and the County Health Rankings Project.
Results: Providers of lung cancer care were unevenly distributed among the U.S. counties. For example, 41.4% of the U.S. population reside in counties with less than four thoracic surgeons per 100,000 people, 23.4% in counties with 4 to 15 surgeons per 100,000 people, and 35.3% in counties with more than 15 surgeons per 100,000 people. Geographically, 4.3% of whites compared with 11.2% of blacks lived in high lung cancer mortality zones. Lung cancer mortality did not vary by density of thoracic surgeons or oncology services; however, higher primary care provider density was associated with lung cancer mortality reduction of 4.1 per 100,000 for whites.
Conclusion: Variation in provider density for thoracic oncology in the United States was not associated with a difference in lung cancer mortality. Lower mortality associated with higher primary care provider density suggests that equitable access to primary care may lead to reduced cancer disparities.
C1 [Backhus, Leah M.; Au, David; Zeliadt, Steven B.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Backhus, Leah M.; Hayanga, Awori J.] Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA.
[Au, David] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Au, David; Zeliadt, Steven B.] VA Hlth Serv Res & Dev Serv, Seattle, WA USA.
RP Backhus, LM (reprint author), Univ Washington, Div Cardiothorac Surg, 1959 NE Pacific St,Suite 356310, Seattle, WA 98195 USA.
EM lbackhus@u.washington.edu
OI Backhus, Leah/0000-0002-4553-1003
NR 20
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD MAY
PY 2013
VL 8
IS 5
BP 549
EP 553
DI 10.1097/JTO.0b013e318287c24c
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 125ZX
UT WOS:000317582000017
PM 23446202
ER
PT J
AU Conte, MS
Owens, CD
Belkin, M
Creager, MA
Edwards, KL
Gasper, WJ
Kenagy, RD
LeBoeuf, RC
Sobel, M
Clowes, A
AF Conte, Michael S.
Owens, Christopher D.
Belkin, Michael
Creager, Mark A.
Edwards, Karen L.
Gasper, Warren J.
Kenagy, Richard D.
LeBoeuf, Renee C.
Sobel, Michael
Clowes, Alexander
TI A single nucleotide polymorphism in the p27(Kip1) gene is associated
with primary patency of lower extremity vein bypass grafts
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg (SVS)
ID DEPENDENT KINASE INHIBITORS; SMOOTH-MUSCLE-CELLS; PROMOTER ACTIVITY;
VASCULAR-DISEASE; PREVENT-III; SURGERY; ARTERY; FAILURE; TRIAL;
EDIFOLIGIDE
AB Objective: Factors responsible for the variability in outcomes after lower extremity vein bypass grafting (LEVBG) are poorly understood. Recent evidence has suggested that a single nucleotide polymorphism (SNP) in the promoter region of the p27(Kip1) gene, a cell-cycle regulator, is associated with coronary in-stent restenosis. We hypothesized an association with vein graft patency.
Methods: This was a retrospective genetic association study nested within a prospective cohort of 204 patients from three referral centers undergoing LEVBG for claudication or critical ischemia. The main outcome measure was primary vein graft patency.
Results: All patients were followed up for a minimum of 1 year with duplex graft surveillance (median follow-up, 893 days; interquartile range, 539-1315). Genomic DNA was isolated and SNP analysis for the p27(Kip1)-838C>A variants was performed. Allele frequencies were correlated with graft outcome using survival analysis and Cox proportional hazards modeling. The p27(Kip1)-838C>A allele frequencies observed were CA, 53%; CC, 30%; and AA, 17%, satisfying Hardy-Weinberg equilibrium. Race (P = .025) and history of coronary artery disease (P = .027) were different across the genotypes; all other baseline variables were similar. Primary graft patency was greater among patients with the -838AA genotype (75% AA vs 55% CA/CC at 3 years; P = .029). In a Cox proportional hazards model including age, sex, race, diabetes, critical limb ischemia, redo (vs primary) bypass, vein type, and baseline C-reactive protein level, the p27(Kip1)-838AA genotype was significantly associated with higher graft patency (hazard ratio for failure, 0.4; 95% confidence interval, 0.17-0.93). Genotype was also associated with early (0-1 month) changes in graft lumen diameter by ultrasound imaging.
Conclusions: These data suggest that the p27(Kip1)-838C>A SNP is associated with LEVBG patency and, together with previous reports, underscore a central role for p27(Kip1) in the generic response to vascular injury. (J Vasc Surg 2013;57:1179-85.)
C1 [Conte, Michael S.; Owens, Christopher D.; Gasper, Warren J.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
[Belkin, Michael] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Creager, Mark A.; Sobel, Michael] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Edwards, Karen L.] Univ Washington, Dept Epidemiol, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
[Kenagy, Richard D.; Clowes, Alexander] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[LeBoeuf, Renee C.] Univ Washington, Dept Med, Seattle, WA USA.
[Sobel, Michael] Univ Washington, Div Vasc Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Conte, MS (reprint author), Univ Calif San Francisco, Heart & Vasc Ctr, Div Vasc & Endovasc Surg, 400 Parnassus Ave, San Francisco, CA 94143 USA.
EM michael.conte@ucsfmedctr.org
FU CSRD VA [I01 CX000712]; NHLBI NIH HHS [HL098227, HL30946, HL75771, R01
HL030946, R01 HL075771, R01 HL098227]; NIDDK NIH HHS [P30 DK017047]
NR 32
TC 9
Z9 12
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
BP 1179
EP +
DI 10.1016/j.jvs.2012.11.040
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 127RS
UT WOS:000317716700001
PM 23312942
ER
PT J
AU Kougias, P
Orcutt, S
Pak, T
Pisimisis, G
Barshes, NR
Lin, PH
Bechara, CF
AF Kougias, Panos
Orcutt, Sonia
Pak, Taemee
Pisimisis, George
Barshes, Neal R.
Lin, Peter H.
Bechara, Carlos F.
TI Impact of postoperative nadir hemoglobin and blood transfusion on
outcomes after operations for atherosclerotic vascular disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT William J. Von Liebig Forum at the Rapid Session of the Vascular Annual
Meeting of the Society-for-Vascular-Surgery (SVS) /
Peripheral-Vascular-Surgery-Society Session
CY JUN 07-09, 2012
CL National Harbor, MD
SP Soc Vasc Surg (SVS), Peripheral Vasc Surg Soc
ID ACUTE MYOCARDIAL-INFARCTION; CLINICAL-PRACTICE GUIDELINE; ACUTE CORONARY
SYNDROMES; CELL TRANSFUSION; RESTRICTIVE TRANSFUSION; NONCARDIAC
SURGERY; CARDIAC-SURGERY; CRITICAL-CARE; TRIAL; REQUIREMENTS
AB Objective: Controversy surrounds the topic of transfusion policy after noncardiac operations. This study assessed the combined impact of postoperative nadir hemoglobin (nHb) levels and blood transfusion on adverse events after open surgical intervention in patients who undergo operative intervention for atherosclerotic vascular disease. Methods: Consecutive patients who underwent peripheral arterial disease (PAD)-related operations were balanced on baseline characteristics by inverse weighting on propensity score calculated as their probability to have nHb greater than 10 gm/dL on the basis of operation type, demographics, and comorbidities, including the revised cardiac risk index. A multivariate generalized estimating equation analysis was performed to investigate associations between nHb, transfusion, and a composite outcome of perioperative death and myocardial infarction. Logistic and Cox proportional hazards regressions were used to assess the impact of nHb and transfusion on respiratory and wound complications; and a composite end point (CE) of death, myocardial infarction during a 2-year follow-up. Level of statistical significance was set at alpha of 0.0125 to adjust for the increased probability of type I error attributable to multiple comparisons. Results: The analysis cohort included 880 patients (1074 operations). After adjusting for nHb level, the number of units transfused was not associated with the perioperative occurrence of the CE(odds ratio[OR], 1.13; P = .025). Adjusted for the number of units transfused, nHb had no impact on the perioperative CE (OR, 0.62; P = .22). An interaction term between transfusion and nHb level remained nonsignificant (P = .312), indicating that the impact of blood transfusion was the same regardless of the nHb level. Perioperative respiratory complications were more likely in patients receiving transfusions (OR, 1.22; P = .009), and perioperative wound infections were less common in patients with nHb > 10 gm/dL (OR, 0.65; P = .01). During an average follow-up of 24 months, transfused patients were more likely to develop the CE (hazard ratio [HR], 1.15, P = .009), whereas nHb level did not impact the long-term adverse event rate (HR, 0.78; P = .373). The above associations persisted even after adjusting the Cox regression model for the occurrence of perioperative cardiac events. Conclusions: Although nHb less than 10 gm/dL is not associated with death or ACS after PAD-related operations, maintaining nHb greater than 10 gm/dL appears to decrease the risk of wound infection. Blood transfusion is associated with increased risk of perioperative respiratory complications. Until a randomized trial settles this issue definitively, a restrictive transfusion strategy is justified in patients undergoing operations for atherosclerotic vascular disease. (J Vasc Surg 2013;57:1331-7.)
C1 [Kougias, Panos; Pisimisis, George; Barshes, Neal R.; Bechara, Carlos F.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Kougias, Panos; Orcutt, Sonia; Pak, Taemee; Pisimisis, George; Barshes, Neal R.; Lin, Peter H.; Bechara, Carlos F.] Baylor Coll Med, Houston, TX 77030 USA.
RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM pkougias@bcm.edu
NR 33
TC 3
Z9 3
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
BP 1331
EP 1337
DI 10.1016/j.jvs.2012.10.108
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 127RS
UT WOS:000317716700026
PM 23384496
ER
PT J
AU Palevsky, PM
Liu, KD
Brophy, PD
Chawla, LS
Parikh, CR
Thakar, CV
Tolwani, AJ
Waikar, SS
Weisbord, SD
AF Palevsky, Paul M.
Liu, Kathleen D.
Brophy, Patrick D.
Chawla, Lakhmir S.
Parikh, Chirag R.
Thakar, Charuhas V.
Tolwani, Ashita J.
Waikar, Sushrut S.
Weisbord, Steven D.
TI KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for
Acute Kidney Injury
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Editorial Material
ID CONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; RANDOMIZED
CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; PERCUTANEOUS CORONARY
INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; INTRAVENOUS
N-ACETYLCYSTEINE; GOAL-DIRECTED THERAPY; ISOTONIC SODIUM-BICARBONATE;
PLACEBO-CONTROLLED TRIAL
AB In response to the recently released 2012 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for acute kidney injury (AKI), the National Kidney Foundation organized a group of US experts in adult and pediatric AKI and critical care nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The first portion of the KDIGO guideline attempts to harmonize earlier consensus definitions and staging criteria for AKI. While the expert panel thought that the KDIGO definition and staging criteria are appropriate for defining the epidemiology of AKI and in the design of clinical trials, the panel concluded that there is insufficient evidence to support their widespread application to clinical care in the United States. The panel generally concurred with the remainder of the KDIGO guidelines that are focused on the prevention and pharmacologic and dialytic management of AKI, although noting the dearth of clinical trial evidence to provide strong evidence-based recommendations and the continued absence of effective therapies beyond hemodynamic optimization and avoidance of nephrotoxins for the prevention and treatment of AKI. Am J Kidney Dis. 61(5): 649-672. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Palevsky, Paul M.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA.
[Brophy, Patrick D.] Univ Iowa, Dept Pediat, Carver Coll Med, Div Nephrol, Iowa City, IA 52242 USA.
[Chawla, Lakhmir S.] George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC USA.
[Chawla, Lakhmir S.] George Washington Univ, Dept Med, Div Renal Dis & Hypertens, Washington, DC USA.
[Parikh, Chirag R.] VA Connecticut Healthcare Syst, Renal Sect, West Haven, CT USA.
[Parikh, Chirag R.] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA.
[Thakar, Charuhas V.] Cincinnati VA Med Ctr, Renal Sect, Cincinnati, OH USA.
[Thakar, Charuhas V.] Univ Cincinnati, Dept Internal Med, Div Nephrol & Hypertens, Cincinnati, OH USA.
[Tolwani, Ashita J.] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
[Waikar, Sushrut S.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Rm 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 164
TC 99
Z9 122
U1 1
U2 22
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2013
VL 61
IS 5
BP 649
EP 672
DI 10.1053/j.ajkd.2013.02.349
PG 24
WC Urology & Nephrology
SC Urology & Nephrology
GA 121WV
UT WOS:000317276600003
PM 23499048
ER
PT J
AU Koyner, JL
Garg, AX
Shlipak, MG
Patel, UD
Sint, K
Hong, K
Devarajan, P
Edelstein, CL
Zappitelli, M
Thiessen-Philbrook, H
Parikh, CR
AF Koyner, Jay L.
Garg, Amit X.
Shlipak, Michael G.
Patel, Uptal D.
Sint, Kyaw
Hong, Kwangik
Devarajan, Prasad
Edelstein, Charles L.
Zappitelli, Michael
Thiessen-Philbrook, Heather
Parikh, Chirag R.
CA Translational Res Investigating
TI Urinary Cystatin C and Acute Kidney Injury After Cardiac Surgery
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Acute kidney injury biomarkers; cystatin C; dialysis; perioperative
ID GLOMERULAR-FILTRATION-RATE; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE;
PREDICTS MORTALITY; POOR OUTCOMES; BIOMARKERS; DURATION; THERAPY;
MARKERS
AB Background: Acute kidney injury (AKI) is common after cardiac surgery and is associated with adverse patient outcomes. Urinary cystatin C (CysC) level is a biomarker of proximal tubule function and may increase earlier in AKI than serum creatinine level.
Study Design: Prospective cohort study.
Settings & Participants: The TRIBE AKI (Translational Research Investigating Biomarker Endpoints in AKI) Consortium prospectively enrolled 1,203 adults and 299 children and adolescents at 8 institutions in 2007-2009.
Index Test: Urinary CysC (in milligrams per liter) within the first 12 hours after surgery.
Outcome: Serum creatinine-based AKI was defined as AKI Network stage 1 (mild AKI) and doubling of serum creatinine from the preoperative value or need for dialysis during hospitalization (severe AKI).
Other Measurements: Analyses were adjusted for characteristics used clinically for AKI risk stratification, including age, sex, race, estimated glomerular filtration rate, diabetes, hypertension, heart failure, nonelective surgery, cardiac catheterization within 72 hours, type of surgery, myocardial infarction, and cardiopulmonary bypass time longer than 120 minutes.
Results: Urinary CysC level measured in the early postoperative period (0-6 and 6-12 hours postoperatively) correlated with both mild and severe AKI in adults and children. However, after analyses were adjusted for other factors, the effect was attenuated for both forms of AKI in both cohorts.
Limitations: Limited numbers of patients with severe AKI and in-hospital dialysis treatment.
Conclusions: Urinary CysC values are not associated significantly with the development of AKI after cardiac surgery in adults and children. Am J Kidney Dis. 61(5): 730-738. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Koyner, Jay L.] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
[Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
[Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA.
[Patel, Uptal D.] Duke Univ, Sch Med, Durham, NC USA.
[Sint, Kyaw; Hong, Kwangik; Parikh, Chirag R.] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06510 USA.
[Sint, Kyaw; Hong, Kwangik; Parikh, Chirag R.] Vet Affairs Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA.
[Devarajan, Prasad] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Edelstein, Charles L.] Univ Colorado, Div Renal Dis, Denver, CO 80202 USA.
[Zappitelli, Michael] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Pediat,Div Nephrol, Montreal, PQ H3H 1P3, Canada.
RP Parikh, CR (reprint author), Yale Univ, Program Appl Translat Res, 60 Temple St,Ste 6C, New Haven, CT 06510 USA.
EM chirag.parikh@yale.edu
FU American Heart Association Clinical Development Award; National Heart,
Lung and Blood Institute [R01HL-085757]; National Center for Research
Resources [UL1 RR024139]; National Institute of Diabetes and Digestive
and Kidney Diseases [K23DK081616]; National Institutes of Health
[K24DK090203, U01DK082185]
FX The research reported in this article was supported by the American
Heart Association Clinical Development Award and National Heart, Lung
and Blood Institute grant R01HL-085757 (to Dr Parikh). The study was
also supported by Clinical and Translational Science Award grant UL1
RR024139 from the National Center for Research Resources. Dr Koyner was
supported by National Institute of Diabetes and Digestive and Kidney
Diseases grant K23DK081616. Dr Parikh was also supported by National
Institutes of Health grants K24DK090203 and U01DK082185. Urinary CysC
assays were donated by Sekisui Diagnostics LLC. Sekisui Diagnostics LLC
did not participate in the protocol development, analysis, or
interpretation of the results.
NR 32
TC 15
Z9 19
U1 0
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2013
VL 61
IS 5
BP 730
EP 738
DI 10.1053/j.ajkd.2012.12.006
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 121WV
UT WOS:000317276600014
PM 23332602
ER
PT J
AU Robertson, SM
Amspoker, AB
Cully, JA
Ross, EL
Naik, AD
AF Robertson, S. M.
Amspoker, A. B.
Cully, J. A.
Ross, E. L.
Naik, A. D.
TI Affective symptoms and change in diabetes self-efficacy and glycaemic
control
SO DIABETIC MEDICINE
LA English
DT Article
ID DEPRESSION; STRESS; DISTRESS; ADULTS; TRIAL; CARE
AB Aims To examine the role of baseline depression, anxiety and stress symptoms on post-intervention diabetes self-efficacy and glycaemic control (HbA1c). Methods The current study analysed data from patients (n=85) with treated but uncontrolled Type2 diabetes who participated in a comparative effectiveness study of two diabetes self-management interventions. Hierarchical linear regression was used to examine the relationships between baseline affective symptoms and post-intervention diabetes self-efficacy and the moderating effects of baseline affective symptoms on the relationship between changes in diabetes self-efficacy and post-intervention HbA1c. Results Baseline depression was inversely associated with post-intervention diabetes self-efficacy (P=0.0001) after adjusting for baseline characteristics including diabetes self-efficacy. In contrast, normalmild levels of stress were associated with higher post-intervention diabetes self-efficacy (P=0.04). Anxiety and stress symptoms significantly and independently moderated the relationship between changes in diabetes self-efficacy and post-intervention HbA1c (P=0.02 and P=0.03, respectively). Further evaluation of these interactions demonstrated that changes in diabetes self-efficacy were associated with lower post-intervention HbA1c, but only among those with higher baseline affective symptoms. Conclusions We found a moderating effect across affective symptoms on the relationship between diabetes self-efficacy changes and post-intervention HbA1c in the context of a self-management intervention. Results suggest that patients with poorly controlled diabetes who have higher levels of depression, anxiety and stress symptoms may derive greater benefits from self-management interventions known to improve diabetes self-efficacy.
C1 [Robertson, S. M.; Amspoker, A. B.; Cully, J. A.; Ross, E. L.; Naik, A. D.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res &Development Ctr Excellence, Houston, TX 77004 USA.
[Robertson, S. M.; Amspoker, A. B.; Naik, A. D.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Amspoker, A. B.; Cully, J. A.; Naik, A. D.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Cully, J. A.; Naik, A. D.] Univ Houston, VA South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Ross, E. L.] Univ Houston, Dept Psychol, Houston, TX USA.
RP Robertson, SM (reprint author), Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res &Development Ctr Excellence, Houston, TX 77004 USA.
EM smr1@bcm.tmc.edu
FU Agency for Healthcare Research and Quality; Centers for Research and
Education on Therapeutics [U18HS016093]; Doris Duke Charitable
Foundation; Veterans Affairs Office of Academic Affiliations; National
Institute of Aging [5K23AG027144]
FX This manuscript is supported with resources and the use of facilities at
the Houston Veterans Affairs Health Services Research and Development
Center of Excellence (HEP90-020) at the Michael E. DeBakey Veterans
Affairs Medical Center, Houston, TX. The parent study from which the
data for the current analysis were derived was funded by the Agency for
Healthcare Research and Quality, Centers for Research and Education on
Therapeutics (U18HS016093) and a Doris Duke Charitable Foundation
Clinical Scientist Development Award (Naik). SMR is a Veterans Affairs
Health Services Research post-doc fellow supported by Veterans Affairs
Office of Academic Affiliations. ADN received support from a National
Institute of Aging Career Development Award (5K23AG027144).
NR 27
TC 7
Z9 7
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD MAY
PY 2013
VL 30
IS 5
BP E189
EP E196
DI 10.1111/dme.12146
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 129SQ
UT WOS:000317863000006
PM 23350920
ER
PT J
AU Cheng, G
Torigian, D
Zhuang, HM
Alavi, A
AF Cheng, Gang
Torigian, Drew A.
Zhuang, Hongming
Alavi, Abass
TI When should we recommend use of dual time-point and delayed time-point
imaging techniques in FDG PET?
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Review
DE FDG; PET/CT; Dual time-point imaging; Cancer; Diagnosis
ID CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; PHASE F-18-FDG PET;
LYMPH-NODE METASTASES; TUBERCULOSIS-ENDEMIC COUNTRY; SOLITARY PULMONARY
NODULES; BREAST-CANCER; GALLBLADDER CARCINOMA; HEPATIC METASTASES;
GLUCOSE-METABOLISM
AB FDG PET and PET/CT are now widely used in oncological imaging for tumor characterization, staging, restaging, and response evaluation. However, numerous benign etiologies may cause increased FDG uptake indistinguishable from that of malignancy. Multiple studies have shown that dual time-point imaging (DTPI) of FDG PET may be helpful in differentiating malignancy from benign processes. However, exceptions exist, and some studies have demonstrated significant overlap of FDG uptake patterns between benign and malignant lesions on delayed time-point images. In this review, we summarize our experience and opinions on the value of DTPI and delayed time-point imaging in oncology, with a review of the relevant literature. We believe that the major value of DTPI and delayed time-point imaging is the increased sensitivity due to continued clearance of background activity and continued FDG accumulation in malignant lesions, if the same diagnostic criteria (as in the initial standard single time-point imaging) are used. The specificity of DTPI and delayed time-point imaging depends on multiple factors, including the prevalence of malignancies, the patient population, and the cut-off values (either SUV or retention index) used to define a malignancy. Thus, DTPI and delayed time-point imaging would be more useful if performed for evaluation of lesions in regions with significant background activity clearance over time (such as the liver, the spleen, the mediastinum), and if used in the evaluation of the extent of tumor involvement rather than in the characterization of the nature of any specific lesion. Acute infectious and non-infectious inflammatory lesions remain as the major culprit for diminished diagnostic performance of these approaches (especially in tuberculosis-endemic regions). Tumor heterogeneity may also contribute to inconsistent performance of DTPI. The authors believe that selective use of DTPI and delayed time-point imaging will improve diagnostic accuracy and interpretation confidence in FDG PET imaging.
C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Cheng, Gang; Torigian, Drew A.; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Zhuang, Hongming] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM abass.alavi@uphs.upenn.edu
NR 93
TC 50
Z9 50
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD MAY
PY 2013
VL 40
IS 5
BP 779
EP 787
DI 10.1007/s00259-013-2343-9
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 126NP
UT WOS:000317624700017
PM 23361859
ER
PT J
AU Salgado, CD
Sepkowitz, KA
John, JF
Cantey, JR
Attaway, HH
Freeman, KD
Sharpe, PA
Michels, HT
Schmidt, MG
AF Salgado, Cassandra D.
Sepkowitz, Kent A.
John, Joseph F.
Cantey, J. Robert
Attaway, Hubert H.
Freeman, Katherine D.
Sharpe, Peter A.
Michels, Harold T.
Schmidt, Michael G.
TI Copper Surfaces Reduce the Rate of Healthcare-Acquired Infections in the
Intensive Care Unit
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL PATHOGENS;
CLOSTRIDIUM-DIFFICILE; MICROBIAL BURDEN; ENVIRONMENT; RISK;
CONTAMINATION; SURVEILLANCE; TRANSMISSION; ENTEROCOCCUS
AB OBJECTIVE. Healthcare-acquired infections (HAIs) cause substantial patient morbidity and mortality. Items in the environment harbor microorganisms that may contribute to HAIs. Reduction in surface bioburden may be an effective strategy to reduce HAIs. The inherent biocidal properties of copper surfaces offer a theoretical advantage to conventional cleaning, as the effect is continuous rather than episodic. We sought to determine whether placement of copper alloy-surfaced objects in an intensive care unit (ICU) reduced the risk of HAI.
DESIGN. Intention-to-treat randomized control trial between July 12, 2010, and June 14, 2011.
SETTING. The ICUs of 3 hospitals.
PATIENTS. Patients presenting for admission to the ICU.
METHODS. Patients were randomly placed in available rooms with or without copper alloy surfaces, and the rates of incident HAI and/or colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) in each type of room were compared.
RESULTS. The rate of HAI and/or MRSA or VRE colonization in ICU rooms with copper alloy surfaces was significantly lower than that in standard ICU rooms (0.071 vs 0.123; P = .020). For HAI only, the rate was reduced from 0.081 to 0.034 (P = .013).
CONCLUSIONS. Patients cared for in ICU rooms with copper alloy surfaces had a significantly lower rate of incident HAI and/or colonization with MRSA or VRE than did patients treated in standard rooms. Additional studies are needed to determine the clinical effect of copper alloy surfaces in additional patient populations and settings. Infect Control Hosp Epidemiol 2013;34(5):479-486
C1 [Salgado, Cassandra D.; Cantey, J. Robert] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[John, Joseph F.] Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC USA.
[Attaway, Hubert H.; Schmidt, Michael G.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Freeman, Katherine D.] Extrapolate LLC, Delray Beach, FL USA.
[Sharpe, Peter A.] Sharpe & Associates, W Orange, NJ USA.
[Michels, Harold T.] Copper Dev Assoc, New York, NY USA.
RP Salgado, CD (reprint author), Div Infect Dis, 135 Rutledge Ave, Charleston, SC 29425 USA.
EM salgado@musc.edu
OI Schmidt, Michael G/0000-0002-7794-7265
FU US Army Materiel Command, US Department of Defense (DOD)
[W81XWH-07-C-0053]
FX This study was funded by a grant from the US Army Materiel Command, US
Department of Defense (DOD; contract W81XWH-07-C-0053). The funding
source was not involved in the preparation, submission, and review of
the manuscript.
NR 36
TC 88
Z9 93
U1 2
U2 48
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY
PY 2013
VL 34
IS 5
SI SI
BP 479
EP 486
DI 10.1086/670207
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 123XC
UT WOS:000317424200006
PM 23571364
ER
PT J
AU Townsend, JD
Sugar, CA
Walshaw, PD
Vasquez, RE
Foland-Ross, LC
Moody, TD
Bookheimer, SY
McGough, JJ
Altshuler, LL
AF Townsend, Jennifer D.
Sugar, Catherine A.
Walshaw, Patricia D.
Vasquez, Roxanne E.
Foland-Ross, Lara C.
Moody, Teena D.
Bookheimer, Susan Y.
McGough, James J.
Altshuler, Lori L.
TI Frontostriatal neuroimaging findings differ in patients with bipolar
disorder who have or do not have ADHD comorbidity
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Euthymia; fMRI; ADHD; Response inhibition; Inferior
frontal cortex
ID ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT HYPERACTIVITY
DISORDER; RESPONSE-INHIBITION; PREFRONTAL CORTEX; COGNITIVE CONTROL;
BRAIN ACTIVATION; CINGULATE CORTEX; DEPRESSION; MANIA; CONNECTIVITY
AB Background: The inferior frontal cortical (IFC)-striatal network plays an integral role in response inhibition and is compromised in patients with Bipolar Disorder (BP) or Attention-Deficit/Hyperactivity Disorder (ADHD). Prior BP functional neuroimaging studies have not accounted for ADHD comorbidity despite its high prevalence.
Methods: The authors conducted an fMRI study using a response inhibition task (Go-NoGo) in 32 euthymic adults with BP, half with comorbid ADHD (BP/ADHD); 16 adults with ADHD alone; and 30 healthy controls. Within- and between-group whole-brain analyses were performed to assess for significant neural function differences.
Results: All groups activated frontal and striatal regions involved in response inhibition. ANOVA results demonstrated significant interaction effects of BP and ADHD in the anterior and posterior cingulate, left superior and middle frontal gyri and left inferior parietal lobule. Follow-up comparisons showed significant differences between BP subjects with and without ADHD. Other regions demonstrated main effects of BP (left inferior frontal gyms, left middle frontal gyms, right superior frontal gyrus and left insula) and ADHD (left inferior frontal gyms, left precentral gyrus and right anterior cingulate).
Limitations: This study, as the first of its kind, requires replication using large sample sizes and controlling for potential effects of medication.
Conclusions: Euthymic bipolar adults with comorbid ADHD have significantly different neural activation patterns from BP patients without this comorbidity. If understanding of the neurobiology of bipolar disorder is to be achieved, it is critical to control for this potential confound, something not done by most prior fMRI studies of adults with BP. Published by Elsevier B.V.
C1 [Townsend, Jennifer D.; Sugar, Catherine A.; Walshaw, Patricia D.; Vasquez, Roxanne E.; Moody, Teena D.; Bookheimer, Susan Y.; McGough, James J.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.; Moody, Teena D.; McGough, James J.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
FU Furlotti Family Foundation; National Institutes of Health (NIH):
National Institute of Mental Health [K24 MH001848, R21 MH075944,
5F31MH078556]; National Institutes of Health (NIH): National Center for
Research Resources (NCRR) [RR12169, RR13642, RR00865]; Abbott
Laboratories; Eli Lilly; NeuroSigma Inc.; Supranus; Shionogi
Pharmaceuticals
FX This study was supported by the Furlotti Family Foundation and the
following two components of the National Institutes of Health (NIH): the
National Institute of Mental Health (K24 MH001848 (LA), R21 MH075944
(LA), 5F31MH078556 (LF)) and the National Center for Research Resources
(NCRR) (RR12169, RR13642 and RR00865).; Drs. Bookheimer, Foland-Ross,
Moody and Sugar, Ms. Townsend and Ms. Vasquez report no financial
relationships with commercial interests. Dr. Altshuler has received
research support from Abbott Laboratories; consulting honoraria from Eli
Lilly, Abbott Laboratories, Forest Laboratories and Sepracor; and
speakers bureau honoraria from Forest Laboratories, GlaxoSmith Kline,
Bristol Meyer Squibb/Otsuka America.; Dr. McGough has received
consulting honoraria from Eli Lilly & Co., MedImmune, Shionogi
Pharmaceuticals, Shire, Sunovion, and Targacept, and research support
from Eli Lilly, NeuroSigma Inc., Supranus and Shionogi Pharmaceuticals.
None of the above affiliations should result in a conflict of interest
related to the subject of the manuscript being submitted.
NR 41
TC 5
Z9 6
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAY
PY 2013
VL 147
IS 1-3
BP 389
EP 396
DI 10.1016/j.jad.2012.08.019
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 115CQ
UT WOS:000316790400056
PM 23057969
ER
PT J
AU Amorosa, VK
Aibana, O
Shire, NJ
Dorey-Stein, Z
Ferrara, T
Gilmore, J
Kostman, JR
Lo Re, V
AF Amorosa, Valerianna K.
Aibana, Omowunmi
Shire, Norah J.
Dorey-Stein, Zachariah
Ferrara, Thomas
Gilmore, Joanne
Kostman, Jay R.
Lo Re, Vincent
TI Willingness to Undergo a Repeat Liver Biopsy Among HIV/Hepatitis C
Virus-coinfected and Hepatitis C Virus-monoinfected Patients
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE liver biopsy; hepatitis C; HIV/hepatitis C coinfection; HIV; staging of
fibrosis
ID FIBROSIS PROGRESSION
AB Background: Guidelines for chronic hepatitis C virus (HCV) management have recommended that a liver biopsy be repeated at 3-year intervals for HIV/HCV-coinfected patients and 5-year intervals for those with HCV monoinfection to assess fibrosis progression. However, it is unclear if patients are willing to repeat this procedure.
Objective: To determine the prevalence and factors, particularly HIV coinfection, associated with willingness to repeat a liver biopsy.
Methods: A questionnaire was administered to 235 HCV-infected patients (113 with HIV coinfection) between January 2008 and June 2011 who previously underwent liver biopsy. The main outcome was self-reported willingness to repeat the biopsy. The questionnaire collected data on other hypothesized determinants of willingness to repeat the biopsy. These were evaluated by logistic regression.
Results: Among 235 subjects who completed the questionnaire, 32 (14%) reported unwillingness to repeat the biopsy, most commonly because of a perception that it was unimportant for care [13(41%)], concerns regarding pain [12(38%)], and a poor experience with the prior biopsy [7(21%)]. Considering biopsy to be safe [odds ratio (OR), 4.45; 95% CI, 1.50-13.27], important (OR, 4.87; 95% CI, 1.83-12.95), and knowing a person who underwent liver biopsy (OR, 3.45; 95% CI, 1.16-10.23) were associated with willingness to repeat the biopsy. HIV was not associated with willingness to repeat the biopsy (OR, 1.42; 95% CI, 0.67-3.03).
Conclusions: Eighty-six percent of chronic HCV-infected patients were willing to repeat a liver biopsy. HIV was not associated with unwillingness. In patients in whom a repeat liver biopsy is indicated, education on the utility and safety of the biopsy is important to its acceptance.
C1 [Amorosa, Valerianna K.; Lo Re, Vincent] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Amorosa, Valerianna K.; Dorey-Stein, Zachariah; Ferrara, Thomas; Gilmore, Joanne; Kostman, Jay R.; Lo Re, Vincent] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Shire, Norah J.; Lo Re, Vincent] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Aibana, Omowunmi] Harvard Univ, Sch Med, Boston, MA USA.
[Shire, Norah J.] Merck & Co Inc, Whitehouse Stn, NJ 08889 USA.
RP Amorosa, VK (reprint author), Philadelphia VAMC, Infect Dis Sect, Dept Med, Philadelphia, PA 19104 USA.
EM valerianna.amorosa@uphs.upenn.edu
RI Lo Re, Vincent/N-7817-2015
FU National Institutes of Health Research [K01 AI070001]
FX V.L.R. was financially supported by the National Institutes of Health
Research Grant K01 AI070001.
NR 8
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAY-JUN
PY 2013
VL 47
IS 5
BP 457
EP 460
DI 10.1097/MCG.0b013e318266fe70
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 124PO
UT WOS:000317477400020
PM 23328300
ER
PT J
AU Lysaght, S
Ersek, M
AF Lysaght, Susan
Ersek, Mary
TI Settings of Care Within Hospice New Options and Questions About Dying
"At Home"
SO JOURNAL OF HOSPICE & PALLIATIVE NURSING
LA English
DT Article
DE caregiving; hospice; inpatient hospice; place of death
ID FACTORS INFLUENCING DEATH; LIFE CANCER CARE; NO PLACE LIKE; OF-LIFE;
FAMILY CAREGIVERS; HOSPITALIZED-PATIENTS; PEOPLE DIE; END; DETERMINANTS;
PERSPECTIVES
AB Although place of death has been routinely studied in end-of-life care, more analysis on place of death within hospice is needed because of the recent, dramatic rise in the number of hospice patients dying in inpatient settings. Using a case study to illustrate the complexity of determinants of place of death within hospice, this article highlights important known factors and elucidates gaps for further research. Individual- and system-level factors, sociocultural meanings, caregiving, and preferences are shown to have important implications. Additionally, the unique components of home hospice, inpatient hospice, and transitions between these settings may have a fundamental role in the future of quality end-of-life care. Further research on determinants of hospice settings of care is essential to the care of older adults at the end of life.
C1 [Lysaght, Susan; Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Performance Reporting & Outcomes Mea, Philadelphia, PA USA.
RP Lysaght, S (reprint author), Univ Penn, Sch Nursing, Claire M Fagin Hall,310g,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM slysaght@nursing.upenn.edu
FU John A. Hartford Building Academic Geriatric Nursing Capacity Scholar
Award; Ruth L. Kirschstein Individual NRSA Predoctoral Fellowship
[1F31NR013103]; NINR Individualized Care for At-Risk Older Adults
[T32NR009356]
FX Dr Lysaght was supported by a John A. Hartford Building Academic
Geriatric Nursing Capacity Scholar Award 2010-2012 and a Ruth L.
Kirschstein Individual NRSA Predoctoral Fellowship (1F31NR013103); Dr
Lysaght also received funding through NINR T32NR009356 Individualized
Care for At-Risk Older Adults from 2008 to 2010.
NR 40
TC 5
Z9 5
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1522-2179
J9 J HOSP PALLIAT NURS
JI J. Hosp. Palliat. Nurs.
PD MAY
PY 2013
VL 15
IS 3
BP 171
EP 176
DI 10.1097/NJH.0b013e3182765a17
PG 6
WC Nursing
SC Nursing
GA 124QG
UT WOS:000317479700006
PM 23853526
ER
PT J
AU Li, H
Wu, Q
Li, J
Yang, PA
Zhu, ZL
Luo, B
Hsu, HC
Mountz, JD
AF Li, Hao
Wu, Qi
Li, Jun
Yang, PingAr
Zhu, Zilu
Luo, Bao
Hsu, Hui-Chen
Mountz, John D.
TI Cutting Edge: Defective Follicular Exclusion of Apoptotic Antigens Due
to Marginal Zone Macrophage Defects in Autoimmune BXD2 Mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRECURSOR B-CELLS; INDOLEAMINE
2,3-DIOXYGENASE; PATHOGENIC AUTOANTIBODIES; DENDRITIC CELLS; T-CELLS;
TOLERANCE; INTERLEUKIN-17; RECEPTORS; TRANSPORT
AB Marginal zone macrophages (MZMs) act as a barrier to entry of circulating apoptotic debris into the follicles of secondary lymphoid organs. In autoimmune BXD2 mice, there is a progressive reduction in the function and numbers of MZMs. Absence of MZMs results in retention of apoptotic cell (AC) debris within the marginal zone (MZ) and increased loading of AC Ags on MZ B cells and MZ-precursor (MZ-P) B cells. The MZ-P B cells are capable of translocating the AC Ags to the follicular zone and stimulating T cells. Both MZMs and MZ-P B cells from BXD2 mice express low levels of tolerogenic signals and high levels of inflammatory signals. Thus, the current study suggests a multifaceted mechanism in which MZMs maintain tolerance to apoptotic autoantigens and suppress their translocation to follicles. Lack of clearance of apoptotic debris by MZMs drives follicular Ag-transportation by MZ-P B cells to stimulate an autoimmune response. The Journal of Immunology, 2013, 190:4465-4469.
C1 [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Luo, Bao; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Li, Hao; Mountz, John D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Zhu, Zilu] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA.
[Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Hsu, HC (reprint author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Room 307,Shelby Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM rheu078@uab.edu; jdmountz@uab.edu
RI Li, Hao/N-7406-2015
OI Li, Hao/0000-0002-2171-8826; Zhu, Zilu/0000-0002-1944-0108
FU VA Merit Review Grant [1I01BX000600-01]; National Institutes of
Health/National Institute of Allergy and Infectious Disease [1AI 071110,
ARRA 3RO1AI71110-02S1, 1RO1 AI083705]; American College of Rheumatology
Research and Education Foundation; Arthritis Foundation; Lupus Research
Institute
FX This work was supported by a VA Merit Review Grant (1I01BX000600-01), as
well as grants from the National Institutes of Health/National Institute
of Allergy and Infectious Disease (1AI 071110, ARRA 3RO1AI71110-02S1,
and 1RO1 AI083705), the American College of Rheumatology Research and
Education Foundation, the Arthritis Foundation, and the Lupus Research
Institute. Flow cytometry and confocal imaging were carried out at the
University of Alabama at Birmingham Comprehensive Flow Cytometry Core
(P30 AR048311 and P30 AI027767) and University of Alabama at Birmingham
Analytic Imaging and Immunoreagents Core (P30 AR048311), respectively.
NR 23
TC 9
Z9 9
U1 1
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
IS 9
BP 4465
EP 4469
DI 10.4049/jimmunol.1300041
PG 5
WC Immunology
SC Immunology
GA 130IP
UT WOS:000317907900008
PM 23543760
ER
PT J
AU Ioannou, GN
Haigh, WG
Thorning, D
Savard, C
AF Ioannou, George N.
Haigh, W. Geoffrey
Thorning, David
Savard, Christopher
TI Hepatic cholesterol crystals and crown-like structures distinguish NASH
from simple steatosis
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE Kupffer cells; foam cells; steatohepatitis; nonalcoholic steatohepatitis
ID FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; DIETARY-CHOLESTEROL;
ADIPOCYTE DEATH; ADIPOSE-TISSUE; UNITED-STATES; MICE; EZETIMIBE; OBESE;
INFLAMMATION
AB We sought to determine whether hepatic cholesterol crystals are present in patients or mice with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH), and whether their presence or distribution correlates with the presence of NASH as compared with simple steatosis. We identified, by filipin staining, free cholesterol within hepatocyte lipid droplets in patients with NASH and in C57BL/6J mice that developed NASH following a high-fat high-cholesterol diet. Under polarized light these lipid droplets exhibited strong birefringence suggesting that some of the cholesterol was present in the form of crystals. Activated Kupffer cells aggregated around dead hepatocytes that included strongly birefringent cholesterol crystals, forming "crown-like structures" similar to those recently described in inflamed visceral adipose tissue. These Kupffer cells appeared to process the lipid of dead hepatocytes turning it into activated lipid-laden "foam cells" with numerous small cholesterol-containing droplets. In contrast, hepatocyte lipid droplets in patients and mice with simple steatosis did not exhibit cholesterol crystals and their Kupffer cells did not form crown-like structures or transform into foam cells. Our results suggest that cholesterol crystallization within hepatocyte lipid droplets and aggregation and activation of Kupffer cells in crown-like structures around such droplets represent an important, novel mechanism for progression of simple steatosis to NASH.-Ioannou, G. N., W. G. Haigh, D. Thorning, and C. Savard. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 2013. 54: 1326-1334.
C1 [Ioannou, George N.; Haigh, W. Geoffrey; Savard, Christopher] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
[Thorning, David] Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA.
[Ioannou, George N.; Haigh, W. Geoffrey; Savard, Christopher] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
EM georgei@medicine.washington.edu
FU Research Enhancement Award Program, Office of Research and Development,
Veterans Affairs Puget Sound Health Care System, Seattle, WA
FX This work was supported by a grant from the Research Enhancement Award
Program (to G.N.I.), Office of Research and Development, Veterans
Affairs Puget Sound Health Care System, Seattle, WA. The authors report
no conflicts of interest.
NR 29
TC 37
Z9 40
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD MAY
PY 2013
VL 54
IS 5
BP 1326
EP 1334
DI 10.1194/jlr.M034876
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 123MO
UT WOS:000317394300018
PM 23417738
ER
PT J
AU Golden-Mason, L
McMahan, RH
Strong, M
Reisdorph, R
Mahaffey, S
Palmer, BE
Cheng, LL
Kulesza, C
Hirashima, M
Niki, T
Rosen, HR
AF Golden-Mason, Lucy
McMahan, Rachel H.
Strong, Michael
Reisdorph, Richard
Mahaffey, Spencer
Palmer, Brent E.
Cheng, Linling
Kulesza, Caroline
Hirashima, Mitsuomi
Niki, Toshiro
Rosen, Hugo R.
TI Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NASOPHARYNGEAL CARCINOMA-CELLS; C VIRUS-INFECTION; NK CELLS; T-CELLS;
ADAPTIVE IMMUNITY; VIRAL-INFECTIONS; LIGAND-BINDING; TIM-3; INNATE;
RECEPTOR
AB Galectin-9 is a pleiotropic immune modulator affecting numerous cell types of innate and adaptive immunity. Patients with chronic infection with either hepatitis C virus (HCV) or HIV have elevated circulating levels. Limited data exist on the regulation of natural killer (NK) cell function through interaction with galectin-9. We found that galectin-9 ligation downregulates multiple immune-activating genes, including eight involved in the NK cell-mediated cytotoxicity pathway, impairs lymphokine-activated killing, and decreases the proportion of gamma interferon (IFN-gamma)-producing NK cells that had been stimulated with interleukin-12 (IL-12)/IL-15. We demonstrate that the transcriptional and functional changes induced by galectin-9 are independent of Tim-3. Consistent with these results for humans, we find that the genetic absence of galectin-9 in mice is associated with greater IFN-gamma production by NK cells and enhanced degranulation. We also show that in the setting of a short-term (4-day) murine cytomegalovirus infection, terminally differentiated NKs accumulate in the livers of galectin-9 knockout mice, and that hepatic NKs spontaneously produce significantly more IFN-gamma in this setting. Taken together, our results indicate that galectin-9 engagement impairs the function of NK cells, including cytotoxicity and cytokine production.
C1 [Golden-Mason, Lucy; McMahan, Rachel H.; Cheng, Linling; Rosen, Hugo R.] UCD, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Aurora, CO USA.
[Golden-Mason, Lucy; Reisdorph, Richard; Mahaffey, Spencer; Rosen, Hugo R.] UCD, Integrated Program Immunol, Denver, CO USA.
[Golden-Mason, Lucy; Reisdorph, Richard; Mahaffey, Spencer; Rosen, Hugo R.] NJH, Denver, CO USA.
[Golden-Mason, Lucy; McMahan, Rachel H.; Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA.
[Strong, Michael] NJH, Ctr Genes Environm & Hlth, Denver, CO USA.
[Reisdorph, Richard] NJH, Dept Pediat, Denver, CO USA.
[Palmer, Brent E.] UCD, Div Allergy & Clin Immunol, Aurora, CO USA.
[Kulesza, Caroline] UCD, Dept Microbiol, Aurora, CO USA.
[Hirashima, Mitsuomi; Niki, Toshiro] Kagawa Univ, Fac Med, Dept Immmunol & Immunopathol, Kagawa, Japan.
RP Rosen, HR (reprint author), UCD, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Aurora, CO USA.
EM hugo.rosen@ucdenver.edu
FU VA [R21AIO76161, R21AIO76161-01A2S1]; [U19 AI 1066328]; [K24AI083742]
FX This work was supported by U19 AI 1066328 (H.R.R.), K24AI083742
(H.R.R.), a VA Merit Review grant (H.R.R.), R21AIO76161 (B.E.P.), and
R21AIO76161-01A2S1 (B.E.P.).
NR 50
TC 22
Z9 26
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2013
VL 87
IS 9
BP 4835
EP 4845
DI 10.1128/JVI.01085-12
PG 11
WC Virology
SC Virology
GA 123UK
UT WOS:000317416400006
PM 23408620
ER
PT J
AU Buttenheim, AM
Asch, DA
AF Buttenheim, Alison M.
Asch, David A.
TI Behavioral Economics: The Key to Closing the Gap on Maternal, Newborn
and Child Survival for Millennium Development Goals 4 and 5?
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Behavior change; Behavioral economics; Maternal and child health;
Millennium development goals
ID FINANCIAL INCENTIVES; CONTROLLED-TRIAL; HEALTH BEHAVIOR; VOUCHER SCHEME;
BANGLADESH; DECISIONS; COVERAGE; MODEL
AB Millennium Development Goals (MDGs) 4 and 5 set ambitious targets to reduce maternal, newborn and child mortality by 2015. With 2015 fast approaching, there has been a concerted effort in the global health community to "close the gap" on the MDG targets. Recent consensus initiatives and frameworks have refocused attention on evidence-based, low-cost interventions that can reduce mortality and morbidity, and have argued for additional funding to increase access to and coverage of these life-saving interventions. However, funding alone will not close the gap on MDGs 4 and 5. Even when high-quality, affordable products and services are readily available, uptake is often low. Progress will therefore require not just money, but also advances in health-related behavior change and decision-making. Behavioral economics offers one way to achieve real progress by improving our understanding of how individuals make choices under information and time constraints, and by offering new approaches to make it easier for individuals to do what is in their best interest and harder to do what is not. We introduce five behavioral economic principles and demonstrate how they could boost efforts to improve maternal, newborn, and child health in pursuit of MDGs 4 and 5.
C1 [Buttenheim, Alison M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.
[Buttenheim, Alison M.] Univ Penn, LDI Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Buttenheim, AM (reprint author), Univ Penn, Sch Nursing, Dept Family & Community Hlth, Fagin 235L,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM abutt@nursing.upenn.edu
OI Asch, David/0000-0002-7970-286X
NR 30
TC 2
Z9 2
U1 0
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD MAY
PY 2013
VL 17
IS 4
BP 581
EP 585
DI 10.1007/s10995-012-1042-7
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 126IS
UT WOS:000317608200002
PM 22618489
ER
PT J
AU Voils, CI
Maciejewski, ML
Hoyle, RH
Reeve, BB
Gallagher, MP
Bryson, CL
Yancy, WS
AF Voils, Corrine I.
Maciejewski, Matthew L.
Hoyle, Rick H.
Reeve, Bryce B.
Gallagher, Matthew P.
Bryson, Christopher L.
Yancy, William S., Jr.
TI Behavioral Science and Reasons for Nonadherence to Medication Response
SO MEDICAL CARE
LA English
DT Letter
C1 [Voils, Corrine I.; Maciejewski, Matthew L.; Gallagher, Matthew P.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27706 USA.
[Voils, Corrine I.; Maciejewski, Matthew L.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA.
[Hoyle, Rick H.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27706 USA.
[Reeve, Bryce B.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Bryson, Christopher L.] Univ Washington, Vet Affairs Puget Sound, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98195 USA.
[Bryson, Christopher L.] Univ Washington, Dept Med, Seattle, WA USA.
RP Voils, CI (reprint author), Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27706 USA.
OI Voils, Corrine/0000-0003-1913-663X
FU NIA NIH HHS [R21 AG035233]
NR 3
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2013
VL 51
IS 5
BP 468
EP 469
DI 10.1097/MLR.0b013e31828fadbf
PG 3
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 126WU
UT WOS:000317653900016
PM 23552432
ER
PT J
AU Chen, BB
Coon, TA
Glasser, JR
McVerry, BJ
Zhao, J
Zhao, YT
Zou, CB
Ellis, B
Sciurba, FC
Zhang, YZ
Mallampalli, RK
AF Chen, Bill B.
Coon, Tiffany A.
Glasser, Jennifer R.
McVerry, Bryan J.
Zhao, Jing
Zhao, Yutong
Zou, Chunbin
Ellis, Bryon
Sciurba, Frank C.
Zhang, Yingze
Mallampalli, Rama K.
TI A combinatorial F box protein directed pathway controls TRAF adaptor
stability to regulate inflammation
SO NATURE IMMUNOLOGY
LA English
DT Article
ID RECEPTOR-ASSOCIATED FACTOR-3; SCF UBIQUITIN LIGASE; FAMILY; DEGRADATION;
ACTIVATION; SEPSIS; IDENTIFICATION; SUBUNIT; FBXL2
AB Uncontrolled activation of tumor necrosis factor receptor-associated factor (TRAF) proteins may result in profound tissue injury by linking surface signals to cytokine release. Here we show that a ubiquitin E3 ligase component, Fbxo3, potently stimulates cytokine secretion from human inflammatory cells by destabilizing a sentinel TRAF inhibitor, Fbxl2. Fbxo3 and TRAF protein in circulation positively correlated with cytokine responses in subjects with sepsis, and we identified a polymorphism in human Fbxo3, with one variant being hypofunctional. A small-molecule inhibitor targeting Fbxo3 was sufficient to lessen severity of cytokine-driven inflammation in several mouse disease models. These studies identified a pathway of innate immunity that may be useful to detect subjects with altered immune responses during critical illness or provide a basis for therapeutic intervention targeting TRAF protein abundance.
C1 [Chen, Bill B.; Coon, Tiffany A.; Glasser, Jennifer R.; McVerry, Bryan J.; Zhao, Jing; Zhao, Yutong; Zou, Chunbin; Ellis, Bryon; Sciurba, Frank C.; Zhang, Yingze; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
EM chenb@upmc.edu; mallampallirk@upmc.edu
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; Merit Review Award from the US Department of Veterans
Affairs; National Institutes [HL096376, HL097376, HL081784, HL068135,
HL098174, HL116472, HL01916, P50HL084948]; American Heart Association
[12SDG9050005, 12SDG12040330, 12GRNT11820019]
FX We thank A. Lagneaux and S. Barge for assistance with studies. This
material is based upon work supported, in part, by the US Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development. This work
was supported by a Merit Review Award from the US Department of Veterans
Affairs and National Institutes of Health R01 grants HL096376, HL097376,
HL081784, HL068135 and HL098174 (to R. K. M.), HL116472 (to B. B. C.),
HL01916 (to Y.Z.) and P50HL084948 (F. C. S.), American Heart Association
awards 12SDG9050005 (to J.Z.) and 12SDG12040330 (to C.Z.), and American
Heart Association Grant-in-Aid 12GRNT11820019 (B.J.M.). The contents
presented do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 43
TC 47
Z9 49
U1 3
U2 26
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD MAY
PY 2013
VL 14
IS 5
BP 470
EP +
DI 10.1038/ni.2565
PG 11
WC Immunology
SC Immunology
GA 127XL
UT WOS:000317732100012
PM 23542741
ER
PT J
AU Park, CH
Lee, IS
Grippo, P
Pandol, SJ
Gukovskaya, AS
Edderkaoui, M
AF Park, Chang-Hwan
Lee, In-Seok
Grippo, Paul
Pandol, Stephen J.
Gukovskaya, Anna S.
Edderkaoui, Mouad
TI Akt Kinase Mediates the Prosurvival Effect of Smoking Compounds in
Pancreatic Ductal Cells
SO PANCREAS
LA English
DT Article
DE pancreatic cancer; smoking; apoptosis; autophagy
ID TOBACCO-SPECIFIC CARCINOGEN; CANCER CELLS; CIGARETTE-SMOKE;
PROTEIN-KINASE; EPITHELIAL-CELLS; NADPH OXIDASE; AUTOPHAGY; GROWTH;
EXPRESSION; RECEPTORS
AB Objectives: Cigarette smoking is a major risk factor for pancreatic cancer (PaCa). However, the mechanisms of smoking-induced PaCa remain unknown. Here we investigated the effect of smoking compounds on cell death pathways in pancreatic ductal cells, precursors of PaCa.
Methods: Human pancreatic ductal cells (HPDE6-c7) were cultured with cigarette smoke extract (CSE) or smoking compound 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Apoptosis and autophagy were assessed by DNA fragmentation and immunofluorescence, respectively.
Results: Exposure to CSE or NNK decreased DNA fragmentation and up-regulated Bcl(XL). Akt kinase was activated by smoking compounds through reactive oxygen species-dependent mechanism. Specifically, Akt activation was prevented by inhibition of nicotinamide adenine dinucleotide oxidase. Molecular or pharmacologic inhibitions of Akt prevented the antiapoptotic effect of smoking compounds. Smoking compounds stimulated rapid (1 hour) and transient activation of 5'-adenosine monophosphate-activated protein kinase and formation of autophagic vacuoles, indicating stimulation of autophagy. Repeated exposure to CSE/NNK (48 hours or longer) abolished the early activation of autophagic markers. Inhibition of Akt prevented the antiautophagic effect of long exposure to smoking compounds, indicating that smoking-induced late activation of Akt prevents autophagy.
Conclusions: Long exposure of pancreatic ductal cells to smoking compounds inhibited apoptosis and autophagy. The results revealed a central role for Akt kinase in mediating key procarcinogenic effects of smoking compounds.
C1 [Park, Chang-Hwan; Lee, In-Seok; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Park, Chang-Hwan; Lee, In-Seok; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA.
[Park, Chang-Hwan] Chonnam Natl Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Kwangju, South Korea.
[Lee, In-Seok] Catholic Univ Korea, Div Gastroenterol, Dept Internal Med, Seoul, South Korea.
[Grippo, Paul] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
RP Edderkaoui, M (reprint author), Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM medderkaoui@mednet.ucla.edu
FU National Institute on Alcohol Abuse and Alcoholism [K01 AA019996];
National Center for Complementary and Alternative Medicine; National
Cancer Institute
FX This study was supported by the National Institute on Alcohol Abuse and
Alcoholism (grant K01 AA019996 to M.E.), the National Center for
Complementary and Alternative Medicine (to S.J.P.), and the National
Cancer Institute (to A.S.G.).
NR 37
TC 5
Z9 5
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAY
PY 2013
VL 42
IS 4
BP 655
EP 662
DI 10.1097/MPA.0b013e3182762928
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 126XF
UT WOS:000317655200014
PM 23271397
ER
PT J
AU Carrion, IV
Nedjat-Haiem, FR
Martinez-Tyson, D
Castaneda, H
AF Carrion, Iraida V.
Nedjat-Haiem, Frances R.
Martinez-Tyson, Dinorah
Castaneda, Heide
TI Advance care planning among Colombian, Mexican, and Puerto Rican women
with a cancer diagnosis
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Advance care planning; Latina; Cancer; Health decisions
ID HEALTH; DISPARITIES; LIFE; END; PREFERENCES; DISCUSSIONS; HISPANICS;
ATTITUDES; CULTURE; CUBANS
AB Limited knowledge exists pertaining to advance care planning (ACP) among Colombian, Mexican, and Puerto Rican women with a cancer diagnosis living in Central Florida, in the USA. The purpose of the study is to identify factors that facilitated the completion of ACP and decisions making patterns among the three groups of Latinas.
The research method used was an exploratory qualitative in-depth open-ended semi-structured interview with a grounded theoretical approach and thematic analysis. The interviews were conducted in Spanish with a purposeful sample of 45 Latinas (15 in each group) diagnosed with cancer.
A total of ten women (22 %) in the study documented at least one form of ACP. Thirty-five women identified obstacles to accessing information regarding ACP, relating this to insurance and financial factors. Among the Colombian women, one completed a living will, health care surrogate, and power of attorney (all forms of ACP), and three just a living will. Two Puerto Rican women completed all, two a living will, and one both a living will and an enduring power of attorney. Only one Mexican woman completed a living will.
This study identifies a knowledge gap regarding ACP among Latina women with cancer diagnosis living in Central Florida, in the USA. Differences between the three groups exist as a result of migration/immigration history, family support, education, English language proficiency, income, knowledge gaps, and information ascertained by medical and health professionals. These differences contribute to their readiness, receptiveness, and willingness to engage in documenting a living will, a health care surrogate, and an enduring power of attorney for health decisions.
C1 [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA.
[Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Martinez-Tyson, Dinorah] Univ S Florida, Dept Child & Family, Tampa, FL USA.
[Castaneda, Heide] Univ S Florida, Dept Anthropol, Tampa, FL 33620 USA.
RP Carrion, IV (reprint author), Univ S Florida, Sch Social Work, 13301 Bruce B Downs Blvd MHC 1438, Tampa, FL 33612 USA.
EM icarrion@usf.edu
OI Carrion, Iraida/0000-0003-4076-6644
FU Division of Population Sciences; H. Lee Moffitt Cancer Center and
Research Institute; Division for Equal Health, University of South
Florida in Tampa, FL; National Institute of Health [P20 MDD00375-01]
FX The authors would like to thank Dr. Lee Green and Dr. Richard Roetzheim
for their support and the Latina women who generously participated in
the study. They also thank Ingrid Asmar and Milagros Porter for all
their contributions as research assistants. This study was supported by
the Division of Population Sciences, H. Lee Moffitt Cancer Center and
Research Institute and the Division for Equal Health, University of
South Florida in Tampa, FL, National Institute of Health grant number
P20 MDD00375-01.
NR 39
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY
PY 2013
VL 21
IS 5
BP 1233
EP 1239
DI 10.1007/s00520-012-1652-z
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 117OK
UT WOS:000316962600005
PM 23192672
ER
PT J
AU Huddle, TS
AF Huddle, Thomas S.
TI Don't Ban the Sunset in Pharmaceutical Advertising If It Doesn't Darken
the Sky
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Editorial Material
C1 Univ Alabama, Bimingham Sch Med, Birmingham VA Med Ctr, Tuscaloosa, AL 35487 USA.
RP Huddle, TS (reprint author), Univ Alabama, Bimingham Sch Med, Birmingham VA Med Ctr, 700 19th St S, Tuscaloosa, AL 35487 USA.
EM thuddle@uab.edu
NR 16
TC 1
Z9 1
U1 0
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD MAY 1
PY 2013
VL 13
IS 5
BP 27
EP 30
DI 10.1080/15265161.2013.776141
PG 4
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 120NI
UT WOS:000317176900014
PM 23557043
ER
PT J
AU Clancy, CJ
Nguyen, MH
AF Clancy, Cornelius J.
Nguyen, M. Hong
TI Finding the "Missing 50%" of Invasive Candidiasis: How Nonculture
Diagnostics Will Improve Understanding of Disease Spectrum and Transform
Patient Care
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Review
DE invasive candidiasis; candidemia; diagnostic; PCR; beta-D-glucan
ID POLYMERASE-CHAIN-REACTION; D-GLUCAN ASSAY; REAL-TIME PCR; BLOOD
CULTURES; SYSTEMIC CANDIDIASIS; FUNGAL-INFECTIONS; ANTIMANNAN
ANTIBODIES; HEPATIC CANDIDIASIS; ANTIFUNGAL AGENTS; CANCER-PATIENTS
AB Blood cultures are limited for diagnosing invasive candidiasis by poor sensitivity and slow turn-around time. New diagnostics are needed to complement cultures, in particular to identify the "missing 50%" of patients who are blood culture-negative. Mannan/anti-mannan immunoglobulin G, beta-D-glucan (BDG) and polymerase chain reaction (PCR) assays can diagnose candidemia before blood cultures and show promising sensitivity/specificity, but they are not widely investigated in blood culture-negative, deep-seated candidiasis. In a recent study, BDG and PCR were superior to blood cultures in deep-seated candidiasis, suggesting they may identify currently undiagnosed patients and expand our understanding of disease spectrum. Positive predictive values of nonculture tests are limited by the low prevalence of invasive candidiasis, which mandates that results be interpreted judiciously. When used as biomarkers that assess a patient's risk of having invasive candidiasis, tests will facilitate preemptive antifungal strategies. Because negative predictive values are excellent, tests will also be useful for ruling out invasive candidiasis and discontinuing unnecessary antifungal therapy.
C1 [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA.
[Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Pittsburgh, PA 15261 USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Scaife Hall,Ste 869,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM cjc76@pitt.edu
FU ClinicalTrials.gov [NCT01525095]; ViraCor-IBT Laboratories for the
BDG/PCR
FX C. J. C. is a site principal investigator for a multicenter trial of the
T2 Candida Bioassay for candidemia (T2 Biosystems; ClinicalTrials.gov
identifier: NCT01525095). M. H. N. received investigator-initiated
research funding from ViraCor-IBT Laboratories for the BDG/PCR study
cited in this paper [31].
NR 40
TC 90
Z9 93
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2013
VL 56
IS 9
BP 1284
EP 1292
DI 10.1093/cid/cit006
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 123QC
UT WOS:000317404300015
PM 23315320
ER
PT J
AU Knaub, LA
McCune, S
Chicco, AJ
Miller, M
Moore, RL
Birdsey, N
Lloyd, MI
Villarreal, J
Keller, AC
Watson, PA
Reusch, JEB
AF Knaub, Leslie A.
McCune, Sylvia
Chicco, Adam J.
Miller, Matthew
Moore, Russell L.
Birdsey, Nicholas
Lloyd, Monique I.
Villarreal, Juan
Keller, Amy C.
Watson, Peter A.
Reusch, Jane E. B.
TI Impaired response to exercise intervention in the vasculature in
metabolic syndrome
SO DIABETES & VASCULAR DISEASE RESEARCH
LA English
DT Article
DE Cyclic adenosine monophosphate response element binding protein;
mitochondria; exercise; SHHF; diabetes; vasculature
ID ELEMENT-BINDING PROTEIN; LOW CARDIORESPIRATORY FITNESS; MUSCLE
CELL-PROLIFERATION; ZUCKER OBESE RATS; MITOCHONDRIAL BIOGENESIS;
INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; HEART-FAILURE; NITRIC-OXIDE;
DISEASE RISK
AB Physical activity decreases risk for diabetes and cardiovascular disease morbidity and mortality; however, the specific impact of exercise on the diabetic vasculature is unexamined. We hypothesized that an acute, moderate exercise intervention in diabetic and hypertensive rats would induce mitochondrial biogenesis and mitochondrial antioxidant defence to improve vascular resilience. SHHF/Mcc-fa(cp) lean (hypertensive) and obese (hypertensive, insulin resistant), as well as Sprague Dawley (SD) control rats were run on a treadmill for 8 days. In aortic lysates from SD rats, we observed a significant increase in subunit proteins from oxidative phosphorylation (OxPhos) complexes I-III, with no changes in the lean or obese SHHF rats. Exercise also increased the expression of mitochondrial antioxidant defence uncoupling protein 3 (UCP3) (p < 0.05) in SHHF lean rats, whereas no changes were observed in the SD or SHHF obese rats with exercise. We evaluated upstream signalling pathways for mitochondrial biogenesis, and only peroxisome proliferators-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) significantly decreased in SHHF lean rats (p < 0.05) with exercise. In these experiments, we demonstrate absent mitochondrial induction with exercise exposure in models of chronic vascular disease. These findings suggest that chronic vascular stress results in decreased sensitivity of vasculature to the adaptive mitochondrial responses normally induced by exercise.
C1 [Knaub, Leslie A.; Miller, Matthew; Birdsey, Nicholas; Lloyd, Monique I.; Villarreal, Juan; Keller, Amy C.; Watson, Peter A.; Reusch, Jane E. B.] Univ Colorado Denver, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA.
[Knaub, Leslie A.; Miller, Matthew; Birdsey, Nicholas; Lloyd, Monique I.; Keller, Amy C.; Watson, Peter A.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA.
[McCune, Sylvia; Moore, Russell L.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA.
[Chicco, Adam J.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA.
RP Reusch, JEB (reprint author), Univ Colorado Denver, Div Endocrinol Diabet & Metab, Anschutz Med Campus,12801 E 17th Ave,MS8106, Aurora, CO 80045 USA.
EM jane.reusch@ucdenver.edu
FU Department of Veterans Affairs Office of Research and Development;
National Institutes of Health [HL14985, UL1 RR025780]; American Heart
Association [0835545N]
FX This work was supported by the Department of Veterans Affairs Office of
Research and Development (Merit Review JEBR and PAW), National
Institutes of Health (HL14985, UL1 RR025780, JEBR) and American Heart
Association Grant (0835545N, AJC).
NR 65
TC 8
Z9 8
U1 0
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1479-1641
J9 DIABETES VASC DIS RE
JI Diabetes Vasc. Dis. Res.
PD MAY
PY 2013
VL 10
IS 3
BP 222
EP 238
DI 10.1177/1479164112459664
PG 17
WC Endocrinology & Metabolism; Peripheral Vascular Disease
SC Endocrinology & Metabolism; Cardiovascular System & Cardiology
GA 122CR
UT WOS:000317293900005
PM 23162060
ER
PT J
AU Luo, H
Zhang, LH
Liu, XD
Leung, FW
Liu, ZG
Wang, XP
Xue, L
Wu, KC
Fan, DM
Pan, YL
Guo, XG
AF Luo, Hui
Zhang, Linhui
Liu, Xiaodong
Leung, Felix W.
Liu, Zhiguo
Wang, Xiangping
Xue, Ling
Wu, Kaichun
Fan, Daiming
Pan, Yanglin
Guo, Xuegang
TI Water exchange enhanced cecal intubation in potentially difficult
colonoscopy. Unsedated patients with prior abdominal or pelvic surgery:
a prospective, randomized, controlled trial
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID COLORECTAL-CANCER; INCOMPLETE COLONOSCOPY; SEDATION; IMMERSION;
METAANALYSIS; PREVENTION; VETERANS; STANDARD
AB Background: Colonoscopy is widely used for management of colorectal diseases. A history of abdominal or pelvic surgery is a well-recognized factor associated with difficult colonoscopy. Although water exchange colonoscopy (WEC) was effective in small groups of male U.S. veterans with such a history, its application in other cultural settings is uncertain.
Objective: To investigate the application of WEC in such patients.
Design: Prospective, randomized, controlled, patient-blinded study.
Setting: Tertiary-care referral center in China.
Patients: Outpatients with prior abdominal or pelvic surgery undergoing unsedated diagnostic, screening, or surveillance colonoscopy.
Intervention: Patients were randomized to examination by either WEC or conventional air colonoscopy (AC).
Main Outcome Measurements: Cecal intubation rate.
Results: A total of 110 patients were randomized to the WEC (n = 55) or AC (n = 55) group. WEC significantly increased the cecal intubation rate (92.7% vs 76.4%; P = .033). The maximum pain scores (+/- standard deviation) were 2.1 +/- 1.8 (WEC) and 4.6 +/- 1.7 (AC), respectively (P < .001). Multivariate analysis showed that the colonoscopy method was the only independent predictor of failed colonoscopy (odds ratio 11.44, 95% confidence interval, 1.35-97.09). A higher proportion of patients examined by WEC would be willing to have a repeat unsedated colonoscopy (90.9% vs 72.7%, P = .013).
Limitations: Single center; unblinded but experienced endoscopists.
Conclusion: This randomized, controlled trial confirms that the water exchange method significantly enhanced cecal intubation in potentially difficult colonoscopy in unsedated patients with prior abdominal or pelvic surgery. The lower pain scores and higher proportion accepting repeat of the unsedated option suggest that WEC is promising. It may enhances compliance with colonoscopy in specific populations. (Clinical trial registration number: NCT01485133.) (Gastrointest Endosc 2013; 77:767-73.)
C1 [Luo, Hui; Zhang, Linhui; Liu, Xiaodong; Liu, Zhiguo; Wang, Xiangping; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China.
[Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Xue, Ling] Jinan Mil Gen Hosp, Dept Cardiol, Jinan, Peoples R China.
RP Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 169 Changle West Rd, Xian 710032, Peoples R China.
OI liu, zhiguo/0000-0002-8485-7356
FU National Natural Science Foundation of China [81172288]; Science
Foundation of the Ministry of Education; Technology Innovation
Foundation of Xijing Hospital
FX This work was supported in part by the National Natural Science
Foundation of China (81172288). Y. Pan received support from the Science
Foundation of the Ministry of Education. X. Guo received support from
the Technology Innovation Foundation of Xijing Hospital. No other
financial relationships relevant to this publication were disclosed.
NR 28
TC 16
Z9 17
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAY
PY 2013
VL 77
IS 5
BP 767
EP 773
DI 10.1016/j.gie.2012.12.007
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 122XY
UT WOS:000317353100015
PM 23394837
ER
PT J
AU Hartwell, KJ
Maria, MMMS
Twal, WO
Shaftman, S
DeSantis, SM
McRae-Clark, AL
Brady, KT
AF Hartwell, Karen J.
Maria, Megan M. Moran-Santa
Twal, Waleed O.
Shaftman, Stephanie
DeSantis, Stacia M.
McRae-Clark, Aimee L.
Brady, Kathleen T.
TI Association of elevated cytokines with childhood adversity in a sample
of healthy adults
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Life stress; Biological stress; Innate immunity; Cytokines; C-reactive
protein
ID POSTTRAUMATIC-STRESS-DISORDER; C-REACTIVE PROTEIN; PITUITARY-ADRENAL
AXIS; NECROSIS-FACTOR-ALPHA; EARLY-LIFE ADVERSITY; PSYCHOLOGICAL STRESS;
TNF-ALPHA; PLASMA INTERLEUKIN-6; MAJOR DEPRESSION; MENTAL STRESS
AB Objective: Childhood trauma has been associated adult stress-related disorders. However, little is known about physiologic alterations in adults with a history of early life trauma that do not have current psychiatric or medical diagnoses. In this study, the relationships between childhood adversity and cytokine and C-reactive protein (CRP) levels in healthy adults were examined.
Method: Participants included men (n = 18) and women (n = 20) who did not meet DSM-IV criteria for Axis I psychiatric disorders or any major medical illness. Cytokine and CRP levels were obtained from baseline blood samples. Subjects completed the Early Trauma Inventory Self Report (ETI-SR). The primary outcomes included serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL1-beta), and CRP levels. In addition, the mean numbers of traumatic experiences (sexual, physical, emotional, general, and the summed total) were measured.
Results: Significant positive associations were found between the total ETI score and IL-6 (p = 0.05), IL1-beta (p < 0.05), and TNF-alpha (p = 0.01). Significant positive correlations were found between the number of general traumas and IL1-beta (p < 0.05), TNF-alpha (p < 0.05), and IL-6 (p < 0.01). Neither the total number of traumas nor any of the trauma subscales were significantly associated with CRP levels.
Conclusions: The positive association between childhood trauma and basal cytokine levels supports the extant literature demonstrating the long-term impact of childhood trauma and stress on homeostatic systems. Importantly, this association was found in healthy adults, suggesting that these alterations may precede the development of significant stress-related psychiatric disorder or disease. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Hartwell, Karen J.; Maria, Megan M. Moran-Santa; McRae-Clark, Aimee L.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC 29401 USA.
[Twal, Waleed O.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Shaftman, Stephanie; DeSantis, Stacia M.] Med Univ S Carolina, Dept Biostat & Epidemiol, Charleston, SC 29425 USA.
RP Maria, MMMS (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, 125 Doughty St, Charleston, SC 29425 USA.
EM moranm@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU NIDA [P50 DA016511-07]; NIH-NCRR [M01 RR01070-30]; Abbott;
GlaxoSmithKline; Forest; Wyeth-Ayerst; Bristol-Myers Squibb; Eli Lilly;
Shire
FX Funding for this study was provided by NIDA P50 DA016511-07 and NIH-NCRR
M01 RR01070-30. The NIDA and the NIH had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.; Authors Hartwell, Moran-Santa Maria, Shaftman, Twal, and
DeSantis have no relevant financial relationships with a commercial
interest to disclose. Kathleen Brady has no current conflicts of
interest. Past relationships include the following: Past Consultant:
Pfizer, Eli Lilly, Abbott, GlaxoSmithKline, Forest, Ovation, Marinus,
Novartis; Past Speakers' Bureau: Pfizer, Eli Lilly, Abbott,
GlaxoSmithKline, Forest; Past Research Support: Abbott, GlaxoSmithKline,
Forest, Wyeth-Ayerst; Past Scientific Advisory Board: Embera
NeuroTherapeutics; Past Independent Contractor: Medscape; Past
Investigator: Titan Pharmaceuticals. Aimee McRae-Clark has no current
conflicts of interest. Past relationships include: Past Research
Support: Bristol-Myers Squibb, Eli Lilly, Wyeth-Ayerst, Shire, and
GlaxoSmithKline.
NR 75
TC 17
Z9 18
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAY
PY 2013
VL 47
IS 5
BP 604
EP 610
DI 10.1016/j.jpsychires.2013.01.008
PG 7
WC Psychiatry
SC Psychiatry
GA 124EU
UT WOS:000317447400007
PM 23415658
ER
PT J
AU Rissling, AJ
Park, SH
Young, JW
Rissling, MB
Sugar, CA
Sprock, J
Mathias, DJ
Pela, M
Sharp, RF
Braff, DL
Light, GA
AF Rissling, Anthony J.
Park, Sung-Hyouk
Young, Jared W.
Rissling, Michelle B.
Sugar, Catherine A.
Sprock, Joyce
Mathias, Daniel J.
Pela, Marlena
Sharp, Richard F.
Braff, David L.
Light, Gregory A.
TI Demand and modality of directed attention modulate "pre-attentive"
sensory processes in schizophrenia patients and nonpsychiatric controls
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Attention; Event related potential; Modulation; Mismatch negativity;
P300
ID EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY GENERATION;
SELECTIVE-ATTENTION; TREATING SCHIZOPHRENIA; 1ST-EPISODE PSYCHOSIS;
CLINICAL-TRIALS; TASK DEMANDS; HIGH-RISK; DEFICITS; BRAIN
AB Background: Mismatch negativity(MNN) and P3a are event related potential (ERP) measures of early sensory information processing. These components are usually conceptualized as being "pre-attentive" and therefore immune to changes with variations in attentional functioning. This study aimed to determine whether manipulations of attention influence the amplitudes and latencies of MMN and P3a and, if so, the extent to which these early sensory processes govern concurrent behavioral vigilance performance in schizophrenia patients and normal subjects.
Methods: Schizophrenia patients (SZ; n = 20) and Nonpsychiatric Control Subjects (NCS; n = 20) underwent auditory ERP testing to assess MMN and P3a across 4 EEG recording sessions in which attentional demand (low vs. high) and sensory modality of directed attention (visual vs. auditory) were experimentally varied.
Results: Across conditions, SZ patients exhibited deficits in MMN and P3a amplitudes. Significant amplitude and latency modulation were observed in both SZ and NCS but there were no group-by-condition interactions. The amount of MMN amplitude attenuation from low-to high-demand tasks was significantly associated with increased vigilance performance in both SZ and NCS groups (r = -0.67 and r = -0.60). Several other robust associations were also observed among neurophysiologic, clinical and cognitive variables.
Conclusions: Attentional demand and modality of directed attention significantly influence the amplitude and latencies of "pre-attentive" ERP components in both SZ and NCS. Deficits in MMN and P3a were not "normalized" when attention was directed to the auditory stimuli in schizophrenia patients. The adaptive modulation of early sensory information processing appears to govern concurrent attentional task performance. The temporal window reflecting automatic sensory discrimination as indexed as MMN and P3a may serve as a gateway to some higher order cognitive operations necessary for psychosocial functioning. Published by Elsevier B.V.
C1 [Rissling, Anthony J.; Park, Sung-Hyouk; Young, Jared W.; Rissling, Michelle B.; Sprock, Joyce; Mathias, Daniel J.; Pela, Marlena; Sharp, Richard F.; Braff, David L.; Light, Gregory A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Park, Sung-Hyouk] Chookryoung Evangel Hosp, Dept Psychiat, Namyangju, Gyeonggi, South Korea.
[Young, Jared W.; Sprock, Joyce; Mathias, Daniel J.; Pela, Marlena; Braff, David L.; Light, Gregory A.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, San Diego, CA USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA.
[Sugar, Catherine A.] Greater Los Angeles VA Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Los Angeles, CA USA.
RP Light, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM glight@ucsd.edu
FU National Institute of Mental Health [MH079777, MH042228, MH065571];
Department of Veteran Affairs (VISN 22 Mental Illness Research,
Education, and Clinical Center); NARSAD
FX This work was supported by the National Institute of Mental Health
(MH079777, MH042228 and MH065571), the Department of Veteran Affairs
(VISN 22 Mental Illness Research, Education, and Clinical Center) and
NARSAD. The funding agencies had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 99
TC 22
Z9 22
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 326
EP 335
DI 10.1016/j.schres.2013.01.035
PG 10
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500049
PM 23490760
ER
PT J
AU Shores, M
AF Shores, Molly
TI TESTOSTERONE AT THE HEART OF DISEASE - THE ASSOCIATION BETWEEN
TESTOSTERONE AND CARDIOVASCULAR EVENTS
SO ANDROLOGY
LA English
DT Meeting Abstract
C1 [Shores, Molly] Univ Washington, Seattle, WA 98195 USA.
[Shores, Molly] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
J9 ANDROLOGY-US
JI Andrology
PD MAY
PY 2013
VL 1
SU 2
SI SI
BP 33
EP 33
PG 1
WC Andrology
SC Endocrinology & Metabolism
GA 116WD
UT WOS:000316912900013
ER
PT J
AU Jarrett, RB
Minhajuddin, A
Kangas, JL
Friedman, ES
Callan, JA
Thase, ME
AF Jarrett, Robin B.
Minhajuddin, Abu
Kangas, Julie L.
Friedman, Edward S.
Callan, Judith A.
Thase, Michael E.
TI Acute phase cognitive therapy for recurrent major depressive disorder:
Who drops out and how much do patient skills influence response?
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Depression; Cognitive therapy; Predictors; Patient skills; Response
patterns; Attrition
ID COLLABORATIVE RESEARCH-PROGRAM; BEHAVIORAL THERAPY; PRIVATE-PRACTICE;
MOOD DISORDERS; NIMH-TREATMENT; PREDICTORS; INVENTORY; VARIABLES;
ALLIANCE; PHARMACOTHERAPY
AB Objective: The aims were to predict cognitive therapy (CT) noncompletion and to determine, relative to other putative predictors, the extent to which the patient skills in CT for recurrent major depressive disorder predicted response in a large, two-site trial.
Method: Among 523 outpatients aged 18-70, exposed to 12-14 weeks of CT, 21.6% dropped out. Of the 410 completers, 26.1% did not respond. To predict these outcomes, we conducted logistic regression analyses of demographics, pre-treatment illness characteristics and psychosocial measures, and mid-treatment therapeutic alliance.
Results: The 17-item Hamilton Rating Scale for Depression (HRSD17) scores at entry predicted dropout and nonresponse. Patients working for pay, of non-Hispanic white race, who were older, or had more education were significantly more likely to complete. Controlling for HRSD17, significant predictors of nonresponse included: lower scores on the Skills of Cognitive Therapy-Observer Version (SoCT-O), not working for pay, history of only two depressive episodes, greater pre-treatment social impairment. Mid-phase symptom reduction was a strong predictor of final outcome.
Conclusions: These prognostic indicators forecast which patients tend to be optimal candidates for standard CT, as well as which patients may benefit from changes in therapy, its focus, or from alternate modalities of treatment. Pending replication, the findings underscore the importance of promoting patients' understanding and use of CT skills, as well as reducing depressive symptoms early. Future research may determine the extent to which these findings generalize to other therapies, providers who vary in competency, and patients with other depressive subtypes or disorders. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Jarrett, Robin B.; Kangas, Julie L.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
[Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Callan, Judith A.] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15260 USA.
[Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Robin.Jarrett@UTSouthwestern.edu
FU NCATS NIH HHS [KL2 TR000146, UL1 TR000005]; NIMH NIH HHS [R01 MH058397,
K24 MH001571, R01 MH058356, R01 MH069618, R01 MH069619]; NINR NIH HHS
[T32 NR008857]
NR 50
TC 18
Z9 18
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAY
PY 2013
VL 51
IS 4-5
BP 221
EP 230
DI 10.1016/j.brat.2013.01.006
PG 10
WC Psychology, Clinical
SC Psychology
GA 115RW
UT WOS:000316830600006
PM 23485420
ER
PT J
AU Macrae, F
Ahnen, DJ
AF Macrae, Finlay
Ahnen, Dennis J.
TI Acceleration in colorectal carcinogenesis: the hare, the tortoise or
myth?
SO GUT
LA English
DT Editorial Material
ID MUTYH-ASSOCIATED POLYPOSIS; SURVEILLANCE COLONOSCOPY; COLON-CANCER;
ADENOMAS
C1 [Macrae, Finlay] Royal Melbourne Hosp, Dept Colorectal Med & Genet, Melbourne, Vic 3050, Australia.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO USA.
RP Macrae, F (reprint author), Royal Melbourne Hosp, Dept Colorectal Med & Genet, POB 2010, Melbourne, Vic 3050, Australia.
EM Finlay.macrae@mh.org.au
NR 20
TC 1
Z9 1
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD MAY
PY 2013
VL 62
IS 5
BP 657
EP 659
DI 10.1136/gutjnl-2012-302880
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 117YV
UT WOS:000316990200001
PM 22961679
ER
PT J
AU Montgomery, AE
Hill, LL
Kane, V
Culhane, DP
AF Montgomery, Ann Elizabeth
Hill, Lindsay L.
Kane, Vincent
Culhane, Dennis P.
TI HOUSING CHRONICALLY HOMELESS VETERANS: EVALUATING THE EFFICACY OF A
HOUSING FIRST APPROACH TO HUD-VASH
SO JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
ID PSYCHIATRIC DISABILITIES; MENTAL-ILLNESS; INDIVIDUALS; COMMUNITY;
SUPPORTS
AB Rapidly placing homeless Veterans with severe mental illness into permanent housing is one important goal of the U.S. Department of Housing and Urban Development-Veterans Affairs Supportive Housing (HUD-VASH) program; however, no research has tested whether an explicit organizational alignment of this goal with revised practices could improve outcomes. A demonstration project initiated in 2010 to reform housing placement practices in a metropolitan area enabled researchers to compare an explicit Housing First programoffering immediate permanent housing without requiring treatment compliance, abstinence, or housing readinesswith a treatment-first program for 177 homeless Veterans. The Housing First initiative successfully reduced time to housing placement, from 223 to 35 days, housing retention rates were significantly higher among Housing First tenants, and emergency room use declined significantly among the Housing First cohort. The results suggest that a national Housing First model for the VA would be associated with improved outcomes for Veterans experiencing homelessness.
C1 [Montgomery, Ann Elizabeth; Hill, Lindsay L.; Kane, Vincent; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Washington, DC USA.
RP Montgomery, AE (reprint author), Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA.
EM montga@upenn.edu
NR 14
TC 8
Z9 8
U1 0
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0090-4392
J9 J COMMUNITY PSYCHOL
JI J. Community Psychol.
PD MAY
PY 2013
VL 41
IS 4
BP 505
EP 514
DI 10.1002/jcop.21554
PG 10
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA 113TW
UT WOS:000316692600009
ER
PT J
AU Paintlia, AS
Paintlia, MK
Singh, AK
Singh, I
AF Paintlia, A. S.
Paintlia, M. K.
Singh, A. K.
Singh, I.
TI Rho family GTPase inhibition protects immature oligodendrocytes against
cytokine toxicity via PPAR-alfa dependent mechanism
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Paintlia, A. S.; Paintlia, M. K.; Singh, I.] Med Univ S Carolina, Charleston, SC USA.
[Singh, A. K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 206
EP 206
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700468
ER
PT J
AU Yu, J
Zhu, H
Gattoni-Celli, S
Kindy, MS
AF Yu, J.
Zhu, H.
Gattoni-Celli, S.
Kindy, M. S.
TI Pim-1 kinase inhibits pathological injury by promoting neuroprotective
signaling
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Yu, J.; Zhu, H.; Gattoni-Celli, S.; Kindy, M. S.] Med Univ S Carolina, Charleston, SC USA.
[Gattoni-Celli, S.; Kindy, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 214
EP 214
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700487
ER
PT J
AU Khan, M
Dhammu, TS
Shunmugavel, A
Paintlia, M
Singh, AK
Singh, I
AF Khan, M.
Dhammu, T. S.
Shunmugavel, A.
Paintlia, M.
Singh, A. K.
Singh, I.
TI S-Nitrosoglutathione stimulates mediators of neurorepair following
cerebral ischemia reperfusion injury in rats
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Khan, M.; Dhammu, T. S.; Shunmugavel, A.; Paintlia, M.; Singh, I.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Singh, A. K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 216
EP 216
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700493
ER
PT J
AU Joshi, SK
Liu, XH
Samagh, SP
Lovett, DH
Bodine, SC
Kim, HT
Feeley, BT
AF Joshi, Sunil K.
Liu, Xuhui
Samagh, Sanjum P.
Lovett, David H.
Bodine, Sue C.
Kim, Hubert T.
Feeley, Brian T.
TI mTOR regulates fatty infiltration through SREBP-1 and PPAR gamma after a
combined massive rotator cuff tear and suprascapular nerve injury in
rats
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE rotator cuff tear; fatty infiltration; Akt; mTOR signaling; SREBP-1;
PPAR gamma
ID ADIPOSE-TISSUE; MUSCLE ATROPHY; ANIMAL-MODEL; STEM-CELL; EXPRESSION;
REPAIR; SUPRASPINATUS; ADIPOCYTE; RAPAMYCIN; GROWTH
AB Rotator cuff tears (RCTs) are among the most common injuries seen in orthopedic patients. Chronic tears can result in the development of muscular atrophy and fatty infiltration. Despite the prevalence of RCTs, little is known about the underlying molecular pathways that produce these changes. Recently, we have shown that mammalian target of rapamycin (mTOR) signaling plays an important role in muscle atrophy that results from massive RCTs in a rat model. The purpose of this study was therefore to extend our understanding of mTOR signaling and evaluate its role in fatty infiltration after a combined tendon transection and suprascapular nerve denervation surgery. Akt/mTOR signaling was significantly increased and resulted in the up-regulation of two transcription factors: SREBP-1 and PPAR gamma. We also saw an increase in expression of adipogenic markers: C/EBP-alpha and FASN. Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration. Therefore, our study suggests that mTOR signaling mediates rotator cuff fatty infiltration via SREBP-1 and PPAR gamma. Clinically, our finding may alter current treatment methods to address rotator cuff fatty infiltration. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 724730, 2013
C1 [Joshi, Sunil K.; Liu, Xuhui; Lovett, David H.; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, San Francisco, CA 94153 USA.
[Liu, Xuhui; Samagh, Sanjum P.; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94153 USA.
[Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94153 USA.
[Bodine, Sue C.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA.
RP Feeley, BT (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, 1500 Owens Ave, San Francisco, CA 94153 USA.
EM feeleyb@orthosurg.ucsf.edu
FU Orthopaedic Research & Education Foundation (OREF)
FX Grant sponsor: Orthopaedic Research & Education Foundation (OREF).
NR 40
TC 19
Z9 19
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAY
PY 2013
VL 31
IS 5
BP 724
EP 730
DI 10.1002/jor.22254
PG 7
WC Orthopedics
SC Orthopedics
GA 117RK
UT WOS:000316970600010
PM 23239524
ER
PT J
AU Fiellin, DA
McGinnis, KA
Maisto, SA
Justice, AC
Bryant, K
AF Fiellin, David A.
McGinnis, Kathleen A.
Maisto, Stephen A.
Justice, Amy C.
Bryant, Kendall
TI Measuring Alcohol Consumption Using Timeline Followback in
Non-Treatment-Seeking Medical Clinic Patients With and Without HIV
Infection: 7-, 14-, or 30-day Recall
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID QUICK DRINKING SCREEN; VETERANS; INTOXICATION; INDIVIDUALS; ADHERENCE;
INTERVIEW; DRINKERS; CARE
AB Objective: The measurement of alcohol consumption is an essential component of research in patients at risk for or infected with HIV. Daily estimation measures such as the Timeline Followback (TLFB) have been validated, yet the optimal time window and its performance in non-treatment-seeking medical clinic subjects and among those with HIV are not known. Method: In 1,519 HIV-infected and 1,612 uninfected men receiving medical care in general medical or infectious disease clinics, we compared the association between 7-, 14-, and 30-day TLFB reports, obtained via telephone, of alcohol consumption using Spearman's correlation coefficients. To evaluate agreement between 7-, 14-, and 30-day reports of heavy episodic drinking, we evaluated percent agreement, sensitivity, and kappa statistics, considering 30-day report as the gold standard. Results: The estimated prevalence of heavy episodic drinking was progressively higher for longer TLFB intervals (7 days: 6.3%; 14 days: 8.0%; 30 days: 9.5%). Correlation coefficients with 30-day TLFB were higher for 14 days (.94) than for 7 days (.86) overall (p < .001) and among HIV-infected (.94 vs. .86, p < .001) and uninfected (.95 vs. .87, p < 001). Correlations were similar by HIV status. When considered overall and by HIV status, the sensitivity, percent agreement, and kappa statistics are better for heavy episodic drinking based on 14 days compared with 7 days. Conclusions: A TLFB for alcohol consumption of 14 days is preferable to 7 days for non-treatment-seeking patients in medical clinics with and without HIV infection when compared with 30 days. (J Stud. Alcohol Drugs, 74, 500-504, 2013)
C1 [Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA.
[Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA.
[McGinnis, Kathleen A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
[Bryant, Kendall] NIAAA, Bethesda, MD 90034 USA.
RP Fiellin, DA (reprint author), Yale Univ, Sch Med, 367 Cedar St,POB 208093, New Haven, CT 06520 USA.
EM david.fiellin@yale.edu
OI Fiellin, David/0000-0002-4006-010X
FU National Institute on Alcohol Abuse and Alcoholism [U10AA013566,
U01AA020795, U01AA020790, U24AA020794]
FX This research was supported by National Institute on Alcohol Abuse and
Alcoholism Grants U10AA013566, U01AA020795, U01AA020790, and
U24AA020794. The views are not those of the Department of Veterans
Affairs or of the United States Government.
NR 25
TC 4
Z9 4
U1 4
U2 11
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2013
VL 74
IS 3
BP 500
EP 504
PG 5
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA 113CR
UT WOS:000316644300018
PM 23490581
ER
PT J
AU Subramanian, A
Clapp, ML
Hicks, SC
Awad, SS
Liang, MK
AF Subramanian, Anuradha
Clapp, Marissa L.
Hicks, Stephanie C.
Awad, Samir S.
Liang, Mike K.
TI Laparoscopic ventral hernia repair: Primary versus secondary hernias
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Hernia; Incisional hernia; Ventral hernia; Umbilical hernia; Epigatric
hernia; Spigelian hernia; Laparoscopy; Laparoscopic; Recurrence
ID INCISIONAL HERNIA; RECURRENCE; EXPERIENCE
AB Background: Most studies regarding laparoscopic ventral hernia repair (LVHR) have merged primary hernias (PHs) and secondary (incisional) hernias (SHs) into one group of ventral hernias. This grouping could produce falsely favorable results for LVHR. Our objective was to review and compare the outcomes of laparoscopic repair of PHs and SHs.
Methods: A retrospective chart review of patients from 2000 to 2010 identified the cases of LVHR at two affiliated institutions. The demographics, comorbidities, type of hernia (PH versus SH), and short- and long-term complications were analyzed. The postoperative pain, cosmetic satisfaction, and Activities Assessment Scale scores were assessed by telephone survey.
Results: A total of 201 cases of LVHR were identified: 73 PHs (36%) and 128 SHs (64%). No difference was found in the mean age between the two groups. The PH group had a greater percentage of black patients (34% versus 14%; P < 0.05), and the SH group had a greater percentage of white patients (85% versus 65%; P < 0.05). More female patients had SHs (34% versus 14%; P < 0.05), and more male patients had PHs (86% versus 66%; P < 0.05). More patients in the SH group had chronic obstructive pulmonary disease (19% versus 7%; P < 0.05) and prostate disease (32% versus 9%; P < 0.05). Overall, the SHs were larger (37.9 +/- 4.9 cm(2) versus 11.5 +/- 1.9 cm(2); P < 0.01). No differences were found in early postoperative complications, including pneumonia, urinary tract infection, surgical site infection, and seromas between the two groups. However, those with SHs had a greater incidence of recurrence (16% versus 5%; P < 0.05) and mesh explantation (7% versus 0%; P < 0.05). The patients who also under went SH repairs had greater postoperative pain scores when followed up for a median of 25 mo than those who underwent PH repairs when followed up for a median of 24 mo (3.5 +/- 0.4 versus 1.8 +/- 0.4; P < 0.05). More patients in the SH group had chronic pain issues (26% versus 5%; P = 0.0003) and had lower satisfaction scores (7.5 +/- 0.3 versus 8.6 +/- 0.3; P < 0.05). Overall, the Activities Assessment Scale scores were not significantly different.
Conclusions: Our data have demonstrated that PHs and SHs are different. LVHR of SHs is associated with increased recurrence, greater postoperative pain scores, chronic pain issues, and lower patient satisfaction scores. We recommend that future studies evaluate LVHR for PHs separate from those for SHs. Published by Elsevier Inc.
C1 [Subramanian, Anuradha; Clapp, Marissa L.; Awad, Samir S.; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Hicks, Stephanie C.] Rice Univ, Dept Stat, Houston, TX 77251 USA.
RP Liang, MK (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, 2002 Holcomble Blvd,OCL 112, Houston, TX 77030 USA.
EM ml3@bcm.edu
RI ; Liang, Mike/L-8493-2015
OI Hicks, Stephanie/0000-0002-7858-0231; Liang, Mike/0000-0001-7063-7291
NR 19
TC 12
Z9 12
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAY 1
PY 2013
VL 181
IS 1
BP E1
EP E5
DI 10.1016/j.jss.2012.06.028
PG 5
WC Surgery
SC Surgery
GA 115BX
UT WOS:000316788400001
PM 22795342
ER
PT J
AU Watson, AMM
Prasad, KM
Klei, L
Wood, JA
Yolken, RH
Gur, RC
Bradford, LD
Calkins, ME
Richard, J
Edwards, N
Savage, RM
Allen, TB
Kwentus, J
McEvoy, JP
Santos, AB
Wiener, HW
Go, RCP
Perry, RT
Nasrallah, HA
Gur, RE
Devlin, B
Nimgaonkar, VL
AF Watson, A. M. M.
Prasad, K. M.
Klei, L.
Wood, J. A.
Yolken, R. H.
Gur, R. C.
Bradford, L. D.
Calkins, M. E.
Richard, J.
Edwards, N.
Savage, R. M.
Allen, T. B.
Kwentus, J.
McEvoy, J. P.
Santos, A. B.
Wiener, H. W.
Go, R. C. P.
Perry, R. T.
Nasrallah, H. A.
Gur, R. E.
Devlin, B.
Nimgaonkar, V. L.
TI Persistent infection with neurotropic herpes viruses and cognitive
impairment
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Cognition; cytomegalovirus; HSV-1; HSV-2; schizophrenia
ID ALZHEIMERS-DISEASE BRAINS; SIMPLEX-VIRUS; CYTOMEGALOVIRUS-INFECTION;
SCHIZOPHRENIA PAARTNERS; PRINCIPAL-COMPONENTS; AFRICAN-AMERICANS;
LINKAGE ANALYSIS; EXPLORE RISKS; TYPE-1; HERITABILITY
AB Background. Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed persons that is untraceable to encephalitis. These studies were conducted among schizophrenia (SZ) patients or older community dwellers, among whom it is difficult to control for the effects of co-morbid illness and medications. To determine whether the associations can be generalized to other groups, we examined a large sample of younger control individuals, SZ patients and their non-psychotic relatives (n = 1852).
Method. Using multivariate models, cognitive performance was evaluated in relation to exposures to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV), controlling for familial and diagnostic status and sociodemographic variables, including occupation and educational status. Composite cognitive measures were derived from nine cognitive domains using principal components of heritability (PCH). Exposure was indexed by antibodies to viral antigens.
Results. PCH1, the most heritable component of cognitive performance, declines with exposure to CMV or HSV-1 regardless of case/relative/control group status (p = 1.09 x 10(-5) and 0.01 respectively), with stronger association with exposure to multiple herpes viruses (beta = -0.25, p = 7.28 x 10(-10)). There were no significant interactions between exposure and group status.
Conclusions. Latent/persistent herpes virus infections can be associated with cognitive impairments regardless of other health status.
C1 [Watson, A. M. M.; Prasad, K. M.; Klei, L.; Wood, J. A.; Nimgaonkar, V. L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Yolken, R. H.] Johns Hopkins Univ, Sch Med, Stanley Div Dev Neurovirol, Baltimore, MD USA.
[Gur, R. C.; Calkins, M. E.; Richard, J.; Gur, R. E.] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA.
[Gur, R. C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Bradford, L. D.] Morehouse Sch Med, Dept Psychiat, Atlanta, GA 30310 USA.
[Edwards, N.] Univ Tennessee, Coll Med, Dept Psychiat, Memphis, TN USA.
[Savage, R. M.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA.
[Allen, T. B.; McEvoy, J. P.] Duke Univ, John Umstead Hosp, Med Ctr, Butner, NC USA.
[Kwentus, J.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA.
[Santos, A. B.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Wiener, H. W.; Go, R. C. P.; Perry, R. T.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Nasrallah, H. A.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA.
[Nasrallah, H. A.] Univ Cincinnati, Coll Med, Dept Behav Neurosci, Cincinnati, OH USA.
[Devlin, B.; Nimgaonkar, V. L.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA USA.
[Devlin, B.; Nimgaonkar, V. L.] Western Psychiat Inst & Clin, Grad Sch Publ Hlth, Pittsburgh, PA USA.
RP Nimgaonkar, VL (reprint author), TDH, Room 441,3811 OHara St, Pittsburgh, PA 15213 USA.
EM nimga@pitt.edu
OI Prasad, Konasale/0000-0003-0245-1393
FU National Institute of Mental Health at the National Institute of Health
[RO1] [MH66006, R01 MH66278, R01 MH-066049, R01MH66181-03, R01 MH66121,
R01 MH066005, R01 MH66050, R01 MH66263, RO1 MH66004, K08 MH79364];
University of Mississippi; Eli Lilly; AstraZeneca; Pfizer; Bristol
Meyers; Johnson Johnson; Takeda
FX This work was supported by the National Institute of Mental Health at
the National Institute of Health [RO1 grant numbers: MH66006 (L.D.B.),
R01 MH66278 (B.D.), R01 MH-066049 (N.E.), R01MH66181-03 (R.C.P.G.), R01
MH66121 (R.E.G.), R01 MH066005 (J.K.), R01 MH66050 (J.P.M.), R01 MH66263
(V.L.N.), RO1 MH66004 (A.S.) and K08 MH79364 (M.E.C.).; Dr Kwentus
receives grant support through collaborations of the University of
Mississippi with Eli Lilly, AstraZeneca, Pfizer, Bristol Meyers, Johnson
& Johnson and Takeda.
NR 45
TC 11
Z9 11
U1 3
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
J9 PSYCHOL MED
JI Psychol. Med.
PD MAY
PY 2013
VL 43
IS 5
BP 1023
EP 1031
DI 10.1017/S003329171200195X
PG 9
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 119AC
UT WOS:000317067800012
PM 22975221
ER
PT J
AU Kim, KY
Cho, HJ
Yu, SN
Kim, SH
Yu, HS
Park, YM
Mirkheshti, N
Kim, SY
Song, CS
Chatterjee, B
Ahn, SC
AF Kim, Kwang-Youn
Cho, Hyo-Jin
Yu, Sun-Nyoung
Kim, Sang-Hun
Yu, Hak-Sun
Park, Yeong-Min
Mirkheshti, Nooshin
Kim, So Young
Song, Chung Seog
Chatterjee, Bandana
Ahn, Soon-Cheol
TI Interplay of reactive oxygen species, intracellular Ca2+ and
mitochondrial homeostasis in the apoptosis of prostate cancer cells by
deoxypodophyllotoxin
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DEOXYPODOPHYLLOTOXIN (DPT); APOPTOSIS; MITOCHONDRIAL MEMBRANE POTENTIAL
(MMP); REACTIVE OXYGEN SPECIES (ROS); Ca2+OVERLOAD
ID EARLY EVENT; HYPERPOLARIZATION; CHEMOTHERAPY; DYSFUNCTION; INDUCTION;
DAMAGE
AB The limited treatment option for recurrent prostate cancer and the eventual resistance to conventional chemotherapy drugs has fueled continued interest in finding new anti-neoplastic agents of natural product origin. We previously reported anti-proliferative activity of deoxypodophyllotoxin (DPT) on human prostate cancer cells. Using the PC-3 cell model of human prostate cancer, the present study reveals that DPT induced apoptosis via a caspase-3-dependent pathway that is activated due to dysregulated mitochondrial function. DPT-treated cells showed accumulation of the reactive oxygen species (ROS), intracellular Cai2+ surge, increased mitochondrial membrane potential (MMP, m), Bax protein translocation to mitochondria and cytochrome c release to the cytoplasm. This resulted in caspase-3 activation, which in turn induced apoptosis. The antioxidant N-acetylcysteine (NAC) reduced ROS accumulation, MMP and Cai2+ surge, on the other hand the Ca2+ chelator BAPTA inhibited the Cai2+ overload and MMP without affecting the increase of ROS, indicating that the generation of ROS occurred prior to Ca2+ flux. This suggested that both ROS and Cai2+ signaling play roles in the increased MMP via Cai2+-dependent and/or -independent mechanisms, since m elevation was reversed by NAC and BAPTA. This study provides the first evidence for the involvement of both ROS- and Cai2+-activated signals in the disruption of mitochondrial homeostasis and the precedence of ROS production over the failure of Ca2+ flux homeostasis. J. Cell. Biochem. 114: 11241134, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Kim, Kwang-Youn; Yu, Sun-Nyoung; Kim, Sang-Hun; Park, Yeong-Min; Ahn, Soon-Cheol] Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Yangsan 626870, South Korea.
[Cho, Hyo-Jin] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 443749, South Korea.
[Yu, Hak-Sun] Pusan Natl Univ, Sch Med, Dept Parasitol, Yangsan 626870, South Korea.
[Mirkheshti, Nooshin; Kim, So Young; Song, Chung Seog; Chatterjee, Bandana; Ahn, Soon-Cheol] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
[Mirkheshti, Nooshin; Kim, So Young; Song, Chung Seog; Chatterjee, Bandana; Ahn, Soon-Cheol] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78245 USA.
[Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Ahn, Soon-Cheol] Pusan Natl Univ, Med Res Inst, Yangsan 626870, South Korea.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu; ahnsc@pusan.ac.kr
FU National Research Foundation of Korea (NRF) [2012R1A1A2022587]; US
Department of Veterans Affairs [1I01BX000280]; Basic Science Research
Program through the National Research Foundation of Korea (NRF);
Ministry of Education, Science and Technology [2012R1A1A2022587]
FX Grant sponsor: National Research Foundation of Korea (NRF); Grant
number: 2012R1A1A2022587; Grant sponsor: US Department of Veterans
Affairs 1I01BX000280.; This research was supported by Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology
(2012R1A1A2022587) and by a Merit Review grant (1I01BX000280) from the
US Department of Veterans Affairs. B. C. is a VA Senior Research Career
Scientist.
NR 21
TC 18
Z9 18
U1 1
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2013
VL 114
IS 5
BP 1124
EP 1134
DI 10.1002/jcb.24455
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 108YL
UT WOS:000316332200018
PM 23192945
ER
PT J
AU Katon, WJ
Young, BA
Russo, J
Lin, EHB
Ciechanowski, P
Ludman, EJ
Von Korff, MR
AF Katon, Wayne J.
Young, Bessie A.
Russo, Joan
Lin, Elizabeth H. B.
Ciechanowski, Paul
Ludman, Evette J.
Von Korff, Michael R.
TI Association of Depression With Increased Risk of Severe Hypoglycemic
Episodes in Patients With Diabetes
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE depression; diabetes; hypoglycemia; mental health
ID PROSPECTIVE COHORT; SELF-CARE; TYPE-2; COMPLICATIONS; INSULIN;
SULFONYLUREAS; MORTALITY; DEMENTIA; MELLITUS; ADULTS
AB PURPOSE Although psychosocial and clinical factors have been found to be associated with hypoglycemic episodes in patients with diabetes, few studies have examined the association of depression with severe hypoglycemic episodes. This study examined the prospective association of depression with risk of hypoglycemic episodes requiring either an emergency department visit or hospitalization.
METHODS In a longitudinal cohort study, a sample of 4,117 patients with diabetes enrolled between 2000 and 2002 were observed from 2005 to 2007. Meeting major depression criteria on the Patient Health Questionnaire-9 was the exposure of interest, and the outcome of interest was an International Classification of Disease, Ninth Revision code for a hypoglycemic episode requiring an emergency department visit or hospitalization. Proportional hazard models were used to analyze the association of baseline depression and risk of one or more severe hypoglycemic episodes. Poisson regression was used to determine whether depression status was associated with the number of hypoglycemic episodes.
RESULTS After adjusting for sociodemographic, clinical measures of diabetes severity, non-diabetes-related medical comorbidity, prior hypoglycemic episodes, and health risk behaviors, depressed compared with nondepressed patients who had diabetes had a significantly higher risk of a severe hypoglycemic episode (hazard ratio = 1.42, 95% CI, 1.03-1.96) and a greater number of hypoglycemic episodes (odds ratio = 1.34, 95% CI, 1.03-1.74).
CONCLUSION Depression was significantly associated with time to first severe hypoglycemic episode and number of hypoglycemic episodes. Research assessing whether recognition and effective treatment of depression among persons with diabetes prevents severe hypoglycemic episodes is needed.
C1 [Katon, Wayne J.; Russo, Joan; Ciechanowski, Paul] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA.
[Young, Bessie A.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Kidney Res Inst, Seattle, WA USA.
[Lin, Elizabeth H. B.; Ludman, Evette J.; Von Korff, Michael R.] Grp Hlth Res Inst, Seattle, WA USA.
RP Katon, WJ (reprint author), 1959 NE Pacific St, Seattle, WA 98195 USA.
EM wkaton@u.washington.edu
FU Services Division of the National Institute of Mental Health [MH069741,
MH073686]
FX Supported by grants MH069741 (Katon) and MH073686 (Von Korff) from the
Services Division of the National Institute of Mental Health.
NR 28
TC 29
Z9 30
U1 0
U2 11
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD MAY-JUN
PY 2013
VL 11
IS 3
BP 245
EP 250
DI 10.1370/afm.1501
PG 6
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3WS
UT WOS:000336796600010
PM 23690324
ER
PT J
AU Shah, A
Kraigher-Krainer, E
Pieske, B
Zile, M
Voors, A
Bransford, T
Lefkowitz, M
Packer, M
Mcmurray, J
Solomon, S
AF Shah, A.
Kraigher-Krainer, E.
Pieske, B.
Zile, M.
Voors, A.
Bransford, T.
Lefkowitz, M.
Packer, M.
Mcmurray, J.
Solomon, S.
TI Relationship of NT-proBNP to systolic and diastolic function in HFpEF:
Findings from the PARAMOUNT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Shah, A.; Solomon, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kraigher-Krainer, E.; Pieske, B.] Med Univ Graz, Graz, Austria.
[Zile, M.] Med Univ S Carolina, Charleston, SC USA.
[Zile, M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Voors, A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Bransford, T.; Lefkowitz, M.] Novartis Pharmaceut, E Hanover, NJ USA.
[Packer, M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Mcmurray, J.] Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S275
EP S276
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489101312
ER
PT J
AU Pamarthy, S
Bohnen, N
Assaly, WB
Gross, M
Fig, L
AF Pamarthy, Sarika
Bohnen, Nicolaas
Assaly, Wessam Bou
Gross, Milton
Fig, Lorraine
TI MRI for correlative imaging of the nigrostriatal dopaminergic system: A
guide for nuclear medicine physicians
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Pamarthy, Sarika; Bohnen, Nicolaas] Univ Michigan, Radiol Nucl Med, Ann Arbor, MI 48109 USA.
[Assaly, Wessam Bou; Gross, Milton; Fig, Lorraine] US Dept Vet Affairs, Nucl Med, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 1282
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700103
ER
PT J
AU McAndrew, LM
D'Andrea, E
Lu, SE
Abbi, B
Yan, GW
Engel, C
Quigley, KS
AF McAndrew, Lisa M.
D'Andrea, Elizabeth
Lu, Shou-En
Abbi, Bhavna
Yan, Grace W.
Engel, Charles
Quigley, Karen S.
TI What pre-deployment and early post-deployment factors predict health
function after combat deployment?: a prospective longitudinal study of
Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) soldiers
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Health function; Quality of life; Veterans; Military; Prospective;
SF-36; Iraq; Afghanistan; Combat
ID POSTTRAUMATIC-STRESS-DISORDER; OF-VETERANS-AFFAIRS; MENTAL-HEALTH;
PHYSICAL HEALTH; SOCIAL SUPPORT; WAR VETERANS; VIETNAM VETERANS; SOMATIC
SYMPTOMS; CARE UTILIZATION; AFGHANISTAN
AB Background: Physical and mental function are strong indicators of disability and mortality. OEF/OIF Veterans returning from deployment have been found to have poorer function than soldiers who have not deployed; however the reasons for this are unknown.
Methods: A prospective cohort of 790 soldiers was assessed both pre- and immediately after deployment to determine predictors of physical and mental function after war.
Results: On average, OEF/OIF Veterans showed significant declines in both physical (t=6.65, p<.0001) and mental function (t=7.11, p<.0001). After controlling for pre-deployment function, poorer physical function after deployment was associated with older age, more physical symptoms, blunted systolic blood pressure reactivity and being injured. After controlling for pre-deployment function, poorer mental function after deployment was associated with younger age, lower social desirability, lower social support, greater physical symptoms and greater PTSD symptoms.
Conclusions: Combat deployment was associated with an immediate decline in both mental and physical function. The relationship of combat deployment to function is complex and influenced by demographic, psychosocial, physiological and experiential factors. Social support and physical symptoms emerged as potentially modifiable factors.
C1 [McAndrew, Lisa M.; Abbi, Bhavna; Yan, Grace W.] Dept Vet Affairs, NJ War Related Illness & Injury Study Ctr, E Orange, NJ 07018 USA.
[McAndrew, Lisa M.; Lu, Shou-En] Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA.
[D'Andrea, Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Engel, Charles] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA.
[Quigley, Karen S.] Bedford Mem Hosp, Dept Vet Affairs, Bedford, MA USA.
[Quigley, Karen S.] Northeastern Univ, Interdisciplinary Affect Sci Lab, Boston, MA USA.
RP McAndrew, LM (reprint author), Dept Vet Affairs, NJ War Related Illness & Injury Study Ctr, 385 Tremont Ave Mailstop 129, E Orange, NJ 07018 USA.
EM Lisa.mcandrew@va.gov
FU Department of Veterans Affairs, Health Services Research & Development
Service [IIR 0202-296]; NJ War Related Illness and Injury Study Center;
NJ REAP [REA 03-021]; Deployment Health Clinical Center, Walter Reed
Army Medical Center
FX This study was supported by grants from the Department of Veterans
Affairs, Health Services Research & Development Service (IIR 0202-296 to
K. Quigley); the NJ War Related Illness and Injury Study Center, the NJ
REAP (REA 03-021); and the Deployment Health Clinical Center, Walter
Reed Army Medical Center.
NR 52
TC 11
Z9 11
U1 3
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD APR 30
PY 2013
VL 11
AR 73
DI 10.1186/1477-7525-11-73
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 178NR
UT WOS:000321455200001
PM 23631419
ER
PT J
AU Ueno, K
Hirata, H
Shahryari, V
Deng, G
Tanaka, Y
Tabatabai, ZL
Hinoda, Y
Dahiya, R
AF Ueno, K.
Hirata, H.
Shahryari, V.
Deng, G.
Tanaka, Y.
Tabatabai, Z. L.
Hinoda, Y.
Dahiya, R.
TI microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; miRNA-183; Dkk-3; SMAD4
ID GROWTH-FACTOR-BETA; DPC4 SMAD4; EXPRESSION; CELLS; GENE; PROGRESSION;
CARCINOMA; RISK; APOPTOSIS; DEATH
AB Background: The purpose of this study was to identify prostate cancer (PC) oncogenic microRNAs (miRs) based on miR microarray and to investigate whether these oncogenic miRs may be useful as PC biomarkers.
Methods: Initially, we carried out miR microarray and real-time PCR using RWPE-1, PC-3, DU-145 and LNCaP cells. To investigate the function of miR-183, we used a miR-183 knockdown inhibitor in cell growth and wound-healing assays. We used several algorithms and confirmed that they are directly regulated by miR-183.
Results: We identified three potential oncogenic miRs (miR-146a, miR-183 and miR-767-5P). The expression of miR-183 in PC cells (PC-3, DU-145 and LNCaP) was upregulated compared with RWPE-1 cells. MiR-183 expression was also significantly higher in PC tissues compared with that in matched normal prostate tissues. Additionally, miR-183 expression was correlated with higher prostate-specific antigen, higher pT and shorter overall survival. MiR-183 knockdown decreased cell growth and motility in PC cells and significantly decreased prostate tumour growth in in vivo nude mice experiments. We identified Dkk-3 and SMAD4 as potential target genes of miR-183.
Conclusion: Our data suggest that oncogenic miR-183 may be useful as a new PC biomarker and that inhibition of miR-183 expression may be therapeutically beneficial as a PC treatment.
C1 [Ueno, K.; Hirata, H.; Shahryari, V.; Deng, G.; Tanaka, Y.; Dahiya, R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Tabatabai, Z. L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Hinoda, Y.] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan.
RP Dahiya, R (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [R01CA138642, R01CA130860, R01CA160079]; VA Merit Review grants;
VA Program Project
FX We thank Dr Roger Erickson for his support and assistance with the
preparation of the manuscript. This study was supported by National
Center for Research Resources of the National Institutes of Health
through Grant Number R01CA138642, R01CA130860, R01CA160079, VA Merit
Review grants and VA Program Project.
NR 31
TC 45
Z9 49
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD APR 30
PY 2013
VL 108
IS 8
BP 1659
EP 1667
DI 10.1038/bjc.2013.125
PG 9
WC Oncology
SC Oncology
GA 137AJ
UT WOS:000318406400014
PM 23538390
ER
PT J
AU Nallamothu, BK
Spertus, JA
Lansky, AJ
Cohen, DJ
Jones, PG
Kureshi, F
Dehmer, GJ
Drozda, JP
Walsh, MN
Brush, JE
Koenig, GC
Waites, TF
Gantt, S
Kichura, G
Chazal, RA
O'Brien, PK
Valentine, CM
Rumsfeld, JS
Reiber, JHC
Elmore, JG
Krumholz, RA
Weaver, WD
Krumholz, HM
AF Nallamothu, Brahmajee K.
Spertus, John A.
Lansky, Alexandra J.
Cohen, David J.
Jones, Philip G.
Kureshi, Faraz
Dehmer, Gregory J.
Drozda, Joseph P., Jr.
Walsh, Mary Norine
Brush, John E., Jr.
Koenig, Gerald C.
Waites, Thad F.
Gantt, Scott
Kichura, George
Chazal, Richard A.
O'Brien, Peter K.
Valentine, C. Michael
Rumsfeld, John S.
Reiber, Johan H. C.
Elmore, Joann G.
Krumholz, Richard A.
Weaver, W. Douglas
Krumholz, Harlan M.
TI Comparison of Clinical Interpretation With Visual Assessment and
Quantitative Coronary Angiography in Patients Undergoing Percutaneous
Coronary Intervention in Contemporary Practice The Assessing Angiography
(A2) Project
SO CIRCULATION
LA English
DT Article
DE coronary angiography; health policy; outcome assessment (health care);
percutaneous coronary intervention; quality improvement
ID COMPUTER-AIDED DETECTION; ASSOCIATION TASK-FORCE; CARDIOVASCULAR
ANGIOGRAPHY; CARDIAC-CATHETERIZATION; SCREENING MAMMOGRAPHY; PRACTICE
GUIDELINES; LESION SEVERITY; STENOSIS; ARTERIOGRAMS; VARIABILITY
AB Background-Studies conducted decades ago described substantial disagreement and errors in physicians' angiographic interpretation of coronary stenosis severity. Despite the potential implications of such findings, no large-scale efforts to measure or improve clinical interpretation were subsequently undertaken.
Methods and Results-We compared clinical interpretation of stenosis severity in coronary lesions with an independent assessment using quantitative coronary angiography (QCA) in 175 randomly selected patients undergoing elective percutaneous coronary intervention at 7 US hospitals in 2011. To assess agreement, we calculated mean difference in percent diameter stenosis between clinical interpretation and QCA and a Cohen weighted kappa statistic. Of 216 treated lesions, median percent diameter stenosis was 80.0% (quartiles 1 and 3, 80.0% and 90.0%), with 213 (98.6%) assessed as >= 70%. Mean difference in percent diameter stenosis between clinical interpretation and QCA was 8.2 +/- 8.4%, reflecting an average higher percent diameter stenosis by clinical interpretation (P<0.001). A weighted kappa of 0.27 (95% confidence interval, 0.18-0.36) was found between the 2 measurements. Of 213 lesions considered >= 70% by clinical interpretation, 56 (26.3%) were <70% by QCA, although none were <50%. Differences between the 2 measurements were largest for intermediate lesions by QCA (50% to <70%), with variation existing across sites.
Conclusions-Physicians tended to assess coronary lesions treated with percutaneous coronary intervention as more severe than measurements by QCA. Almost all treated lesions were >= 70% by clinical interpretation, whereas approximately one quarter were <70% by QCA. These findings suggest opportunities to improve clinical interpretation of coronary angiography. (Circulation. 2013;127:1793-1800.)
C1 [Nallamothu, Brahmajee K.] Ann Arbor VA Ctr Clin Management & Res, Ann Arbor, CT USA.
[Nallamothu, Brahmajee K.] Univ Michigan Hlth Syst, Ann Arbor, CT USA.
[Spertus, John A.; Cohen, David J.; Jones, Philip G.; Kureshi, Faraz] St Lukes Mid Amer Heart Inst, Kansas City, CT USA.
[Spertus, John A.; Cohen, David J.; Jones, Philip G.; Kureshi, Faraz] Univ Missouri Kansas City, Kansas City, CT USA.
[Lansky, Alexandra J.] Yale Univ, Sch Med, New Haven, CT USA.
[Dehmer, Gregory J.] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA.
[Dehmer, Gregory J.] Scott & White Healthcare, Temple, TX USA.
[Drozda, Joseph P., Jr.; Kichura, George] Mercy Hlth, St Louis, MO USA.
[Walsh, Mary Norine] St Vincent Heart Ctr Indiana, Indianapolis, VA USA.
[Brush, John E., Jr.] Sentara Cardiovasc Res Inst, Norfolk, VA USA.
[Brush, John E., Jr.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
[Koenig, Gerald C.; Weaver, W. Douglas] Henry Ford Hlth Syst, Detroit, MI USA.
[Waites, Thad F.; Weaver, W. Douglas] Wayne State Univ, Detroit, MI USA.
[Waites, Thad F.] Forrest Gen, Hattiesburg, MS USA.
[Chazal, Richard A.] Lee Mem Hlth Syst, Ft Myers, FL USA.
[O'Brien, Peter K.; Valentine, C. Michael] Centra Lynchburg Gen Hosp, Lynchburg, VA USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Reiber, Johan H. C.] Leiden Univ, Dept Radiol, Med Ctr, Leiden, Netherlands.
[Elmore, Joann G.] Univ Washington, Dept Med, Seattle, FL USA.
[Krumholz, Richard A.] ImageCor, Bradenton, FL USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
[Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Adm, New Haven, CT USA.
RP Nallamothu, BK (reprint author), Univ Michigan, Ctr Cardiovasc, SPC 5869,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM bnallamo@umich.edu
FU Aetna, Inc.; National Institutes of Health [T32HL110837]; Yale
University, from Medtronic; National Heart, Lung, and Blood Institute
[U01 HL105270-03]
FX Dr Spertus reports grant funding from Aetna, Inc. Dr Cohen reports
consulting income from United Healthcare. Dr Kureshi received support
from National Institutes of Health grant T32HL110837. Dr Walsh reports
consulting income from United Healthcare and Eli Lilly. Dr Chazal
reports being a member of the Scientific Advisory Board of United
Healthcare. Dr Rumsfeld reports being the chief science officer for the
NCDR. Dr Reiber reports being the president and chief executive officer
of Medis, which provides software for the quantification of
cardiovascular images. Dr Richard Krumholz reports being the General
Manager of ImageCor, a company focused on improving clinical
interpretation of medical imaging. Dr Harlan Krumholz reports equity
interest in ImageCor and being chair of the Scientific Advisory Board of
United Healthcare and a recipient of a research grant, through Yale
University, from Medtronic. Dr Harlan Krumholz also is supported by
grant U01 HL105270-03 (Center for Cardiovascular Outcomes Research at
Yale University) from the National Heart, Lung, and Blood Institute. The
other authors report no conflicts.
NR 32
TC 35
Z9 36
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 30
PY 2013
VL 127
IS 17
BP 1793
EP +
DI 10.1161/CIRCULATIONAHA.113.001952
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 134MT
UT WOS:000318215000013
PM 23470859
ER
PT J
AU Hage, FG
AlJaroudi, W
Aggarwal, H
Bhatia, V
Miller, J
Doppalapudi, H
Wazni, O
Iskandrian, AE
AF Hage, Fadi G.
AlJaroudi, Wael
Aggarwal, Himanshu
Bhatia, Vikas
Miller, John
Doppalapudi, Harish
Wazni, Oussama
Iskandrian, Ami E.
TI Outcomes of patients with chronic kidney disease and implantable cardiac
defibrillator: Primary versus secondary prevention
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Chronic kidney disease; Implantable cardiac defibrillator; Mortality;
Primary prevention; Secondary prevention; Sudden cardiac death
ID GLOMERULAR-FILTRATION-RATE; CORONARY-ARTERY-DISEASE; SERUM CREATININE
VALUES; CARDIOVERTER-DEFIBRILLATOR; RENAL-FUNCTION; INDEPENDENT
PREDICTOR; SUDDEN-DEATH; MORTALITY; THERAPY; IMPACT
AB Background: Chronic kidney disease (CKD) is associated with worse survival in patients with implantable cardiac defibrillators (ICDs). This study examined the association of outcomes with CKD in patients receiving an ICD for primary versus secondary prevention.
Methods: The study included 696 patients who underwent ICD placement for clinical reasons (59% primary, 41% secondary prevention) at the University of Alabama at Birmingham between January 2002 and September 2007. CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m(2) but not on dialysis. Outcomes of interest included overall mortality and first appropriate ICD therapy (shocks or anti-tachycardia pacing).
Results: After a follow-up of 50 +/- 24 months, 213 patients died (31%) and 111 (16%) received appropriate ICD therapy. Patients with CKD had higher mortality than patients with no CKD in the primary (43% vs. 15%, p<0.001) and secondary prevention (37% vs. 23%, p=0.003) groups. Patients with CKD were at higher risk of receiving an appropriate ICD therapy than patients without CKD in the primary (p<0.001) but not secondary prevention (p=0.9) cohort. After adjusting for age, gender and multiple risk factors, CKD was independently associated with all-cause mortality and ICD therapy in the primary prevention group (HR 2.08 [1.34-3.23] and 3.53 [1.75-7.10], p=0.001 and <0.0001, respectively) but not in the secondary prevention group (HR 1.27 [0.81-2.00], and 0.63 [0.35-1.13], p=0.3 and 0.2, respectively).
Conclusions: CKD is independently associated with increased mortality and appropriate ICD therapy in patients undergoing ICD implantation for primary but not secondary prevention. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Hage, Fadi G.; Doppalapudi, Harish; Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
[AlJaroudi, Wael; Wazni, Oussama] Cleveland Clin, Div Cardiovasc Med, Sect Imaging, Cleveland, OH USA.
[Aggarwal, Himanshu; Bhatia, Vikas; Miller, John] Univ Alabama Birmingham, Dept Med, Div Internal Med, Birmingham, AL 35294 USA.
RP Hage, FG (reprint author), Zeigler Res Bldg 1024,1530 3rd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 19
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD APR 30
PY 2013
VL 165
IS 1
BP 113
EP 116
DI 10.1016/j.ijcard.2011.07.087
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 122VU
UT WOS:000317347100026
PM 21862150
ER
PT J
AU Salmon, DA
Proschan, M
Forshee, R
Gargiullo, P
Bleser, W
Burwen, DR
Cunningham, F
Garman, P
Greene, SK
Lee, GM
Vellozzi, C
Yih, WK
Gellin, B
Lurie, N
AF Salmon, Daniel A.
Proschan, Michael
Forshee, Richard
Gargiullo, Paul
Bleser, William
Burwen, Dale R.
Cunningham, Francesca
Garman, Patrick
Greene, Sharon K.
Lee, Grace M.
Vellozzi, Claudia
Yih, W. Katherine
Gellin, Bruce
Lurie, Nicole
CA H1N1 GBS Meta-Anal Working Grp
TI Association between Guillain-Barre syndrome and influenza A (H1N1) 2009
monovalent inactivated vaccines in the USA: a meta-analysis
SO LANCET
LA English
DT Article
ID SAFETY DATALINK PROJECT; PRACTICE RESEARCH DATABASE; UNITED-STATES;
IMMUNIZATION-SAFETY; VACCINATION; SURVEILLANCE; RECEIPT; PROGRAM;
KINGDOM; COHORT
AB Background The influenza A (H1N1) 2009 monovalent vaccination programme was the largest mass vaccination initiative in recent US history. Commensurate with the size and scope of the vaccination programme, a project to monitor vaccine adverse events was undertaken, the most comprehensive safety surveillance agenda in the USA to date. The adverse event monitoring project identified an increased risk of Guillain-Barre syndrome after vaccination; however, some individual variability in results was noted. Guillain-Barre syndrome is a rare but serious health disorder in which a person's own immune system damages their nerve cells, causing muscle weakness, sometimes paralysis, and infrequently death. We did a meta-analysis of data from the adverse event monitoring project to ascertain whether influenza A (H1N1) 2009 monovalent inactivated vaccines used in the USA increased the risk of Guillain-Barre syndrome.
Methods Data were obtained from six adverse event monitoring systems. About 23 million vaccinated people were included in the analysis. The primary analysis entailed calculation of incidence rate ratios and attributable risks of excess cases of Guillain-Barre syndrome per million vaccinations. We used a self-controlled risk-interval design.
Findings Influenza A (H1N1) 2009 monovalent inactivated vaccines were associated with a small increased risk of Guillain-Barre syndrome (incidence rate ratio 2.35, 95% CI 1.42-4.01, p=0.0003). This finding translated to about 1.6 excess cases of Guillain-Barre syndrome per million people vaccinated.
Interpretation The modest risk of Guillain-Barre syndrome attributed to vaccination is consistent with previous estimates of the disorder after seasonal influenza vaccination. A risk of this small magnitude would be difficult to capture during routine seasonal influenza vaccine programmes, which have extensive, but comparatively less, safety monitoring. In view of the morbidity and mortality caused by 2009 H1N1 influenza and the effectiveness of the vaccine, clinicians, policy makers, and those eligible for vaccination should be assured that the benefits of inactivated pandemic vaccines greatly outweigh the risks.
C1 [Salmon, Daniel A.; Bleser, William; Gellin, Bruce] Dept Hlth & Human Serv, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC USA.
[Lurie, Nicole] Dept Hlth & Human Serv, Washington, DC USA.
[Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA.
[Proschan, Michael] NIH, Bethesda, MD 20892 USA.
[Forshee, Richard; Burwen, Dale R.] US FDA, Rockville, MD 20857 USA.
[Gargiullo, Paul; Vellozzi, Claudia] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Cunningham, Francesca] US Dept Vet Affairs, Hines, IL USA.
[Garman, Patrick] US Dept Def, Washington, DC 20305 USA.
[Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
[Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
RP Salmon, DA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA.
EM dsalmon@jhsph.edu
OI Jacobsen, Steven/0000-0002-8174-8533; Bleser,
William/0000-0002-4640-8680
FU US Federal Government
FX US Federal Government.
NR 40
TC 56
Z9 56
U1 0
U2 74
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 27
PY 2013
VL 381
IS 9876
BP 1461
EP 1468
DI 10.1016/S0140-6736(12)62189-8
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 139TK
UT WOS:000318607300035
PM 23498095
ER
PT J
AU Wang, JM
Ma, CJ
Li, GY
Wu, XY
Thayer, P
Greer, P
Smith, AM
High, KP
Moorman, JP
Yao, ZQ
AF Wang, Jia M.
Ma, Cheng J.
Li, Guang Y.
Wu, Xiao Y.
Thayer, Penny
Greer, Pamela
Smith, Ashley M.
High, Kevin P.
Moorman, Jonathan P.
Yao, Zhi Q.
TI Tim-3 alters the balance of IL-12/IL-23 and drives T(H)17 cells: Role in
hepatitis B vaccine failure during hepatitis C infection
SO VACCINE
LA English
DT Article
DE Tim-3; IL-12; IL-23; IL-17; Hepatitis B vaccine; Hepatitis C infection
ID VIRUS CORE PROTEIN; T-CELL; ELEVATED FREQUENCIES; IMMUNE-RESPONSE;
LIVER-DISEASE; EXPRESSION; IL-23; CYTOKINE; PD-1; INDIVIDUALS
AB Hepatitis B virus (HBV) vaccination is recommended for individuals with hepatitis C virus (HCV) infection given their shared risk factors and increased liver-related morbidity and mortality upon super-infection. Vaccine responses in this setting are often blunted, with poor response rates to HBV vaccinations in chronically HCV-infected individuals compared to healthy subjects. In this study, we investigated the role of T cell immunoglobulin mucin domain-3 (Tim-3)-mediated immune regulation in HBV vaccine responses during HCV infection. We found that Tim-3, a marker for T cell exhaustion, was over-expressed on monocytes, leading to a differential regulation of IL-12/IL-23 production which in turn T(H)17 cell accumulation, in HCV-infected HBV vaccine non-responders compared to HCV-infected HBV vaccine responders or healthy subjects (HS). Importantly, ex vivo blockade of Tim-3 signaling corrected the imbalance of IL-12/IL-23 as well as the IL-17 bias observed in HBV vaccine non-responders during HCV infection. These results suggest that Tim-3-mediated dysregulation of innate to adaptive immune responses is involved in HBV vaccine failure in individuals with chronic HCV infection, raising the possibility that blocking this negative signaling pathway might improve the success rate of HBV immunization in the setting of chronic viral infection. Published by Elsevier Ltd.
C1 [Thayer, Penny; Greer, Pamela; Smith, Ashley M.; Moorman, Jonathan P.; Yao, Zhi Q.] US Dept Vet Affairs, James H Quillen VA Med Ctr, Hepatitis HCV HIV Program, Johnson City, TN USA.
[Wang, Jia M.; Ma, Cheng J.; Li, Guang Y.; Wu, Xiao Y.; Moorman, Jonathan P.; Yao, Zhi Q.] E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Infect Dis, Johnson City, TN 37614 USA.
[Wang, Jia M.] Soochow Univ, Sch Med, Dept Biochem & Mol Biol, Suzhou, Peoples R China.
[High, Kevin P.] Wake Forest Univ, Baptist Med Ctr, Infect Dis Sect, Dept Internal Med, Winston Salem, NC 27109 USA.
RP Moorman, JP (reprint author), E Tennessee State Univ, Coll Med, Dept Internal Med, Div Infect Dis, Johnson City, TN 37614 USA.
EM Moorman@etsu.edu
RI sebastianovitsch, stepan/G-8507-2013
FU NIH NIDDK [R01DK093526]; Wake Forrest University; East Tennessee State
University
FX This work was supported by an NIH NIDDK grant to ZQY/JPM (R01DK093526)
and by a Wake Forrest University and East Tennessee State University
Collaborative Research Pilot Award. This publication is the result of
work supported with resources and the use of facilities at the James H.
Quillen Veterans Affairs Medical Center. The contents in this
publication do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 58
TC 10
Z9 13
U1 0
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 26
PY 2013
VL 31
IS 18
BP 2238
EP 2245
DI 10.1016/j.vaccine.2013.03.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 135ZP
UT WOS:000318329500004
PM 23499521
ER
PT J
AU Bai, XY
Feldman, NE
Chmura, K
Ovrutsky, AR
Su, WL
Griffin, L
Pyeon, D
McGibney, MT
Strand, MJ
Numata, M
Murakami, S
Gaido, L
Honda, JR
Kinney, WH
Oberley-Deegan, RE
Voelker, DR
Ordway, DJ
Chan, ED
AF Bai, Xiyuan
Feldman, Nicole E.
Chmura, Kathryn
Ovrutsky, Alida R.
Su, Wen-Lin
Griffin, Laura
Pyeon, Dohun
McGibney, Mischa T.
Strand, Matthew J.
Numata, Mari
Murakami, Seiji
Gaido, Loretta
Honda, Jennifer R.
Kinney, William H.
Oberley-Deegan, Rebecca E.
Voelker, Dennis R.
Ordway, Diane J.
Chan, Edward D.
TI Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of
Mycobacterium tuberculosis in Human Macrophages
SO PLOS ONE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; DRUG-RESISTANT TUBERCULOSIS; TOLL-LIKE RECEPTORS;
NITRIC-OXIDE; TRANSCRIPTION FACTOR; HOST-DEFENSE; TNF-ALPHA; ALVEOLAR
MACROPHAGES; MURINE MACROPHAGES; INTERLEUKIN-8 GENE
AB Nuclear factor-kappa B (NF kappa B) is a ubiquitous transcription factor that mediates pro-inflammatory responses required for host control of many microbial pathogens; on the other hand, NF kappa B has been implicated in the pathogenesis of other inflammatory and infectious diseases. Mice with genetic disruption of the p50 subunit of NF kappa B are more likely to succumb to Mycobacterium tuberculosis (MTB). However, the role of NF kappa B in host defense in humans is not fully understood. We sought to examine the role of NFkB activation in the immune response of human macrophages to MTB. Targeted pharmacologic inhibition of NF kappa B activation using BAY 11-7082 (BAY, an inhibitor of I kappa B alpha kinase) or an adenovirus construct with a dominant-negative IkBa significantly decreased the number of viable intracellular mycobacteria recovered from THP-1 macrophages four and eight days after infection. The results with BAY were confirmed in primary human monocyte-derived macrophages and alveolar macrophages. NF kappa B inhibition was associated with increased macrophage apoptosis and autophagy, which are well-established killing mechanisms of intracellular MTB. Inhibition of the executioner protease caspase-3 or of the autophagic pathway significantly abrogated the effects of BAY. We conclude that NF kappa B inhibition decreases viability of intracellular MTB in human macrophages via induction of apoptosis and autophagy.
C1 [Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
[Bai, Xiyuan; Feldman, Nicole E.; Chmura, Kathryn; Ovrutsky, Alida R.; McGibney, Mischa T.; Strand, Matthew J.; Numata, Mari; Murakami, Seiji; Honda, Jennifer R.; Kinney, William H.; Oberley-Deegan, Rebecca E.; Voelker, Dennis R.; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO USA.
[Bai, Xiyuan; Chmura, Kathryn; Ovrutsky, Alida R.; Honda, Jennifer R.; Kinney, William H.; Chan, Edward D.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
[Gaido, Loretta] Denver Hlth Med Ctr, Denver, CO USA.
[Griffin, Laura; Pyeon, Dohun] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA.
[Su, Wen-Lin] Natl Def Med Ctr, Dept Med, Tri Serv Gen Hosp, Taipei, Taiwan.
[Ordway, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Bai, XY (reprint author), Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
EM baix@njhealth.org; chane@njhealth.org
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development [1 I01 BX001028-01A2]; National Institutes
of Health (NIH) [PHL073907]; General Clinical Research Center Program
Grant [M01-RR00051]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development 1 I01
BX001028-01A2 (to EDC), National Institutes of Health (NIH) PHL073907
(to DRV), and General Clinical Research Center Program Grant No.
M01-RR00051. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 75
TC 13
Z9 14
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2013
VL 8
IS 4
AR e61925
DI 10.1371/journal.pone.0061925
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DM
UT WOS:000318341400027
PM 23634218
ER
PT J
AU Shimamoto, SA
Ryapolova-Webb, ES
Ostrem, JL
Galifianakis, NB
Miller, KJ
Starr, PA
AF Shimamoto, Shoichi A.
Ryapolova-Webb, Elena S.
Ostrem, Jill L.
Galifianakis, Nicholas B.
Miller, Kai J.
Starr, Philip A.
TI Subthalamic Nucleus Neurons Are Synchronized to Primary Motor Cortex
Local Field Potentials in Parkinson's Disease
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID DEEP BRAIN-STIMULATION; BASAL GANGLIA; OSCILLATORY ACTIVITY;
SENSORIMOTOR CORTEX; BETA-OSCILLATIONS; GLOBUS-PALLIDUS;
CEREBRAL-CORTEX; SPECTRAL-ANALYSIS; DOPAMINE; SPIKE
AB In Parkinson's disease (PD), striatal dopamine denervation results in a cascade of abnormalities in the single-unit activity of downstream basal ganglia nuclei that include increased firing rate, altered firing patterns, and increased oscillatory activity. However, the effects of these abnormalities on cortical function are poorly understood. Here, in humans undergoing deep brain stimulator implantation surgery, we use the novel technique of subdural electrocorticography in combination with subthalamic nucleus (STN) single-unit recording to study basal ganglia-cortex interactions at the millisecond time scale. We show that in patients with PD, STN spiking is synchronized with primary motor cortex (M1) local field potentials in two distinct patterns: first, STN spikes are phase-synchronized with M1 rhythms in the theta, alpha, or beta (4-30 Hz) bands. Second, STN spikes are synchronized with M1 gamma activity over a broad spectral range (50-200Hz). The amplitude of STN spike-synchronized gamma activity in M1 is itself rhythmically modulated by the phase of a lower-frequency rhythm (phase-amplitude coupling), such that "waves" of phase-synchronized gamma activity precede the occurrence of STN spikes. We show the disease specificity of these phenomena in PD, by comparison with STN-M1 paired recordings performed in a group of patients with a different disorder, primary craniocervical dystonia. Our findings support a model of the basal ganglia-thalamocortical loop in PD in which gamma activity in primary motor cortex, modulated by the phase of low-frequency rhythms, drives STN unit discharge.
C1 [Shimamoto, Shoichi A.; Ryapolova-Webb, Elena S.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Ostrem, Jill L.; Galifianakis, Nicholas B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Galifianakis, Nicholas B.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA 94143 USA.
[Miller, Kai J.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 779 Moffitt,505 Parnassus Ave, San Francisco, CA 94143 USA.
EM starrp@neurosurg.ucsf.edu
FU National Institutes of Health [R01NS069779]; Dystonia Medical Research
Foundation
FX This work was supported by the National Institutes of Health (Grant
R01NS069779 to P. A. S.), and the Dystonia Medical Research Foundation.
We thank Leslie Markun and Marta San Luciano for assistance with
clinical data and statistical analyses, and Coralie de Hemptinne for
critical review of the paper.
NR 63
TC 45
Z9 46
U1 6
U2 24
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 24
PY 2013
VL 33
IS 17
BP 7220
EP 7233
DI 10.1523/JNEUROSCI.4676-12.2013
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 137EW
UT WOS:000318419300011
PM 23616531
ER
PT J
AU Gu, LY
Dai, Y
Xu, J
Mallipattu, S
Kaufman, L
Klotman, PE
He, JC
Chuang, PY
AF Gu, Leyi
Dai, Yan
Xu, Jin
Mallipattu, Sandeep
Kaufman, Lewis
Klotman, Paul E.
He, John C.
Chuang, Peter Y.
TI Deletion of podocyte STAT3 mitigates the entire spectrum of
HIV-1-associated nephropathy
SO AIDS
LA English
DT Article
DE dedifferentiation; glomerular disease; HIV-1-associated nephropathy;
kidney; podocyte; STAT3
ID HIV-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY;
DIABETIC-NEPHROPATHY; SIGNAL TRANSDUCER; KIDNEY; MICE; EXPRESSION;
GLOMERULI; INFECTION; ACTIVATOR
AB Objective: HIV-1 gene expression in kidney epithelial cells is thought to be responsible for the pathogenesis of HIV-1-associated nephropathy (HIVAN). Signal transducer and activator of transcription (STAT) 3 signaling is activated in podocytes of patients with HIVAN and drives the dedifferentiation and proliferation of podocytes in culture. We confirm here that deletion of podocyte STAT3 is sufficient to mitigate the glomerular as well as tubulointerstitial findings of HIVAN.
Methods: To demonstrate the functional role of podocyte STAT3 in the pathogenesis of HIVAN we compared the development of HIVAN in Tg26 HIV-transgenic mice with and without deletion of STAT3 in the podocyte.
Results: Tg26 mice with podocyte-specific STAT3 deletion developed significantly less weight loss, albuminuria, and renal function impairment compared to Tg26 mice without STAT3 deletion. Tg26 mice with podocyte STAT3 deletion also had significantly less glomerular collapse, sclerosis, epithelial cell hyperplasia, podocyte dedifferentiation, and proinflammatory STAT3 target gene expression; and tubulointerstitial changes of HIVAN, including tubular atrophy, degeneration, apoptosis, and lymphocyte infiltration, were also significantly reduced compared to Tg26 mice without STAT3 deletion.
Conclusion: Development of glomerular as well as tubulointerstitial injuries in the Tg26 HIVAN model is dependent on podocyte STAT3 expression. Inhibition of STAT3 could be a potential adjunctive therapy for the treatment of HIVAN. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1091-1098
C1 [Gu, Leyi; Dai, Yan; Xu, Jin; Mallipattu, Sandeep; Kaufman, Lewis; He, John C.; Chuang, Peter Y.] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA.
[Gu, Leyi] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Renal, Shanghai 200030, Peoples R China.
[Gu, Leyi] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Mol Cell Lab Kidney Dis, Shanghai 200030, Peoples R China.
[Dai, Yan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Div Nephrol, Shanghai 200030, Peoples R China.
[Klotman, Paul E.] Baylor Coll Med, Houston, TX 77030 USA.
[He, John C.] James J Peter Vet Affairs Med Ctr, Renal Sect, Bronx, NY USA.
RP Chuang, PY (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM peter.chuang@mssm.edu
RI Mallipattu , Sandeep/M-7009-2014
FU NIH [1R01DK078897, 1R01DK088541-01A1, 5K08DK082760, R01DK078897,
K08DK082760, R01DK088541-01A1, RC4DK090860, P01DK056492]; Veterans
Affairs Merit Review Award [1I01BX000345]
FX J.C.H. is supported by NIH 1R01DK078897 and 1R01DK088541-01A1 and a
Veterans Affairs Merit Review Award 1I01BX000345; P.Y.C. is supported by
NIH 5K08DK082760.; Source of Support: NIH R01DK078897, K08DK082760,
R01DK088541-01A1, RC4DK090860, P01DK056492 and Veterans Affairs Merit
Review Award 1I01BX000345.
NR 31
TC 16
Z9 16
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD APR 24
PY 2013
VL 27
IS 7
BP 1091
EP 1098
DI 10.1097/QAD.0b013e32835f1ea1
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 124QE
UT WOS:000317479500005
PM 23343908
ER
PT J
AU London, MJ
Hur, K
Schwartz, GG
Henderson, WG
AF London, Martin J.
Hur, Kwan
Schwartz, Gregory G.
Henderson, William G.
TI Association of Perioperative beta-Blockade With Mortality and
Cardiovascular Morbidity Following Major Noncardiac Surgery
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID OF-VETERANS-AFFAIRS; QUALITY IMPROVEMENT PROGRAM; VASCULAR-SURGERY;
AMERICAN-COLLEGE; PRACTICE GUIDELINES; HEART-ASSOCIATION; SURGICAL CARE;
OUTCOMES; RISK; THERAPY
AB Importance The effectiveness of perioperative beta-blockade in patients undergoing noncardiac surgery remains controversial.
Objective To determine the associations of early perioperative exposure to beta-blockers with 30-day postoperative outcome in patients undergoing noncardiac surgery.
Design, Setting, and Patients A retrospective cohort analysis evaluating exposure to beta-blockers on the day of or following major noncardiac surgery among a population-based sample of 136 745 patients who were 1: 1 matched on propensity scores (37 805 matched pairs) treated at 104 VA medical centers from January 2005 through August 2010.
Main Outcomes and Measures All cause 30-day mortality and cardiac morbidity (cardiac arrest or Q-wave myocardial infarction).
Results Overall 55 138 patients (40.3%) were exposed to beta-blockers. Exposure was higher in the 66.7% of 13 863 patients undergoing vascular surgery (95% CI, 65.9%-67.5%) than in the 37.4% of 122 882 patients undergoing nonvascular surgery (95% CI, 37.1%-37.6%; P<.001). Exposure increased as Revised Cardiac Risk Index factors increased, with 25.3% (95% CI, 24.9%-25.6%) of those with no risk vs 71.3% (95% CI, 69.5%-73.2%) of those with 4 risk factors or more exposed to beta-blockers (P<.001). Death occurred among 1.1% (95% CI, 1.1%-1.2%) and cardiac morbidity occurred among 0.9% (95% CI, 0.8%-0.9%) of patients. In the propensity matched cohort, exposure was associated with lower mortality (relative risk [RR], 0.73; 95% CI, 0.65-0.83; P<.001; number need to treat [NNT], 241; 95% CI, 173-397). When stratified by cumulative numbers of Revised Cardiac Risk Index factors, beta-blocker exposure was associated with significantly lower mortality among patients with 2 factors (RR, 0.63 [95% CI, 0.50-0.80]; P<.001; NNT, 105 [95% CI, 69-212]), 3 factors (RR, 0.54 [95% CI, 0.39-0.73]; P<.001; NNT, 41 [95% CI, 28-80]), or 4 factors or more (RR, 0.40 [95% CI, 0.25-0.73]; P<.001; NNT, 18 [95% CI, 12-34]). This association was limited to patients undergoing nonvascular surgery. beta-Blocker exposure was also associated with a lower rate of nonfatal Q-wave infarction or cardiac arrest (RR, 0.67 [95% CI, 0.57-0.79]; P<.001; NNT, 339 [95% CI, 240-582]), again limited to patients undergoing nonvascular surgery.
Conclusions and Relevance Among propensity-matched patients undergoing noncardiac, nonvascular surgery, perioperative beta-blocker exposure was associated with lower rates of 30-day all-cause mortality in patients with 2 or more Revised Cardiac Risk Index factors. Our findings support use of a cumulative number of Revised Cardiac Risk Index predictors in decision making regarding institution and continuation of perioperative beta-blockade. A multicenter randomized trial involving patients at a low to intermediate risk by these factors would be of interest to validate these observational findings. JAMA. 0;0(16):1704-1713 www.jama.com
C1 [London, Martin J.] US Dept Vet Affairs Med Ctr, Dept Anesthesia & Perioperat Care, San Francisco, CA USA.
[London, Martin J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hur, Kwan] US Dept Vet Affairs Med Ctr, Ctr Medicat Safety, Pharm Benefits Management Serv, Hines, IL USA.
[Schwartz, Gregory G.] US Dept Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA.
[Schwartz, Gregory G.] Univ Colorado, Denver, CO 80202 USA.
[Henderson, William G.] Colorado Sch Publ Hlth, Hlth Outcomes Program, Aurora, CO USA.
[Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
RP London, MJ (reprint author), San Francisco VA Med Ctr, Dept Anesthesia & Perioperat Care, 4150 Clement St, San Francisco, CA 94121 USA.
EM londonm@anesthesia.ucsf.edu
FU Anesthesia Patient Safety Foundation
FX This study was supported by a grant from the Anesthesia Patient Safety
Foundation.
NR 37
TC 86
Z9 87
U1 3
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 24
PY 2013
VL 309
IS 16
BP 1704
EP 1713
DI 10.1001/jama.2013.4135
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130IG
UT WOS:000317906700027
PM 23613075
ER
PT J
AU Freiberg, MS
Chang, CCH
Kuller, LH
Skanderson, M
Lowy, E
Kraemer, KL
Butt, AA
Goetz, MB
Leaf, D
Oursler, KA
Rimland, D
Barradas, MR
Brown, S
Gibert, C
McGinnis, K
Crothers, K
Sico, J
Crane, H
Warner, A
Gottlieb, S
Gottdiener, J
Tracy, RP
Budoff, M
Watson, C
Armah, KA
Doebler, D
Bryant, K
Justice, AC
AF Freiberg, Matthew S.
Chang, Chung-Chou H.
Kuller, Lewis H.
Skanderson, Melissa
Lowy, Elliott
Kraemer, Kevin L.
Butt, Adeel A.
Goetz, Matthew Bidwell
Leaf, David
Oursler, Kris Ann
Rimland, David
Barradas, Maria Rodriguez
Brown, Sheldon
Gibert, Cynthia
McGinnis, Kathy
Crothers, Kristina
Sico, Jason
Crane, Heidi
Warner, Alberta
Gottlieb, Stephen
Gottdiener, John
Tracy, Russell P.
Budoff, Matthew
Watson, Courtney
Armah, Kaku A.
Doebler, Donna
Bryant, Kendall
Justice, Amy C.
TI HIV Infection and the Risk of Acute Myocardial Infarction
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID CORONARY-HEART-DISEASE; REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY;
CARDIOVASCULAR-DISEASE; VETERANS; HEALTH; COHORT; PREVALENCE; ADULTS;
MEN
AB Importance: Whether people infected with human immunodeficiency virus (HIV) are at an increased risk of acute myocardial infarction (AMI) compared with uninfected people is not clear. Without demographically and behaviorally similar uninfected comparators and without uniformly measured clinical data on risk factors and fatal and nonfatalAMIevents, any potential association between HIV status and AMI may be confounded.
Objective: To investigate whether HIV is associated with an increased risk of AMI after adjustment for all standard Framingham risk factors among a large cohort of HIV-positive and demographically and behaviorally similar (ie, similar prevalence of smoking, alcohol, and cocaine use) uninfected veterans in care.
Design and Setting: Participants in the Veterans Aging Cohort Study Virtual Cohort from April 1, 2003, through December 31, 2009.
Participants: After eliminating those with baseline cardiovascular disease, we analyzed data on HIV status, age, sex, race/ethnicity, hypertension, diabetes mellitus, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease, anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and incidence of AMI.
Main Outcome Measure: Acute myocardial infarction.
Results: We analyzed data on 82 459 participants. During a median follow-up of 5.9 years, there were 871 AMI events. Across 3 decades of age, the mean (95% CI) AMI events per 1000 person-years was consistently and significantly higher for HIV-positive compared with uninfected veterans: for those aged 40 to 49 years, 2.0 (1.6-2.4) vs 1.5 (1.3-1.7); for those aged 50 to 59 years, 3.9 (3.3-4.5) vs 2.2 (1.9-2.5); and for those aged 60 to 69 years, 5.0 (3.8-6.7) vs 3.3 (2.6-4.2) (P<.05 for all). After adjusting for Framingham risk factors, comorbidities, and substance use, HIV-positive veterans had an increased risk of incident AMI compared with uninfected veterans (hazard ratio, 1.48; 95% CI, 1.27-1.72). An excess risk remained among those achieving an HIV-1 RNA level less than 500 copies/mL compared with uninfected veterans in time-updated analyses (hazard ratio, 1.39; 95% CI, 1.17-1.66).
Conclusions and Relevance: Infection with HIV is associated with a 50% increased risk of AMI beyond that explained by recognized risk factors.
C1 [Freiberg, Matthew S.; Chang, Chung-Chou H.; Kraemer, Kevin L.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Freiberg, Matthew S.; Chang, Chung-Chou H.; Kuller, Lewis H.; Armah, Kaku A.; Doebler, Donna] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Skanderson, Melissa; McGinnis, Kathy; Sico, Jason; Justice, Amy C.] West Haven Vet Adm, Med Ctr, Vet Affairs VA Connecticut Hlth Care Syst, West Haven, CT USA.
[Sico, Jason; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
[Lowy, Elliott] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Lowy, Elliott] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Crothers, Kristina; Crane, Heidi] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA.
[Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Goetz, Matthew Bidwell; Leaf, David; Warner, Alberta] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles, CA USA.
[Budoff, Matthew] Los Angeles Biomed Res Inst, Los Angeles, CA USA.
[Oursler, Kris Ann; Gottlieb, Stephen; Gottdiener, John] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Oursler, Kris Ann] Baltimore VA Hlth Care Syst, Baltimore, MD USA.
[Bryant, Kendall] NIAAA, Bethesda, MD 90034 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Barradas, Maria Rodriguez] Baylor Coll Med, Houston, TX 77030 USA.
[Barradas, Maria Rodriguez] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Brown, Sheldon] James J Peters VA Med Ctr, Bronx, NY USA.
[Brown, Sheldon] Mt Sinai Sch Med, New York, NY USA.
[Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA.
[Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Burlington, VT 05405 USA.
[Watson, Courtney] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
RP Freiberg, MS (reprint author), Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
EM Freibergms@upmc.edu
OI Goetz, Matthew/0000-0003-4542-992X; Crothers,
Kristina/0000-0001-9702-0371
FU Merck [P08569 MIISP 39996]; National Heart, Lung, and Blood Institute
[HL095136-04]; National Institute on Alcohol Abuse and Alcoholism at the
National Institutes of Health [AA013566-10, AA020790, AA020794]
FX Dr Butt reports that he received Investigator-Initiated Studies Program
grant P08569 MIISP 39996 from Merck and gave a scientific talk for
Gilead in 2011.; This work was supported by grant HL095136-04 from the
National Heart, Lung, and Blood Institute and grants AA013566-10,
AA020790, and AA020794 from the National Institute on Alcohol Abuse and
Alcoholism at the National Institutes of Health.
NR 40
TC 264
Z9 267
U1 4
U2 31
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 614
EP 622
DI 10.1001/jamainternmed.2013.3728
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600002
PM 23459863
ER
PT J
AU Sen, S
Kranzler, HR
Didwania, AK
Schwartz, AC
Amarnath, S
Kolars, JC
Dalack, GW
Nichols, B
Guille, C
AF Sen, Srijan
Kranzler, Henry R.
Didwania, Aashish K.
Schwartz, Ann C.
Amarnath, Sudha
Kolars, Joseph C.
Dalack, Gregory W.
Nichols, Breck
Guille, Constance
TI Effects of the 2011 Duty Hour Reforms on Interns and Their Patients A
Prospective Longitudinal Cohort Study
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID RESIDENTS WORK HOURS; MEDICAL ERRORS; ACCREDITATION-COUNCIL; 1ST-YEAR
RESIDENTS; ADVERSE EVENTS; FOLLOW-UP; SLEEP; LIMITS; DEPRESSION;
EDUCATION
AB Importance: In 2003, the first phase of duty hour requirements for US residency programs recommended by the Accreditation Council for Graduate Medical Education (ACGME) was implemented. Evidence suggests that this first phase of duty hour requirements resulted in a modest improvement in resident well-being and patient safety. To build on these initial changes, the ACGME recommended a new set of duty hour requirements that took effect in July 2011.
Objective: To determine the effects of the 2011 duty hour reforms on first-year residents (interns) and their patients.
Design: As part of the Intern Health Study, we conducted a longitudinal cohort study comparing interns serving before (2009 and 2010) and interns serving after (2011) the implementation of the new duty hour requirements.
Setting: Fifty-one residency programs at 14 university and community-based GME institutions.
Participants: A total of 2323 medical interns.
Main Outcome Measures: Self-reported duty hours, hours of sleep, depressive symptoms, well-being, and medical errors at 3, 6, 9, and 12 months of the internship year.
Results: Fifty-eight percent of invited interns chose to participate in the study. Reported duty hours decreased from an average of 67.0 hours per week before the new rules to 64.3 hours per week after the new rules were instituted (P < .001). Despite the decrease in duty hours, there were no significant changes in hours slept (6.8.-> 7.0; P = .17), depressive symptoms (5.8.-> 5.7; P =. 55) or wellbeing score (48.5 -> 48.4; P = .86) reported by interns. With the new duty hour rules, the percentage of interns who reported concern about making a serious medical error increased from 19.9% to 23.3% (P = .007).
Conclusions and Relevance: Although interns report working fewer hours under the new duty hour restrictions, this decrease has not been accompanied by an increase in hours of sleep or an improvement in depressive symptoms or well-being but has been accompanied by an unanticipated increase in self-reported medical errors.
C1 [Sen, Srijan; Dalack, Gregory W.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Kolars, Joseph C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Kranzler, Henry R.] Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
[Kranzler, Henry R.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Didwania, Aashish K.] Northwestern Univ Feinberg Sch Med, Dept Internal Med, Chicago, IL USA.
[Schwartz, Ann C.] Emory Univ Sch Med, Dept Psychiat, Atlanta, GA USA.
[Amarnath, Sudha] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA.
[Nichols, Breck] Los Angeles Cty Univ Southern Calif Med Ctr, Keck Univ Southern Calif Sch Med, Dept Pediat, Los Angeles, CA USA.
[Nichols, Breck] Los Angeles Cty Univ So Calif Med Ctr, Keck Univ Southern Calif Sch Med, Dept Med, Los Angeles, CA USA.
[Guille, Constance] Med Univ S Carolina, Dept Psychiat, Charleston, SC USA.
RP Sen, S (reprint author), Univ Michigan, Dept Psychiat, 5047 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM srijan@umich.edu
RI Sen, Srijan/J-8053-2013
FU American Foundation for Suicide Prevention; National Center for Research
Resources [UL1RR024986]; National Institute of Mental Health [MH095109];
National Institute on Alcohol Abuse and Alcoholism [AA013736]; Lilly;
Lundbeck; Abbott; Pfizer
FX The project was supported by the following grants: a Young Investigator
Grant from the American Foundation for Suicide Prevention (Dr Sen),
UL1RR024986 from the National Center for Research Resources (Dr Sen),
MH095109 from the National Institute of Mental Health (Dr Sen), and
AA013736 from the National Institute on Alcohol Abuse and Alcoholism (Dr
Kranzler).; Dr Krantzler has been a consultant or advisory board member
for Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of
the American Society of Clinical Psychopharmacology, which is supported
by Lilly, Lundbeck, Abbott, and Pfizer.
NR 40
TC 41
Z9 41
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 657
EP 662
DI 10.1001/jamainternmed.2013.351
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600011
PM 23529201
ER
PT J
AU Gellad, WF
Yealy, D
Fine, M
AF Gellad, Walid F.
Yealy, Donald
Fine, Michael
TI Computers and the Diagnosis of Pneumonia
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID COMMUNITY-ACQUIRED PNEUMONIA; OUTCOMES
C1 [Gellad, Walid F.; Fine, Michael] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Gellad, Walid F.; Fine, Michael] Univ Pittsburgh, Dept Med, Div Gen Med, Pittsburgh, PA USA.
[Yealy, Donald] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA.
RP Gellad, WF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM walid.gellad@va.gov
NR 8
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 701
EP 702
DI 10.1001/jamainternmed.2013.4083
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600022
PM 23553079
ER
PT J
AU Singh, H
Spitzmueller, C
Petersen, NJ
Sawhney, MK
Sittig, DF
AF Singh, Hardeep
Spitzmueller, Christiane
Petersen, Nancy J.
Sawhney, Mona K.
Sittig, Dean F.
TI Information Overload and Missed Test Results in Electronic Health
Record-Based Settings
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.] Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA Hlth Serv Res & Dev Ctr Excellence, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Spitzmueller, Christiane] Univ Houston, Dept Psychol, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA.
RP Singh, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU NCI NIH HHS [K23 CA125585, K23CA125585]
NR 11
TC 34
Z9 34
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 702
EP 704
DI 10.1001/2013.jamainternmed.61
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600023
PM 23460235
ER
PT J
AU Deo, AJ
Goldszer, IM
Li, SY
DiBitetto, JV
Henteleff, R
Sampson, A
Lewis, DA
Penzes, P
Sweet, RA
AF Deo, Anthony J.
Goldszer, Isaac M.
Li, Siyu
DiBitetto, James V.
Henteleff, Ruth
Sampson, Allan
Lewis, David A.
Penzes, Peter
Sweet, Robert A.
TI PAK1 Protein Expression in the Auditory Cortex of Schizophrenia Subjects
SO PLOS ONE
LA English
DT Article
ID DENDRITIC SPINE DENSITY; CORTICAL PYRAMIDAL NEURONS; PREFRONTAL CORTEX;
IN-VIVO; KINASE; MORPHOGENESIS; SPINOPHILIN; MECHANISMS; DEFICITS;
GENERATION
AB Deficits in auditory processing are among the best documented endophenotypes in schizophrenia, possibly due to loss of excitatory synaptic connections. Dendritic spines, the principal post-synaptic target of excitatory projections, are reduced in schizophrenia. p21-activated kinase 1 (PAK1) regulates both the actin cytoskeleton and dendritic spine density, and is a downstream effector of both kalirin and CDC42, both of which have altered expression in schizophrenia. This study sought to determine if there is decreased auditory cortex PAK1 protein expression in schizophrenia through the use of quantitative western blots of 25 schizophrenia subjects and matched controls. There was no significant change in PAK1 level detected in the schizophrenia subjects in our cohort. PAK1 protein levels within subject pairs correlated positively with prior measures of total kalirin protein in the same pairs. PAK1 level also correlated with levels of a marker of dendritic spines, spinophilin. These latter two findings suggest that the lack of change in PAK1 level in schizophrenia is not due to limited sensitivity of our assay to detect meaningful differences in PAK1 protein expression. Future studies are needed to evaluate whether alterations in PAK1 phosphorylation states, or alterations in protein expression of other members of the PAK family, are present in schizophrenia.
C1 [Deo, Anthony J.; Goldszer, Isaac M.; DiBitetto, James V.; Henteleff, Ruth; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA.
[Deo, Anthony J.] Univ Pittsburgh, Sch Med, Phys Scientist Training Program, Pittsburgh, PA USA.
[Li, Siyu; Sampson, Allan] Univ Pittsburgh, Dept Stat, Pittsburgh, PA USA.
[Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA.
[Penzes, Peter] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Penzes, Peter] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Lewis, David/G-4053-2014; Penzes, Peter/L-3987-2016
OI Lewis, David/0000-0002-3225-6778; Penzes, Peter/0000-0001-5449-1640
FU National Institutes of Mental Health [MH071533, MH084053, MH071316];
Doris Duke Charitable Foundation; Johnson & Johnson Pharmaceutical
Research and Development
FX This work was supported by grants MH071533, MH084053 and MH071316 from
the National Institutes of Mental Health. Anthony Deo was supported by a
Clinical Research Fellow grant from the Doris Duke Charitable Foundation
to the University of Pittsburgh School of Medicine. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.; Allan R. Sampson is a paid
statistical consultant on design and analysis issues to Johnson &
Johnson Pharmaceutical Research and Development. This does not alter his
adherence to all the PLOS ONE policies on sharing data and materials.
NR 44
TC 5
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2013
VL 8
IS 4
AR e59458
DI 10.1371/journal.pone.0059458
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130JR
UT WOS:000317911500002
PM 23613712
ER
PT J
AU Storb, R
Gyurkocza, B
Storer, BE
Sorror, ML
Blume, K
Niederwieser, D
Chauncey, TR
Pulsipher, MA
Petersen, FB
Sahebi, F
Agura, ED
Hari, P
Bruno, B
McSweeney, PA
Maris, MB
Maziarz, RT
Langston, AA
Bethge, W
Vindelov, L
Franke, GN
Laport, GG
Yeager, AM
Hubel, K
Deeg, HJ
Georges, GE
Flowers, MED
Martin, PJ
Mielcarek, M
Woolfrey, AE
Maloney, DG
Sandmaier, BM
AF Storb, Rainer
Gyurkocza, Boglarka
Storer, Barry E.
Sorror, Mohamed L.
Blume, Karl
Niederwieser, Dietger
Chauncey, Thomas R.
Pulsipher, Michael A.
Petersen, Finn B.
Sahebi, Firoozeh
Agura, Edward D.
Hari, Parameswaran
Bruno, Benedetto
McSweeney, Peter A.
Maris, Michael B.
Maziarz, Richard T.
Langston, Amelia A.
Bethge, Wolfgang
Vindelov, Lars
Franke, Georg-Nikolaus
Laport, Ginna G.
Yeager, Andrew M.
Huebel, Kai
Deeg, H. Joachim
Georges, George E.
Flowers, Mary E. D.
Martin, Paul J.
Mielcarek, Marco
Woolfrey, Ann E.
Maloney, David G.
Sandmaier, Brenda M.
TI Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After
Allogeneic Hematopoietic Cell Transplantation
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BONE-MARROW TRANSPLANTATION; MATCHED UNRELATED DONORS; TOTAL-BODY
IRRADIATION; HEMATOLOGIC MALIGNANCIES; MYELOGENOUS LEUKEMIA; RISK;
OUTCOMES; RELAPSE; HCT; IMMUNOSUPPRESSION
AB Purpose
We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities.
Patients and Methods
Patients received low-dose total-body irradiation +/- fludarabine before HCT from HLA-matched related (n = 611) or unrelated (n = 481) donors, followed by mycophenolate mofetil and a calcineurin inhibitor to aid engraftment and control GVHD. Median patient age was 56 years (range, 7 to 75 years). Forty-five percent of patients had comorbidity scores of >= 3. Median follow-up time was 5 years (range, 0.6 to 12.7 years).
Results
Depending on disease risk, comorbidities, and GVHD, lasting remissions were seen in 45% to 75% of patients, and 5-year survival ranged from 25% to 60%. At 5 years, the nonrelapse mortality (NRM) rate was 24%, and the relapse mortality rate was 34.5%. Most NRM was a result of GVHD. The most significant factors associated with GVHD-associated NRM were serious comorbidities and grafts from unrelated donors. Most relapses occurred early while the immune system was compromised. GVT effects were comparable after unrelated and related grafts. Chronic GVHD, but not acute GVHD, further increased GVT effects. The potential benefit associated with chronic GVHD was outweighed by increased NRM.
Conclusion
Allogeneic HCT relying on GVT effects is feasible and results in cures of an appreciable number of malignancies. Improved results could come from methods that control progression of malignancy early after HCT and effectively prevent GVHD. J Clin Oncol 31:1530-1538. (C) 2013 by American Society of Clinical Oncology
C1 [Storb, Rainer; Gyurkocza, Boglarka; Storer, Barry E.; Sorror, Mohamed L.; Deeg, H. Joachim; Georges, George E.; Flowers, Mary E. D.; Martin, Paul J.; Mielcarek, Marco; Woolfrey, Ann E.; Maloney, David G.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Storb, Rainer; Gyurkocza, Boglarka; Storer, Barry E.; Sorror, Mohamed L.; Chauncey, Thomas R.; Deeg, H. Joachim; Georges, George E.; Flowers, Mary E. D.; Martin, Paul J.; Mielcarek, Marco; Woolfrey, Ann E.; Maloney, David G.; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Blume, Karl; Laport, Ginna G.] Stanford Univ, Palo Alto, CA 94304 USA.
[Sahebi, Firoozeh] City Hope Kaiser Permanente Med Grp, Duarte, CA USA.
[Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA.
[Petersen, Finn B.] Intermt Hlth Care LDS Hosp, Salt Lake City, UT USA.
[Agura, Edward D.] Baylor Univ, Dallas, TX USA.
[Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[McSweeney, Peter A.; Maris, Michael B.] Colorado Blood Canc Inst Presbyterian St Lukes, Denver, CO USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR USA.
[Langston, Amelia A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Yeager, Andrew M.] Univ Arizona Canc Ctr, Tucson, AZ USA.
[Niederwieser, Dietger; Franke, Georg-Nikolaus] Univ Leipzig, D-04109 Leipzig, Germany.
[Bethge, Wolfgang] Univ Tubingen, Tubingen, Germany.
[Huebel, Kai] Univ Hosp Cologne, Cologne, Germany.
[Bruno, Benedetto] Univ Turin, Turin, Italy.
[Vindelov, Lars] Univ Copenhagen Rigshosp, Copenhagen, Denmark.
RP Storb, R (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mail Stop D1-100,POB 19024, Seattle, WA 98109 USA.
EM rstorb@fhcrc.org
OI Gyurkocza, Boglarka/0000-0002-2933-2119; Hari,
Parameswaran/0000-0002-8800-297X
FU National Institutes of Health, Bethesda, MD [P01 HL036444, P01 CA078902,
P01 CA018029, P30 CA015704, P30 CA023074, R01 HL108307, R00 HL088021];
Leukemia/Lymphoma Society [7008-08]; Laura Landro Salomon Endowment
Fund; Danish Cancer Society; Lundbeck Foundation; Ricerca Finalizzata;
Compagnia di San Paolo and Comitato Gigi Ghirotti
FX Supported by Grants No. P01 HL036444, P01 CA078902, P01 CA018029, P30
CA015704, P30 CA023074, R01 HL108307, and R00 HL088021 from the National
Institutes of Health, Bethesda, MD. Further support came from grants
from the Leukemia/Lymphoma Society (Grant No. 7008-08), the Laura Landro
Salomon Endowment Fund, the Danish Cancer Society, the Lundbeck
Foundation, the Ricerca Finalizzata 2008-2009, and the Compagnia di San
Paolo and Comitato Gigi Ghirotti.
NR 39
TC 72
Z9 74
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 20
PY 2013
VL 31
IS 12
BP 1530
EP 1538
DI 10.1200/JCO.2012.45.0247
PG 9
WC Oncology
SC Oncology
GA 129IC
UT WOS:000317831500015
PM 23478054
ER
PT J
AU Luo, NL
Wang, XD
Zhang, W
Garvey, WT
Fu, YC
AF Luo, Nanlan
Wang, Xiangdong
Zhang, Wei
Garvey, W. T.
Fu, Yuchang
TI AdR1-TG/TALLYHO mice have improved lipid accumulation and insulin
sensitivity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Adiponectin receptor; TALLYHO mouse model; Diabetes
ID MONOCYTE-DERIVED MACROPHAGES; PIMA INDIAN POPULATION; MOUSE MODEL;
ADIPONECTIN RECEPTORS; METABOLIC SYNDROME; DIABETES RESEARCH; OBESITY;
GLUCOSE; DISEASE; PROTEIN
AB Background: Overexpression of adiponectin receptor 1 in macrophages can physiologically modulate metabolic activities in vivo by enhancing adiponectin actions in distal metabolically active tissues. To investigate the effects of enhanced adiponectin actions in TALLYHO (TH) diabetic mouse model, we crossed the adiponectin receptor 1 macrophage-specific transgenic mice (AdR1-TG) with the TALLYHO diabetic mice (TH) to examine the changes of lipid accumulation and insulin sensitivity in these mice.
Methods: AdR1-TG/TH and the control WT/TH mice were fed either normal diet or high fat diet for 28 weeks. Whole body weights of these mice were measured and mouse sera were analyzed for the levels of cholesterol, triglyceride, and free fatty acids. Glucose tolerance testing (GTT) and insulin tolerance testing (ITT) in these mice were performed to investigate systemic insulin sensitivity in vivo. Molecular markers for insulin signaling pathway in mouse skeletal muscle tissues, IRS-1 and AKT, were examined. Mouse serum insulin levels were measured and Sirt1 gene expression in mouse pancreatic tissues was also quantified related to the insulin secretion. The Caspase 3 protein levels were analyzed by Western blot methods.
Results: Compared to the control WT/TH mice, AdR1-TG/TH mice showed significantly lower body weights under either normal diet or high fat diet and the mouse serum levels of cholesterol, triglyceride and free fatty acids were significantly decreased in the transgenic crossed mice when compared to those from the control mice. Improved GTF and ITT tests indicating increased systemic insulin sensitivity in the transgenic crossed mice demonstrated the enhanced adiponectin actions on the systemic metabolism in vivo. The increases of insulin secretion and its related gene expression were also detected in the transgenic crossed mice. In contrast, the control mice showed hypertrophy pancreases companying with high apoptosis gene expression. These results suggest that enhanced adiponectin actions by overexpressing adiponectin receptor 1 in macrophages can provide unique interactions with the metabolic tissues/cells, improving lipid accumulation and insulin sensitivity in TALLYHO diabetic mice. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Luo, Nanlan; Zhang, Wei; Garvey, W. T.; Fu, Yuchang] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Wang, Xiangdong] Shandong Univ, Inst Cell Biol, Jinan 250012, Peoples R China.
[Garvey, W. T.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Fu, YC (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Shelby Bldg 1213,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM yfu@uab.edu
FU American Diabetes Association [1-07-RA-49, 1-13-IN-19]; NIH [DK-083562]
FX We are grateful to the UAB Diabetes Research and Training Center for
providing outstanding core services (NIH P30 DK-56336). This work was
supported by grants from American Diabetes Association (1-07-RA-49 and
1-13-IN-19) to Y.F., and grant from NIH (DK-083562) to T.G.
NR 29
TC 2
Z9 3
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 19
PY 2013
VL 433
IS 4
BP 567
EP 572
DI 10.1016/j.bbrc.2013.03.030
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 135AT
UT WOS:000318259100037
PM 23523784
ER
PT J
AU Shanmugasundaram, K
Block, K
Nayak, BK
Livi, CB
Venkatachalam, MA
Sudarshan, S
AF Shanmugasundaram, K.
Block, K.
Nayak, B. K.
Livi, C. B.
Venkatachalam, M. A.
Sudarshan, S.
TI PI3K regulation of the SKP-2/p27 axis through mTORC2
SO ONCOGENE
LA English
DT Article
DE p27; SKP-2; mTOR; RICTOR
ID RENAL-CELL CARCINOMA; RAPAMYCIN COMPLEX 2; PROTEIN-KINASE B; TISSUE
MICROARRAY; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; AKT
PHOSPHORYLATION; MAMMALIAN TARGET; UBIQUITIN LIGASE; SKP2
AB The cyclin-dependent kinase inhibitor p27 is a key regulator of cell-cycle progression. Its expression and localization are altered in several types of malignancies, which has prognostic significance in cancers such as renal cell carcinoma (RCC). S-phase kinase-associated protein 2 (SKP-2) is an F-box protein that is part of the SKP-1/Cul1/F-box ubiquitin ligase complex that targets nuclear p27 among many other cell-cycle proteins for proteosomal degradation. Its overexpression has been observed in several tumor types. Signaling by phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) has previously been shown to regulate the SKP-2/p27 axis. Recent evidence suggests that PI3K signaling may activate mammalian target of rapamycin complex 2 (mTORC2) activity. As PI3K signaling is known to regulate SKP-2 and p27, we sought to determine whether these effects were mediated by mTORC2. Here we provide additional genetic evidence that PI3K signaling activates mTORC2 kinase activity. We also demonstrate a novel role for mTORC2 in the modulation of nuclear p27 levels. In particular, mTORC2 signaling promotes the reduction of nuclear p27 protein levels through the increased protein expression of SKP-2. These are the first data to demonstrate a role for mTOR in the regulation of SKP-2. In concordance with these findings, mTORC2 activity promotes cell proliferation of RCC cells at the G1-S interphase of the cell cycle. Collectively, these data implicate mTORC2 signaling in the regulation of the SKP-2/p27 axis, a signaling node commonly altered in cancer. Oncogene (2013) 32, 2027-2036; doi:10.1038/onc.2012.226; published online 25 June 2012
C1 [Shanmugasundaram, K.; Sudarshan, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Block, K.; Nayak, B. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Livi, C. B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
[Venkatachalam, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Block, K.] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Sudarshan, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 7703 Floyd Curl Dr,MC 7845, San Antonio, TX 78229 USA.
EM sudarshan@uthscsa.edu
FU Cancer Therapy and Research Center (CTRC) at the University of Texas
Health Science Center [NIH P30 CA054174-17]; NIH [K08 CA138774, R01 NCI
CA131272]; Voelcker Fund Young Investigator Award; AUA
Foundation/Astellas Rising Star Award; Veterans Administration Career
Development Award [CDA-2]
FX This work was supported in part by the Cancer Therapy and Research
Center (CTRC) at the University of Texas Health Science Center (NIH P30
CA054174-17). SS is supported by NIH K08 CA138774, Voelcker Fund Young
Investigator Award, AUA Foundation/Astellas Rising Star Award and a
special gift from Mr Charles Butt and the employees of HEB. KB is
supported by Veterans Administration Career Development Award (CDA-2)
and NIH R01 NCI CA131272. We thank Z David Sharp for critical review of
the manuscript. We thank William Friedrichs and Korri Weldon for
technical assistance.
NR 43
TC 12
Z9 14
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD APR 18
PY 2013
VL 32
IS 16
BP 2027
EP 2036
DI 10.1038/onc.2012.226
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 130LY
UT WOS:000317919900004
PM 22733130
ER
PT J
AU Lane, RF
Steele, JW
Cai, DM
Ehrlich, ME
Attie, AD
Gandy, S
AF Lane, Rachel F.
Steele, John W.
Cai, Dongming
Ehrlich, Michelle E.
Attie, Alan D.
Gandy, Sam
TI Protein Sorting Motifs in the Cytoplasmic Tail of SorCS1 Control
Generation of Alzheimer's Amyloid-beta Peptide
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PRECURSOR PROTEIN; RETROMER COMPLEX; DOWN-SYNDROME; DISEASE; VARIANTS;
SORL1; TRAFFICKING; ASSOCIATION; RECEPTOR; NEURODEGENERATION
AB Endosomal sorting of the Alzheimer amyloid precursor protein (APP) plays a key role in the biogenesis of the amyloid-beta (A beta) peptide. Genetic lesions underlying Alzheimer's disease (AD) can act by interfering with this physiological process. Specifically, proteins involved in trafficking between endosomal compartments and the trans-Golgi network (TGN) [including the retromer complex (Vps35, Vps26) and its putative receptors (sortilin, SorL1, SorCS1)] have been implicated in the molecular pathology of late-onset AD. Previously, we demonstrated a role for SorCS1 in APP metabolism and A beta production and, while we implicated a role for the retromer in this regulation, the underlying mechanism remained poorly understood. Here, we provide evidence for a motif within the SorCS1c cytoplasmic tail that, when manipulated, results in perturbed sorting of APP and/or its fragments to endosomal compartments, decreased retrograde TGN trafficking, and increased A beta production in H4 neuroglioma cells. These perturbations apparently do not involve turnover of the cell surface APP pool, but rather they involve intracellular APP and/or its fragments, downstream of APP endocytosis.
C1 [Lane, Rachel F.; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol & Psychiat, New York, NY 10029 USA.
[Lane, Rachel F.; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Lane, Rachel F.] Alzheimers Drug Discovery Fdn, New York, NY 10019 USA.
[Steele, John W.] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.
[Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Pediat & Neurol, New York, NY 10029 USA.
[Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
[Cai, Dongming; Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
RP Lane, RF (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol & Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM rlane@alzdiscovery.org; Samuel.gandy@mssm.edu
FU National Institutes of Health (NIH) [NS075685]; Cure Alzheimer's Fund;
U.S. Department of Veterans Affairs; National Institute of Diabetes and
Digestive and Kidney Diseases [DK58037, DK66369]; American Diabetes
Association Research Award; National Institute of General Medical
Sciences [T32GM062754]; NIH-National Cancer Institute [5R24
CA095823-04]; National Science Foundation [DBI-9724504]; NIH Shared
Instrumentation Grant [1 S10 RR0 9145-01]
FX This research was supported by National Institutes of Health (NIH) Grant
NS075685 (to S. G.), the Cure Alzheimer's Fund (to S. G.), the U.S.
Department of Veterans Affairs (to S. G.), National Institute of
Diabetes and Digestive and Kidney Diseases Grants DK58037 and DK66369
(to A. D. A.), and an American Diabetes Association Research Award (to
M. E. E). J.W.S. was a trainee in the Integrated Pharmacological
Sciences Training Program supported by Grant T32GM062754 from the
National Institute of General Medical Sciences to Terry Krulwich (Icahn
School of Medicine at Mount Sinai). Confocal laser scanning microscopy
was performed at the Icahn School of Medicine at Mount Sinai Microscopy
Shared Resource Facility, supported with funding from NIH-National
Cancer Institute Shared Resources Grant 5R24 CA095823-04, National
Science Foundation Major Research Instrumentation Grant DBI-9724504, and
NIH Shared Instrumentation Grant 1 S10 RR0 9145-01. We thank Rudolph E.
Tanzi for cDNA constructs.
NR 35
TC 15
Z9 15
U1 0
U2 11
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 17
PY 2013
VL 33
IS 16
BP 7099
EP 7107
DI 10.1523/JNEUROSCI.5270-12.2013
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 127TZ
UT WOS:000317723000040
PM 23595767
ER
PT J
AU Weiner, SJ
Schwartz, A
Sharma, G
Binns-Calvey, A
Ashley, N
Kelly, B
Dayal, A
Patel, S
Weaver, FM
Harris, I
AF Weiner, Saul J.
Schwartz, Alan
Sharma, Gunjan
Binns-Calvey, Amy
Ashley, Naomi
Kelly, Brendan
Dayal, Amit
Patel, Sonal
Weaver, Frances M.
Harris, Ilene
TI Patient-Centered Decision Making and Health Care Outcomes An
Observational Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID INTERACTION ANALYSIS SYSTEM; CONTEXTUAL ERRORS; COMMUNICATION
AB Background: Patient-centered decision making (PCDM) is the process of identifying clinically relevant, patient-specific circumstances and behaviors to formulate a contextually appropriate care plan.
Objective: To ascertain whether encounters in which PCDM occurs are followed by improved health care outcomes compared with encounters where there is inattention to patient context.
Design: Patients surreptitiously audio-recorded encounters with their physicians. Medical records of these encounters were then screened for "contextual red flags," such as deteriorating self-management of a chronic condition, that could reflect such underlying contextual factors as competing responsibilities or loss of social support. When a contextual factor was identified, either as a result of physician questioning or because a patient volunteered information, physicians were scored on the basis of whether they adapted the care plan to it.
Setting: Internal medicine clinics at 2 Veterans Affairs facilities.
Participants: 774 patients audio-recorded encounters with 139 resident physicians.
Measurements: Individualized outcome measures were based on the contextual red flag, such as improved blood pressure control in a patient presenting with hypertension and loss of medication coverage. Outcome coders were blinded to physician performance.
Results: Among 548 contextual red flags, 208 contextual factors were confirmed, either when physicians probed or patients volunteered information. Physician attention to contextual factors (both probing for them and addressing them in care plans) varied according to the presenting contextual red flags. Outcome data were available for 157 contextual factors, of which PCDM was found to address 96. Of these, health care outcomes improved in 68 (71%), compared with 28 (46%) of the 61 that were not addressed by PCDM (P = 0.002).
Limitation: The extent to which the findings can be generalized to other clinical settings is unknown.
Conclusion: Attention to patient needs and circumstances when planning care is associated with improved health care outcomes.
C1 Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
[Weiner, Saul J.] Univ Illinois, Chicago, IL 60607 USA.
US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
Durham Vet Affairs Med Ctr, Durham, NC USA.
RP Weiner, SJ (reprint author), Univ Illinois, 2730 UH MC 103,601 South Morgan, Chicago, IL 60607 USA.
EM sweiner@uic.edu
OI Schwartz, Alan/0000-0003-3809-6637
FU U.S. Department of Veterans Affairs, Health Services Research &
Development Service
FX U.S. Department of Veterans Affairs, Health Services Research &
Development Service.
NR 15
TC 42
Z9 43
U1 4
U2 24
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 16
PY 2013
VL 158
IS 8
BP 573
EP +
DI 10.7326/0003-4819-158-8-201304160-00001
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 132IW
UT WOS:000318062100013
PM 23588745
ER
PT J
AU Martinez, ME
Ahnen, D
Greenberg, ER
AF Martinez, Maria Elena
Ahnen, Dennis
Greenberg, E. Robert
TI One-Year Risk for Advanced Colorectal Neoplasia RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Martinez, Maria Elena] Moores Canc Ctr, La Jolla, CA USA.
[Martinez, Maria Elena] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Ahnen, Dennis] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Ahnen, Dennis] Univ Colorado, Sch Med, Denver, CO USA.
[Greenberg, E. Robert] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Martinez, ME (reprint author), Moores Canc Ctr, La Jolla, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 16
PY 2013
VL 158
IS 8
BP 639
EP 639
DI 10.7326/0003-4819-158-8-201304160-00019
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 132IW
UT WOS:000318062100028
PM 23588762
ER
PT J
AU Gaweska, HM
Taylor, AB
Hart, PJ
Fitzpatrick, PF
AF Gaweska, Helena M.
Taylor, Alexander B.
Hart, P. John
Fitzpatrick, Paul F.
TI Structure of the Flavoprotein Tryptophan 2-Monooxygenase, a Key Enzyme
in the Formation of Galls in Plants
SO BIOCHEMISTRY
LA English
DT Article
ID MONOAMINE-OXIDASE-B; MAIZE POLYAMINE OXIDASE; L-PHENYLALANINE OXIDASE;
CONSERVED ACTIVE-SITE; PSEUDOMONAS SP P-501; AMINO-ACID OXIDASE;
CROWN-GALL; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; INDOLEACETIC-ACID
AB The flavoprotein tryptophan 2-monooxygenase catalyzes the oxidative decarboxylation of tryptophan to yield indole-3-acetamide. This is the initial step in the biosynthesis of the plant growth hormone indole-acetic acid by bacterial pathogens that cause crown gall and related diseases. The structure of the enzyme from Pseudomonas savastanoi has been determined by X-ray diffraction methods to a resolution of 1.95 A. The overall structure of the protein shows that it has the same fold as members of the monoamine oxidase family of flavoproteins, with the greatest similarities to the L-amino acid oxidases. The location of bound indole-3-acetamide in the active site allows identification of residues responsible for substrate binding and specificity. Two residues in the enzyme are conserved in all members of the monoamine oxidase family, Lys365 and Trp466. The K365M mutation decreases the k(cat) and k(cat)/K-Trp values by 60000- and 2 million-fold, respectively. The deuterium kinetic isotope effect increases to 3.2, consistent with carbon-hydrogen bond cleavage becoming rate-limiting in the mutant enzyme. The W466F mutation decreases the k(cat) value <2-fold and the k(cat)/K-Trp, value only 5-fold, while the W466M mutation results in an enzyme lacking Flavin and detectable activity. This is consistent with a role for Trp466 in maintaining the structure of the flavin-binding site in the more conserved FAD domain.
C1 [Gaweska, Helena M.; Taylor, Alexander B.; Hart, P. John; Fitzpatrick, Paul F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Fitzpatrick, PF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM fitzpatrick@biochem.uthscsa.edu
FU National Institutes of Health [R01 GM058698, F32 GM097762]; Welch
Foundation [AQ-1399]
FX This work was supported in part by National Institutes of Health Grants
R01 GM058698 to P.F.F. and F32 GM097762 to H.M.G. and by The Welch
Foundation Grant AQ-1399 to P.J.H.
NR 50
TC 6
Z9 7
U1 2
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 16
PY 2013
VL 52
IS 15
BP 2620
EP 2626
DI 10.1021/bi4001563
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 128UG
UT WOS:000317794600013
PM 23521653
ER
PT J
AU Hansen, JE
Chan, G
Liu, YF
Hegan, DC
Dalal, S
Dray, E
Kwon, Y
Xu, YY
Xu, XH
Peterson-Roth, E
Geiger, E
Liu, YL
Gera, J
Sweasy, JB
Sung, P
Rockwell, S
Nishimura, RN
Weisbart, RH
Glazer, PM
AF Hansen, James E.
Chan, Grace
Liu, Yanfeng
Hegan, Denise C.
Dalal, Shibani
Dray, Eloise
Kwon, Youngho
Xu, Yuanyuan
Xu, Xiaohua
Peterson-Roth, Elizabeth
Geiger, Erik
Liu, Yilun
Gera, Joseph
Sweasy, Joann B.
Sung, Patrick
Rockwell, Sara
Nishimura, Robert N.
Weisbart, Richard H.
Glazer, Peter M.
TI Lupus antibody-based cancer therapy.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Hansen, James E.; Liu, Yanfeng; Hegan, Denise C.; Dalal, Shibani; Dray, Eloise; Kwon, Youngho; Xu, Yuanyuan; Peterson-Roth, Elizabeth; Geiger, Erik; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, New Haven, CT USA.
[Chan, Grace; Gera, Joseph; Nishimura, Robert N.; Weisbart, Richard H.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Xu, Xiaohua; Liu, Yilun] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
RI Dray, Eloise/E-3938-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4319
DI 10.1158/1538-7445.AM2013-4319
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603326
ER
PT J
AU Katiyar, SK
Vaid, M
AF Katiyar, Santosh K.
Vaid, Mudit
TI Bioactive phytochemical proanthocyanidins target beta-catenin signaling
in preventing invasive potential of human melanoma cells.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Katiyar, Santosh K.; Vaid, Mudit] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3683
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602319
ER
PT J
AU Katiyar, SK
Vaid, M
AF Katiyar, Santosh K.
Vaid, Mudit
TI Bioactive phytochemical proanthocyanidins target beta-catenin signaling
in preventing invasive potential of human melanoma cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Katiyar, Santosh K.; Vaid, Mudit] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3683
DI 10.1158/1538-7445.AM2013-3683
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600303
ER
PT J
AU Tobi, M
Weinstein, D
Vizgoft, E
Pedersen, S
AF Tobi, Martin
Weinstein, Douglas
Vizgoft, Emma
Pedersen, Susanne
TI Anti-adenoma Adnab-9 antibody recognizes a serum GI cancer candidate
biomarker
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Tobi, Martin; Weinstein, Douglas] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Vizgoft, Emma; Pedersen, Susanne] Clin Genom, N Ryde, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3499
DI 10.1158/1538-7445.AM2013-3499
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602203
ER
PT J
AU Trautner, BW
Bhimani, RD
Amspoker, AB
Hysong, SJ
Garza, A
Kelly, PA
Payne, VL
Naik, AD
AF Trautner, Barbara W.
Bhimani, Rupal D.
Amspoker, Amber B.
Hysong, Sylvia J.
Garza, Armandina
Kelly, P. Adam
Payne, Velma L.
Naik, Aanand D.
TI Development and validation of an algorithm to recalibrate mental models
and reduce diagnostic errors associated with catheter-associated
bacteriuria
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Catheter-associated bacteriuria; Urinary tract infections; Evidence
based guidelines; Diagnostic errors
ID URINARY-TRACT-INFECTION; ASYMPTOMATIC BACTERIURIA; INAPPROPRIATE
TREATMENT; DISEASES-SOCIETY; NURSING-HOMES; GUIDELINES; CARE; ADULTS;
INTERVENTION; RESIDENTS
AB Background: Overtreatment of catheter-associated bacteriuria is a quality and safety problem, despite the availability of evidence-based guidelines. Little is known about how guidelines-based knowledge is integrated into clinicians' mental models for diagnosing catheter-associated urinary tract infection (CA-UTI). The objectives of this research were to better understand clinicians' mental models for CA-UTI, and to develop and validate an algorithm to improve diagnostic accuracy for CA-UTI.
Methods: We conducted two phases of this research project. In phase one, 10 clinicians assessed and diagnosed four patient cases of catheter associated bacteriuria (n= 40 total cases). We assessed the clinical cues used when diagnosing these cases to determine if the mental models were IDSA guideline compliant. In phase two, we developed a diagnostic algorithm derived from the IDSA guidelines. IDSA guideline authors and non-expert clinicians evaluated the algorithm for content and face validity. In order to determine if diagnostic accuracy improved using the algorithm, we had experts and non-experts diagnose 71 cases of bacteriuria.
Results: Only 21 (53%) diagnoses made by clinicians without the algorithm were guidelines-concordant with fair inter-rater reliability between clinicians (Fleiss' kappa = 0.35, 95% Confidence Intervals (CIs) = 0.21 and 0.50). Evidence suggests that clinicians' mental models are inappropriately constructed in that clinicians endorsed guidelines-discordant cues as influential in their decision-making: pyuria, systemic leukocytosis, organism type and number, weakness, and elderly or frail patient. Using the algorithm, inter-rater reliability between the expert and each non-expert was substantial (Cohen's kappa = 0.72, 95% CIs = 0.52 and 0.93 between the expert and non-expert # 1 and 0.80, 95% CIs = 0.61 and 0.99 between the expert and non-expert # 2).
Conclusions: Diagnostic errors occur when clinicians' mental models for catheter-associated bacteriuria include cues that are guidelines-discordant for CA-UTI. The understanding we gained of clinicians' mental models, especially diagnostic errors, and the algorithm developed to address these errors will inform interventions to improve the accuracy and reliability of CA-UTI diagnoses.
C1 [Trautner, Barbara W.; Amspoker, Amber B.; Hysong, Sylvia J.; Garza, Armandina; Payne, Velma L.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Trautner, Barbara W.; Bhimani, Rupal D.; Amspoker, Amber B.; Hysong, Sylvia J.; Garza, Armandina; Naik, Aanand D.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA.
[Kelly, P. Adam] Tulane Univ, Sch Med, Dept Internal Med, New Orleans, LA 70112 USA.
[Trautner, Barbara W.] Michael E DeBakey VA Med Ctr 152, Houston, TX 77030 USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
EM anaik@bcm.edu
RI Hysong, Sylvia/B-8420-2008
OI Hysong, Sylvia/0000-0002-9063-5207
FU Veterans Administration, Health Services Research and Development
Program [IIR 09-104]; Houston VA HSR& D Center of Excellence
[HFP90-020]; VA Rehabilitation Research and Development career
development award [B4623]
FX This work was supported by a grant from the Veterans Administration,
Health Services Research and Development Program (IIR 09-104, Trautner
PI) and with resources and use of facilities at the Houston VA HSR& D
Center of Excellence (HFP90-020) at the Michael E. DeBakey VA. Dr.
Trautner received support from a VA Rehabilitation Research and
Development career development award (B4623). Dr. Payne receives support
from the Office of Academic Affiliations, post-doctoral fellowship
program in Health Services Research. Dr. Naik received additional
support from a Doris Duke Charitable Foundation Clinical Scientist
Development Award.
NR 28
TC 19
Z9 20
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD APR 15
PY 2013
VL 13
AR 48
DI 10.1186/1472-6947-13-48
PG 9
WC Medical Informatics
SC Medical Informatics
GA 151FR
UT WOS:000319446600001
PM 23587259
ER
PT J
AU Lee, JP
Wang, YJ
AF Lee, Jennifer Pai
Wang, Yi-Jiun
TI Testing the predictive ability of the "spinal cord injury equation" in
estimating vancomycin clearance
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; SERUM CREATININE; DIET;
PERFORMANCE; THERAPY
AB Purpose. A new method of estimating drug clearance in patients with spinal cord injury (SCI) was tested against other methods through a retrospective analysis of its predictive ability in estimating vancomycin clearance.
Methods. A retrospective chart-based investigation was conducted at a hospital with a large SCI population. Using data collected from electronic patient records, 179 cases were reviewed, and 87 cases met the inclusion criteria: a diagnosis of longstanding SCI, administration of vancomycin via i.v. infusion during the 18-month study period, and at least one documented steady-state vancomycin concentration. Using the "spinal cord injury equation" (i.e., CLSCI equation), pharmacokinetic analysis was performed to determine patient-specific clearance values, which were compared to values resulting from five widely used methods of estimating the glomerular filtration rate in spinal cord-injured patients. The primary outcome measures were bias and precision, as indicated by statistical analyses to determine the mean prediction error (ME) and the square root of the mean squared prediction error (RMSE) of each method.
Results. Compared with the other evaluated methods, the CLSCI equation was found to be less biased and more precise, with the smallest calculated ME and RMSE values (p < 0.05). The five alternative methods significantly overestimated vancomycin clearance, by 45-92% (p < 0.05). The CLSCI method underestimated vancomycin clearance (by 6%) but not to a significant degree (p = 0.06).
Conclusion. The study results suggest that the CLSCI equation for predicting vancomycin clearance was unbiased and may be more precise relative to other frequently used methods in the study population of patients with long-term SCI. Am J Health-Syst Pharm. 2013; 70:669-74
C1 [Lee, Jennifer Pai] Vet Affairs Long Beach Healthcare Syst, Crit Care, Long Beach, CA 90822 USA.
[Wang, Yi-Jiun] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lee, JP (reprint author), Vet Affairs Long Beach Healthcare Syst, 5901 East 7th St, Long Beach, CA 90822 USA.
EM jennifer.lee4332a@va.gov
NR 23
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD APR 15
PY 2013
VL 70
IS 8
BP 669
EP 674
DI 10.2146/ajhp120329
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 129AU
UT WOS:000317811600009
PM 23552044
ER
PT J
AU Feng, S
Dakhova, O
Creighton, CJ
Ittmann, M
AF Feng, Shu
Dakhova, Olga
Creighton, Chad J.
Ittmann, Michael
TI Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer
Progression
SO CANCER RESEARCH
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; SERUM-CALCIUM; TUMOR-GROWTH; EXPRESSION;
FIBROBLAST-GROWTH-FACTOR-19; KLOTHO; METABOLISM; THERAPY; SPECIFICITY;
DETERMINES
AB Prostate cancer is the most common visceral malignancy and the second leading cause of cancer deaths in US men. There is broad evidence that fibroblast growth factor (FGF) receptors are important in prostate cancer initiation and progression, but the contribution of particular FGFs in this disease is not fully understood. The FGF family members FGF19, FGF21, and FGF23 comprise a distinct subfamily that circulate in serum and act in an endocrine manner. These endocrine FGFs require alpha-Klotho (KL) and/or beta-Klotho (KLB), two related single-pass transmembrane proteins restricted in their tissue distribution, to act as coreceptors along with classic FGF receptors (FGFR) to mediate potent biologic activity. Here we show that FGF19 is expressed in primary and metastatic prostate cancer tissues, where it functions as an autocrine growth factor. Exogenous FGF19 promoted the growth, invasion, adhesion, and colony formation of prostate cancer cells at low ligand concentrations. FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo. Consistent with these observations, KL and/or KLB were expressed in prostate cancer cells in vitro and in vivo, raising the possibility that additional endocrine FGFs may also exert biologic effects in prostate cancer. Our findings support the concept that therapies targeting FGFR signaling may have efficacy in prostate cancer and highlight FGF19 as a relevant endocrine FGF in this setting. Cancer Res; 73(8); 2551-62. (C) 2013 AACR.
C1 [Feng, Shu; Dakhova, Olga; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Feng, Shu; Dakhova, Olga; Ittmann, Michael] Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Houston, TX 77030 USA.
RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM mittmann@bcm.tmc.edu
FU Department of Veterans Affairs Merit Review program; National Cancer
Institute [P30 CA125123]
FX This work was supported by grants from the Department of Veterans
Affairs Merit Review program (MI), the National Cancer Institute to the
Dan L. Duncan Cancer (P30 CA125123), and by the use of the facilities of
the Michael E. DeBakey VAMC.
NR 42
TC 33
Z9 34
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
BP 2551
EP 2562
DI 10.1158/0008-5472.CAN-12-4108
PG 12
WC Oncology
SC Oncology
GA 126ER
UT WOS:000317595800018
PM 23440425
ER
PT J
AU Vaid, M
Prasad, R
Singh, T
Elmets, CA
Xu, H
Katiyar, SK
AF Vaid, Mudit
Prasad, Ram
Singh, Tripti
Elmets, Craig A.
Xu, Hui
Katiyar, Santosh K.
TI Silymarin inhibits ultraviolet radiation-induced immune suppression
through DNA repair-dependent activation of dendritic cells and
stimulation of effector T cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE DNA repair; Contact hypersensitivity; Cyclobutane pyrimidine dimer;
Nucleotide excision repair; Silymarin; Ultraviolet radiation
ID UV-INDUCED IMMUNOSUPPRESSION; ANTIGEN-PRESENTING ACTIVITY; CONTACT
HYPERSENSITIVITY; SKIN-CANCER; TRANSPLANT RECIPIENTS; PYRIMIDINE DIMERS;
IRRADIATED MICE; RISK-FACTOR; IN-VITRO; INDUCTION
AB Silymarin inhibits UVB-induced immunosuppression in mouse skin. To identify the molecular mechanisms underlying this effect, we used an adoptive transfer approach in which dendritic cells (DCs) from the draining lymph nodes of donor mice that had been UVB-exposed and sensitized to 2,4,-dinitrofluorobenzene (DNFB) were transferred into naive recipient mice. The contact hypersensitivity (CHS) response of the recipient mice to DNFB was then measured. When DCs were obtained from UVB-exposed donor mice that were not treated with silymarin, the CHS response was suppressed confirming-the role of DCs in the UVB-induced immunosuppression. Silymarin treatment of UVB-exposed donor mice relieved this suppression of the CHS response in the recipients. Silymarin treatment was associated with rapid repair of UVB-induced cyclobutane pyrimidine dimers (CPDs) in DCs and silymarin treatment did not prevent UV-induced immunosuppression in XPA-deficient mice which are unable to repair UV-induced DNA damage. The CHS response in mice receiving DCs from silymarin-treated UV-exposed donor mice also was associated with enhanced secretion of Th1-type cytokines and stimulation of T cells. Adoptive transfer of T cells revealed that transfer of either CD8(+) or CD4(+) cells from silymarin-treated, UVB-exposed donors resulted in enhancement of the CHS response. Cell culture study showed enhanced secretion of IL-2 and IFN gamma by CD8(+) T cells, and reduced secretion of Th2 cytokines by CD4(+) T cells, obtained from silymarin-treated UVB-exposed mice. These data suggest that DNA repair-dependent functional activation of DCs, a reduction in CD4(+) regulatory T-cell activity, and stimulation of CD8(+) effector T cells contribute to silymarin-mediated inhibition of UVB-induced immunosuppression. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Vaid, Mudit; Prasad, Ram; Singh, Tripti; Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU National Institutes of Health [CA140197]; DAB Skin Diseases Research
Center [AR050948]; Veterans Administration Merit Review Award
[5I01BX001059, 1I01BX001410]
FX This work was supported by the funds from National Institutes of Health
(Grant # CA140197) to S.K.K. and H.X., the DAB Skin Diseases Research
Center (AR050948), and the Veterans Administration Merit Review Award
(5I01BX001059 and 1I01BX001410) to C.A.E. and S.K.K. We thank Dr. Fiona
Hunter for her assistance in editing the manuscript.
NR 39
TC 5
Z9 6
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR 15
PY 2013
VL 85
IS 8
BP 1066
EP 1076
DI 10.1016/j.bcp.2013.01.026
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 115XS
UT WOS:000316845800005
PM 23395695
ER
PT J
AU Li, XB
Hartwell, KJ
Owens, M
LeMatty, T
Borckardt, JJ
Hanlon, CA
Brady, KT
George, MS
AF Li, Xingbao
Hartwell, Karren J.
Owens, Max
LeMatty, Todd
Borckardt, Jeffrey J.
Hanlon, Colleen A.
Brady, Kathleen T.
George, Mark S.
TI Repetitive Transcranial Magnetic Stimulation of the Dorsolateral
Prefrontal Cortex Reduces Nicotine Cue Craving
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Craving; dorsolateral prefrontal cortex; nicotine; smoking; tobacco;
transcranial magnetic stimulation
ID PREDICTING SMOKING-CESSATION; FAGERSTROM TEST; STRIATAL DOPAMINE;
RANDOMIZED-TRIAL; TOBACCO SMOKING; MOTOR CORTEX; DEPRESSION; DEPENDENCE;
ADDICTION; BRAIN
AB Background: Repetitive transcranial magnetic stimulation (rTMS) can noninvasively stimulate the brain and transiently amplify or block behaviors mediated through a region. We hypothesized that a single high-frequency rTMS session over the left dorsolateral prefrontal cortex (DLPFC) would reduce cue craving for cigarettes compared with a sham TMS session.
Methods: Sixteen non-treatment-seeking, nicotine-dependent participants were randomized to receive either real high-frequency rTMS (10 Hz, 100% resting motor threshold, 5-sec on, 10-sec off for 15 min; 3000 pulses) or active sham (eSham) TMS over the DLPFC in two visits with 1 week between visits. The participants received cue exposure before and after rTMS and rated their craving after each block of cue presentation.
Results: Stimulation of the left DLFPC with real, but not sham, rTMS reduced craving significantly from baseline (64.1 +/- .5.9 vs. 45.7 +/- 6.4, t = 2.69, p = .018). When compared with neutral cue craving, the effect of real TMS on cue craving was significantly greater than the effect of sham TMS (12.5 +/- 10.4 vs. 9.1 +/- 10.4; t = 2.07, p = .049). More decreases in subjective craving induced by TMS correlated positively with higher Fagerstrom Test for Nicotine Dependence score (r = .58, p =.031) and more cigarettes smoked per day (r = .57, p = .035).
Conclusions: One session of high-frequency rTMS (10 Hz) of the left DLPFC significantly reduced subjective craving induced by smoking cues in nicotine-dependent participants. Additional studies are needed to explore rTMS as an aid to smoking cessation.
C1 [Li, Xingbao; Hartwell, Karren J.; Owens, Max; LeMatty, Todd; Borckardt, Jeffrey J.; Hanlon, Colleen A.; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Hartwell, Karren J.; Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Li, XB (reprint author), Med Univ South Carolina IOP, Dept Psychiat, Brain Stimulat Lab, 502 N,67 President St, Charleston, SC 29425 USA.
EM lixi@musc.edu
FU Brain Stimulation Laboratory at the Medical University of South
Carolina; National Institute of Health [5R21DA026085]; Cyberonics; Force
Protection; GlaxoSmithKline; Jazz Pharmaceuticals; MECTA; Neurospace;
Pure Tech Ventures
FX The study was funded by a Grant-in-Kind from the Brain Stimulation
Laboratory at the Medical University of South Carolina and a grant from
National Institute of Health (Grant No. 5R21DA026085 to KTB, MSG); Mark
George has served as a paid consultant to or received research support
from Cyberonics, Force Protection, GlaxoSmithKline, Jazz
Pharmaceuticals, MECTA, Neurospace, and Pure Tech Ventures and as an
unpaid consultant to Brainsonix, Brainsway, Cephos, MECTA, NeoSync, and
Neuronetics. All other authors report no biomedical financial interests
or potential conflicts of interest.
NR 68
TC 37
Z9 38
U1 6
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 15
PY 2013
VL 73
IS 8
BP 714
EP 720
DI 10.1016/j.biopsych.2013.01.003
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 120GT
UT WOS:000317159500005
PM 23485014
ER
PT J
AU Ueno, K
Hirata, H
Hinoda, Y
Dahiya, R
AF Ueno, Koji
Hirata, Hiroshi
Hinoda, Yuji
Dahiya, Rajvir
TI Frizzled homolog proteins, microRNAs and Wnt signaling in cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Review
DE FZD; cancer; microRNA; Wnt signaling
ID RENAL-CELL CARCINOMA; HUMAN HEPATOCELLULAR-CARCINOMA; WNT/BETA-CATENIN
PATHWAY; EPITHELIAL-MESENCHYMAL TRANSITION; POTENTIAL THERAPEUTIC
TARGET; HUMAN SYNOVIAL SARCOMA; HUMAN BLADDER-CANCER; BETA-CATENIN;
MOLECULAR-CLONING; OVARIAN-CANCER
AB Wnt signaling pathways play important roles in tumorigenesis and are initiated by binding of Wnt to various receptors including frizzleds (FZDs). FZDs are one of several families of receptors comprised of FZD/LRP/ROR2/RYK in the Wnt signaling pathway. Expression of some FZD receptors are up regulated, thereby activating the Wnt signaling pathway and is correlated with cancer malignancy and patient outcomes (recurrence and survival) in many cancers. The FZD family contains ten genes in humans and their function has not been completely examined including the regulatory mechanisms of FZD genes in cancer. Knockdown of FZDs may suppress the Wnt signaling pathway resulting in decreased cell growth, invasion, motility and metastasis of cancer cells. Recently a number of microRNAs (miRNAs) have been identified and reported to be important in several cancers. MiRNAs regulate target gene expression at both the transcription and translation levels. The study of miRNA is a newly emerging field and promises to be helpful in understanding the pathogenesis of FZDs in cancer. In addition, miRNAs may be useful in regulating FZDs in cancer cells. Therefore, the aim of this review is to discuss current knowledge of the functional mechanisms of FZDs in cancer, including regulation by miRNAs and the potential for possible use of miRNAs and FZDs in future clinical applications.
C1 [Ueno, Koji; Hirata, Hiroshi; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Ueno, Koji; Hirata, Hiroshi; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [R01CA138642, R01CA130860, R01CA160079]; VA Merit Review; VA
Program Project
FX Grant sponsors: National Center for Research Resources of the National
Institutes of Health; Grant numbers: R01CA138642, R01CA130860,
R01CA160079; Grant sponsors: VA Merit Review, VA Program Project
NR 158
TC 25
Z9 27
U1 2
U2 94
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2013
VL 132
IS 8
BP 1731
EP 1740
DI 10.1002/ijc.27746
PG 10
WC Oncology
SC Oncology
GA 090OE
UT WOS:000314987800002
PM 22833265
ER
PT J
AU Singh, H
Ash, JS
Sittig, DF
AF Singh, Hardeep
Ash, Joan S.
Sittig, Dean F.
TI Safety Assurance Factors for Electronic Health Record Resilience
(SAFER): study protocol
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Electronic health records; Health information technology; Patient
safety; Risk assessment; Resilience
ID PHYSICIAN ORDER ENTRY; INFORMATION-TECHNOLOGY; PATIENT-SAFETY;
MEDICATION ERRORS; CLASSIFICATION; SYSTEMS; CARE; MANAGEMENT
AB Background: Implementation and use of electronic health records (EHRs) could lead to potential improvements in quality of care. However, the use of EHRs also introduces unique and often unexpected patient safety risks. Proactive assessment of risks and vulnerabilities can help address potential EHR-related safety hazards before harm occurs; however, current risk assessment methods are underdeveloped. The overall objective of this project is to develop and validate proactive assessment tools to ensure that EHR-enabled clinical work systems are safe and effective.
Methods/Design: This work is conceptually grounded in an 8-dimension model of safe and effective health information technology use. Our first aim is to develop self-assessment guides that can be used by health care institutions to evaluate certain high-risk components of their EHR-enabled clinical work systems. We will solicit input from subject matter experts and relevant stakeholders to develop guides focused on 9 specific risk areas and will subsequently pilot test the guides with individuals representative of likely users. The second aim will be to examine the utility of the self-assessment guides by beta testing the guides at selected facilities and conducting on-site evaluations. Our multidisciplinary team will use a variety of methods to assess the content validity and perceived usefulness of the guides, including interviews, naturalistic observations, and document analysis. The anticipated output of this work will be a series of self-administered EHR safety assessment guides with clear, actionable, checklist-type items.
Discussion: Proactive assessment of patient safety risks increases the resiliency of health care organizations to unanticipated hazards of EHR use. The resulting products and lessons learned from the development of the assessment guides are expected to be helpful to organizations that are beginning the EHR selection and implementation process as well as those that have already implemented EHRs. Findings from our project, currently underway, will inform future efforts to validate and implement tools that can be used by health care organizations to improve the safety of EHR-enabled clinical work systems.
C1 [Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
[Ash, Joan S.] Oregon Hlth & Sci Univ, Sch Med, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU Westat [HHSP-23320095655WC0095655]; Office of the National Coordinator
for Health Information Technology (ONC) [HHSP23337003T]; Houston VA
Health Services Research and Development Center of Excellence
[HFP90-020]
FX The SAFER project is supported through a subcontract from Westat
(HHSP-23320095655WC0095655; Anticipating the Unintended Consequences of
Health IT) funded by the Office of the National Coordinator for Health
Information Technology (ONC) (HHSP23337003T; to Drs. Singh, Ash, and
Sittig); and the Houston VA Health Services Research and Development
Center of Excellence (HFP90-020) (Dr. Singh). Neither ONC nor its funds
were involved in the manuscript writing process.
NR 33
TC 9
Z9 9
U1 1
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD APR 12
PY 2013
VL 13
AR 46
DI 10.1186/1472-6947-13-46
PG 8
WC Medical Informatics
SC Medical Informatics
GA 139FH
UT WOS:000318566700001
PM 23587208
ER
PT J
AU Dell'Italia, LJ
Ferrario, CM
AF Dell'Italia, Louis J.
Ferrario, Carlos M.
TI The Never-ending Story of Angiotensin Peptides Beyond Angiotensin I and
II
SO CIRCULATION RESEARCH
LA English
DT Editorial Material
DE Editorial; alamandine; angiotensin-converting enzyme; renin-angiotensin
system
ID SYSTEM; RENIN; RECEPTORS; ENZYMES; FAMILY; HEART; MAS
C1 [Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.] UAB Comprehens Cardiovasc Ctr, Birmingham, AL USA.
[Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Div Surg Sci, Winston Salem, NC 27103 USA.
RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiol, 434 BMRII,901 19th St S, Birmingham, AL 35294 USA.
EM loudell@uab.edu
FU NHLBI NIH HHS [P01 HL051952]
NR 18
TC 3
Z9 3
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
J9 CIRC RES
JI Circ.Res.
PD APR 12
PY 2013
VL 112
IS 8
BP 1086
EP 1087
DI 10.1161/CIRCRESAHA.113.301246
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA 124QW
UT WOS:000317481700002
PM 23580768
ER
PT J
AU Asch, DA
Muller, RW
Volpp, KG
AF Asch, David A.
Muller, Ralph W.
Volpp, Kevin G.
TI Conflicts and Compromises in Not Hiring Smokers
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Muller, Ralph W.] Univ Penn, Univ Penn Hlth Syst, Philadelphia, PA 19104 USA.
RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
OI Asch, David/0000-0002-7970-286X
NR 5
TC 11
Z9 11
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 11
PY 2013
VL 368
IS 15
BP 1371
EP 1373
DI 10.1056/NEJMp1303632
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122QT
UT WOS:000317333600002
PM 23534547
ER
PT J
AU Clark, KB
Hassert, DL
AF Clark, Kevin B.
Hassert, Derrick L.
TI Undecidability and opacity of metacognition in animals and humans
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Editorial Material
ID SELF-AWARENESS; MINDS; CONFIDENCE; CHILDREN
C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
[Hassert, Derrick L.] Trinity Christian Coll, Dept Psychol, Palos Hts, IL USA.
RP Clark, KB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
EM kbclarkphd@yahoo.com
NR 42
TC 2
Z9 2
U1 2
U2 11
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD APR 9
PY 2013
VL 4
AR 171
DI 10.3389/fpsyg.2013.00171
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA AA2PU
UT WOS:000330937300001
PM 23576999
ER
PT J
AU Schonberg, MA
Walter, LC
AF Schonberg, Mara A.
Walter, Louise C.
TI Talking About Stopping Cancer Screening-Not So Easy
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID OLDER; WOMEN; CARE
C1 [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gen Med & Primary Care,Dept Med, Boston, MA 02215 USA.
[Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Schonberg, MA (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 1309 Beacon,Off 219, Brookline, MA 02446 USA.
EM mschonbe@bidmc.harvard.edu
FU NCI NIH HHS [R01 CA134425]; NIA NIH HHS [K23AG028584, K24AG041180]
NR 10
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 8
PY 2013
VL 173
IS 7
BP 532
EP 533
DI 10.1001/jamainternmed.2013.3233
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154NR
UT WOS:000319683400011
PM 23479053
ER
PT J
AU Singh, T
Katiyar, SK
AF Singh, Tripti
Katiyar, Santosh K.
TI Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting
PGE(2)-Mediated Activation of beta-Catenin Signaling
SO PLOS ONE
LA English
DT Article
ID NATURAL-PRODUCT; NITRIC-OXIDE; GUANYLATE-CYCLASE; COX-2 EXPRESSION;
COLON-CANCER; IN-VIVO; CYCLOOXYGENASE-2; APOPTOSIS; CARCINOMA; GROWTH
AB Lung cancer remains a leading cause of death due to its metastasis to distant organs. We have examined the effect of honokiol, a bioactive constituent from the Magnolia plant, on human non-small cell lung cancer (NSCLC) cell migration and the molecular mechanisms underlying this effect. Using an in vitro cell migration assay, we found that treatment of A549, H1299, H460 and H226 NSCLC cells with honokiol resulted in inhibition of migration of these cells in a dose-dependent manner, which was associated with a reduction in the levels of cyclooxygenase-2 (COX-2) and prostaglandin E-2 (PGE(2)). Celecoxib, a COX-2 inhibitor, also inhibited cell migration. Honokiol inhibited PGE(2)-enhanced migration of NSCLC cells, inhibited the activation of NF-kappa B/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappa B, also inhibited migration of NSCLC cells. PGE(2) has been shown to activate beta-catenin signaling, which contributes to cancer cell migration. Therefore, we checked the effect of honokiol on beta-catenin signaling. It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis. Honokiol enhanced: (i) the levels of casein kinase-1 alpha, glycogen synthase kinase-3 beta, and (ii) phosphorylation of beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41). These events play important roles in degradation or inactivation of beta-catenin. Treatment of celecoxib also reduced nuclear accumulation of beta-catenin in NSCLC cells. FH535, an inhibitor of Wnt/beta-catenin pathway, inhibited PGE(2)-enhanced cell migration of A549 and H1299 cells. These results indicate that honokiol inhibits non-small cell lung cancer cells migration by targeting PGE(2)-mediated activation of delta-catenin signaling.
C1 [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Singh, Tripti; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
EM skatiyar@uab.edu
FU Veterans Administration [1I01BX001410-01]
FX This research was financially supported by the Veterans Administration
Merit Review Award (1I01BX001410-01, S.K.K.). The funding agencies had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 40
TC 26
Z9 30
U1 3
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2013
VL 8
IS 4
AR e60749
DI 10.1371/journal.pone.0060749
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130FG
UT WOS:000317898000059
PM 23580348
ER
PT J
AU LeBlanc, MA
Fairn, GD
Russo, SB
Czyz, O
Zaremberg, V
Cowart, LA
McMaster, CR
AF LeBlanc, Marissa A.
Fairn, Gregory D.
Russo, Sarah B.
Czyz, Ola
Zaremberg, Vanina
Cowart, L. Ashley
McMaster, Christopher R.
TI The Yeast Oxysterol Binding Protein Kes1 Maintains Sphingolipid Levels
SO PLOS ONE
LA English
DT Article
ID PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; STEROL MOVEMENT;
TRAFFICKING; PATHWAYS; CELL; ER; PHOSPHATIDYLINOSITOL; HOMEOSTASIS;
METABOLISM
AB The oxysterol binding protein family are amphitropic proteins that bind oxysterols, sterols, and possibly phosphoinositides, in a conserved binding pocket. The Saccharomyces cerevisiae oxysterol binding protein family member Kes1 (also known as Osh4) also binds phosphoinositides on a distinct surface of the protein from the conserved binding pocket. In this study, we determine that the oxysterol binding protein family member Kes1 is required to maintain the ratio of complex sphingolipids and levels of ceramide, sphingosine-phosphate and sphingosine. This inability to maintain normal sphingolipid homeostasis resulted in misdistribution of Pma1, a protein that requires normal sphingolipid synthesis to occur to partition into membrane rafts at the Golgi for its trafficking to the plasma membrane.
C1 [LeBlanc, Marissa A.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.
[Fairn, Gregory D.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
[Russo, Sarah B.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Czyz, Ola; Zaremberg, Vanina] Univ Calgary, Dept Biol, Calgary, AB T2N 1N4, Canada.
[Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[McMaster, Christopher R.] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada.
RP McMaster, CR (reprint author), Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada.
EM christopher.mcmaster@dal.ca
FU CIHR; NIH; VA; NSERC
FX This work was supported by CIHR (http://www.cihr-irsc.gc.ca/e/193.html),
NIH (http://www.nih.gov/), VA (http://www.research.va.gov/funding/), and
NSERC (http://www.nserc-crsng.gc.ca/). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 24
TC 4
Z9 5
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e60485
DI 10.1371/journal.pone.0060485
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100047
PM 23593226
ER
PT J
AU Houchens, N
Dhaliwal, G
Askari, F
Kim, B
Saint, S
AF Houchens, Nathan
Dhaliwal, Gurpreet
Askari, Frederick
Kim, Benjamin
Saint, Sanjay
TI The Essential Element
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ALKALINE-PHOSPHATASE ACTIVITY; FULMINANT HEPATIC-FAILURE; ACUTE
LIVER-FAILURE; WILSONS-DISEASE; HEMOLYTIC-ANEMIA; DIAGNOSIS; UPDATE
C1 [Houchens, Nathan; Askari, Frederick; Saint, Sanjay] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Saint, Sanjay] Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs VA, Ann Arbor, MI USA.
[Dhaliwal, Gurpreet; Kim, Benjamin] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Houchens, N (reprint author), Univ Michigan Hlth Syst, 3119 Taubman Ctr,1500 E Med Ctr Dr,SPC 5376, Ann Arbor, MI 48109 USA.
EM nathanho@umich.edu
FU Doximity
FX Dr. Saint reports receiving payment for board membership from and
holding stock in Doximity. No other potential conflict of interest
relevant to this article was reported.
NR 15
TC 0
Z9 0
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1345
EP 1351
DI 10.1056/NEJMcps1203173
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900013
PM 23550673
ER
PT J
AU Jiang, XJ
Castelao, JE
Vandenberg, D
Carracedo, A
Redondo, CM
Conti, DV
Cotore, JPP
Potter, JD
Newcomb, PA
Passarelli, MN
Jenkins, MA
Hopper, JL
Gallinger, S
Le Marchand, L
Martinez, ME
Ahnen, DJ
Baron, JA
Lindor, NM
Haile, RW
Gago-Dominguez, M
AF Jiang, Xuejuan
Esteban Castelao, J.
Vandenberg, David
Carracedo, Angel
Redondo, Carmen M.
Conti, David V.
Paredes Cotore, Jesus P.
Potter, John D.
Newcomb, Polly A.
Passarelli, Michael N.
Jenkins, Mark A.
Hopper, John L.
Gallinger, Steven
Le Marchand, Loic
Martinez, Maria E.
Ahnen, Dennis J.
Baron, John A.
Lindor, Noralane M.
Haile, Robert W.
Gago-Dominguez, Manuela
TI Genetic Variations in SMAD7 Are Associated with Colorectal Cancer Risk
in the Colon Cancer Family Registry
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GROWTH-FACTOR-BETA; TGF-BETA; CANDIDATE GENES;
SUSCEPTIBILITY; EXPRESSION; VARIANTS; CELLS; 18Q21; EPIDEMIOLOGY
AB Background: Recent genome-wide studies identified a risk locus for colorectal cancer at 18q21, which maps to the SMAD7 gene. Our objective was to confirm the association between SMAD7 SNPs and colorectal cancer risk in the multi-center Colon Cancer Family Registry.
Materials and Methods: 23 tagging SNPs in the SMAD7 gene were genotyped among 1,592 population-based and 253 clinic-based families. The SNP-colorectal cancer associations were assessed in multivariable conditional logistic regression.
Results: Among the population-based families, both SNPs rs12953717 (odds ratio, 1.29; 95% confidence interval, 1.12-1.49), and rs11874392 (odds ratio, 0.80; 95% confidence interval, 0.70-0.92) were associated with risk of colorectal cancer. These associations were similar among the population-and the clinic-based families, though they were significant only among the former. Marginally significant differences in the SNP-colorectal cancer associations were observed by use of nonsteroidal anti-inflammatory drugs, cigarette smoking, body mass index, and history of polyps.
Conclusions: SMAD7 SNPs were associated with colorectal cancer risk in the Colon Cancer Family Registry. There was evidence suggesting that the association between rs12953717 and colorectal cancer risk may be modified by factors such as smoking and use of nonsteroidal anti-inflammatory drugs.
C1 [Jiang, Xuejuan; Vandenberg, David; Conti, David V.; Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Esteban Castelao, J.; Redondo, Carmen M.] Complejo Hosp Univ Vigo, Oncol & Genet Unit, Serv Galego Saude SERGAS, Vigo, Spain.
[Carracedo, Angel; Gago-Dominguez, Manuela] Complejo Hosp Univ Santiago, Genom Med Grp, Galician Fdn Genom Med, Serv Galego Saude SERGAS,Inst Invest Sanitaria Sa, Santiago De Compostela, Spain.
[Paredes Cotore, Jesus P.] Univ Hosp Santiago de Compostela, Dept Surg, Santiago De Compostela, Spain.
[Potter, John D.; Newcomb, Polly A.; Passarelli, Michael N.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Jenkins, Mark A.; Hopper, John L.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia.
[Gallinger, Steven] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA.
[Martinez, Maria E.] Univ Calif San Diego, San Diego Moores Canc Ctr, San Diego, CA 92103 USA.
[Ahnen, Dennis J.] Denver VA Med Ctr, Denver, CO USA.
[Ahnen, Dennis J.] Univ Colorado, Denver, CO 80202 USA.
[Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[Lindor, Noralane M.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA.
RP Gago-Dominguez, M (reprint author), Complejo Hosp Univ Santiago, Genom Med Grp, Galician Fdn Genom Med, Serv Galego Saude SERGAS,Inst Invest Sanitaria Sa, Santiago De Compostela, Spain.
EM manuela.gago.dominguez@sergas.es
RI Gallinger, Steven/E-4575-2013; Jenkins, Mark/P-7803-2015
OI Jenkins, Mark/0000-0002-8964-6160; Potter, John/0000-0001-5439-1500;
Carracedo, Angel/0000-0003-1085-8986
FU National Cancer Institute, National Institutes of Health
[5R01CA114472-02, RFA CA-95-011]; Australasian Colorectal Cancer Family
Registry [U01 CA097735]; University of Southern California Familial
Colorectal Neoplasia Collaborative Group [U01 CA074799]; Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies [U01 CA074800];
Ontario Registry for Studies of Familial Colorectal Cancer [U01
CA074783]; Seattle Colorectal Cancer Family Registry [U01 CA074794];
University of Hawaii Colorectal Cancer Family Registry [U01 CA074806];
University of California, Irvine Informatics Center [U01 CA078296];
Accion Estrategica de Salud del Instituto de Salud Carlos III [FIS
PI12/02125]; FIS Intrasalud [PS09/02368]; Botin Foundation
FX This work was supported by National Cancer Institute, National
Institutes of Health, grant # 5R01CA114472-02 and RFA # CA-95-011 and
through cooperative agreements with members of the Colon Cancer Family
Registry and P.I.s: the Australasian Colorectal Cancer Family Registry
(U01 CA097735); the University of Southern California Familial
Colorectal Neoplasia Collaborative Group (U01 CA074799); the Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies (U01 CA074800); the
Ontario Registry for Studies of Familial Colorectal Cancer (U01
CA074783); the Seattle Colorectal Cancer Family Registry (U01 CA074794);
the University of Hawaii Colorectal Cancer Family Registry (U01
CA074806); the University of California, Irvine Informatics Center (U01
CA078296); FIS PI12/02125 Accion Estrategica de Salud del Instituto de
Salud Carlos III; FIS Intrasalud (PS09/02368); and the Botin Foundation.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 34
TC 7
Z9 7
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2013
VL 8
IS 4
AR e60464
DI 10.1371/journal.pone.0060464
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143BA
UT WOS:000318840100075
PM 23560096
ER
PT J
AU O'Hare, AM
AF O'Hare, Ann M.
TI Measures to Define Chronic Kidney Disease
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID MORTALITY RISK; AGE
C1 VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
RP O'Hare, AM (reprint author), VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
EM ann.o'hare@va.gov
NR 5
TC 4
Z9 4
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 3
PY 2013
VL 309
IS 13
BP 1343
EP 1343
DI 10.1001/jama.2013.1328
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117EC
UT WOS:000316934500010
PM 23549569
ER
PT J
AU Junco, SE
Wang, RJ
Gaipa, JC
Taylor, AB
Schirf, V
Gearhart, MD
Bardwell, VJ
Demeler, B
Hart, PJ
Kim, CA
AF Junco, Sarah E.
Wang, Renjing
Gaipa, John C.
Taylor, Alexander B.
Schirf, Virgil
Gearhart, Micah D.
Bardwell, Vivian J.
Demeler, Borries
Hart, P. John
Kim, Chongwoo A.
TI Structure of the Polycomb Group Protein PCGF1 in Complex with BCOR
Reveals Basis for Binding Selectivity of PCGF Homologs
SO STRUCTURE
LA English
DT Article
ID SOMATIC MUTATIONS; REPRESSIVE COMPLEX; COREPRESSOR; DOMAIN; PRC1;
IDENTIFICATION; LEUKEMIA; SUBTYPE; SYSTEM; RING1B
AB Polycomb-group RING finger homologs (PCGF1, PCGF2, PCGF3, PCGF4, PCGF5, and PCGF6) are critical components in the assembly of distinct Polycomb repression complex 1 (PRC1)-related complexes. Here, we identify a protein interaction domain in BCL6 corepressor, BCOR, which binds the RING finger- and WD40-associated ubiquitin-like (RAWUL) domain of PCGF1 (NSPC1) and PCGF3 but not of PCGF2 (MEL18) or PCGF4 (BMW. Because of the selective binding, we have named this domain PCGF Ub-like fold discriminator (PUFD). The structure of BCOR PUFD bound to PCGF1 reveals that (1) PUFD binds to the same surfaces as observed for a different Polycomb group RAWUL domain and (2) the ability of PUFD to discriminate among RAWULs stems from the identity of specific residues within these interaction surfaces. These data show the molecular basis for determining the binding preference for a PCGF homolog, which ultimately helps determine the identity of the larger PRC1-like assembly.
C1 [Junco, Sarah E.; Wang, Renjing; Gaipa, John C.; Taylor, Alexander B.; Schirf, Virgil; Demeler, Borries; Hart, P. John; Kim, Chongwoo A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Junco, Sarah E.; Wang, Renjing; Gaipa, John C.; Taylor, Alexander B.; Schirf, Virgil; Demeler, Borries; Hart, P. John; Kim, Chongwoo A.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA.
[Gearhart, Micah D.; Bardwell, Vivian J.] Univ Minnesota, Dept Genet Cell Biol & Dev, Mason Canc Ctr, Minneapolis, MN 55455 USA.
[Gearhart, Micah D.; Bardwell, Vivian J.] Univ Minnesota, Ctr Dev Biol, Minneapolis, MN 55455 USA.
[Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Kim, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM chong@biochem.uthscsa.edu
FU American Heart Association [0830111N]; American Cancer Society
[RSG-08-285-01-GMC]; Department of Defense Breast Cancer Research
Program [BC075278]; National Institutes of Health [5R01CA071540];
NIH-NCI [2P30 CA054174-17]; XSEDE [TG-MCB070039]; Welch Foundation
[AQ-1399]; UTHSCSA Executive Research Committee; Cancer Therapy Research
Center; Office of Science, Office of Basic Energy Sciences, of the U.S.
Department of Energy [DE-AC02-05CH11231]; U.S. Department of Energy,
Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357];
Michigan Economic Development Corporation; Michigan Technology
Tr-Corridor [085P1000817]
FX This work was supported by the American Heart Association (0830111N to
OAK.), the American Cancer Society (RSG-08-285-01-GMC to C.A.K.), the
Department of Defense Breast Cancer Research Program (BC075278 to
C.A.K.), the National Institutes of Health (5R01CA071540 to V.J.B.),
NIH-NCI (2P30 CA054174-17 to B.D. and P.J.H.), XSEDE (TG-MCB070039 to
B.D.), and the Welch Foundation (AQ-1399 to P.J.H.). UTHSCSA core
facilities are supported by the UTHSCSA Executive Research Committee and
the Cancer Therapy Research Center. This work is based upon research at
Beamline 4.2.2 of the Molecular Biology Consortium at the Advance Light
Source (ALS). ALS is supported by the Director, Office of Science,
Office of Basic Energy Sciences, of the U.S. Department of Energy under
Contract No. DE-AC02-05CH11231. Advanced Photon Source is supported by
the U.S. Department of Energy, Office of Science, Office of Basic Energy
Sciences, under Contract No. DE-AC02-06CH11357. LS-CAT Sector 21 was
supported by the Michigan Economic Development Corporation and the
Michigan Technology Tr-Corridor (Grant 085P1000817). We also thank Dr.
Jay Nix (ALS) and Dr. Dmitri Ivanov (APS) for assistance with the data
collection.
NR 42
TC 25
Z9 29
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
J9 STRUCTURE
JI Structure
PD APR 2
PY 2013
VL 21
IS 4
BP 665
EP 671
DI 10.1016/j.str.2013.02.013
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 128WJ
UT WOS:000317800100016
PM 23523425
ER
PT J
AU Kullgren, JT
Troxel, AB
Loewenstein, G
Asch, DA
Norton, LA
Wesby, L
Tao, YY
Zhu, JS
Volpp, KG
AF Kullgren, Jeffrey T.
Troxel, Andrea B.
Loewenstein, George
Asch, David A.
Norton, Laurie A.
Wesby, Lisa
Tao, Yuanyuan
Zhu, Jingsan
Volpp, Kevin G.
TI Individual- Versus Group-Based Financial Incentives for Weight Loss A
Randomized, Controlled Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID LOSS PROGRAM; EATING QUESTIONNAIRE-R18; MONETARY INCENTIVES; FOOD
PROVISION; OBESITY; HEALTH; PREDICTORS; OVERWEIGHT; ATTRITION; REGRET
AB Background: Data on the effectiveness of employer-sponsored financial incentives for employee weight loss are limited.
Objective: To test the effectiveness of 2 financial incentive designs for promoting weight loss among obese employees.
Design: Randomized, controlled trial. (ClinicalTrials.gov: NCT01208350)
Setting: Children's Hospital of Philadelphia.
Participants: 105 employees with a body mass index between 30 and 40 kg/m(2).
Intervention: 24 weeks of monthly weigh-ins (control group; n = 35); individual incentive, designed as $100 per person per month for meeting or exceeding weight-loss goals (n = 35); and group incentive, designed as $500 per month split among participants within groups of 5 who met or exceeded weight-loss goals (n = 35).
Measurements: Weight loss after 24 weeks (primary outcome) and 36 weeks and changes in behavioral mediators of weight loss (secondary outcomes).
Results: Group-incentive participants lost more weight than control participants (mean between-group difference, 4.4 kg [95% CI, 2.0 to 6.7 kg]; P < 0.001) and individual-incentive participants (mean between-group difference, 3.2 kg [CI, 0.9 to 5.5 kg]; P = 0.008). Twelve weeks after incentives ended and after adjustment for 3-group comparisons, group-incentive participants maintained greater weight loss than control group participants (mean between-group difference, 2.9 kg [CI, 0.5 to 5.3 kg]; P = 0.016) but not greater than individual-incentive participants (mean between-group difference, 2.7 kg [CI, 0.4 to 5.0 kg]; P = 0.024).
Limitation: Single employer and short follow-up.
Conclusion: A group-based financial incentive was more effective than an individual incentive and monthly weigh-ins at promoting weight loss among obese employees at 24 weeks.
C1 Univ Michigan, Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Sch Med, Ann Arbor, MI 48109 USA.
Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
Univ Penn, Perelman Sch Med,Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Penn CMU Roybal Ctr Behav Econ & Hlth, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, POB 130170, Ann Arbor, MI 48113 USA.
EM jkullgre@med.umich.edu
OI Asch, David/0000-0002-7970-286X; Troxel, Andrea/0000-0002-1393-3075
FU National Institute on Aging [RC2103282621]; Department of Veterans
Affairs; Robert Wood Johnson Foundation
FX National Institute on Aging.; By grant RC2103282621 (National Institute
on Aging). Support was also provided by the Department of Veterans
Affairs and the Robert Wood Johnson Foundation.
NR 52
TC 57
Z9 57
U1 2
U2 29
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 2
PY 2013
VL 158
IS 7
BP 505
EP +
DI 10.7326/0003-4819-158-7-201304020-00002
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 123VM
UT WOS:000317419400001
PM 23546562
ER
PT J
AU Kumar, RS
Douglas, PS
Peterson, ED
Anstrom, KJ
Dai, D
Brennan, JM
Hui, PYM
Booth, ME
Messenger, JC
Shaw, RE
AF Kumar, Robert S.
Douglas, Pamela S.
Peterson, Eric D.
Anstrom, Kevin J.
Dai, David
Brennan, J. Matthew
Hui, Peter Y. M.
Booth, Michael E.
Messenger, John C.
Shaw, Richard E.
TI Effect of Race and Ethnicity on Outcomes With Drug-Eluting and Bare
Metal Stents Results in 423 965 Patients in the Linked National
Cardiovascular Data Registry and Centers for Medicare & Medicaid
Services Payer Databases
SO CIRCULATION
LA English
DT Article
DE continental population groups; coronary artery disease; drug-eluting
stents; ethnic groups; outcome assessment; percutaneous coronary
intervention
ID PERCUTANEOUS CORONARY INTERVENTION; RACIAL-DIFFERENCES; DYNAMIC
REGISTRY; ARTERY-DISEASE; HEART-DISEASE; REVASCULARIZATION; VETERANS;
SURVIVAL; RISK
AB Background-Black, Hispanic, and Asian patients have been underrepresented in percutaneous coronary intervention clinical trials; therefore, there are limited data available on outcomes for these race/ethnicity groups.
Methods and Results-We examined outcomes in 423 965 patients in the National Cardiovascular Data Registry CathPCI Registry database linked to Medicare claims for follow-up. Within each race/ethnicity group, we examined trends in drug-eluting stent (DES) use, 30-month outcomes, and relative outcomes of DES versus bare metal stents. Overall, 390 351 white, 20 191 black, 9342 Hispanic, and 4171 Asian patients >65 years of age underwent stent implantation from 2004 through 2008 at 940 National Cardiovascular Data Registry participating sites. Trends in adoption of DES were similar across all groups. Relative to whites, black and Hispanic patients undergoing percutaneous coronary intervention had higher long-term risks of death and myocardial infarction (blacks: hazard ratio, 1.28; 95% confidence interval, 1.24-1.32; Hispanics: hazard ratio, 1.15; 95% confidence interval, 1.10-1.21). Long-term outcomes were similar in Asians and whites (hazard ratio, 0.99; 95% confidence interval, 0.92-1.08). Use of DES was associated with better 30-month survival and lower myocardial infarction rates compared with the use of bare metal stents among all race/ethnicity groups except Hispanics, who had similar outcomes with DES or bare metal stents.
Conclusions-Black and Hispanic patients undergoing percutaneous coronary intervention had worse long-term outcomes relative to white and Asian patients. Compared with bare metal stent use, DES use was generally associated with superior long-term outcomes in all racial and ethnic groups, although these differences were not statistically significant in Hispanic patients. (Circulation. 2013;127:1395-1403.)
C1 [Kumar, Robert S.] Lenox Hill Hosp, New York, NY 10021 USA.
[Douglas, Pamela S.; Peterson, Eric D.; Anstrom, Kevin J.; Dai, David; Brennan, J. Matthew; Booth, Michael E.] Duke Clin Res Inst, Durham, NC USA.
[Hui, Peter Y. M.; Shaw, Richard E.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Messenger, John C.] Denver VA Med Ctr, Denver, CO USA.
RP Kumar, RS (reprint author), Virginia Hart, Lenox Hill Intervent Cardiac & Vasc Serv, 130 E 77th St,9th Floor Black Hall, New York, NY 10075 USA.
EM robertskumar@gmail.com
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services, Rockville, MD, as part of the Cardiovascular Consortium;
Developing Evidence to Inform Decisions About Effectiveness (DEcIDE)
program [24-EHC-1, HHSAA290-2005-0032-TO4-WA2]; Eli Lilly; Johnson
Johnson; AstraZeneca; Eli Lilly Co; Medtronic; Proctor and Gamble
FX This project was sponsored by the Agency for Healthcare Research and
Quality, US Department of Health and Human Services, Rockville, MD, as
part of the Cardiovascular Consortium and funded under project
identification 24-EHC-1 and work assignment number
HHSAA290-2005-0032-TO4-WA2 as part of the Developing Evidence to Inform
Decisions About Effectiveness (DEcIDE) program. The authors of this
report are responsible for its content. Statements in the report should
not be construed as endorsement by the Agency for Healthcare Research
and Quality or the US Department of Health and Human Service.; Dr
Peterson reports research support from Eli Lilly and Johnson & Johnson.
Dr. Anstrom has received research support from AstraZeneca, Eli Lilly &
Co, Medtronic, and Proctor and Gamble; has served as a consultant for
Abbott Vascular, AstraZeneca, Bristol Meyer Squibb, and Ikaria; and has
served on Data Monitoring committees for Pfizer and Vertex. The other
authors report no conflicts.
NR 27
TC 15
Z9 16
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 2
PY 2013
VL 127
IS 13
BP 1395
EP +
DI 10.1161/CIRCULATIONAHA.113.001437
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 117JG
UT WOS:000316948900015
PM 23547179
ER
PT J
AU Ibrahim, SA
Franklin, PD
AF Ibrahim, Said A.
Franklin, Patricia D.
TI Race and Elective Joint Replacement: Where a Disparity Meets Patient
Preference
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 [Ibrahim, Said A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Franklin, Patricia D.] Univ Massachusetts, Med Ctr, Dept Orthoped & Phys Rehabil, Worcester, MA USA.
RP Ibrahim, SA (reprint author), Philadelphia VA Med Ctr ANNEX, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM said.ibrahim2@va.gov
OI Franklin, Patricia D/0000-0002-4441-0533
FU AHRQ HHS [P50 HS018910, P50 HS018910-01]; NIAMS NIH HHS
[1K24AR055259-01, K24 AR055259]
NR 6
TC 6
Z9 6
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2013
VL 103
IS 4
BP 583
EP 584
DI 10.2105/AJPH.2012.301077
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA0DU
UT WOS:000330766100019
PM 23409914
ER
PT J
AU Gupta, S
Vemulakonda, GA
Suhler, EB
Yeh, S
Albini, TA
Mandelcorn, E
Flaxel, CJ
AF Gupta, Seema
Vemulakonda, G. A.
Suhler, Eric B.
Yeh, Steven
Albini, Thomas A.
Mandelcorn, Efrem
Flaxel, Christina J.
TI Cytomegalovirus retinitis in the absence of AIDS
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID IMMUNOCOMPETENT PATIENT; TRIAMCINOLONE; INFECTION; ADULT
AB Objective: The purpose of this study was to evaluate systemic and ophthalmic features associated with Cytomegalovirus (CMV) retinitis in immunocompetent patients.
Design: Retrospective chart review.
Participants: Nine patients with CMV retinitis who were clinically immunocompetent at the time of diagnosis.
Methods: Retrospective chart review of patients evaluated at the Casey Eye Institute, University of Washington, Bascom Palmer Eye Institute and University of Toronto. IRB approval was obtained. Retrospective chart review of patients evaluated at the Casey Eye Institute, University of Washington, Bascom Palmer Eye Institute and University of Toronto. IRB approval was obtained.
Results: Seven of the nine patients in our series were 60 years of age or above. Three patients had intravitreal steroid and VEGF inhibitor injections in the preceding year in the affected eye. Five of the nine patients were initially misdiagnosed to have acute retinal necrosis (ARN) for which they were on Valacyclovir for a variable period of time. Seven patients had anterior chamber and eight had vitreous inflammation. Six of the nine patients exhibited vascular attenuation or obliteration. All patients showed improvement in retinitis within weeks following therapy with intravitreal foscarnet and/or ganciclovir and systemic valganciclovir.
C1 [Gupta, Seema; Suhler, Eric B.; Flaxel, Christina J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
[Vemulakonda, G. A.] Univ Washington, Seattle, WA 98195 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Yeh, Steven] Emory Eye Ctr, Decatur, GA USA.
[Albini, Thomas A.] Bascom Palmer Eye Inst, Miami, FL USA.
[Mandelcorn, Efrem] Univ Toronto, Toronto, ON, Canada.
RP Flaxel, CJ (reprint author), OHSU, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM flaxelc@ohsu.edu
OI Albini, Thomas/0000-0003-2199-9047
NR 10
TC 8
Z9 8
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2013
VL 48
IS 2
BP 126
EP 129
DI 10.1016/j.jcjo.2012.12.002
PG 4
WC Ophthalmology
SC Ophthalmology
GA AA5NX
UT WOS:000331147800026
PM 23561607
ER
PT J
AU Russell, DC
Smith, TL
Krahn, DD
Graskamp, P
Singh, D
Kolden, GG
Sigmund, H
Zhang, ZJ
AF Russell, Douglas C.
Smith, Tracey L.
Krahn, Dean D.
Graskamp, Peter
Singh, Dalip
Kolden, Gregory G.
Sigmund, Heidi
Zhang, Zhengjun
TI HEMODYNAMIC EFFECTS OF COGNITIVE BEHAVORAL STRESS MANAGEMENT IN
RECIPIENTS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS: A RANDOMIZED
CLINICAL TRIAL
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 71st Annual Scientific Meeting of the American-Psychosomatic-Society
CY MAR 13-16, 2013
CL Miami, FL
SP Amer Psychosomat Soc
C1 [Russell, Douglas C.; Smith, Tracey L.; Krahn, Dean D.; Sigmund, Heidi] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Graskamp, Peter; Singh, Dalip] Med Coll Wisconsin, Zablocki Vet Adm Med Ctr, Milwaukee, WI 53226 USA.
[Kolden, Gregory G.; Zhang, Zhengjun] Univ Wisconsin, Madison, WI USA.
RI Smith, Tracey/J-2030-2014
OI Smith, Tracey/0000-0001-5338-9142
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2013
VL 75
IS 3
BP A50
EP A51
PG 2
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MG
UT WOS:000330467400163
ER
PT J
AU Nguyen, T
Edmonds, S
Solimeo, S
Wolinsky, F
Roblin, D
Saag, K
Cram, P
AF Thuy Nguyen
Edmonds, Stephanie
Solimeo, Samantha
Wolinsky, Fredric
Roblin, Douglas
Saag, Kenneth
Cram, Peter
TI SEX AND RACIAL DIFFERENCES OF OSTEO POROSIS KNOWLEDGE AMONG PATIENTS
PRESENTING FOR DXA
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT Interdisciplinary Symposium on Osteoporosis - Patient-Centered Care -
Developing Successful Bone Health Teams
CY APR 18-21, 2013
CL Chicago, IL
SP Natl Osteoporosis Fdn
C1 [Thuy Nguyen; Edmonds, Stephanie; Wolinsky, Fredric; Cram, Peter] Univ Iowa, Iowa City, IA USA.
[Solimeo, Samantha] US Dept Vet Affairs, Iowa City, IA USA.
[Roblin, Douglas] Kaiser Permanente, Atlanta, GA USA.
[Saag, Kenneth] Univ Alabama Birmingham, Birmingham, AL USA.
RI Cram, Peter/K-4472-2014
OI Cram, Peter/0000-0002-1910-346X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD APR
PY 2013
VL 24
SU 2
MA P25
BP S436
EP S437
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 270WN
UT WOS:000328350000025
ER
PT J
AU Cucciare, MA
Simpson, T
Hoggatt, KJ
Gifford, E
Timko, C
AF Cucciare, Michael A.
Simpson, Tracy
Hoggatt, Katherine J.
Gifford, Elizabeth
Timko, Christine
TI SUBSTANCE USE AMONG WOMEN VETERANS: EPIDEMIOLOGY TO EVIDENCE-BASED
TREATMENT
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE Substance misuse; women Veterans; alcohol; drugs; screening;
evidence-based treatment
ID BRIEF ALCOHOL INTERVENTION; BEHAVIORAL-COUNSELING INTERVENTIONS;
RANDOMIZED CONTROLLED-TRIAL; DRUG-DEPENDENT WOMEN; AFFAIRS HEALTH-CARE;
USE DISORDERS; FEMALE VETERANS; GENDER-DIFFERENCES; PREGNANT-WOMEN;
CLINICAL-TRIAL
AB An increasing percentage of women are U.S. Military Veterans. We review the substance misuse rates and comorbidities and the risk factors for and consequences of substance use among women Veterans. Women Veterans may have higher rates of substance misuse and comorbid psychiatric and medical disorders than male Veterans and women who are not Veterans. Studies support the AUDIT-C as a scaled marker of alcohol-related risk among female Veterans, but validated drug screening instruments are needed. We discuss evidence-based approaches in terms of treating women Veterans' substance misuse in primary and specialty care settings, along with knowledge gaps and potential research priorities to improve care in this special population.
C1 [Cucciare, Michael A.; Gifford, Elizabeth; Timko, Christine] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Simpson, Tracy] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Hoggatt, Katherine J.] Vet Affairs Greater Los Angeles Hlth Care Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Gifford, Elizabeth] Vet Affairs Palo Alto Hlth Care Syst, Program Evaluat Resource Ctr, Menlo Pk, CA 94025 USA.
[Timko, Christine] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
RP Cucciare, MA (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd 152, Menlo Pk, CA 94025 USA.
EM michael.cucciare@va.gov
NR 98
TC 14
Z9 14
U1 4
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD APR 1
PY 2013
VL 32
IS 2
BP 119
EP 139
DI 10.1080/10550887.2013.795465
PG 21
WC Substance Abuse
SC Substance Abuse
GA 262SD
UT WOS:000327757000001
PM 23815420
ER
PT J
AU Kalapatapu, RK
Lewis, DF
Vinogradov, S
Batki, SL
Winhusen, T
AF Kalapatapu, Raj K.
Lewis, Daniel F.
Vinogradov, Sophia
Batki, Steven L.
Winhusen, Theresa
TI RELATIONSHIP OF AGE TO IMPULSIVITY AND DECISION MAKING: A BASELINE
SECONDARY ANALYSIS OF A BEHAVIORAL TREATMENT STUDY IN STIMULANT USE
DISORDERS
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE Cocaine; methamphetamine; aging; addiction; neurocognitive
ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; COCAINE-DEPENDENT
INDIVIDUALS; IOWA GAMBLING TASK; BORDERLINE PERSONALITY-DISORDER;
DRUG-ABUSE; OLDER-ADULTS; COGNITIVE REHABILITATION; METHAMPHETAMINE USE;
EXECUTIVE FUNCTIONS
AB Because stimulant use disorders remain prevalent across the lifespan, cognition is an important area of clinical care and research focus among aging adults with stimulant use disorders. This secondary analysis of a National Institute on Drug Abuse Clinical Trials Network study suggests that decision making, verbal learning/memory, executive function, and set shifting are important cognitive domains to screen clinically and treat in aging adults with stimulant use disorders. Some suggestions are made on how clinical treatment providers can practically use these results. An important direction for future research is the development of cognitively remediating treatments for impaired cognitive domains in aging adults with stimulant use disorders.
C1 [Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Lewis, Daniel F.; Winhusen, Theresa] Univ Cincinnati, Coll Med, Cincinnati Addict Res Ctr, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Bldg 8 Mental Hlth,Room 4C,4150 Clement St, San Francisco, CA 94121 USA.
EM kalapatapu.raj.k@gmail.com
OI Winhusen, Theresa/0000-0002-3364-0739
FU NIDA NIH HHS [T32 DA007294, K23 DA034883, U10DA013732, K23DA 034883, U10
DA013732]
NR 94
TC 2
Z9 2
U1 1
U2 10
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD APR 1
PY 2013
VL 32
IS 2
BP 206
EP 216
DI 10.1080/10550887.2013.795471
PG 11
WC Substance Abuse
SC Substance Abuse
GA 262SD
UT WOS:000327757000007
PM 23815427
ER
PT J
AU Zivin, K
AF Zivin, Kara
TI How Are Prescribing Decisions Made?
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 [Zivin, Kara] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
[Zivin, Kara] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Zivin, K (reprint author), US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP 295
EP 295
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100007
PM 23543162
ER
PT J
AU Yang, S
AF Yang, Suzanne
TI The Routledge Handbook of Deviant Behavior
SO PSYCHIATRIC SERVICES
LA English
DT Book Review
C1 [Yang, Suzanne] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Yang, S (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP E4
EP E4
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100004
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Patient-Reported Outcomes in Gastroenterology: Clinical and Research
Applications
SO JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Review
DE Gastroenterology; Patient-reported outcomes; Quality of life
ID QUALITY-OF-LIFE; GASTROESOPHAGEAL-REFLUX DISEASE;
IRRITABLE-BOWEL-SYNDROME; TREATMENT SATISFACTION QUESTIONNAIRE; UPPER
GASTROINTESTINAL DISORDERS; LAPAROSCOPIC NISSEN FUNDOPLICATION; FECAL
INCONTINENCE QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL;
INFORMATION-SYSTEM PROMIS; NEPEAN DYSPEPSIA INDEX
AB Patient-generated reports, also known as Patient-Reported Outcomes (PROs), capture the patients' illness experience in a structured format and may help bridge the gap between patients and providers. PROs measure any aspect of patient-reported health (e. g., physical, emotional or social symptoms) and can help to direct care and improve clinical outcomes. When clinicians systematically collect patient-reported data in the right place at the right time, PRO measurement can effectively aid in detection and management of conditions, improve satisfaction with care and enhance the patient-provider relationship. This review article summarizes the latest approaches to PRO measuring for clinical trials and clinical practice, with a focus on use of PROs in gastroenterology.
C1 [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
NR 139
TC 10
Z9 10
U1 2
U2 6
PU KOREAN SOC NEUROGASTERONTEROL & MOTILITY
PI GANGNAM-GU
PA RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU,
SEOUL 135-839, SOUTH KOREA
SN 2093-0879
J9 J NEUROGASTROENTEROL
JI J. Neurogastroenterol. Motil.
PD APR
PY 2013
VL 19
IS 2
BP 137
EP 148
DI 10.5056/jnm.2013.19.2.137
PG 12
WC Gastroenterology & Hepatology; Clinical Neurology
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 225ZV
UT WOS:000325004700004
PM 23667745
ER
PT J
AU Basu, P
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI EFFECT OF N ACETYLCYSTEINE (NAC) IN HYPOXIA INDUCED LIVER INJURY (HILI)
- A RANDOMIZED PLACEBO CONTROL CLINICAL TRIAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
EM ravisiriki@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 358
BP S148
EP S148
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000359
ER
PT J
AU Basu, PP
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P. P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI ROMIPLOSTIM'S EFFECT TO OPTIMIZE SVR WITH TELAPRAVIR, RIBAVIRIN, AND PEG
INTERFERON-alfa 2a IN THROMBOCYTOPENIC CIRRHOTICS WITH CHRONIC HEPATITIS
C. RESTRAINT C- PLACEBO RCT
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P. P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P. P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
EM ravisiriki@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 906
BP S373
EP S374
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983001168
ER
PT J
AU Basu, PP
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P. P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND
TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P. P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P. P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
EM basu.patrick@gmail.com
NR 0
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 67
BP S30
EP S31
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000068
ER
PT J
AU Mohanty, A
Erqou, S
Butt, AA
AF Mohanty, A.
Erqou, S.
Butt, A. A.
TI ERYTHROPOIETIN USE FOR THERAPY ASSOCIATED ANEMIA IN HEPATITIS C VIRUS
INFECTION AND RISK OF MORTALITY
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Mohanty, A.; Erqou, S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Butt, A. A.] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, A. A.] VA Pittsburgh Healthcare Syst, Div Infect Dis, Internal Med, Pittsburgh, PA USA.
[Butt, A. A.] Sheikh Khalifa Med City, Internal Med, Abu Dhabi, U Arab Emirates.
EM mohantya@upmc.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 478
BP S196
EP S196
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000479
ER
PT J
AU Waldron, TJ
Quatromoni, JG
Karakasheva, TA
Singhal, S
Rustgi, AK
AF Waldron, Todd J.
Quatromoni, Jon G.
Karakasheva, Tatiana A.
Singhal, Sunil
Rustgi, Anil K.
TI Myeloid derived suppressor cells: Targets for therapy
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Myeloid derived suppressor cells; docetaxol; RNA aptamer; CpG
oligodeoxynucleotides (ODN); cyclophosphamide; gemcitabine; curcumin
ID TUMOR-BEARING HOST; NITRIC-OXIDE SYNTHASE; CD8(+) T-CELLS;
CANCER-PATIENTS; IMMUNOSUPPRESSIVE ACTIVITY; ESTABLISHED TUMORS;
ANTITUMOR IMMUNITY; EQUILIBRIUM STATE; POOR SURVIVAL; OCCULT CANCER
AB The goal of achieving measurable response with cancer immunotherapy requires counteracting the immunosuppressive characteristics of tumors. One of the mechanisms that tumors utilize to escape immunosurveillance is the activation of myeloid derived suppressor cells (MDSCs). Upon activation by tumor-derived signals, MDSCs inhibit the ability of the host to mount an anti-tumor immune response via their capacity to suppress both the innate and adaptive immune systems. Despite their relatively recent discovery and characterization, anti-MDSC agents have been identified, which may improve immunotherapy efficacy.
C1 [Waldron, Todd J.; Karakasheva, Tatiana A.; Rustgi, Anil K.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Waldron, Todd J.; Karakasheva, Tatiana A.; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Quatromoni, Jon G.; Singhal, Sunil] Hosp Univ Penn, Dept Surg, Div Thorac Surg, Sch Med, Philadelphia, PA 19104 USA.
[Singhal, Sunil] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
[Rustgi, Anil K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
RP Rustgi, AK (reprint author), Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
EM anil2@mail.med.upenn.edu
FU National Institutes of Health/NCI [P01-CA098101, U01-CA14305603];
National Institutes of Health/NIDDK [T32-DK007066]; National Institutes
of Health [F32-CA162719]; National Institutes of Health/NIDDK Center for
Molecular Studies in Digestive and Liver Diseases [P30-DK050306];
American Cancer Society [RP-10-033-01-CCE]
FX This work was supported by the National Institutes of Health/NCI grant
P01-CA098101 (AKR, TW), National Institutes of Health/NCI grant
U01-CA14305603 (AKR), National Institutes of Health/NIDDK (T32-DK007066)
(TW), National Institutes of Health (F32-CA162719) (TW), National
Institutes of Health/NIDDK Center for Molecular Studies in Digestive and
Liver Diseases (P30-DK050306), and American Cancer Society
(RP-10-033-01-CCE). We are grateful for members of the Rustgi and
Singhal labs for discussions.
NR 89
TC 24
Z9 24
U1 0
U2 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD APR 1
PY 2013
VL 2
IS 4
AR e24117
DI 10.4161/onci.24117
PG 7
WC Oncology; Immunology
SC Oncology; Immunology
GA 193NJ
UT WOS:000322566200024
PM 23734336
ER
PT J
AU Stengel, A
Rivier, J
Tache, Y
AF Stengel, Andreas
Rivier, Jean
Tache, Yvette
TI Modulation of the adaptive response to stress by brain activation of
selective somatostatin receptor subtypes
SO PEPTIDES
LA English
DT Review
DE ACTH; Anxiety; Autonomic nervous system; Catecholamines; CRF; Food
intake; Gastrointestinal motility; Octreotide; ODT8-SST; Stress
ID CORTICOTROPIN-RELEASING-FACTOR; CENTRAL-NERVOUS-SYSTEM; COLONIC MOTOR
FUNCTION; GROWTH-HORMONE SECRETION; FOOD-INTAKE; INDUCED INHIBITION;
MESSENGER-RNA; NEUROPEPTIDE-Y; CENTRAL CRF; C-FOS
AB Somatostatin-14 was discovered in 1973 in the hypothalamus as a peptide inhibiting growth hormone release. Somatostatin interacts with five receptor subtypes (sst(1-5)) which are widely distributed in the brain with a distinct, but overlapping, expression pattern. During the last few years, the development of highly selective peptide agonists and antagonists provided new insight to characterize the role of somatostatin receptor subtypes in the pleiotropic actions of somatostatin. Recent evidence in rodents indicates that the activation of selective somatostatin receptor subtypes in the brain blunts stress-corticotropin-releasing factor (CRF) related ACTH release (sst(2/5)), sympathetic-adrenal activaton (sst(5)), stimulation of colonic motility (sst(1)), delayed gastric emptying (sst(5)), suppression of food intake (sst(2)) and the anxiogenic-like (sst(2)) response. These findings suggest that brain somatostatin signaling pathways may play an important role in dampening CRF-mediated endocrine, sympathetic, behavioral and visceral responses to stress. Published by Elsevier Inc.
C1 [Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90095 USA.
[Stengel, Andreas; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Stengel, Andreas] Charite Med Ctr, Dept Med, Div Psychosomat Med, Berlin, Germany.
[Stengel, Andreas] Charite Med Ctr, Dept Med, Obes Ctr Berlin, Berlin, Germany.
[Stengel, Andreas] Univ Berlin, Berlin, Germany.
[Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU German Research Foundation [STE 1765/3-1]; Charite university [89441
176]; Sonnenfeld foundation; VA Research Career Scientist Award; VA
Merit Award; NIH R01 [DK 33061, DK57238]
FX A.S. received funding from the German Research Foundation (STE 1765/3-1)
Charite university funding (89441 176) and an equipment grant of the
Sonnenfeld foundation. Y.T. is in receipt of the VA Research Career
Scientist Award, VA Merit Award and NIH R01grants DK 33061 and DK57238.
J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor.
NR 109
TC 9
Z9 9
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD APR
PY 2013
VL 42
BP 70
EP 77
DI 10.1016/j.peptides.2012.12.022
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 165OI
UT WOS:000320492800010
PM 23287111
ER
PT J
AU Cowart, LA
AF Cowart, L. Ashley
TI Dietary Fat Composition Modifies Cell Sphingolipid Biosynthesis to
Mediate the consequences of obesity.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Cowart, L. Ashley] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 453.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500557
ER
PT J
AU Donnelly, BF
Needham, PG
Snyder, AC
Roy, A
Khadem, S
Brodsky, JL
Subramanya, AR
AF Donnelly, Bridget F.
Needham, Patrick G.
Snyder, Avin C.
Roy, Ankita
Khadem, Shaheen
Brodsky, Jeffrey L.
Subramanya, Arohan R.
TI Cytoplasmic Hsp70 and Hsp90 regulate functionally distinct ER quality
control checkpoints during thiazide-sensitive NaCl cotransporter
biogenesis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Donnelly, Bridget F.; Snyder, Avin C.; Roy, Ankita; Khadem, Shaheen; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Needham, Patrick G.; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
[Khadem, Shaheen; Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1210.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505287
ER
PT J
AU Ingram, KH
Thalacker-Mercer, A
Garvey, WT
AF Ingram, Katherine Heimburger
Thalacker-Mercer, Anna
Garvey, W. Timothy
TI Individual amino acids and insulin sensitivity: relationships determined
by race and gender
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ingram, Katherine Heimburger] Kennesaw State Univ, Kennesaw, GA USA.
[Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 631.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504260
ER
PT J
AU Kellogg, DL
Zhao, J
Wu, YB
Roman, L
Johnson, JM
AF Kellogg, Dean Lundt
Zhao, Joan
Wu, Yubo
Roman, Linda
Johnson, John Marshall
TI Evidence that chronic inhibition of the mammalian Target of Rapamycin
(mTOR) reduces skin blood flow in humans
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kellogg, Dean Lundt] South Texas Vet Hlth Care Syst, Geriatr Educ & Clin Ctr, San Antonio, TX USA.
[Kellogg, Dean Lundt; Zhao, Joan; Wu, Yubo; Roman, Linda; Johnson, John Marshall] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb668
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860506258
ER
PT J
AU Reddy, AT
Lakshmi, SP
Dornadula, S
Pinni, S
Rampa, DR
Reddy, RC
AF Reddy, Aravind T.
Lakshmi, Sowmya P.
Dornadula, Sireesh
Pinni, Sudheer
Rampa, Dileep R.
Reddy, Raju C.
TI Suppressing Allergic Airway Disease with Nitrated Fatty Acids
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1216.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500483
ER
PT J
AU Ross, JS
Hu, W
Rosen, B
Snider, AJ
Obeid, LM
Cowart, LA
AF Ross, Jessica Shavonne
Hu, Wei
Rosen, Bess
Snider, Ashley J.
Obeid, Lina M.
Cowart, L. Ashley
TI Sphingosine Kinase 1 is regulated by PPAR alpha in response to free
fatty acids and mediates skeletal muscle IL-6 production and signaling
in diet-induced obesity
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ross, Jessica Shavonne; Hu, Wei; Snider, Ashley J.; Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Ross, Jessica Shavonne] Med Univ S Carolina, Mol & Cellular Biol & Pathobiol Program, Charleston, SC 29425 USA.
[Rosen, Bess] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Snider, Ashley J.; Cowart, L. Ashley] Ralph H Johnson VA Ctr, Charleston, SC USA.
[Obeid, Lina M.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
[Obeid, Lina M.] Northport VA Ctr, Northport, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 813.18
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505050
ER
PT J
AU Russo, SB
Tidhar, R
Futerman, A
Cowart, LA
AF Russo, Sarah Brice
Tidhar, Rotem
Futerman, Anthony
Cowart, L. Ashley
TI Myristate-derived d16:o-sphingolipids constitute an abundant cardiac
sphingolipid pool with distinct synthetic routes and functional
properties
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Tidhar, Rotem; Futerman, Anthony] Weizmann Inst Sci, IL-76100 Rehovot, Israel.
[Cowart, L. Ashley] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 813.15
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504450
ER
PT J
AU Thalacker-Mercer, A
Ingram, KH
Garvey, WT
AF Thalacker-Mercer, Anna
Ingram, Katherine Heimburger
Garvey, W. Timothy
TI Fat utilization impacts the negative relationship between insulin
sensitivity and Leucine
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Ingram, Katherine Heimburger] Kennesaw State Univ, Kennesaw, GA USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 226.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504131
ER
PT J
AU Wilkinson, CW
Colasurdo, EA
Pagulayan, KF
Shofer, JB
Peskind, ER
AF Wilkinson, Charles W.
Colasurdo, Elizabeth A.
Pagulayan, Kathleen F.
Shofer, Jane B.
Peskind, Elaine R.
TI Prevalence of chronic hypopituitarism after blast concussion
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Wilkinson, Charles W.; Colasurdo, Elizabeth A.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Pagulayan, Kathleen F.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, VA Northwest Network Mental Illness Res, Seattle, WA USA.
[Wilkinson, Charles W.; Pagulayan, Kathleen F.; Shofer, Jane B.; Peskind, Elaine R.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 935.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500321
ER
PT J
AU Zhang, JH
Dodson, M
Liang, QL
Benavides, G
Darley-Usmar, VM
AF Zhang, Jianhua
Dodson, Matthew
Liang, Qiuli
Benavides, Gloria
Darley-Usmar, Victor M.
TI Autophagy in neuronal bioenergetics and survival
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Zhang, Jianhua; Dodson, Matthew; Liang, Qiuli; Benavides, Gloria; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol & Med, Birmingham, AL USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1086.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504007
ER
PT J
AU Walker, RH
AF Walker, Ruth H.
TI Commentary for "Delayed onset of progressive chorea after acute basal
ganglia injury"
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID DISORDERS
C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA.
RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, 130 W Kingbridge Rd, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR
PY 2013
VL 28
IS 5
BP 587
EP 588
DI 10.1002/mds.25481
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 144QG
UT WOS:000318953900010
PM 23629806
ER
PT J
AU Bergstrom, B
Louis, S
Peterson, F
Aguiar, H
Friedman, M
Malinoski, D
AF Bergstrom, B.
Louis, S.
Peterson, F.
Aguiar, H.
Friedman, M.
Malinoski, D.
TI The Use of the Flotrac System To Guide Donor Management Is Associated
with Increased Organs Transplanted Per Donor.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Bergstrom, B.] Donor Network Arizona, Phoenix, AZ USA.
[Louis, S.; Malinoski, D.] Portland VA Med Ctr, Portland, OR USA.
[Peterson, F.; Aguiar, H.; Friedman, M.] OneLegacy, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 138
EP 138
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240300346
ER
PT J
AU Baddley, J
Klausing, B
Brizendine, K
Kumar, V
Julian, B
Eckhoff, D
Tallaj, J
Wille, K
Moser, S
Pappas, P
AF Baddley, J.
Klausing, B.
Brizendine, K.
Kumar, V.
Julian, B.
Eckhoff, D.
Tallaj, J.
Wille, K.
Moser, S.
Pappas, P.
TI Treatment of Cryptococcosis in Solid-OrganTransplant Recipients: Relapse
Is Rare after Discontinuation of Therapy.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Baddley, J.; Klausing, B.; Kumar, V.; Julian, B.; Eckhoff, D.; Tallaj, J.; Wille, K.; Moser, S.; Pappas, P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Baddley, J.] Birmingham VAMC, Birmingham, AL USA.
[Brizendine, K.] Cleveland Clin, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 344
EP 344
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301266
ER
PT J
AU Myaskovsky, L
Pleis, J
Ramkumar, M
Mittalhenkle, A
Langone, A
Thomas, C
AF Myaskovsky, L.
Pleis, J.
Ramkumar, M.
Mittalhenkle, A.
Langone, A.
Thomas, C.
TI Has the VA Found a Way To Reduce Racial Disparities in Kidney Transplant
Evaluation? Preliminary Results from the National VA Kidney Transplant
Study.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 13th American Transplant Congress (ATC)
CY MAY 18-22, 2013
CL Seattle, WA
C1 [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Myaskovsky, L.; Pleis, J.; Ramkumar, M.] U Pittsburgh, Pittsburgh, PA USA.
[Mittalhenkle, A.] Portland VA Med Ctr, Portland, Dorset, England.
[Langone, A.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Thomas, C.] Iowa City VA Healthcare, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2013
VL 13
SU 5
SI SI
BP 541
EP 541
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 134UL
UT WOS:000318240301941
ER
PT J
AU Penuelas, O
Frutos-Vivar, F
Gordo, F
Apezteguia, C
Restrepo, MI
Gonzalez, M
Arabi, Y
Santos, C
Alhashemi, JA
Perez, F
Esteban, A
Anzueto, A
AF Penuelas, O.
Frutos-Vivar, F.
Gordo, F.
Apezteguia, C.
Restrepo, M. I.
Gonzalez, M.
Arabi, Y.
Santos, C.
Alhashemi, J. A.
Perez, F.
Esteban, A.
Anzueto, A.
TI Outcome of tracheotomized patients following reintubation
SO MEDICINA INTENSIVA
LA Spanish
DT Article
DE Reintubation; Tracheotomy; Mechanical ventilation; Mortality
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION;
ICU PATIENTS; TRACHEOSTOMY; DURATION
AB Objective: To evaluate the outcome of tracheotomized patients after reintubation.
Method: Secondary analysis from a prospective, multicenter and observational study including 36 Intensive Care Units (ICUs) from 8 countries.
Patients: A total of 180 patients under mechanical ventilation for more than 48 hours, extubated and reintubated within 48 hours.
Interventions: None.
Outcomes: ICU mortality, length of ICU stay, organ failure.
Results: Fifty-two patients (29%) underwent tracheotomy after reintubation. The median time from reintubation to tracheotomy was 2.5 days (interquartile range (IQR) 1-8 days). The length of ICU stay was significantly longer in the tracheotomy group compared with the group without tracheotomy (median time 25 days, IQR 17-43 versus 16.5 days (IQR 11-25); p < 0.001). ICU mortality in the tracheotomy group was not significantly different (31% versus 27%; p 0.57).
Conclusions: In our cohort of reintubated patients, tracheotomy is a common procedure in the ICU. Patients with tracheotomy had an outcome similar to those without tracheotomy. (C) 2012 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.
C1 [Penuelas, O.; Frutos-Vivar, F.; Esteban, A.] Hosp Univ Getafe, Madrid, Spain.
[Penuelas, O.; Frutos-Vivar, F.; Esteban, A.] CIBER Enfermedades Resp, Madrid, Spain.
[Gordo, F.] Hosp Henares, Madrid, Spain.
[Apezteguia, C.] Hosp Prof A Posadas, Buenos Aires, DF, Argentina.
[Restrepo, M. I.; Anzueto, A.] South Texas Vet Hlth Care Syst, VERDICT, Audie L Murphy Div, San Antonio, TX USA.
[Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Gonzalez, M.] Clin Medellin, Medellin, Colombia.
[Gonzalez, M.] Univ Pontificia Bolivariana, Medellin, Colombia.
[Arabi, Y.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
[Santos, C.] Hosp Clin Montevideo, Montevideo, Uruguay.
[Alhashemi, J. A.] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia.
[Perez, F.] Hosp Clin Caracas, Caracas, Venezuela.
RP Penuelas, O (reprint author), Hosp Univ Getafe, Madrid, Spain.
EM openuelas@gmail.com
RI Restrepo, Marcos/H-4442-2014
OI Frutos-Vivar, Fernando/0000-0002-4648-9636
FU NHLBI NIH HHS [K23 HL096054]
NR 19
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0210-5691
J9 MED INTENSIVA
JI Med. Intensiv.
PD APR
PY 2013
VL 37
IS 3
BP 142
EP 148
DI 10.1016/j.medin.2012.03.013
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 139LE
UT WOS:000318583400003
PM 22608302
ER
PT J
AU Sacanell, J
Rey, T
Lopez, E
Vicente, R
Ballesteros, MA
Iranzo, R
Robles, JC
Restrepo, MI
Rello, J
AF Sacanell, J.
Rey, T.
Lopez, E.
Vicente, R.
Ballesteros, M. A.
Iranzo, R.
Robles, J. C.
Restrepo, M. I.
Rello, J.
CA Network PLUTO Postoperative Lung
TI Antifungal prophylaxis in the postoperative period of lung transplant
surgery in Spain
SO MEDICINA INTENSIVA
LA Spanish
DT Article
DE Prophylaxis; Postoperative period; Lung transplant
ID LIPOSOMAL AMPHOTERICIN-B; ASPERGILLUS INFECTION; PHARMACOKINETICS;
PREVENTION; RECIPIENTS; SAFETY
AB Objectives: To examine the type and duration of antifungal prophylaxis provided during the postoperative period of lung transplant recipients, together with the most frequent complications during admission to Intensive Care Units in Spain.
Patients and methods: A questionnaire was developed including demographic data on each transplant center, the type of antifungal prophylaxis used, its duration, and the most frequent complications. The questionnaire was distributed among the 7 Spanish national lung transplant centers, followed by analysis of the results obtained.
Results: All 7 centers completed the questionnaire. All of them provided universal prophylaxis in lung transplant patients. Monotherapy was the most widely used protocol (5/7; 71.4%), with ambhotericin B in liposomal or conventional form being the most frequent drug, administered via the inhalatory route. In the case of combination therapy, a great diversity of drugs was observed. The most frequently administered second choice drug was anidulafungin (3/7; 43%), followed by voriconazole (2/7; 28.5%). Antifungal therapy was maintained on an indefinite basis by 43% of the centers.
Invasive fungal infection (IFI) in the postoperative period of transplantation during admission to the Intensive Care Unit was suspected in 5-10% of the cases but was confirmed in less than 5%.
Among other complications registered in these patients in the Intensive Care Unit, the most frequent problems were respiratory infections (5/7; 71.5%). Conclusions: Antifungal prophylaxis during the postoperative period of lung transplantation is provided on a universal basis, though consensus is lacking as to the drug of choice, the administration route and the duration of such treatment. (C) 2012 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.
C1 [Sacanell, J.; Rello, J.] Hosp Univ Vall dHebron, Serv Med Intens, Barcelona, Spain.
[Rey, T.] Hosp Univ A Coruna, Serv Anestesiol & Reanimac, La Coruna, Spain.
[Lopez, E.] Hosp Univ Doce Octubre, Serv Anestesiol & Reanimac, Madrid, Spain.
[Vicente, R.] Hosp Univ La Fe, Serv Anestesiol & Reanimac, Valencia, Spain.
[Ballesteros, M. A.] Hosp Univ Marques de Valdecilla, Serv Med Intens, Santander, Spain.
[Iranzo, R.] Hosp Univ Puerta de Hierro, Serv Anestesiol & Reanimac, Madrid, Spain.
[Robles, J. C.] Hosp Univ Reina Sofia, Serv Med Intens, Cordoba, Spain.
[Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Audie L Murphy Div, Vet Evidence Res Implementat & Disseminat Ctr, San Antonio, TX 78229 USA.
[Rello, J.] Univ Automona Barcelona, Serv Med Intens, Hosp Univ Vall dHebron, Ctr Invest Biomed Red Enfermedades Resp, Barcelona, Spain.
RP Sacanell, J (reprint author), Hosp Univ Vall dHebron, Serv Med Intens, Barcelona, Spain.
EM jsacanell@vhebron.net
RI Restrepo, Marcos/H-4442-2014
OI Masclans, Joan R/0000-0002-0809-6823; Rello, Jordi/0000-0003-0676-6210
FU NHLBI NIH HHS [K23 HL096054]
NR 20
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0210-5691
J9 MED INTENSIVA
JI Med. Intensiv.
PD APR
PY 2013
VL 37
IS 3
BP 201
EP 205
DI 10.1016/j.medin.2012.10.003
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA 139LE
UT WOS:000318583400009
PM 23260267
ER
EF